// Auto-generated file. Do not edit manually.
// Last updated: 2025-07-01T03:55:18.253Z

export interface ProductImage {
  url: string;
  caption?: string;
}

export interface Product {
  id: string;
  name: string;
  description: string;
  strength: string;
  uom: string;
  categoryId: string;
  insertFile: string | null;
  images: string[];
}

export const products: Product[] = [
  {
    "id": "1721",
    "name": "Abiret",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>COMPOSITION</strong></p><p class=\"MsoNormal\" xss=\"removed\">Each tablet\r\ncontains Abiraterone Acetate USP 250mg Tablet.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>INDICATIONS</strong></p><p class=\"MsoNormal\" xss=\"removed\">Abiraterone\r\nAcetate is indicated in combination with Prednisone for the treatment of\r\npatients with</p><p class=\"MsoNormal\" xss=\"removed\">• Metastatic castration-resistant\r\nprostate cancer (CRPC)</p><p class=\"MsoNormal\" xss=\"removed\">• Metastatic\r\nhigh-risk castration-sensitive prostate cancer (CSPC)</p><p class=\"MsoNormal\" xss=\"removed\"><strong>DOSAGE\r\nAND ADMINISTRATION</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Recommended\r\nDose For Metastatic CRPC:</strong>\r\nThe recommended dose of Abiraterone Acetate is 1,000 mg (two 500 mg tablets or\r\nfour 250 mg tablets) orally once daily with Prednisone 5 mg orally twice daily.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Recommended\r\nDose For Metastatic High-Risk CSPC:</strong>\r\nThe recommended dose of Abiraterone Acetate is 1,000 mg (two 500 mg tablets or\r\nfour 250 mg tablets) orally once daily with Prednisone 5 mg administered orally\r\nonce daily.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Important\r\nAdministration Instructions :</strong>\r\nPatients receiving Abiraterone Acetate should also receive a</p><p class=\"MsoNormal\" xss=\"removed\">gonadotropin-releasing\r\nhormone (GnRH) analog concurrently or should have had bilateral orchiectomy.\r\nAbiraterone Acetate must be taken on an empty stomach, at least one hour before\r\nor at least two hours after a meal. The tablets should be swallowed whole with\r\nwater. Do not crush or chew tablets. </p><p class=\"MsoNormal\" xss=\"removed\">Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Pregnancy:</strong></p><p class=\"MsoNormal\" xss=\"removed\">The safety and\r\nefficacy of Abiraterone Acetate have not been established in females. The drug\r\ncan cause fetal harm and potential loss of pregnancy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Lactation:</strong></p><p class=\"MsoNormal\" xss=\"removed\">There is no\r\ninformation available on the presence of Abiraterone Acetate in human milk, or\r\non the effects on the breastfed child or milk production.</p><p><strong>Packing:</strong> <strong>Abiret: </strong>Each</p><p>box contains 7 tablets in Alu-Alu blister pack.</p>",
    "strength": "250",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1569397505Abiret 250mg - Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744019568Abiret.png"
    ]
  },
  {
    "id": "1819",
    "name": "Acalanib",
    "description": "<p><strong>Composition: </strong>Each\r\ncapsule contains Acalabrutinib INN 100mg.</p>\r\n\r\n<p class=\"MsoNormal\"><strong>Indications:</strong>\r\n<strong>Mantle Cell Lymphoma: </strong>Acalabrutinib is indicated for the treatment of\r\nadult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. <strong>Chronic\r\nLymphocytic Leukemia or Small Lymphocytic Lymphoma: </strong>Acalabrutinib is\r\nindicated for the treatment of adult patients with chronic lymphocytic leukemia\r\n(CLL) or small lymphocytic lymphoma (SLL).<o></o></p>\r\n\r\n<p class=\"MsoNormal\"><strong>Dosage and Administration:</strong>\r\n<strong>Acalabrutinib as Monotherapy: </strong>For patients with MCL, CLL, or SLL, the\r\nrecommended dose of Acalabrutinib is 100 mg taken orally approximately every 12\r\nhours until disease progression or unacceptable toxicity. <strong>Acalabrutinib in\r\nCombination with Obinutuzumab: </strong>For patients with previously untreated CLL\r\nor SLL, the recommended dose of Acalabrutinib is 100 mg taken orally\r\napproximately every 12 hours until disease progression or unacceptable\r\ntoxicity. Start Acalabrutinib at Cycle 1 (each cycle is 28 days). Start\r\nObinutuzumab at Cycle 2 for a total of 6 cycles and refer to the Obinutuzumab\r\nprescribing information for recommended dosing. Administer Acalabrutinib prior\r\nto Obinutuzumab when given on the same day. Advise patients to swallow capsule\r\nwhole with water. Advise patients not to open, break or chew the capsules.\r\nAcalabrutinib may be taken with or without food. If a dose of Acalabrutinib is\r\nmissed by more than 3 hours, it should be skipped and the next dose should be\r\ntaken at its regularly scheduled time. Extra capsules of Acalabrutinib should\r\nnot be taken to make up for a missed dose. <strong>Recommended Dosage for Hepatic\r\nImpairment: </strong>Avoid administration of Acalabrutinib in patients with severe\r\nhepatic impairment. Dose modifications are not required for patients with mild\r\nor moderate hepatic impairment. Or, as directed by the registered physicians.<o></o></p>\r\n\r\n<p class=\"MsoNormal\"><strong>Use in Pregnancy and Lactation: </strong>Acalabrutinib\r\nmay cause fetal harm and dystocia when administered to a pregnant woman. There\r\nare no available data in pregnant women to inform the drug-associated risk.\r\nPregnant women should be advised of the potential risk to a fetus.<o></o></p>\r\n\r\n<p><strong>Packing: </strong>Each\r\ncontainer contains 60 capsules in a box.</p>",
    "strength": "100",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1643533653Acalanib Capsule- Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1643533653Acalanib 60 Capsule- Bottle Carton Pic.png"
    ]
  },
  {
    "id": "958",
    "name": "Acepril",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Lisinopril 5mg & 10mg\r\nTablet.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong> Acepril is indicated for all\r\ngrades of essential hypertension and\r\nrenovascular hypertension. Acepril can\r\nbe used alone or with other anti\r\nhypertensive agents.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong>Treatment\r\nshould be started with 2.5 mg once daily.\r\nIn patients with uncomplicated essential\r\nhypertension, not on diuretic therapy, the\r\nrecommended initial dose is 10mg once\r\ndaily. Dosage should be adjusted\r\naccording to blood pressure response.\r\nThe usual dosage range is 10-20 mg\r\nonce daily. Maximum dose is 40 mg per\r\nday as a single dose or as directed by\r\nthe physician.</p><p style=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><strong></strong>Acepril 10mg : 2 x 14's Tablets in blister\r\npack. </p><p style=\"text-align: justify;\">Acepril 5mg : 4 x 14's Tablets in blister pack. </p>",
    "strength": "10,5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/15675892761530937985Acepril.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744019616ACEPRIL-10.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744019616ACEPRIL-5.png"
    ]
  },
  {
    "id": "959",
    "name": "Acetor",
    "description": "<p><strong></strong><strong>Composition : </strong>Captopril 25 mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Mild-to-moderate hyprtension\r\n: As an adjunct to thiazide therapy in patients\r\nwho have not responded effectively to\r\nthiazide treatment alone.\r\nSevere hypertension : Where standard\r\ntherapy has failed.\r\nCongestive heart failure : Acetor is\r\nindicated for the treatment of congestive\r\nheart failure. The drug should be used\r\ntogether with diuretics and where\r\nappropriate, digitalis.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adults : Mild-to-moderate\r\nhypertension: The initial dose is\r\n12.5 mg twice daily. The usual maintenance\r\ndose is 25 mg twice daily which can be\r\nincreased incrementally, at two to four week\r\nintervals, until a satisfactory response is\r\nachieved, to a maximum of 50 mg twice daily.\r\nSevere hypertension : In severe\r\nhypertension the starting dose is 12.5 mg b.d.\r\nThe dosage may be increased incrementally\r\nto a maximum of 50 mg t.d.s.\r\nHeart failure : A starting dose of 6.25 mg or\r\n12.5 mg may minimise a transient\r\nhypotensive effect. The usual maintenance\r\ndose is 25 mg three times a day. The usual\r\nmaximum dose is 150 mg daily.\r\nAcetor must be taken 1 hour before meals to\r\nensure maximum absorption.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Acetor :10 x 10 tablets in blister\r\npack.</span></p>",
    "strength": "25",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1635134463ACETOR.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744019682ACETOR.png"
    ]
  },
  {
    "id": "1012",
    "name": "Aclene",
    "description": "<p><strong></strong><strong>Composition :</strong> Adapalene INN 0.1%.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Adapalene 0.1% cream is\r\nindicated for topical treatment of acne\r\nvulgaris.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">1. Adapalene 0.1% cream should be\r\napplied to the affected areas of skin,\r\nonce daily at night.\r\n2. A thin film of cream should be applied\r\nto the areas where lesions present, using\r\nenough to cover the entire affected areas\r\nlightly. Or, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Administration of drugs during pregnancy and lactation should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus or child. There is insufficient experience of the use of Salmeterol Xinafoate and Fluticasone Propionate in human pregnancy and lactation. There are no data available for human breast milk.</p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Aclene Cream : 10gm Cream in a\r\ntube.</span></p>",
    "strength": "0.1%",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530938904Aclene.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745120501Aclene.png"
    ]
  },
  {
    "id": "1048",
    "name": "Aclene Plus",
    "description": "<p><strong>Composition :</strong> Adapalene 1 mg + Benzoyl Peroxide 25 mg.</p><p style=\"text-align: justify;\"><strong>Indications :</strong> It is indicated for the topical treatment of Acne Vulgaris.Dosage and administration : A thin film is applied to affected areas of the face and/or trunk once daily after washing. Or, as directed by the registered physician.</p><p style=\"text-align: justify;\"><strong>Packing : </strong>Aclene Plus :<strong> </strong>10gm gel in a tube.<br></p>",
    "strength": "(0.1% + 2.5%) w/w",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530939216Aclene_plus.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Aclene Plus.jpg"
    ]
  },
  {
    "id": "1163",
    "name": "AH Suspension",
    "description": "<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Composition:<o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>AH-400\r\nChewable Tablet:</strong>\r\nEach chewable tablet contains Albendazole USP 400mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>AH Oral\r\nSuspension:</strong>\r\nEach 5ml contains Albendazole USP 200mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications: </strong>Albendazole\r\nis indicated in single and mixed infestations, sush as- <strong>1.</strong> Hookworm (Ancylostoma, Necator); <strong>2.</strong> Roundworm (Ascaris); <strong>3.</strong>\r\nThreadworm (Enterobius); <strong>4.</strong> Whipworm\r\n(Trichuris); <strong>5.</strong> Strongyloides; <strong>6.</strong> Tapeworm (Taenia sp.); <strong>7.</strong> Opistorchis; <strong>8.</strong> Hydatid disease (Echinococcus); <strong>9.</strong> Neurocysticercosis; <strong>10.</strong>\r\nSystemic nematodes; <strong>11.</strong> Giardiasis; <strong>12.</strong> Microsporidiosis.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Dosage and administration : </strong><strong>Adults or children over 2 years of\r\nage:</strong>\r\n400mg (1 AH tablet or 10ml suspension) as a single dose in cases of <i>Enterobius vermicularis, Trichuris\r\ntrichiura, Ascaris lumbricoides, Ancylostoma duodenale and Necator americanus</i>.\r\nIn cases of strongyloidiasis or taeniasis, 400mg (1 <strong>AH </strong>tablet or 10ml\r\nsuspension) as a single dose should be given for 3 consecutive days. If the patient\r\nis not cured on follow-up after three weeks, a second course of treatment is\r\nindicated. <strong>AH </strong>400mg tablets must be chewed. Both the preparations may be crushed and mixed with food. <strong>Children\r\nunder 2 years of age:</strong> Not recommended. Or, as directed by the registered\r\nphysicians.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Use\r\nin pregnancy and lactation:</strong> Pregnancy category C. It should\r\nnot be administered during pregnancy or in women thought to be pregnant. It is\r\nnot known whether it is excreted in human milk. Caution should be exercised\r\nwhen Albendazole is administered to a nursing women.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Packing:<o:p></o:p></strong></p><p class=\"MsoNormal\"><strong>AH-400\r\nTablet:</strong> Each box contains 24’s tablets in blister pack.<o:p></o:p></p><p><strong>AH\r\nOral Suspension:</strong> Bottle containing 10ml suspension.<br><strong></strong></p>",
    "strength": "200/5",
    "uom": "mg/ml",
    "categoryId": "43",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1660727188AH Local Insert English Part Com.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740568706AHBOX.png"
    ]
  },
  {
    "id": "1186",
    "name": "AH-400 Tablet",
    "description": "<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Composition:<o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>AH-400\r\nChewable Tablet:</strong>\r\nEach chewable tablet contains Albendazole USP 400mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>AH Oral\r\nSuspension:</strong>\r\nEach 5ml contains Albendazole USP 200mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications: </strong>Albendazole\r\nis indicated in single and mixed infestations, sush as- <strong>1.</strong> Hookworm (Ancylostoma, Necator); <strong>2.</strong> Roundworm (Ascaris); <strong>3.</strong>\r\nThreadworm (Enterobius); <strong>4.</strong> Whipworm\r\n(Trichuris); <strong>5.</strong> Strongyloides; <strong>6.</strong> Tapeworm (Taenia sp.); <strong>7.</strong> Opistorchis; <strong>8.</strong> Hydatid disease (Echinococcus); <strong>9.</strong> Neurocysticercosis; <strong>10.</strong>\r\nSystemic nematodes; <strong>11.</strong> Giardiasis; <strong>12.</strong> Microsporidiosis.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Dosage and administration : </strong><strong>Adults or children over 2 years of\r\nage:</strong>\r\n400mg (1 AH tablet or 10ml suspension) as a single dose in cases of <i>Enterobius vermicularis, Trichuris\r\ntrichiura, Ascaris lumbricoides, Ancylostoma duodenale and Necator americanus</i>.\r\nIn cases of strongyloidiasis or taeniasis, 400mg (1 <strong>AH </strong>tablet or 10ml\r\nsuspension) as a single dose should be given for 3 consecutive days. If the patient\r\nis not cured on follow-up after three weeks, a second course of treatment is\r\nindicated. <strong>AH </strong>400mg tablets must be chewed. Both the preparations may be crushed and mixed with food. <strong>Children\r\nunder 2 years of age:</strong> Not recommended. Or, as directed by the registered\r\nphysicians.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Use\r\nin pregnancy and lactation:</strong> Pregnancy category C. It should\r\nnot be administered during pregnancy or in women thought to be pregnant. It is\r\nnot known whether it is excreted in human milk. Caution should be exercised\r\nwhen Albendazole is administered to a nursing women.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Packing:<o:p></o:p></strong></p><p class=\"MsoNormal\"><strong>AH-400\r\nTablet:</strong> Each box contains 24’s tablets in blister pack.<o:p></o:p></p><p><strong>AH\r\nOral Suspension:</strong> Bottle containing 10ml suspension.<br></p><p style=\"text-align: justify;\"><br></p>",
    "strength": "400",
    "uom": "mg",
    "categoryId": "43",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1660727093AH Local Insert English Part Com.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740568574ah400.png"
    ]
  },
  {
    "id": "1851",
    "name": "AKNO-10",
    "description": "<p><strong>Composition:\r\n</strong>Each\r\nSoft Gelatin Capsule Contains Isotretinoin USP 10mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication:\r\n</strong>It\r\nis indicated in severe forms of acne (such as nodular or conglobate acne or\r\nacne at risk of permanent scarring) resistant to adequate courses of standard\r\ntherapy with systemic anti-bacterials and topical therapy.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration: </strong>The\r\ncapsules should be taken with food once or twice daily. Isotretinoin should only\r\nbe prescribed by or under the supervision of physicians with expertise in the\r\nuse of systemic retinoids for the treatment of severe acne and a full\r\nunderstanding of the risks of Isotretinoin therapy and monitoring requirements.\r\n<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><i>Adults\r\nincluding adolescents and the elderly:</i> Isotretinoin therapy should be started\r\nat a dose of 0.5 mg/kg daily. The therapeutic response to Isotretinoin and some\r\nof the adverse effects are dose-related and vary between patients. This\r\nnecessitates individual dosage adjustment during therapy. For most patients,\r\nthe dose ranges from 0.5-1.0 mg/kg per day. <o></o></p><p class=\"MsoNormal\" xss=\"removed\"><i>Patients\r\nwith severe renal impairment:</i> In patients with severe renal\r\ninsufficiency treatment should be started at a lower dose (e.g. 10 mg/day). The\r\ndose should then be increased up to 1 mg/kg/day or until the patient is\r\nreceiving the maximum tolerated dose. <o></o></p><p class=\"MsoNormal\" xss=\"removed\"><i>Patients\r\nwith intolerance:</i>\r\nIn patients who show severe intolerance to the recommended dose, treatment may\r\nbe continued at a lower dose with the consequences of alonger therapy duration\r\nand a higher risk of relapse. In order to achieve the maximum possible efficacy\r\nin these patients the dose should normally be continued at the highest\r\ntolerated dose. Or, as directed by the registered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy\r\nand lactation :</strong>\r\nPregnancy is an absolute contraindication to treatment with isotretinoin: If\r\npregnancy does occur in spite of these precautions during treatment with\r\nIsotretinoin or in the month following: there is a great risk of very severe\r\nand serious malformation of the foetus.|f pregnancy occurs in a woman treated\r\nwith isotretinoin, treatment must be stopped and the patient should be referred\r\nto a physician specialised or experienced in teratology for evaluation and\r\nadvice ‘ Isotretinoin is highly lipophilic, therefore the passage of\r\nisotretinoin into human milk is very likely. Due to the potential for adverse\r\neffects in the child exposed via mother’s milk, Isotretinoin is contraindicated\r\nduring breast-feeding.<o></o></p><p><strong>Packing:\r\n</strong>Each\r\nbox contains 15’s soft capsule in blister pack.</p>",
    "strength": "10",
    "uom": "mg",
    "categoryId": "104",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1710308142Akn-10 Soft Capsule Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745120550AKNO-10.png"
    ]
  },
  {
    "id": "884",
    "name": "ALBASINE",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Almitrine Bismesylate INN 30 mg +\r\nRaubasine INN 10mg Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This tablet is indicated for\r\nreduction of neurological damage &\r\naccelerates recovery after cerebral\r\nstroke, Minor age related neurological\r\ndisorders, some visual disorders related\r\nto the circulation, some disorders of the\r\ninner ear related to the circulation\r\n(hearing loss, dizziness, buzzing sounds\r\nin the ear).</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">1 tablet\r\nonce or twice daily (taken separately,\r\nseveral hours apart), without exceeding\r\n2 tablets per day. Or, as directed by the\r\nregistered physicians.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">It is\r\nnot recommended in pregnancy. It\r\nshould be used with caution only when\r\nthe expected benefit to the mother is\r\ngreater than the possible risk to the\r\nfetas.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Albasine : 2x14's tablets in\r\nalu alu blister pack.</span></p>",
    "strength": "30+10",
    "uom": "mg",
    "categoryId": "105",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530940467ALBASINE.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745120597ALBASINE.png"
    ]
  },
  {
    "id": "1315",
    "name": "Alkamax",
    "description": "<p><strong>Composition : </strong>Alkamax Oral Solution:<strong> </strong>Each 5 ml oral solution contains Potassium Citrat BP 1500 mg and Citric Acid Monohydrate BP 250 mg. </p><p style=\"text-align: justify;\"><strong>Indications : </strong>It is indicated to\r\nrelieve discomfort in urinary tract infections due to decreased pH or acidic urine. It is\r\nalso indicated in preventing kidney stone formation specially caused by uric\r\nacid with or without the presence of calcium stones and in gout therapy as a\r\nvaluable adjuvant with uricosuric agents. This medicine is also effective in\r\ncorrecting acidosis caused by kidney disease.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong><o> </o></strong></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and\r\nadministration : </strong>To relieve discomfort in UTI : Adults and children over 6\r\nyears : 10\r\nml 3 times daily, diluted<strong> </strong>with1 glass of water.<strong></strong> Children 1-6 years : 5<strong>\r\n</strong>ml 3 times daily, diluted with ½ glass of<strong> </strong>water. <o></o><strong></strong>To prevent kidney\r\nstones & acidosis caused by kidney diseases : Adults :<strong> </strong>10-15 ml 4 times\r\ndaily diluted with<strong> </strong>1 glass of water.<strong></strong> Children :<strong> </strong>5-10 ml 4 times<strong>\r\n</strong>daily diluted with ½ glass of water.<o></o><strong></strong> In gout therapy (with uricosuric agent):\r\nAdults :<strong> </strong>10-15 ml 4 times daily diluted with 1 glass of<strong> </strong>water.<o></o><strong></strong> Children :<strong> </strong>5-10 ml 4 times daily<strong> </strong>diluted\r\nwith ½ glass of water. Or, as directed<strong> </strong>by the\r\nregistered physician.</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>This drug should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. It is not known if this drug is found in breast milk or not. Caution should be advised when this medicine is administered to nursing women.</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><o> </o></p><p style=\"text-align: justify;\"><strong>Packing : </strong>Alkamax\r\nOral Solution <strong>: </strong>Each\r\nbottle contains 200ml Oral Solution.</p>",
    "strength": "200",
    "uom": "ML",
    "categoryId": "111",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530940867alkamax.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745304749Alkamax.png"
    ]
  },
  {
    "id": "994",
    "name": "Amlocard",
    "description": "<p style=\"margin: 0in 0in 5.65pt; line-height: 115%; background-image: initial; background-color: white;\"><br></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Composition: Amlocard-5: </strong><strong> </strong>Amlodipine 5mg (as Amlodipine Besylate).<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Amlocard -10: </strong>Amlodipine 10mg (as Amlodipine Besylate).<o:p></o:p></p><p style=\"margin: 12pt 0in 0.0001pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Indication: </strong><strong>Amlodipine\r\nis used in severe and mild to moderate hypertension, myocardial ischemia,\r\nangina pectoris. </strong><strong><o:p></o:p></strong></p><p style=\"margin: 12pt 0in 0.0001pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Dosage and\r\nadministration: </strong><strong> </strong>Adult- For both hypertension and angina,\r\nthe recommended dose is 5mg Amlocard orally once daily, which may be increased\r\nto a maximum dose of 10mg. Amlocard is well tolerated in elderly patients.\r\nNormal dosage is recommended in patients with renal impairment. Children- Use\r\nbelow 18 years is not currently recommended.<strong>Or, as\r\ndirected by a registered physician. </strong><o:p></o:p></p><p style=\"margin: 12pt 0in 0.0001pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Use in pregnancy and\r\nlactation: </strong>There are no adequate and well-controlled studies in\r\npregnant women. Amlodipine should be used during pregnancy only if the\r\npotential benefit justifies the potential risk to the fetus. It is not known\r\nwhether amlodipine is excreted in human milk. In the absence of this\r\ninformation, it is recommended that nursing be discontinued while NORVASC is\r\nadministered.<o:p></o:p></p><p style=\"margin: 12pt 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Packing: Amlocard-5:\r\n</strong><strong>Each box contains 7</strong><strong> </strong>x<strong> 14’s Tablet in a blister pack.<o:p></o:p></strong></p><p><strong>Amlocard\r\n-10: </strong><strong>Each box contains 4</strong><strong> </strong>x<strong> 14’s Tablet in a blister pack.</strong><br><strong></strong></p>",
    "strength": "10,5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530941290Amlocard.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744019816AMLOCARD-10.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744019816Amlocard 5.png"
    ]
  },
  {
    "id": "989",
    "name": "Amlocard Plus",
    "description": "<p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Composition: Amlocard Plus-25: </strong> Amlodipine  5mg (as Amlodipine Besylate) plus Atenolol  25 mg<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Amlocard Plus-50:</strong>  Amlodipine 10mg (as Amlodipine Besylate) plus Atenolol  50 mg.<o:p></o:p></p><p style=\"margin: 12pt 0in 0.0001pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Indication: </strong><strong>1. </strong>Patients with essential hypertension, 2. Patients with angina pectoris\r\n& hypertension as co-existing diseases, 3. In post MI patients, 4. In\r\npatients with refractory angina pectoris where nitrate therapy has failed.<strong><o:p></o:p></strong></p><p style=\"margin: 12pt 0in 0.0001pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Dosage and\r\nadministration: </strong><strong> </strong>The therapy is initiated with a single\r\ndose of Amlodipine 5 mg plus Atenolol 50 mg depending upon the therapeutic\r\nresponse, titration of the dosage is recommended. In elderly patients, it is\r\nadvisable to initiate the therapy with 1/2 tablet to fixed dose combination of\r\nAmlodipine & Atenolol i.e. 2.5 mg of Amlodipine & 25 mg Atenolol.<strong> <o:p></o:p></strong></p><p style=\"margin: 12pt 0in 0.0001pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Use in pregnancy and\r\nlactation: </strong>The\r\ncombination should be used during pregnancy only if the expected benefit\r\noutweighs the potential fetal risk. The combination should not be used by\r\nnursing mothers. If its use is considered necessary, breast-feeding should be\r\nstopped.<strong><o:p></o:p></strong></p><p style=\"margin: 12pt 0in 0.0001pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Packing: </strong>Amlocard\r\nPlus-25:  Each box\r\ncontains 4 x 14’s tablets in a blister pack.<o:p></o:p></p><p>Amlocard\r\nPlus-50: Each box contains 4 x 14’s tablets in a blister pack.<br><strong></strong></p>",
    "strength": "5+50,5+25",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530942058Amlocard_pl.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744019856Amlocard Plus 50.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744019856Amlocard plus 25.png"
    ]
  },
  {
    "id": "1354",
    "name": "Anacare",
    "description": "<p class=\"MsoNormal\" xss=removed><strong>Composition:</strong> <strong>Anacare Tablet:</strong> Each film coated tablet contains\r\nAnastrozole USP 1 mg.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed><strong>Indications:</strong> Anastrozole is indicated for adjuvant treatment of\r\npostmenopausal women with hormone receptor-positive early breast cancer. Anastrozole\r\nis indicated for the first-line treatment of postmenopausal women with hormone\r\nreceptor-positive or hormone receptor unknown locally advanced or metastatic\r\nbreast cancer. Anastrozole is indicated for the second-line treatment of\r\nadvanced breast cancer in postmenopausal women with disease progression\r\nfollowing tamoxifen therapy. Patients with ER-negative disease and patients who\r\ndid not respond to previous tamoxifen therapy rarely responded to Anastrozole.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed><strong>Dosage\r\n& Administration:</strong> The dose of Anacare is one tablet 1\r\nmg taken once a day. For patients with advanced breast cancer, Anastrozole\r\nshould be continued until tumor progression. For adjuvant treatment of early\r\nbreast cancer in postmenonausal women, the optimal duration of therapy is\r\nunknown. Patients with Hepatic Impairment: No changes in dose are recommended\r\nfor patients with mild- to-moderate hepatic impairment. Anastrozole has not\r\nbeen studied in patients with severe hepatic impairment. Patients with Renal\r\nImpairment: No changes in dose are necessary for patients with renal\r\nimpairment.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed><strong>Pregnancy:</strong> <strong>Pregnancy Category X.</strong> <strong>Nursing Mothers:</strong> It is\r\nnot known it Anastrozole is excreted in human milk. Because many drugs are\r\nexcreted in human milk or the potential for serious adverse reactions in nursing\r\ninfants, a decision should be made whether to discontinue nursing or to\r\ndiscontinue the drug, taking into account the importance of the drug to the\r\nmother. <strong>Pediatric Use:</strong> The safety and efficacy of Anastrozole in\r\npediatric patients have not been established. <strong>Geriatric Use:</strong> The\r\npharmacokinetics of Anastrozole are not affected by age.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed><strong>Packing:\r\nAnacare Tablet: </strong>Each box contains 28 tablets in\r\nAlu-Alu blister pack.</p>\r\n\r\n\r\n\r\n",
    "strength": "1",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/15438326931530766929Anacare.pdf.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/15438326931530766929ana_C.jpg"
    ]
  },
  {
    "id": "1008",
    "name": "Angicard",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Nitroglycerin\r\n0.5 mg </span><span class=\"redactor-invisible-space\">Sublingual</span><span class=\"redactor-invisible-space\"> Tablet.</span></p><p style=\"margin: 12pt 0in 0.0001pt; text-align: justify; background-image: initial; background-color: white;\" rel=\"margin: 12pt 0in 0.0001pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Indication: </strong>Angicard is indicated for the acute\r\nrelief of an attack or acute prophylaxis of angina pectoris due to coronary\r\nartery disease.<strong><o:p></o:p></strong></p><p style=\"margin: 12pt 0in 0.0001pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Dosage and administration: </strong><strong> </strong>One tablet should be dissolved under the\r\ntongue at the first sign of an acute anginal attack. The dose may be repeated\r\napproximately every five minutes, until relief is obtained. Or, as directed by\r\nthe registered physician.<o:p></o:p></p><p style=\"margin: 12pt 0in 0.0001pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Use in pregnancy and\r\nlactation: </strong>Nitroglycerin should be given to a pregnant woman\r\nonly if clearly needed. It is not known whether Nitroglycerin is excreted in\r\nhuman milk. <o:p></o:p></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong><br></strong></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing: \r\n</strong>Each box contains 3 x 14’s tablets in a blister pack.<br></p>",
    "strength": "0.5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633323265Angicard.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744019928Angicard.png"
    ]
  },
  {
    "id": "1781",
    "name": "Anib- 40",
    "description": "<p class=\"MsoNormal\">Afatinib INN 40 mg</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Composition: </strong>Each\r\nfilm coated tablet contains Afatinib 40 mg as Afatinib Dimaleate INN.<br xss=\"removed\">\r\n<br xss=\"removed\">\r\n</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong>\r\n<strong>EGFR Mutation-Positive, Metastatic Non-Small Cell Lung Cancer:</strong> Anib is\r\nindicated for the first-line treatment of patients with metastatic non-small\r\ncell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor\r\n(EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected\r\nby an FDA-approved test. <strong>Limitation of Use: </strong>The safety and efficacy of\r\nAnib have not been established in patients whose tumors have other EGFR\r\nmutations. <strong>Previously Treated, Metastatic Squamous NSCLC: </strong>Anib is\r\nindicated for the treatment of patients with metastatic squamous NSCLC\r\nprogressing after platinum-based chemotherapy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and\r\nAdministration:</strong> <strong>Patient Selection for EGFR\r\nMutation-Positive Metastatic NSCLC:</strong> Patients should be selected for\r\nfirst-line treatment of metastatic NSCLC with GILOTRIF based on the presence of\r\nEGFR exon 19 deletions or exon 21 (L858R) substitution mutations in tumor\r\nspecimens. <strong>Recommended Dose: </strong>The recommended dose of Anib is 40 mg\r\norally, once daily until disease progression or no longer tolerated by the\r\npatient. <strong>Severe Renal Impairment: </strong>The recommended dose of Anib in\r\npatients with severe renal impairment (estimated glomerular filtration rate\r\n[eGFR*] 15 to 29 mL/min /1.73 m²) is 30 mg orally, once daily. Anib should be\r\ntaken at least 1 hour before or 2 hours after a meal. A missed dose should not\r\nbe taken within 12 hours of the next dose. Or, as directed by the registered\r\nphysicians.</p><p class=\"MsoNormal\"><strong>Use in Pregnancy and Lactation: </strong>Anib\r\ncan cause fetal harm when administered to a pregnant woman. There are no\r\navailable data on the use of Anib in pregnant women. <strong>Lactation: </strong>There\r\nare no data on the presence of Afatinib in human milk or its effects on the\r\nbreastfed infant or on milk production. Because of the potential for serious\r\nadverse reactions in nursing infants from Anib, a<br>\r\nlactating woman should be advised not to breastfeed during treatment with Anib\r\nand for 2 weeks after the final dose.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packaging: </strong>Each\r\nbox contains 30 tablets in a blister pack.</p>",
    "strength": "40",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1632048499Anib Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1632215767Anib-40 Tablet- Carton Pic.png"
    ]
  },
  {
    "id": "817",
    "name": "Anilic",
    "description": "<p><strong></strong><strong>Composition : </strong>Tolfenamic Acid 200 mg\r\nTablet. </p><p style=\"text-align: justify;\"><strong>Indication :</strong> It is indicated for the\r\ntreatment of acute migraine.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong>Adults :\r\n200 mg when the first symptoms of\r\nmigraine appear. The treatment can be\r\nrepeated once after 1-2 hours if a\r\nsatisfactory response is not obtained.\r\nChildren : A paediatric doses regimen\r\nhas not yet been established.\r\nOr, as directed by the registered\r\nphysicians.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong> There are no adequate and wellcontrolled\r\nstudies in pregnant women.\r\nDuring the first and second trimester of\r\npregnancy, Tolfenamic acid should not\r\nbe given unless clearly necessary. Like\r\nother NSAIDs, Tolfenamic acid should\r\nnot be given in the last trimester.\r\nTolfenamic acid can appear in breast\r\nmilk in very low concentrations. It should\r\nbe avoided when breast feeding.</p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Anilic: 3 x 10's tablets in blister\r\npack.</span></p>",
    "strength": "200",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530943015anilic.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745120715Anilic.png"
    ]
  },
  {
    "id": "1348",
    "name": "Apit",
    "description": "<p><strong><span></span></strong><br></p><p class=\"MsoNormal\" style=\"text-align:justify\" rel=\"text-align:justify\"><strong>Composition:</strong><br>\r\n<strong>Apit-40: </strong>Each film coated tablet contains Megestrol Acetate USP 40mg.<br>\r\n<strong>Apit-160: </strong>Each film coated tablet contains Megestrol Acetate USP 160mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications:</strong>\r\nMegestrol Acetate is indicated for the palliative treatment of advanced\r\ncarcinoma of the breast or endometrium (i.e., recurrent, inoperable, or\r\nmetastatic disease). It should not be used in lieu of currently accepted\r\nprocedures such as surgery, radiation, or chemotherapy. It is also indicated\r\nfor the treatment of anorexia, cachexia, or weight loss secondary to metastatic\r\ncancer.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Dosage and Administration:<o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Breast Cancer: </strong>160mg/day\r\n(160mg taken once daily). <strong>Endometrial Carcinoma: </strong>40 to 320mg/day in\r\ndivided doses (40-80mg one to four times daily or one to two 160mg tablets\r\ndaily). At least 2 months of continuous treatment is considered an adequate\r\nperiod for determining the efficacy of Megestrol Acetate. <strong>Cachexia: </strong>400\r\nto 800mg/day. <strong>Use in Children: </strong>Safety and effectiveness in pediatric\r\npatients have not been established. <strong>Use in the Elderly: </strong>Insufficient\r\ndata from clinical studies of Megestrol Acetate are available for patients 65\r\nyears of age and older to determine whether they respond differently than\r\nyounger patients. Other reported clinical experience has not identified differences\r\nin responses between elderly and younger patients. In general, dose selection\r\nfor an elderly patient should be cautious, usually starting at the low end of\r\nthe dosing range, reflecting the greater frequency of decreased hepatic, renal,\r\nor cardiac function, and of concomitant disease or other drug therapy. <strong>Maximu\r\nTolerated Daily Dose:</strong> <strong>Breast Cancer: </strong>160mg/day. <strong>Endometrial\r\nCarcinoma: </strong>320mg/day. <strong>Cachexia: </strong>800mg/day. Or, as directed by the\r\nregistered physicians.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Use in Pregnancy: </strong>Pregnancy\r\nCategory D. There are no adequate and well-controlled studies in pregnant\r\nwomen. If this drug is used during pregnancy, or if the patient becomes\r\npregnant while<br>\r\ntaking this drug, the patient should be apprised of the potential hazard to the\r\nfetus. Women of childbearing potential should be advised to avoid becoming\r\npregnant. <strong>Use in Lactation: </strong>Because many drugs are excreted in human\r\nbreast milk and because of the potential for adverse reactions in nursing\r\ninfants, nursing should be discontinued when receiving Megestrol Acetate\r\ntherapy.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Packing: <o:p></o:p></strong></p><p class=\"MsoNormal\"><strong>Apit-40: </strong>Each\r\nbox contains 30 tablets in Alu-Alu blister pack.<br></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Apit-160: </strong>Each box contains 30 tablets in Alu-Alu blister pack.<br></p>",
    "strength": " 160,40",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1543644213Mestrol- Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744020012Apit-160.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744020012Apit-40.png"
    ]
  },
  {
    "id": "1804",
    "name": "Apit",
    "description": "<p><strong>Composition: </strong>Each\r\nml suspension contains Megestrol Acetate USP 40mg.</p><p class=\"MsoNormal\"><strong>Indications: </strong>lt\r\nis indicated for the treatment of anorexia, cachexia, or an unexplained,\r\nsignificant<br><o:p></o:p></p><p>weight loss in patients with a diagnosis of acquired immunedeficiency syndrome\r\n(AIDs) & cancer.<br></p><p><strong>Dosage and administration: </strong>The\r\nrecommended adult initial dosage is 800 mg/day (20 ml/day). The bottle should\r\nbe shaken well before use. Or, as directed by the registered physician.<br></p><p><strong>Use in pregnancy and lactation: </strong>Pregnancy\r\ncategory X. There are no adequate and well controlled studies of Megestrol\r\nadministration in pregnant Women. It is a progesterone derivative, which may\r\ninduce vaginal bleeding in women. It should be used during pregnancy only if\r\nthe potential benefit justifies the potential risk to the fetus. Because of the\r\npotential for adverse effects on the newborn, nursing should be discontinued if\r\nMegestrol oral suspension is required.<br></p><p><strong>Packing: </strong>Each\r\nbottle contains 100ml oral suspension.<br></p><p class=\"MsoNormal\"><o:p></o:p></p>",
    "strength": " 100",
    "uom": "ML",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1637662786Apit PDF Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1637662786Resized Apit Suspension Carton Pic.png"
    ]
  },
  {
    "id": "1872",
    "name": "Apridex",
    "description": "<p> <strong>Composition\r\n: </strong>Each Capsule\r\nContains Aprepitant USP40mg.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications : </strong>Apridex\r\nis indicated for- Prevention of postoperative nausea and vomiting (PONV).\r\nPrevention of chemotherapy induced nausea and vomiting (CINV).<o:p></o:p></p><p class=\"MsoNormal\"><strong>Dosage\r\nand administration</strong></p><p class=\"MsoNormal\"><strong>Post Operative Nausea and Vomiting</strong>:\r\nThe recommended oral dosage of Aprepitant is 40 mg within 3 hours prior to\r\ninduction of anesthesia. <o:p></o:p></p><p class=\"MsoNormal\"><strong>Chemotherapy-Induced Nausea and Vomiting</strong>:\r\nThe following regimen should be used for the prevention of nausea and vomiting\r\nassociated with highlyemetogenic cancer chemotherapy-<o:p></o:p></p><p class=\"MsoNormal\"><strong>Day 1</strong>: Aprepitant 125\r\nmg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron): 24 mg\r\n30minutes before the start of chemotherapy.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Day 2</strong>: Aprepitant 80\r\nmg orally, Dexamethasone 8 mg orally<o:p></o:p></p><p class=\"MsoNormal\"><strong>Day 3</strong>: Aprepitant 80\r\nmg orally, Dexamethasone 8 mg orally<o:p></o:p></p><p class=\"MsoNormal\"><strong>Day 4</strong>: Dexamethasone\r\n8 mg orally<o:p></o:p></p><p class=\"MsoNormal\">Aprepitant is administered orally 1 hour prior to\r\nchemotherapy treatment on Day 1 and in the morning on Days 2 and3.\r\nDexamethasone is administered 30 minutes prior to chemotherapy treatment on Day\r\n1 and in the morning on Days2 through 4. The dose of dexamethasone accounts for\r\ndrug interactions.** The following regimen should be used for the prevention of\r\nnausea and vomiting associated with moderately emetogenic cancer chemotherapy:\r\n<o:p></o:p></p><p class=\"MsoNormal\"><strong>Day 1</strong>: Aprepitant 125\r\nmg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron): one 8 mg\r\ntablet30 minutes before chemotherapy followed by an 8 mg dose 8 hours later.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Day 2</strong>: Aprepitant 80\r\nmg orally, 5-HT3 antagonist (Ondansetron): 8 mg tablet twice a day<o:p></o:p></p><p class=\"MsoNormal\"><strong>Day 3</strong>: Aprepitant 80\r\nmg orally, 5-HT3 antagonist (Ondansetron): 8 mg tablet twice a day.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">Apridex is administered orally 1\r\nhour prior to chemotherapy treatment on Day 1 and in the morning on Days 2 and\r\n3.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">Dexamethasone is administered 30\r\nminutes prior to chemotherapy treatment on Day 1. The dose of dexamethasone<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">accounts for drug interactions.\r\nApridex may be taken with or without food. No dosage adjustment is necessary\r\nfor<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">the elderly patients. Patients\r\nwith Renal Impairment- No dosage adjustment isnecessary for patients with renal\r\nimpairment or for patients with end stage renal disease (ESRD) undergoing\r\nhemodialysis. Patients with Hepatic Impairment-No dosage adjustment is\r\nnecessary for patients with mild to moderate hepatic impairment. There are no\r\nclinical data in patients with severe hepatic impairment. Or, as directed by\r\nthe registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"> <strong>Use in pregnancy\r\nand lactation :</strong>Pregnancy: Pregnancy Category B. There are no adequate and well\r\ncontrolled</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">studies in pregnant\r\nwomen. Aprepitant should be used during pregnancy only if clearly needed. It is\r\nnot known<o:p></o:p></p><p class=\"MsoNormal\">whether this drug is excreted in human\r\nmilk.<o:p></o:p></p><p><strong>Packing\r\n:</strong>Each box\r\ncontains 1 x 5’s capsules in blisterpack.</p>",
    "strength": "40",
    "uom": "mg",
    "categoryId": "39",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1684651317Apridex Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745120800Apridex-40.png"
    ]
  },
  {
    "id": "1368",
    "name": "Aprila",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition :  <br></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong><span></span>Aprila-10 Tablet: </strong>Each Film Coated\r\nTablet Contains Apremilast INN 10 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong><span></span>Aprila Tablet: </strong>Each Film Coated\r\nTablet Contains Apremilast INN 30 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications : </strong>Apremilast is\r\nindicated for the treatment of adult patients with active psoriatic arthritis\r\nand patients with moderate to severe plaque psoriasis who are candidates for\r\nphototherapy or systemic therapy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration : </strong></p><p class=\"MsoNormal\" xss=\"removed\">To reduce risk of gastrointestinal\r\nsymptoms, titrate to recommended</p><p class=\"MsoNormal\" xss=\"removed\">dose of 30 mg twice daily starting\r\non day 6 according to the following 5 day titration schedule :</p><p class=\"MsoNormal\" xss=\"removed\">Day 1: 10 mg in morning.</p><p class=\"MsoListParagraphCxSpFirst\" xss=\"removed\">·        \r\nDay\r\n2: 10 mg in morning and 10 mg in evening.</p><p class=\"MsoListParagraphCxSpMiddle\" xss=\"removed\">·        \r\nDay\r\n3: 10 mg in morning and 20 mg in evening.</p><p class=\"MsoListParagraphCxSpMiddle\" xss=\"removed\">·        \r\nDay\r\n4: 20 mg in morning and 20 mg in evening.</p><p class=\"MsoListParagraphCxSpMiddle\" xss=\"removed\">·        \r\nDay\r\n5: 20 mg in morning and 30 mg in evening.</p><p class=\"MsoListParagraphCxSpLast\" xss=\"removed\">·        \r\nDay\r\n6 and thereafter: 30 mg twice daily.<strong>      <br></strong></p><p class=\"MsoListParagraph\" xss=\"removed\"><strong>      Dosage in Severe Renal Impairment:</strong> <span></span>Recommended\r\ndose is 30 mg once daily.</p><p class=\"MsoNormal\" xss=\"removed\"><span></span>Or, as directed by the registered\r\nphysician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy\r\nand lactation : </strong><strong>Pregnancy\r\ncategory C</strong>. There are no adequate and wellcontrolled studies in pregnant\r\nwoman. This product should be used during pregnancy only if the potential\r\nbenefit justifies the potential risk to the fetus. It is not known whether this\r\nmedicine is excreted in human milk. Caution should be exercised when this product\r\nis administered to a nursing woman.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing : Aprila-10\r\nTablet: </strong>Each\r\nbox contains 1x14's tablets in blister pack.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>                 Aprila Tablet: </strong>Each\r\nbox contains 1x14's tablets in blister pack.</p>",
    "strength": "30,10",
    "uom": "mg",
    "categoryId": "117",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1557120412Aprila 30 & 10 Tablet - Insert Corr.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1557120412Aprila 30mg- Carton Pic.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1557120412Aprila 10mg- Carton Pic.png"
    ]
  },
  {
    "id": "1355",
    "name": "Aqua Care",
    "description": "<p><strong>Composition :</strong> Urea 100 mg.</p><p><br><strong>Indications :</strong> Urea cream is indicated for Ichthyosis and dry skin conditions,cracked skin of feet, management of eczemas, management of psoriasis.</p><p><br><strong>Dosage and administration : </strong>Urea cream is applied topically. Wash affected areas well, rinse off all traces of soap, dry and apply sparingly twice daily.Occlusive dressings may be used, but are usually unnecessary because of the self-occlusive nature of the cream. Or as directed by the registered physician.</p><p><strong>Side effects :</strong> No serious toxicity has been reported with topical urea.Historically it is considered a safe drug.But on some occasions, topical urea has  been shown to cause burning and irritation, if applied to inflamed, broken or exudative skin eruptions.</p><p><strong>Use in Pregnancy and lactation :</strong> Urea cream can be used during pregnancy<br>and lactation.</p><p><br></p><p><strong>Packing : Aqua Care Cream :</strong> 30 gram in a tube.<br></p>",
    "strength": "30",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1546847675Aqua Care..pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745304910Aqua Care 30gm.png"
    ]
  },
  {
    "id": "1294",
    "name": "Ardium",
    "description": "<p><strong>Composition :</strong><span class=\"redactor-invisible-space\"> Each film coated tablet\r\ncontains Micronised purified flavonoid\r\nfraction 500mg (Diosmin BP 450mg and\r\nHesperidin BP 50mg).</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Indications : </strong><span class=\"redactor-invisible-space\">This medicine is venotonic\r\n(it increases venous tone) and a\r\nvasculoprotector (it increases resistance\r\nin small blood vessels). It is\r\nrecommended for treating venous\r\ncirculation disorders (swelling leg, pain,\r\nrestless legs) and for treating symptoms\r\ndue to acute hemorrhoidal attack.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Venous\r\nInsufficiency: 2 tablets daily, one at\r\nmidday and one at night upto 2 months.\r\nAcute hemorrhoidal attack: 6 tablets\r\ndaily for the first 4 days followed by 4\r\ntablets daily for the next 3 days. Chronic\r\nhemorrhoidal attack: 2 tablets daily.\r\nThe tablets should be taken at meal\r\ntimes. Or, as directed by the registered\r\nphysician.</span><br></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">There are no adequate and wellcontrolled\r\nstudies in pregnant women.\r\nThis drug should be used during\r\npregnancy only if clearly needed.\r\nBreastfeeding is not recommended\r\nduring the treatment period.</span><br></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Packing :</strong><span class=\"redactor-invisible-space\"> 3x10's\r\ntablets in blister pack.</span><br></span></span></span></span></p>",
    "strength": "500",
    "uom": "mg",
    "categoryId": "106",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633323424Ardium.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744020079Ardium.png"
    ]
  },
  {
    "id": "717",
    "name": "ASLOR ",
    "description": "<p><strong>Composition :</strong> Desloratadine INN 5mg Tablet. <strong></strong></p><p style=\"text-align: justify;\"><strong>Indications : </strong>Allergic Rhinitis :\r\nDesloratadine is indicated for the relief of\r\nthe nasal and non-nasal symptoms of\r\nallergic rhinitis (seasonal and perennial)\r\nin patients 12 years of age or older.\r\nChronic Idiopathic Urticaria :\r\nDesloratadine is indicated for the\r\nsymptomatic relief of pruritus, reduction\r\nin the number of hives and size of hives\r\nin patients with Chronic Idiopathic\r\nUrticaria 12 years of age and older Rhinitis :\r\nDesloratadine is indicated for the relief of\r\nthe nasal and non-nasal symptoms of\r\nallergic rhinitis (seasonal and perennial)\r\nin patients 12 years of age or older.\r\nChronic Idiopathic Urticaria :\r\nDesloratadine is indicated for the\r\nsymptomatic relief of pruritus, reduction\r\nin the number of hives and size of hives\r\nin patients with Chronic Idiopathic\r\nUrticaria 12 years of age and older.<strong><br></strong></p><p style=\"text-align: justify;\"><strong>Dosage and Administration :</strong>  Adults and\r\n12 years of age or older children 5mg\r\nonce daily. Child 6-11 years: 2.5mg once\r\ndaily, 1-5 years: 1.25mg once daily.\r\nPatients with liver or renal impairment : A\r\nstarting dose of one Aslor tablet\r\n(Desloratadine 5mg) every other day is\r\nrecommended. Or, as directed by the\r\nregistered physician.<br></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong> Desloratadine has been assigned to\r\n<strong></strong>pregnancy category C by the FDA.<br></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Aslor tablet : 10 x 10's tablets\r\nin blister pack.</span><br></p>",
    "strength": "5",
    "uom": "mg",
    "categoryId": "41",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530943466ASLOR.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744020138Aslor.png"
    ]
  },
  {
    "id": "991",
    "name": "AV",
    "description": "<p xss=\"removed\"><strong>Composition : </strong>AV 5/80:<strong> </strong><span class=\"redactor-invisible-space\">Amlodipine 5 mg + Valsartan 80mg Tablet.<br></span></p><p xss=\"removed\" style=\"text-align: justify;\" rel=\"text-align: justify;\">AV 5: <span class=\"redactor-invisible-space\">Amlodipine 5 mg + Valsartan 160mg </span> <span class=\"redactor-invisible-space\">Tablet.<br></span></p><p xss=\"removed\" style=\"text-align: justify;\" rel=\"text-align: justify;\">AV 10: <span class=\"redactor-invisible-space\">Amlodipine 10 mg + Valsartan 160mg </span> <span class=\"redactor-invisible-space\"></span><span class=\"redactor-invisible-space\">Tablet.</span></p><p xss=\"removed\" style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This tablet is indicated for the\r\ntreatment of hypertension : In patients not adequately controlled on\r\nmonotherapy. As initial therapy in patients likely to need\r\nmultiple drugs to achieve their blood\r\npressure goals.</span></p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Amlodipine\r\nis an effective treatment of hypertension in\r\nonce daily doses of 2.5mg-10mg while\r\nvalsartan is effective in doses of 80mg-\r\n320mg. In clinical trials with amlodipine\r\nand valsartan, the antihypertensive effects\r\nincreased with increasing doses. Or, as\r\ndirected by the registered physician.</span></p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy Category- Amlodipine-C\r\nValsartan-D by FDA.</span></p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">: AV-5/80 : 3x14's tablets in blister\r\npack.\r\n<br></span></p><p xss=\"removed\" style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">AV-10 : 2x10's tablets in blister pack. \r\n<br></span></p><p xss=\"removed\" style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">AV-5 : 2x10's tablets in blister pack.</span></p>",
    "strength": "5+80,10+160,5+160",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530944660AV.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/AV-580.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/AV-10.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/AV-5.jpg"
    ]
  },
  {
    "id": "1835",
    "name": "Avalet -20",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong> Each film coated\r\ntablet contains Avatrombopag 20mg as Avatrombopag Maleate INN.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications : </strong><strong>Treatment of Thrombocytopenia in\r\nPatients with Chronic Liver Disease (CLD): </strong>It is indicated for the treatment\r\nof<strong> </strong>thrombocytopenia in adult patients with chronic liver disease who<strong> </strong>are\r\nscheduled to undergo a procedure. <strong>Treatment of<o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Thrombocytopenia\r\nin Patients with Chronic Immune Thrombocytopenia (ITP): </strong>It is indicated\r\nfor the treatment of<strong> </strong>thrombocytopenia in adult patients with chronic\r\nimmune<strong> </strong>thrombocytopenia who have had an insufficient response to a<strong> </strong>previous\r\ntreatment.<strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage & Administration :</strong><strong> Recommended\r\nDosage for Patients with Chronic Liver Disease:<o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Table 1:\r\nRecommended Dose and Duration in Patients with Chronic Liver Disease Scheduled\r\nto Undergo a Procedure<o:p></o:p></p><table class=\"MsoTableGrid\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\" style=\"margin-left: 63.9pt;\">\r\n <tbody><tr>\r\n  <td width=\"150\" valign=\"top\" style=\"width: 112.5pt; border-width: 1pt; border-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal;mso-layout-grid-align:none;text-autospace:\r\n  none\"><strong>Platelet\r\n  Count<o:p></o:p></strong></p>\r\n  </td>\r\n  <td width=\"114\" valign=\"top\" style=\"width: 85.5pt; border-top-width: 1pt; border-right-width: 1pt; border-bottom-width: 1pt; border-top-color: black; border-right-color: black; border-bottom-color: black; border-left: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Once Daily\r\n  Dose</strong><o:p></o:p></p>\r\n  </td>\r\n  <td width=\"96\" valign=\"top\" style=\"width: 1in; border-top-width: 1pt; border-right-width: 1pt; border-bottom-width: 1pt; border-top-color: black; border-right-color: black; border-bottom-color: black; border-left: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Duration</strong><o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"150\" valign=\"top\" style=\"width: 112.5pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Less than 40 X\r\n  109/L<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"114\" valign=\"top\" style=\"width: 85.5pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">60 mg (3\r\n  tablets)<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"96\" valign=\"top\" style=\"width: 1in; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">5 days<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"150\" valign=\"top\" style=\"width: 112.5pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">40 to less\r\n  than 50 109/L<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"114\" valign=\"top\" style=\"width: 85.5pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">40 mg (2\r\n  tablets)<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"96\" valign=\"top\" style=\"width: 1in; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">5 days<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Recommended\r\nDosage for Patients With Chronic Immune<o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Thrombocytopenia:\r\n</strong>Initial\r\nDose Regimen: Begin Avatrombopag at a starting dose of 20mg (1tablet) once\r\ndaily with food. Table 2: Avatrombopag Dose Adjustments for Patients with\r\nChronic Immune Thrombocytopenia.<o:p></o:p></p><table class=\"MsoTableGrid\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\r\n <tbody><tr>\r\n  <td width=\"247\" valign=\"top\" style=\"width: 185.4pt; border-width: 1pt; border-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Platelet Count</strong><o:p></o:p></p>\r\n  </td>\r\n  <td width=\"391\" valign=\"top\" style=\"width: 293.4pt; border-top-width: 1pt; border-right-width: 1pt; border-bottom-width: 1pt; border-top-color: black; border-right-color: black; border-bottom-color: black; border-left: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dose\r\n  Adjustment or Action</strong><o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"247\" valign=\"top\" style=\"width: 185.4pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Less than 50\r\n  after at least 2 weeks of Avatrombopag x 109/L<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"391\" valign=\"top\" style=\"width: 293.4pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">-Increase One Dose Level per Table 3.Wait 2 weeks to assess the\r\n  effects of this regimen and any subsequent dose adjustments<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"247\" valign=\"top\" style=\"width: 185.4pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Between 200\r\n  and 400 x 109/L<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"391\" valign=\"top\" style=\"width: 293.4pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">-Decrease One Dose Level per Table\r\n  3.Wait 2 weeks to assess the effects of this regimen and any subsequent dose\r\n  adjustments.<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"247\" valign=\"top\" style=\"width: 185.4pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Greater than\r\n  400 x 109/L<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"391\" valign=\"top\" style=\"width: 293.4pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">-Stop Avatrombopag. Increase platelet\r\n  monitoring to twice weekly.<o:p></o:p></p>\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">-When platelet count is less than 150\r\n  x109/L, decrease One Dose Level per Table 3 and reinitiate therapy<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"247\" valign=\"top\" style=\"width: 185.4pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Less than 50\r\n  after 4 weeks of<o:p></o:p></p>\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Avatrombopag\r\n  40 mg once daily x 109/L<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"391\" valign=\"top\" style=\"width: 293.4pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Discontinue\r\n  Avatrombopag.<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"247\" valign=\"top\" style=\"width: 185.4pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Greater than\r\n  400 after 2 weeks of<o:p></o:p></p>\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Avatrombopag\r\n  20 mg weekly x 109/L<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"391\" valign=\"top\" style=\"width: 293.4pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Discontinue\r\n  Avatrombopag.<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Table 3:\r\nAvatrombopag Dose Levels for Titration in Patients with Chronic Immune\r\nThrombocytopenia<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Table 4:\r\nAvatrombopag Recommended Starting Dose for Patients with Chronic Immune\r\nThrombocytopenia Based on Concomitant Medications.<o:p></o:p></p><table class=\"MsoTableGrid\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\" style=\"margin-left: 18.9pt;\">\r\n <tbody><tr>\r\n  <td width=\"210\" valign=\"top\" style=\"width: 157.5pt; border-width: 1pt; border-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Concomitant\r\n  Medications</strong><o:p></o:p></p>\r\n  </td>\r\n  <td width=\"210\" valign=\"top\" style=\"width: 157.5pt; border-top-width: 1pt; border-right-width: 1pt; border-bottom-width: 1pt; border-top-color: black; border-right-color: black; border-bottom-color: black; border-left: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Recommended\r\n  Starting Dose</strong><o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"210\" valign=\"top\" style=\"width: 157.5pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Moderate or\r\n  strong dual inhibitors<o:p></o:p></p>\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">of CYP2C9 and\r\n  CYP3A4<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"210\" valign=\"top\" style=\"width: 157.5pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">20 mg (1\r\n  tablet) three times a week<o:p></o:p></p>\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">40 mg (2\r\n  tablets) once daily<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"210\" valign=\"top\" style=\"width: 157.5pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Moderate or\r\n  strong dual inducers<o:p></o:p></p>\r\n  <p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\n  justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">of CYP2C9 and\r\n  CYP3A4<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"210\" valign=\"top\" style=\"width: 157.5pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  \r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\" style=\"margin-bottom: 5.35pt; line-height: normal; background-image: initial; background-color: white;\">For Detail  Please see  PDF File.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Or, as directed\r\nby the registered physician<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use in pregnancy and lactation :</strong><strong> </strong>Pregnant women\r\nshould be advised of the potential risk to a fetus. Females of reproductive\r\npotential should be advised to inform their prescriber of a known or suspected\r\npregnancy. <strong>Nursing Mother: </strong>Women should be advised not to breastfeed\r\nduring treatment with Avatrombopag and for at least 2 weeks after the final\r\ndose.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Packing : </strong>Each box contains 10's tablets in blister pack.<br></p>",
    "strength": "20",
    "uom": "mg",
    "categoryId": "101",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1659608371Avalet-20 book style  Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1659608371Avalet-20 Carton.png"
    ]
  },
  {
    "id": "1767",
    "name": "Avalet-20",
    "description": "<p class=\"MsoNormal\">Avatrombopag(<span lang=\"ZH-CN\">阿伐曲波帕</span> ) INN 20mg<span lang=\"ZH-CN\">片剂</span>Avalet\r\n-20</p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">组成</span>:<span lang=\"ZH-CN\">每片薄膜包衣片含马来酸阿维菌素</span>20mg</p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">药理学</span>:Avatrombopag <span lang=\"ZH-CN\">是一种口服生物利用的小分子</span>TPO<span lang=\"ZH-CN\">受体激动剂</span>,<span lang=\"ZH-CN\">可刺激骨髓祖细胞巨核细胞的增殖和分化</span>,<span lang=\"ZH-CN\">从而增加血小板的生成。中位最高浓度时间</span>(Tmax)<span lang=\"ZH-CN\">出现在给药后</span>5~6<span lang=\"ZH-CN\">小时。</span>Avatrombopagl\r\n<span lang=\"ZH-CN\">的平均分布容积</span>(C<span lang=\"ZH-CN\">估计为</span>180<span lang=\"ZH-CN\">升</span>(25%)Avatrombopag-<span lang=\"ZH-CN\">与人血浆蛋白的结合率大于</span>96%avatrombopag\r\n<span lang=\"ZH-CN\">的平均血浆消除半衰期</span>(%CV<span lang=\"ZH-CN\">约为</span>19<span lang=\"ZH-CN\">小时</span>(19%)<span lang=\"ZH-CN\">。</span>avatrombopag\r\n<span lang=\"ZH-CN\">清除率的平均值</span>(%C)<span lang=\"ZH-CN\">估计为</span>6.9/hr(29%)Avatromopag\r\n<span lang=\"ZH-CN\">主要由细胞色素</span>P450<span lang=\"ZH-CN\">、</span>yP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">代谢粪便排泄量占给药剂量的</span>88%,<span lang=\"ZH-CN\">其中</span>34%<span lang=\"ZH-CN\">以无变化的</span>Avatronopag\r\n<span lang=\"ZH-CN\">形式排出。只有</span>6%<span lang=\"ZH-CN\">的给药剂量是在尿液中发现的</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">适应症</span>:<span lang=\"ZH-CN\">慢性肝病患者血小板减少症</span>(CLD)<span lang=\"ZH-CN\">的治疗</span>:<span lang=\"ZH-CN\">适用于计划接受手术的成人慢性肝病患者血小板减少症的治疗。慢性免疫性血小板减少症</span>(ITP)<span lang=\"ZH-CN\">患者血小板减少症的治疗</span>:<span lang=\"ZH-CN\">适用于对既往治疗反应不足的成人慢性免疫性血小板减少症患者血小板减少症的治疗。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">剂量与给药</span>:<span lang=\"ZH-CN\">慢性肝病患者推荐剂量</span>:</p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>1:<span lang=\"ZH-CN\">计划接受手术的慢性肝病患者的推荐剂量和持续时间</span></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\">\r\n <tbody><tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"189\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">血小板计数</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"189\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每日一次</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"189\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">时长</span></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"189\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">小于</span> 40×10₉/L</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"189\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">60mg (3<span lang=\"ZH-CN\">片剂</span>)</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"189\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">5<span lang=\"ZH-CN\">天</span></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"189\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">40 <span lang=\"ZH-CN\">小于</span>50 10₉/L</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"189\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">40mg (2<span lang=\"ZH-CN\">片剂</span>)</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"189\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">5<span lang=\"ZH-CN\">天</span></p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">慢性免疫性血小板减少症患者的推荐剂量：初始剂量方案：开始剂量为</span>20mg<span lang=\"ZH-CN\">（</span>1<span lang=\"ZH-CN\">片）的</span>Avatromopag<span lang=\"ZH-CN\">，每天随食物服用一次。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>2<span lang=\"ZH-CN\">：慢性免疫性血小板减少症患者的</span>Avatrombopag<span lang=\"ZH-CN\">剂量调整</span></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\"><tbody><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">血小板计数</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">剂量调整或作用</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">使用</span>Avatrombopag x10 9/L<span lang=\"ZH-CN\">至少</span>2<span lang=\"ZH-CN\">周后少于</span>50</p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">根据表</span>3<span lang=\"ZH-CN\">增加一个剂量水平。</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">等待</span>2<span lang=\"ZH-CN\">周以评估此方案的效果和随后的剂量调整。</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">200<span lang=\"ZH-CN\">到</span>400×10\r\n  9/L<span lang=\"ZH-CN\">之间</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">根据表</span>3<span lang=\"ZH-CN\">减少一个剂量水平。</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">我等了</span>2<span lang=\"ZH-CN\">周来评估这个方案的效果和随后的剂量调整。</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">大于</span>400 10 9/L</p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">停止阿伐曲波帕</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">增加血小板监测到每周两次。</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">当血小板计数低于</span>150x10 9/L<span lang=\"ZH-CN\">时，根据表</span>3<span lang=\"ZH-CN\">减少一个剂量水平并重新开始治疗。</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">4<span lang=\"ZH-CN\">周后少于</span>50<span lang=\"ZH-CN\">每天服用一次</span>40<span lang=\"ZH-CN\">毫克</span>X\r\n  10 9/L <span lang=\"ZH-CN\">阿伐曲波帕</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">停止阿伐曲波帕</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">2<span lang=\"ZH-CN\">周后大于</span>400<span lang=\"ZH-CN\">每周服用</span>20<span lang=\"ZH-CN\">毫克阿伐曲波帕</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">停止阿伐曲波帕</span></p></td></tr></tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>3<span lang=\"ZH-CN\">：用于慢性免疫性血小板减少症患者滴定的</span>Avatrombopag<span lang=\"ZH-CN\">剂量水平</span></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\">\r\n <tbody><tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">剂量</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">剂量水平</span></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每日</span>40<span lang=\"ZH-CN\">毫克</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">6</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每周</span>3<span lang=\"ZH-CN\">次，每次</span>40<span lang=\"ZH-CN\">毫克，每周剩余</span>4<span lang=\"ZH-CN\">天服用</span>20<span lang=\"ZH-CN\">毫克</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">5</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每日</span>20<span lang=\"ZH-CN\">毫克</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">4</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">20<span lang=\"ZH-CN\">毫克每周三次</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">3</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每周两次服用</span>20<span lang=\"ZH-CN\">毫克或每周服用</span>40<span lang=\"ZH-CN\">毫克</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">2</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">20<span lang=\"ZH-CN\">毫克每周</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">1</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td colspan=\"2\" xss=\"removed\" width=\"568\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">*<span lang=\"ZH-CN\">除</span>CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">中、强双重抑制剂或中、强双重抑制剂外，所有患者的初始剂量方案</span></p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>4<span lang=\"ZH-CN\">：基于联合用药的慢性免疫性血小板减少症患者的</span>Avatrombopag<span lang=\"ZH-CN\">推荐起始剂量</span><a name=\"_GoBack\"></a></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\">\r\n <tbody><tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">联合用药</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">推荐起始剂量</span></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">的中度或强双重抑制物</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">20mg<span lang=\"ZH-CN\">（</span>1<span lang=\"ZH-CN\">片），每周</span>3<span lang=\"ZH-CN\">次</span></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">的模式比率或强双产业</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"284\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">40mg<span lang=\"ZH-CN\">（</span>2<span lang=\"ZH-CN\">片），每日</span></p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">或按照注册医生的指示。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">禁忌：对</span>Avatronopag<span lang=\"ZH-CN\">或本品任何成分过敏的患者禁用。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">预防措施：血栓性</span>/<span lang=\"ZH-CN\">血栓栓塞性并发症：</span>Avatrombopag<span lang=\"ZH-CN\">是血小板生成素（</span>TPO<span lang=\"ZH-CN\">）受体激动剂，</span>TPO<span lang=\"ZH-CN\">受体激动剂与慢性肝病或慢性免疫性血小板减少症患者的血栓性和血栓塞性并发症有关。监测血小板计数和血栓栓塞事件，并及时进行治疗。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">副作用：在慢性肝病患者中，最常见的不良反应是发热、腹痛、恶心、头痛、疲劳和周围水肿。在慢性免疫性血小板减少症患者中，最常见的不良反应是头痛、疲劳、神志不清、鼻出血、上呼吸道感染、关节痛、牙龈出血、瘀斑和鼻咽炎。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">在怀孕和哺乳期使用：孕妇应被告知对胎儿的潜在风险。具有生殖潜力的女性应告知其处方医生已知或疑似怀孕。哺乳期母亲：建议妇女在使用</span>Avatrombopag<span lang=\"ZH-CN\">治疗期间和最后一次给药后至少</span>2<span lang=\"ZH-CN\">周内不要母乳喂养。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">在</span>Child<span lang=\"ZH-CN\">中使用：没有可用的数据。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">药物相互作用：在接受</span>Avatrombopag<span lang=\"ZH-CN\">的同时开始中度或重度</span>CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">双重抑制剂治疗的患者，监测血小板计数并根据需要调整</span>Avatrombopag<span lang=\"ZH-CN\">的剂量。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">过量：没有可用的数据。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">贮存：在</span>30℃<span lang=\"ZH-CN\">以下干燥处贮存。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">包装：每盒含</span>28<span lang=\"ZH-CN\">片泡罩包装。</span></p>",
    "strength": "20",
    "uom": "mg",
    "categoryId": "101",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745639680avalet26052025.jpeg"
    ]
  },
  {
    "id": "893",
    "name": "Avro ",
    "description": "<p><strong></strong><strong>Composition : </strong>Travoprost USP 0.04mg/ml.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is indicated for the\r\nreduction of elevated intraocular\r\npressure in patients with open-angle\r\nglaucoma.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adults :\r\nOne drop in the affected eye once daily\r\nin the evening. The dosage of travoprost\r\nshould not exceed once daily since it has\r\nbeen shown that more frequent\r\nadministration may decrease the normal\r\nintraocular pressure. Paediatric patients:\r\nThe efficacy and safety of travoprost eye\r\ndrops patients below the age of 18 years\r\nhave not been established. Or, as\r\ndirected by the registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy category C by FDA.</p><p style=\"text-align: justify;\"><strong>Packing : </strong>3ml in plastic dropper bottle.</p>",
    "strength": "0.004%",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530944905Avro_eyedrops.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/AvroBoxPic.jpg"
    ]
  },
  {
    "id": "1217",
    "name": "AZIMEX Suspension",
    "description": "<p><strong>Composition : </strong>Azithromycin USP 200mg/5ml Suspension.</p><p style=\"text-align: justify;\"><strong>Indication : </strong>Azithromycin is indicated for the treatment of Acute bacterial exacerbations of chronic obstructive pulmonary disease, Acute bacterial sinusitis, Community acquired pneumonia due to Chlamydia pneumoniae. Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. It is also indicated for pharyngitis, tonsillitis, uncomplicated skin and skin structure infections, urethritis and cervicitis and Genital ulcer disease.<br></p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> Please see prescribing description.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation</strong> : Azithromycin has been assigned to pregnancy category B by the FDA.</p><p style=\"text-align: justify;\"><strong>Packing :</strong><br></p><p style=\"text-align: justify;\">Azimex Suspension : 15ml, 30ml and 50ml suspension.</p>",
    "strength": "50,30,15",
    "uom": "mg/5ml",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530945210azimex.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121641Azimex-50 ml.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745121641Azimex-3OML.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745121641Azimex-15ml.png"
    ]
  },
  {
    "id": "752",
    "name": "AZIMEX Tablet",
    "description": "<p><strong></strong><strong>Composition :</strong> Azithromycin USP 250 mg & 500 mg Tablet. </p><p style=\"text-align: justify;\"><strong>Indication : </strong>Azithromycin is indicated for the treatment of\r\nAcute bacterial exacerbations of chronic obstructive pulmonary disease, Acute bacterial sinusitis, Community\r\nacquired pneumonia due to Chlamydia pneumoniae.\r\nHaemophilus influenzae, Mycoplasma pneumoniae or\r\nStreptococcus pneumoniae in patients appropriate for oral\r\ntherapy. It is also indicated for pharyngitis, tonsillitis,\r\nuncomplicated skin and skin structure infections, urethritis\r\nand cervicitis and Genital ulcer disease.<br></p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> Please see prescribing description.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation</strong> : Azithromycin has been\r\nassigned to pregnancy category B by the FDA.</p><p style=\"text-align: justify;\"><strong>Packing :</strong><br></p><p style=\"text-align: justify;\">Azimex-250 Tablet : 1 x 10's tablet in blister pack. </p><p style=\"text-align: justify;\">Azimex-500 Tablet : 2 x 5's tablet in blister pack. </p><p style=\"text-align: justify;\"><br><strong></strong></p>",
    "strength": "500,250",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530945354azimex.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121671Azimex-500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745121671Azimex-250.png"
    ]
  },
  {
    "id": "858",
    "name": "Bacmax",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Baclofen USP 5 mg & 10 mg\r\nTablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Baclofen is useful for the\r\nalleviation of signs and symptoms of\r\nspasticity resulting from multiple\r\nsclerosis, particularly for the relief of\r\nflexor spasms and concomitant pain,\r\nclonus and muscular rigidity.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The\r\ndetermination of optimal dosage requires\r\nindividual titration. Starting therapy at a low\r\ndosage and increase gradually until\r\noptimum effect is achieved (usually\r\nbetween 40-80mg daily). The following\r\ndosage titration schedule is suggested :</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\n5mg t.i.d. for </span>3 days</p><p style=\"text-align: justify;\">\r\n10mg t.i.d. for 3 days</p><p style=\"text-align: justify;\">\r\n15mg t.i.d. for 3 days </p><p style=\"text-align: justify;\">20mg t.i.d. for 3 days </p><p style=\"text-align: justify;\">Thereafter additional increased dose may be\r\nnecessary but the total daily dose should\r\nnot exceed a maximum of 80mg daily\r\n(20mg q.i.d.). Or, as directed by the\r\nregistered physician.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy Category-C. There are no\r\nadequate and well-controlled studies in\r\npregnant women. Baclofen should be\r\nused during pregnancy only if the\r\npotential benefit justifies the potential risk\r\nto the fetus. It is not known whether this\r\ndrug is excreted in human milk. Because\r\nmany drugs are excreted in human milk,\r\ncaution should be exercised when\r\nbaclofen is administered to a nursing\r\nwoman.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Bacmax-5 : 4x14's tablets\r\nin blister pack.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nBacmax-10 : 2x14's tablets in blister\r\npack.</span></p>",
    "strength": "10,5",
    "uom": "mg",
    "categoryId": "55",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530945710bacmax.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121893Bacmax-10.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745121893Bacmax-5.png"
    ]
  },
  {
    "id": "1858",
    "name": "Barinib",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph\"><strong>Composition:\r\nBarinib-2 Tablet: </strong>Each film coated tablet contains\r\nBaricitinib INN 2.00 mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph\"><strong>Barinib-4\r\nTablet: </strong>Each film coated tablet contains Baricitinib INN 4.00\r\nmg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal\"><strong>Indications: </strong>Baricitinib is a\r\nJanus kinase (JAK) inhibitor indicated for the treatment of adult patients with\r\nmoderately to severely active rheumatoid arthritis who have had an inadequate response\r\nto one or more TNF blockers. Limitation of Use: • Not recommended for use in combination\r\nwith other JAK inhibitors, biologic DMARDs, or with potent immunosuppressant’s such\r\nas azathioprine and cyclosporine. • For the treatment of COVID-19 in\r\nhospitalized adults requiring supplemental oxygen, non-invasive or invasive\r\nmechanical ventilation, or ECMO. • It is indicated for the treatment of adult\r\npatients with severe alopecia areata.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph\"><strong>Dosage\r\nand Administration: Administration Instruction:</strong>\r\n* <strong>Rheumatoid Arthritis and Alopecia\r\nAreata:</strong> Should be avoid initiation or interrupt Barinib in patients with anemia.\r\n<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph\">* <strong>COVID-19:</strong> Should be avoid initiation or interrupt Barinib in\r\npatients with lymphopenia.<strong> <o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph\"><strong>Recommended\r\nDosage:</strong> <strong>Rheumatoid\r\nArthritis:</strong> 2 mg once daily. Barinib may be used as monotherapy or in\r\ncombination with methotrexate or other non-biologic DMARDs. <strong>COVID-19:</strong> 4 mg once daily for up to 14\r\ndays. <strong>Alopecia Areata:</strong> 2 mg once\r\ndaily. Increase to 4 mg once daily, if the response to treatment is not\r\nadequate. For patients with nearly complete or complete scalp hair loss, with\r\nor without substantial eyelash or eyebrow hair loss, consider treating with 4\r\nmg once daily. Or, as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal\"><strong>Administration instruction: • </strong>Rheumatoid\r\nArthritis and Alopecia Areata: Avoid initiation or interrupt Barinib in\r\npatients with anemia (hemoglobin &lt;8 g/dL) or neutropenia (ANC &lt;1000 cells/mm3).\r\n• COVID-19: Avoid initiation or interrupt Barinib in patients with lymphopenia\r\n(ALC &lt;200 cells/mm3) or neutropenia (ANC &lt;500 cells/mm3).<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal\"><strong>Use in Pregnancy and lactation: </strong>Pregnancy: This\r\nmedicine may cause fetal harm. Lactation: Advise not to breastfeed.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal\"><strong>Packing: <o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal\"><strong>Barinib-2 Tablet: </strong>Each box\r\ncontains 10's tablet in a blister pack.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal\"><strong>Barinib-4 Tablet: </strong>Each box\r\ncontains 10's tablet in a blister pack.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><strong> </strong></p><p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal\"><strong> </strong><br></p><p class=\"MsoNormal\" xss=\"removed\"><o></o></p><p><strong> </strong></p>",
    "strength": " 4,2",
    "uom": "mg",
    "categoryId": "107",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745122234Barinib-4.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745122234Barinib-2.png"
    ]
  },
  {
    "id": "1850",
    "name": "Barinib",
    "description": "<p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal\"><strong>Composition: </strong>Each film coated\r\ntablet contains Baricitinib INN 2.00 mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal\"><strong>Indication: </strong>Baricitinib is a\r\nJanus kinase (JAK) inhibitor indicated for the treatment of adult patients with\r\nmoderately to severely active rheumatoid arthritis who have had an inadequate response\r\nto one or more TNF blockers. Limitation of Use: • Not recommended for use in combination\r\nwith other JAK inhibitors, biologic DMARDs, or with potent immunosuppressant’s such\r\nas azathioprine and cyclosporine. • For the treatment of COVID-19 in\r\nhospitalized adults requiring supplemental oxygen, non-invasive or invasive\r\nmechanical ventilation, or ECMO. • It is indicated for the treatment of adult\r\npatients with severe alopecia areata.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal\"><strong>Dosage and administration: </strong>The recommended\r\ndose of Barictinib is 2 mg once daily. It may be used as monotherapy or in\r\ncombination with methotrexate or other DMARDs. It is given orally with or\r\nwithout food. Lymphopenia: It should be avoided the initiation or interrupt in\r\npatients with an Absolute Lymphocyte Count less than 500 cells/mm3. Alopecia\r\nAreata: 2mg once daily. Increase to 4mg once daily, if the response to\r\ntreatment is not adequate. Or, as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal\"><strong>Administration instruction: • </strong>Rheumatoid\r\nArthritis and Alopecia Areata: Avoid initiation or interrupt Barinib in\r\npatients with anemia (hemoglobin&lt;8 g/dL) or neutropenia (ANC &lt;1000 cells/mm3).\r\n<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal\">•\r\nCOVID-19: Avoid initiation or interrupt Barinib in patients with lymphopenia\r\n(ALC &lt;200 cells/mm3) or neutropenia (ANC &lt;500 cells/mm3).<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal\"><strong>Use in Pregnancy and lactation: </strong>Pregnancy: This\r\nmedicine may cause fetal harm. Lactation: Advise not to breastfeed.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal\"><strong>Packing: </strong>Each box\r\ncontains 60's tablets in a blister pack.<br></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph\"><o:p></o:p></p>",
    "strength": "2",
    "uom": "mg",
    "categoryId": "107",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1663237541Barinib 2 (Export)  Web Insert (15-09-22).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1748509583Barinib Carton.png"
    ]
  },
  {
    "id": "744",
    "name": "BECOVENT  HFA Inhaler",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Each Metered dose (Puff)\r\ncontains Beclometasone Dipropionate BP 100\r\nmcg.</span><span class=\"redactor-invisible-space\"></span><strong></strong></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Becovent is indicated in the\r\nmaintenance treatment of asthma as\r\nprophylactic therapy in patients 5 years of\r\nage and older. Becovent is also indicated\r\nfor asthma patients who require systemic\r\ncorticosteroid administration, where adding\r\nBecovent may reduce or eliminate the need\r\nfor the systemic corticosteroids.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :  </strong><span class=\"redactor-invisible-space\">Becovent\r\ninhaler is for oral inhalation use only.\r\nPatients should be given a starting dose of\r\ninhaled Becovent appropriate to the\r\nseverity of their disease. The dose may\r\nthen be adjusted until control is achieved or\r\nreduced to the minimum effective dose\r\naccording to individual response.\r\nManagement of chronic asthma (Adults\r\n& Children over 12 years): 100-400 mcg\r\ntwice daily. Maximum 1000 mcg twice daily.\r\nChildren (5-12 years): 100-200 mcg twice\r\ndaily. the dose may be adjusted as\r\nnecessary</span><span class=\"redactor-invisible-space\"></span><strong><br></strong></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :  </strong><span class=\"redactor-invisible-space\">Each\r\nbox contains one inhaler of 200 Puffs.</span><br></p>",
    "strength": "100",
    "uom": "mcg/puf",
    "categoryId": "53",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530946162BECOVENT.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745301869Becovent.png"
    ]
  },
  {
    "id": "1014",
    "name": "Benzac",
    "description": "<p><strong></strong><strong>Composition : </strong>Benzoyl Peroxide 4% Cream.</p><p style=\"text-align: justify;\"><strong>Indication :</strong>: It is used alone topically for\r\nmild to moderate acne and as an adjunct\r\nin acne treatment. </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Wash and\r\ndry affected areas prior to application.\r\nApply sparingly one or more times daily.\r\nOr, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">It is\r\nnot known whether benzoyl peroxide can\r\ncause fetal harm when administered to a\r\npregnant woman or can affect\r\nreproduction capacity. Benzoyl peroxide\r\nshould be given to a pregnant woman\r\nonly if clearly needed. It is not known\r\nwhether this drug is excreted in human\r\nmilk. Because many drugs are excreted\r\nin human milk, caution should be\r\nexercised when benzoyl peroxide is\r\nadministered to a nursing woman.\r\nPregnancy Category C.</span></p><p style=\"text-align: justify;\"><strong>Packing : <em></em></strong><span class=\"redactor-invisible-space\">Benzac Cream : Each Tube\r\nContains 15gm Cream.</span></p>",
    "strength": "4%",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530951710Benzac.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745304954Benzac.png"
    ]
  },
  {
    "id": "1881",
    "name": "Betaloc",
    "description": "<p><strong>Composition:Betaloc-25<a name=\"_GoBack\"></a>:</strong> Each film coated tablet contains\r\nMetoprolol Tartrate USP 25mg.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Betaloc-50:</strong>\r\nEach tablet contains Metoprolol Tartrate USP 50mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Indication: </strong>Betaloc  is \r\nindicated  for  hypertension, \r\nangina,  arrhythmia  (including \r\narrhythmias \r\nduringanaesthesia),  early  intervention \r\nin acute myocardial \r\ninfarction,  heart  failure, \r\nmigraine  prophylaxis  and thyrotoxicosis.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Dosage & Administration</strong>:<strong>Hypertension:</strong><strong> Initially 100mg tablets daily, for maintenance therapy 100-200mg tablets\r\ndaily in 1-2 doses for adults and 25mg tablet once daily for elderly.</strong><strong>Angina:</strong> 50-100mg tablet 2-3 times daily.<strong>Arrhythmias:</strong>\r\nUsually 50mg tablet 2-3 times daily upto 300mg tablets daily in divided doses,\r\nif necessary.<strong>Myocardial \r\nInfarction  :</strong>  If \r\npatient  cannot  tolerate \r\nIV  doses  then \r\nhe/she  should  be \r\nswitched  to  oraltreatment. Starting dose for such patient\r\nis 25mg tablets 6 hourly for 48 hours.<strong>Heart Failure:</strong>  12.5-25mg once daily.  Dose is increased at intervals of 2 weeks, to\r\na maximum of 200mgonce daily.<strong>Migraine Prophylaxis:</strong> 100-200mg tablets\r\ndaily in divided doses.<strong>Thyrotoxicosis:</strong> 50mg tablet 4 times daily. Or, as\r\ndirected by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Pregnancy & Lactation</strong>: Metoprolol\r\nshould not be used in pregnancy or lactating mothers unlessthe physician\r\nconsiders that the benefit outweighs the possible hazard to the fetus or infant.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Packing: Betaloc-25: </strong>Each\r\nbox contains 7 x 14's tablets in blister pack.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Betaloc-50: </strong>Each\r\nbox contains 7 x 14's tablets in blister pack.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><br></p><h4 style=\"margin:0in;margin-bottom:.0001pt;text-align:justify\"> </h4>",
    "strength": "50,25",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1687173595",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744020309BETALOC-50.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744020309BETALOC-25.png"
    ]
  },
  {
    "id": "1882",
    "name": "Betaloc XR",
    "description": "<p><strong>Composition:Betaloc-XR-50:</strong>  Each extended release tablet contains\r\nMetoprolol Succinate USP47.5mg (eqv. to Metoprolol Tartrate 50mg).</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>BetaIoc-XR-100:</strong>\r\nEach extended release tablet containsMetoprolol Succinate USP 95mg (eqv. ToMetoprolol\r\nTartrate100mg).<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indication:\r\n</strong>Hypertension:  Extended release Metoprolol Succinate tablet  is \r\nindicated  for  thetreatment of hypertension. It may be used\r\nalone or in combination with other antihypertensive agents.<strong>Angina Pectoris:</strong> Extended release Metoprolol Succinate tablet is\r\nindicated in the long-term treatmentof angina pectoris. <a name=\"_GoBack\"></a><strong>Heart Failure: BetaIoc-XR</strong> Tablet is\r\nindicated for the treatment of stable, symptomatic (NYHA Class Ilor Ill) heart\r\nfailure of ischemic, hypertensive, or cardiomyopathic origin. <o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage & Administration</strong>:<strong>Hypertension:</strong><strong> The usual initial dosage is 25 to 100mg daily in a singledose, whether\r\nused alone or added to a diuretic.</strong><strong>Angina Pectoris:</strong><strong> The dosage of extended release Metoprolol Succinate should be individualized.\r\nTheusual initial dosage is 100mg daily, in a single dose.</strong><strong>Heart Failure:</strong><strong>  The recommended starting dose of </strong><strong>BetaIoc-XR</strong><strong> is 25mg once daily for two weeks inpatients with NYHA class Il heart\r\nfailure and 12.5mg once daily in patients with more severe heart failure. The\r\ndosage may be increased at weekly (or longer) intervals until optimum blood\r\npressure reduction isachieved. If treatment is to be discontinued, the dosage\r\nshould be reduced gradually over a period of(1-2 weeks). Or, as directed by the\r\nregistered physician.</strong><o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt; text-align: justify;\"><strong>Pregnancy & Lactation</strong>: There\r\nare no adequateand well-controlled studies in pregnantwomen. Metoprolol is\r\nexcreted in breast milk in very small quantities. Caution should be\r\nexercisedwhen extended release Metoprolol Succinate\r\nis administered to a nursing woman.</p><p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt; text-align: justify;\"><strong>Packing: Betaloc-XR-50: </strong>Each\r\nbox contains 10 x 10's tablets in blister pack.</p><p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt; text-align: justify;\"><strong>Betaloc-XR-100: </strong>Each\r\nbox contains 5 x 10's tablets in blister pack.<br></p><h4 style=\"text-align:justify\"><br></h4><h4 style=\"margin:0in;margin-bottom:.0001pt;text-align:justify\"><o:p></o:p></h4>",
    "strength": "100,50",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1687173743",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744020353BETALOC-XR-100.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744020353BETALOC-XR-50.png"
    ]
  },
  {
    "id": "1015",
    "name": "Betavate - CL",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\">Betamethasone (as 17 valerate)  BP 1% + Clotrimazole BP 1%.</span></p><p xss=\"removed\" style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This ointments combines the broad spectrum antifungal activity of clotrimazole with the sustained antiinflammatory, antipruritic and vasoconstrictive actions of Betamethasone and is indicated for short term topical treatment of the following dermal infections: Trichophyton rubrum, T. mentagrophytes, Epider-mophyton, and Microsporum, candidiasis due to Candida albicans.</span></p><p xss=\"removed\" style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Gently massage sufficient ointment into the affected and surrounding skin areas twice daily, in the morning and evening for two weeks in tinea cruris, candidiasis and four weeks in tinea pedis. Or, as directed by the registered physician.</span></p><p xss=\"removed\" style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :<em> </em></strong><span class=\"redactor-invisible-space\" xss=\"removed\"><em><strong></strong></em><strong>Betavate-CL Ointment :</strong> 10 gram in a tube.</span></p>",
    "strength": "0.1%",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530952502Betavate-CL.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745304988Betavate-CL.png"
    ]
  },
  {
    "id": "1016",
    "name": "Betavate - N",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Betamethasone (as 17-\r\nvalerate) 0.1% and Neomycin sulphate\r\n0.5%.</span></p><p style=\"text-align: justify;\"><strong>Indication :<em> </em></strong><span class=\"redactor-invisible-space\"><em>Betavate-N </em>preparations\r\nare indicated for the treatment of the\r\nfollowing conditions where secondary\r\nbacterial infection is present, suspected,\r\nor likely to occur: eczema in children and\r\nadults, including atopic and discoid\r\neczema, prurigo nodularis; psoriasis\r\n(excluding widespread plaque psoriasis).\r\nneurodermatoses, seborrhoeic dermatitis,\r\ncontact sensitivity reactions and it may be\r\nused as an adjunct to systemic steroid\r\ntherapy in generalised erythroderma. This\r\npreparation can also be used in the\r\nmanagement of secondarily infected\r\ninsect bites and anal and genital\r\nintertrigo.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Apply to\r\nthe affected area once or twice daily until\r\nimprovement occurs. Therapy should be\r\ndiscontinued when control is achieved.\r\nOr as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Betavate-N Cream: 10 gram\r\nin a tube.</span></p>",
    "strength": "0.1%+0.5%",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530953168Betavate-N.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745305013Betavate-N.png"
    ]
  },
  {
    "id": "1214",
    "name": "Bicalon ",
    "description": "<p><strong>COMPOSITION :</strong> Each film coated tablet contains Bicalutamide USP 50mg.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>INDICATIONS :</strong><span class=\"redactor-invisible-space\"> It is indicated for use in combination therapy with a luteinizing hormone-releasing\r\nhormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>DOSAGE AND ADMINISTRATION :</strong><span class=\"redactor-invisible-space\"> The recommended dose for Bicalutamide therapy in\r\ncombination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or\r\nwithout food. It is recommended that Bicalutamide should be taken at the same time each\r\nday.Treatment with Bicalutamide should be started at the same time as treatment with an LHRH\r\nanalog.</span><br></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dosage Adjustment in Renal Impairment </strong>: No dosage adjustment is necessary for patients with\r\nrenal impairment. </span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dosage Adjustment in Hepatic Impairment : </strong>No dosage adjustment is necessary for patients with\r\nmild to moderate hepatic impairment.In patients with severe liver impairment, although there was a\r\n76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the\r\nactive enantiomer of Bicalutamide no dosage adjustment is necessary. Or, as directed by the\r\nregistered physicians.<br></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Use in pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> There are no adequate and well controlled studied in pregnant\r\nand lactating women. It may cause fetal harm when administered to a pregnant woman. If this drug\r\nis used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient\r\nshould be apprised of the potential hazard to a fetus.</span><br></span></span></span></p><p style=\"text-align: justify;\"><strong>Packing :</strong> Each box contains 28 tablets in Alu-Alu blister pack.<br></p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532580220Bicalon.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744020441Bicalon.png"
    ]
  },
  {
    "id": "1820",
    "name": "Biganib",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom: 4.8pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Composition: <o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom: 4.8pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Brigatinib:</strong> Each film coated tablet contains Brigatinib INN 90 mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom: 4.8pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Brigatinib-180:</strong> Each film coated tablet contains Brigatinib INN 180 mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom: 4.8pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Indications: </strong>Brigatinib<strong> </strong>is indicated for the treatment of adult patients with\r\nanaplastic lymphoma kinase (ALK)- positive metastatic non-small cell lung\r\ncancer (NSCLC).<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom: 4.8pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Dosage and\r\nAdministration:</strong>  The recommended dosing regimen for Brigatinib is 90mg\r\norally once daily for the first 7 days; if 90mg is tolerated during the first 7\r\ndays, the dose should be increased to 180mg orally once daily. Brigatinib\r\nshould be administered until disease progression or unacceptable toxicity. If Brigatinib\r\nis interrupted for 14 days or longer for reasons other than adverse reactions,\r\nresume treatment at 90 mg once daily for 7 days before increasing to the\r\npreviously tolerated dose. Brigatinib may be taken with or without food. Patients\r\nshould be instructed to swallow tablets whole. Tablet should not be crushed or\r\nchewed. If a dose of Brigatinib is missed or vomiting occurs after taking a\r\ndose, an additional dose should be administered and the next dose of Brigatinib\r\nshould be taken at the scheduled time. Or, as\r\ndirected by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom: 4.8pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Use in Pregnancy\r\nand Lactation: </strong>Brigatinib can\r\ncause fetal harm when administered to a pregnant woman. There are no clinical\r\ndata on the use of Brigatinib in pregnant women. Pregnant women should be\r\nadvised of the potential risk to a fetus. <strong>Lactation: </strong>There\r\nare no data regarding the secretion of Brigatinib in human milk or its effects\r\non the breastfed infant or milk production. Because of the potential for\r\nadverse reactions in breastfed infants, lactating women should not advise to\r\nbreastfeed during treatment with Brigatinib and for 1 week following the final\r\ndose.<strong> <o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom: 4.8pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Packing: <o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom: 4.8pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Biganib: </strong>Each box contains 10 tablets in blister\r\npack.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom: 4.8pt; text-align: justify; background-image: initial; background-color: white;\"><strong>Biganib-180: </strong>Each box contains 7 tablets in blister\r\npack.<o:p></o:p></p><p> <br></p>",
    "strength": " 180,90",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740626809biganib-180.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740568875biganib.png"
    ]
  },
  {
    "id": "1821",
    "name": "Biganib-180",
    "description": "<p class=\"MsoNormal\"><strong>Composition: Biganib: </strong>Each\r\ntablet contains Brigatinib INN 90mg.<br>\r\n<strong>Biganib-180: </strong>Each tablet contains Brigatinib INN 180mg.<o></o></p><p class=\"MsoNormal\"><strong> </strong></p><p class=\"MsoNormal\"><strong>Indications: </strong>Biganib\r\nis indicated for the treatment of patients with anaplastic lymphoma kinase\r\n(ALK)-positive metastatic Non-small cell lung cancer<br>\r\n(NSCLC) who have progressed on or are intolerant to Crizotinib.<o></o></p><p class=\"MsoNormal\"><strong> </strong></p><p class=\"MsoNormal\"><strong>Dosage and Administration: </strong>The\r\nrecommended dosing regimen for Biganib is:<br>\r\n• 90 mg orally once daily for the first 7 days;<br>\r\n• If 90 mg is tolerated during the first 7 days, the dose should be increased\r\nto 180 mg orally once daily. Biganib should be administered until disease\r\nprogression or unacceptable toxicity. If Biganib is interrupted for 14 days or\r\nlonger for reasons other than adverse reactions, treatment should be resumed at\r\n90 mg once daily for 7 days before increasing to the previously tolerated dose.\r\nBiganib may be taken with or without food. Patients should be instructed to\r\nswallow tablets whole. Tablets should not be crushed or chewed. If a dose of\r\nBiganib is missed or vomiting occurs after taking a dose, an additional dose\r\nshould not be administered and take the next dose of Biganib should be taken at\r\nthe scheduled time. Or, as directed by the registered physicians.<o></o></p><p class=\"MsoNormal\"><strong>Use in Pregnancy and Lactation: </strong>There\r\nare no clinical data on the use of Biganib in pregnant women. If this drug is\r\nused during pregnancy, or if the<br>\r\npatient becomes pregnant while taking this drug, advise the patient of the\r\npotential risk to a fetus.<o></o></p><p class=\"MsoNormal\"><strong> </strong></p><p class=\"MsoNormal\"><strong>Packing: Biganib: </strong>Each\r\nbox contains 30 tablets in a blister pack.<br><o></o></p><p><strong>Biganib-180: </strong>Each container contains 30 tablets in a box.</p>",
    "strength": "180",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1643534354Biganib 90mg, 180mg Tablet - Web Insert(1).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740568976biganib-180.png"
    ]
  },
  {
    "id": "904",
    "name": "Block - T",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Tranexamic acid BP 500 mg Tablet.</span></p><span></span><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Block-T is indicated to prevent\r\nbleeding or to treat bleeding associated with\r\nexcessive fibrinolysis. Local fibrinolysis may\r\noccurs in the following conditions: Prostatectomy\r\nand bladder surgery, epistaxis, menorrhagia,\r\nTraumatic Hyphaema, conisation of the cervix,\r\nmanagement of dental extraction in patients with\r\nhemophilic & Hereditary angioneurotic oedema.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Tablet : The\r\nrecommended standard dosage is 2-3 tablets of\r\n500 mg (15-25 mg/kg). </span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong>Pregnancy\r\ncategory \"B\". There are no adequate and wellcontrolled\r\nstudies in pregnant women.\r\nTranexamic acid passes into breast milk to a\r\nconcentration of approximately one hundredth of\r\nthe concentration in the maternal blood. So\r\ncaution should be exercised when this product\r\nis administered to a nursing woman.</p><p style=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Block-T 500 Tablet : 2 x 10's tablets\r\nin blister pack. </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><br></span></p>",
    "strength": "500",
    "uom": "mg",
    "categoryId": "109",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530953323block-t.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745127881Block-T 500.png"
    ]
  },
  {
    "id": "1306",
    "name": "Block - T Injection",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Tranexamic acid BP 500mg/5ml IV/IM Injection.</span></p><span></span><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Block-T is indicated to prevent bleeding or to treat bleeding associated with excessive fibrinolysis. Local fibrinolysis may occurs in the following conditions: Prostatectomy and bladder surgery, epistaxis, menorrhagia, Traumatic Hyphaema, conisation of the cervix, management of dental extraction in patients with hemophilic & Hereditary angioneurotic oedema.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The recommended standard dosage is 500 mg (15-25 mg/kg).</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong>Pregnancy category \"B\". There are no adequate and wellcontrolled studies in pregnant women. Tranexamic acid passes into breast milk to a concentration of approximately one hundredth of the concentration in the maternal blood. So caution should be exercised when this product is administered to a nursing woman.</p><p style=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\">Block-T IV/IM Injection : 1 x 3's Ampoules (5ml) in a blister pack.</p>",
    "strength": "500",
    "uom": "mg/5ml",
    "categoryId": "109",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530953406block-t.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745309225Block-T.png"
    ]
  },
  {
    "id": "1760",
    "name": "Budetrol 12/400 Mycap",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt; line-height: normal; text-align: justify;\"><strong>Composition : Budetrol 6/100 Mycap: </strong>Each Capsule Contains Formoterol Fumarate Dihydrate BP 6 mcg and Budesonide BP 100 mcg inhalation powder.</p><p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt; line-height: normal; text-align: justify;\"><strong>Budetrol 6/200 Mycap: </strong>Each Capsule Contains Formoterol Fumarate Dihydrate BP 6 mcg and Budesonide BP 200 mcg inhalation powder.</p><p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt; line-height: normal;\"><strong>Budetrol 12/400 Mycap:</strong><strong> </strong>Each Capsule Contains Formoterol Fumarate Dihydrate BP 12 mcg and Budesonide BP 400 mcg inhalation powder.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt; line-height: normal; text-align: justify;\"><strong>Indications : Asthma : </strong>Formoterol and Budesonide combination is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting β2-agonist) is appropriate. This includes :</p><p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt; line-height: normal; text-align: justify;\"><strong>• </strong>Patients who are not adequately controlled with inhaled corticosteroid therapy and as needed inhaled short-acting β2-adrenoceptor agonists.</p><p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt; line-height: normal; text-align: justify;\"><strong>• </strong>Patients who are already adequately controlled on regular separate long-acting β2-agonist and inhaled corticosteroid therapies.</p><p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt; line-height: normal; text-align: justify;\" rel=\"margin-bottom: 0.0001pt; line-height: normal; text-align: justify;\"><strong>COPD : </strong>Formoterol and Budesonide combination is indicated in the regular treatment of adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) with frequent symptoms despite β2-agonist use and a history of exacerbations.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt; line-height: normal; text-align: justify;\"><strong>Dosage and administration : Asthma : Dosage and administration : Asthma : </strong>Dosage is individual and should be adjusted according to disease severity. When control has been achieved, the dose should be titrated to the lowest effective dose. For <strong>Budetrol Mycap </strong>there are two treatment approaches: <strong>1.</strong> <strong>Maintenance Therapy: Budetrol Mycap </strong>is taken as regular maintenance treatment with a separate rapid acting bronchodilator as rescue. <strong>2. Single Maintenance And Reliever Therapy:</strong> <strong>Budetrol Mycap </strong>is taken as regular maintenance and as needed in response to symptoms. <strong>1. Maintenance Therapy: </strong>Patients should be advised to have their separate rapid acting bronchodilator available for rescue use at all times. <strong>Adults (18 Years and Older): Budetrol 6/100 Mycap: </strong>1-2 Mycap capsules, twice daily. Maximum dose is 4 Mycap capsules, twice daily. <strong>Budetrol 6/200 Mycap: </strong>1-2 Mycap capsules, twice daily. Maximum dose is 4 Mycap capsules, twice daily. <strong>Budetrol 12/400 Mycap: </strong>1 Mycap capsule, twice daily. Maximum dose is 2 Mycap<strong> </strong>capsules, twice daily.<strong> Adolescents (12-17 Years): Budetrol 6/100 Mycap: </strong>1-2 Mycap<strong> </strong>capsules, twice daily. <strong>Budetrol 6/200 Mycap: </strong>1-2 Mycap capsules, twice daily. <strong>Budetrol 12/400 Mycap: </strong>1 Mycap capsule, twice daily. <strong>Children (6-11 Years): Budetrol 6/100 Mycap: </strong>2 Mycap capsules, twice daily. <strong>2. Single Maintenance And Reliever Therapy (For Budetrol</strong> <strong>6/100 and Budetrol 6/200): </strong>Patients take a daily maintenance dose of Budetrol Mycap and in combination take Budetrol Mycap as needed in response to symptoms. Patients should be advised to always have Budetrol Mycap available for use. <strong>Adults (12 years and older): </strong>The recommended maintenance dose is 2 <strong>Budetrol </strong>Mycap per day, given either as one inhalation in the morning and evening or as 2 <strong>Budetrol </strong>Mycap in either the morning or evening. For some patients a maintenance dose of 2 <strong>Budetrol </strong>Mycap twice daily may be appropriate. Patients should take 1 additional <strong>Budetrol </strong>Mycap as needed in response tosymptoms. If symptoms persist after a few minutes, an additional <strong>Budetrol </strong>Mycap should be taken. Not more than 6 <strong>Budetrol </strong>Mycap should be taken on any single occasion. A total daily dose of more than 8 <strong>Budetrol </strong>Mycap is not normally needed; however, a total daily dose of up to 12 <strong>Budetrol </strong>Mycap could be used for a limited period. Patients using more than 8 <strong>Budetrol </strong>Mycap daily should be strongly recommended to seek medical advice. <strong>COPD (Chronic Obstructive Pulmonary Disease): Budetrol</strong> <strong>6/200 Mycap: </strong>2 Mycap capsules, twice daily. <strong>Budetrol 12/400</strong> <strong>Mycap: </strong>1 Mycap capsule, twice daily. Or, as directed by the registered physician. Rinsing the mouth after each inhalation is advised.</p><p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt; line-height: normal; text-align: justify;\"><strong>Use in Pregnancy and lactation : </strong>Pregnancy category C. There are no adequate and well controlled studies in pregnant woman. It should be used during pregnancy only if the potential benefit justifies the potential risk of fetus. Budesonide is excreted in human milk. It is not known whether formoterol is excreted in human milk. Caution should be exercised when formoterol is administered to a nursing woman.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Packing : Budetrol 6/100 Mycap: </strong>Each box contains 3x10's capsules in Alu-Alu blister pack.<strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Budetrol 6/200 Mycap: </strong>Each box contains 3x10's capsules in Alu-Alu blister pack.<o:p></o:p></p><p><strong>Budetrol 12/400 Mycap: </strong>Each box contains 3x10's capsules in Alu-Alu blister pack.</p>",
    "strength": "12/400",
    "uom": "Mcg",
    "categoryId": "115",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1710402528Budetrol Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1615023164Budetrol 00.png"
    ]
  },
  {
    "id": "1726",
    "name": "Budetrol 6/100 Mycap",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong> Composition\r\n: Budetrol 6/100 Mycap: </strong>Each Capsule Contains Formoterol Fumarate Dihydrate\r\nBP 6 mcg and Budesonide BP 100 mcg inhalation powder.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Budetrol\r\n6/200 Mycap: </strong>Each\r\nCapsule Contains Formoterol Fumarate Dihydrate BP 6\r\nmcg and Budesonide  BP 200 mcg\r\ninhalation powder.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Budetrol 12/400 Mycap:</strong><strong> </strong>Each\r\nCapsule Contains Formoterol Fumarate Dihydrate BP 12 mcg and Budesonide BP 400\r\nmcg inhalation powder.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Indications\r\n: Asthma : </strong>Formoterol\r\nand Budesonide combination is indicated in the regular treatment of asthma\r\nwhere use of a combination (inhaled corticosteroid and long acting β2-agonist)\r\nis appropriate. This includes :</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>• <strong></strong></strong>Patients\r\nwho are not adequately controlled with inhaled corticosteroid therapy and as\r\nneeded inhaled short-acting β2-adrenoceptor agonists.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>• </strong>Patients\r\nwho are already adequately controlled on regular separate long-acting\r\nβ2-agonist and inhaled corticosteroid therapies.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>COPD\r\n: </strong>Formoterol\r\nand Budesonide combination is indicated in the regular treatment of adult\r\npatients with moderate to severe chronic obstructive pulmonary disease (COPD)\r\nwith frequent symptoms despite β2-agonist use and  a history of exacerbations.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Dosage\r\nand administration : Asthma : Dosage and administration : Asthma : </strong>Dosage is\r\nindividual and should be adjusted according to disease severity. When control has\r\nbeen achieved, the dose should be titrated to the lowest effective dose. For <strong>Budetrol\r\nMycap </strong>there are two treatment approaches: <strong>1.</strong> <strong>Maintenance Therapy:\r\nBudetrol Mycap </strong>is taken as regular maintenance treatment with a separate\r\nrapid acting bronchodilator as rescue. <strong>2. Single Maintenance And Reliever\r\nTherapy:</strong> <strong>Budetrol Mycap </strong>is taken as regular maintenance and as\r\nneeded in response to symptoms. <strong>1. Maintenance Therapy: </strong>Patients should\r\nbe advised to have their separate rapid acting bronchodilator available for\r\nrescue use at all times. <strong>Adults (18 Years and Older): Budetrol 6/100 Mycap: </strong>1-2\r\nMycap capsules, twice daily. Maximum dose is 4 Mycap capsules, twice daily. <strong>Budetrol\r\n6/200 Mycap: </strong>1-2 Mycap capsules, twice daily. Maximum\r\ndose is 4 Mycap capsules, twice daily. <strong>Budetrol 12/400 Mycap: </strong>1 Mycap\r\ncapsule, twice daily. Maximum dose is 2 Mycap<strong> </strong>capsules, twice daily.<strong> Adolescents\r\n(12-17 Years): Budetrol 6/100 Mycap: </strong>1-2 Mycap<strong> </strong>capsules, twice\r\ndaily. <strong>Budetrol 6/200 Mycap: </strong>1-2 Mycap capsules,\r\ntwice daily. <strong>Budetrol 12/400 Mycap: </strong>1 Mycap capsule, twice daily. <strong>Children\r\n(6-11 Years): Budetrol 6/100 Mycap: </strong>2 Mycap capsules, twice daily. <strong>2.\r\nSingle Maintenance And Reliever Therapy (For Budetrol</strong> <strong>6/100 and Budetrol\r\n6/200): </strong>Patients take a daily maintenance dose\r\nof Budetrol Mycap and in combination take Budetrol Mycap as needed in response\r\nto symptoms. Patients should be advised to always have Budetrol Mycap available\r\nfor use. <strong>Adults\r\n(12 years and older): </strong>The recommended maintenance dose is 2 <strong>Budetrol </strong>Mycap\r\nper day, given either as one inhalation in the morning and evening or as 2 <strong>Budetrol\r\n</strong>Mycap in either the morning or evening. For some patients a maintenance\r\ndose of 2 <strong>Budetrol </strong>Mycap twice daily may be appropriate. Patients should\r\ntake 1 additional <strong>Budetrol </strong>Mycap as needed in response tosymptoms. If\r\nsymptoms persist after a few minutes, an additional <strong>Budetrol </strong>Mycap\r\nshould be taken. Not more than 6 <strong>Budetrol </strong>Mycap should be taken on any\r\nsingle occasion. A total daily dose of more than 8 <strong>Budetrol </strong>Mycap is not\r\nnormally needed; however, a total daily dose of up to 12 <strong>Budetrol </strong>Mycap\r\ncould be used for a limited period. Patients using more than 8 <strong>Budetrol </strong>Mycap\r\ndaily should be strongly recommended to seek medical advice. <strong>COPD (Chronic\r\nObstructive Pulmonary Disease): Budetrol</strong> <strong>6/200 Mycap: </strong>2 Mycap\r\ncapsules, twice daily. <strong>Budetrol 12/400</strong> <strong>Mycap: </strong>1 Mycap capsule,\r\ntwice daily. Or, as directed by the registered\r\nphysician. Rinsing the mouth after each inhalation is advised.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Use\r\nin Pregnancy and lactation : </strong>Pregnancy category C. There are no\r\nadequate and well controlled studies in pregnant woman. It should be used\r\nduring pregnancy only if the potential benefit justifies the potential risk of\r\nfetus. Budesonide is excreted in human milk. It is not known whether formoterol\r\nis excreted in human milk. Caution should be exercised when formoterol is\r\nadministered to a nursing woman.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><strong>Packing\r\n: Budetrol 6/100 Mycap: </strong>Each box contains 3x10's capsules\r\nin Alu-Alu blister pack.<strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><strong>Budetrol\r\n6/200 Mycap: </strong>Each box contains 3x10's capsules in\r\nAlu-Alu blister pack.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Budetrol 12/400 Mycap: </strong>Each box contains 3x10's capsules\r\nin Alu-Alu blister pack.<o:p></o:p></p>",
    "strength": "6+100",
    "uom": "mcg/puf",
    "categoryId": "116",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1710401593Budetrol Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1674550691Budetrol 6-200 Carton.png"
    ]
  },
  {
    "id": "819",
    "name": "Bufen-SR",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">lbuprofen BP 300mg SR\r\nCapsule.</span></p><p><strong>Indication : </strong><span class=\"redactor-invisible-space\">lbuprofen is a non-steroidal\r\nanti-inflammatory agent with analgesic\r\nand antipyretic properties. Bufen-SR is\r\nindicated for the treatment of rheumatoid\r\narthritis, osteoarthritis, ankylosing\r\nspondylitis. It is also indicated in acute\r\nperiarticular disorders such as bursitis,\r\nFrozen shoulder (capsulitis), tendinitis,\r\ntenosynovitis and for the relief of mild to\r\nmoderate pain in sprains, strains, low\r\nback pain, dysmenorrhoea and dental\r\nand post operative pain. Bufen-SR is\r\nalso indicated for the relief of migraine.</span></p><p><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adults &\r\nchildren over 12 years : Usual starting\r\ndose is one capsule 300mg twice daily,\r\ntaken at night & morning. This may be\r\nincreased to three capsules (900mg)\r\ndaily until the acute pain is controlled.</span></p><p><span class=\"redactor-invisible-space\">Maintenance dose : One capsule twice\r\ndaily. Or, as directed by the registered\r\nphysician.<br></span></p><p><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy Category C. Based on animal\r\nstudies and clinical experience, there is\r\nno evidence to suggest associated foetal\r\nabnormalities. However, as with other\r\nNSAIDs, Bufen-SR  capsules\r\nshould be avoided during pregnancy and\r\nlactation unless essential, Traces of\r\nlbuprofen have been detected in breast\r\nmilk, but no adverse effects have been\r\nreported.</span></p><p><strong>Packing : </strong>: Bufen-SR : 6 x 5's capsules</p>",
    "strength": "300",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1683366271Bufen-SR Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745130762Bufen-SR.png"
    ]
  },
  {
    "id": "771",
    "name": "Butibac Capsule",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Ceftibuten Dihydrate INN 400 mg\r\nCapsule.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong> Ceftibuten is used to treat\r\nacute bacterial exacerbations of chronic\r\nbronchitis (ABECB), acute bacterial otitis\r\nmedia, pharyngitis and tonsillitis. It is\r\nalso indicated for pneumonia, infections\r\nof the urinary tract, enteritis and\r\ngastroenteritis</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The usual\r\ndose of Ceftibuten is 400mg once\r\ndaily.Or, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy\r\ncategory \"B\". There are no adequate well\r\ncontrolled studies in pregnant women.\r\nThis drug should be used during\r\npregnancy only if clearly needed.\r\nCaution should be exercised when this\r\ndrug is administered to nursing women.</span><br></span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Butibac 1 x 7's capsules in\r\nblister pack.</span></p>",
    "strength": "400",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1686544544Butibac Capsule Insert for Web (Not Usual Format).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745131589Butibac.png"
    ]
  },
  {
    "id": "1251",
    "name": "Butibac Suspension",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\">Each 5 ml reconstituted\r\nsuspension contains Ceftibuten 90mg as\r\nCeftibuten Dihydrate INN.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Indications :</strong><span class=\"redactor-invisible-space\"> Ceftibuten is used to treat\r\nacute bacterial exacerbations of chronic\r\nbronchitis (ABECB), acute bacterial otitis\r\nmedia, pharyngitis and tonsillitis. It is also\r\nindicated for pneumonia, infections of the\r\nurinary tract, enteritis and gastroenteritis.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Dosage and administration :</strong><span class=\"redactor-invisible-space\"> Please see prescribing description for more information.<br></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> Pregnancy\r\ncategory \"B\". There are no adequate well\r\ncontrolled studies in pregnant women. This\r\ndrug should be used during pregnancy only\r\nif clearly needed. Caution should be\r\nexercised when this drug is administered to\r\nnursing women.</span><br></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Packing :</strong><span class=\"redactor-invisible-space\"> Each box contains dry powder\r\nof Ceftibuten Dihydrate to reconstituted\r\nsuspension of 60ml.</span><br></span></span></span></span></p>",
    "strength": "90",
    "uom": "mg/5ml",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1686544628Butibac Suspension Insert for Web (Not Usual Format).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745131637Butibac 60 ml.png"
    ]
  },
  {
    "id": "1783",
    "name": "Butinib",
    "description": "<p class=\"MsoNormal\"><strong>Composition: </strong>Each\r\ncapsule contains Ibrutinib INN 140 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong>\r\n<strong>Mantle Cell Lymphoma: </strong>Butinib is indicated for the treatment of adult\r\npatients with mantle cell lymphoma (MCL) who have received at least one prior\r\ntherapy. <strong>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: </strong>Butinib\r\nis indicated for the treatment of adult patients with chronic lymphocytic\r\nleukemia (CLL)/small lymphocytic lymphoma (SLL). <strong>Chronic Lymphocytic\r\nLeukemia/Small Lymphocytic Lymphoma with 17p</strong> <strong>Deletion: </strong>Butinib is\r\nindicated for the treatment of adult patients with chronic lymphocytic leukemia\r\n(CLL)/small lymphocytic lymphoma (SLL) with 17p<br>\r\ndeletion. <strong>Waldenström’s Macroglobulinemia: </strong>Butinib is indicated for the\r\ntreatment of adult patients with Waldenström's macroglobulinemia (WM). <strong>Marginal\r\nZone Lymphoma: </strong>Butinib is indicated for the treatment of adult patients\r\nwith marginal zone lymphoma (MZL) who require systemic therapy and have\r\nreceived at least one prior anti-CD20-based therapy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and\r\nAdministration: Mantle Cell Lymphoma and Marginal Zone Lymphoma: </strong>The\r\nrecommended dose of Butinib for MCL and MZL is 560 mg orally once daily until\r\ndisease<br>\r\nprogression or unacceptable toxicity. <strong>Chronic Lymphocytic Leukemia/Small\r\nLymphocytic Lymphoma and</strong> <strong>Waldenström’s Macroglobulinemia: </strong>The\r\nrecommended dose of Butinib for<br>\r\nCLL/SLL and WM as a single agent, in combination with Rituximab for WM, or in\r\ncombination with Bendamustine and Rituximab for CLL/SLL is 420 mg orally once\r\ndaily until disease progression or unacceptable toxicity. When madministering\r\nButinib in combination with Rituximab, it should be administered prior to\r\nRituximab when given on the same day.<br>\r\n<strong>Chronic Graft versus Host Disease: </strong>The recommended dose of Butinib for\r\ncGVHD is 420 mg orally once daily until cGVHD progression, recurrence of an\r\nunderlying malignancy, or unacceptable toxicity. When a patient no longer\r\nrequires therapy for the treatment of cGVHD, Butinib should be discontinued\r\nconsidering the medical assessment of the individual patient. Or, as directed by the registered physicians.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and\r\nLactation: </strong>There are no available data on Butinib\r\nuse in pregnant women to inform a drug-associated risk of major birth defects\r\nand miscarriage. If Butinib is used during pregnancy or if the patient becomes\r\npregnant while taking Butinib, the patient should be apprised of the potential\r\nhazard to the fetus.<strong> Lactation: </strong>There is no information regarding the\r\npresence of Ibrutinib or its metabolites in human milk, the effects on the\r\nbreastfed infant, or the effects on milk production.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: </strong>Each\r\nbox contains 30 capsules in a blister pack.</p>",
    "strength": "140",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1634022913Butinib - Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1632215841Butinib 25mg Capsule- Carton Pic.png"
    ]
  },
  {
    "id": "1904",
    "name": "Cabanib",
    "description": "<p><strong>Composition: Cabanib-20: </strong>Each film coated tablet contains Cabozantinib 20mg as Cabozantinib (S) Malate INN.<strong> </strong></p><p><strong></strong><strong>Cabanib-60: </strong>Each film coated tablet contains Cabozantinib 60mg as Cabozantinib (S) Malate INN.</p><p class=\"MsoNormal\"><strong>Indications:</strong> <strong>Renal Cell Carcinoma: </strong>Cabozantinib is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). <strong>Hepatocellular Carcinoma: </strong>Cabozantinib is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Sorafenib.<o></o></p><p class=\"MsoNormal\"><strong>Dosage and Administration:</strong> <strong>Recommended Dosage for Renal Cell Carcinoma: </strong>The recommended dosage of Cabozantinib is 60mg once daily without food until the patient no longer experiences clinical benefit or experiences unacceptable toxicity. <strong>Recommended Dosage for Hepatocellular Carcinoma: </strong>The recommended dosage of Cabozantinib is 60mg once daily without food until disease progression or unacceptable toxicity. Or, as directed by the<br>registered physicians.<o></o></p><p class=\"MsoNormal\"><strong>Use in Pregnancy and Lactation: </strong>Cabozantinib can cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk.<o></o></p><p><strong>Packing: </strong><strong>Cabanib-20: </strong><strong></strong>Each container contains 30 tablets in a blister pack.</p><p><strong>Cabanib-60: </strong><strong></strong>Each container contains 30 tablets in a blister pack.<br></p>",
    "strength": " 60mg, 20mg",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1710311951Cabanib Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744020702Cabanib-60.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744020702Cabanib-20.png"
    ]
  },
  {
    "id": "1733",
    "name": "Cabanib",
    "description": "<p><strong>Composition:</strong></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Cabanib-20: Each capsule contains Cabozantinib 20mg as Cabozantinib (S) Malate INN<o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Cabanib-60: Each capsule contains Cabozantinib 60mg as Cabozantinib (S) Malate INN</strong><strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom: 4.8pt; background-image: initial; background-color: white; text-align: justify;\"><strong>Indications: </strong>Cabozantinib is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom: 4.8pt; background-image: initial; background-color: white; text-align: justify;\"><strong>Dosage and Administration:</strong> The recommended daily dose of <strong>Cabozantinib</strong> is 140 mg once daily without food until disease progression or unacceptable toxicity. Patients should not be instructed to eat for at least 2 hours before and at least 1 hour after taking <strong>Cabozantinib</strong>. <strong>Cabozantinib </strong>capsules should be swallowed whole and it should be opened. A missed dose should not be taken within 12 hours of the next dose. Foods (e.g., grapefruit, grapefruit juice) or nutritional supplements should not be taken that are known to inhibit cytochrome P450 while taking <strong>Cabozantinib</strong>.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom: 4.8pt; background-image: initial; background-color: white; text-align: justify;\"><strong>Use in Pregnancy and Lactation: </strong>It can cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. Pregnant women or women of childbearing potential should be advised of the potential hazard to a fetus. The estimated background risk of major birth defect and miscarriage for the indicated population is unknown. <strong>Lactation:</strong> There is no information regarding the presence of Cabozantinib or its metabolites in human milk, or their effects on the breastfed infant, or milk production. Because of the potential for serious adverse reactions in a breastfed infant from Cabozantinib, a lactating woman should not to be advised breastfeed during treatment with Cabozantinib and for 4 months after the final dose.<strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom: 4.8pt; background-image: initial; background-color: white; text-align: justify;\"><strong>Packing:<o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Cabanib-20: Each box contains 30 capsules in a blister pack.</strong></p><p><strong>Cabanib-60: Each box contains 30 capsules in a blister pack.</strong></p>",
    "strength": "20",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1678341282Cabanib Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744020612Cabanib-20.png"
    ]
  },
  {
    "id": "1822",
    "name": "Cabanib-60",
    "description": "<p><strong>Composition: </strong>Each\r\nfilm coated tablet contains Cabozantinib 60mg as Cabozantinib (S) Malate INN.</p><p class=\"MsoNormal\"><strong>Indications:</strong>\r\n<strong>Renal Cell Carcinoma: </strong>Cabozantinib is indicated for the treatment of\r\npatients with advanced renal cell carcinoma (RCC). <strong>Hepatocellular Carcinoma:\r\n</strong>Cabozantinib is indicated for the treatment of patients with hepatocellular\r\ncarcinoma (HCC) who have been previously treated with Sorafenib.<o></o></p><p class=\"MsoNormal\"><strong>Dosage and Administration:</strong>\r\n<strong>Recommended Dosage for Renal Cell Carcinoma: </strong>The recommended dosage of\r\nCabozantinib is 60mg once daily without food until the patient no longer\r\nexperiences clinical benefit or experiences unacceptable toxicity. <strong>Recommended\r\nDosage for Hepatocellular Carcinoma: </strong>The recommended dosage of Cabozantinib\r\nis 60mg once daily without food until disease progression or unacceptable\r\ntoxicity. Or, as directed by the<br>\r\nregistered physicians.<o></o></p><p class=\"MsoNormal\"><strong>Use in Pregnancy and Lactation: </strong>Cabozantinib\r\ncan cause fetal harm when administered to a pregnant woman. There are no\r\navailable data in pregnant women to inform the drug-associated risk.<o></o></p><p><strong>Packing: </strong>Each\r\ncontainer contains 30 tablets in a box.</p>",
    "strength": "60",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1643534590Cabanib-60- Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744020730Cabanib-60.png"
    ]
  },
  {
    "id": "1805",
    "name": "Cabazol",
    "description": "<p><strong>Composition: </strong>Each\r\ngram cream contains Clotrimazole BP 10mg.</p><p class=\"MsoNormal\"><strong>Indications: </strong>The\r\nconfirmed indication for Clotrimazole include:<br>\r\n● All dermatomycoses due to dermatophytes (e.g. Trichophyton species).<br>\r\n● All dermatomycoses due to yeasts (Candida species).<br>\r\n● Dermatomycoses due to moulds and other fungi.<br>\r\n● Skin diseases showing superinfections with these fungi.<br></p><p class=\"MsoNormal\"><strong>Dosage and administration: </strong>Wash\r\nskin with soap and water and water and dry thoroughly. Apply a thin layer of\r\nthe cream or solution 2-3 times daily and gently massage over affected area as\r\ndirected by the doctor. For Athlete's foot, pay special attention to the spaces\r\nbetween the toes. Best results in Athlete's foot and ringworm are usually\r\nobtained with 4 weeks use of this product. The cream should be applied two or\r\nthree times daily for one month or for at least two weeks after the\r\ndisappearance of all signs of infection. If satisfactory results have not\r\noccurred within these times consultation with doctor is essential. For best\r\nresults, follow directions and continue treatment for length of time indicated.\r\nThe duration of treatment varies; it depends among other factors on the extent\r\nand localization of the disease. Or, as directed by the registered physician.</p><p class=\"MsoNormal\"><strong>Use in pregnancy and lactation: </strong>Pregnancy\r\nCategory C. It is recommended during pregnancy only after first consulting a\r\ndoctor. <strong>Lactation: </strong>Because systemic absorption of Clotrimazole following\r\ntopical application is marginal, there should be no risk for the infant during\r\nlactation.</p><p><strong>Packing: </strong>Each\r\ntube contains 10gm cream.</p>",
    "strength": " 10",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1637663257Cabazol PDF Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745131667Cabazol.png"
    ]
  },
  {
    "id": "1152",
    "name": "Cabita Tablet",
    "description": "<p><strong>COMPOSITION:</strong> Each film coated tablet contains Capecitabine USP 500 mg.</p><p style=\"text-align: justify;\"><strong>INDICATIONS:</strong><span class=\"redactor-invisible-space\"> <strong>Colorectal Cancer: </strong>Capecitabine is indicated as a single agent for adjuvant treatment in patients\r\nwith Dukes' C colon cancer who have undergone complete resection of the primary tumor when\r\ntreatment with fluoropyrimidine therapy alone is preferred. Capecitabine was non-inferior to 5-\r\nflourouracil and Calcium folinate for disease-free survival (DFS). Although neither Capecitabine nor\r\ncombination chemotherapy prolongs overall survival (OS), combination chemotherapy has been\r\ndemonstrated to improve disease-free survival compared to 5-fluorouracil or Calcium folinate.\r\nCapecitabine is indicated as first-line treatment of patients with metastatic colorectal carcinoma\r\nwhen treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has\r\nshown a survival benefit compared to 5-fluorouracil or Calcium folinate alone. A survival benefit\r\nover 5 fluorouracil or Calcium folinate has not been demonstrated with Capecitabine\r\nmonotherapy.Use of Capecitabine instead of 5-fluorouracil or Calcium folinate in combinations has\r\nnot been adequately studied to assure safety or preservation of the survival advantage. </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Breast Cancer: </strong>Capecitabine in combination with Docetaxel is indicated for the treatment of\r\npatients with metastatic breast cancer after failure of prior anthracycline-containing\r\nchemotherapy. Capecitabine monotherapy is also indicated for the treatment of patients with\r\nmetastatic breast cancer resistant to both Paclitaxel and an anthracycline-containing\r\nchemotherapy regimen or resistant to Paclitaxel and for whom further anthracycline therapy is not\r\nindicated eg, patients who have received cumulative doses of 400mg/m2 of Doxorubicin or\r\nDoxorubicin equivalents. Resistance is defined as progressive disease while on treatment, with or\r\nwithout an initial response, or relapse within 6 months of completing treatment with an\r\nanthracycline- containing adjuvant regimen</span><br></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>DOSAGE AND ADMINISTRATION:</strong><span class=\"redactor-invisible-space\"> The recommended dose of Cabita is 1250 mg/m2 administered\r\norally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks\r\nfollowed by a 1-week rest period given as 3-week cycles. Cabita tablets should be swallowed with\r\nwater within 30 minutes after a meal. In combination with Docetaxel, the recommended dose of\r\nCabita is 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period, combined with\r\nDocetaxel at 75mg/m2 as a 1-hour intravenous infusion every 3 weeks. Pre-medication, according\r\nto the Docetaxel labeling, should be started prior to Docetaxel administration for patients\r\nreceiving the Cabita plus Docetaxel combination.\r\nAdjuvant treatment in patients with Dukes' C colon cancer is recommended for a total of 6 months,\r\nie, Cabita 1250 mg/m2 orally twice daily for 2 week followed by a 1-week rest period, given as 3-\r\nweek cycles for a total of 8 cycles (24 weeks). Or, as directed by the registered physicians.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Use in Pregnancy & Lactation:</strong><span class=\"redactor-invisible-space\"> This medicine should not be used during pregnancy as it may be\r\nharmful to the unborn baby. Women who could get pregnant should use effective contraception\r\nto prevent pregnancy, and men should use effective contraception to prevent fathering a child,\r\nboth during treatment, and for at least a few months after treatment is finished.\r\n<strong>Lactation:</strong> It is not known if this medicine passes into breast milk. Mothers who need to take this\r\nmedicine should not breastfeed.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Packing:</strong><span class=\"redactor-invisible-space\"> Each box contains 28 tablets in Alu-Alu blister pack.<br></span></span></p>",
    "strength": "500",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/Cabita-Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745301790Cabita.png"
    ]
  },
  {
    "id": "934",
    "name": "Calcirol",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Cholecalciferol (Vitamin\r\nD3) 2,00000 I.U/ml (Ampoul).</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is indicated in the\r\nprevention and treatment of Vitamin D\r\ndeficiencies. These are osteoporosis,\r\nosteomalacia, hypocalcaemia, tetany\r\nand rickets.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">By oral or\r\nintramuscular injection. Prevention:\r\nInfants receiving Vitamin D enriched\r\nmilk: 1/2 ampoule (0.5ml) i.e. 1,00000\r\nI.U. every 6 months. Nursed infants or\r\ninfants not receiving Vitamin D enriched\r\nmilk or young children up to 5 years of\r\nage: 1 ampoule (1ml) i.e. 2,00000 I.U.\r\nevery 6 months.\r\nAdolescents : 1 ampoule (1ml) i.e.\r\n2,00000 I.U. every 6 months during\r\nwinter.\r\nPregnancy : 1/2 ampoule (0.5ml) i.e.\r\n1,00000 I.U. from the 6th or 7th month of\r\npregnancy.\r\nElderly : 1/2 ampoule (0.5ml) i.e.\r\n1,00000 I.U. every 3 months. Digestive\r\ndisorders, concomitant treatment with\r\nantiepileptics & other particular condition\r\nnot described above; 1/2 ampoule\r\n(0.5ml) i.e. 1,00000 I.U. or 1 ampoule\r\n(1ml) i.e. 2,00000 I.U. every 3 or 6\r\nmonths. Vitamin D deficiency : 1\r\nampoule (1ml) i.e. 2,00000 I.U. which\r\ncan be repeated 1 to 6 months later. Or,\r\nas directed by the registered physician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>Calcirol Inj. : 1 x 1 ampoule.</p>",
    "strength": "200000",
    "uom": "ML",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530954250calcirol.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745301930CALCIROL.png"
    ]
  },
  {
    "id": "935",
    "name": "Caldil - OT",
    "description": "<p><strong>Composition : <em></em></strong><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">Each film coated tablet\r\ncontains Calcium Orotate Dihydrate\r\neq.to Calcium Orotate 400mg.</span></span><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This medication is used-1.\r\nTo prevent or treat low blood calcium\r\nlevels. 2. To fulfill the calcium deficiency\r\nin conditions like, Osteomalacia, Drug\r\ninduced osteoporosis (phenytoin,\r\nphenobarbital or prednisone), Rickets,\r\nLatent tetany, Pregnancy and lactation,\r\nPostmenopausal osteoporosis,\r\npremenstrual syndrome (PMS), senile\r\nosteoporosis, Hypoparathyroidism,\r\njuvenile osteoporosis, Hip joint plastic\r\nsurgery. 3. It is also used number of\r\ninflammatory diseases like, Arthritis,\r\nMultiple sclerosis, Spondylitis. 4. It is\r\nalso beneficial in reducing the effects of\r\nmood swings. 5. Proved to be quite\r\neffective in cognitive enhancement. 6.\r\nProtects the heart by enhancing the\r\nefficiency of cardiac muscles.</span><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration :</strong><span class=\"redactor-invisible-space\"> As an\r\naddition to the daily diet, 2-3 tablets are\r\nusually recommended with meal Or, as\r\ndirected by the registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Women who are pregnant and breastfeeding\r\nneed more calcium. Pregnancy\r\nrelated high blood pressure is a common\r\nand serious risk for women and their\r\nbabies and taking supplemental forms of\r\ncalcium orotate can help reduce this risk.</span><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong><span class=\"redactor-invisible-space\" style=\"background-color: initial;\"> Caldil-OT : 3x10's tablets in\r\nblister pack.</span></p>",
    "strength": "400",
    "uom": "mg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1530954702caldil-OT.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744021023Caldil-OT.png"
    ]
  },
  {
    "id": "933",
    "name": "Caldil Plus",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\">Calcium Carbonate\r\n1250mg (Eq. to. Elemental Calcium\r\n500mg) & Cholecalciferol 200 I.U\r\n(Vitamin D3) Tablet.</span><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Calcium and Vitamin D is\r\nprescribed for treatment of osteoporosis,\r\nosteomalacia, rickets, tetany, and\r\nparathyroid disease. Calcium\r\nsupplements are often used to ensure\r\nadequatey intake in conditions such as\r\npregnancy, nursing, kidney disease, and\r\npancreatitis or during therapy with antiseizure\r\nmedications.</span><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Two tablets\r\ndaily or one tablet twice daily. It is best\r\ntaken with or just after a meal to improve\r\nabsorption. Each dose should be taken\r\nwith a full glass of water. Or, as directed\r\nby the registered physician.</span><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Caldil-Plus should be used as directed\r\nby registered physician during pregnancy\r\nor while breast feeding</span><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Caldil-Plus : 50's tablets\r\nin a container.</span><span class=\"redactor-invisible-space\" style=\"background-color: initial;\"></span></p>",
    "strength": "500+200",
    "uom": "mg(IV)",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1634027800Caldil-Plus (1).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745131731CALDIL-PLUS.png"
    ]
  },
  {
    "id": "932",
    "name": "Caldil-500",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong> <strong> </strong>Each film coated\r\ntablet contains Calcium Carbonate USP equivalent to 500mg Calcium.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications : </strong>Calcium cation are used for the\r\ntreatment or prevention of calcium depletion in patients in whom dietary\r\nmeasures are inadequate. Calcium therapy used for the treatment of osteoporosis\r\nin elderly, tooth formation, osteomalacia, chronic hypoparathyroidism, rickets,\r\nlatent tetany, hypocalcemia and as supplemental therapy for pregnancy and\r\nlactation, pre and post menopausal woman, children and adolescents (specially\r\ngirls). Calcium deficiency include achlorhydria, chronic diarrhea, vitamin D\r\ndeficiency, steatorrhea, sprue, pancreatitis, renal failure, alkalosis and hyperphosphatemia.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage & Administration :</strong><strong> </strong>1\r\ntablet daily. calcium carbonate used as a dietary supplement, such as for the\r\nprevention of osteoporosis (500-1500 mg calcium) daily is recommended in\r\ngeneral, but again this will need to be tailored to the individual patient\r\ndepending on any specific disease such as calcium deficiency malabsorption or\r\nparathyroid function. In pregnancy and lactation the Calcium Carbonate Calcium\r\nsupplement. Or, as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use in pregnancy and lactation :</strong><strong> </strong>Calcium\r\ncontaining drugs have been widely used in pregnancy by way to oral calcium\r\nsupplementation or antacid therapy. Calcium carbonate can be used in lactating\r\nwomen too.<o:p></o:p></p><p><strong>Packing : </strong>Each box contains 50's tablets in blister pack.<br><strong></strong></p>",
    "strength": "500",
    "uom": "mg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1655630360Caldil BOOK STYLE INSERT.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745131709CALDIL-500.png"
    ]
  },
  {
    "id": "977",
    "name": "Camiton",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition :</strong><strong></strong>  Vinpocetin 5mg.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Action :</strong> <strong>Camiton</strong> improves\r\ncerebral metabolism : Increases the glucose and oxygen consumption and utilization\r\nof the brain tissue; improves the hypoxia tolerance of the brain cells; shifts\r\nglucose metabolism toward the energetically more favorable aerobic pathway,\r\nexerts antioxidant activity; as a result of all these effects it is a\r\ncerebroprotective compound.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Camiton considerably improves\r\ncerebral microcirculation :</strong></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong><em>Inhibits platelet aggregation :</em></strong>\r\nreduces pathologically increased blood viscosity; promotes the oxygen transport\r\ninto the brain tissue.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Camiton</strong> selectively and\r\nintensively increases cerebral blood flow and the cerebral fraction of cardiac\r\noutput, reduces cerebral vascular resistance without affecting systemic\r\ncirculation.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indications </strong>: All forms of acute\r\nand chronic cerebral circulatory insufficiency: TIA, reversible ischaemic\r\nneurological deficiency, progressive stroke, completed stroke, multi-infarct\r\ndementia, cerebral arteriosclerosis, hypertensive encephalopathy etc. For the\r\nreduction of psychic or neurological symptoms of cerebral insufficiency (e.g.\r\nmemory disturbances, dizziness, headache, aphasia, locomotor disorders etc.).</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and\r\nadministration: </strong>Dosage and administration: 1-2 tablet 3\r\ntimes daily. Or, as directed by the\r\nregistered physician.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Packing :</strong> Each box contains 7 x\r\n14's tablets in blister pack.</p><p><br></p>",
    "strength": "5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633323762Camiton.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1633252359Camiton.png"
    ]
  },
  {
    "id": "820",
    "name": "Canasa",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Mesalamine USP 400mg Enteric Coated Delayed Release Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Mesalamine delayed release\r\ntablet is indicated for the\r\ntreatment of mildly to moderately active\r\nulcerative colitis and for the maintenance\r\nof remission of ulcerative colitis.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">For the\r\ntreatment of mildly to moderately\r\nactive ulcerative colitis: For Adults :\r\nThe usual dosage in adults is two 400-\r\nmg tablets to be taken three times daily\r\nwith or without food (for a total daily dose\r\nof 2.4 grams), for a duration of 6 weeks. For the maintenance of remission of\r\nulcerative colitis: The recommended\r\ndosage in adults is 1.6 grams daily, in\r\ndivided doses. Or, as directed by the\r\nregistered physician</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy category \"C\". There are no\r\nadequate & well controlled studies in\r\npregnant women. Mesalamine should be\r\nused during pregnancy only if the\r\npotential benefit justifies the potential risk\r\nto the fetus. Mesalamine & its N-acetyl\r\nmetabolite are excreted into human milk.\r\nCaution should be exercised when\r\nMesalamine is administered to nursing\r\nwomen.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Each box contains 3 x 10's\r\ntablets in blister pack.\r\n</span></p>",
    "strength": "400",
    "uom": "mg",
    "categoryId": "61",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531023620Canasa Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/canasa.jpg"
    ]
  },
  {
    "id": "1906",
    "name": "Capnib-200",
    "description": "<p><strong>Composition:\r\n</strong>Each film coated tablet contains Capmatinib 200mg as Capmatinib\r\nHCl INN.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:\r\n</strong>It is indicated for the treatment of adult patients with\r\nmetastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that\r\nleads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected\r\nby an FDA approved test.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\n& administration: </strong>The recommended\r\ndosage of Capnib-200 is 400mg orally twice daily with or without food. Swallow\r\nthe tablets whole. Do not break, crush or chew the tablets. If a patient misses\r\nor vomits a dose, instruct the patient not to make up the dose, but to take the\r\nnext dose at its scheduled time. Or, as directed by the registered physicians.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in\r\npregnancy & lactation: </strong>It can cause fetal\r\nharm when administered to a pregnant woman. There are no available data on\r\nCapnib-200 use in pregnant women.<strong> Lactation: </strong>There are no data on the\r\npresence of Capmatinib or its metabolites in either human or animal milk or its\r\neffects on the breastfed child or on milk production.<o></o></p><p><strong>Packing: </strong>Each box contains 56 tablets in a container.</p>",
    "strength": "200",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1716099556Capnib-200 Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1733890849Capnib-200 Carton.png"
    ]
  },
  {
    "id": "1899",
    "name": "Carbogel Single Use Eye Drop",
    "description": "<p><strong>Composition:\r\n</strong>Each ml Carbogel\r\neye drops contains Sodium Carboxymethyl Cellulose USP 10 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication:\r\n</strong>It is used as a\r\nlubricant to relieve irritation and discomfort due to dryness of the eye or due\r\nto exposure to wind or sun.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration: </strong>Instill\r\n1 or 2 drops in the affected eye(s) as needed or, as directed by the registered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and lactation: </strong>There\r\nis no data on the use of Sodium Carboxymethyl Cellulose 1% during pregnancy\r\n& lactation.<o></o></p><p><strong>Packing: </strong>Each\r\nbox contains 25’s (0.4ml) single use plastic containers enclosed in a plastic\r\npouch overwrap.</p>",
    "strength": " ",
    "uom": "",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1707215370Carbogel Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1707214839Carbogel Carton.png"
    ]
  },
  {
    "id": "971",
    "name": "Cardinex",
    "description": "<p><strong></strong><strong>Composition : </strong></p><p style=\"text-align: justify;\"><strong></strong>Active ingredient :</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"> Enoxaparin\r\nsodium Solvent :</span>Water for injections. </p><p style=\"text-align: justify;\">Each ml of the solution contains : </p><p style=\"text-align: justify;\">10000 anti-Xa IU\r\nequivalent to </p><p style=\"text-align: justify;\">100mg Enoxaparin sodium. </p><p style=\"text-align: justify;\">Cardinex-40 : 4000 anti-Xa IU/0.4ml.</p><p style=\"text-align: justify;\">\r\nCardinex-60 : 6000 anti-Xa IU/0.6ml. </p><p style=\"text-align: justify;\">Cardinex-80 : 8000 anti-Xa IU/0.8ml.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Cardinex is indicated for o\r\nProphylaxis of venous thromboembolic disease\r\n(prevention of blood clot formation in the veins). \r\nPrevention of thrombus formation in the\r\nextracorporal circluation during haemodialysis.Treatment of unstable angina and non-Q-wave\r\nmyocardial infarction during acute stage.Treatment of established deep vein thrombosis\r\nwith or without pulmonary embolism.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong></p><p style=\"text-align: justify;\"><strong></strong>1mg (0.01ml) of enoxaparin corresponds\r\napproximately to 100 anti-Xa I.U. Enoxaparin\r\nshould be injected by deep SUBCUTANEOUS\r\nROUTE in prophylactic and curative treatment and\r\nby INTRAVASCULAR ROUTE during\r\nhaemodialysis. Do not administer by\r\nINTRAMASCULAR ROUTE.\r\nProphylaxis of venous thrombo-embolic\r\ndisease in medical patients. </p><p style=\"text-align: justify;\">The recommended\r\ndose of enoxaparin sodium is 4000 anti-Xa IU\r\n(0.4ml) once daily. Treatment of established deep vein thrombosis\r\nwith or without pulmonary embolism: A dose of\r\n1mg/kg should be given subcutaneously every 12\r\nhours. The duration of the treatment should not\r\nexceed a preiod of 10 days.\r\nTreatment of unstable angina and non-Q-wave\r\nmyocardial infarction : A dose of 1mg/kg should\r\nbe given subcutaneously every 12 hours. The\r\nrecommended treatment should be prescribed for\r\na period of 2 to 8 days, until clinical stabilization of\r\nthe patient.\r\nElderly : No dosage adjustment is necessary in\r\npreventive therapy.\r\nChildren : Enoxaparin is not recommended in\r\nchildren.\r\nOr, as directed by the registered physician. </p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Enoxaparin has\r\nbeen assigned to pregnancy category B by the\r\nFDA. There are no controlled data in women\r\npregnancy. It can be used in pregnancy if potential\r\nbenefits outweigh the risk or as directed by the\r\nregistered physician. Enoxaparin is likely to be\r\nexcreted into the breast milk. A decision should be\r\nmade whether to discontinue nursing or to\r\ndiscontinue the drug, taking into account the\r\nbenefit of the drug to the mother.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Cardinex-40 : 1x1's prefilled syringe BP (0.4ml) in\r\na blister pack. </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Cardinex-60 : 1x1's prefilled syringe BP (0.6ml) in\r\na blister pack.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nCardinex-80 : 1x1's prefilled syringe BP (0.8ml) in\r\na blister pack.</span></p>",
    "strength": "80,60,40",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531024019Cardinex.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745302086Cardinex-80.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745302086Cardinex-60.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745302086Cardinex-40.png"
    ]
  },
  {
    "id": "976",
    "name": "Cardiron",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:</strong> Amiodarone Hydrochloride 200mg Tablet. </p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indications:</strong> Cardiron is indicated for the treatment of arrhythmias\r\nparticularly when other drugs are ineffective or contraindicated. It may be\r\nused for paroxysmal supraventricular, nodal and ventricular tachycardias,\r\natrial fibrillation and flutter and ventricular fibrillation.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dos age and administration : Initial dose :</strong> Treatment should be s tarted with 200mg, three times a day and\r\nmay be continued for 1 week. Maintenance dose: After the initial period the\r\ndosage should be reduced to 200mg daily, or, les s if appropriate. or as directed\r\nby the physician.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Packing\r\n:</strong> Each box contains 3x10's tablets in blister pack.</p>",
    "strength": "200",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531025287Cardiron.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744021465CARDIRON.png"
    ]
  },
  {
    "id": "962",
    "name": "Cardival",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Valsartan USP 80mg\r\nTablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Hypertension : Cardival\r\n(valsartan) is indicated for the treatment\r\nof hypertension. It may be used alone or\r\nin combination with other\r\nantihypertensive agents.\r\nHeart Failure : Cardival (valsartan) is\r\nindicated for the treatment of heart\r\nfailure (NYHA class II-IV) in patients who\r\nare intolerant of angiotensin converting\r\nenzyme inhibitors.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Usually\r\n80mg once daily if necessary increased\r\nafter at least 4 weeks to 160mg daily\r\n(elderly over 75years, mild to moderate\r\nhepatic impairment, moderate to severe\r\nrenal impairment, intravascular volume\r\ndepletion initially 40mg once daily). Or,\r\nas directed by a registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">The\r\nuse of valsartan is not advised at the\r\ntime of pregnancy. Decision should be\r\nmade whether to discontinue nursing or\r\ndiscontinue the drug, taking into account\r\nthe importance of the drug to the mother.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Cardival : 3x10's tablets in\r\nblister pack.</span></p>",
    "strength": "80",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1635135012CARDIVAL.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744021560CARDIVAL.png"
    ]
  },
  {
    "id": "963",
    "name": "Cardival Plus",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Cardival Plus 80 :</span><span class=\"redactor-invisible-space\"> Valsartan USP </span><span class=\"redactor-invisible-space\">80mg</span><span class=\"redactor-invisible-space\"> +\r\nHydrochlorothiazide USP </span><span class=\"redactor-invisible-space\">12.5mg</span><span class=\"redactor-invisible-space\"> Tablet.<br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Cardival Plus  :</span><span class=\"redactor-invisible-space\"> Valsartan USP </span><span class=\"redactor-invisible-space\">160 mg</span><span class=\"redactor-invisible-space\"> +\r\nHydrochlorothiazide </span><span class=\"redactor-invisible-space\">USP 12.5mg</span><span class=\"redactor-invisible-space\"> </span><span class=\"redactor-invisible-space\">Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong>It is indicated for the\r\ntreatment of hypertension & myocardial\r\ninfraction with left ventricular failure.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">A patient\r\nwhose blood pressure is not adequately\r\ncontrolled with valsartan monotherapy\r\nmay add hydrochlorothiazide by\r\nswitching to Cardival Plus (Valsartan\r\n80mg / hydrochlorothiazide 12.5mg or\r\nValsartan 160mg/hydrochlorothiazide\r\n12.5mg) once daily. The clinical\r\nresponse to Cardival Plus should be\r\nsubsequently evaluated and if blood\r\npressure remains uncontrolled after 3-4\r\nweeks of therapy, the dose may be\r\ntitrated up to valsartan\r\n160mg/hydrochlorothiazide 25mg. Or, as\r\ndirected by the registered physician.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><strong> </strong><span class=\"redactor-invisible-space\">Cardival Plus 80 : 2 x 10's tablets in\r\nblister pack. </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Cardival Plus 160 : 1 x 10's tablets in\r\nblister pack.</span></p>",
    "strength": "160+12.5,80+12.5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531025980CardivalPlus.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/cardival-plus_80 Wr.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/cardival-plus_80 Wr.jpg"
    ]
  },
  {
    "id": "1880",
    "name": "Cardizem SR",
    "description": "<p><strong>Composition:Cardizem-SR\r\n90:</strong>  Each sustained release tablet contains 90mg\r\nofDiltiazem Hydrochloride USP.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Cardizem-SR120:</strong>  Each sustained release tablet contains 120mg\r\nofDiltiazem Hydrochloride USP.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Indication: </strong>1.\r\nMild to moderate cases of hypertension. 2. Angina pectoris.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Dosage & Administration</strong>: Dosage must be   adjusted according\r\nto each patient’sneeds. <strong>Mild  to \r\nmoderate  cases  of \r\nhypertension:</strong> Initially  90mg \r\nor  120mg  twice \r\ndaily(elderly once daily); up to 360mg daily may be required (elderly up\r\nto 240mg daily) <strong>Relief  of Anginal\r\nPain:</strong><strong> </strong>Initially  90mg or 120mg twice daily in divided doses\r\nmay be required(elderly up to 240mg daily). Or, as directed by a registered\r\nphysician.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Packing: Cardizem-SR 90: </strong>Each\r\nbox contains 5 x 10's tablet in blister pack.<strong></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Cardizem-SR 120: </strong>Each\r\nbox contains 5 x 10's tablet in blister pack.<strong></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><br></p><h4 style=\"margin:0in;margin-bottom:.0001pt;text-align:justify\"><br></h4>",
    "strength": "120,90",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1687173337",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744021675CARDIZEM-SR-120.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744021675CARDIZEM-SR-90.png"
    ]
  },
  {
    "id": "882",
    "name": "CARNITEN",
    "description": "<p><strong>Composition :</strong> Levocarnitine USP 330mg\r\nTablet.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Levocarnitine\r\nsupplementation may benefit individuals\r\nwith the following conditions : </span></p><p style=\"text-align: justify;\">1. Congestive Heart Failure (CHF) </p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">2.\r\nHypercholesterolemia </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">3. Intermittent\r\nclaudication </span></p><p style=\"text-align: justify;\">4. Athletic performance </p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">5.\r\nWeight loss</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"> 6. Chronic Obstructive\r\nPulmonary Disease (COPD) </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">7.\r\nAlzheimer's disease </span></p><p style=\"text-align: justify;\">8. Mild depression</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\n9. Hyperthyroidism</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"> 10. Peyronie's\r\ndisease & </span></p><p style=\"text-align: justify;\">11. Male infertility.</p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> Adults :\r\nThe recommended dosage for adult is\r\n990mg (3 tablets) two or three times a\r\nday depending on clinical response.\r\nInfants and children : The recommended\r\noral dosage for infants and children is\r\nbetween 50 -100mg kg/day in divided\r\ndoses, with a maximum of 3g/day.\r\nDosage should begin at 50mg/kg/day.\r\nThe exact dosage will depend on clinical\r\nresponse. Or, as directed by the\r\nregistered physician.</p><p style=\"text-align: justify;\"><strong>Pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy\r\nCategory B by FDA.</span><br></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Carniten : 7 x 7's tablets in\r\nblister pack.</span></p>",
    "strength": "330",
    "uom": "mg",
    "categoryId": "106",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1634022032CARNITEN.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744021753Carniten.png"
    ]
  },
  {
    "id": "1091",
    "name": "Carplatin Injection",
    "description": "<p><strong></strong><strong>Composition : </strong></p><p>Carplatin150 Injection: Each vial contains 15 ml solution of Carboplatin BP 150 mg (10 mg/ mI).</p><p>Carplatin 450 Injection: Each vial contains 45 ml solution of Carboplatin BP 450 mg (10 mg/ mI).<br></p><p><strong></strong></p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma of epithelial origin in established\r\ncombination with other approved chemotherapeutic agents. It is also indicated for the palliative treatment of patient with ovarian carcinoma\r\nrecurrent after prior chemo therapy.</span></p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\"><strong>Dosage and administration :</strong> Notes Needles or intravenous sets containing aluminum parts that may come in contact with Carplatin injection should not be used for the\r\npreparation or administration. Aluminum reacts with Carplatin causing precipitate formation and/or loss of potency. Procedures for proper\r\nhandling and disposal of anti-cancer drugs should be implemented. Several guidelines on this subject have been published. There is no\r\ngeneral agreement that all of the procedures recommended in the guidelines are necessary or appropriate. Please see prescribing description for more information.</p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\"><strong>Use in pregnancy and lactation :</strong> Pregnancy Category D. There are no adequate and well controlled studies in pregnant women.\r\nCarplatin has been reported to be found in human milk. It is not known whether Carboplatin is excreted in human.<strong></strong></p><p><strong>Packing : </strong><span class=\"redactor-invisible-space\">Carplatin 150 Injection: Each box contains 1 vial of 15 ml solution.\r\nCarplatin 450 Injection: Each box contains 1 vial of 45 ml solution</span></p>",
    "strength": "450/50,150/15",
    "uom": "mg/ml",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/Carplatin- Insert- 2.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/carplatin045.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/carplatin015.jpg"
    ]
  },
  {
    "id": "984",
    "name": "Cavelon ",
    "description": "<p><strong>Coposition   :</strong> Carvedilol   6.25mg   &   12.5mg Tablet.</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Indication : </strong><strong></strong> Cavelon is indicated\r\nfor the management of essential hypertension. It can be used alone or in\r\ncombination with other antihypertensive agents, especially thiazide type diuretics.<strong><br></strong></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Dosage and administration :Hypertension: </strong>Take with food to slow the rate of absorption and reduce the incidence of orthostatic\r\nef fects. The recommended starting dose is 6.25mg twice daily. If this dose is tolerated,\r\nusing standing systolic pressure measured ~ 1 hour after dosing as a guide, maintain\r\nthe dose for 7 to 14 days, and then increase to 12.5mg twice daily, if needed, based\r\non through blood pressure, again using standing systolic pressure 1 hour after dosing\r\nas a guide for tolerance. This dose should also be maintained for 7 to 14 days\r\nand can then be adjusted upward to 25mg twice daily if tolerated and needed.<br></p><p class=\"MsoNormal\" style=\"text-align: justify;\">Please see prescribing description for more information.<br></p><p style=\"text-align: justify;\"><strong>Packing : </strong><strong> Cavelon-6.25  : </strong>5  x  10's  tablets  in blister pack.</p><p style=\"text-align: justify;\">  <strong> Cavelon :</strong> 5 x 10's tablets in blister pack.</p>",
    "strength": "12.5,6.25",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531029057Cavelon.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Cavelon.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1744021819CAVELON-6-25.png"
    ]
  },
  {
    "id": "1741",
    "name": "Cefaking",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition: Cefaking-500 Injection:\r\n</strong>Each vial contains Cefoperazone\r\n500mg as Cefoperazone Sodium USP.<br></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Cefaking-1gm Injection: </strong>Each vial contains Cefoperazone 1000mg as Cefoperazone\r\nSodium USP.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Cefaking-2gm Injection: </strong>Each vial contains Cefoperazone 2000mg as Cefoperazone\r\nSodium USP.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>It is indicated for the treatment of the following\r\ninfections when caused by susceptible organisms: Respiratory Tract Infections,\r\nPeritonitis & Other Intra-abdominal Infections, Bacterial Septicemia, Skin\r\nand Skin Structures Infections, Pelvic Inflammatory Disease, Endometritis &\r\nOther Infections of the Female Genital Tract, Urinary Tract Infections,\r\nEnterococcal Infections etc.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and administration: </strong>The usual adult daily dose of sterile Cefoperazone is 2 to 4\r\ngm per day administered in equally divided doses every 12 hours. In severe\r\ninfections or infections caused by less sensitive organisms, the total daily\r\ndose and/or frequency may be increased. Patients have been successfully treated\r\nwith a total daily dosage of 6 to12 gm divided into 2, 3 or 4 administrations\r\nranging from 1.5 to 4 gm per dose. When treating infections caused by <i>Streptococcus pyogenes</i>, therapy should\r\nbe continued for at least 10 days. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation: </strong>Pregnancy Category B. There are no\r\nadequate and well controlled clinical studies in pregnant or breastfeeding\r\nwomen. It should only be used in pregnant women if the potential benefit\r\njustifies the potential risk to the foetus. Since it is not known if\r\nCefoperazone is distributed into milk, the drug should be used with caution in\r\nnursing women.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing : Cefaking-500 Injection: </strong>Blister pack of 1 vial containing 500mg Cefoperazone (As\r\nsterile  Cefoperazone Sodium USP) accompanied\r\nby one ampoule of 5ml water for injection BP for IM/IV injection.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Cefaking-1gm Injection: </strong>Blister pack of 1 vial containing 1000mg Cefoperazone (As\r\nsterile  Cefoperazone Sodium USP) accompanied\r\nby one ampoule of 10ml water for injection BP for IM/IV injection.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Cefaking-2gm Injection: </strong>Blister pack of 1 vial containing 2000mg Cefoperazone (As\r\nsterile  Cefoperazone Sodium USP) accompanied\r\nby one ampoule of 10ml water for injection BP for IM/IV injection.</p>",
    "strength": "2,2,1",
    "uom": "gm(IV/IM)",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1614237902",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1614237902Cefaking 2gm Carton With InjPic.png",
      "https://www.admin.drug-international.com/uploads/product_images/1614237902Cefaking 1gm Carton With Inj Pic.png",
      "https://www.admin.drug-international.com/uploads/product_images/1614237902Cefaking 500 Carton With Inj Pic.png"
    ]
  },
  {
    "id": "1830",
    "name": "Cefalin",
    "description": "<p><strong>Composition: </strong>Each vial contains Cefazolin 1gm sterile\r\npowder (As Cefazolin Sodium USP).</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>Cefazolin is indicated for the treatment\r\nof the following infections caused by susceptible organisms: Respiratory Tract\r\nInfections, Urinary Tract Infections, Skin and Skin Structure Infections,\r\nBiliary Tract Infections, Bone and Joint Infections, Genital Infections,\r\nSepticemia, Endocarditis and Perioperative Prophylaxis.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and administration: </strong>Cefazolin should\r\nbe administered intravenously or intramuscularly. For detail please see PDF File. <o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation: </strong>Pregnancy\r\nCategory B. There are no adequate and well-controlled studies in pregnant\r\nwomen.This drug should be used during pregnancy only if clearly needed.\r\nCefazolin is present in very low concentrations in the milk of nursing mothers.\r\nCaution should be exercised when Cefazolin is administered to a nursing woman.</p><p class=\"MsoNormal\" xss=\"removed\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p><strong>Packing : </strong>Each combipack contains 1 vial of\r\nCefazolin 1gm sterile powder (As Cefazolin Sodium USP) with 1 ampoule of 5ml water\r\nfor injection BP.</p>",
    "strength": "1",
    "uom": "gm(IV/IM)",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1651127616Cefalin Book Style Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1651127616Cefalin-1gm Carton Pic.png"
    ]
  },
  {
    "id": "1298",
    "name": "CEFORAN Suspension",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Cefpodoxime USP 40mg/5ml & 80mg/5ml Suspension.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Cefpodoxime is indicated for the treatment of- *Upper respiratory-tract infections, *Lower respiratory-tract infections, *Skin and soft tissue infections, *Uncomplicated urinarytract infections, *Sexually transmitted diseases.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong></p><p style=\"text-align: justify;\"><strong></strong>Upper respiratory-tract infections (but in pharyngitis and tonsillitis reserved for infections which are recurrent, chronic, or resistant to other antibacterial), 100mg twice daily (200mg twice daily in sinusitis) 14 days. *Lower respiratorytract infections (including bronchitis and pneumonia), 100mg to 200mg twice daily 10 days. *Skin and soft tissue infections, 200mg twice daily 7 to 14 days. *Uncomplicated urinary-tract infections 100mg twice daily 7 days. (200mg twice daily in uncomplicated upper urinary-tract infections) *Uncomplicated gonorrhea & rectal gonococcal infection in women: 200mg as a single dose Children : 15 days to 6 months: 4mg/kg every 12 hours, 6 months to 2 years : 40mg every 12 hours, 3 to 8 years : 80mg every 12 hours. Over 9 years : 100mg every 12 hours. Please see prescribing description for more information.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Cefpodoxime has been assigned to pregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Ceforan Suspension : 50ml and 100ml suspension.</span></p><p style=\"text-align: justify;\">Ceforan-DS Suspension : 50ml suspension.</p>",
    "strength": "80,40,40",
    "uom": "mg/5ml",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531029463ceforan.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1517308493ceforan_ds01.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1517308493Ceforan100-ml.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1517308493ceforan 100ml.jpg"
    ]
  },
  {
    "id": "1297",
    "name": "CEFORAN Tablet",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Cefpodoxime USP 100mg, 200mg Tablet.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Cefpodoxime is indicated for the treatment of- *Upper respiratory-tract infections, *Lower respiratory-tract infections, *Skin and soft tissue infections, *Uncomplicated urinarytract infections, *Sexually transmitted diseases.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration :</strong></p><p style=\"text-align: justify;\"><strong></strong>Upper respiratory-tract infections (but in pharyngitis and tonsillitis reserved for infections which are recurrent, chronic, or resistant to other antibacterial), 100mg twice daily (200mg twice daily in sinusitis) 14 days. *Lower respiratorytract infections (including bronchitis and pneumonia), 100mg to 200mg twice daily 10 days. *Skin and soft tissue infections, 200mg twice daily 7 to 14 days. *Uncomplicated urinary-tract infections 100mg twice daily 7 days. (200mg twice daily in uncomplicated upper urinary-tract infections) *Uncomplicated gonorrhea & rectal gonococcal infection in women: 200mg as a single dose Children : 15 days to 6 months: 4mg/kg every 12 hours, 6 months to 2 years : 40mg every 12 hours, 3 to 8 years : 80mg every 12 hours. Over 9 years : 100mg every 12 hours. Please see prescribing description for more information.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Cefpodoxime has been assigned to pregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\">Ceforan-100 : 2 x 7's tablets in blister pack.</p><p style=\"text-align: justify;\">Ceforan-200 : 2 x 7's tablets in blister pack.</p>",
    "strength": "200,100",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531029561ceforan.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745309284Ceforan-200.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745309284Ceforan-100.png"
    ]
  },
  {
    "id": "896",
    "name": "CELUDEX",
    "description": "<p><strong></strong><strong>Composition : </strong>Dexamethasone 1.0 mg / ml.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Eye : Non-infectious forms\r\nof conjunctivitis, keratitis and blepharitis,\r\nespecially of allergic origin. Inflammation\r\nof the anterior uvea (iritis, iridocyclitis),\r\nscleritis, episcleritis, orbital myositis and\r\nsympathetic ophthalmia.\r\nEar : Redness, itching and swelling\r\ncaused by certain ear problems.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong>Eye :\r\nAdminister 1 drop 3-5 times daily into the\r\nconjunctival sac.\r\nAcute cases : up to 1 drop hourly.\r\nEar : 3 or 4 drops in the ear two or three\r\ntimes a day.\r\nOr, as directed by the registered\r\nphysician.</p><p style=\"text-align: justify;\"><strong>Packing : </strong>5 ml in plastic dropper bottle.</p>",
    "strength": "0.10",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531029843CELUDEX.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745136865celudex 5ml.png"
    ]
  },
  {
    "id": "1784",
    "name": "Cerinib",
    "description": "<p class=\"MsoNormal\">Ceritinib INN 150 mg Capsule</p><p class=\"MsoNormal\"><strong>Composition: </strong>Each\r\ncapsule contains Ceritinib INN 150 mg.</p><p class=\"MsoNormal\"><strong>Indications: </strong>Cerinib\r\nis indicated for the treatment of patients with metastatic Non- small Cell Lung\r\nCancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)- positive as\r\ndetected by an FDA- approved test.</p><p class=\"MsoNormal\"><strong>Dosage and Administration:</strong>\r\n<strong>Patient Selection: </strong>Patients should be selected for treatment of\r\nmetastatic NSCLC with Cerinib based on the presence of ALK positivity in tumor\r\nspecimens. The recommended dose of Cerinib is 450 mg orally once daily with\r\nfood until disease progression or unacceptable toxicity. If a dose of Cerinib\r\nis missed, that dose should be made up unless the next dose is due within 12\r\nhours. If vomiting occurs during the course of treatment, an additional dose\r\nshould not be administered and the next scheduled dose of Cerinib should be\r\ncontinued. Or, as directed by the registered physician.</p><p class=\"MsoNormal\"><strong>Use in Pregnancy and Lactation: </strong>Cerinib\r\ncan cause fetal harm when administered to a pregnant woman. If it is used\r\nduring pregnancy or if the patient becomes pregnant while taking it, the\r\npatient should be apprised of the potential hazard to the fetus. <strong>Lactation: </strong>There\r\nare no data regarding the presence of Ceritinib or its metabolites in human\r\nmilk, the effects of Ceritinib on the breastfed infant, or its effects on milk\r\nproduction. Because of the potential for serious adverse reactions including\r\ngastrointestinal adverse reactions,<br>\r\nhepatotoxicity, pneumonitis, bradycardia and pancreatitis, a woman should be\r\nadvised not to breastfeed during treatment with Cerinib and for 2 weeks\r\nfollowing completion of therapy.</p><p class=\"MsoNormal\"><strong>Packing: </strong>Each\r\nbox contains 30 capsules in blister pack.</p>",
    "strength": "150 ",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1632208125Cerinib 150 mg- Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1632208125Cerinib 150 mg- Carton Pic.png"
    ]
  },
  {
    "id": "718",
    "name": "CETRIN  ",
    "description": "<p><strong>Composition :</strong> Cetirizine Dihydrochloride BP 10mg Tablet.<strong></strong></p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\" sans-serif;=\"\" background-color:=\"\" rgb(255,=\"\"><strong>Indication :  </strong><span class=\"redactor-invisible-space\">Cetrin is indicated in -\r\n Allergic rhinitis for relief from nasal\r\ncongestion, sneezing, rhinorrhoea,\r\nocular symptoms like redness,\r\nlacrimation and itching. Allergic\r\ndermatological conditions like urticaria,\r\ndermographism, atopic eczema and\r\ncontact dermatitis. Acute allergic\r\nreactions due to drugs, foods insect\r\nbites, etc.</span></p><p><strong>Packing : </strong>10x10's tablets in blister pack.</p>",
    "strength": "10",
    "uom": "mg",
    "categoryId": "41",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/CETRIN2.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1622628487Cetrin.png"
    ]
  },
  {
    "id": "718",
    "name": "CETRIN  ",
    "description": "<p><strong>Composition :</strong> Cetirizine Dihydrochloride BP 10mg Tablet.<strong></strong></p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\" sans-serif;=\"\" background-color:=\"\" rgb(255,=\"\"><strong>Indication :  </strong><span class=\"redactor-invisible-space\">Cetrin is indicated in -\r\n Allergic rhinitis for relief from nasal\r\ncongestion, sneezing, rhinorrhoea,\r\nocular symptoms like redness,\r\nlacrimation and itching. Allergic\r\ndermatological conditions like urticaria,\r\ndermographism, atopic eczema and\r\ncontact dermatitis. Acute allergic\r\nreactions due to drugs, foods insect\r\nbites, etc.</span></p><p><strong>Packing : </strong>10x10's tablets in blister pack.</p>",
    "strength": "10,10",
    "uom": "mg",
    "categoryId": "41",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/CETRIN2.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1622628487Cetrin.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744022041Cetrin.png"
    ]
  },
  {
    "id": "1017",
    "name": "Champion",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Camphor 4%, Menthol\r\n10% and Methyl Salicylate 30%.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This cream is used to treat\r\ntemporarily relieve the minor aches and\r\npains of muscles and joints associated\r\nwith: simple backache, bruises, arthritis,\r\nsprains, strains. </span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adults\r\nand Children 12 years of Age and Older:\r\nApply to affected area not more than 3 to\r\n4 times daily. Or, as directed by the\r\nregistered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">There are no well-controlled studies in\r\npregnant and nursing women.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Champion : Each tube\r\ncontains 15 gm & 30 gm cream.<br></span></p>",
    "strength": "4%+10%+30%",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531030162Champion.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745309375Champion.png"
    ]
  },
  {
    "id": "1777",
    "name": "Charm",
    "description": "<p class=\"MsoNormal\"><strong>Composition: Charm-25: </strong>Each\r\nfilm coated tablet contains Sildenafil 25 mg as Sildenafil Citrate USP.<br>\r\n<strong>Charm-50: </strong>Each film coated tablet contains Sildenafil 50 mg as\r\nSildenafil Citrate USP.<br>\r\n<strong>Charm-100: </strong>Each film coated tablet contains Sildenafil 1 00 mg as\r\nSildenafil Citrate USP.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Indications: </strong>It\r\nis indicated for the treatment of erectile dysfunction.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Dosage and administration: </strong>For\r\nmost patients, the recommended dose is 50mg taken, as needed, approximately 1\r\nhour before sexual activity. However, it may be taken anywhere from 30 minutes\r\nto 4 hours before sexual activity. The maximum recommended dosing frequency is\r\nonce per day. Based on effectiveness and toleration, the dose may be increased\r\nto a maximum recommended dose of 100mg or decreased to 25mg, It may be taken\r\nwith<br>\r\nor without food. Age &gt;65, hepatic impairment and severe renal impairment are\r\nassociated with increased plasma levels of Sildenafil. A starting oral dose of\r\n25mg should be considered in those patients. Or, as directed by the registered\r\nphysician.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Use in pregnancy and lactation: </strong>Pregnancy\r\nCategory B. It is not indicated for use in women. There are no adequate and\r\nwell- controlled studies of Sildenafil in pregnant women.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Packing: Charm-25: </strong>Each\r\nbox contains 4 tablets in a blister pack.<br>\r\n<strong>Charm-50: </strong>Each box contains 4 tablets in a blister pack.<br><o:p></o:p></p><p class=\"MsoNormal\"><strong>Charm-100: </strong>Each box contains 4 tablets in a blister pack.<br></p>",
    "strength": " 100, 25,50",
    "uom": "mg",
    "categoryId": "113",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740569480charm100.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569380Charm 25.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569380charm 50.png"
    ]
  },
  {
    "id": "1248",
    "name": "Cikolin Injection",
    "description": "<p><strong>Composition :</strong><span class=\"redactor-invisible-space\"> \r\nCikolin Injection (IM/IV) : Each Ampoule\r\n(4ml) contains Citicoline 500 mg as\r\nCiticoline Sodium INN.</span></p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Indications :</strong><span class=\"redactor-invisible-space\"> It is indicated in the\r\ntreatment of Alzheimer's disease and\r\nother types of dementia, head trauma,\r\namblyopia, cerebrovascular disease such\r\nas ischaemic stroke, age-related memory\r\nloss, Parkinson's disease, attention\r\ndeficit-hyperactive disorder (ADHD) and\r\nglaucoma.</span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Dosage and Administration :</strong>  i) For decline in thinking\r\nskills due to age: 1000-2000mg of\r\nCiticoline per day.\r\nii) For ongoing disease of the blood\r\nvessels that serve the brain (chronic\r\ncerebrovascular disease): 600mg of\r\nCiticoline per day.\r\niii) For immediate treatment of stroke due\r\nto a clot (ischemic stroke): 500-2000mg\r\nof Citicoline per day starting within 24\r\nhours of stroke.\r\nCikolin Injection (IM/IV): It is given by\r\nintravenous or intramuscular injection in\r\ndoses of up to 1g daily. Or, as directed by\r\nthe registered physician.<br></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> Pregnancy: There is not enough reliable\r\ninformation about the safety of taking\r\nCiticoline to pregnant women. Therefore,\r\nit should be used during pregnancy only\r\nif clearly needed. Nursing mothers: It is\r\nnot known whether Citicoline is excreted\r\nin human milk. So, it should be exercised\r\nif the potential benefits justify the\r\npotential risks.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">\r\nCikolin Injection (IM/IV) : Each box\r\ncontains 1 x 3's Ampoules (4 ml) in a\r\nblister pack.</span></p>",
    "strength": "500",
    "uom": "mg/4ml(IV/IM)",
    "categoryId": "48",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531030630Cikolin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745137295Cikolin injection.png"
    ]
  },
  {
    "id": "1273",
    "name": "Cikolin Tablet",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong><strong> </strong>Each\r\nfilm coated tablet contains Citicoline 500mg as Citicoline Sodium USP.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications :</strong><strong> </strong>Citicoline\r\nsodium indicated inzCerebrovascular disease e.g. ischemia due to stroke, where\r\nCiticoline accelerates the recovery of consciousness & overcoming motor\r\ndeficit. Treatment within the first 24 hours after onset in patients with\r\nmoderate to severe stroke increases the probability of complete recovery in 3\r\nmonths. Cerebral insufficiency (e.g. dizziness, memory loss, poor concentration\r\n& disorientation) due to head trauma or brain injury.Cognitive dysfunction\r\ndue to degenerative disease (Alzheimer's disease) Parkinson's disease:\r\nCiticoline has\r\nbeen shown to be effective as co-therapy for Parkinson's disease.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage and administration : </strong>i) For decline in\r\nthinking skills due to age: 1000 -2000mg of Citicoline per day. ii) For ongoing\r\ndisease of the blood vessels that serve the brain (chronic cerebrovascular disease):\r\n600mg of Citicoline per day. iii) For immediate treatment of stroke due to a clot\r\n(ischemic stroke): 500-2000mg of Citicoline per day starting within 24 hours of\r\nstroke. Or, as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use in pregnancy and lactation : </strong><strong>Pregnancy:\r\n</strong>There is not enough reliable information about the safety of\r\ntaking Citicoline to pregnant women. Therefore, it should be used during\r\npregnancy only if clearly needed. <strong>Nursing mothers: </strong>It is not known\r\nwhether Citicoline is excreted in human milk. So, it should be exercised if the\r\npotential benefits justify the potential risks.<strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p><strong>Packing :</strong><strong> </strong>Each\r\nbox contains 7's tablets in blister pack.<br></p>",
    "strength": "500",
    "uom": "mg",
    "categoryId": "48",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1636429154cikolin book style insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744022107Cikolin-500.png"
    ]
  },
  {
    "id": "895",
    "name": "CIPROCORT",
    "description": "<p><strong></strong><strong>Composition :</strong> Ciprofloxacin+\r\nHydrocortisone Acetate (3mg+10mg)/ml.</p><p style=\"text-align: justify;\"><strong>Indication :</strong> Ciprocort otic suspension is\r\nindicated for the treatment of acute otitis\r\nexterna in adult and paediatric patients\r\ndue to susceptible strains of\r\npseudomonas aeruginosa,\r\nstaphylococcus aureus and proteus\r\nmirabilis. </p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong>: Adults and\r\nchildren (one year and older) : After\r\ncleansing 2-4 drops instilled thrice to four\r\ntimes a day and at night. Or as directed\r\nby the physician.</p><p style=\"text-align: justify;\"><strong>Packing : </strong>10ml in plastic dropper bottle</p>",
    "strength": "0.3,1",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531031008CIPROCORT.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745137798Ciprocort.png"
    ]
  },
  {
    "id": "894",
    "name": "CIPROZID - DX   ",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Ciprofloxacin +\r\nDexamethasone (3mg+1mg)/ml.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong>  Eye:Ciprozid-DX drop is\r\nindicated for the treatment of\r\ninflammatory ocular conditions for which\r\na corticosteroid is indicated and where\r\nbacterial infection or risk of bacterial\r\ninfection exists. The combination can\r\nalso be used for postoperative\r\ninflammation and any other ocular\r\ninflammation associated with infection.\r\nEar : Ciprozid-DX is also indicated for\r\nthe treatment of ear infections\r\naccompanied by inflammation such as\r\notitis externa, acute and chronic otitis\r\nmedia etc. The combination may also be\r\nused postoperatively in the ear. </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Eye :\r\nOne or two drops to be instilled into\r\nconjunctival sac (s) every four to six\r\nhours. During the initial 24 to 48 hours,\r\nthe dosage may be increased to one to\r\ntwo drops every two hours.\r\nEar : Instill 2-4 drops 3-4 times daily.\r\nOr as directed by the registered\r\nphysician</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>5 ml in plastic dropper bottle. </p>",
    "strength": "0.3,0.1",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531031482CIPROZID-DX.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745138105Ciprozid-DX.png"
    ]
  },
  {
    "id": "892",
    "name": "CIPROZID Eye & Ear Drops",
    "description": "<p><strong>Composition : </strong>Ciprofloxacin 3 mg/ml.</p><p><strong>Indication : </strong><span class=\"redactor-invisible-space\">Eye : Ciprofloxacin is indicated for the treatment of corneal ulcers and superficial infections of the eye and adnexa caused by suceptible strains of bacteria. Ear : Otitis Externa</span></p><p><strong>Dosage and administration :</strong></p><p><strong></strong><span class=\"redactor-invisible-space\">Eye : Adults : Superficial ocular infection: The usual dose is one or two drops in the affected eye (s) four times a day. In severe infections, the dosage for the first two days may be one or two drops every two hours during waling hours.</span></p><p><span class=\"redactor-invisible-space\">Bacterial corneal ulcer : Two drops into the affected eye every 15 minutes for the six hours and then two drops into affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third to the fourteenth day, place two drops is the affected eye every four hours. Treatment may be continued after 14 days if corneal reepithelialization has not occured.</span></p><p><span class=\"redactor-invisible-space\">Children : The safety & efficacy of Ciprofloxacin in children under the age of 11 years has not been established.</span></p><p>Ear : One or two drops is instilled into the infected ear every four hours. Or, as directed by the registered physician.</p><p><strong>Packing : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">10 ml in plastic dropper bottle.</span></p>",
    "strength": "0.30,0.3,0.1",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1683111545Ciprozid Eye &Ear Drops Book Style Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/CIPROZI.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1745138105Ciprozid-DX.png"
    ]
  },
  {
    "id": "894",
    "name": "CIPROZID - DX   ",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Ciprofloxacin +\r\nDexamethasone (3mg+1mg)/ml.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong>  Eye:Ciprozid-DX drop is\r\nindicated for the treatment of\r\ninflammatory ocular conditions for which\r\na corticosteroid is indicated and where\r\nbacterial infection or risk of bacterial\r\ninfection exists. The combination can\r\nalso be used for postoperative\r\ninflammation and any other ocular\r\ninflammation associated with infection.\r\nEar : Ciprozid-DX is also indicated for\r\nthe treatment of ear infections\r\naccompanied by inflammation such as\r\notitis externa, acute and chronic otitis\r\nmedia etc. The combination may also be\r\nused postoperatively in the ear. </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Eye :\r\nOne or two drops to be instilled into\r\nconjunctival sac (s) every four to six\r\nhours. During the initial 24 to 48 hours,\r\nthe dosage may be increased to one to\r\ntwo drops every two hours.\r\nEar : Instill 2-4 drops 3-4 times daily.\r\nOr as directed by the registered\r\nphysician</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>5 ml in plastic dropper bottle. </p>",
    "strength": "0.3,0.1,250",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531031482CIPROZID-DX.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745138105Ciprozid-DX.png",
      "https://www.admin.drug-international.com/uploads/product_images/1660730471Ciprozid Sus Carton.png"
    ]
  },
  {
    "id": "784",
    "name": "CIPROZID Tablet",
    "description": "<p><strong></strong><strong>Composition : </strong>Ciprofloxacin 250mg, 500mg & 750mg Tablet. </p><p style=\"text-align: justify;\"><strong>Indication : </strong>Ciprofloxacin is a synthetic, 4-\r\nquinolone derivative with bactericidal activities\r\nagainst a wide range of gram-negative and grampositive\r\norganisms. Ciprofloxacin is indicated for\r\nthe treatment of the following infections caused\r\nby sensitive bacteria like Severe systemic\r\ninfections, Respiratory tract infections, Ear, nose\r\nand throat infections, Urinary tract infections,\r\nSkin & soft tissue infections, Gastro-intestinal\r\ninfections, Eye infections, Biliary tract infections,\r\nIntra abdominal infections, Bone and joint\r\ninfections, Pelvic infections and gonorrhoea.</p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> Please see prescribing description for more information.</p><p style=\"text-align: justify;\"><strong>Pregnancy :</strong><span class=\"redactor-invisible-space\"> Category C by FDA.<br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing : </strong>Ciprozid : 5 x 10's blister per box. </p><p style=\"text-align: justify;\">Ciprozid-Ds : 3 x 10's blister per box. </p><p style=\"text-align: justify;\">Ciprozid-750 : 3 x 10's blister per box. </p><p><br><span class=\"redactor-invisible-space\">\r\n</span></p>",
    "strength": "750,500,250,0.3,0.1",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531032339Ciprozid.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745138057Ciprozid-750.png",
      "https://www.admin.drug-international.com/uploads/product_images/1614162692Ciprozid DS Carton Unit 3.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745138057Ciprozid-250.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745138105Ciprozid-DX.png"
    ]
  },
  {
    "id": "894",
    "name": "CIPROZID - DX   ",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Ciprofloxacin +\r\nDexamethasone (3mg+1mg)/ml.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong>  Eye:Ciprozid-DX drop is\r\nindicated for the treatment of\r\ninflammatory ocular conditions for which\r\na corticosteroid is indicated and where\r\nbacterial infection or risk of bacterial\r\ninfection exists. The combination can\r\nalso be used for postoperative\r\ninflammation and any other ocular\r\ninflammation associated with infection.\r\nEar : Ciprozid-DX is also indicated for\r\nthe treatment of ear infections\r\naccompanied by inflammation such as\r\notitis externa, acute and chronic otitis\r\nmedia etc. The combination may also be\r\nused postoperatively in the ear. </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Eye :\r\nOne or two drops to be instilled into\r\nconjunctival sac (s) every four to six\r\nhours. During the initial 24 to 48 hours,\r\nthe dosage may be increased to one to\r\ntwo drops every two hours.\r\nEar : Instill 2-4 drops 3-4 times daily.\r\nOr as directed by the registered\r\nphysician</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>5 ml in plastic dropper bottle. </p>",
    "strength": "0.3,0.1,1000",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531031482CIPROZID-DX.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745138105Ciprozid-DX.png",
      "https://www.admin.drug-international.com/uploads/product_images/1669804426Ciprozid XR 1000 Product Pic.png"
    ]
  },
  {
    "id": "1262",
    "name": "CLARIGEN ",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Levocetirizine Dihydrochloride INN 5mg Tablet<strong>.</strong></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong></strong></p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\" sans-serif;=\"\" background-color:=\"\" rgb(255,=\"\" style=\"text-align: justify;\"><strong>Indication : </strong>Clarigen is indicated for the treatment of Seasonal allergic rhinitis, Perennial allergic rhinitis, chronic idiopathic urticaria, Food allergy, Allergic bronchial asthma, Eczema.</p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\" sans-serif;=\"\" background-color:=\"\" rgb(255,=\"\" style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Levocetirizine is indicated for all ages above six years. It should be taken as a single dose with or without food. Adult : One Levocetirizine 5mg tablet once daily. Children &gt; 6 years : One Levocetirizine tablet (5mg) once daily. Dose adjustment is indicated in moderate or severe renal impairment. A reduction in the dose of Levocetirizine by 50% should be considered in patients with moderate to severe renal dysfunction. Or, as directed by the registered physician.</span><br></p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\" sans-serif;=\"\" background-color:=\"\" rgb(255,=\"\" style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong> Levocetirizine has been assigned to Pregnancy Category B by the FDA.<strong><br></strong></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Clarigen Tablet : 10x10's tablets in blister pack.</span></p>",
    "strength": "5",
    "uom": "mg",
    "categoryId": "41",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531032731CLARIGEN.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744022272Clarigen.png"
    ]
  },
  {
    "id": "762",
    "name": "CLARIN",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Clarithromycin USP 250mg &\r\n500mg Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong> Clarin is indicated for the\r\ntreatment of mild to moderate infections\r\nlike pharyngitis, tonsillitis, acute maxillary\r\nsinusitis, acute bacterial exacerbation of\r\nchronic bronchitis, pneumonia,\r\nuncomplicated skin and skin structure\r\ninfections, disseminated mycobacterial\r\ninfections.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Usual dose\r\nis 250mg twice daily, may be increased\r\nto 500mg twice daily, if necessary in\r\nsevere infection. A course is usually for 7\r\nto 14 days. In patients with severe renal\r\nimpairment dosage may need to be\r\nhalved to 250mg once daily or 250mg\r\ntwice daily in severe infection or as\r\ndirected by a registered physician.</span></p><p style=\"text-align: justify;\"><strong>Pregnancy and lactation :</strong><span class=\"redactor-invisible-space\">Clarithromycin has been assigned to\r\npregnancy category B by the FDA.\r\nClarithromycin is likely to be excreted\r\ninto the breast milk. A decision should be\r\nmade whether to discontinue nursing or\r\nto discontinue the drug, taking into\r\naccount the benefit of the drug to the\r\nmother</span><br></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Clarin-250 : 1 x 10's tablets in blister\r\npack. </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Clarin-500 : 1 x 10's tablets in blister\r\npack.</span></p>",
    "strength": "500,250",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531032987clarin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745138315Clarin-500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745138315Clarin-250.png"
    ]
  },
  {
    "id": "775",
    "name": "Clavuran",
    "description": "<p> <strong></strong><strong>Composition : </strong>Clavuran-100 :<span class=\"redactor-invisible-space\">Cefpodoxime USP 100 mg + Clavulanic Acid USP 62.5 mg Tablet.<br></span></p><p><strong> </strong>Clavuran-200 :<span class=\"redactor-invisible-space\"> Cefpodoxime USP 200 mg + Clavulanic Acid USP 125 mg Tablet. </span><br><span class=\"redactor-invisible-space\"> </span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong>It is indicated in the following\r\ninfections when caused by susceptible\r\norganisms: Acute bacterial exacerbations of\r\nchronic bronchitis, Acute community\r\nacquired pneumonia, Upper and lower\r\nrespiratory tract infections, Skin and soft\r\ntissue infections, Urinary tract infections,\r\nPharyngitis and/or tonsillitis, General\r\ngonorrhea (men and women) and rectal\r\ngonococcal infections (women), Acute\r\nmaxillary sinusitis. </p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> Please see prescribing description for more information.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Cefpodoxine has been assigned to\r\npregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\"><strong></strong>Clavuran-100 : 2x7's tablets in blister pack.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nClavuran-200 : 2x7's tablets in blister pack.</span></p>",
    "strength": "200+125,100+62.5",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531033300Clavuran.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745309421Clavuran-200.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745309421Clavuran-100.png"
    ]
  },
  {
    "id": "1019",
    "name": "Clobederm",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Clobetasol propionate\r\n0.05%.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Clobetasol propionate is a\r\nvery active topical corticosteroid which is\r\nof particular value when used in short\r\ncourses for the treatment of more\r\nresistant dermatoses such as psoriasis\r\n(excluding wide spread plaque\r\npsoriasis), eczema, lichen planus,\r\ndiscoid lupus erythe-matosus, and other\r\nconditions which do not respond\r\nsatisfactorily to less active steroids.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Apply\r\nsparingly to the affected area once or\r\ntwice daily until improvement occurs. As\r\nwith other highly active topical steroid\r\npreparations, therapy should be\r\ndiscontinued when control is achieved. In\r\nthe more responsive conditions this may\r\nbe within a few days. Or, as directed by\r\nthe physician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"> Clobederm Cream : 10 gram\r\nin a tubes. </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Clobederm Ointment : 10 gram in a\r\ntubes.</span></p>",
    "strength": "0.05%,0.05%",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531113300Clobederm.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745309580Clobederm.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745309580Clobederm 10 gm.png"
    ]
  },
  {
    "id": "974",
    "name": "Clopid",
    "description": "<p><strong></strong><strong>Composition : </strong>Clopidogrel 75 mg Tablet</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Clopid is indicated for the\r\nreduction of atherosclerotic events\r\n(myocardial infarction, stroke and vascular\r\ndeath) in patients with atherosclerosis\r\ndocumented by recent stroke, recent\r\nmyocardial infarction or established\r\nperipheral arterial disease.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The\r\nrecommended dose of Clopid is 75mg\r\nonce daily. It can be taken with or without\r\nfood.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy Category B by FDA.</p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Clopid : 2 x 14's tablets in\r\nblister pack.</span></p>",
    "strength": "75",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531113542clopid.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744022373Clopid.png"
    ]
  },
  {
    "id": "975",
    "name": "Clopid As",
    "description": "<p><strong></strong><strong>Composition :</strong> Clopidogrel+Aspirin;\r\n(75mg+75mg) Tablet.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This tablet is indicated for\r\nthe reduction of atherosclerotic events\r\n(myocardial infarction, stroke and\r\nvascular death) in patients with\r\natherosclerosis documented by recent\r\nstroke, recent myocardial infarction or\r\nestablished peripheral arterial disease.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The\r\nrecommended dose of this tablet is one\r\ntablet once daily or, as directed by the\r\nregistered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">There are no adequate and wellcontrolled\r\nstudies of Clopidogrel with\r\nAspirin in pregnant women. However,\r\nClopidogrel with Aspirin should be used\r\nduring pregnancy only if clearly needed.\r\nThis tablet should not be prescribed to\r\nnursing mother unless absolutely\r\nnecessary.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Clopid-As : 3x10's tablets in\r\nblister pack.</span></p>",
    "strength": "75+75",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531113740Clopid_as.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744022330Clopid- As.png"
    ]
  },
  {
    "id": "1252",
    "name": "Cod Liver Oil ",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong> <strong> </strong><strong>Cod Liver Oil : </strong>Each soft\r\ngelatin capsule contains Cod Liver Oil BP 0.30 ml (which Provides Vitamin A 600\r\nIU, Vitamin D3 85 IU, Omega-3 fatty acids) and Vitamin E 0.3 IU (as excipient).<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications : </strong>Cod liver oil relieves of joint pains\r\nand stiffness. It is used as prophylaxis for vitamin A & D deficiency. For\r\ndietary supplementation in pregnancy, infancy, childhood & for adults with\r\npoor diet. Cod liver oil builds a healthy body, sturdy bones, strong teeth\r\n& supports healthy skin. Cod liver oil increases resistance against coughs,\r\ncolds and other infections. It has antiarrhythmic, anti-inflammatory,\r\nantihypertensive effects. It decreases triglycerides and increases high density\r\nlipoproteins, facilitates the normal growth, development & function of the\r\nfetus and infant's central nervous system. It also improves the symptoms of\r\nrheumatoid arthritis depression and schizophrenia<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage & Administration </strong><strong>Adults &\r\nchildren over 6 years : </strong>1-2 Cod Liver<strong> </strong>Oil Capsules 3 times daily with\r\nmeals;<strong> Children (under 6 years): </strong>As directed<strong> </strong>by the registered\r\nphysician. <strong>Pregnant & lactating women: </strong>1 capsule 3 times daily with\r\nmeals. Or, as directed by the registered physician.<strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use in pregnancy and lactation :</strong><strong> </strong>Moderate dose of\r\nvitamin A (8000-10000 IU) is safe in pregnancy & lactation.<o:p></o:p></p><p><strong>Packing : Cod\r\nLiver Oil : </strong>Each\r\nbox contains 60's soft Capsules in a blister pack.<br></p><p class=\"MsoNormal\"><o></o></p><p><span></span></p>",
    "strength": "0.3",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1655630727Cod Liver Oil book style insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745138751Cod Liver Oil.png"
    ]
  },
  {
    "id": "888",
    "name": "Combomax ",
    "description": "<p><strong>Composition: </strong>Each Capsule Contains Tamsulosin Hydrochloride modified release & Dutasteride immediate release pellets ph. Gr. eqv to Tamsulosin Hydrochloride USP O.4mg & Dutasteride INN O.5mg.</p><p style=\"text-align: justify;\"><strong>Indications: </strong>This Capsule is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate.</p><p style=\"text-align: justify;\"><strong>Dosage & Administration: </strong>The recommended dose of this capsule is one capsule once daily approximately 30 minutes after the same meal each day.This capsule should be swallowed whole and should not be crushed or chewed. No dosage adjustment is required for subjects with renal impairment or for the elderly. Or, as directed by the registered physicians.</p><p style=\"text-align: justify;\"><strong>Use in Pregnancy & Lactation: </strong>This Capsule is not indicated for use in woman. These Capsules are not indicated for use in nursing mothers.</p><p style=\"text-align: justify;\"><strong>Packing: </strong>Each box contains 4 x 7's capsules in blister pack.</p><p style=\"text-align: justify;\"><br></p>",
    "strength": "0.4,0.5",
    "uom": "mg",
    "categoryId": "46",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531115880Combomax.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745139568Combomax.png"
    ]
  },
  {
    "id": "1189",
    "name": "Cosec Capsule",
    "description": "<p><strong>Composition :</strong> Omeprazole 20mg, 40mg Capsule</p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Indication :</strong> Healing of erosive reflux oesophagitis, Zollinger - Ellison syndrome, For the treatment of gastric ulcers, For the treatment of duodenal ulcers.</p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration :</strong> <strong>Erosive Reflux Oesophagitis :</strong> The recommended dosage is one 20mg Cosec capsule once daily before meal, given for 4 weeks. For those patients not fully healed after the initial course, healing usually occurs during a further 4 weeks treatment. <strong>Patients With Reflux Oesophagitis Refractory to Other Therapy : </strong>The recommended dosage is 40mg Cosec once daily before meal. Healing usually occurs within 8 weeks. <strong>Duodenal Ulcer :</strong> The usual dose is one 20mg Cosec capsule once daily, before meal for 4 weeks. In severe cases the dose may be increased to 40mg Cosec capsule once daily before meal.<strong> Gastric Ulcer :</strong> The usual dose is one 20mg Cosec capsule once daily before meal for 8 weeks. In severe cases, the dose may be increased to 40mg Cosec capsule once daily. Long-term maintenance treatment with Cosec capsule is not recommended. <strong>Zollinger-Ellison Syndrome : </strong>The recommended initial dosage is 60mg (40mg + 20mg) once daily before meal. The dosage should be adjusted individually and treatment continued as long as clinically indicated. More than 90% of patients with severe disease and inadequate response to other therapies have been effectively controlled on doses of 20mg - 120mg daily. With doses above 80mg daily, the dose should be divided and given twice daily. Elderly : Dose adjustment is not required in the elderly. <strong>Children :</strong> There is no experience of the use of Cosec capsule in children.<strong> Impaired Renal or Hepatic Function :</strong> Dose adjustment is not required in patients with impaired renal or hepatic function. Patients with severe liver disease should not require more than one 20mg Cosec daily or as directed by a registered physician.</p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong> Omeprazole has been assigned to pregnancy category C by the FDA.</p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Packing :</strong></p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Cosec 20mg Capsule :</strong> 5 x 10's capsules in blister pack.</p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Cosec 40mg Capsule :</strong> 6 x 7's capsules in blister pack.</p><p><br></p>",
    "strength": "40,20",
    "uom": "mg",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531116493Cosec.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744022594COSEC-40.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744022594COSEC-20.png"
    ]
  },
  {
    "id": "1202",
    "name": "Cosec Injection",
    "description": "<p><strong>Composition:</strong> Omeprazole BP  40mg Injection</p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Indication :</strong> Healing of erosive reflux oesophagitis, Zollinger - Ellison syndrome, For the treatment of gastric ulcers, For the treatment of duodenal ulcers.</p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration </strong>: <strong>Erosive Reflux Oesophagitis : </strong>The recommended dosage is one 20mg Cosec capsule once daily before meal, given for 4 weeks. For those patients not fully healed after the initial course, healing usually occurs during a further 4 weeks treatment. <strong>Patients With Reflux Oesophagitis Refractory to Other Therapy : </strong>The recommended dosage is 40mg Cosec once daily before meal. Healing usually occurs within 8 weeks. <strong>Duodenal Ulcer :</strong> The usual dose is one 20mg Cosec capsule once daily, before meal for 4 weeks. In severe cases the dose may be increased to 40mg Cosec capsule once daily before meal. <strong>Gastric Ulcer :</strong> The usual dose is one 20mg Cosec capsule once daily before meal for 8 weeks. In severe cases, the dose may be increased to 40mg Cosec capsule once daily. Long-term maintenance treatment with Cosec capsule is not recommended. <strong>Zollinger-Ellison Syndrome : </strong>The recommended initial dosage is 60mg (40mg + 20mg) once daily before meal. The dosage should be adjusted individually and treatment continued as long as clinically indicated. More than 90% of patients with severe disease and inadequate response to other therapies have been effectively controlled on doses of 20mg - 120mg daily. With doses above 80mg daily, the dose should be divided and given twice daily. Elderly : Dose adjustment is not required in the elderly. <strong>Children : </strong>There is no experience of the use of Cosec capsule in children.<strong>Impaired Renal or Hepatic Function : </strong>Dose adjustment is not required in patients with impaired renal or hepatic function. Patients with severe liver disease should not require more than one 20mg Cosec daily or as directed by a registered physician.</p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Omeprazole has been assigned to pregnancy category C by the FDA.</p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Packing :</strong></p><p xss=\"removed\" style=\"text-align: justify;\">Cosec 40mg Injection : 1 combipack.</p>",
    "strength": "40",
    "uom": "mg(IV)",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531116704Cosec.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744022626COSEC-40 Injection.png"
    ]
  },
  {
    "id": "1746",
    "name": "Cosec-MUPS 20 ",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition: </strong>Cosec-MUPS 20 Tablet: Each film coated\r\nMUPS (Multiple-Unit Pellet System) tablet contains Omeprazole USP 20mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>It is used for duodenal and Gastric\r\nUlcers, NSAID-induced gastric and duodenal ulcers, Reflux Oesophagitis, GERD (Gastroesophageal\r\nReflux Disease), eradication of H.pylori with appropriate antibiotics\r\n&Zollinger-Ellison Syndrome.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and administration: </strong>Adult from age\r\nof 18 Erosive Reflux Oesophagitis: The recommended dosage is one 20mg once\r\ndaily before meal, given for 4 weeks. For those patients not fully healed after\r\nthe initial course, healing usually occurs during a further 4 weeks treatment.\r\nPatients with Reflux OesophagitisRefractory to Other Therapy: The recommended\r\ndosage is 40mg once daily before meal. Healing usually occurs within 8 weeks.\r\nDuodenal Ulcer: The usual dose is one 20mg once daily, before meal for 4 weeks.\r\nIn severe cases the dose may be increased to 40mg once daily before meal.\r\nGastric Ulcer : The usual dose is one 20mg tablet once daily before meal for 8\r\nweeks. In severe cases, the dose may be increased to 40mg tablet once daily.\r\nLong-term maintenance treatment with is not recommended. Zollinger-Ellison\r\nSyndrome: The recommended initial dosage is 60mg (40mg + 20mg) once daily\r\nbefore meal. The dosage should be adjusted individually and treatment continued\r\nas long as clinically indicated. More than 90% of patients with severe disease\r\nand inadequate response to other therapies have been effectively controlled on\r\ndoses of 20mg 120mg daily,With doses above 80mg daily, the dose should be\r\ndividedand given twice daily. Elderly: Dose adjustment is not required in the\r\nelderly. Or, as directed by the registered physicians.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:</strong>Cosec-MUPS 20\r\nTablet: Each box contains 28's tablets in bister pack.</p>",
    "strength": " 40,20",
    "uom": "mg",
    "categoryId": "37",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744022516COSEC- MUPS 40.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744022516COSEC- MUPS 20.png"
    ]
  },
  {
    "id": "883",
    "name": "COZYME",
    "description": "<p><strong>Composition: </strong><strong>Cozyme-3</strong><strong>0 :</strong> Each Soft Gelatin Capsule contains Coenzyme Q10 (Ubidecarenone) USP 30mg.</p><p style=\"text-align: justify;\"><strong>Cozyme-60 </strong>: Each Soft Gelatin Capsule contains Coenzyme Q10 (Ubidecarenone) USP 60mg.</p><p style=\"text-align: justify;\"><strong>Indications: </strong><span class=\"redactor-invisible-space\"></span>Coenzyme Q1O is indicated for 1. Known coenzyme QI 0 deficiency; 2.Heart failure in adults; 3. To reduce the risk of future cardiac events in patients with recent myocardial infarction; 4. High blood pressure; 5. Isolated systolic hypertension; 6. For preventing migraine headache; 7. Parkinson’s diseases: 8. Infertility in men: 9. Muscular dystrophy; 10. Pre-eclampsia.</p><p style=\"text-align: justify;\"><strong>Dosage & Administration: </strong>Daily doses of Coenzyme 010 range from 30mg - 300mg in divided doses. The following dose have been studied in scientific research : <strong>ORAL:</strong> <strong>Known </strong><strong>coenzymeQlO deficiency : </strong>150mg/day;<strong> </strong><strong>Heart failure in adults :</strong> 100mg/day in 2-3 divided doses; To reduce the risk of future cardiac events in patients with recent<strong> </strong><strong>myocardial infarction : </strong>120mg/day in 2 divided doses;<strong> High blood pressure:</strong> 120- 200mg/day in 2 divided doses;<strong> Isolated </strong><strong>systolic hypertension: </strong>60mg 2 times/day; For preventing <strong><strong>migraine </strong></strong>: 100mg 3 times/day, 1-3mg/kg is used in pediatric and adolescent patients; <strong>Parkinson’s </strong><strong>disease:</strong> 300mg, 600mg, 1200mg and 2400mg/day in 3-4 divided doses; <strong>Infertility in men: </strong>200-300mg/day; <strong>MAscular dystrophy</strong>: 100mg/day; <strong>Pre-eclamsia:</strong>100mg 2 times/day starting at week 20 to pregnancy until delivery. Or, as directed by the registered physician.</p><p style=\"text-align: justify;\"><strong>Pregnancy & Lactation: </strong>Because of lack of information on long term safety, pregnant women and nursing mothers should avoid Coenzyme Q10. Drug Interactions Warfarin: Supplemental Coenzyme 010 may decrease the effectiveness of warfarin. Statins: The stalin drugs are known to decrease Coenzyme Qi 0 levels in humans. Doxorubucin : Coenzyme Q10 may help to increase the cardiotoxicity of doxorubicin. Antidia betic medications: Coenzyme 010 may improve glycemic control in some type II diabetics. If this were to occur, antidiabetics medications might need appropriate adjusting. Beta blockers: Some beta blockers, in particular propanolol, have been reported to inhibit some Coenzyme 010 dependent enzymes.</p><p style=\"text-align: justify;\"><strong>Packing: Cozyme-30: </strong> 3x10’s soft capsules in blister pack.</p><p style=\"text-align: justify;\"><strong>Cozyme-60: </strong> 2x10’s soft capsules in blister<br></p><p style=\"text-align: justify;\"><br></p>",
    "strength": "60,30",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531117106Cozyme.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/COZYME6.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/Cozyme 30 Box.jpg"
    ]
  },
  {
    "id": "1359",
    "name": "Cyphos",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong><u>Composition:</u></strong> <strong>Cyphos-200mg\r\nInjection:</strong> Each vial contains Cyclophosphamide 200mg (As Cyclophosphamide\r\nMonohydrate USP) Lyophilized Powder for Solution for IV Infusion. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Cyphos-1gm Injection:</strong> Each vial contains Cyclophosphamide 1gm (As\r\nCyclophosphamide Monohydrate USP) Lyophilized Powder for Solution for IV\r\nInfusion.</p><p class=\"MsoNormal\" xss=\"removed\"><strong><u>Indications:</u> Malignant diseases:</strong> Cyclophosphamide, although\r\neffective alone in susceptible malignancies, is more frequently used\r\nconcurrently or sequentially with other antineoplastic drugs. The following\r\nmalignancies are often susceptible to Cyclophosphamide treatment: 1. Malignant\r\nlymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s\r\ndisease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma,\r\nhistiocytic lymphoma, Burkitt's lymphoma. 2. Multiple myeloma. 3. Leukemias:\r\nChronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually\r\nineffective in acute blastic crisis), acute myelogenous and monocytic leukemia,\r\nacute lymphoblastic (stem-cell) leukemia in children (Cyclophosphamide given\r\nduring remission is effective in prolonging its duration). 4. Mycosis fungoides\r\n(advanced disease). 5. Neuroblastoma (disseminated disease). 6. Retinoblastoma.\r\n7. Metastasizing and non-metastasizing malignant solid tumors: Ovarian cancer,\r\ntesticular cancer, breast cancer, small cell lung cancer, neuroblastoma,\r\nEwing's sarcoma. 8. Progressive autoimmune diseases: Rheumatoid arthritis,\r\npsoriatic arthropathy, systemic lupus erythematosus, scleroderma, systemic\r\nvasculitides, certain types of glomerulonephritis, myasthenia gravis,\r\nautoimmune hemolytic anemia, cold agglutinin disease.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> Nonmalignant Disease: </strong>Biopsy\r\nProven \"Minimal Change\" Nephrotic Syndrome in Children\r\nCyclophosphamide is useful in carefully selected cases of biopsy proven\r\n\"minimal change\" nephrotic syndrome in children but should not be\r\nused as primary therapy. In children whose disease fails to respond adequately\r\nto appropriate adrenocorticosteroid therapy or in whom the adrenocorticosteroid\r\ntherapy produces or threatens to produce intolerable side effects,\r\nCyclophosphamide may induce a remission. Cyclophosphamide is not indicated for\r\nthe nephrotic syndrome in adults or for any other renal disease.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:</strong> </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Cyphos-200mg Injection:</strong> Each box contains 1 vial of\r\nCyclophosphamide 200mg lyophilized Powder. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Cyphos-1gm\r\nInjection:</strong> Each box contains 1 vial of Cyclophosphamide 1gm lyophilized\r\nPowder.</p>",
    "strength": "1000,200",
    "uom": "mg(IV)",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1551609646Cyphos 1gm 200mg- Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1551609646Cyphos 1mg- Carton Pic.png",
      "https://www.admin.drug-international.com/uploads/product_images/1551609646Cyphos 200mg- Carton Pic.png"
    ]
  },
  {
    "id": "1358",
    "name": "Cytogem",
    "description": "<p class=\"MsoNormal\" xss=removed><strong>Composition\r\n: Cytogem injection :</strong>\r\nEach vial contains Gemcitabine 1 gm as Gemcitabine Hydrochloride USP\r\nlyophilized powder for injection.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed><strong>Cytogem-200\r\ninjection :</strong> Each vial\r\ncontains Gemcitabine USP 200 mg as Gemcitabine Hydrochloride lyophilized powder\r\nfor injection.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed><strong>Indications\r\n: Non-Small Cell Lung Cancer:</strong>\r\nGemcitabine, in combination with Cisplatin, is indicated as a first-line\r\ntreatment of patients  with locally\r\nadvanced (inoperable Stage lllA or IIIB) or metastatic (Stage IV) non-small\r\ncell lung cancer. Gemcitabine is \r\nindicated for the palliative treatment of adult patients with locally\r\nadvanced or metastatic non-small cell lung cancer.<strong>Pancreatic Cancer :</strong> Gemcitabine is indicated for the treatment of\r\nadult patients with locally advanced or metastatic adenocarcinoma of the\r\npancreas. Gemcitabine is indicated for patients with 5-FU refractory pancreatic\r\ncancer. <strong>Bladder Cancer :</strong> Gemcitabine\r\nis indicated for treatment of advanced bladder cancer (muscle invasive Stage IV\r\ntumors with or without metastases) in combination with Cisplatin therapy. <strong>Breast Cancer :</strong> Gemcitabine in\r\ncombination with Paclitaxel, is indicated for the treatment of patients with\r\nmetastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy.\r\nPrior chemotherapy should have included an anthracycline, unless clinically\r\ncontra-indicated. <strong>Ovarian Cancer :</strong>\r\nGemcitabine in combination with Carboplatin, is indicated for the treatment of\r\npatients with recurrent epithelial ovarian carcinoma who have relapsed\r\nfollowing platinum-based therapy.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed><strong>Dosage\r\n& Administration :</strong>\r\nGemcitabine is for intravenous use only. <strong>Non-Small\r\nCell Lung Cancer : (Single-agent Use): Adults - </strong>the recommended dose of\r\nGemcitabine is 1000 mg/m2, given by 30-minute intravenous infusion. This should\r\nbe repeated once weekly for three weeks, followed by a one-week rest period.\r\nThis four-week cycle is then repeated. Dosage reduction with each cycle or\r\nwithin a cycle may be applied based upon the amount of toxicity experienced by\r\nthe patient. <strong>Non-Small Cell Lung Cancer\r\n: (Combination Use) : Adults-</strong> Gemcitabine, in combination with Cisplatin\r\nhas been investigated using two dosing regimens. One regimen used a three-week\r\nschedule and the over used a four-week schedule. The three-week schedule used\r\nGemcitabine 1250 mg/m2, given by 30-minute intravenous infusion, on days 1 and\r\n8 of each 21-day cycle. Dosage reduction with each cycle or within a cycle may\r\nbe applied based upon the amount of toxicity experienced by the patient. The\r\nfour-week schedule used Gemcitabine 1000 mg/m2, given by 30-minute intravenous\r\ninfusion, on days 1,8, and 15 of each 28-day cycle. Dosage reduction with each\r\ncycle or within a cycle may be applied based upon the amount of toxicity\r\nexperienced by the patient . <strong>Pancreatic\r\nCancer : Adults-</strong> The recommended dose of Gemcitabine is 1000 mg/m2, given\r\nby 30-minute intravenous infusion. This should be repeated once weekly for up\r\nto 7 weeks followed by a week of rest. Subsequent cycles should consist of\r\ninjections once weekly for 3 consecutive weeks out of every 4 weeks. Dosage\r\nreduction with each cycle or within a cycle may be applied based upon the\r\namount of toxicity experienced by the patient. <strong>Bladder Cancer : (Single agent use): Adults-</strong> The recommended dose\r\nof Gemcitabine is 1250 mg/m2, given by 30-minute intravenous infusion. The dose\r\nshould be given on days 1,8 and 15 of each 28-day cycle. This 4-week cycle is\r\nthen repeated. Dosage reduction with each cycle or within a cycle may be\r\napplied based upon the amount of toxicity experienced by the patient. <strong>Bladder Cancer : (Combination use): Adults-</strong>\r\nThe recommended dose for Gemcitabine is 1000 mg/m2, given by 30-minute\r\ninfusion, The dose should be given on days 1,8 and 15 of each 28-day cycle in\r\ncombination with Cisplatin. Cisplatin is given \r\nat a recommended dose of 70 mg/m2 on day 1 following Gemcitabine or day\r\n2 of each 28-day cycle. This 4-week cycle is then repeated. Dosage reduction\r\nwith each cycle or within a cycle may be applied based upon the amount of\r\ntoxicity experienced by the patient. A clinical trial showed more\r\nmyelosuppression when Cisplatin was used in doses of 100 mg/m2. <strong>Breast Cancer : (Combination Use): Adults-</strong>\r\nGemcitabine in combination with Paclitaxel is recommended using Paclitaxel (175\r\nmg/m2) administered on Day 1 over approximately 3 hours as an intravenous\r\ninfusion, followed by Gemcitabine (1250 mg/m2) as a 30-minute intravenous\r\ninfusion on Days 1 and 8 of each 21-day cycle. Dose reduction with each cycle\r\nor within a cycle may be applied based upon the amount of toxicity experienced\r\nby the patient. Patients should have an absolute granulocyte count of at least\r\n1,500 (x106/L) prior to initiation of Gemcitabine + Paclitaxel combination. <strong>Ovarian Cancer : (Combination use): Adults-</strong>\r\nGemcitabine in combination with Carboplatin is recommended using  Gemcitabine 1000 mg/m2 administered on days 1\r\nand 8 of each 21-day cycle as a 30-minute intravenous infusion. After\r\nGemcitabine, Carboplatin should be given on day 1 consistent with target AUC of\r\n4.0 mg/mL/min. Dosage reduction with \r\neach cycle or within a cycle may be applied based upon the amount of\r\ntoxicity experienced by the patient. Or, as directed by the registered\r\nphysicians. Please see the enclosed insert.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed><strong>Use\r\nin pregnancy and lactation :</strong>\r\nPregnancy Category D. Gemcitabine should be used during pregnancy. It is not\r\nknown whether Gemcitabine is excreted in human breast milk.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed><strong>Packing\r\n: Cytogem injection :</strong>\r\nEach box contains one vial of Gemcitabine Hydrochloride USP 1 gm lyophilized\r\nfor injection.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed><strong>Cytogem-200\r\ninjection :</strong> Each box\r\ncontains one vial of Gemcitabine Hydrochloride USP 200 mg lyophilized powder\r\nfor injection.</p>\r\n\r\n",
    "strength": "1000,200",
    "uom": "mg(IV)",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1550294386Cytogem web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1550294386Cytogem 1 gm Inj- Carton Pic.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1550294386Cytogem 200 mg Inj- Carton Pic.jpg"
    ]
  },
  {
    "id": "1342",
    "name": "Cytomia",
    "description": "<p><strong>COMPOSITION:</strong> Cytomia Injection: Each vial\r\ncontains Cytarabine USP 100 mg (100 mg / 1 ml).</p><p class=\"MsoNormal\" xss=\"removed\"><strong>INDICATIONS:</strong> Cytarabine may be used alone or in\r\ncombination with other chemotherapeutic agents. It is indicated for induction\r\nof remission of leukaemia, particularly for acute myeloid leukaemia, in adults\r\nand children. Cytarabine has been used for remission induction in acute\r\nlymphocytic leukaemia, chronic myeloid leukaemia and erythroleukaemia; and in\r\nthe treatment and maintenance therapy of meningeal leukaemia and other\r\nmeningeal neoplasms. Chidren with non-Hodgkin's lymphoma have beneﬁtted from a\r\ncombination drug programme (LSA2L2) that includes cytarabine<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>DOSAGE AND\r\nADMINISIRATION</strong>\r\nBeing orally inactive, cytarabine is administered by a variety of parenteral\r\nroutes: subcutaneously, intravenously either as a bolus \"push\" or as\r\na continuous infusion, or intrathecally. Thrombophlebitis has occurred at the\r\nsite of drug injection or infusion in some patients. Pain and inﬂammation at\r\nsubcutaneous injection sites are rare. Subcutaneous injection sites should be\r\nrotated around the areas of body fat: the abdomen, thighs and ﬂank region. The\r\ndrug is generally well tolerated in most instances. Higher total doses can be\r\nbetter tolerated when administered by rapid IV injection as compared to slow\r\ninfusion. Such a phenomenon can be explained by the rapid inactivation of the\r\ndrug and the brief exposure of susceptible normal neoplastic cells to\r\nsigniﬁcant levels after rapid injection. Normal and neoplastic cells appear to\r\nrespond in almost parallel manner to these two modes of administration and no\r\ndistind advantage has been established for either. Clinical experience to date\r\nindicates that success with cytarabine therapy depends more on adeptness in\r\nmodifying day-to-day dosage to obtain maximum leukaemic cell killed with\r\ntolerable toxicity, then on the fundamental treatment protocol selected at the\r\nstart of therapy.Toxicity necessitating dosage modiﬁcation almost always\r\noccurs. Dosage of cytarabine must be based on the clinical and haematological\r\nresponse and tolerance of the patient so as to obtain optimum therapeutic\r\nresults with minimum adverse effects. Even though higher total doses of\r\ncytarabine can be given by IV injection compared to continuous IV infusion with\r\nsimilar haematologic toxicity, the most effective dosage schedule and method of\r\nadministration are yet to be established. Moreover, cytarabine is often used in\r\ncombination with other cytotoxic drugs, thereby necessitating dose modiﬁcation\r\nof cytarabine and other chemotherapeutic agents, and the method as well as the\r\nsequence of administration. Following is an outline of dosage schedules for\r\ncytarabine therapy as reported in the literature.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy</strong>: Cytarabine is suspected to have\r\ncaused or may be expected to cause an increased incidence of human fetal\r\nmalformations or irreversible damages. It may also have adverse pharmacological\r\neffects. Cytarabine has been shown to be teratogenic in some animal species and\r\nshould not be used during pregnancy, especially during the ﬁrst trimester, not\r\nin women likely to become pregnant.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"> <strong>Use in\r\nLactation:</strong> It is not known whether cytarabine is excreted in human milk.\r\nWomen should be advised not to breast feed while being treated with cytarabine,\r\nbecause of the risks to the infant<o></o></p><p><strong>Packaging:</strong> Cytomia Injection: Each commercial\r\nbox contains 1 vial of Cytarabine 100 mg Injection</p>",
    "strength": "100",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1537950642Cytomia- Insert-2.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1537950642Cytomia- Carton Pic1.jpg"
    ]
  },
  {
    "id": "1290",
    "name": "D-CAP",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong><strong> </strong><strong>D-CAP\r\n800 : </strong>Each Soft Gelatin Capsule Contains Colecalciferol (Vitamin D3)</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">BP 800 IU.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>D-CAP\r\n1000 : </strong>Each Soft Gelatin Capsule Contains Colecalciferol (Vitamin D3) BP\r\n1000 IU.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>D-CAP\r\n2000 : </strong>Each Soft Gelatin Capsule Contains Colecalciferol (Vitamin D3) BP\r\n2000 IU.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>D-Cap\r\n20000 : </strong>Each Soft Gelatin Capsule Contains Colecalciferol (Vitamin D3) USP\r\n20000 IU.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>D-Cap\r\n40000 : </strong>Each Soft Gelatin Capsule Contains Colecalciferol (Vitamin D3) USP\r\n40000 IU.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indication :</strong><strong> </strong>It\r\nis indicated in the prevention and treatment of vitamin D3 deficiency. As adadjunct\r\nto specific therapy for osteoporosis in patients with vitamin D3 deficiency or\r\nat risk ofvitamin D3 insufficiency.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage & Administration :</strong><strong> </strong><strong>Use\r\nin adults :</strong>The recommended dose for :<strong>Prevention of vitamin D deficiency : </strong>1000<strong>\r\n</strong>IU/day or (20000 IU) once a month.<strong> Addition to specific therapy for osteoporosis:\r\n</strong>1,000 IU/day or (20000 IU) once a month.<strong>Treatment of vitamin D\r\ndeficiency:</strong>1000 IU-4,000 IU/day for up to 12 weeks, followed bymaintenance\r\ntherapy of 1400 IU-2000 IU/day or<strong> </strong>40000 IU once weekly for 7 weeks,\r\nfollowed by<strong> </strong>maintenance\r\ntherapy such as 2-3 capsule per<strong> </strong>month.<strong></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use in children\r\nand adolescents : </strong>The\r\nrecommended dose for :</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">* <strong>Prevention of deficiency\r\n10-18 years :</strong>doses of up to 1000 IU/day may be required to<strong> </strong>prevent deficiency\r\nin some children.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">* <strong>Treatment of deficiency\r\n10-18 years : </strong>2000 IU/day for 6 weeks followed by a maintenance therapy of\r\n400 IU-1000 IU/day (such as one 1000 IU soft capsule per day). Or, as directed\r\nby the registered physician.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use in Pregnancy and Lactation :</strong><strong> </strong>If\r\nanyone are pregnant or breast-feeding, think may be pregnant or are planning to\r\nhave a baby, should consult with doctor or pharmacist for advice before taking\r\nthis medicine.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Packing :</strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong><strong>D-CAP 800 : </strong>Each\r\nbox contains 60's soft capsules in blister pack._</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>D-CAP\r\n1000 : </strong>Each box contains 60's soft capsules in blister pack._</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>D-CAP\r\n2000 : </strong>Each box contains 50's soft capsules in blister pack.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>D-Cap\r\n20000 : </strong>Each box contains 10's soft capsules in blister pack.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>D-Cap\r\n40000 : </strong>Each box contains 10's soft capsules in blister pack.</p>",
    "strength": " 2000, 1000,800",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "67",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745139902D-CAP 2000.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745139902D-CAP 1000.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745139902D-CAP 800.png"
    ]
  },
  {
    "id": "1287",
    "name": "D-Cap 20000",
    "description": "<p><strong>Composition: </strong>D-Cap 20000 : Each Soft Gelatin Capsule Contains Colecalciferol (Vitamin D3) USP 20000 IU.</p><p style=\"text-align: justify;\"><strong>Indications: </strong>It is indicated in the prevention and treatment of vitamin D3 deficiency. As an adjunct to specific therapy for osteoporos is in patients with vitamin D3 deficiency or at risk of vitamin D3 insufficiency. Vitamin D3 20000 IU Capsules is indicated in adults .</p><p style=\"text-align: justify;\"><strong>Dosage & Administration: </strong>Prevention of Vitamin D3 deficiency :Starting dose of 1 capsule (20000 IU) once a month. As an adjunct to specific therapy for os teoporos is : 1 capsule (20000 IU) once a month.Treatment of Vitamin D3 deficiency :40000 IU once weekly for 7 weeks , followed by maintenance therapy such as 2-3 capsules per month. Or, as directed by the registered physician.</p><p style=\"text-align: justify;\"><strong>Use in Pregnancy & Lactation: </strong>This High Strength Formulation is not recommended in Pregnancy and Lactation.</p><p style=\"text-align: justify;\"><strong>Packing: </strong>D-Cap 20000 : Each box contains 1x10's soft capsules in blister pack.</p>",
    "strength": "20000",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1517303964D-cap20_40insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745309711D-CAP 20000.png"
    ]
  },
  {
    "id": "1289",
    "name": "D-Cap 40000",
    "description": "<p><strong>Composition: </strong>D-Cap 40000 : Each Soft Gelatin Capsule Contains Colecalciferol (Vitamin D3) USP 40000 IU.</p><p><o></o></p><p><strong>Indications: </strong>It is indicated in the prevention and treatment of vitamin D3 deficiency. As an adjunct to specific therapy for osteoporos is in patients with vitamin D3 deficiency or at risk of vitamin D3 insufficiency. Vitamin D3 40000 IU Capsules is indicated in adults .<o></o></p><p><strong>Dosage & Administration: </strong>Prevention of Vitamin D3 deficiency :<o></o></p><p>Starting dose of 1 capsule (20000 IU) once a month. As an adjunct to specific therapy for os teoporos is : 1 capsule (20000 IU) once a month.<o></o></p><p>Treatment of Vitamin D3 deficiency :40000 IU once weekly for 7 weeks , followed by maintenance therapy such as 2-3 capsules per month. Or, as directed by the registered physician.<o></o></p><p><strong>Use in Pregnancy & Lactation: </strong>This High Strength Formulation is not recommended in Pregnancy and Lactation.<o></o></p><p><o></o></p><p><strong>Packing: </strong>D-Cap 40000 : Each box contains 1x10's soft capsules in blister pack.</p>",
    "strength": "40000",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1517304469D-cap20_40insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745309760D-CAP 40000.png"
    ]
  },
  {
    "id": "1167",
    "name": "D-Dopa",
    "description": "<p style=\"margin-top:0in;margin-right:0in;margin-bottom:5.35pt;margin-left:\r\n0in;background:white\"><strong>Levodopa & Carbidopa</strong></p><p style=\"margin-top:0in;margin-right:0in;margin-bottom:5.35pt;margin-left:\r\n0in;background:white\"><strong>Composition : </strong>D-dopa 110 :<strong> </strong>Levodopa USP 100 mg + Carbidopa USP 10 mg\r\nTablet.</p><p style=\"margin-top:0in;margin-right:0in;margin-bottom:5.35pt;margin-left:\r\n0in;text-align:justify;background:white\">D-dopa 275 : Levodopa\r\nUSP 250 mg + Carbidopa USP 25 mg Tablet.</p><p style=\"margin-top:0in;margin-right:0in;margin-bottom:5.35pt;margin-left:\r\n0in;text-align:justify;background:white\"><strong>Indications : </strong>D-dopa is indicated for the treatment of idiopathic Parkinson's\r\ndisease, post-encephalitic parkinsonism and symptomatic parkinsonism which may\r\nfollow injury to the nervous system by carbon monoxide intoxication or\r\nmanganese intoxication.</p><p style=\"margin-top:0in;margin-right:0in;margin-bottom:5.35pt;margin-left:\r\n0in;text-align:justify;background:white\"><strong>Dosage and administration\r\n: </strong>Dosage is initiated with 50-100mg Levodopa and 10-\r\n12.5mg Carbidopa 3-4 times daily. If necessary dosage may be increased by\r\n50-100mg daily or on alternate days according to response upto Levodopa 800mg\r\nand Carbidopa 80-100mg daily in divided doses. Or, as directed by the\r\nregistered physician.</p><p style=\"margin-top:0in;margin-right:0in;margin-bottom:5.35pt;margin-left:\r\n0in;text-align:justify;background:white\"><strong>Pregnancy and\r\nlactation : </strong>Pregnancy Category C.</p><p style=\"margin-top:0in;margin-right:0in;margin-bottom:5.35pt;margin-left:\r\n0in;text-align:justify;background:white\"><strong>Packing :</strong></p><p style=\"margin-top:0in;margin-right:0in;margin-bottom:5.35pt;margin-left:\r\n0in;text-align:justify;background:white\">D-dopa 110 : 3x10's\r\ntablets in blister pack.</p><p style=\"margin-top:0in;margin-right:0in;margin-bottom:5.35pt;margin-left:\r\n0in;text-align:justify;background:white\">D-dopa 275 : 5x10's\r\ntablets in blister pack.</p>",
    "strength": "250+25,100+10",
    "uom": "mg",
    "categoryId": "48",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531196402D-Dopa.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745140220D-dopa 275.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745140220D-dopa 110.png"
    ]
  },
  {
    "id": "978",
    "name": "D-Dopamine",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition :</strong> Dopamine\r\nhydrochloride USP 200mg concentrated sterile solution.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indications :</strong> Shock\r\nsymptom due to myocardial infarction, trauma, endotoxic septicemia, renal\r\nfailure, open heart surgery, chronic cardiac decompensation as in refractory\r\ncongestive failure.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration :</strong>\r\nInfusion of dopamine hydrochloride solution should be started at doses of\r\n2.5mcg/kg/min in patients who are likely to respond to modest increments of\r\nheart force & renal perfusion. In more seriously ill patients, begin\r\ninfusion of dopamine hydrochloride solution at doses of 5mcg/kg/min and\r\nincrease gradually using 5 to 10 mcg/kg/min increments up to a rate of 20 to 50\r\nmcg/kg/min as needed. In patients who do not respond to this doses, additional\r\nincrements of dopamine may be give in an effort to achieve adequent blood\r\npressure urine flow and perfusion. Or as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dilution for IV infusion :</strong>\r\nD-Dopamine is administered by intravenous infusion as a dilute solution\r\n(usually 1.6 to 3.2mg/ml) in 5% glucose, 0.9% sodium chloride solution or other\r\nsuitable diluents.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Packing :</strong> <strong>D-Dopamine injection :\r\n</strong>Each box contains 1 x 3's ampoules in blister pack.</p><p class=\"MsoNormal\" xss=\"removed\"><br></p>",
    "strength": "200",
    "uom": "mg/5ml",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531197236D-Dopamine.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745302409D-Dopamine.png"
    ]
  },
  {
    "id": "850",
    "name": "D-FEN",
    "description": "<p><strong>Composition :</strong>Pizotifen Malate 0.5mg.\r\n& 1.5mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Pizotifen (D-fen) is indicated\r\nfor the prophylactic treatment of vascular\r\nheadaches of migraine type such as\r\nclassical migraine, common migraine and\r\ncluster headache.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The\r\nrecommended dose is as followings : Adult:\r\nThe initial dose is 1.5mg daily; this may be\r\ntaken at bedtime as a single dose or in\r\nthree divided doses. Dosage can be\r\nadjusted according to the individual\r\npatient's requirements up to a maximum of\r\n4.5mg daily. Up to 3mg may be given as a\r\nsingle daily dose.\r\nChildren : Up to 1.5mg daily, usually as a\r\ndivided dose. Use of 1.5mg at a time is not\r\nrecommended, but up to 1mg can be given\r\nas a single daily dose at night. Children\r\nbelow two years of age should not be given\r\npizotifen (D-fen). Or, as directed by the\r\nregistered physician.\r\n</span></p><p style=\"text-align: justify;\"><strong>Pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">As clinical\r\ndata with Pizotifen in pregnancy is very\r\nlimited, it should only be administered\r\nduring pregnancy under compelling\r\ncircumstances. </span><br></p><p style=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><strong> </strong> D-fen 0.5 : 5x10’s tablets in blister pack. </p><p style=\"text-align: justify;\">D-fen 1.5 : 5x10’s tablets in blister pack.</p>",
    "strength": "1.5,0.5",
    "uom": "mg",
    "categoryId": "42",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531197451D-FEN.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744024074D-fen 1.5.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744024073D-fen 0.5.png"
    ]
  },
  {
    "id": "1172",
    "name": "D-pira ",
    "description": "<p><strong></strong><strong>Composition : </strong>Piracetam BP 800 mg Tablet.</p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Indications : </strong>Piracetam is indicated for patients suffering from myoclonus of cortical origin. Cerebral vascular accidents like stroke, head injuries and other acute cases. Aging disorders such as reduced cerebral functioning evidenced by memory loss, intellectual decay, character disorders, psychomotor disorders etc. It is also used for the treatment of mental retardation in children.</p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> Initially 7.2 gm daily in 2-3 divided dose, increased according to response by 4.8 gm every 3-4 days to max. 24gm daily (subsequently, attempts should be made to reduce dose of concurrent therapy). Child under 16 years not recommended. Or, as directed by the registered physicians.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>There are no adequate and wellcontrolled studies in pregnant women. Piracetam passes into breast milk. Piracetam is to be avoided during pregnancy and lactation.<span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\">D-pira : 3 x 10's tablets in blister pack.<br></p>",
    "strength": "800",
    "uom": "mg",
    "categoryId": "48",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531197691D-Pira.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745142490D-pira.png"
    ]
  },
  {
    "id": "1173",
    "name": "D-Toin ",
    "description": "<p><strong></strong><strong>Composition : </strong>Phenytoin USP 100mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indications : </strong>Phenytoin is an anticonvulsant which is used in the treatment of status epilepticus of the grandmal type. It may also be used in the prevention and treatment of seizures occur during neurosurgery.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong>Adults: 150-300mg (as a single dose or in 2 divided doses) daily increased to 400mg (Maximum 600mg/day) daily in divided doses or 3-4mg/kg daily in divided doses. For adult patients (who have received no previous medication) the treatment is one tablet three times daily. Children: Initially, 5mg/kg per day in two or three equally dosage with subsequent dosage individualized to a maximum 300mg daily. A recommended daily maintenance dosage is usually 4 to 8 mg/kg. Or, as directed by the registered physicians.</p><p style=\"text-align: justify;\"><strong>Use in Pregnancy and lactation :</strong> Pregnancy Category D. </p><p style=\"text-align: justify;\"><strong>Packing : </strong>D-Toin : 10 x 10's tablets in blister pack.</p>",
    "strength": "100",
    "uom": "mg",
    "categoryId": "48",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531197917D-Toin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744025288D-Toin.png"
    ]
  },
  {
    "id": "1755",
    "name": "D-Zole",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:\r\n</strong>Each Film Coated Tablet Contains Secnidazole INN 1000 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>Secnidazole\r\nis used in the treatment of Intestinal amoebiasis, Hepatic amoebiasis,\r\nUrethritis and vaginitis due to Trichomonas vaginalis, Giardiasis.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration: </strong>Secnidazole\r\ntablet should be administered orally. The dosages schedule of this tablet is\r\nmentioned below: Acute Intestinal Amoebiasis: Adults: 2 gm single dose, taken\r\npreferably just before meal. Children: 30mg/kg single dose, taken<br>\r\npreferably just before meal. Asymptomatic Amoebiasis (minute & cystic\r\nform): Adults: 2gm once daily for only 3 days, taken preferably just before\r\nmeal. Children: 30 mg/kg once daily for only 3 days, taken preferably just\r\nbefore meal. Hepatic Amoebiasis:Adults: 1 .50gm/day in a single or divided\r\ndose, just before meal, for 5 days. Children: 30mg/kg/day in a single or\r\ndivided dose, just before meal, for 5 days. N.B. Evacuation of pus must be\r\nperformed simultaneously with Secnidazole treatment at the suppurative stage of\r\nhepatic amoebiasis. Giardiasis: Adults: 2 gm single dose, taken preferably just\r\nbefore meal. Children: 35-50mg/kg single dose, taken preferably just before\r\nmeal. Trichomoniasis: Adults: 2gm single dose, taken preferably just before\r\nmeal. The partner should also receive the same treatment concomitantly. Or, as\r\ndirected by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and Lactation:</strong> Secnidazole may be prescribed in pregnancy after the first\r\ntrimester. As with other similar drugs, Secnidazole should not be administered\r\nduring the first trimester of pregnancy or lactation because secnidazole is\r\nfound in placenta and breast milk.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:\r\n</strong>Each box contains 2 x 5's tablets in blister pack.<strong></strong></p>",
    "strength": "1000 ",
    "uom": "mg",
    "categoryId": "43",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1614491185D-Zole Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740570270DZOLE_TOP.png"
    ]
  },
  {
    "id": "1740",
    "name": "Dalatic injection",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;text-align:justify;line-height:\r\n12.0pt\"><strong>Composition:</strong><o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;text-align:justify;line-height:\r\n12.0pt\"><strong>Dalatic-300: Clindamycin\r\nUSP 300mg Capsule.</strong><o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;text-align:justify;line-height:\r\n12.0pt\"><strong>Dalatic-300\r\nInjection (IV/IM): </strong>Clindamycin\r\nUSP 300mg/2ml Injection.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;text-align:justify;line-height:\r\n12.0pt\"><strong>Dalatic-600\r\nInjection (IV/IM): </strong>Clindamycin\r\nUSP 600mg/4ml Injection.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;text-align:justify;line-height:\r\n12.0pt\"><strong>Indications: </strong>Clindamycin is indicated in the treatment of\r\nthe following infections casued by susceptible anaerobic bacteria or\r\nsusceptible strains of gram positive bacteria such as streptococci, Pneumococci\r\nand staphylococci in Lower respiratory tract infections, skin and soft tissue\r\ninfections, Bone and joint infections, Septicemia, Dental infections and also\r\nindicated for the treatment of AIDS associated Pneumonia.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;text-align:justify;line-height:\r\n12.0pt\"><strong>Dosage\r\nand Adminstration: Dosage of Dalactic Capsule: Adult Patients: </strong>Serious infections: 150 to 300mg every 6\r\nhours. More severe infections: 300 to 450mg every 6 hours. <strong>Pediatric Patients:</strong> Serious infections: 8 to 16mg/kg/day\r\ndivided into three or four equal doses. More severe infections: 16 to 20mg/kg/day\r\ndivided into three or four equal doses. To avoid the possibility of esophageal\r\nirritation, Clindamycin capsules should be taken with a full glass of water. In\r\ncases of β-hemolytic streptococcalinfections, treatment should continue for at\r\nleast 10 days. <o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;text-align:justify;line-height:\r\n12.0pt\"><strong>Dosage\r\nof Dalatic Injection (IV/IM): Adults: </strong>For Serious infections: 600-1200mg/day in 2-4 equal doses. More\r\nsevere infections, 1200-2700 mg/day in 2-4 equal doses. For more Serious\r\ninfections, these doses may have to be increased. Doses of as much as 4800 mg\r\ndaily have been given intravenously to adults.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;text-align:justify;line-height:\r\n12.0pt\">For Detail Please see\r\nPDF File.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;text-align:justify;line-height:\r\n12.0pt\"><strong>Use\r\nin pregnancy & lactation: </strong>Pregnancy category B.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;text-align:justify;line-height:\r\n12.0pt\"><strong>Packing:</strong> <strong>Dalatic-300:</strong> 2 x 7’s capsules in blister pack.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;text-align:justify;line-height:\r\n12.0pt\"><strong>Dalatic-300\r\nInjection (IV/IM): </strong>1\r\nx 5’s ampoules in blister pack.<o:p></o:p></p><p><strong>Dalatic-600\r\nInjection (IV/IM): </strong>1\r\nx 3’s ampoules in blister pack.</p>",
    "strength": " 600mg,300mg",
    "uom": "ML",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1611547588Dalatic Cap & Injection Insert Final 2021.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745139844Dalatic 600.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745139844Dalatic 300.png"
    ]
  },
  {
    "id": "1739",
    "name": "Dalatic plus gel",
    "description": "<p xss=\"removed\"><strong>Dalatic\r\nPlus</strong></p><p class=\"MsoNormal\" align=\"center\" xss=\"removed\"><strong>Clindamycin\r\nPhosphate USP & Tretinoin USP<o></o></strong></p><p class=\"MsoNormal\"><strong>Composition:\r\nDalatic Plus:</strong> Clindamycin Phosphate USP 1.2% &\r\nTretinoin USP 0.025% Gel.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:\r\n</strong>This\r\ngel is indicated for the topical treatment of acne vulgaris in patients 12\r\nyears or older.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand Adminstration: </strong>Clindamycin & Tretinoin gel should\r\nbe applied once daily in the evening, gently rubbing the medication to lightly\r\ncover the entire affected area. Approximately a pea sized amount will be needed\r\nfor each application. Avoid the eyes, lips, and mucous membranes. Clindamycin\r\n& Tretinoin gel is not for oral, ophthalmic or intravaginal use. Or, as\r\ndirected by the registered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy & lactation: </strong>There are no\r\nwell-controlled studies in pregnant women treated clindamycin phosphate and\r\ntretinoin gel. This gel should be used during pregnancy only if the potential\r\nbenefit justifies the potential risk to the fetus. It is not known whether clindamycin\r\nis excreted in human milk following use of clindamycin phosphate and tretinoin\r\ngel. Because many drugs are excreted in human milk, caution should be exercised\r\nwhen this gel is administered to a nursing woman.<o></o></p><p><strong>Packing:</strong>\r\n<strong>Dalatic Plus:</strong> 15gm gel in a tube.</p>",
    "strength": "1.2% & 0.025%",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1611397112Dalatic Plus Gel Insert Final 2021.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745139799Dalatic Plus Gel.png"
    ]
  },
  {
    "id": "1738",
    "name": "Dalatic-300 capsule",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;line-height:12.0pt\"><strong>Composition: </strong><strong>Dalatic-300:</strong> Clindamycin USP 300mg Capsule.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;line-height:12.0pt\"><strong>Dalatic-300 Injection\r\n(IV/IM): </strong>Clindamycin USP\r\n300mg/2ml Injection.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;line-height:12.0pt\"><strong>Dalatic-600 Injection\r\n(IV/IM): Clindamycin USP 600mg/4ml Injection.</strong><o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;line-height:12.0pt\"><strong>Indications: </strong>Clindamycin is indicated in the treatment of\r\nthe following infections casued by susceptible anaerobic bacteria or\r\nsusceptible strains of gram positive bacteria such as streptococci, Pneumococci\r\nand staphylococci in Lower respiratory tract infections, skin and soft tissue\r\ninfections, Bone and joint infections, Septicemia, Dental infections and also\r\nindicated for the treatment of AIDS associated Pneumonia.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;line-height:12.0pt\"><strong>Dosage and\r\nAdminstration: Dosage of Dalactic Capsule: Adult Patients: </strong>Serious infections: 150 to 300mg every 6\r\nhours. More severe infections: 300 to 450mg every 6 hours. <strong>Pediatric Patients:</strong> Serious infections: 8 to 16mg/kg/day\r\ndivided into three or four equal doses. More severe infections: 16 to\r\n20mg/kg/day divided into three or four equal doses. To avoid the possibility of\r\nesophageal irritation, Clindamycin capsules should be taken with a full glass\r\nof water. In cases of β-hemolytic streptococcalinfections, treatment should\r\ncontinue for at least 10 days. <strong>Dosage of Dalatic Injection (IV/IM):\r\nAdults: </strong>For Serious\r\ninfections: 600-1200mg/day in 2-4 equal doses. More severe infections,\r\n1200-2700 mg/day in 2-4 equal doses. For more Serious infections, these doses\r\nmay have to be increased. Doses of as much as 4800 mg daily have been given\r\nintravenously to adults.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;line-height:12.0pt\">For Detail Please see PDF File.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;line-height:12.0pt\"><strong>Use in pregnancy &\r\nlactation: </strong>Pregnancy category B.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;line-height:12.0pt\"><strong>Packing:</strong> <strong>Dalatic-300:</strong> 2 x 7’s capsules in blister pack.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;line-height:12.0pt\"><strong>Dalatic-300 Injection\r\n(IV/IM): </strong>1 x 5’s ampoules in\r\nblister pack.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:3.55pt;line-height:12.0pt\"><strong>Dalatic-600 Injection\r\n(IV/IM): </strong>1 x 3’s ampoules in\r\nblister pack.<o:p></o:p></p>",
    "strength": "300",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1686545182Dalatic-300 Insert for Web (Not Usual Format).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745139772Dalatic 300 capsules.png"
    ]
  },
  {
    "id": "928",
    "name": "Daparol",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Dapagliflozin INN 5 mg\r\nTablet.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong>Dapagliflozin is indicated\r\nas an adjunct to diet and exercise to\r\nimprove glycemic control in adults with\r\ntype 2 diabetes mellitus </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The\r\nrecommended starting dose is 5 mg\r\nonce daily, taken in the morning, with or\r\nwithout food. It may increase to 10 mg\r\norally once a day in patients tolerating\r\ntherapy with 5 mg and requiring\r\nadditional glycemic control. Or, as\r\ndirected by the registered physicians.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Daparol : 1 x 14's tablets in\r\nblister pack.</span></p>",
    "strength": "5",
    "uom": "mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531198820daparol.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1659605879Daparol-5.png"
    ]
  },
  {
    "id": "1748",
    "name": "Dasinib",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition</strong>: Each\r\nfilm coated tablet contains Dasatinib 100 mg as Dasatinib Monohydrate INN.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong><strong> </strong>Dasatinib is indicated for the treatment of adult patients with<strong></strong></p><p class=\"MsoListParagraphCxSpFirst\" xss=\"removed\">·        \r\nNewly diagnosed\r\nPhiladelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in\r\nchronic phase.</p><p class=\"MsoListParagraphCxSpMiddle\" xss=\"removed\">·        \r\nChronic, accelerated, or\r\nmyeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior\r\ntherapy including Imatinib.</p><p class=\"MsoListParagraphCxSpLast\" xss=\"removed\">·        \r\nPhiladelphia\r\nchromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or\r\nintolerance to prior therapy.</p><p class=\"MsoNormal\" xss=\"removed\">Dasatinib\r\nis indicated for the treatment of pediatric patients 1 year of age and older\r\nwith</p><p class=\"MsoListParagraphCxSpFirst\" xss=\"removed\">·        \r\nPh+ CML in chronic phase.</p><p class=\"MsoListParagraphCxSpLast\" xss=\"removed\">·        \r\nNewly diagnosed Ph+ ALL in\r\ncombination with chemotherapy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and\r\nAdministration:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage of Dasatinib in\r\nAdult Patients: </strong>The recommended starting dosage of\r\nDasatinib for chronic phase CML in adults is 100 mg administered orally once\r\ndaily. The recommended starting dosage of Dasatinib for accelerated phase CML,\r\nmyeloid or lymphoid blast phase CML, or Ph+ ALL in adults is 140 mg\r\nadministered orally once daily. Tablets should not be crushed, cut, or chewed;\r\nthey should be swallowed whole. The exposure in patients receiving a crushed\r\ntablet is lower than in those swallowing an intact tablet. Dasatinib can be\r\ntaken with or without a meal, either in the morning or in the evening.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage of Dasatinib in Pediatric Patients: </strong>With CML, or Ph+ ALL: The recommended\r\nstarting dosage for pediatrics is based on body weight as shown in Table. The\r\nrecommended dose should be administered orally once daily with or without food.\r\nThe dose should be recalculated every 3 months based on changes in body weight,\r\nor more often if necessary.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"center\"><strong>Table: Dosage of Dasatinib for Pediatric Patients<sup>a</sup></strong></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\">\r\n <tbody><tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"204\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" align=\"center\"><strong>Body Weight (kg)<sup>b</sup></strong><sup></sup></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"198\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" align=\"center\"><strong>Daily Dose (mg)</strong></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"204\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" align=\"center\">1 0 to less than 20</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"198\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" align=\"center\">40 mg</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"204\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" align=\"center\">20 to less than 30</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"198\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" align=\"center\">60 mg</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"204\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" align=\"center\">30 to less than 45</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"198\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" align=\"center\">70 mg</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"204\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" align=\"center\">at least 45</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"198\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" align=\"center\">1 00 mg</p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\" xss=\"removed\"><sup>a</sup>For pediatric patients with Ph+ALL, begin Dasatinib therapy on\r\nor before day 15 of induction chemotherapy, when diagnosis is confirmed and\r\ncontinue for 2 years.</p><p class=\"MsoNormal\" xss=\"removed\"><sup>b</sup>Tablet dosing is not recommended for patients weighing less than\r\n10 kg.</p><p class=\"MsoNormal\" xss=\"removed\">Or, as\r\ndirected by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and\r\nLactation: </strong>Dasatinib can cause fetal harm when administered to a pregnant\r\nwoman. Females of reproductive potential should be advised to avoid pregnancy,\r\nwhich may include the use of effective contraceptive methods, during treatment\r\nwith Dasatinib and for 30 days after the final dose. Women should be advised\r\nthat breastfeeding is not recommended during treatment with Dasatinib and for 2\r\nweeks after the final dose.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: </strong>Each\r\nbox contains 20 tablets in Alu-Alu blister pack.</p>",
    "strength": "100",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1614413269Dasinib Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740569692dasinib.png"
    ]
  },
  {
    "id": "1749",
    "name": "Daxotel",
    "description": "<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Composition:\r\nDaxotel-20:</strong> Each vial contains Docetaxel Anhydrous\r\nUSP 20mg/ml.<br>\r\n<strong>Daxotel-80:</strong> Each vial contains\r\nDocetaxel Anhydrous USP 80mg/4ml.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"> </p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications:\r\nBreast Cancer (BC):</strong> Docetaxel is indicated\r\nfor the treatment of patients with locally advanced or metastatic breast cancer\r\nafter failure of prior chemotherapy. Docetaxel in combination with Doxorubicin\r\nand Cyclophosphamide is indicated for the adjuvant treatment of<br>\r\npatients with operable node-positive breast cancer. <strong>Non-small Cell Lung Cancer (NSCLC):</strong> Docetaxel as a single agent is\r\nindicated for the treatment of patients with locally advanced or metastatic\r\nnon-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel\r\nin combination with Cisplatin is indicated for the treatment of patients with\r\nunresectable, locally advanced or metastatic non-small cell lung cancer who\r\nhave not previously received chemotherapy for this condition. <strong>Castration-Resistant Prostate Cancer\r\n(CRPC):</strong> Docetaxel in combination with prednisone is indicated for the\r\ntreatment of patients with metastatic castration-resistant prostate cancer. <strong>Gastric Adenocarcinoma (GC):</strong> Docetaxel\r\nin combination with Cisplatin and Fluorouracil is indicated for the treatment\r\nof patients with advanced gastric adenocarcinoma, including adenocarcinoma of\r\nthe gastroesophageal junction, who have not received prior chemotherapy for\r\nadvanced disease. <strong>Squamous Cell\r\nCarcinoma of the Head and Neck (SCCHN):</strong> Docetaxel in combination with\r\nCisplatin & Fluorouracil is indicated for the induction treatment of\r\npatients with locally advanced squamous cell carcinoma of the head & neck (SCCHN).\r\n<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"> </p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage\r\nand Administration: Breast Cancer:</strong> For locally advanced\r\nor metastatic breast cancer after failure of prior chemo therapy, the\r\nrecommended dose of Docetaxel is 60mg/m<sup>2</sup> to 100mg/m<sup>2</sup>\r\nadministered intra venously over 1 hour every 3 weeks. <strong>•</strong> For the adjuvant treatment of operable node-positive breast\r\ncancer, the recommended Docetaxel dose is 75mg/m<sup>2</sup> administered 1\r\nhour after Doxorubicin 50mg/m<sup>2</sup> and Cyclophosphamide 500mg/m<sup>2</sup>\r\nevery 3 weeks for 6 courses. Prophylactic G-CSF may be used to mitigate the\r\nrisk of hematological<br>\r\ntoxicities. <strong>Non-small Cell Lung Cancer:</strong>\r\nFor treatment after failure of prior platinum-based chemotherapy, Docetaxel was\r\nevaluated as monotherapy and the recommended dose is 75mg/m<sup>2</sup>\r\nadministered intravenously over 1 hour every 3 weeks. A dose of 100mg/m<sup>2</sup>\r\nin patients previously treated with chemotherapy was associated with increased\r\nhematologic toxicity, infection, and treatment-related mortality in randomized\r\ncontrolled trials. <strong>•</strong> For\r\nchemotherapy-naive patients, Docetaxel was evaluated in combination with\r\nCisplatin. The recommended dose of Docetaxel is 75mg/m<sup>2</sup> administered\r\nintravenously over 1 hour immediately followed by Cisplatin 75mg/m<sup>2</sup>\r\nover 30-60 minutes every 3 weeks. <strong>Prostate\r\nCancer: </strong>For metastatic castration-resistant prostate cancer, the\r\nrecommended dose of Docetaxel is 75mg/m<sup>2</sup> every 3 weeks as a 1 hour\r\nintravenous infusion. Prednisone 5mg orally twice daily is administered\r\ncontinuously. <strong>Gastric Adenocarcinoma:</strong>\r\nFor gastric adenocarcinoma, the recommended dose of Docetaxel is 75mg/m<sup>2</sup>\r\nas a 1 hour intravenous infusion, followed by Cisplatin 75mg/m<sup>2</sup>, as\r\na 1 to 3 hour intravenous infusion (both on day 1 only), followed by Fluorouracil\r\n750mg/m<sup>2</sup> per day given as a 24-hour continuous intravenous infusion\r\nfor 5 days, starting at the end of the Cisplatin infusion. Treatment is\r\nrepeated every three weeks. Patients must receive premedication with\r\nantiemetics and appropriate hydration for Cisplatin administration. <strong>Head and Neck Cancer:</strong> <strong>•</strong> 75mg/m<sup>2</sup> followed by\r\nCisplatin 75mg/m<sup>2</sup> IV (Day 1), followed by Fluorouracil 750mg/m<sup>2</sup>\r\nper day as a 24-hr IV (Days 1-5), starting at end of Cisplatin infusion; for 4\r\ncycles, <strong>• </strong>75mg/m<sup>2</sup>\r\nfollowed by Cisplatin 100mg/m<sup>2</sup> IV (Day 1), followed by Fluorouracil\r\n1000mg/m<sup>2</sup> per day as a 24-hr IV (Days 1-4); for 3 cycles. Or, as\r\ndirected by the registered physicians. <strong><o:p></o:p></strong></p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><br>\r\n<!--[if !supportLineBreakNewLine]--><br>\r\n<!--[endif]--><strong><o:p></o:p></strong></p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Use\r\nin Pregnancy and Lactation:</strong> Docetaxel can cause fetal harm\r\nwhen administered to a pregnant woman. If Docetaxel is used during pregnancy,\r\nor if the patient becomes pregnant while receiving this drug, the patient\r\nshould be apprised of the potential hazard to the fetus. Women of childbearing\r\npotential should be advised to avoid becoming pregnant during therapy with\r\nDocetaxel. <strong>Lactating Mothers:</strong> It is\r\nnot known whether Docetaxel is excreted in human milk. Because many drugs are\r\nexcreted in human milk, and because of the potential for serious<br>\r\nadverse reactions in nursing infants from Docetaxel, a decision should be made\r\nwhether to discontinue nursing or to discontinue the drug, taking into account\r\nthe importance of the drug to the mother.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"> </p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Packaging:\r\nDaxoteI-20:</strong> Each box contains one vial of Docetaxel\r\nAnhydrous USP 20mg/ml solution for IV infusion. <o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Daxotel-80:</strong>\r\nEach box contains one vial of Docetaxel Anhydrous USP 80mg/4ml solution for IV\r\ninfusion.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong> </strong><br></p>",
    "strength": " 20,80mg ",
    "uom": "Mg/2ml",
    "categoryId": "57",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1669024214Daxotel-20 Carton.png",
      "https://www.admin.drug-international.com/uploads/product_images/1688636367Daxotel-80 Carton.png"
    ]
  },
  {
    "id": "1897",
    "name": "Decanib 6 ",
    "description": "<p><strong>Composition:\r\n</strong>Each Film Coated Tablet Contains Deucravacitinib INN 6mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication:\r\n</strong>It is indicated for the treatment of\r\nadults with moderate-to-severe plaque psoriasis who are candidates for systemic\r\ntherapy or phototherapy.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand Administration: </strong>The\r\nrecommended dosage is 6mg taken orally once daily, with or without food. Or, as\r\ndirected by a registered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and Lactation: </strong>Pregnancy: There is no data available. Lactation: There are\r\nno data on the presence of deucravacitinib in human milk, the effects on the\r\nbreastfed infants, or the effects on milk production.<o></o></p><p><strong>Packing:\r\n</strong>Each box contains\r\n30’s tablet in blister pack.</p>",
    "strength": "6",
    "uom": "mg",
    "categoryId": "61",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1704003660Decanib 6 Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1704003660Decanib 6 Carton.png"
    ]
  },
  {
    "id": "1224",
    "name": "Demoxiclave - Forte",
    "description": "<p><strong>Composition :</strong><span class=\"redactor-invisible-space\"> Amoxicillin BP + Clavulanic acid USP; (400mg +\r\n57.5mg) /5ml Suspension.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Indications : </strong><span class=\"redactor-invisible-space\">Co-amoxiclav oral preparation is indicated\r\nfor the short-term treatment of bacterial infections which\r\nis given below-upper respiratory-tract infections\r\n(including ENT) e.g. tonsillitis, sinusitis, otitis media.,\r\nLower respiratory-tract infections (e.g. acute & chronic\r\nbronchitis, bronchopneumonia). Skin and soft tissue\r\ninfections (cellulitis, animal bites) Genito-urinary-tract\r\ninfections e.g. (cystitis, urethritis, pyelonephritis), bone\r\n& Joint infections e.g. osteomyelitis. other infections e.g.\r\nSeptic abortion, purperal sepsis, intra-abdominal sepsis,\r\netc.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Dosage and administration :</strong><span class=\"redactor-invisible-space\"> Please see prescribing description for more information.<br></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> Category B by FDA.<br></span></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">35ml Suspension.<br></span></span></span></span></p>",
    "strength": "400+57.5",
    "uom": "mg/5ml",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1669802539Demoxiclave Fort Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745140607Demoxiclave Forte.png"
    ]
  },
  {
    "id": "1223",
    "name": "Demoxiclave Suspension",
    "description": "<p><strong>Composition :</strong> Amoxycillin BP + clavulanic acid USP (125mg+31.25mg/5ml) suspension.</p><p style=\"text-align: justify;\"><strong>Indications : </strong><span class=\"redactor-invisible-space\">Demoxiclave is indicated for shortterm treatment of bacterial infections at the following sites :</span> Upper respiratory tract infections (including ENT) e.g. tonsillitis, sinusitis, otitis media. Lower respiratory tract infections e.g. acute and chronic bronchitis, lobar and bronchopneumonia. Genito-urinary tract infections e.g. cystitis, urethritis, pyelonephritis. </p><p style=\"text-align: justify;\" rel=\"text-align: justify;\">Skin and soft tissue infections. Bone and joint infections e.g. osteomyelitis.<span class=\"redactor-invisible-space\">Other infections e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, etc.<br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Dosage & administration :</strong><span class=\"redactor-invisible-space\"> Adults : 1 Demoxiclave-625 tablet every 12 hours or 1 Demoxiclave-375 tablet every 8 hours.</span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\">For more severe infections and infections of the respiratory tract 1 Demoxiclave-625 tablet every 8 hours. Demoxiclave is administered at the start of a meal. Children over 6 to 12 years : 2 teaspoonfuls of Demoxiclave oral suspension every 8 hours.</p><p style=\"text-align: justify;\">Children over 1 to 6 years : 1 teaspoonful of Demoxiclave oral suspension every 8 hours. Children below 1 year : 25 mg/kg/day in divided doses every 8 hours.<span class=\"redactor-invisible-space\"> Treatment should not be extended beyond 14 days without review.<br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> Demoxiclave has been assigned to pregnancy category B by the FDA.<br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong><br></p><p style=\"text-align: justify;\">Demoxiclave suspension : 100ml oral suspension</p>",
    "strength": "125+31.25",
    "uom": "mg/5ml",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1669802307Demoxiclave Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745140654Demoxiclave- 100ML.png"
    ]
  },
  {
    "id": "1222",
    "name": "Demoxiclave Tablet",
    "description": "<!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves></w:TrackMoves>\r\n  <w:TrackFormatting></w:TrackFormatting>\r\n  <w:PunctuationKerning></w:PunctuationKerning>\r\n  <w:ValidateAgainstSchemas></w:ValidateAgainstSchemas>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF></w:DoNotPromoteQF>\r\n  <w:LidThemeOther>EN-US</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables></w:BreakWrappedTables>\r\n   <w:SnapToGridInCell></w:SnapToGridInCell>\r\n   <w:WrapTextWithPunct></w:WrapTextWithPunct>\r\n   <w:UseAsianBreakRules></w:UseAsianBreakRules>\r\n   <w:DontGrowAutofit></w:DontGrowAutofit>\r\n   <w:SplitPgBreakAndParaMark></w:SplitPgBreakAndParaMark>\r\n   <w:EnableOpenTypeKerning></w:EnableOpenTypeKerning>\r\n   <w:DontFlipMirrorIndents></w:DontFlipMirrorIndents>\r\n   <w:OverrideTableStyleHps></w:OverrideTableStyleHps>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"></m:mathFont>\r\n   <m:brkBin m:val=\"before\"></m:brkBin>\r\n   <m:brkBinSub m:val=\"--\"></m:brkBinSub>\r\n   <m:smallFrac m:val=\"off\"></m:smallFrac>\r\n   <m:dispDef></m:dispDef>\r\n   <m:lMargin m:val=\"0\"></m:lMargin>\r\n   <m:rMargin m:val=\"0\"></m:rMargin>\r\n   <m:defJc m:val=\"centerGroup\"></m:defJc>\r\n   <m:wrapIndent m:val=\"1440\"></m:wrapIndent>\r\n   <m:intLim m:val=\"subSup\"></m:intLim>\r\n   <m:naryLim m:val=\"undOvr\"></m:naryLim>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"false\"\r\n  DefSemiHidden=\"false\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"371\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" QFormat=\"true\" Name=\"Normal\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal Indent\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footnote text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"header\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footer\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index heading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"caption\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"table of figures\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"envelope address\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"envelope return\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footnote reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"line number\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"page number\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"endnote reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"endnote text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"table of authorities\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"macro\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"toa heading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" QFormat=\"true\" Name=\"Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Closing\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Signature\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"Default Paragraph Font\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Message Header\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" QFormat=\"true\" Name=\"Subtitle\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Salutation\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Date\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text First Indent\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text First Indent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Note Heading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Block Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Hyperlink\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"FollowedHyperlink\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" QFormat=\"true\" Name=\"Strong\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" QFormat=\"true\" Name=\"Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Document Map\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Plain Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"E-mail Signature\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Top of Form\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Bottom of Form\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal (Web)\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Acronym\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Address\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Cite\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Code\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Definition\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Keyboard\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Preformatted\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Sample\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Typewriter\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Variable\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal Table\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation subject\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"No List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Contemporary\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Elegant\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Professional\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Subtle 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Subtle 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Balloon Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"Table Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Theme\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Placeholder Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" QFormat=\"true\" Name=\"No Spacing\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Revision\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" QFormat=\"true\"\r\n   Name=\"List Paragraph\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" QFormat=\"true\" Name=\"Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" QFormat=\"true\"\r\n   Name=\"Intense Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"19\" QFormat=\"true\"\r\n   Name=\"Subtle Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"21\" QFormat=\"true\"\r\n   Name=\"Intense Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"31\" QFormat=\"true\"\r\n   Name=\"Subtle Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"32\" QFormat=\"true\"\r\n   Name=\"Intense Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"33\" QFormat=\"true\" Name=\"Book Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"37\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"Bibliography\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"TOC Heading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"41\" Name=\"Plain Table 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"42\" Name=\"Plain Table 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"43\" Name=\"Plain Table 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"44\" Name=\"Plain Table 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"45\" Name=\"Plain Table 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"40\" Name=\"Grid Table Light\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"Grid Table 1 Light\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"Grid Table 6 Colorful\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"Grid Table 7 Colorful\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"List Table 1 Light\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"List Table 6 Colorful\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"List Table 7 Colorful\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 6\"></w:LsdException>\r\n </w:LatentStyles>\r\n</xml><![endif]--><!--[if gte mso 10]>\r\n<style>\r\n /* Style Definitions */\r\n table.MsoNormalTable\r\n\t{mso-style-name:\"Table Normal\";\r\n\tmso-tstyle-rowband-size:0;\r\n\tmso-tstyle-colband-size:0;\r\n\tmso-style-noshow:yes;\r\n\tmso-style-priority:99;\r\n\tmso-style-parent:\"\";\r\n\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\r\n\tmso-para-margin-top:0in;\r\n\tmso-para-margin-right:0in;\r\n\tmso-para-margin-bottom:10.0pt;\r\n\tmso-para-margin-left:0in;\r\n\tline-height:115%;\r\n\tmso-pagination:widow-orphan;\r\n\tfont-size:11.0pt;\r\n\tfont-family:\"Calibri\",sans-serif;\r\n\tmso-ascii-font-family:Calibri;\r\n\tmso-ascii-theme-font:minor-latin;\r\n\tmso-hansi-font-family:Calibri;\r\n\tmso-hansi-theme-font:minor-latin;\r\n\tmso-bidi-font-family:\"Times New Roman\";\r\n\tmso-bidi-theme-font:minor-bidi;}\r\n</style>\r\n<![endif]--><p class=\"MsoNormal\" style=\"text-align:center\" align=\"center\"><strong><br></strong></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Composition :</strong> <strong>Demoxiclave-375 :</strong> Each film coated\r\ntablet contains amoxicillin 250mg (as Amoxicillin Trihydrate BP) with 125mg\r\nclavulanic acid as potassium clavulanate USP.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Demoxiclave-625 :</strong><strong></strong> Each film coated tablet contains\r\namoxicillin 500mg (as Amoxicillin Trihydrate BP) with 125mg clavulanic acid as\r\npotassium clavulanate USP.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Demoxiclave-1 gm </strong>: Each film coated tablet contains\r\namoxicillin 875mg (as Amoxicillin Trihydrate USP) with 125mg clavulanic acid as\r\npotassium clavulanate USP</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Demoxiclave suspension :</strong> Each 5ml reconstituted suspension\r\ncontains amoxicillin 125mg (as Amoxicillin Trihydrate BP) and clavulanic acid\r\n31.25mg as potassium clavulanate USP.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Description :</strong> Demoxiclave is the brand name of\r\nco-amoxiclav which is an antibacterial combination consisting of the antibiotic\r\namoxicillin and the b-lactamase inhibitor clavulanic acid. Amoxicillin has a\r\nbroad spectrum of bactericidal activity against many gram-positive and\r\ngram-negative microorganisms but it is susceptible to degradation by\r\nb-lactamase and therefore the spectrum of activity does not include\r\nmicroorganisms which produce these enzymes. Clavulanic acid possesses the\r\nability to inactivate a wide range of b-lactamase enzymes commonly found in\r\nmicroorganisms resistant to penicillins and cephalosporins. Thus the\r\nformulation of amoxicillin with clavulanic acid together in Demoxiclave\r\nprotects amoxicillin from degradation by b-lactamase enzymes and effectively\r\nextends the antibiotic spectrum against a wide range of microorganisms.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indication :</strong> Demoxiclave is indicated for\r\nshort-term treatment of bacterial infections at the following sites :</p><p class=\"MsoNormal\" style=\"text-align:justify\">*           Upper\r\nrespiratory tract infections (including ENT) e.g. tonsillitis, sinusitis,\r\notitis media.</p><p class=\"MsoNormal\" style=\"text-align:justify\">*           Lower\r\nrespiratory tract infections e.g. acute and chronic bronchitis, lobar and\r\nbronchopneumonia.</p><p class=\"MsoNormal\" style=\"text-align:justify\">*           Genito-urinary\r\ntract infections e.g. cystitis, urethritis, pyelonephritis.</p><p class=\"MsoNormal\" style=\"text-align:justify\">*           Skin and\r\nsoft tissue infections</p><p class=\"MsoNormal\" style=\"text-align:justify\">*           Bone and\r\njoint infections e.g. osteomyelitis.</p><p class=\"MsoNormal\" style=\"text-align:justify\">*           Other\r\ninfections e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, etc.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage &\r\nadministration :</strong></p><p class=\"MsoNormal\" style=\"text-align:justify\">Adults : 1 Demoxiclave-625 tablet every 12 hours or 1\r\nDemoxiclave-375 tablet every 8 hours. For more severe infections and infections\r\nof the respiratory tract 1 Demoxiclave-625 tablet every 8 hours or 1\r\nDemoxiclave-1 gm tablet every 12 hours.</p><p class=\"MsoNormal\" style=\"text-align:justify\">Demoxiclave is administered at the start of a meal.</p><p class=\"MsoNormal\" style=\"text-align:justify\">Children over 6 to 12 years : 2 teaspoonfuls of Demoxiclave\r\noral suspension every 8 hours.</p><p class=\"MsoNormal\" style=\"text-align:justify\">Children over 1 to 6 years : 1 teaspoonful of Demoxiclave\r\noral suspension every 8 hours.</p><p class=\"MsoNormal\" style=\"text-align:justify\">Children below 1 year : 25 mg/kg/day in divided doses every 8\r\nhours.</p><p class=\"MsoNormal\" style=\"text-align:justify\">Treatment should not be extended beyond 14 days without\r\nreview. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Contraindications : </strong></p><strong></strong><p><strong></strong></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong></strong>*           Penicillin\r\nhypersensitivity. Attention should also be given to possible cross sensitivity\r\nwith other Beta-lactam antibiotics e.g. cephalosporins.</p><p class=\"MsoNormal\" style=\"text-align:justify\">*            A previous\r\nhistory of co-amoxiclav or penicillin associated cholestatic jaundice.</p><p class=\"MsoNormal\" style=\"text-align:justify\">Use in pregnancy and lactation : Pregnancy Category B. There\r\nare no adequate and well controlled studies of use of amoxicillin in pregnant\r\nwomen. Amoxicillin may be administered to pregnant women only if clearly\r\nneeded. Amoxicillin is excreted in human milk; consideration should be given\r\ndiscontinuing nursing temporarily during treatment with cefuroxime.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Side effects :</strong>Side effects as with amoxicillin are uncommon\r\nand mainly of a mild and transitory nature. Diarrhoea, pseudomembranous\r\ncolitis, indigestion, nausea, vomiting and candidiasis have been reported. If\r\ngastrointestinal side effects occur with oral therapy, they may be reduced by\r\ntaking Demoxiclave at the start of meals. Hepatitis and cholestatic jaundice\r\nhave been reported rarely but are usually reversible. Urticarial and\r\nerythematous rashes sometimes occur. Rarely erythema multiforme,\r\nStevens-Johnson Syndrome and exfoliative dermatitis have been reported. In\r\ncommon with other    b-lactam\r\nantibiotics, angioedema and anaphylaxis have been reported.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Precautions :</strong> Demoxiclave should be used with care in\r\npatients on anticoagulation therapy or with severe hepatic dysfunction. In\r\npatients with moderate or severe renal impairment, dose should be adjusted.</p><p class=\"MsoNormal\" style=\"text-align:justify\">Pharmaceutical precaution : After reconstitution, suspension\r\nshould be kept in refrigerator (but not frozen) or within 2 to 8 degree Celsius and used\r\nwithin 7 days.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Packing  :</strong></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Demoxiclave-375 :</strong> Each box contains 3 x 7's tablets in\r\nblister pack.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Demoxiclave-625 :</strong> Each box contains 3 x 7's tablets in\r\nblister pack.<strong></strong></p><strong></strong><p><strong></strong></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Demoxiclave-1 gm :</strong> Each box contains 1 x 7's tablets in\r\nblister pack.<strong></strong></p><strong></strong><p><strong></strong></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Demoxiclave suspension :</strong> Bottle containing dry powder to make\r\n100ml Demoxiclave oral suspension.</p><p><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"></span></span></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><br></span></span></span></span></span></p>",
    "strength": "875+125,500+125,250+125",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1565244271Demoxiclave Insert [Converted].pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745140580Demoxiclave- 1gm.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745140580Demoxiclave-625.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745140580Demoxiclave-375.png"
    ]
  },
  {
    "id": "1285",
    "name": "Demoxil Capsule",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">: Amoxycillin BP 250mg, 500mg Capsule.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Urinary tract infections : nephritis, pyelonephritis, pyelitis, cystitis, gonorrhoea and non-gonococcal urethritis. Skin and soft tissue infections : cellulitis, wounds, carbuncles and furunculosis. Gastro-intestinal infections : enteric fever, ear, nose and throat infections, meningitis.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration</strong> :</p><p style=\"text-align: justify;\"><em><strong></strong></em>Oral <em>: </em>Standard adult dosage : 250mg three times daily, increasing to 500mg three times daily for more severe infections. Children (2 to 10 years) : 125mg three times daily, increasing to 250mg three times daily for more severe infection. Infants (Up to 2 years) : 62.5 - 125mg three times daily or as directed by the physician. In case of severity the dosage may safely be increased. Food does not interfere with absorption of Demoxil.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Amoxycillin has been assigned to pregnancy category B by the FDA</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><strong></strong><span class=\"redactor-invisible-space\">Demoxil 250mg Capsule : 5x10 capsules in blister pack.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Demoxil 500mg Capsule : 3x10 capsules in blister pack.</span></p>",
    "strength": "500,250",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531213715demoxil.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745140829DEMOXIL-500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745140829DEMOXIL-250MG.png"
    ]
  },
  {
    "id": "1218",
    "name": "DEMOXIL Suspension",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">: Amoxycillin BP 125mg/5ml Suspension, 250mg / 5ml DS Suspension</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Urinary tract infections : nephritis, pyelonephritis, pyelitis, cystitis, gonorrhoea and non-gonococcal urethritis. Skin and soft tissue infections : cellulitis, wounds, carbuncles and furunculosis. Gastro-intestinal infections : enteric fever, ear, nose and throat infections, meningitis.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration</strong> :</p><p style=\"text-align: justify;\"><em><strong></strong></em>Oral :<em> </em>Standard adult dosage : 250mg three times daily, increasing to 500mg three times daily for more severe infections. Children (2 to 10 years) : 125mg three times daily, increasing to 250mg three times daily for more severe infection. Infants (Up to 2 years) : 62.5 - 125mg three times daily or as directed by the physician. In case of severity the dosage may safely be increased. Food does not interfere with absorption of Demoxil.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Amoxycillin has been assigned to pregnancy category B by the FDA</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Demoxil : 100ml suspension.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\">Demoxil-DS : 100ml suspension.</p>",
    "strength": "250,125",
    "uom": "mg/5ml",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531213681demoxil.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745140872DEMOXIL-DS.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745140738DEMOXIL-100ML.png"
    ]
  },
  {
    "id": "1318",
    "name": "Depomed ",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition</strong>: <!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves></w:TrackMoves>\r\n  <w:TrackFormatting></w:TrackFormatting>\r\n  <w:PunctuationKerning></w:PunctuationKerning>\r\n  <w:ValidateAgainstSchemas></w:ValidateAgainstSchemas>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF></w:DoNotPromoteQF>\r\n  <w:LidThemeOther>EN-US</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables></w:BreakWrappedTables>\r\n   <w:SnapToGridInCell></w:SnapToGridInCell>\r\n   <w:WrapTextWithPunct></w:WrapTextWithPunct>\r\n   <w:UseAsianBreakRules></w:UseAsianBreakRules>\r\n   <w:DontGrowAutofit></w:DontGrowAutofit>\r\n   <w:SplitPgBreakAndParaMark></w:SplitPgBreakAndParaMark>\r\n   <w:EnableOpenTypeKerning></w:EnableOpenTypeKerning>\r\n   <w:DontFlipMirrorIndents></w:DontFlipMirrorIndents>\r\n   <w:OverrideTableStyleHps></w:OverrideTableStyleHps>\r\n   <w:UseFELayout></w:UseFELayout>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"></m:mathFont>\r\n   <m:brkBin m:val=\"before\"></m:brkBin>\r\n   <m:brkBinSub m:val=\"--\"></m:brkBinSub>\r\n   <m:smallFrac m:val=\"off\"></m:smallFrac>\r\n   <m:dispDef></m:dispDef>\r\n   <m:lMargin m:val=\"0\"></m:lMargin>\r\n   <m:rMargin m:val=\"0\"></m:rMargin>\r\n   <m:defJc m:val=\"centerGroup\"></m:defJc>\r\n   <m:wrapIndent m:val=\"1440\"></m:wrapIndent>\r\n   <m:intLim m:val=\"subSup\"></m:intLim>\r\n   <m:naryLim m:val=\"undOvr\"></m:naryLim>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"true\"\r\n  DefSemiHidden=\"true\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"267\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Normal\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"heading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" QFormat=\"true\" Name=\"caption\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" Name=\"Default Paragraph Font\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtitle\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Strong\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"59\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Table Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Placeholder Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"No Spacing\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Revision\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"List Paragraph\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"19\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"21\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"31\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"32\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"33\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Book Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"37\" Name=\"Bibliography\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" QFormat=\"true\" Name=\"TOC Heading\"></w:LsdException>\r\n </w:LatentStyles>\r\n</xml><![endif]--><!--[if gte mso 10]>\r\n<style>\r\n /* Style Definitions */\r\n table.MsoNormalTable\r\n\t{mso-style-name:\"Table Normal\";\r\n\tmso-tstyle-rowband-size:0;\r\n\tmso-tstyle-colband-size:0;\r\n\tmso-style-noshow:yes;\r\n\tmso-style-priority:99;\r\n\tmso-style-parent:\"\";\r\n\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\r\n\tmso-para-margin-top:0in;\r\n\tmso-para-margin-right:0in;\r\n\tmso-para-margin-bottom:10.0pt;\r\n\tmso-para-margin-left:0in;\r\n\tline-height:115%;\r\n\tmso-pagination:widow-orphan;\r\n\tfont-size:11.0pt;\r\n\tfont-family:\"Calibri\",\"sans-serif\";\r\n\tmso-ascii-font-family:Calibri;\r\n\tmso-ascii-theme-font:minor-latin;\r\n\tmso-hansi-font-family:Calibri;\r\n\tmso-hansi-theme-font:minor-latin;}\r\n</style>\r\n<![endif]--><strong>Depomed\r\n2 Tablet: </strong>Each TabletContains Methylprednisolone USP 2mg.<strong><br></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Depomed\r\n4 Tablet:</strong> Each Tablet Contains Methylprednisolone USP\r\n4mg.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Depomed 8 Tablet: </strong>Each Flim Coated Tablet Contains Methylprednisolone USP\r\n8mg.<!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves></w:TrackMoves>\r\n  <w:TrackFormatting></w:TrackFormatting>\r\n  <w:PunctuationKerning></w:PunctuationKerning>\r\n  <w:ValidateAgainstSchemas></w:ValidateAgainstSchemas>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF></w:DoNotPromoteQF>\r\n  <w:LidThemeOther>EN-US</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables></w:BreakWrappedTables>\r\n   <w:SnapToGridInCell></w:SnapToGridInCell>\r\n   <w:WrapTextWithPunct></w:WrapTextWithPunct>\r\n   <w:UseAsianBreakRules></w:UseAsianBreakRules>\r\n   <w:DontGrowAutofit></w:DontGrowAutofit>\r\n   <w:SplitPgBreakAndParaMark></w:SplitPgBreakAndParaMark>\r\n   <w:EnableOpenTypeKerning></w:EnableOpenTypeKerning>\r\n   <w:DontFlipMirrorIndents></w:DontFlipMirrorIndents>\r\n   <w:OverrideTableStyleHps></w:OverrideTableStyleHps>\r\n   <w:UseFELayout></w:UseFELayout>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"></m:mathFont>\r\n   <m:brkBin m:val=\"before\"></m:brkBin>\r\n   <m:brkBinSub m:val=\"--\"></m:brkBinSub>\r\n   <m:smallFrac m:val=\"off\"></m:smallFrac>\r\n   <m:dispDef></m:dispDef>\r\n   <m:lMargin m:val=\"0\"></m:lMargin>\r\n   <m:rMargin m:val=\"0\"></m:rMargin>\r\n   <m:defJc m:val=\"centerGroup\"></m:defJc>\r\n   <m:wrapIndent m:val=\"1440\"></m:wrapIndent>\r\n   <m:intLim m:val=\"subSup\"></m:intLim>\r\n   <m:naryLim m:val=\"undOvr\"></m:naryLim>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"true\"\r\n  DefSemiHidden=\"true\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"267\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Normal\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"heading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" QFormat=\"true\" Name=\"caption\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" Name=\"Default Paragraph Font\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtitle\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Strong\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"59\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Table Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Placeholder Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"No Spacing\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Revision\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"List Paragraph\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"19\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"21\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"31\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"32\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"33\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Book Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"37\" Name=\"Bibliography\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" QFormat=\"true\" Name=\"TOC Heading\"></w:LsdException>\r\n </w:LatentStyles>\r\n</xml><![endif]--><!--[if gte mso 10]>\r\n<style>\r\n /* Style Definitions */\r\n table.MsoNormalTable\r\n\t{mso-style-name:\"Table Normal\";\r\n\tmso-tstyle-rowband-size:0;\r\n\tmso-tstyle-colband-size:0;\r\n\tmso-style-noshow:yes;\r\n\tmso-style-priority:99;\r\n\tmso-style-parent:\"\";\r\n\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\r\n\tmso-para-margin-top:0in;\r\n\tmso-para-margin-right:0in;\r\n\tmso-para-margin-bottom:10.0pt;\r\n\tmso-para-margin-left:0in;\r\n\tline-height:115%;\r\n\tmso-pagination:widow-orphan;\r\n\tfont-size:11.0pt;\r\n\tfont-family:\"Calibri\",\"sans-serif\";\r\n\tmso-ascii-font-family:Calibri;\r\n\tmso-ascii-theme-font:minor-latin;\r\n\tmso-hansi-font-family:Calibri;\r\n\tmso-hansi-theme-font:minor-latin;}\r\n</style>\r\n<![endif]-->\r\n\r\n</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Depomed 16\r\nTablet: </strong>Each Flim Coated Tablet\r\nContains Methylprednisolone USP 16mg.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Indications: </strong>It is indicated for the treatment of <strong>1. Endocrine Disorders: </strong>Primary or\r\nsecondary adrenocortical insufficiency, congenital adrenal hyperplasia, non suppurative\r\nthyroiditis, hypercalcemia associated with cancer <strong>2. RheumaticDisorders: </strong>Rheumatoid\r\narthritis, including juvenile rheumatoid arthritis, ankylosing spondylitis,\r\nacute and subacute bursitis, synovitis of osteoarthritis, acute non-specific\r\ntenosynovitis, post-traumatic osteoarthritis, psoriatic arthritis,\r\nepicondylitis, acute gouty arthritis <strong>3.\r\nCollagen Diseases: </strong>Systemic lupus erythematosus systemic\r\ndermatomyositis, acute rheumatic carditis <strong>4.\r\nDermatologic Diseases: </strong>Bullous dermatitis\r\nherpetiformis, severe erythema multiforme, severe seborrheic dermatitis,\r\nexfoliative dermatitis, mycosis fungoides, pemphigus, severe psoriasis <strong>5. Allergic States: </strong>Seasonal or\r\nperennial allergic rhinitis, drug hypersensitivity reactions, serum sickness,\r\ncontact dermatitis, bronchial asthma, atopic dermatitis <strong>6. Ophthalmic Diseases: </strong>Allergic corneal\r\nmarginal ulcers, herpes zoster ophthalmicus, anterior segment inflammation,\r\nsympathetic ophthalmic, keratitis, optic neuritis, allergic conjunctivitis\r\nchorioretinitis, iritis and iridocyclitis <strong>7.\r\nRespiratory Diseases: </strong>Symptomatic   sarcoidosis, berylliosis, loeffler's syndrome\r\nnot manageable by other means, fulminating or disseminated pulmonary tuberculosis\r\nwhen used concurrently with appropriate anti tuberculous chemotherapy,\r\naspiration pneumonitis <strong>8. Hematologic\r\nDisorders: </strong>Idiopathic thrombocytopenic purpura in adults,\r\nsecondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia,\r\nerythroblastopenia (RBC anemia), congenital (erythroid) hypo plastic anemia <strong>9. Neoplastic Diseases: </strong>For\r\npalliative management of: Leukemia’s and lymphomas in adults, acute leukemia of\r\nchildhood <strong>10. Edematous States: </strong>To induce a diuresis or remission of proteinuria in the nephrotic\r\nsyndrome, without uremia, of the idiopathic type or that due to lupus\r\nerythematosus <strong>11. Gastrointestinal Diseases: </strong>Ulcerative colitis, regional enteritis <strong>12. Nervous System: </strong>Acute exacerbations\r\nof multiple sclerosis, etc.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Dosage and administration: </strong>The initial dosage of Depomed tablets may vary from 4 mg to 48 mg of\r\nDepomed per day depending on the specific disease entity being treated. In\r\nsituations of less severity lower doses will generally suffice while in\r\nselected patients higher initial doses may be required. The initial dosage\r\nshould be maintained or adjusted until a satisfactory response is noted. If\r\nafter a reasonable period of time there is a lack of satisfactory clinical response,\r\nDepomed should be discontinued and the patient transferred to other appropriate\r\ntherapy. <strong>ITSHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS\r\nARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER\r\nTREATMENT AND THE RESPONSE OF THE PATIENT. </strong>After\r\na favorable response is noted, the proper maintenance dosage should be\r\ndetermined by decreasing the initial drug dosage in small decrements at\r\nappropriate time intervals until them lowest dosage which will maintain an\r\nadequate clinical response is reached. It should be kept in mind that constant\r\nmonitoring is needed in regard to drug dosage. Included in the situations which\r\nmay make dosage adjustments necessary are changes in clinical status secondary\r\nto remissions or exacerbations in the disease process, the patient's individual\r\ndrug responsiveness, and the effect of patient exposure stressful situations\r\nnot directly related to the disease entity under treatment; in this latter\r\nsituation it may be necessary to increase the dosage of Methylprednisolone for\r\na period of time consistent with the patient's condition. If after long term\r\ntherapy the drug is to be stopped, it is recommended that it be withdrawn\r\ngradually rather than abruptly. <strong>Multiple\r\nSclerosis: </strong>In treatment of acute exacerbations of multiple\r\nsclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg\r\nevery other day for 1 month have been shown to be effective (4mg of\r\nmethylprednisolone is equivalent to 5 mg of prednisolone). Or, as directed by\r\nthe registered physician.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Packing : </strong><!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves></w:TrackMoves>\r\n  <w:TrackFormatting></w:TrackFormatting>\r\n  <w:PunctuationKerning></w:PunctuationKerning>\r\n  <w:ValidateAgainstSchemas></w:ValidateAgainstSchemas>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF></w:DoNotPromoteQF>\r\n  <w:LidThemeOther>EN-US</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables></w:BreakWrappedTables>\r\n   <w:SnapToGridInCell></w:SnapToGridInCell>\r\n   <w:WrapTextWithPunct></w:WrapTextWithPunct>\r\n   <w:UseAsianBreakRules></w:UseAsianBreakRules>\r\n   <w:DontGrowAutofit></w:DontGrowAutofit>\r\n   <w:SplitPgBreakAndParaMark></w:SplitPgBreakAndParaMark>\r\n   <w:EnableOpenTypeKerning></w:EnableOpenTypeKerning>\r\n   <w:DontFlipMirrorIndents></w:DontFlipMirrorIndents>\r\n   <w:OverrideTableStyleHps></w:OverrideTableStyleHps>\r\n   <w:UseFELayout></w:UseFELayout>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"></m:mathFont>\r\n   <m:brkBin m:val=\"before\"></m:brkBin>\r\n   <m:brkBinSub m:val=\"--\"></m:brkBinSub>\r\n   <m:smallFrac m:val=\"off\"></m:smallFrac>\r\n   <m:dispDef></m:dispDef>\r\n   <m:lMargin m:val=\"0\"></m:lMargin>\r\n   <m:rMargin m:val=\"0\"></m:rMargin>\r\n   <m:defJc m:val=\"centerGroup\"></m:defJc>\r\n   <m:wrapIndent m:val=\"1440\"></m:wrapIndent>\r\n   <m:intLim m:val=\"subSup\"></m:intLim>\r\n   <m:naryLim m:val=\"undOvr\"></m:naryLim>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"true\"\r\n  DefSemiHidden=\"true\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"267\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Normal\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"heading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" QFormat=\"true\" Name=\"caption\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" Name=\"Default Paragraph Font\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtitle\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Strong\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"59\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Table Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Placeholder Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"No Spacing\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Revision\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"List Paragraph\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 6\"></w:LsdException>--></p>",
    "strength": " 2, 16, 8,4",
    "uom": "mg",
    "categoryId": "63",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1558851217Depomed-2,4, 8 & 16 - Insert(1).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744023755Depomed 2.png",
      "https://www.admin.drug-international.com/uploads/product_images/1558851217Depomed-16- Carton Pic.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1744023755Depomed 8.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744023755Depomed 4.png"
    ]
  },
  {
    "id": "821",
    "name": "Depomed  Injection",
    "description": "<p><strong></strong><strong>Composition : <em></em></strong><span class=\"redactor-invisible-space\">Methylprednisolone Acetate 40mg/ml &\r\n80mg/2ml Injection</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong>Depomed is indicated in the treatment of asthma,\r\natopic dermatitis, contact dermatitis, bullous dermatitis\r\nherpetiformis, mycosis fungoides, pemphigus, severe erythema\r\nmultiforme, primary or secondary adrenocortical insufficiency,\r\nhypercalcemia associated with cancer, nonsuppurative thyroiditis,\r\nulcerative colitis, hematologic disorders, palliative management\r\nof leukemias and lymphomas, sympathetic ophthalmia, keratitis,\r\nallergic conjunctivitis, Juvenile rheumatoid arthritis, ankylosing\r\nspondylitis, symptomatic sarcoidosis, aspiration pneumonitis. </p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">A. Administration For Local\r\nEffect: </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">1. Rheumatoid and Osteoarthritis: The dose for intraarticular\r\nadministration depends upon the size of the joint and\r\nvaries with the severity of the condition in the individual patient.\r\nThe doses in the following table are given as a general guide: Please see prescribing description for more information.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\n2. Miscellaneous (Ganglion, Tendinitis, Epicondylitis):\r\nThe dose in the treatment of the various conditions of the\r\ntendinous or bursal structures varies with the condition\r\nbeing treated and ranges from 4 to 30mg. In recurrent or\r\nchronic conditions, repeated injections may be necessary.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\n3. Dermatological Conditions: 20 to 60mg of the\r\nsuspension is injected into the lesion. It may be necessary\r\nto distribute doses ranging from 20 to 40mg by repeated\r\nlocal injections in the case of large lesions. One to four\r\ninjections are usually employed, the intervals between\r\ninjections varying with the type of lesion being treated and\r\nthe duration of improvement produced by the initial\r\ninjection. B. Administration For Systemic Effect: In\r\npatients with the adrenogenital syndrome, a single\r\nintramuscular injection of 40mg every two weeks may be\r\nadequate. For maintenance of patients with rheumatoid\r\narthritis, the weekly intramuscular dose will vary from 40 to\r\n120mg. The usual dosage for patients with dermatologic\r\nlesions benefited by systemic corticoid therapy is 40 to\r\n120mg of methylprednisolone acetate administered\r\nintramuscularly at weekly intervals for one to four weeks.\r\nIn acute severe dermatitis due to poison ivy, relief may\r\nresult within 8 to 12 hours following intramuscular\r\nadministration of a single dose of 80 to 120mg. In chronic\r\ncontact dermatitis, repeated injections at 5 to 10 day\r\nintervals may be necessary. In seborrheic dermatitis, a\r\nweekly dose of 80mg may be adequate to control the\r\ncondition. Following intramuscular administration of 80 to\r\n120mg to asthmatic patients, relief may result within 6 to 48\r\nhours and persist for several days to two weeks. Similarly in\r\npatients with allergic rhinitis (hay fever), an intramuscular dose of\r\n80 to 120mg may be followed by relief of coryzal symptoms\r\nwithin six hours persisting for several days to three weeks.\r\nMultiple Sclerosis: In treatment of acute exacerbations of\r\nmultiple sclerosis, daily doses of 160mg of methylprednisolone\r\nfor a week followed by 64mg every other day for 1 month have\r\nbeen shown to be effective (4mg of methylprednisolone is\r\nequivalent to 5mg of prednisolone). Or, as directed by the\r\nregistered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy Category C. Since\r\nadequate human reproduction studies have not been done with\r\ncorticosteroids, the use of these drug in pregnancy, nursing\r\nmothers, or women of childbearing potential requires that the\r\npossible benefits of the drug be weighed against the potential\r\nhazards to the mother and embryo or fetus.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\">Depomed-40 Injection : 1 x 3's vial.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nDepomed-80 Injection : 1 x 3's vial.</span></p>",
    "strength": "80,40",
    "uom": "Mg/2ml",
    "categoryId": "63",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531214014depomed.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744023874Depomed-80.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744023874Depomed-40.png"
    ]
  },
  {
    "id": "1328",
    "name": "Depomed-500 Injection ",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Composition : <strong>Depomed 500mg IV/IM Injection :</strong></span></strong><strong><span lang=\"EN-US\"><strong></strong> </span></strong><span lang=\"EN-US\">Each vial contains sterile powder of\r\nMethylprednisolone 500mg as Methylprednisolone Sodium Succinate USP IV/IM\r\nInjection.</span></p><p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Indications : </span></strong><span lang=\"EN-US\">It is indicated for the treatment of <strong>1. Endocrine\r\nDisorders: </strong>Primary or secondary adrenocortical insufficiency,<strong> </strong>congenital\r\nadrenal hyperplasia, nonsuppurative thyroiditis,<strong> </strong>hypercalcemia\r\nassociated with cancer <strong>2. Rheumatic Disorders: </strong>Rheumatoid arthritis,\r\nincluding juvenile rheumatoid<strong> </strong>arthritis, ankylosing spondylitis, acute\r\nand subacute bursitis,<strong> </strong>synovitis of osteoarthritis, acute non-specific\r\ntenosynovitis,<strong> </strong>post-traumatic osteoarthritis, psoriatic arthritis,\r\nepicondylitis, acute gouty arthritis <strong>3. Collagen Diseases: </strong>Systemic\r\nlupus erythematosus systemic dermatomyositis, acute rheumatic carditis <strong>4.\r\nDermatologic Diseases: </strong>Bullous dermatitis herpetiformis, severe erythema\r\nmultiforme, severe seborrheic dermatitis, exfoliative dermatitis, mycosis\r\nfungoides, pemphigus, severe psoriasis <strong>5. Allergic States: </strong>Seasonal or perennial\r\nallergic rhinitis, drug hypersensitivity reactions, serum sickness, contact\r\ndermatitis, bronchial asthma, atopic dermatitis <strong>6. Ophthalmic Diseases: </strong>Allergic\r\ncorneal marginal ulcers, herpes zoster ophthalmicus, anterior segment\r\ninflammation,</span><span lang=\"EN-US\"> sympathetic ophthalmia, keratitis, optic neuritis,\r\nallergic conjunctivitis chorioretinitis, iritis and iridocyclitis <strong>7.\r\nRespiratory</strong> <strong>Diseases: </strong>Symptomatic sarcoidosis, berylliosis,\r\nloeffler's syndrome not manageable by other means, fulminating or disseminated\r\npulmonary tuberculosis when used concurrently with appropriate antituberculous\r\nchemotherapy, aspiration pneumonitis <strong>8. Hematologic Disorders: </strong>Idiopathic\r\nthrombocytopenic purpura in adults, secondary thrombocytopenia in adults,\r\nacquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia),\r\ncongenital (erythroid) hypoplastic anemia <strong>9. Neoplastic Diseases: </strong>For\r\npalliative management of: Leukemias and lymphomas in adults, acute leukemia of\r\nchildhood <strong>10. Edematous States: </strong>To induce a diuresis or remission of proteinuria\r\nin the nephrotic syndrome,</span>\r\n\r\n</p><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">without uremia, of the indiopathic type or that due to\r\nlupus erythematosus <strong>11. Gastrointestinal Diseases: </strong>Ulcerative colitis,\r\nregional enteritis <strong>12. Nervous System: </strong>Acute exacerbations of multiple\r\nsclerosis, etc. It is also indicated for the treatment of terminal cancer,\r\norgan transplantation, cardiovascular condition etc.</span></p><p><span lang=\"EN-US\"> </span></p><p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Dosage and administration : </span></strong><span lang=\"EN-US\">It is depending on the specific disease entity being\r\ntreated in the following conditions :</span></p><span lang=\"EN-US\"> </span><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\">\r\n <tbody><tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"187\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">Indications</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"451\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">Dosage</span></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"187\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">Adjunctive\r\n  therapy in <strong>life-threatening</strong></span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">conditions</span></strong><span lang=\"EN-US\"></span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"451\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Administer 30\r\n  mg/kg IV over a period of at least 30 minutes. </span></strong><span lang=\"EN-US\">Dose may be\r\n  repeated every 4 to 6 </span><span lang=\"EN-US\">hours for up to\r\n  48 hours.</span><span lang=\"EN-US\"></span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\"><br></span></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"187\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Acute\r\n  respiratory distress syndrome (ARDS)</span></strong><span lang=\"EN-US\"></span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"451\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Initially\r\n  2-3mg/kg/day IV, decreasing after 7 days.</span></strong><span lang=\"EN-US\"></span></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"187\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Rheumatic\r\n  disorders </span></strong><span lang=\"EN-US\">unresponsive to standard</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">therapy (or\r\n  during exacerbation episodes).</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"451\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">Administer\r\n  either regimen as IV pulse dosing over at least 30 minutes. The regimen may\r\n  be repeated if</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">improvement has\r\n  not occurred within a week after therapy. <strong>1 g/day for 1 to 4 days, or 1\r\n  g/month for 6 months.</strong></span></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"187\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Systemic Lupus\r\n  Erythematosus (SLE) </span></strong><span lang=\"EN-US\">unresponsive</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">to standard\r\n  therapy (or during exacerbation episodes).</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"451\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Administer 1\r\n  g/day for 3 days as IV pulse dosing over at least 30 minutes. </span></strong><span lang=\"EN-US\">The\r\n  regimen may be</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">repeated if\r\n  improvement has not occurred within a week after therapy, or as the patient's\r\n  condition dictates.</span></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"187\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Multiple\r\n  sclerosis </span></strong><span lang=\"EN-US\">unresponsive to standard</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">therapy (or\r\n  during exacerbation episodes).</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"451\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Administer 1\r\n  g/day for 3 or 5 days as IV pulse dosing over at least 30 minutes. </span></strong><span lang=\"EN-US\">The\r\n  regimen may be</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">repeated if\r\n  improvement has not occurred within a week after therapy, or as the patient's\r\n  condition dictates.</span></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"187\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Acute spinal\r\n  cord injury</span></strong></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"451\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Treatment should\r\n  begin within 8 hours of injury.</span></strong></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Within 3 hours\r\n  of injury : </span></strong><span lang=\"EN-US\">Bolus 30 mg/kg in 50ml IV fluid over 15 minutes,\r\n  wait 45 minutes, then</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">continuous\r\n  infusion of 5.4 mg/kg/hour for 23 hours.</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">3-8 hours after\r\n  injury : </span></strong><span lang=\"EN-US\">Bolus 30mg/kg in 50ml IV fluid over 15 minutes, wait\r\n  45 minutes, then</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">continuous\r\n  infusion of 5.4 mg/kg/hour for 47 hours.</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">There should be\r\n  a separate intravenous site for the infusion pump.</span></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"187\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Edematous\r\n  states, </span></strong><span lang=\"EN-US\">such\r\n  as <strong>glomeulonephritis</strong></span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">or lupus\r\n  nephritis, </span></strong><span lang=\"EN-US\">unresponsive to standard</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">therapy (Or\r\n  during exacerbation episodes).</span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"451\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">Administer\r\n  either regimen as IV pulse dosing over at least 30 minutes. The regimen may\r\n  be repeated if</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">improvement has\r\n  not occurred within 1 week after therapy, or as the patient's condition\r\n  dictates. <strong>30</strong></span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">mg/kg every\r\n  other day for 4 days or 1 g/day for 3, 5 or 7 days.</span></strong><span lang=\"EN-US\"></span></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"187\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Pemphigus &\r\n  Bullous Pemphigoid</span></strong></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"451\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">Administer\r\n  either regimen as IV pulse dosing over at least 30 minutes. The regimen may\r\n  be repeated if</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">improvement has\r\n  not occurred within 1 week after therapy, or as the patient's condition\r\n  dictates. <strong>30</strong></span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">mg/kg every\r\n  other day for 4 days or 1 g/day for 3, 5 or 7 days.</span></strong><span lang=\"EN-US\"></span></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"187\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">In other\r\n  indications</span></strong><span lang=\"EN-US\"></span></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"451\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-US\">Initial dosage\r\n  will vary from 10 to 500 mg depending on the clinical problem being treated. </span></strong><span lang=\"EN-US\">The</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">larger dosage\r\n  may be required for short-term management of severe, acute conditions. The\r\n  initial dose</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">should be given\r\n  intravenously over a period of at least 5 minutes (e.g up to 250mg) to at\r\n  least 30 minutes</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">(e.g doses\r\n  exceeding 250mg). Subsequent doses may be given intravenously or\r\n  intramuscularly at</span></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">intervals\r\n  dictated by the patients response and clinical conditions.</span></p>\r\n  </td>\r\n </tr>\r\n</tbody></table><span lang=\"EN-US\"> </span><p><br></p><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\">Dosage may be\r\nreduced for infants and children but should be governed more by the severity of\r\nthe condition and response of the patient than by age or size. It should not be\r\nless than 0.5mg/kg every 24 hours. Dosage must be decreased or discontinued\r\ngradually when the drug has been administered for more than a few days. Or, as\r\ndirected by the registered physicians.</span></p><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\"></span><strong><span lang=\"EN-US\">Use in Pregnancy & Lactation : </span></strong><span lang=\"EN-US\">Pregnancy Category C. There are no adequate\r\nand well-controlled studies in pregnant women. It should be used during\r\npregnancy only if the potential benefit justifies the potential risk to the\r\nfetus. It is not known whether this medicine is excreted in human milk. Caution\r\nshould be </span><span lang=\"EN-US\">exercised when this medicine is administered to a nursing woman.</span></p><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"EN-US\"> </span><strong><span lang=\"EN-US\">Packing : Depomed 500mg IV/IM Injection : </span></strong><span lang=\"EN-US\">Each Combipack contains 1 vial of\r\nMethylprednisolone 500mg as Methylprednisolone Sodium Succinate USP sterile\r\npowder with 1 ampoule of 10 ml water for injection USP.</span>\r\n\r\n</p>",
    "strength": "500 ",
    "uom": "mg(IV/IM)",
    "categoryId": "63",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531973036Depomed-500 IV.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1531972775Depomed-500 IV Injection-c.jpg"
    ]
  },
  {
    "id": "1322",
    "name": "Dezco",
    "description": "<p><strong>Composition : Dezco Tablet : </strong>Each Tablet Contains Deflazacort\r\nINN 6mg.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Dezco 24 Tablet : </strong>Each Film Coated Tablet Contains Deflazacort INN\r\n24mg.</p><p><br></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Description : </strong>Deflazacort is an oxazoline\r\nderivative of prednisolone with anti-inflammatory and immunosuppressive<o></o> activity. Deflazacort is a glucocorticoid and\r\n6mg of Deflazacort<o></o> has approximately the same anti-inflammatory\r\npotency as 5mg Prednisolone or prednisone.<o></o></p><p class=\"MsoListParagraphCxSpFirst\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indications : </strong>It is indicated for the treatment of a\r\nvariety of inflammatory conditions\r\nincluding: <o></o>Duchenne muscular dystrophy (DMD) in\r\npatients 5 years of age and older, Severe allergic reactions, e.g. anaphylaxis, Asthma, Rheumatoid arthritis, juvenile chronic\r\narthritis, polymyalgia rheumatica, Inflammatory bowel disease such as Crohn's\r\ndisease and ulcerative colitis, Inflammatory disorders of the kidney, such as\r\nnephritic syndrome and interstitial nephritis,Inflammatory eye disorders, e.g. uveitis, optic\r\nneuritis, Inflammatory skin disorders, including\r\npemphigus vularis, bullous pemphigoid and pyoderma gangrenosum, Inflammatory disease of the skin and muscles\r\n(dermatomyositis), Systemic lupus erythematosus, Mixed connective tissue disease, Rare condition involving inflammation in the\r\nwalls of arteries (polyarteritis nodosa), Sarcoidosis, Rheumatic carditis, Cancer of the bone marrow (multiple myeloma), Acute and lymphatic leukaemia, Cancer of the lymph nodes (lymphoma), Idiopathic thrombocytopenic purpura, Anaemia caused by the immune system attacking\r\nred blood cells (autoimmune haemolytic anaemia) Helping to prevent the immune system attacking\r\na transplanted organ, e.g. heart, liver, kidney etc.<br></p><p class=\"MsoListParagraphCxSpLast\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration : </strong>When Deflazacort is used for long\r\nterm, the maintenance dose should be kept as low as possible. Dosage may need\r\nto be increased during exacerbation of illness. It should not stop taking\r\nmedicine<o></o> suddenly if it has been taking for more than\r\nthree weeks. This is because long-term use of corticosteroids can suppress the natural\r\nproduction of corticosteroids by the adrenal glands, which means that the body\r\nbecomes temporarily reliant on the medicine. When it is time to stop treatment\r\nthe dose should be<o></o> tapered down gradually, to allow the adrenal\r\nglands to start producing adequate amounts of natural steroids again.<o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Adults : </strong>The usual dose in adults for most\r\nconditions, including rheumatoid arthritis, is in the range of 3-18mg taken\r\norally per day. In some instances, an initial dose of up to 120mg per day may\r\nbe needed. The dose in adults with severe asthma may be up to 48 to 72mg per\r\nday to begin with. This dose may be gradually reduced once the asthma attack\r\nhas been controlled.<o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Other conditions : </strong>The dose of Deflazacort depends on\r\nclinical need titrated to the lowest effective dose for maintenance. Starting\r\ndoses may be estimated on the basis of ratio of 5mg prednisone or prednisolone\r\nto 6mg.<o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Hepatic Impairment : </strong>In patients with hepatic\r\nimpairment, blood levels of Deflazacort may be increased. Therefore the dose of\r\nDeflazacort should be carefully monitored and adjusted to the minimum effective\r\ndose.<o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Renal Impairment : </strong>In renally impaired patients, no\r\nspecial precautions other than those usually adopted in patients<o></o> receiving glucocorticoid therapy are\r\nnecessary.<o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Elderly : </strong>In elderly patients, no special precautions other than those usually adopted in patients\r\nreceiving glucocorticoid therapy are necessary. The common adverse\r\neffects of<o></o> systemic corticosteroids may be associated\r\nwith more serious consequences in old age.<o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Children : </strong>The usual dose in children with\r\nchronic arthritis is between 0.25-1.0mg/kg bodyweight per day. The usual dose\r\nin children with nephrotic syndrome is 1.5mg/kg bodyweight per day, to begin\r\nwith. This dose may be gradually reduced according to the child's response. The\r\nusual dose for children with asthma is between 0.25-1.0mg/kg bodyweight every\r\nother day. Or, as directed by the registered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Use in pregnancy and lactation\r\n: Pregnancy : </strong>Deflazacort does\r\ncross the placenta. However, when administered for prolonged periods or\r\nrepeatedly during pregnancy, corticosteroids may increase the risk of\r\nintra-uterine growth<o></o> retardation. As with all drugs,\r\ncorticosteroids should only be prescribed when the benefits to the mother and\r\nchild outweigh the risks.<o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Nursing mother : </strong>Corticosteroids are excreted in\r\nbreast milk, although no data are available for Deflazacort. Doses of up to 50mg\r\ndaily of Deflazacort are unlikely to cause systemic effects in the infant.\r\nInfants of mothers taking higher doses than this may have a degree of adrenal\r\nsuppression but the benefits of breast feeding are likely to outweigh any\r\ntheoretical risk.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><o> </o></p><p><strong>Packing : Dezco Tablet : </strong>Each box contains 3 x 10's tablets\r\nin blister pack.</p><p><!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves></w:TrackMoves>\r\n  <w:TrackFormatting></w:TrackFormatting>\r\n  <w:PunctuationKerning></w:PunctuationKerning>\r\n  <w:ValidateAgainstSchemas></w:ValidateAgainstSchemas>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF></w:DoNotPromoteQF>\r\n  <w:LidThemeOther>EN-US</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables></w:BreakWrappedTables>\r\n   <w:SnapToGridInCell></w:SnapToGridInCell>\r\n   <w:WrapTextWithPunct></w:WrapTextWithPunct>\r\n   <w:UseAsianBreakRules></w:UseAsianBreakRules>\r\n   <w:DontGrowAutofit></w:DontGrowAutofit>\r\n   <w:SplitPgBreakAndParaMark></w:SplitPgBreakAndParaMark>\r\n   <w:EnableOpenTypeKerning></w:EnableOpenTypeKerning>\r\n   <w:DontFlipMirrorIndents></w:DontFlipMirrorIndents>\r\n   <w:OverrideTableStyleHps></w:OverrideTableStyleHps>\r\n   <w:UseFELayout></w:UseFELayout>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"></m:mathFont>\r\n   <m:brkBin m:val=\"before\"></m:brkBin>\r\n   <m:brkBinSub m:val=\"--\"></m:brkBinSub>\r\n   <m:smallFrac m:val=\"off\"></m:smallFrac>\r\n   <m:dispDef></m:dispDef>\r\n   <m:lMargin m:val=\"0\"></m:lMargin>\r\n   <m:rMargin m:val=\"0\"></m:rMargin>\r\n   <m:defJc m:val=\"centerGroup\"></m:defJc>\r\n   <m:wrapIndent m:val=\"1440\"></m:wrapIndent>\r\n   <m:intLim m:val=\"subSup\"></m:intLim>\r\n   <m:naryLim m:val=\"undOvr\"></m:naryLim>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"true\"\r\n  DefSemiHidden=\"true\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"267\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Normal\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"heading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" QFormat=\"true\" Name=\"caption\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" Name=\"Default Paragraph Font\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtitle\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Strong\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"59\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Table Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Placeholder Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"No Spacing\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Revision\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"List Paragraph\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"19\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"21\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"31\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"32\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"33\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Book Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"37\" Name=\"Bibliography\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" QFormat=\"true\" Name=\"TOC Heading\"></w:LsdException>\r\n </w:LatentStyles>\r\n</xml><![endif]--><!--[if gte mso 10]>\r\n<style>\r\n /* Style Definitions */\r\n table.MsoNormalTable\r\n\t{mso-style-name:\"Table Normal\";\r\n\tmso-tstyle-rowband-size:0;\r\n\tmso-tstyle-colband-size:0;\r\n\tmso-style-noshow:yes;\r\n\tmso-style-priority:99;\r\n\tmso-style-parent:\"\";\r\n\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\r\n\tmso-para-margin-top:0in;\r\n\tmso-para-margin-right:0in;\r\n\tmso-para-margin-bottom:10.0pt;\r\n\tmso-para-margin-left:0in;\r\n\tline-height:115%;\r\n\tmso-pagination:widow-orphan;\r\n\tfont-size:11.0pt;\r\n\tfont-family:\"Calibri\",\"sans-serif\";\r\n\tmso-ascii-font-family:Calibri;\r\n\tmso-ascii-theme-font:minor-latin;\r\n\tmso-hansi-font-family:Calibri;\r\n\tmso-hansi-theme-font:minor-latin;}\r\n</style>\r\n<![endif]--><strong>Dezco\r\n24 Tablet : </strong>Each\r\nbox contains 2 x 10's tablets in blister pack<br></p>",
    "strength": " 24,6",
    "uom": "mg",
    "categoryId": "63",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1558851751Dezco 24 Web Insert(1).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745302623Dezco 24.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745302623Dezco.png"
    ]
  },
  {
    "id": "916",
    "name": "Dialiptin",
    "description": "<p><strong></strong><strong>Composition : </strong>Vildagliptin INN 50mg Tablet</p><p style=\"text-align: justify;\"><strong>Indication :</strong> Vildagliptin is indicated for\r\nthe treatment of type 2 diabetes mellitus\r\n(in combination with metformin or with a\r\nsulphonylurea or with a\r\nthiazolidinedione). </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adult over\r\n18 years: Vildagliptin administered in\r\ncombination with metformin or a\r\nthiazolidinedione, 50mg twice daily; in\r\ncombination with a sulphonylurea, 50mg\r\ndaily in the morning. Or as directed by\r\nthe registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong> There are no adequate data from the use of vildagliptin in pregnant women.</p><p style=\"text-align: justify;\"><strong>Packing : </strong>Dialiptin: 3x14's tablets in\r\nblister pack.</p>",
    "strength": "50,850+50,500+50",
    "uom": "mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1635133845Dialiptin(1).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740569822Dialiptin 50.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569990Dialiptin-M 850.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569938Dialiptin-M 500.png"
    ]
  },
  {
    "id": "917",
    "name": "Dialiptin - M ",
    "description": "<p><strong></strong><strong>Composition : Dialiptin-M 500:</strong><span class=\"redactor-invisible-space\"> Metformin Hydrochloride\r\n+Vildagliptin (500mg+50mg) &\r\n<strong>Dialiptin-M 850 </strong>(850mg+50mg) Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is indicated in the\r\ntreatment of type 2 diabetes mellitus\r\npatients who are unable to achieve\r\nsufficient glycaemic control at their\r\nmaximally tolerated dose of oral\r\nmetformin alone or who are already\r\ntreated with the combination of\r\nvildagliptin and metformin as separate\r\ntablets.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Dialiptin-M 500:</strong> Max. vildagliptin daily dose:\r\n100mg. Inadequately controlled on\r\nvildagliptin: Initially 50mg/500mg bid.\r\nInadequately controlled on metformin\r\nHCl: one tablet bid. Switching from\r\ncombination therapy of vildagliptin plus\r\nmetformin HCl, as separate tab based\r\nfrom the dose of vildagliptin or metformin\r\nalready being taken.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"> </span><strong>Dialiptin-M 850</strong> Adult over 18 years: one tablet twice\r\ndaily (based on patient's current\r\nmetformin dose). Or, as directed by the\r\nregistered physician.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>There are no adequate data .</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Dialiptin-M 500:</strong> 2x7's tablets\r\nin blister pack.</span></p><p><span class=\"redactor-invisible-space\"><strong>Dialiptin-M 850: </strong>2x7's tablets in blister\r\npack.</span></p>",
    "strength": "850+50,500+50",
    "uom": "mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531284857Dialiptin-M.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740569990Dialiptin-M 850.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569938Dialiptin-M 500.png"
    ]
  },
  {
    "id": "937",
    "name": "Dicaltrol",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong> Each dicaltrol\r\nsoft gelatin capsule contains calcitriol BP 0.25mcg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications :</strong> <strong>Predialysis\r\npatients : </strong>Dicaltrol<strong> </strong>is indicated in the management of secondary\r\nhyperparathyroidism and resultant metabolic bone disease in patients with moderate\r\nto severe chronic renal failure not yet on dialysis. In children, the\r\ncreatinine clearance value must be corrected for a surface area of 1.73 square\r\nmeters..<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage & Administration :</strong><strong> </strong><strong>Predialysis\r\nPatients : </strong>The\r\nrecommended initial dosage of Dicaltrol is 0.25 mcg/day in adults and pediatric\r\npatients 3 years of age and older. This dosage may be increased if necessary to\r\n0.5 mcg/day.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dialysis\r\nPatients : </strong>The\r\nrecommended initial dose of Dicaltrol<strong>\r\n</strong>is 0.25 mcg/day. If a satisfactory response in the biochemical<strong> </strong>parameters\r\nand clinical manifestations of the disease state is<strong> </strong>not observed, dosage\r\nmay be increased by 0.25 mcg/day at 4<strong> </strong>to 8 week intervals. During this\r\ntitration period, serum calcium<strong> </strong>levels should be obtained at least twice\r\nweekly, and if<strong> </strong>hypercalcaemia is noted, the drug should be immediately<strong>\r\n</strong>discontinued until normocalcaemia ensues. Patients with<strong> </strong>normal or\r\nonly slightly reduced serum calcium levels may<strong> </strong>respond to Dicaltrol<strong> </strong>doses of 0.25 mcg\r\nevery other day. Most<strong> </strong>patients undergoing hemodialysis respond to doses\r\nbetween<strong> </strong>0.5 and 1mcg/day.<strong> <o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Hypoparathyroidism\r\n: </strong>The\r\nrecommended initial dosage of Dicaltrol\r\nis 0.25 mcg/day given in the morning. If a satisfactory response in the\r\nbiochemical parameters and clinical manifestations of the disease is not\r\nobserved, the dose may be increased at 2 to 4 week intervals. During the dosage\r\ntitration period, serum calcium levels should be obtained at least twice weekly\r\nand if hypercalcaemia is noted, Dicaltrol<strong>\r\n</strong>should be immediately discontinued until normocalceamia ensues.\r\nCareful consideration should also be given to lowering the dietary calcium\r\nintake. Most adult patients and pediatric patients age 6 years and older have\r\nresponded to dosages in the range of 0.5 mcg to 2 mcg daily. Pediatric patients\r\nin the 1 to 5 year age group with hypoparathyroidism have usually been given\r\n0.25mcg to 0.75mcg daily. The number of treated patients with<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">pseudohypoparathyroidism\r\nless than 6 years of age is too small to make dosage recommendations.<strong> <o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Postmenopausal\r\nOsteoporosis : </strong>The\r\nrecommended dose for Dicaltrol is\r\n0.25 mcg twice daily. Serum calcium and creatinine levels should bedetermined\r\nat 4 weeks, 3 and 6 months and at 6 monthly intervals there after.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use in pregnancy and lactation : </strong>Use in pregnancy and lactation<strong> </strong>Dicaltrol should be given only when\r\nthe potential benefit has been weighed against the possible hazard to the\r\nfetus. Mothers should not breast-feed while taking Dicaltrol.<o:p></o:p></p><p><strong>Packing : </strong>Each box contains 60's capsule in\r\nblister pack.<br></p>",
    "strength": "0.25",
    "uom": "Mcg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1643011474Dicaltrol BOOK DTYLE INSERT.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745141115Dicaltrol.png"
    ]
  },
  {
    "id": "938",
    "name": "Dicaltrol Plus",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong><strong> </strong>Each\r\nfilm coated tablet contains Calcium Citrate USP 1200mg eq. to elemental Calcium\r\n252mg and Calcitriol USP<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\">0.25mcg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications :</strong><strong> </strong>This\r\ncombination is used to prevent or treat low blood calcium levels in people who\r\ndo not get enough calcium from their diets. It may be used to treat conditions caused\r\nby low calcium levels such as bone<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">loss\r\n(osteoporosis), weak bones (osteomalacia, rickets), decreased activity of the\r\nparathyroid gland (hypoparathyroidism) and a certain muscle disease (latent\r\ntetany). It may also be used in certain patients to make sure they are getting\r\nenough calcium (e.g. postmenopausal).<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage and administration :</strong><strong> </strong>1- 4\r\ntablets daily with or without food depending on clinical situation. Or, as\r\ndirected by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use in Pregnancy and lactation : </strong>Pregnancy\r\ncatagory C. Dicaltrol Plus should<strong> </strong>be\r\nused as directed by the registered<strong> </strong>physician\r\nduring pregnancy and lactation.<strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p><strong>Packing :</strong><strong> </strong>Each\r\nbox contains 20's tablets in blister pack.<br><strong></strong></p>",
    "strength": "252+0.25",
    "uom": "Mcg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1634028048Dicaltrol Plus (1).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745141074Dicaltrol Plus.png"
    ]
  },
  {
    "id": "776",
    "name": "Dicef Capsule",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Cephradine USP 250mg &\r\n500mg Capsule. </span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">In the treatment of infections\r\nof the urinary, respiratory and gastrointestinal\r\ntracts and of the skin and soft\r\ntissues. These include : Upper respiratory tract infections :\r\npharyngitis, sinusitis, otitis media,\r\ntonsillitis, laryngo-tracheo bronchitis.\r\nLower respiratory tract infections : acute and chronic bronchitis, lobar and\r\nbronchopneumonia.\r\nUrinary tract infections : cystitis,\r\nurethritis, pyelonephritis.\r\nSkin and soft tissue infections : abscess, cellulitis, furunculosis, impetigo.\r\nGastro-intestinal tract : bacillary dysentery,\r\nenteritis, peritonitis.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Oral : Adults : For urinary tract\r\ninfections the usual dose is 500mg four\r\ntimes daily or 1g twice daily, severe or\r\nchronic infections may require larger\r\ndoses.\r\nFor respiratory tract infections and skin\r\nand soft tissue infections the usual dose is\r\n250mg or 500mg four times daily or\r\n500mg or 1g twice daily depending on the\r\nseverity and site of infections.\r\nFor gastro-intestinal tract infections,\r\n500mg three or four times daily may be\r\nemployed.\r\nChildren : The usual dose is from 25 to\r\n50mg/kg/day total, given in two or four\r\nequally divided doses or as directed by the\r\nregistered physician. For otitis media daily\r\ndoses from 75-100 mg/kg/every 6 to 12\r\nhours are recommended to a maximum\r\ndaily dose of 4g or advised by the\r\nregistered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Cephradine has been assigned to\r\npregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\">Dicef 500 Capsule : 6 x 5's capsules.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nDicef 250 Capsule : 5 x 10's capsules .</span></p>",
    "strength": "500,250",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531285963Dicef.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745141175DICEF-500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745141175DICEF-250.png"
    ]
  },
  {
    "id": "1231",
    "name": "Dicef Suspension",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Cephradine USP 125mg/5ml, 250mg/5ml Suspension & 125mg/1.25ml Paediatric Drops.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">In the treatment of infections of the urinary, respiratory and gastrointestinal tracts and of the skin and soft tissues. These include : Upper respiratory tract infections : pharyngitis, sinusitis, otitis media, tonsillitis, laryngo-tracheo bronchitis. Lower respiratory tract infections : acute and chronic bronchitis, lobar and bronchopneumonia. Urinary tract infections : cystitis, urethritis, pyelonephritis. Skin and soft tissue infections : abscess, cellulitis, furunculosis, impetigo. Gastro-intestinal tract : bacillary dysentery, enteritis, peritonitis.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Oral : Adults : For urinary tract infections the usual dose is 500mg four times daily or 1g twice daily, severe or chronic infections may require larger doses. For respiratory tract infections and skin and soft tissue infections the usual dose is 250mg or 500mg four times daily or 500mg or 1g twice daily depending on the severity and site of infections. For gastro-intestinal tract infections, 500mg three or four times daily may be employed. Children : The usual dose is from 25 to 50mg/kg/day total, given in two or four equally divided doses or as directed by the registered physician. For otitis media daily doses from 75-100 mg/kg/every 6 to 12 hours are recommended to a maximum daily dose of 4g or advised by the registered physician.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Cephradine has been assigned to pregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Dicef Suspension : 100 ml. Suspension.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Dicef Forte Suspension : 100ml Suspension.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\">Dicef Paediatric Drops : 15ml drops with a plastic dropper.</p>",
    "strength": "125,250,125",
    "uom": "mg/1.25ml",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531286084Dicef.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1686547799Dicef Paediatric Drop Carton.png",
      "https://www.admin.drug-international.com/uploads/product_images/Dicef_forte.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1745141374DICEF-100ml.png"
    ]
  },
  {
    "id": "777",
    "name": "Dicephin",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Ceftriaxone Sodium USP 250mg (IV/IM),\r\n500mg (IV/IM), 1gm (IV/IM) & 2gm (IV)\r\nInjection.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Dicephin is indicated for the\r\ntreatment of the following infections when\r\ncaus ed by susceptible organisms: lower\r\nrespiratory tract infections, skin and skin\r\nstructure infections, urinary tract infections,\r\nuncomplicated gonorrhea, pelvic inflammatory\r\ndisease, intra-abdominal infections, bacterial\r\nsepticemia, bone and joint infections, meningitis\r\nand surgical prophylaxis.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Dicephin may\r\nbe administered intra venously or\r\nintramuscularly.\r\nAdults : The usual adult daily dose is 1 to 2\r\ngrams given once a day (or in equally divided\r\ndoses twice a day) depending on the type and\r\nseverity of infection. The total daily dose should\r\nnot exceed 4 grams. For surgical prophylaxis, a\r\nsingle dos e of 1 gram administered\r\nintravenously 1/2 to 2 hours before surgery is\r\nrecommended.\r\nChildren : For the treatment of skin and skin\r\nstructure infections, the recommended total\r\ndaily dose is 50 to 75 mg/kg given once a day\r\n(or in equally divided doses twice a day). The\r\ntotal daily dose should not exceed 2 grams. In\r\nthe treatment of meningitis, it is recommended\r\nthat the initial therapeutic dose be 100mg/kg\r\n(not to exceed 4 grams) or as directed by the\r\nregistered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Ceftriaxone has been assigned to pregnancy\r\ncategory B by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong>1 Combipack / Injection. </p>",
    "strength": "2,1,1,500,500,250,250",
    "uom": "gm(IV)",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531286424Dicephin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745141648DICEPHIN.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745141648DICEPHIN 1gm (GREEN).png",
      "https://www.admin.drug-international.com/uploads/product_images/1745141648DICEPHIN 1gm.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745141648DICEPHIN 500 MG (GREEN).png",
      "https://www.admin.drug-international.com/uploads/product_images/1745141648DICEPHIN 500 MG.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745141647DICEPHIN (BLUE).png",
      "https://www.admin.drug-international.com/uploads/product_images/1745141647DICEPHIN 250 MG.png"
    ]
  },
  {
    "id": "1168",
    "name": "Diconten",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong><strong> </strong>Each Film Coated Tablet Contains Flupentixol dihydrochloride\r\nBP equivalent to 0.5mg Flupentixol and melitracen<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">hydrochloride\r\nINN equivalent to 10mg melitracen.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications :</strong><strong> </strong>Diconten is indicated  for- Anxiety, Depression, Apathy, Psychogenic\r\ndepression, Depressive neuroses, Psychosomatic affections accompanied by\r\nanxiety and apathy,<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Menopausal\r\ndepression, Depression in alcoholics and drug-addicts.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage & Administration :</strong><strong> </strong>Adults: Usually 2 tablets daily: Morning and noon.\r\nIn severe cases the morning dose may be increased to 2 tablets the maximum dose\r\nis 4 tablets daily. Elderly patients: 1 tablet in the morning. In severe cases\r\n1 tablet in the morning and 1 at noon, Maintenance dose : Usually 1 tablet in\r\ntne morning. Or, as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p><strong>Use in pregnancy and lactation\r\n: </strong>Diconten should preferably not be<strong> </strong>given during pregnancy and\r\nlactation.<br><strong></strong></p><p style=\"text-align: justify;\"><strong>Packing : </strong>Diconten : 4 x 14's tablets in blister pack.</p>",
    "strength": "0.5+10",
    "uom": "mg",
    "categoryId": "48",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1634028366DICONTEN.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745141808Diconten.png"
    ]
  },
  {
    "id": "1020",
    "name": "Dicot",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Econazole Nitrate BP 1% &\r\nTriamcinolone Acetonide BP 0.1%.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">For the topical treatment of\r\ninflammatory dermatomycoses and\r\ninflammatory skin conditions complicated\r\nby or threatened by bacterial or fungal\r\nskin infection.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The\r\ncream should be applied by gently\r\nrubbing into the skin twice daily for 14\r\ndays or as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">However, topical steroids should not be\r\nused extensively in pregnancy.\r\nPregnancy Category : Econazole Nitrate-C\r\n& Triamcinolone Acetonide-C.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Dicot Cream: 10 gm in a\r\ntube</span></p>",
    "strength": "1%+0.1%",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531286937Dicot.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745309793DICOT.png"
    ]
  },
  {
    "id": "1775",
    "name": "Dilavir",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition : </strong>Each vial\r\ncontains Remdesivir INN 100mg as lyophilized powder.<br></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication :</strong>\r\nEmergency\r\nuse Authorization (EUA) of Remdesivir is a SARS-CoV-2 nucleotide analog RNA\r\npolymerase inhibitor indicated for adults and pediatric patients (12 years of\r\nage and older and weighing at least 40 kg) for the treatment of coronavirus\r\ndisease 2019 (COVID-19) requiring hospitalization. Remdesivir should only be\r\nadministered in a hospital or in a healthcare setting capable of providing\r\nacute care comparable to inpatient hospital care.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and administration :<i> </i></strong><strong>General\r\nInformation: </strong>• Adult and pediatric\r\npatients (&gt;28 days old) must have an eGFR determined and<strong> </strong>full-term\r\nneonates (&gt;7 days to &lt;_28 days old) must have serum creatinine<strong> </strong>determined\r\nbefore dosing of Remdesivir.<strong> </strong>• Hepatic laboratory testing\r\nshould be performed in all patients prior to starting<strong> </strong>Remdesivir\r\nand while receiving Remdesivir.<strong></strong></p><p class=\"MsoNormal\" xss=\"removed\">• Remdesivir should\r\nbe administered via intravenous (IV) infusion only. Do not administer as an\r\nintramuscular (IM) injection. For Detail Please see PDF File.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation :</strong> There\r\nis no adequate and well-controlled studies in pregnant women. Remdesivir should\r\nbe used during pregnancy only if the potential benefit justifies the potential\r\nrisk for the mother and the fetus. There is no information regarding the\r\npresence of Remdesivir in human milk, the effects on the breastfed infant, or\r\nthe effects on milk production. Because of the potential for viral transmission\r\nto SARS-CoV-2-negative infants and adverse reactions from the drug in\r\nbreastfeeding infants, the developmental and health benefits of</p><p class=\"MsoNormal\" xss=\"removed\">breast feeding should be\r\nconsidered along with the mother’s clinical need for Remdesivir and any\r\npotential adverse effects on the breastfed child from Remdesivir or from the\r\nunderlying maternal condition.</p><p class=\"MsoNormal\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:</strong> Each combipack\r\ncontains one vial of lyophilized powder of Remdesivir INN 100 mg and two\r\nampoules of 10ml water for injection BP.</p>",
    "strength": "100",
    "uom": "mg",
    "categoryId": "45",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1626576935Dilavir Inj- Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1626576935Dilavir Inj- Carton Pic (New Size for Web).png"
    ]
  },
  {
    "id": "925",
    "name": "Dimerol",
    "description": "<p><strong></strong><strong>Composition : </strong>Gliclazide 80mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">For the treatment of\r\nmaturity onset diabetes in patients who\r\ncannot be controlled on diet alone.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The usual\r\ninitial dose by mouth in the treatment of\r\nnon-insulin-dependent diabetes mellitus,\r\nis initially 40mg (1/2 tablet) to 80mg (1\r\ntablet) daily, adjusted according to\r\nresponse up to 160mg (2 tablets) as a\r\nsingle dose, with breakfast. If necessary\r\nup to 320mg can be given daily. It is\r\nsuggested that doses of more than\r\n160mg should be given in 2 divided\r\ndoses or as directed by a registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Dimerol has been assigned to\r\npregnancy category C by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong> Dimerol : 4 x 14's tablets per\r\nbox</p>",
    "strength": "80",
    "uom": "mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531287310Dimerol.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740570120dimerol.png"
    ]
  },
  {
    "id": "926",
    "name": "Dimerol - MR",
    "description": "<p><strong></strong><strong>Composition : Dimerol-MR 30: </strong><span class=\"redactor-invisible-space\">Gliclazide 30mg & </span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Dimerol-MR 60: </strong>\r\nGliclazide 60 mg Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This medication is\r\nrecommended in adults for non-insulindependent\r\ndiabetes (type-II), in\r\nassociation with dietary measures and\r\nwith physical exercise, when these\r\nmeasures alone are not sufficient to\r\nobtain normal blood glucose levels.\r\n</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The usual\r\ndaily dose is 1 to 4 tablets /day as a\r\nsingle dose or as directed by the\r\nphysician. It is recommended that the\r\ndrug should be taken at breakfast time.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Dimerol-MR has been assigned to\r\npregnancy category C by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>Dimerol-MR-30 : 4 x 14's\r\ntablets in blister pack.</p><p style=\"text-align: justify;\">\r\nDimerol-MR-60 : 2 x 10's tablets in\r\nblister pack.</p>",
    "strength": "60,30",
    "uom": "mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531287552Dimerol-MR.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740570157dimerol MR 60.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740570157dimerol MR 30.png"
    ]
  },
  {
    "id": "1316",
    "name": "Dinakion",
    "description": "<p><strong>Composition :</strong>\r\nEach Soft Gelatin Capsule Contains Phytomenadione (Vitamin K1) BP 1 mg.</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Indication :</strong>\r\nPhytomenadione (Vitamin K1) is indicated for the  prevention of Vitamin K1 Deficiency Bleeding\r\n(VKDB) in new born babies.  <o></o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Dosage &\r\nAdministration :</strong> Phytomenadione (Vitamin K1) soft gelatin capsule should be\r\nadministered squeezing the Liquid into the baby's mouth. One capsule is to be\r\nadministered at birth and another dose should be given if the First dose is\r\nspat out. For babies who are being exclusively breastfed, a dose of 1 mg once\r\nweekly for 12 weeks is recommended for the prevention of late Vitamin K1\r\nDeficiency Bleeding. Or, as directed by the registered physician.<o></o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><o> </o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Use in Pregnancy and\r\nLactation :</strong> There is no data available.<o></o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><o></o></p><p style=\"text-align: justify;\"><strong>Packing :</strong> Each\r\nbox contains 1 x 10's soft capsules in blister pack.</p>",
    "strength": "1",
    "uom": "mg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531287918dinakion.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1525758311Dinakion_p.jpg.jpg"
    ]
  },
  {
    "id": "720",
    "name": "DIPA ",
    "description": "<p><strong></strong><strong>Composition : </strong>Rupatadine INN 10mg Tablet<strong></strong></p><p style=\"text-align: justify;\"><strong>Indication : </strong>It is indicated for the\r\nsymptomatic treatment of allergic rhinitis and\r\nurticaria.</p><p style=\"text-align: justify;\"><strong>Dosage and administration :  </strong><span class=\"redactor-invisible-space\">Adults and\r\nadolescents (over 12 years of age) -The\r\nrecommended dose is 10 mg once daily, with\r\nor without food. Or, as directed by the\r\nregistered physician.</span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Rupatadine has been assigned to Pregnancy\r\nCategory B by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong>  3x10's tablets in blister pack.<span></span><br></p>",
    "strength": "10",
    "uom": "mg",
    "categoryId": "41",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531302250DIPA.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1622628395Dipa 01.png"
    ]
  },
  {
    "id": "823",
    "name": "Diproxen Gel",
    "description": "<p><strong></strong><strong>Composition : </strong>: Naproxen Sodium BP 10%.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This gel is indicated for\r\ntreatment of rheumatoid arthritis,\r\nosteoarthritis, ankylosing spondylitis,\r\ntendonitis, bursitis, acute gout and the\r\nmanagement of mild to moderate pain\r\nand primary dysmenorrhoea.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Diproxen\r\nGel is to be applied 2-6 times a day as\r\nrequired and is not recommended for\r\nuse in children. Or, as directed by the\r\nregistered physician</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>Diproxen Gel : 15gm in a\r\ntube.</p>",
    "strength": "200",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531370042diproxen.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745309835DIPROXEN-GEL.png"
    ]
  },
  {
    "id": "1051",
    "name": "Diproxen Tablet",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\">Naproxen 250 mg, 500 mg &\r\n500 mg CR Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Naproxen is indicated for the\r\ntreatment of rheumatoid arthritis, juvenile\r\narthritis, osteoarthritis ankylosing spondylitis,\r\nacute gout and acute musculoskeletal disorder\r\nand dysmenorrhoea.</span><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Dosage for\r\nDiproxen-250 mg & 500 mg : Adults-In\r\nrheumatoid arthritis, osteoarthritis and\r\nankylosing spondylitis : 500 mg to 1 g daily in\r\ntwo doses at 12 hourly intervals with meal. For\r\nAcute Gout- 750 mg at once then 250mg every\r\neight hours until the attack has passed. For\r\nAcute musculoskeletal disorders : 500 mg\r\ninitially followed by 250 mg at 6 to 8 hour\r\nintervals with a maximum daily dose after the\r\nfirst day of 1250 mg. In each step advice from\r\nregistered physician should be followed. Dosage for Diproxen-CR-500 mg : Adults- One\r\nor two tablets once daily. Or, as directed by the\r\nregistered physician.</span><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> Pregnancy\r\nCategory C. Naproxen should be administered\r\nduring pregnancy only if the potential benefits\r\noutweighs the potential risk to the fetus.\r\nNaproxen has been found in the milk of\r\nlactating mothers. The use of Naproxen should\r\ntherefore be avoided in patients who are breast\r\nfeeding.</span><br></p><p style=\"text-align: justify;\"><strong>Packing :</strong><span class=\"redactor-invisible-space\"> Diproxen-250mg : 10 x 10's\r\ntablets. </span></p><p style=\"text-align: justify;\">Diproxen-500mg : 5x10's tablets. </p><p style=\"text-align: justify;\">Diproxen-CR-500mg : 3x10's tablets.</p>",
    "strength": "500,500,250",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531370468diproxen_tablet.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745142466DIPROXEN-CR 500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745142466DIPROXEN-500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745142466DIPROXEN-250.png"
    ]
  },
  {
    "id": "998",
    "name": "Diretic",
    "description": "<p><strong></strong><strong>Composition : </strong>Frusemide+\r\nSpironolactone; (20mg+50mg) &\r\n(40mg+50mg) Tablet.</p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This tablet is indicated for\r\nthe treatment of congestive heart failure,\r\nliver cirrhosis with (ascites), essential\r\nhypertension, swelling of the body due to\r\nexcess fluid retention (edema),\r\noverproduction of aldosterone\r\n(hyperaldosteronism).</span></p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">1 to 4\r\ntablets daily (50 to 200mg of\r\nSpironolactone and 20 to 80mg of\r\nFrusemide) according to the patient's\r\nresponse. The product is not suitable for\r\nuse in children.</span></p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy Category C by FDA.</p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Packing : </strong></p><p xss=\"removed\" style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"> Diretic : 4 x 14's tablets in\r\nblister pack. </span></p><p xss=\"removed\" style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Diretic-DS : 4 x 14's tablets in blister\r\npack.</span></p>",
    "strength": "40+50,20+20",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633324775Diretic DS.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744024157Diretic-DS.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744024157Diretic.png"
    ]
  },
  {
    "id": "995",
    "name": "Disartan",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Disartan 5/20 :</span><strong> </strong><span class=\"redactor-invisible-space\">Amlodipine BP 5 mg + Olmesartan Medoxomil BP 20 mg Tablet & <br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Disartan 5/40 :</span><span class=\"redactor-invisible-space\"> Amlodipine BP 5 mg + Olmesartan Medoxomil BP 40 mg </span><span class=\"redactor-invisible-space\"> Tablet</span></p><p xss=\"removed\" style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This combination drug is\r\nindicated for the treatment of hypertension,\r\nalone or with other antihypertensive agents.\r\nThis fixed combination drug is not indicated\r\nfor the initial therapy of hypertension.</span></p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The usual\r\nstarting dose of Disartan is 5/20mg once\r\ndaily. The dosage can be increased after 1\r\nto 2 weeks of therapy to a maximum dose\r\nof 10/40mg once daily as needed to control\r\nblood pressure. Maximum antihypertensive\r\neffects are attained within 2 weeks after a\r\nchange in dose. Or, as directed by the\r\nregistered physician.</span></p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">When\r\nused in pregnancy during the second and\r\nthird trimesters, drugs that act directly on\r\nthe rennin-angiotensin system can cause\r\ninjury and even death to the developing\r\nfetus. When pregnancy is detected, this\r\ndrug should be discontinued as soon as\r\npossible.</span></p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Packing : </strong></p><p xss=\"removed\" style=\"text-align: justify;\"><strong></strong><span class=\"redactor-invisible-space\">Disartan 5/20: 3x14's tablets in\r\nblister pack.</span></p><p xss=\"removed\" style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nDisartan 5/40 : 2x14's tablets in blister\r\npack.</span></p>",
    "strength": "5+40,5+20",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531371768Disartan.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744024227Disartan 5-40.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744024227Disartan 5-20.png"
    ]
  },
  {
    "id": "1891",
    "name": "Disoral",
    "description": "<p><strong>Composition :</strong>\r\nEach tablet contains Sodium Chloride USP 300 mg & Sodium Chloride USP 600\r\nmg.</p><p class=\"MsoNormal\"><strong>Indications :</strong> For\r\nthe treatment and prophylaxis of Sodium Chloride deficiency.</p><p><strong>Dosage and\r\nadministration :</strong> It is important that the tablet should be swallowed whole\r\nwith water (approx. 70 ml per tablet where kidney function is normal to avoid\r\nhypernatraemia), and not chewed. Adults: For 300 mg tablet, 8-16 tablets per\r\nday. For treatment dosage to be adjusted to individual needs up to a maximum of\r\n40 tablets per day in case of severe salt depletion. For control of muscle\r\ncramps during routine maintenance haemodialysis usually 20-32 tablets per\r\ndialysis. In some cases of chronic renal salt-wasting up to 40 tablets per day\r\nmay be required with appropriate fluid intake. For 600 mg tablet, the dosage\r\nwill be half in every diseases condition. Elderly: No special dosage\r\nadjustment.<br></p><p><strong>Use in Pregnancy and\r\nLactation :</strong> No additional precautions required.<br></p><p class=\"MsoNormal\"><strong>Packing : </strong></p><p class=\"MsoNormal\"><strong></strong>Disoral\r\n300 Tablet : Each box contains 42’s Tablets in Alu-Alu blister pack.</p><p>Disoral 600 Tablet : Each box contains 30’s Tablets in\r\nAlu-Alu blister pack.<br></p><p><br></p>",
    "strength": "600,300",
    "uom": "mg",
    "categoryId": "61",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1695701583",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1695701583Disoral 600 Carton.png",
      "https://www.admin.drug-international.com/uploads/product_images/1695701582Disoral 300 Carton.png"
    ]
  },
  {
    "id": "1002",
    "name": "Divastin ",
    "description": "<p><strong></strong><strong>Composition :</strong>Atorvastatin 10mg, 20mg &\r\n40mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Atorvastatin is indicated as an\r\nadjunct to diet for reduction of elevated total\r\ncholesterol, LDL cholesterol, apolipoprotein B\r\nand triglycerides in patients with primary\r\nhypercholesterolaemia, heterozygous familial\r\nhypercholesterolaemia or combi</span><span class=\"redactor-invisible-space\">ned\r\nhyperlipidaemia when response to diet and\r\nother nonpharmacological measures are\r\ninadequate.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The patient\r\nshould be placed on a standard cholesterollowering\r\ndiet before receiving Atorvastatin\r\nand should continue on this diet during\r\ntreatment with Atorvastatin. The usual starting\r\ndose is 10mg once a day. Dosages should be\r\nindividualized according to baseline LDL-C\r\nlevels, the goal of therapy and patient\r\nresponse. Adjustment of dosage should be\r\nmade at intervals of 4 weeks or more. The\r\nmaximum dose is 80mg once a day. Dosages\r\nmay be given at any time of day with or\r\nwithout food. Or, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\"> Pregnancy Category X. Not for use in\r\nPregnancy.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><strong> </strong>Divastin : 2 x 14's tablets in blister pack. </p><p style=\"text-align: justify;\">Divastin-20 : 2 x 14's tablets in blister pack.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nDivastin-40 : 2 x 14's tablets in blister pack.</span></p>",
    "strength": "40,20,10",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531372246Divastin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744024324Divastin-40.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744024324Divastin-20.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744024324Divastin-10.png"
    ]
  },
  {
    "id": "1247",
    "name": "Divastin Plus",
    "description": "<p><strong>Composition:</strong> Amlodipine BP  5 mg +  Atorvastatin BP 10 mg Tablet.<strong></strong> <br></p><p style=\"text-align: justify;\"><strong>Indications:</strong> This drug is indicated in patients\r\nfor whom treatment with both amlodipine and atorvastatin is appropriate.\r\nAmlodipine is used to treat hypertension, chronic stable angina, vasospastic\r\nangina. Atorvastatin is a lipid lowering agent and it is used to treat\r\nhypercholesterolemia.</p><p style=\"text-align: justify;\"><strong>Dosage and administration:</strong> Dosage of this drug\r\nmust be individualized on the basis of both effectiveness and tolerance for\r\neach individual component in the treatment of hypertension, angina and\r\nhyperlipidemia. This drug may be substituted for its individually titrated\r\ncomponents for patients on amlodipine and atorvastatin.</p><p style=\"text-align: justify;\"><strong>Amlodipine: </strong>The usual initial antihypertensive\r\noral dose is 5mg once daily with a maximum dose of 10mg once daily. Elderly\r\nindividuals or patients with hepatic insufficiency may be started on 2.5mg once\r\ndaily dose and this dose may be used when adding Amlodipine to other\r\nantihypertensive therapy. Dosage should be adjusted according to each patient's\r\nneed. <strong>Atorvastatin: Adults:</strong> The patient should be placed on a standard\r\ncholesterol-lowering diet before receiving Atorvastatin and should continue on\r\nthis diet during treatment with Atorvastatin. Hypercholesterolemia (Heterozygous\r\nFamilial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types lla and llb):\r\nThe recommended starting dose of Atorvastatin is 10mg daily. The dosage range\r\nis 10 to 80 mg once daily. Homozygous Familial Hypercholesterolemia: The dosage\r\nof Atorvastatin in patients with homozygous FH is 10 to 80 mg daily. Patients\r\nwith renal insufficiency: Renal disease has no influence on the plasma\r\nconcentrations or lipid effects of Atorvastatin; thus no adjustment of dose is\r\nrequired.</p><strong>Packing</strong><p style=\"text-align: justify;\"><strong>:</strong> <strong>Divastin Plus :</strong> 3 x 10's tablets in alu-alu blister pack.</p>",
    "strength": "5+10",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531372729Divastin Plus.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Divastin Plus Wr.jpg"
    ]
  },
  {
    "id": "844",
    "name": "DLAC",
    "description": "<p><strong></strong><strong>Composition : </strong>Lactulose 3.35g/5ml Oral Solution.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">DLAC is indicated for the\r\ntreatment of constipation and hepatic\r\nencephalopathy.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong> Please see  prescribing description for more information.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Lactulose has been assigned to\r\npregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">50ml, 100ml, 200ml in each\r\nbottle.</span></p>",
    "strength": "3.35,3.35,3.35",
    "uom": "mg/5ml",
    "categoryId": "54",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531373126Dlac.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1660203340DLAC-300ml.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744024443DLAC 100 ml.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744024443DLAC 50 ml.png"
    ]
  },
  {
    "id": "1154",
    "name": "Dobixin",
    "description": "<p><strong>Composition :</strong></p><p style=\"text-align: justify;\"><strong>Dobixin- 10:</strong><span class=\"redactor-invisible-space\"> Each vial (5 ml) contains Doxorubicin Hydrochloride USP 10 mg\r\nSterile Injectable Solution for Intravenous use.\r\n</span><br></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Dobixin- 50:</strong><span class=\"redactor-invisible-space\"> Each vial (25 ml) contains Doxorubicin Hydrochloride USP 50 mg\r\nSterile Injectable Solution for Intravenous use.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Indications :</strong><span class=\"redactor-invisible-space\"> It is indicated for the treatment of acute lymphoblastic & myeloblastic\r\nleukemia, Hodgkin & non-Hodgkin lymphoma (NHL), metastatic breast cancer,\r\nmetastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue\r\nsarcoma, metastatic bone sarcoma, metastatic ovarian carcinoma, metastatic\r\ntransitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic\r\ngastric carcinoma & metastatic bronchogenic carcinoma.</span><br></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dosage and administration:</strong><br></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Adjuvant Breast Cancer:<br></strong></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">The recommended dose is 60 mg/m2 administered as an intravenous bolus on\r\nday 1 of each 21-day treatment cycle, in combination with cyclophosphamide,\r\nfor a total of four cycles.</span></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Metastatic Disease, Leukemia, or Lymphoma</strong><br></span></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">i) The recommended dose of Doxorubicin HCI when used as a single agent is\r\n60 to 75 mg/m2 intravenously every 21 days. </span></span></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">ii) The recommended dose when administered in combination with other\r\nchemotherapy drugs, is 40 to 75 mg/m2 intravenously every 21 to 28 days. </span></span></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">iii) Consider use of the lower Doxorubicin dose in the recommended dose\r\nrange or longer intervals between cycles for heavily pretreated patients, elderly\r\npatients, or obese patients. <br></span></span></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">iv) Cumulative doses above 550 mg/m2 are\r\nassociated with an increased risk of cardiomyopathy. Or, as directed\r\nby the registered physicians. Please see prescribing description for more information.</span></span></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Use in pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> Pregnancy Category D. There are no adequate and well-controlled studies in\r\npregnant women. If Doxorubicin is to be used during pregnancy, or if the\r\npatient becomes pregnant during therapy, the patient should be apprised of\r\nthe potential hazard to the fetus. Women of childbearing age should be\r\nadvised to avoid becoming pregnant.</span><br></span></span></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Packing :</strong><br></span></span></span></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dobixin- 10:</strong> Each box contains one vial of Doxorubicin Hydrochloride USP 10\r\nmg Sterile Solution. </span></span></span></span></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dobixin- 50:</strong> Each box contains one vial of Doxorubicin Hydrochloride USP 50\r\nmg Sterile Solution.</span></span></span></span></span></span></span></p>",
    "strength": "50,10",
    "uom": "mg (2 mg/ml)",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/Dobixin Insert- 3.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Dobixin_05.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/Dobixin_01.jpg"
    ]
  },
  {
    "id": "1780",
    "name": "Dorubin",
    "description": "<p class=\"MsoNormal\">Daunorubicin\r\nUSP Injection</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Composition: </strong>Each\r\nvial (4ml) contains Daunorubicin 20 mg as Daunorubicin Hydrochloride USP\r\ninjection.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>Dorubin\r\n(Daunorubicin) in combination with other approved anticancer drugs is indicated\r\nfor remission induction in acute nonlymphocytic leukemia (myelogenous,\r\nmonocytic, erythroid) of adults and for remission induction in acute\r\nlymphocytic leukemia of children and adults.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and\r\nAdministration: </strong>Parenteral drug products should be\r\ninspected visually for particulate matter prior to administration. <strong>Representative\r\nDose</strong> <strong>Schedules and Combination for the Approved Indication of Remission</strong>\r\n<strong>Induction in Adult Acute Nonlymphocytic Leukemia: In Combination:</strong> For\r\npatients under age 60, Dorubin (Daunorubicin) 45 mg/m2/day IV on days 1, 2, and\r\n3 of the first course and on days 1, 2 of subsequent courses AND cytosine\r\narabinoside 100 mg/m2/day IV infusion daily for 7 days for the first<br>\r\ncourse and for 5 days for subsequent courses. For patients 60 years of age and\r\nabove, Dorubin (Daunorubicin) 30 mg/m2/day IV on days 1, 2, and 3 of the first\r\ncourse and on days 1, 2 of subsequent courses AND cytosine arabinoside 100\r\nmg/m2/day IV infusion daily for 7 days for the first course and for 5 days for\r\nsubsequent courses. This Dorubin (Daunorubicin) dosereduction is based on a\r\nsingle study and may not be appropriate if optimal supportive care is\r\navailable. <strong>Representative Dose Schedule and</strong> <strong>Combination for the\r\nApproved Indication of Remission Induction in</strong> <strong>Pediatric Acute\r\nLymphocytic Leukemia: </strong>In Combination: Dorubin (Daunorubicin) 25 mg/m2 IV on\r\nday 1 every week, Vincristine 1.5 mg/m2 IV on day 1 every week, prednisone 40\r\nmg/m2 PO daily. Generally, a complete remission will be obtained within four\r\nsuch courses of therapy; however, if after four courses the patient is in\r\npartial remission, an additional one or, if necessary, two courses may be given\r\nin an effort to obtain a complete remission. In children less than 2 years of\r\nage or below 0.5 m2 body surface area, it has been recommended that the Dorubin\r\n(Daunorubicin) dosage calculation should be based on weight (1 mg/kg) instead\r\nof body surface area. <strong>Representative Dose Schedules and Combination for the</strong>\r\n<strong>Approved Indication of Remission Induction in Adult Acute</strong> <strong>Lymphocytic\r\nLeukemia: In Combination: </strong>Dorubin (Daunorubicin) 45 mg/m2/day IV on days 1,\r\n2, and 3 and Vincristine 2 mg IV on days 1, 8, and 15; prednisone 40 mg/m2/day\r\nPO on days 1 through 22, then tapered between days 22 to 29; L-asparaginase 500\r\nIU/kg/day x 10 days IV on days 22 through 32. Or, as directed by the registered\r\nphysicians.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and\r\nlactation: </strong>Pregnancy Category D. <strong>Lactating</strong> <strong>Mothers:\r\n</strong>It is not known whether this drug is excreted in human milk. Because many\r\ndrugs are excreted in human milk and because of the potential for serious\r\nadverse reactions in nursing infants from Dorubin (Daunorubicin), mothers\r\nshould be advised to discontinue nursing during Dorubin therapy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: </strong>Each\r\nbox contains one vial of 20mg/4ml Daunorubicin USP for injection.</p>",
    "strength": "20",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1632046841Dorubin- Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1632046841Dorubin- Carton Pic.png"
    ]
  },
  {
    "id": "1861",
    "name": "Doset",
    "description": "<p><strong>Composition:\r\n</strong>Each soft gelatin capsule contains Docusate Sodium USP 100mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>It is indicated to prevent\r\nand treat chronic constipation as follows:<o></o></p><p class=\"MsoNormal\" xss=\"removed\">• Soften hard, dry stools in order to ease defaecation and\r\nreduce straining at stool.<o></o></p><p class=\"MsoNormal\" xss=\"removed\">• In the presence of haemorrhoids and anal fissure, prevent\r\nhard, dry stools and reduce straining.<o></o></p><p class=\"MsoNormal\" xss=\"removed\">It\r\nis also used as an adjunct in abdominal radiological procedures.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\n& Administration: </strong>Adults and elderly: 1-5 soft capsules\r\nshould be taken daily in divided doses. Treatment should be commenced with\r\nlarge doses, which should be decreased as the condition of the patient\r\nimproves. For use with barium meals: 4 soft capsules to be taken with meal.\r\nOr,as directed by the registered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation: </strong>There are no adequate data\r\nfrom the use of the drug in pregnant women. Use in pregnancy only if the\r\nbenefits outweigh the risks. Docusate sodium is excreted in breast milk and\r\nshould therefore, be used with caution in lactating mothers.<o></o></p><p><strong>Packing: </strong>Each box contains\r\n30’s soft capsules in blister pack.</p>",
    "strength": "30",
    "uom": "mg",
    "categoryId": "54",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1674554697Doset Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744024511Doset.png"
    ]
  },
  {
    "id": "1037",
    "name": "Dovonex ",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition : </strong>Calcipotriol\r\nBP 0.05 mg W/W.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indications : </strong>This ointment\r\nis indicated for the topical treatment of chronic stable plaque type psoriasis\r\nin adult patients. </p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration : </strong>A thin layer\r\nof this ointment should be applied to the affected skin once or twice daily and\r\nrub in gently and completely. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Packing : Dovonex Ointment : </strong>10 gram\r\nin a tube.</p>",
    "strength": "(0.05% + 0.005%) w/w",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531373467dovonex.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Dovonex.jpg"
    ]
  },
  {
    "id": "1199",
    "name": "DOXOMA Syrup",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Doxophylline INN 200mg, 400mg Tablet & 100mg/5ml Syrup.</span></p><p><strong></strong></p><p><br></p><p><strong>Indication : </strong><span class=\"redactor-invisible-space\">Doxoma is mostly administered for maintenance treatment in subjects experiencing COPD (Chronic Obstructive Pulmonary Disease) and bronchial asthma. Doxophylline is not designed for use as an emergency treatment during an asthma attack</span></p><p><br></p><p><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Tablet : Adults : 400mg tablet 1 to 3 times a day as the prescription of a physician. Dosage of Doxophylline depends on patient's response to the medication. If a patient has been advised to dose once a day, he or she may be directed to do so in the evenings to reduce nocturnal symptoms. Please see prescribing details for more information.</span><strong><br></strong></p><p><br></p><p><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy category B. Doxophylline should be given to pregnant women only if already needed.</span><strong><br></strong></p><p><br></p><p><strong>Packing : </strong>Doxoma : 3 x 10's tablets in blister pack.</p><p>Doxoma-200 : 5 x 10's tablets in blister pack.</p><p>Doxoma Syrup : 100 ml syrup and a measuring cup.</p>",
    "strength": "100",
    "uom": "mg/5ml",
    "categoryId": "47",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/doxoma.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744024591Doxoma.png"
    ]
  },
  {
    "id": "1200",
    "name": "DOXOMA Tablet",
    "description": "<p><strong>Composition : Doxoma-200: </strong>Each Film Coated Tablet Contains Doxophylline INN 200mg.<strong><br></strong></p><p>                         <strong>Doxoma:</strong> Each Film Coated Tablet Contains Doxophylline INN 400mg.<strong><br></strong></p><p><strong></strong><strong></strong>                         <strong>Doxoma Syrup:</strong> Each 5ml syrup Contains Doxophylline INN 100mg.<strong></strong><strong></strong><br><strong></strong><span class=\"redactor-invisible-space\" xss=\"removed\"></span></p><p><strong>Indication : </strong><span class=\"redactor-invisible-space\">Doxoma is mostly administered for maintenance treatment in subjects experiencing COPD (Chronic Obstructive Pulmonary Disease) and bronchial asthma. Doxophylline is not designed for use as an emergency treatment during an asthma attack</span></p><p><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\"> Adults : 1 to 3 times a day as the prescription of a physician. Dosage of Doxophylline depends on patient's response to the medication. If a patient has been advised to dose once a day, he or she may be directed to do so in the evenings to reduce nocturnal symptoms. Please see prescribing details for more information.</span><strong><br></strong></p><p><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy category B. Doxophylline should be given to pregnant women only if already needed.</span><strong><br></strong></p><p><strong>Packing : </strong>Doxoma : 3 x 10's tablets in blister pack.</p><p>Doxoma-200 : 5 x 10's tablets in blister pack.</p><p><br></p>",
    "strength": "400,200",
    "uom": "mg",
    "categoryId": "47",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531374032doxoma.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744024765Doxoma-400.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744024764Doxoma-200.png"
    ]
  },
  {
    "id": "1334",
    "name": "Dsec",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition : Dsec-30 : </strong>Each Capsule Contains Dexlansoprazole INN 30mg as enteric\r\ncoated granules.\r\n\r\n</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dsec-60 : </strong>Each\r\nCapsule Contains Dexlansoprazole INN 60mg as enteric coated granules.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indications : </strong>Dexlansoprazole\r\nis indicated for-</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\">•\r\nHealing of Erosive Esophagitis (EE).</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\">•\r\nMaintenance of Healed Erosive Esophagitis.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\">•\r\nSymptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD).<br></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration : </strong>Dexlansoprazole dosing recommendations:</p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\">\r\n <tbody><tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"231\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong>Indication</strong></p>\r\n  \r\n  </td>\r\n  <td xss=\"removed\" width=\"231\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong>Recommended Dose</strong></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"231\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong>Frequency</strong></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"231\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\">Healing of EE</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"231\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">60 mg</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"231\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">Once daily for up to 8 weeks</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"231\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\">Maintenance of Healed EE</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"231\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">30 mg</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"231\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">Once daily</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"231\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p>\r\n  <p class=\"MsoNormal\" xss=\"removed\">Symptomatic Non-Erosive GERD</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"231\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">30 mg</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"231\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">Once daily for 4 weeks</p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\">•\r\nDexlansoprazole can be taken with or without food.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\">•\r\nThis capsules should be swallowed whole; Should not be chewed.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\">•\r\nAlternatively, capsules can be administered as follows:</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\">-\r\nOpen capsule.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\">-\r\nSprinkle intact granules on 1 table spoon.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\">-\r\nSwallow immediately. Granules should not be chewed.\r\nOr, as directed by the registered physicians.\r\n\r\n</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy Category\r\nB. There are no adequate and well-controlled studies  in\r\npregnant women.\r\nIt is not known whether dexlansoprazole is excreted in human milk.</p> <p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Packing : Dsec-30 : </strong>Each\r\nbox contains 30 capsules in alu-alu blister pack.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dsec-60 : </strong>Each\r\nbox contains 28 capsules in alu-alu blister pack.</p>",
    "strength": "60,30",
    "uom": "mg",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1534570829Dsec.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744024834dsec-60.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744024834dsec-30.png"
    ]
  },
  {
    "id": "889",
    "name": "Dutamax",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\">Dutasteride INN 0.5mg\r\nCapsule.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong>It is indicated for the\r\ntreatment of symptomatic benign\r\nprostatic hyperplasia (BPH) in men with\r\nan enlarged prostate to; 1. Improve\r\nsymptoms, 2. Reduce the risk of acute\r\nurinary retention, 3. Reduce the risk of\r\nthe need for BPH-related surgery.<strong></strong></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The\r\nrecommended dose of Dutasteride is\r\none capsule (0.5mg) taken orally once a\r\nday. Dutasteride may be administered\r\nwith or without food. No dosage\r\nadjustment is necessary for subjects with\r\nrenal impairment or for the elderly\r\npatients. Or, as directed by the\r\nregistered physician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Dutamax : 3 x 7’s soft\r\ncapsules in blister pack.</span></p>",
    "strength": "0.5",
    "uom": "mg",
    "categoryId": "46",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531374341Dutamax.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745309935Dutamax.png"
    ]
  },
  {
    "id": "940",
    "name": "E - Cap",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong> <strong> </strong><strong>E-Cap 200 :</strong> Each E-Cap soft gelatin capsule contains\r\nVitamin-E USP 200 I.U. <strong>E-Cap 400</strong> :\r\nEach E-Cap soft gelatin capsule contains Vitamin- E USP 400 I.U.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>E-Cap 600 :</strong> Each E-Cap soft gelatin capsule\r\ncontains Vitamin- E USP 600 I.U.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications </strong>: Vitamin-E is\r\nused for the treatment & prevention of Vitamin E deficiency. There is a\r\npossible need for supplementation of Vitamin-E in the diet of pregnant &\r\nlactating women and for new born infants where anemia can arise as a result of insufficiency\r\nof Vitamin-E.Vitamin-E has been tried in the treatment of various disorders including\r\nangina pectoris hypercholesterolaemia , intermittent claudication, fibrocystic\r\nbreast disease, cancer, nocturnal leg cramps, osteoarthritis etc. Vitamin-E has\r\nalso been claimed to enhance athletic performance.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage & Administration :</strong><strong> </strong>1-\r\n2 Capsules daily, or as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Side effects : </strong>Vitamin-E is usually\r\nwell tolerated. Large doses may cause diarrhoea, abdominal pain and other\r\ngastrointestinal disturbances.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Contraindication:</strong>\r\nKnown hypersensitivity to Vitamin-E.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Packing : <o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>E-Cap 200</strong>\r\n: Each box contains 60 capsules in blister pack.             <o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>E-Cap 400 :</strong>\r\nEach box contains 60 capsules in blister pack.                 <o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>E-Cap 600 :</strong>\r\nEach box contains 30 capsules in blister pack<br></p>",
    "strength": " 600,400,200",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "67",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745142957E-CAP 600.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745142957E-CAP-400.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745142957E-CAP.png"
    ]
  },
  {
    "id": "941",
    "name": "E - Cap Plus",
    "description": "<p><strong>Composition :</strong> Vitamin C USP (250mg)  + Vitamin E USP (200mg) Soft Capsule.</p><p style=\"text-align: justify;\"><strong>Indications : </strong>The active ingredients of Vitamin C and Vitamin E have been linked with reduced risks of cardiovascular diseases in human. Concurrent intake of Vitamin E and Vitamin C suggests that their action may be synergistic.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong>Vitamin C & E capsule is administered orally. The adult dose is 1 capsule daily or as directed by the registered physician.</p><p style=\"text-align: justify;\"><strong>Packing : </strong>E-Cap Plus : 5 x 6's Soft Capsules in blister pack.</p>",
    "strength": "200+250",
    "uom": "mg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531387007E_plus.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745142744E-CAP PLUS.png"
    ]
  },
  {
    "id": "1849",
    "name": "E-Coxib ",
    "description": "<p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition:</strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal\"><strong>E-Coxib 60:</strong> Each film coated tablet contains Etoricoxib INN 60mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal\"><strong>E-Coxib 90:</strong> Each film coated tablet contains Etoricoxib INN 90mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong></strong><strong>E-Coxib 120:</strong> Each film coated tablet contains Etoricoxib INN 120mg.<br></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications: </strong>Etoricoxib helps to reduce the pain and swelling\r\n(inflammation) in the joints and muscles of people 16 years of age and older\r\nwith osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and gout.\r\nEtoricoxib is also used for the short term treatment of moderate pain after\r\ndental surgery in people 16 years of age and older.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage and Administration:\r\nAdult and adolescent over 16 years: Osteoarthritis: </strong>The recommended\r\ndose is 30mg once a day, increase to a maximum of 60 mg once a day if needed. <strong>Rheumatoid\r\narthritis:</strong>The recommended dose is 60 mg etoricoxib once a day. The dose can\r\nbe increased to a maximum of 90mg. <strong>Ankylosing spondylitis: </strong>The\r\nrecommended dose is 60 mg etoricoxib once a day. The dose can be increased to a\r\nmaximum of 90 mg once a day if needed. <strong>Acute pain conditions: </strong>Etoricoxib\r\nshould be used only for the acute painful period. <strong>Gout: </strong>The recommended dose\r\nis 120 mg once a day which should only be used for the acute painful period, limited\r\nto a maximum of 8 days treatment. <strong>Postoperative dental surgery pain: </strong>The\r\nrecommended dose is 90 mg once daily, limited to a maximum of 3 days treatment.\r\nOr, as directed by the registered physician.<strong> </strong><o:p></o:p></p><p class=\"Default\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;\r\nmargin-left:0in;text-align:justify;text-justify:inter-ideograph\"><strong>Use in\r\npregnancy and lactation: </strong>Etoricoxib, as with\r\nother medicinal products inhibiting prostaglandin synthesis, may cause uterine\r\ninertia and premature closure of the ductus arteriosus during the last\r\ntrimester. Etoricoxib is contraindicated in pregnancy. If a woman becomes\r\npregnant during treatment, etoricoxib must be discontinued. The use of\r\netoricoxib, as with any drug substance known to inhibit COX2, is not\r\nrecommended in women attempting to conceive. It is not known whether etoricoxib\r\nis excreted in human milk. Women who use etoricoxib must not breast feed.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Packing: </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal\"><strong>E-Coxib 60: </strong>Each box contains\r\n28’s tablets in a blister pack.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal\"><strong>E-Coxib 90: </strong>Each box contains 28’s tablets in a blister pack.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>E-Coxib 120: </strong>Each box contains 30’s tablets in a blister pack.<br></p>",
    "strength": " 120, 90,60",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745143094E-coxib 120.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745143094E-coxib 90.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745143094E-coxib 60.png"
    ]
  },
  {
    "id": "905",
    "name": "Ejalong",
    "description": "<p><strong></strong><strong>Composition :</strong> Dapoxetine 30 mg &\r\n60 mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is indicated for the\r\ntreatment of premature ejaculation (PE)\r\nin adult men aged 18 to 64 years of age.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adult\r\nmen (aged 18 to 64 years):The\r\nrecommended starting dose for all\r\npatients is 30 mg, taken as needed\r\napproximately 1 to 3 hours prior to\r\nsexual activity. If the individual response\r\nto 30 mg is insufficient and the patient\r\nhas not experienced moderate or\r\nsevere adverse reactions, the dose may\r\nbe increased to a maximum\r\nrecommended dose of 60 mg taken as\r\nneeded approximately 1 to 3 hours prior\r\nto sexual activity. Or,as directed by the\r\nregistered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">This\r\ntablet is not indicated for women.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><strong> </strong><span class=\"redactor-invisible-space\">Ejalong 30 : 1 x 6's tablets in\r\nblister pack. </span></p><p style=\"text-align: justify;\">Ejalong 60 : 1 x 6's tablets in blister pack.</p>",
    "strength": "60,30",
    "uom": "mg",
    "categoryId": "113",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531387475ejalong.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/images/Eja-60.jpg",
      "https://www.admin.drug-international.com/uploads/images/Eja-30.jpg"
    ]
  },
  {
    "id": "1720",
    "name": "Emparol",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Emparol 10 : </strong>Each\r\nfilm coated tablet contains Empagliflozin INN 10mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong><br></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Emparol 25 : </strong>Each\r\nfilm coated tablet contains Empagliflozin INN 25mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication: </strong>It\r\nis indicated - as an adjunct to diet and exercise to improve glycemic control\r\nin adults with type 2 diabetes mellitus and - to reduce the risk of\r\ncardiovascular death in adult patients with type 2 diabetes mellitus and established\r\ncardiovascular disease.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>D o s a g e a n d A d m i n i s t r a t i o n\r\n: </strong>T h e recommended dose is 10mg once daily, taken in the\r\nmorning, with or without food. In patients tolerating Empagliflozin, the dose\r\nmay be increased to 25mg once daily. In patients with volume depletion,\r\ncorrecting this condition prior</p><p class=\"MsoNormal\" xss=\"removed\">to\r\ninitiation of Empagliflozin is recommended. Or, as directed by the registered\r\nphysician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: Emparol 10 : </strong>Each\r\nbox contains 1 x 14's tablets in blister pack.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Emparol 25 : </strong>Each\r\nbox contains 1 x 14's tablets in blister pack.</p>",
    "strength": "25,10",
    "uom": "mg",
    "categoryId": "93",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1569221973Emparol - Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740570581emparol 25.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740570581emparol 10.png"
    ]
  },
  {
    "id": "1870",
    "name": "Emparol-L ",
    "description": "<p>Composition: Emparol-L 10/5 Tablet : Each film\r\ncoated tablet contains Empagliflozin INN 10mg & Linagliptin INN 5mg.</p><p>Emparol-L 25/5 Tablet : Each film coated tablet contains Empagliflozin INN 25mg & Linagliptin INN 5mg.</p><p class=\"MsoNormal\" xss=\"removed\">Indications :\r\nEmparol-L is indicated: * As an adjunct to diet and exercise to improve glycemic\r\ncontrol in adults with type 2 diabetes mellitus to reduce the risk of\r\ncardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular\r\ndisease.<o></o></p><p class=\"MsoNormal\" xss=\"removed\">Dosage\r\n& Administration : The recommebded dose is Empagliflozin 10 mg / Linagliptin\r\n5 mg (Emparol-L 10/5) once daily, taken in the morning, with or without food.\r\nDose may be increased to Empagliflozin 25 mg / Linagliptin 5 mg (Emparol-L\r\n10/5) once daily. Or, as directed by the registered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\">Use in pregnancy and lactation :Pregnancy:Empagliflozin or Empagliflozin & </p><p class=\"MsoNormal\" xss=\"removed\">Linaglipin combionation is not recommended during the second and third trimesters of pregnancy. The limited available data\r\nin pregnant woman are not sufficient to determine a drug-associated risk for amjor\r\nbirth defects and miscarriage. There are risks to the mother and fetus\r\nassociated with poorly controlled diabetes</p><p class=\"MsoNormal\" xss=\"removed\">in pregnancy.\r\nLactation: There is no information regarding the presence of Empagliflozin&Linagliptin,\r\nor its individual components in human milk, the effects on the breastfed infant,\r\nor the effects on milk production. Use is recommended while breastfeeding.<o></o></p><p>Packing : Emparol-L 10/5 Tablet : Each box\r\ncontains 14’s Tablets in blister pack.</p><p>Emparol-L 25/5 Tablet : Each box contains 14’s Tablets in blister pack.<br></p>",
    "strength": " 25+5,10+5",
    "uom": "mg",
    "categoryId": "93",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745143300Emparol-L.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740571052emparol- L.png"
    ]
  },
  {
    "id": "1877",
    "name": "Emparol-M ",
    "description": "<p><strong>Composition : </strong>Each film\r\ncoated tablet contains Empagliflozin INN 5 mg & Metformin Hydrochloride USP\r\n500 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication : Emparol-M </strong>is indicated\r\nas an adjunct to diet and exercise to improve glycemic control in adults with\r\ntype 2 diabetes when treatment with bothempagliflozin and metformin is\r\nappropriate. Empagliflozin is indicated to reduce the risk of cardiovascular\r\ndeath in adults with type 2 diabetes mellitus and established cardiovascular\r\ndisease.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration: </strong>Individualize\r\nthe starting dose of <strong>Emparol-M </strong>based\r\non the patient's current regimen. The maximum recommended dose is 12.5mg\r\nEmpagliflozin/1000 mg Metformin twice daily. Take twice daily with meals, with\r\ngradual dose escalation to reduce the gastrointestinal side effects due to metformin.\r\nAssess renal function before initiating <strong>Emparol-M</strong>. Do not initiate or continue <strong>Emparol-M\r\n</strong>if creatinine levels &gt; 1.5 mg/dL(males), &gt;\r\n1.4 mg/dL (females), or if eGFR is below 45</p><p class=\"MsoNormal\" xss=\"removed\">mL/min/1.73\r\nm2.Or, as directed by the registerd physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and Lactation : Pregnancy: </strong>There are no adequate and well-controlled studies of\r\nEmpagliflozin& Metformin combination in pregnant women. This combination\r\nshould be used duing pregnancy only if the potential benefit justifies the\r\npotential <a name=\"_GoBack\"></a>risk to the fetus. <strong>Lactation: </strong>It is not recommended when\r\nbreastfeeding.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing</strong> : Each box contains 2 x 7's tablets in bilster pack.</p>",
    "strength": "5+500",
    "uom": "mg",
    "categoryId": "93",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1684658593Emparol-M 5-500- Insert (1).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740571021emparol- M.png"
    ]
  },
  {
    "id": "1862",
    "name": "Endozol",
    "description": "<p><strong>Composition\r\n:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Endozol\r\n100 Capsule: </strong>Each\r\nCapsule Contains Danazol BP 100 mg.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Endozol\r\n200 Capsule: </strong>Each\r\nCapsule Contains Danazol BP 200 mg.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong>It is indicated for\r\nthe treatment of Endometriosis, Benign breast disease, Severe cyclical mastalgia,\r\nMenorrhagia, Gynaecomastia, Preoperative thinning of the endometrium be for ethyst<a name=\"_GoBack\"></a>eronscopic endometrial ablation.<strong><o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration: </strong>Usually given in up to 4 divided doses, in women of\r\nchild bearing potential, treatment should start during menstruation, preferably\r\non first day. <strong>Endometriosis :</strong> 200-800mg daily in up to 4 divided doses,\r\nadjusted to achieve amenorrhoea,  usually\r\nfor 6 months (up to 9 months in some cases). <strong>Benign breast cysts:</strong> 300mg\r\ndaily usually for 3-6 months. <strong>Severe cyclical mastalgia:</strong> 100-400mg daily\r\nusually for 3-6 months. <strong>Menorrhagia:</strong> In menorrhagia daily doses of\r\n100-200mg have been found effective but 200mg daily for 3 months is usually\r\nsufficient to reduce menstrual blood flow to acceptable levels. <strong>Gynaecomastia\r\n:</strong> 400mg daily in up to 4 divided doses for 6 months (adolescents 200mg\r\ndaily,  increased to 400mg daily if no\r\nresponse after 2 months). For pre-operative thinning of endometrium: 400-800mg\r\ndaily in up to 4 divided doses for 3-6 weeks. Or, as directed by the registered\r\nphysician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Pregnancy and lactation: </strong>The drug\r\nshould not be given to pregnant women, because of  risk of virilization of a female fetus,\r\nparticularly when high doses are given for several weeks.  Patients taking the drug should not breast\r\nfeed.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing\r\n:Endozol 100 Capsule : </strong>Each box contains 30's\r\ncapsule in blister pack.<o></o></p><p><strong>Endozol 200 Capsule :</strong>Each box contains 20's capsule in blister pack.</p>",
    "strength": "100",
    "uom": "mg",
    "categoryId": "123",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1677994349Endozol Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1677994349Endozol 100 Carton.png"
    ]
  },
  {
    "id": "1279",
    "name": "Entavir ",
    "description": "<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\nline-height:normal\"><strong>Composition : Entavir-0.5: </strong>Entecavir USP 0.5 mg Tablet.</p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\nline-height:normal\"><strong>Entavir-1: </strong>Entecavir USP 1 mg Tablet.</p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Indication:</strong> This tablet is indicated for the treatment of chronic\r\nhepatitis B virus infection in adults with evidence of active viral replication\r\nand either evidence of persistent elevations in serum aminotransferases or\r\nhistologically active disease.</p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Dosage\r\nand administration :<i> </i></strong>The\r\nrecommended dose of Entecavir for chronic hepatitis B virus infection in\r\nnucleoside-treatment-naive adults and adolescents 16 years of age and older is\r\n0.5mg once daily. The recommended dose of Entecavir in adults and adolescents\r\n(&gt;16years of age) with a history of hepatitis B viremia while receiving\r\nlamivudine is 1mg once daily. Entecavir should be administered on an empty\r\nstomach (at least 2 hours after a meal and 2 hours before the next meal). Or,\r\nas directed by the registered physician.</p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Use\r\nin pregnancy and lactation :</strong>\r\nEntecavir should be used during pregnancy only if clearly needed and after\r\ncareful consideration of the risks and benefits. It is not known whether this\r\ndrug is excreted in human milk. Mothers should be instructed not to breast feed\r\nif they are taking Entecavir.</p><p class=\"MsoNormal\"><strong>Packing:</strong>\r\n<strong>Entavir-0.5: </strong>1x14’s\r\ntablets in blister pack.</p><p class=\"MsoNormal\"><strong>Entavir-1:\r\n</strong>1x14’s\r\ntablets in blister pack.</p>",
    "strength": "1,0.5",
    "uom": "mg",
    "categoryId": "45",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531387807Entavir.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745143335Entavir-1.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745143335Entavir-0.5.png"
    ]
  },
  {
    "id": "1907",
    "name": "Epimet ",
    "description": "<p><strong>Composition: Epimet 25 : </strong>Each tablet\r\ncontains Topiramate USP 25mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Epimet 50: </strong>Each tablet contains Topiramate USP 50\r\nmg.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications : </strong>It is indicated to treat certain types\r\nof seizures (partial onset seizure and primary generalized tonic- clonic\r\nseizures) and the preventive treatment of migraine in patients 12 years of age\r\nand older.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage & Administration :</strong><strong> </strong>The recommended\r\ndose for Topiramate monotherapy in adults and pediatric 10 yeras of age and\r\nolder is 400mg/day in two divided doses, the initial dose of topiramate is\r\n25mg/day for the first week,the dosage can be increased by 25-50mg/- day.For\r\nthe preventive treatement of migraine patients in 12 years of age and older\r\nThre recommended dose is 100mg/day administered in two divided doses.The dose\r\nshould not exceed the maximum maintenance dose or, as directed by a registered\r\nphysician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation :</strong><strong> </strong><strong>Pregnancy : </strong>Topiramate\r\nshould not be given during pregnancy and lactation.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: Epimet 25  : </strong>Each box contains 50 tablets in blister\r\npack.</p><p><strong>Epimet 50 </strong><strong> :\r\n</strong>Each\r\nbox contains 50 tablets in blister pack.</p>",
    "strength": " 25",
    "uom": "mg",
    "categoryId": "48",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1716100140Epimet Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1716100140Epimet 25 Carton.png"
    ]
  },
  {
    "id": "1833",
    "name": "Epiruba-10",
    "description": "<p><strong>Composition:\r\nEpiruba-10:</strong> Each vial contains Epirubicin\r\nHydrochloride USP 10mg solution for injection.</p><p class=\"MsoNormal\">\r\n<strong>Epiruba-50:</strong> Each vial contains Epirubicin\r\nHydrochloride USP 50mg solution for injection.<o></o></p>\r\n\r\n<p class=\"MsoNormal\"><strong>Indications:</strong>\r\nEpirubicin Injection is indicated as a component of adjuvant therapy in\r\npatients with evidence of axillary node tumor involvement following resection\r\nof primary breast cancer.<o></o></p>\r\n\r\n<p class=\"MsoNormal\"><strong>Dosage\r\nand Administration: Recommended Dose:</strong> The recommended dose\r\nof Epirubicin is 100 to 120mg/m². The following regimens are recommended:<o></o></p>\r\n\r\n<table class=\"MsoTableGrid\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\r\n <tbody><tr xss=removed>\r\n  <td width=\"213\" rowspan=\"4\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed><strong>CEF-120:<o></o></strong></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed>Cyclophosphamide<o></o></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed>75 mg/m² PO D 1-14<o></o></p>\r\n  </td>\r\n </tr>\r\n <tr xss=removed>\r\n  <td width=\"213\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed>Epirubicin<o></o></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed>60mg/m² IV D 1,8<o></o></p>\r\n  </td>\r\n </tr>\r\n <tr xss=removed>\r\n  <td width=\"213\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed>5-Fluorouracil<o></o></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed>500mg/m² IV D 1,8<o></o></p>\r\n  </td>\r\n </tr>\r\n <tr xss=removed>\r\n  <td width=\"426\" colspan=\"2\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed><strong>Repeated every\r\n  28 days for 6 cycles<o></o></strong></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"213\" rowspan=\"3\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed><strong>FEC-100:<o></o></strong></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed>5-Fluorouracil<o></o></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed>500mg/m²<o></o></p>\r\n  </td>\r\n </tr>\r\n <tr xss=removed>\r\n  <td width=\"213\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed>Epirubicin<o></o></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed>100mg/m²<o></o></p>\r\n  </td>\r\n </tr>\r\n <tr xss=removed>\r\n  <td width=\"213\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed>Cyclophosphamide<o></o></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" xss=removed>\r\n  <p class=\"MsoNormal\" align=\"center\" xss=removed>500mg/m²<o></o></p>\r\n  </td>\r\n </tr>\r\n</tbody></table>\r\n\r\n<p class=\"MsoNormal\"> </p>\r\n\r\n<p class=\"MsoNormal\">All drugs administered intravenously on day 1 and\r\nrepeated every 21 days for 6 cycles. Patients administered the 120mg/m² regimen\r\nof Epirubicin should receive prophylactic antibiotic therapy. Or, as directed\r\nby the registered physician.<o></o></p>\r\n\r\n<p class=\"MsoNormal\"><strong>Use\r\nin Pregnancy and lactation:</strong> Pregnancy Category D. There are no\r\nadequate and well controlled studies in pregnant women. It should be used in\r\npregnancy only if the potential benefit justifies the potential risk to the\r\nfetus. It is not known whether this drug is excreted in human milk. Because of\r\nthe potential for serious adverse reactions from Epirubicin in nursing infants,\r\na decision should be made whether to discontinue nursing or to discontinue the\r\ndrug, taking into account the importance of the drug to the mother.<o></o></p>\r\n\r\n<p class=\"MsoNormal\"><strong>Packaing:\r\nEpiruba-10:</strong> Each box contains one vial of 10mg\r\nEpirubicin Hydrochloride USP solution for injection.<br><o></o></p><p><strong>Epiruba-50:</strong> Each box contains one\r\nvial of 50mg Epirubicin Hydrochloride USP solution for injection.</p>",
    "strength": "10",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1651129327Epiruba 10 & 50 web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1651129327Epiruba-10 IV Inj Carton Pic.png"
    ]
  },
  {
    "id": "1331",
    "name": "Epiruba-50",
    "description": "<p class=\"MsoNormal\"><strong>Composition:\r\nEpiruba-10:</strong> Each vial contains Epirubicin\r\nHydrochloride USP 10mg solution for injection.<br>\r\n<strong>Epiruba-50:</strong> Each vial contains Epirubicin\r\nHydrochloride USP 50mg solution for injection.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Indications:</strong>\r\nEpirubicin Injection is indicated as a component of adjuvant therapy in\r\npatients with evidence of axillary node tumor involvement following resection\r\nof primary breast cancer.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Dosage\r\nand Administration: Recommended Dose:</strong> The recommended dose\r\nof Epirubicin is 100 to 120mg/m². The following regimens are recommended:<o:p></o:p></p><table class=\"MsoTableGrid\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\r\n <tbody><tr style=\"mso-yfti-irow:0;mso-yfti-firstrow:yes;height:16.5pt\">\r\n  <td width=\"213\" rowspan=\"4\" valign=\"top\" style=\"width: 159.6pt; border-width: 1pt; border-color: windowtext; padding: 0in 5.4pt; height: 16.5pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\"><strong>CEF-120:<o:p></o:p></strong></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" style=\"width: 159.6pt; border-top-width: 1pt; border-right-width: 1pt; border-bottom-width: 1pt; border-top-color: windowtext; border-right-color: windowtext; border-bottom-color: windowtext; border-left: none; padding: 0in 5.4pt; height: 16.5pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Cyclophosphamide<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" style=\"width: 159.6pt; border-top-width: 1pt; border-right-width: 1pt; border-bottom-width: 1pt; border-top-color: windowtext; border-right-color: windowtext; border-bottom-color: windowtext; border-left: none; padding: 0in 5.4pt; height: 16.5pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">75 mg/m² PO D 1-14<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr style=\"mso-yfti-irow:1;height:13.9pt\">\r\n  <td width=\"213\" valign=\"top\" style=\"width: 159.6pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 13.9pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Epirubicin<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" style=\"width: 159.6pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 13.9pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">60mg/m² IV D 1,8<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr style=\"mso-yfti-irow:2;height:13.0pt\">\r\n  <td width=\"213\" valign=\"top\" style=\"width: 159.6pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 13pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">5-Fluorouracil<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" style=\"width: 159.6pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 13pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">500mg/m² IV D 1,8<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr style=\"mso-yfti-irow:3;height:13.5pt\">\r\n  <td width=\"426\" colspan=\"2\" valign=\"top\" style=\"width: 319.2pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 13.5pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\"><strong>Repeated every\r\n  28 days for 6 cycles<o:p></o:p></strong></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"213\" rowspan=\"3\" valign=\"top\" style=\"width: 159.6pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\"><strong>FEC-100:<o:p></o:p></strong></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" style=\"width: 159.6pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">5-Fluorouracil<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" style=\"width: 159.6pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">500mg/m²<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr style=\"mso-yfti-irow:5;height:14.5pt\">\r\n  <td width=\"213\" valign=\"top\" style=\"width: 159.6pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 14.5pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Epirubicin<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" style=\"width: 159.6pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 14.5pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">100mg/m²<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr style=\"mso-yfti-irow:6;mso-yfti-lastrow:yes;height:13.5pt\">\r\n  <td width=\"213\" valign=\"top\" style=\"width: 159.6pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 13.5pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Cyclophosphamide<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"213\" valign=\"top\" style=\"width: 159.6pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 13.5pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">500mg/m²<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\">All drugs administered intravenously on day 1 and\r\nrepeated every 21 days for 6 cycles. Patients administered the 120mg/m² regimen\r\nof Epirubicin should receive prophylactic antibiotic therapy. Or, as directed\r\nby the registered physician.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Use\r\nin Pregnancy and lactation:</strong> Pregnancy Category D. There are no\r\nadequate and well controlled studies in pregnant women. It should be used in\r\npregnancy only if the potential benefit justifies the potential risk to the\r\nfetus. It is not known whether this drug is excreted in human milk. Because of\r\nthe potential for serious adverse reactions from Epirubicin in nursing infants,\r\na decision should be made whether to discontinue nursing or to discontinue the\r\ndrug, taking into account the importance of the drug to the mother.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Packaing:\r\nEpiruba-10:</strong> Each box contains one vial of 10mg\r\nEpirubicin Hydrochloride USP solution for injection.<br><o:p></o:p></p><p><strong>Epiruba-50:</strong> Each box contains one\r\nvial of 50mg Epirubicin Hydrochloride USP solution for injection.<br></p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1651128344Epiruba 10 & 50 web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1534563816Epiruba_50c.jpg"
    ]
  },
  {
    "id": "1363",
    "name": "Epomax",
    "description": "<p>Recombinant Human Erythropoietin Injection</p><p><strong>Presentation </strong><strong>:</strong>Epomax 5000 Injection : Each 0.5 ml Pre-filled Syringe contains Erythropoietin concentrated solution (rDNA) BP 5000 IU</p><p><br></p><p><strong>Indications:</strong> Erythropoietin is indicated for the treatment of<strong> 1.</strong>Anemia associated with Chronic Renal Failure, including patients on dialysis (ESRD) and patients not on dialysis.<strong>2</strong>.Anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. <strong>3</strong>. Anemic patients (hemoglobin &gt; 10 to &lt; 13&gt;4. Anemia related to therapy with zidovudine in HIV-infected patients. </p><p><strong>Dosage</strong> <strong><br></strong></p><p><strong>Treatment of anemia In chronic renal failure:</strong> Erythropoietin is<strong> </strong>administered to maintain hemoglobin concentration between 11 to 12 g/dl and hematocrit of 33 - 36 % in adults. <strong><br></strong></p><p><strong>Starting dose: Adult:</strong> usually 50 to 100 IU/kg three times in a week (TIW) by IV or Subcutaneous route Pediatric: 50 IU/kg TIW by IV or Subcutaneous route </p><p><strong>Dose adjustment:</strong> Dose should be increased if hematocrit doses not increase by 5 to 6 points after 8 weeks therapy, and hematocrit is below suggested target range. Dose should be reduced when hematocrit approaches 36% or hematocrit increases &gt; 4 points in any 2-week period.</p><p><br></p><p><strong>Treatment of anemia in cancer patients on chemotherapy Starting dose:</strong> <strong>Adult</strong>: 150 IU/kg TlW by Subcutaneous route or 40,000 IU Subcutaneous route weekly Pediatric: 25 to 300 IU/kg 3 to 7 times per week by Subcutaneous or IV route.</p><p><br></p><p><strong>Packing Epomax-5000 IU:</strong> Each box contains 1 pre-filied syringe containing 5000 IU of recombinant Erythropoietin.<br></p>",
    "strength": "5000",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "114",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1551956446Epomax 5000 IU- Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1683110748Epomax Carton.png"
    ]
  },
  {
    "id": "1757",
    "name": "Epomax 3000 Injection",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Epomax 3000 Injection: </strong>Each\r\nPre-filled Syringe contains 0.3 ml Erythropoietin concentrated solution (rDNA)\r\nBP 3000 IU.</p><p xss=\"removed\"><strong>Indications:</strong> Erythropoietin is indicated for the treatment of<strong> 1.</strong>Anemia\r\nassociated with Chronic Renal Failure, including patients on dialysis (ESRD)\r\nand patients not on dialysis.<strong>2</strong>.Anemia in patients with\r\nnon-myeloid malignancies where anemia is due to the effect of concomitantly\r\nadministered chemotherapy. <strong>3</strong>. Anemic patients (hemoglobin\r\n&gt; 10 to &lt; 13&gt;4. Anemia related to therapy with zidovudine in\r\nHIV-infected patients.</p><p xss=\"removed\"><strong>Dosage</strong></p><p xss=\"removed\"><strong>Treatment\r\nof anemia In chronic renal failure:</strong> Erythropoietin\r\nis<strong> </strong>administered to maintain hemoglobin\r\nconcentration between 11 to 12 g/dl and hematocrit of 33 - 36 % in adults.</p><p xss=\"removed\"><strong>Starting\r\ndose: Adult:</strong> usually 50 to 100 IU/kg\r\nthree times in a week (TIW) by IV or Subcutaneous route Pediatric: 50 IU/kg TIW<a name=\"_GoBack\"></a> by IV or Subcutaneous route</p><p xss=\"removed\"><strong>Dose\r\nadjustment:</strong> Dose should be increased if\r\nhematocrit doses not increase by 5 to 6 points after 8 weeks therapy, and\r\nhematocrit is below suggested target range. Dose should be reduced when\r\nhematocrit approaches 36% or hematocrit increases &gt; 4 points in any 2-week\r\nperiod.</p><p xss=\"removed\"><strong>Treatment\r\nof anemia in cancer patients on chemotherapy Starting dose:</strong> <strong>Adult</strong>: 150 IU/kg TlW by\r\nSubcutaneous route or 40,000 IU Subcutaneous route weekly Pediatric: 25 to 300\r\nIU/kg 3 to 7 times per week by Subcutaneous or IV route.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation </strong><i>Pregnancy Category C. </i>Since there are no controlled studies oferythropoietin in pregnant\r\nwomen, and because animal reproduction studiesare not always predictive of\r\nhuman responses, erythropoietin should beused during pregnancy only if clearly\r\nneeded.<strong></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Epomax-3000 Injection: </strong>Each box\r\ncontains 1 pre-filied syringe containing 3000 IU of recombinant Erythropoietin.</p>",
    "strength": "3000 IU.",
    "uom": "",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1614682186Epomax- Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1614682186Epomax 3000 IU Carton pic.png"
    ]
  },
  {
    "id": "1847",
    "name": "Erdanib",
    "description": "<p><strong>Composition:</strong> <strong>Erdanib-4:</strong>\r\nEach film coated tablet contains Erdafitinib INN 4.00 mg.</p><h4> </h4><p class=\"MsoNormal\"><strong>Indications:</strong> It\r\nis indicated for the treatment of adult patients with locally advanced or\r\nmetastatic Urothelial Carcinoma (mUC), that has- </p><p class=\"MsoListParagraph\">·        \r\nSusceptible FGFR3 or FGFR2\r\ngenetic alterations, and </p><p class=\"MsoListParagraph\">·        \r\nProgressed during or\r\nfollowing at least one line of prior platinum-containing chemotherapy,\r\nincluding within 12 months of neoadjuvant or adjuvant platinum-containing\r\nchemotherapy. </p><p class=\"MsoNormal\"><strong>Dosage & Administration:</strong> The\r\nrecommended starting dose of Erdafitinib is 8 mg (two 4 mg tablets) orally once\r\ndaily, with a dose increase to 9 mg (three 3 mg tablets) once daily based on\r\nserum phosphate (PO4) levels and tolerability at 14 to 21 days. Whole tablets\r\nshould be swallowed with or without food. If vomiting occurs any time after\r\ntaking Erdafitinib, the next dose should be taken the next day. Treatment\r\nshould be continued until disease progression or unacceptable toxicity occurs.\r\nIf a dose is missed, it can be taken as soon as possible on the same day. The\r\nregular daily dose schedule for Erdafitinib should be resumed the next day.\r\nExtra tablets should not be taken to make up for the missed dose. Or, as\r\ndirected by the registered physicians.  </p><p class=\"MsoNormal\"><strong><u>Dose Modification: </u></strong></p><p class=\"MsoNormal\"><strong><u> </u></strong></p><table class=\"MsoTableGrid\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\">\r\n <tbody><tr>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\"><strong>Dose</strong></p>\r\n  </td>\r\n  <td width=\"96\" valign=\"top\">\r\n  <p class=\"MsoNormal\"><strong>1<sup>st </sup> Dose</strong></p>\r\n  <p class=\"MsoNormal\"><strong>Reduction</strong></p>\r\n  </td>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\"><strong>2<sup>nd</sup> Dose</strong></p>\r\n  <p class=\"MsoNormal\"><strong>Reduction</strong></p>\r\n  </td>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\"><strong>3<sup>nd</sup> Dose</strong></p>\r\n  <p class=\"MsoNormal\"><strong>Reduction</strong></p>\r\n  </td>\r\n  <td width=\"108\" valign=\"top\">\r\n  <p class=\"MsoNormal\"><strong>4<sup>nd</sup> Dose</strong></p>\r\n  <p class=\"MsoNormal\"><strong>Reduction</strong></p>\r\n  </td>\r\n  <td width=\"85\" valign=\"top\">\r\n  <p class=\"MsoNormal\"><strong>5<sup>nd</sup> Dose</strong></p>\r\n  <p class=\"MsoNormal\"><strong>Reduction</strong></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">9mg (three 3mg\r\n  tablets)<strong></strong></p>\r\n  </td>\r\n  <td width=\"96\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">8mg (two 4mg\r\n  tablets)<strong></strong></p>\r\n  </td>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">6mg (two 3mg\r\n  tablets)</p>\r\n  </td>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">5mg (one 5mg\r\n  tablet)</p>\r\n  </td>\r\n  <td width=\"108\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">4mg (one 4mg</p>\r\n  <p class=\"MsoNormal\" align=\"center\">tablet)<strong></strong></p>\r\n  </td>\r\n  <td width=\"85\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">Stop<strong></strong></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">8mg (two 4mg\r\n  tablets)<strong></strong></p>\r\n  </td>\r\n  <td width=\"96\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">6mg (two 3mg\r\n  tablets)</p>\r\n  </td>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">5mg (one 5mg\r\n  tablet)</p>\r\n  </td>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">4mg (one 4mg\r\n  tablet)</p>\r\n  </td>\r\n  <td width=\"108\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">Stop<strong></strong></p>\r\n  </td>\r\n  <td width=\"85\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\"><strong> </strong></p>\r\n  <br></td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\"><strong> </strong></p><p class=\"MsoNormal\"><strong>Use in Pregnancy and Lactation: </strong>Erdafitinib\r\ncan cause fetal harm when administered to a pregnant woman. Pregnancy \r\ntesting\r\nis recommended for females of reproductive potential prior to initiating\r\ntreatment with Erdafitinib. Advise pregnant\r\nwomen and females of reproductive potential of the potential risk to the\r\n fetus.\r\nMales and females of reproductive potential are advised to use effective\r\ncontraception during treatment with Erdafitinib\r\nand for one month after the last dose. Based on findings from animal \r\nstudies, Erdafitinib may impair fertility in females of reproductive \r\npotential.<strong> </strong></p><p class=\"MsoNormal\"><strong>Lactation: </strong>Because of the potential for\r\nserious adverse reactions from Erdafitinib in a breastfed child, lactating\r\nwomen should not to breastfeed during treatment with Erdafitinib and for one month following the last dose. </p><p class=\"MsoNormal\"><strong> </strong></p><p class=\"MsoNormal\"><strong>Packaging:</strong> </p><p class=\"MsoNormal\"><strong>Erdanib-4:</strong> Each box contains 60 tablets in a container.</p>",
    "strength": "4",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1662625071erdanib-4.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1661421217Erdanib-4 Carton.png"
    ]
  },
  {
    "id": "1848",
    "name": "Erdanib-5",
    "description": "<p class=\"MsoNormal\"><strong>Erdanib-5:</strong> Each film coated tablet contains Erdafitinib INN 5.00\r\nmg. </p><h4> </h4><p class=\"MsoNormal\"><strong>Indications:</strong> It\r\nis indicated for the treatment of adult patients with locally advanced or\r\nmetastatic Urothelial Carcinoma (mUC), that has- </p><p class=\"MsoListParagraph\">·        \r\nSusceptible FGFR3 or FGFR2\r\ngenetic alterations, and </p><p class=\"MsoListParagraph\">·        \r\nProgressed during or\r\nfollowing at least one line of prior platinum-containing chemotherapy,\r\nincluding within 12 months of neoadjuvant or adjuvant platinum-containing\r\nchemotherapy. </p><p class=\"MsoNormal\"><strong>Dosage & Administration:</strong> The\r\nrecommended starting dose of Erdafitinib is 8 mg (two 4 mg tablets) orally once\r\ndaily, with a dose increase to 9 mg (three 3 mg tablets) once daily based on\r\nserum phosphate (PO4) levels and tolerability at 14 to 21 days. Whole tablets\r\nshould be swallowed with or without food. If vomiting occurs any time after\r\ntaking Erdafitinib, the next dose should be taken the next day. Treatment\r\nshould be continued until disease progression or unacceptable toxicity occurs.\r\nIf a dose is missed, it can be taken as soon as possible on the same day. The\r\nregular daily dose schedule for Erdafitinib should be resumed the next day.\r\nExtra tablets should not be taken to make up for the missed dose. Or, as\r\ndirected by the registered physicians.  </p><p class=\"MsoNormal\"><strong><u>Dose Modification: </u></strong></p><p class=\"MsoNormal\"><strong><u> </u></strong></p><table class=\"MsoTableGrid\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\">\r\n <tbody><tr>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\"><strong>Dose</strong></p>\r\n  </td>\r\n  <td width=\"96\" valign=\"top\">\r\n  <p class=\"MsoNormal\"><strong>1<sup>st </sup> Dose</strong></p>\r\n  <p class=\"MsoNormal\"><strong>Reduction</strong></p>\r\n  </td>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\"><strong>2<sup>nd</sup> Dose</strong></p>\r\n  <p class=\"MsoNormal\"><strong>Reduction</strong></p>\r\n  </td>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\"><strong>3<sup>nd</sup> Dose</strong></p>\r\n  <p class=\"MsoNormal\"><strong>Reduction</strong></p>\r\n  </td>\r\n  <td width=\"108\" valign=\"top\">\r\n  <p class=\"MsoNormal\"><strong>4<sup>nd</sup> Dose</strong></p>\r\n  <p class=\"MsoNormal\"><strong>Reduction</strong></p>\r\n  </td>\r\n  <td width=\"85\" valign=\"top\">\r\n  <p class=\"MsoNormal\"><strong>5<sup>nd</sup> Dose</strong></p>\r\n  <p class=\"MsoNormal\"><strong>Reduction</strong></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">9mg (three 3mg\r\n  tablets)<strong></strong></p>\r\n  </td>\r\n  <td width=\"96\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">8mg (two 4mg\r\n  tablets)<strong></strong></p>\r\n  </td>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">6mg (two 3mg\r\n  tablets)</p>\r\n  </td>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">5mg (one 5mg\r\n  tablet)</p>\r\n  </td>\r\n  <td width=\"108\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">4mg (one 4mg</p>\r\n  <p class=\"MsoNormal\" align=\"center\">tablet)<strong></strong></p>\r\n  </td>\r\n  <td width=\"85\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">Stop<strong></strong></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">8mg (two 4mg\r\n  tablets)<strong></strong></p>\r\n  </td>\r\n  <td width=\"96\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">6mg (two 3mg\r\n  tablets)</p>\r\n  </td>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">5mg (one 5mg\r\n  tablet)</p>\r\n  </td>\r\n  <td width=\"102\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">4mg (one 4mg\r\n  tablet)</p>\r\n  </td>\r\n  <td width=\"108\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\">Stop<strong></strong></p>\r\n  </td>\r\n  <td width=\"85\" valign=\"top\">\r\n  <p class=\"MsoNormal\" align=\"center\"><strong> </strong></p>\r\n  <br></td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\"><strong> </strong></p><p class=\"MsoNormal\"><strong>Use in Pregnancy and Lactation: </strong>Erdafitinib\r\ncan cause fetal harm when administered to a pregnant woman. Pregnancy \r\ntesting\r\nis recommended for females of reproductive potential prior to initiating\r\ntreatment with Erdafitinib. Advise pregnant\r\nwomen and females of reproductive potential of the potential risk to the\r\n fetus.\r\nMales and females of reproductive potential are advised to use effective\r\ncontraception during treatment with Erdafitinib\r\nand for one month after the last dose. Based on findings from animal \r\nstudies, Erdafitinib may impair fertility in females of reproductive \r\npotential.<strong> </strong></p><p class=\"MsoNormal\"><strong>Lactation: </strong>Because of the potential for\r\nserious adverse reactions from Erdafitinib in a breastfed child, lactating\r\nwomen should not to breastfeed during treatment with Erdafitinib and for one month following the last dose. </p><p class=\"MsoNormal\"><strong> </strong></p><p class=\"MsoNormal\"><strong>Packaging:</strong> </p><p class=\"MsoNormal\"><strong>Erdanib-5:</strong> Each box contains 30 tablets in a container.</p>",
    "strength": "5",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1662626412erdanib-4.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/16626264121661421217Erdanib-5 Carton.png"
    ]
  },
  {
    "id": "1350",
    "name": "Eronib-150",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition</strong>:<strong>Eronib-150</strong> Each ﬁlm coated tablet contains Erlotinib 150 mg as\r\nErlotinib HCl INN.</p><p class=\"MsoNormal\" xss=\"removed\"> <strong>Indications:\r\nNon-Small Cell Lung Cancer (NSCLC):</strong> It is indicated for the treatment of\r\npatients with metastatic non-small cell lung cancer (NSCLC) whose tumors have\r\nepidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R)\r\nsubstitution mutations as detected by an FDA-approved test receiving ﬁrst-line,\r\nmaintenance, or second or greater line treatment after progression following at\r\nleast one prior chemotherapy regimen. <strong>Pancreatic\r\nCancer:</strong> Erlotinib in combination with Gemcitabine is indicated for the\r\nﬁrst-line treatment of patients with locally advanced, unresectable or\r\nmetastatic pancreatic cancer. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration: Recommended Dose – NSCLC: </strong>The\r\nrecommended daily dose of Eronib for NSCLC is 150 mg taken on an empty stomach,\r\ni.e., at least one hour before or two hours after the ingestion of food.\r\nTreatment should be continued until disease progression or unacceptable\r\ntoxicity occurs. <strong>Recommended Dose -\r\nPancreatic Cancer:</strong> The recommended daily dose of Eronib for pancreatic\r\ncancer is 100 mg taken once daily in combination with Gemcitabine. Eronib\r\nshould be taken on an empty stomach, i.e., at least one hour before or two\r\nhours after the ingestion of food. Treatment should be continued until disease\r\nprogression or unacceptable toxicity occurs. Or, as directed by the registered\r\nphysicians. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation: </strong>Pregnancy category D. Eronib can\r\ncause fetal harm when administered to a pregnant woman. If it is used during\r\npregnancy, or if the patient becomes pregnant while taking this drug, the\r\npatient should be apprised of the potential hazard to the fetus. <strong>Lactation:</strong> There is no information\r\nregarding the presence of Erlotinib or its metabolites in human milk, the\r\neffects on the breastfed infant, or the effects on milk production. Women\r\nshould be advised not to breastfeed during treatment with Eronib and for 2\r\nweeks after the ﬁnal dose. <strong>Females and\r\nMales of Reproductive Potential:</strong> <strong>Contraception:\r\nFemales:</strong> Eronib can cause fetal harm when administered to a pregnant\r\nwoman.Females of reproductive potential should be advised to use effective\r\ncontraception during treatment with Eronib and for one month after the last\r\ndose of it. Patients should be counseled on pregnancy planning and prevention. <strong>*</strong> Females of reproductive potential\r\nshould be advised to use highly effective contraception during treatment with\r\nEronib, and for at least 2 weeks after the last dose of Eronib. <strong>*</strong>Patients should be advised to contact\r\ntheir healthcare provider if they become pregnant, or if pregnancy is\r\nsuspected, during treatment with Eronib.<strong>*</strong>Breast-feeding\r\nmothers should be advised to discontinue nursing while receiving Eronib.\r\nPatients should be advised to stop smoking and the dose of Eronib may need to\r\nbe adjusted if they smoke. <strong>Pediatric\r\nUse:</strong> The safety and effectiveness of Eronib in pediatric patients have not\r\nbeen established. <strong>Hepatic Impairment:</strong>\r\nHepatic failure and hepatorenal syndrome, including fatal cases, can occur with\r\nEronib treatment in patients with normal hepatic function; the risk of hepatic\r\ntoxicity is increased in patients with baseline hepatic impairment. Patients\r\nwith hepatic impairment should be monitored (total bilirubin greater than upper\r\nlimit of normal (ULN) or Child-Pugh A, B and C) during therapy with Eronib.\r\nTreatment with Eronib should be used with increased monitoring in patients with\r\ntotal bilirubin greater than 3 x ULN. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:</strong><strong> Eronib-150:</strong>Each box contains 2x14’s tablets in Alu- Alu blister pack.</p>",
    "strength": "150",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1543830191Eronib Insert(2).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745302666Eronib-150.png"
    ]
  },
  {
    "id": "1799",
    "name": "Erutic",
    "description": "<p><strong>Compositio</strong>n: Erutic-25: Each film coated tablet <strong></strong>contains Eplerenone BP 25 mg.</p><p>Erutic-50:  Each film coated tablet <strong></strong>contains Eplerenone BP 50 mg.<span></span></p><p><strong>Indications: </strong>It is indicated for improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction, and the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.</p><p><strong>Dosage and Administrations: </strong><span class=\"redactor-invisible-space\"></span>Heart failure with reduced ejection fraction (HFrEF) post an acute myocardial infarction: Initiate treatment with 25 mg once daily. Titrate to maximum of 50 mg once daily within 4 weeks, as tolerated. Dose adjustments may be required based on potassium levels. Hypertension: 50 mg once daily, alone or combined with other antihypertensive agents. For inadequate response, increase to 50 mg twice <span class=\"redactor-invisible-space\">daily. Or, as directed by the registered physician.</span></p><p><span class=\"redactor-invisible-space\"><strong>Use in Pregnancy and Lactation:  </strong><span class=\"redactor-invisible-space\"></span></span>Pregnancy : There are no adequate and well-controlled studies in pregnant women. Eplerenone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers : The concentration of Eplerenone in human breast milk after oral administration is unknown, because many drugs are excreted in human milk and because of the unknown potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the <span class=\"redactor-invisible-space\" style=\"background-color: initial;\"><span class=\"redactor-invisible-space\">importance of the drug to the mother.</span></span></p><p><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Packing: </strong><span class=\"redactor-invisible-space\"></span></span></span>Erutic-25: Each box contains 28's <span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">tablets in blister pack.</span></span></span><strong><strong></strong><strong></strong></strong></p><p><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">Erutic-50: </span></span></span>Each box contains 98's <span class=\"redactor-invisible-space\">tablets in blister pack.</span></p>",
    "strength": " 25",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1635410874Erutic- 25, 50  Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1635410874Erutic- 28 Tab Carton Pic.png"
    ]
  },
  {
    "id": "1800",
    "name": "Erutic - 50",
    "description": "<p>Composition: Erutic-25: Each film coated tablet contains Eplerenone BP 25 mg.</p><p>Erutic-50: Each film coated tablet contains Eplerenone BP 50 mg.</p><p>Indications: It is indicated for improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction, and the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.</p><p>Dosage and Administrations: Heart failure with reduced ejection fraction (HFrEF) post myocardial infarction: Initiate treatment with 25 mg once daily. Titrate to maximum of 50 mg once daily within 4 weeks, as tolerated. Dose adjustments may be required based on potassium levels. Hypertension: 50 mg once daily, alone or combined with other antihypertensive agents. For inadequate response, increase to 50 mg twice daily. Or, as directed by the registered physician.</p><p>Use in Pregnancy and Lactation: Pregnancy : There are no adequate and well-controlled studies in pregnant women. Eplerenone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers : The concentration of Eplerenone in human breast milk after oral administration is unknown, because many drugs are excreted in human milk and because of the unknown potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p><p>Packing: Erutic-25: Each box contains 28's tablets in blister pack.</p><p>Erutic-50: Each box contains 98's tablets in blister pack.</p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/16376387941635410874Erutic- 25, 50  Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/16376387941637571133Erutic - 50 Carton.png"
    ]
  },
  {
    "id": "1282",
    "name": "ERYBAC Suspension",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Erythromycin USP 250mg, 500mg Tablet & 125mg/5ml Suspension.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Erythromycin has been used in the treatment of a wide variety of infections caused by susceptible organism. Its uses include bronchitis, severe campylobacter enteritis, chancroid, diphtheria, and legionella infection. It is used as an alternative to penicillin in penicillin-allergic patients with various conditions like anthrax, actinomycosis, leptospirosis, pelvic inflammatory disease, pharyngitis, the prevention of perinatal streptococcal infection and rheumatic fever. It is used as an alternative to tetracycline in patients with Chlamydia infections.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration :<em></em></strong><em></em></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><em></em>Adults and Children (over 8 years) <em>: </em>The usual dose is 1gm/day in divided doses. This may be increased upto 4gm per day according to the severity of the infection. Children : ( upto 8 years) : 30 mg / kg / day in divided dose. In severe infection, up to 50mg/kg/day in divided doses. or directed by the registered physician.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Pregnancy :</strong> Category B by FDA</p><p style=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Erybac-250 : 5 x 10's tablets in blister pack. </span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Erybac-500: 6</span> x 5's tablets in blister pack<span class=\"redactor-invisible-space\" style=\"background-color: initial;\"></span><strong></strong></p><p style=\"text-align: justify;\">Erybac : 100ml suspension.</p>",
    "strength": "125",
    "uom": "mg/5ml",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1686548130Erybac Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745143381ERYBAC.png"
    ]
  },
  {
    "id": "763",
    "name": "ERYBAC Tablet",
    "description": "<p><strong></strong><strong> Composition : </strong><span class=\"redactor-invisible-space\">Erythromycin USP 250mg,\r\n500mg Tablet & </span>125mg/5ml Suspension.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Erythromycin has been\r\nused in the treatment of a wide variety of\r\ninfections caused by susceptible\r\norganism. Its uses include bronchitis,\r\nsevere campylobacter enteritis,\r\nchancroid, diphtheria, and legionella\r\ninfection. It is used as an alternative to\r\npenicillin in penicillin-allergic patients\r\nwith various conditions like anthrax,\r\nactinomycosis, leptospirosis, pelvic\r\ninflammatory disease, pharyngitis, the\r\nprevention of perinatal streptococcal\r\ninfection and rheumatic fever. It is used\r\nas an alternative to tetracycline in\r\npatients with Chlamydia infections.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :<em> </em></strong><em></em></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><em></em>Adults\r\nand Children (over 8 years) : The usual\r\ndose is 1gm/day in divided doses. This\r\nmay be increased upto 4gm per day\r\naccording to the severity of the infection.\r\nChildren : ( upto 8 years) : 30 mg / kg /\r\nday in divided dose. In severe infection,\r\nup to 50mg/kg/day in divided doses. or\r\ndirected by the registered physician.</span></p><p style=\"text-align: justify;\"><strong>Pregnancy :</strong> Category B by FDA</p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\"><strong></strong><span class=\"redactor-invisible-space\">Erybac-250 : 5 x 10's tablets in blister\r\npack.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nErybac-500 : 6 x 5's tablets in blister\r\npack.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nErybac : 100ml suspension.</span></p>",
    "strength": "500,250",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531388476Erybac.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745143403ERYBAC-500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745143403ERYBAC-250.png"
    ]
  },
  {
    "id": "1788",
    "name": "EYEBROM",
    "description": "<p><strong>Composition : </strong>Each ml ophthalmic solution contains Bromfenac 0.9mg as\r\nBromfenac sodium INN.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication\r\n:</strong> Bromfenac ophthalmic solution is\r\nindicated for treatment of postoperative inflammation and in patients who have\r\nundergone cataract extraction, prevention of miosis in cataract surgery,\r\ntreatment of pseudophakic cystoid macular edema (CME), treatment of external\r\nanterior ocular inflammatory diseases such as blepharitis, conjunctivitis and\r\nscleritis.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration :<i> </i></strong>For\r\nthe treatment of postoperative inflammation and in patients who have undergone\r\ncataract extraction, one drop of Bromfenac ophthalmic solution should be\r\napplied to the affected eye (s) two times daily beginning 24 hours after\r\ncataract surgery and continuing through the first two weeks of the\r\npostoperative period. Prevention of miosis in cataract surgery: beginning 1\r\nhour prior to surgery, instill bromfenac every 30 minutes. Treatment of\r\npseudophakic CME: 1 drop 2 times daily for 3 months. Or, as directed by the\r\nregistered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation :</strong>\r\nThere are no adequate and well-controlled studies in pregnant women. This drug\r\nshould be used during pregnancy only if the potential benefit to the mother\r\njustifies the potential risk to the fetus. Caution should be exercised when\r\nbromfenac ophthalmic solution is administered to a nursing women.<o></o></p><p><strong>Packing:</strong>\r\n5ml in plastic dropper bottle.</p>",
    "strength": "0.9",
    "uom": "mg/ml",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633342024Eyebrom Eye Drop.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745143426Eyebrom 5ml.png"
    ]
  },
  {
    "id": "866",
    "name": "EYETEAR",
    "description": "<p><strong>Composition :</strong> Ea<strong></strong>ch ml contains\r\nPovidone BP 50 mg.</p><p style=\"text-align: justify;\"><strong>Indications :</strong> Povidone Eye Drops is\r\nused for the symptomatic treatment of\r\ndry eye conditions including\r\nKeratoconjunctivitis sicca. It is also given\r\nas a substitute of tear fluid in case of\r\nunstable tear film or insufficient\r\nmoistening of the eye surface.</p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> 1 drop 4\r\ntimes daily or as required, depending\r\nupon the severity of the disease, to be\r\ninstilled into the conjunctival sac. Or, as\r\ndirected by the registered physician.</p><p style=\"text-align: justify;\"><strong>Use in Pregnancy and lactation :</strong> There is no experience regarding the\r\nsafety of the Povidone Eye Drops in\r\nhuman pregnancy or lactation.\r\nAdministration during pregnancy and\r\nlactation is therefore not recommended,\r\nexcept for compelling reasons.</p><p style=\"text-align: justify;\"><strong>Packing :</strong> 10 ml in plastic dropper bottle.</p>",
    "strength": "5",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531388805Eyetear Insert- 2.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745122711Eyetear.png"
    ]
  },
  {
    "id": "1893",
    "name": "Eyetear Single Use Eye Drops",
    "description": "<p><strong>Composition:\r\n</strong>Each\r\nml eye drops contains Povidone BP 50 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>Povidone\r\nEye Drops is used for the symptomatic treatment of dry eye conditions including\r\nKeratoconjunctivitis sicca. It is also given as a substitute of tear fluid in\r\ncase of unstable tear film or insufficient moistening of the eye surface.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration: </strong>Adults\r\n(including the elderly): Instill 2 to 3 drops of the solution onto the eye/eyes\r\nand leave for two minutes or as required. Or, as directed by the registered\r\nphysician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and lactation: </strong>Eyetear\r\n5% eye drops can be used during pregnancy. No effects on the breastfed/infant\r\nare anticipated since the systemic exposure of the breast-feeding woman to iodine\r\nis negligible.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: </strong>Each\r\nbox contains 25’s (0.4ml) single use plastic containers enclosed in a plastic\r\npouch overwrap.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1704000386Eyetear Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745143536Eyetear.png"
    ]
  },
  {
    "id": "1814",
    "name": "F-Pro",
    "description": "<p><strong>Composition\r\n:</strong></p><p><strong>F-Pro Nasal\r\nSpray : </strong>Each\r\nMetered Spray Contains Fluticasone Propionate BP 50 mcg.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Indications\r\n: </strong>The\r\nprophylaxis and treatment of seasonal allergic rhinitis (including hay fever)\r\nand perennial rhinitis. Fluticasone propionate has potent anti-inflammatory\r\nactivity but when used topically on the nasal mucosa has no<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\">detectable\r\nsystemic activity.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Dosage\r\nand administration: Adults : Recommended usual dosage : </strong>2 sprays<strong> </strong>(50\r\nμgm/spray) in each nostril once daily,<strong> </strong>preferably in the morning. In\r\nsome cases, 2<strong> </strong>sprays in each nostril twice daily may be<strong> </strong>required.\r\nTotal daily doses of 200 μgm (4<strong> </strong>sprays) should not generally be\r\nexceeded.<strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Children\r\n(4 to 11 years of age) : Usual dose : </strong>1 spray in each nostril once daily. In<strong>\r\n</strong>some cases, 1 spray in each nostril twice<strong> </strong>daily may be required.\r\nTotal daily doses of<strong> </strong>100 μgm (2 sprays) should not generally be<strong> </strong>exceeded.\r\nOr, as directed by the registered<strong> </strong>physician.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Use\r\nin Pregnancy and lactation : </strong>There are no adequate & well\r\ncontrolled studies in pregnant women. Fluticasone propionate should be used\r\nduring pregnancy, if the potential benefit justifies the potential risks to\r\nfetus. It is not known whether Fluticasone is excreted in breast milk. As other\r\ncorticosteroids are excreted in human milk, caution should be exercised when\r\nFluticasone nasal spray is administered to a lactating mother.</p><p><strong>Packing\r\n: F-Pon Nasal Spray : </strong>Each container contains 120 Metered doses for\r\nsprays.</p>",
    "strength": " 50,125+50",
    "uom": "mcg/Spray",
    "categoryId": "56",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1641104323F-Pro.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744087554F-Pro.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744086541F-Pro plus.png"
    ]
  },
  {
    "id": "1863",
    "name": "F-Pro Plus ",
    "description": "<p><strong>Composition\r\n:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>F-Pro\r\nPlus Nasal Spray :</strong>F-Pro\r\nPlus Nasal Spray : Each Metered Spray Contains Azelastine Hydrochloride BP\r\n137mcg (Eqv. to 125mcg Azelastine) & Fluticasone Propionate BP 50 mcg.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><a name=\"_GoBack\"></a> </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications\r\n:</strong>Azelastine\r\nand Fluticasone NasalSpray is indicated for the relief of symptoms ofseasonal\r\nallergie rhinitis in patients 6 years ofage and older who require treatment\r\nwith bothAzelastine Hydrochloride and FluticasonePropionate for symptomatic\r\nrelief.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration: Adult :</strong>Therecommended dosage is 1 spray each nostriltwice\r\ndaily. Or, as directed by the registeredphysicians.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Pregnancy and lactation :</strong>Pregnancy category C. There are no\r\nadequate and wellcontrolled clinical trials of Azelastine Hydrochloride and\r\nFluticasone Propionate Nasal Spray, Azelastine Hydrochloride only orFluticasone\r\nPropionate only in pregnant women. It should be used in pregnant women only if\r\nthe potential benefit to the mother justifies the potential risk to the fetus. <strong>Nursing\r\nMothers: </strong>It is not known whether Azelastine Hydrochloride and Fluticasone\r\nPropionate Nasal Spray is excreted in human breast milk. Because many drugs are\r\nexcreted in human milk, caution should beexercised when administered to a\r\nnursing woman.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing\r\n:F-Pro Plus Nasal Spray : </strong>Each container contains 120 metered doses for spray.<o></o></p>",
    "strength": "125+50",
    "uom": "Mcg",
    "categoryId": "56",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1677994789F-Pro Plus.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744086541F-Pro plus.png"
    ]
  },
  {
    "id": "1730",
    "name": "F-Son",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition\r\n:</strong><strong>\r\n</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>F-Son\r\nNasal Spray : </strong>Each\r\nmetered spray contains<strong> </strong>Fluticasone Furoate INN 27.5 mcg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications\r\n:</strong><strong>\r\n</strong>This nasal spray indicated for the treatment of the symptoms of\r\nseasonal and perennial allergic rhinitis in patients aged 2</p><p class=\"MsoNormal\" xss=\"removed\">years and older.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration: Adults & Children over 12 years : </strong>2 sprays<strong> </strong>in\r\neach nostril once a day. In some cases 2 sprays into each nostril twice daily,\r\nnot exceeding 4 sprays. <strong>Children under 12 years (2-11</strong> <strong>Years) : </strong>1\r\nspray in each nostril once a day. Patients should use Fluticasone<strong> </strong>Furoate\r\nnasal spray at regular intervals as directed since its effectiveness depends on\r\nits regular use. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Pregnancy and lactation :</strong><strong> </strong>Pregnancy category C. There are no adequate\r\nand well controlled studies in pregnant women. Fluticasone Furoate nasal spray\r\nshould be used during pregnancy only if the potential benefit justifies the\r\npotential risk to the fetus. It is not known whether Fluticasone Furoate is\r\nexcreted in human milk. However, other corticosteroids have been detected in\r\nhuman milk. Caution should be exercised when Fluticasone Furoate nasal spray is\r\nadministered to a nursing woman.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing\r\n: F-Son Nasal Spray : </strong>Each container contains 120 Metered doses for\r\nsprays.</p>",
    "strength": "27.5",
    "uom": "mcg/Spray",
    "categoryId": "56",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1577702883F-son- Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744090534F-Son.png"
    ]
  },
  {
    "id": "801",
    "name": "FAMOTID ",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\"> Famotidine USP 20 mg &\r\n40 mg Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\"> Gastric ulcer, duodenal\r\nulcer, anastomotic ulcer, acute stress\r\nulcer, reflux esophagitis and ZollingerEllison\r\nsyndrome. Famotid (Famotidine)\r\nis also indicated for the treatment of\r\nacute gastritis, chronic gastritis in acute\r\nexacerbation stage.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\"> For gastric\r\nulcer, duodenal ulcer, anastomotic ulcer,\r\nupper gastro-intestinal hemorrhage,\r\nreflux esophagitis and Zollinger-Ellison\r\nsyndrome: Usual dose for adults:\r\nFamotid-20 twice daily (after breakfast\r\nand after supper or before bed time) or\r\nFamotid-40 can be administered orally\r\nonce daily at bed time.\r\nFor the treatment of acute gastritis,\r\nchronic gastritis in acute exacerbation\r\nstage : Usual dosage for adults is\r\nFamotid-20 orally twice a day (after\r\nbreakfast and after supper or before bed\r\ntime). Also Famotid-40 can be orally\r\nadministered once a day (before bed\r\ntime), dosage should be adjusted\r\naccording to age and symptoms. Most\r\nulcer patients heal within 4-8 weeks. For\r\nmaintenance therapy the recommended\r\noral dose is 20mg once daily.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Famotidine has been assigned to\r\npregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Famotid-20 : 10 x 10's blister\r\npack. <br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Famotid-40 : 10 x 10's blister\r\npack.</span></p><p><br></p>",
    "strength": "40,20",
    "uom": "mg",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531713555Famotid.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744025484FAMOTID-40.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744025484FAMOTID-20.png"
    ]
  },
  {
    "id": "1766",
    "name": "Famotid syrup",
    "description": "<p xss=\"removed\"><strong>Composition : </strong><strong>Each 5 ml\r\nreconstituted suspension contains </strong>Famotidine USP 40 mg.</p><p xss=\"removed\"><strong>Indication\r\n: </strong><span class=\"redactor-invisible-space\">Famotidine is indicated in Duodenal ulcer, gastric ulcer,\r\n gastroesophageal reflux disease, acute\r\nstress ulcer and Zollinger-Ellison syndrome. It is also indicated in acute\r\ngastritis, chronic gastritis in acute exacerbation stage.</span></p><p xss=\"removed\"><strong>Dosage\r\nand administration: </strong></p><p xss=\"removed\">Gastroesophageal reflux disease (GERD):</p><p xss=\"removed\"><strong>‹1 year of age:</strong> 0.5 mg/kg/dose of famotidine oral suspension up to\r\n8weeks once daily in patients. </p><p xss=\"removed\"><span class=\"redactor-invisible-space\"><strong>Age 3 to 11\r\nmonths :</strong> 0.5 mg/kg/dose twice daily up\r\nto 8weeks    </span></p><p xss=\"removed\"><span class=\"redactor-invisible-space\"><strong>Age 1 to 2\r\nmonths :</strong> 0.5 mg/kg/dose once daily up to\r\n8weeks       </span></p><p xss=\"removed\"><strong>Neonates :</strong> 0.5 mg/kg/dose maximum once daily up to 8weeks</p><p xss=\"removed\"><span class=\"redactor-invisible-space\"><strong>Patients 1-16\r\nyears of age: </strong></span></p><p xss=\"removed\"><span class=\"redactor-invisible-space\"><strong>Gastroesophageal\r\nReflux Disease (GERD):</strong> 1 mg/kg/day p.o.\r\ndivided b.i.d. up to 40 mg b.i.d.</span></p><p xss=\"removed\"><span class=\"redactor-invisible-space\"><strong>Duodenal Ulcer:\r\n</strong>0.5 mg/kg/day p.o. at bed time or\r\ndivided b.i.d. up to 40 mg/day. </span></p><p xss=\"removed\"><strong>Peptic ulcer:</strong> 0.5 mg/kg/day p.o. at bed time or divided b.i.d. up to\r\n40 mg/day.</p><p xss=\"removed\"><span class=\"redactor-invisible-space\"><strong>Maintenance\r\nTherapy:</strong> 40 mg at daily night.</span></p><p xss=\"removed\"><span class=\"redactor-invisible-space\"><strong>Reflux\r\nesophagitis:</strong> 2 mg/kg/day.</span></p><p xss=\"removed\"><span class=\"redactor-invisible-space\"><strong>Zollinger-Ellison\r\nsyndrome:</strong> 40 mg 3 times daily. </span></p><p xss=\"removed\">Or, as directed by a registered physician.</p><p xss=\"removed\"><strong>Use in\r\npregnancy and lactation : </strong><strong>P</strong><span class=\"redactor-invisible-space\">regnancy category B.\r\nThere are no adequate and well-controlled studies in pregnant women. This drug\r\nshould be used during pregnancy only if clearly needed. Caution should be\r\nexercised when famotidine is administered to a nursing woman.  </span></p><p xss=\"removed\"><strong> </strong></p><p xss=\"removed\"><strong>Packing: </strong><strong>Famotid Suspension:</strong>\r\nEach bottle contains dry powder for preparation of 50 ml suspension.</p>",
    "strength": "40",
    "uom": "mg",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1623138096Famotid.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744025424FAMOTID 50 ML.png"
    ]
  },
  {
    "id": "1776",
    "name": "Favira",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition : </strong>Each Film Coated Tablet Contains\r\nFavipiravir INN 200mg.<br></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication :</strong>\r\nNew\r\nor emerging influenza virus infections, provided that other anti-influenza\r\nvirus drugs are ineffective or insufficiently effective.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and administration :<i> </i></strong>In general, for\r\nadults, favipiravir is orally administered at a dose of 1600mg twice a day on\r\nthe first day and 600mg twice a day on the second to fifth days. The total\r\nadministration period should be 5 days. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation :</strong> 1.\r\nDo not administer to pregnant women or women who may be pregnant. 2. If\r\nadministered to a nursing woman, instruct to stop lactation (It has been observed\r\nthat the hydroxylated form, the main metabolite of this drug, migrates into\r\nhuman breast milk).</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:</strong> Each box\r\ncontains 20 tablets in a container.</p>",
    "strength": "200",
    "uom": "mg",
    "categoryId": "45",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1626591227Favira Tablet Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1626591227Favira Carton.png"
    ]
  },
  {
    "id": "792",
    "name": "Faxan",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Rifaximin BP 200 mg &\r\n550 mg Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\"> <span class=\"redactor-invisible-space\">Faxan 200 mg tablets are\r\nused to treat traveler's diarrhea by\r\nnoninvasive strains of E. coli in adults\r\nand children at least 12 years of age.\r\nFaxan 550 mg tablets are used to prevent\r\nepisodes of hepatic encephalopathy in\r\npeople at least 18 years of age who have\r\nliver disease. Rifaximin tablet is used to\r\ntreat bacterial over growth of irritable\r\nbowel syndrome</span></span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Traveler's\r\nDiarrhea: The recommended dose of\r\nRifaximin is one 200 mg tablet taken\r\norally three times a day for 3 days.\r\nRifaximin can be administered orally,\r\nwith or without food. Hepatic\r\nEncephalopathy: The recommended\r\ndose of Rifaximin is one 550 mg tablet\r\ntaken orally two times a day for 1 to 3\r\nweeks. Rifaximin can be administered\r\norally, with or without food. Bacterial over\r\ngrowth of irritable bowel syndrome\r\nRifaximin 400 mg, 3 times daily for 10\r\ndays. Or, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Rifaximin has been assigned to\r\npregnancy category C by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><strong> </strong><span class=\"redactor-invisible-space\">Faxan-200 : 2x7's tablets in alu-alu\r\nblister pack. </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Faxan-550 : 2x7's tablets in alu-alu\r\nblister pack.</span></p>",
    "strength": "550,200",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531713698Faxan.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745143748Faxan-550.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745143748Faxan-200.png"
    ]
  },
  {
    "id": "1794",
    "name": "Febox-40 ",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition : </strong>Each film coated tablet contains Febuxostat INN 40mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication\r\n:</strong> It is a xanthine oxidase (XO)\r\ninhibitor indicated for the chronic management of hyperuricemia in adult\r\npatients with gout who have an inadequate response to a maximally titrated dose\r\nof Allopurinol, who are intolerant to Allopurinol, or for whom treatment with\r\nAllopurinol is not advisable. It is not recommended for the treatment of\r\nasymptomatic hyperuricemia. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration :<i> </i></strong>Recommended\r\nDose: The recommended Febuxostat dosage is 40 mg or 80 mg once daily. The\r\nrecommended starting dosage of Febuxostat is 40 mg once daily. For patients who\r\ndo not achive a serum uric acid (sUA) less than 6 mg/dL after two weeks, the\r\nrecommended Febuxostat dosage is 80 mg once daily. Febuxostat can be taken\r\nwithout regard to food or antacid use. Dose adjustment: For Renal Impairment:\r\nNo dose adjustment is necessary when administering Febuxostat in patients with\r\nmild or moderate renal impairment. The recommended dosage of Febuxostat is\r\nlimited to 40 mg once daily in patients with severe renal impairment. For\r\nHepatic Impairment: No dose adjustment is necessary in patients with mild to\r\nmoderate hepatic impairment. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation :</strong>\r\nPregnancy : There are no adequate and well-controlled studies in pregnant\r\nwomen. It should be used during pregnancy only if the potential benefit\r\njustifies the potential risk to be fetus. Nursing mothers: It is not known\r\nwhether this drug is excreted in human milk. Because many drugs are excreted in\r\nhuman milk, caution should be exercised when Febuxostat is administered to a\r\nnursing woman.</p><p class=\"MsoNormal\"><strong>Packing:</strong>\r\nEach box contains 3x10’s tablets in blister pack.</p>",
    "strength": "40",
    "uom": "mg",
    "categoryId": "108",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633863837Febox 40 Insert_27.02.21.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744085559Febox-40.png"
    ]
  },
  {
    "id": "1789",
    "name": "FENAT",
    "description": "<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\nline-height:normal\"><strong>Composition : </strong>Each ml of Fenat eye drop contains: Ketotifen BP 0.25mg (as\r\nKetotifen Fumarate).<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Indication\r\n:</strong> Ketotifen eye drop is indicated for\r\nthe temporary prevention of itching of the eye due to allergic conjunctivitis.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Dosage\r\nand administration :<i> </i></strong><strong>Adult use:</strong>\r\nThe recommended dose is one drop in the affected eye twice daily every 8-12\r\nhours, no more than twice per day.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Pediatric use: </strong>Safety\r\nand efficacy of this eye drop have not been established in pediatric patients\r\nbelow the age of 3 years. Or, as directed by the registered physician.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Use\r\nin pregnancy and lactation :</strong>\r\nThere is no well-controlled study in human pregnancy. Fenat eye drop should be\r\nused during pregnancy only if clearly needed. Nevertheless , caution should be\r\nexercised when ketotifen is administered to a nursing mother.<o:p></o:p></p>\r\n\r\n<p><strong>Packing:</strong>\r\n5ml in plastic dropper bottle.<br></p>",
    "strength": "0.25",
    "uom": "mg/ml",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633343127Fenat Eye Drop.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1633342881Fenat Ear Drop Carton Pic.png"
    ]
  },
  {
    "id": "1263",
    "name": "FENAT  Tablet",
    "description": "<p><strong>Composition : </strong>Ketotifen BP 1mg Tablet. </p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Indication :</strong> 1. Bronchial asthma as a prophylactic treatment. 2. Symptomatic treatment of allergic conditions including rhinitis and conjunctivitis.</p><p style=\"text-align: justify;\"><strong>Dosage and administration</strong> :<strong> Fenat Tablet :</strong> Adults- 1mg twice daily with food. If necessary the dose may be increased to 2mg twice daily. Children from 2 years- 0.5mg to 1mg twice daily with food. Elderly- Same as adults or as advised by the registered physician.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation </strong>: Pregnancy category C by the FDA.<strong><br></strong></p><p style=\"text-align: justify;\"><strong>Packing :</strong> Fenat Tablet : 10 x 10's tablets in blister pack.</p><p><strong></strong><br></p>",
    "strength": "1",
    "uom": "mg",
    "categoryId": "41",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531715884FENAT.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744085854Fenat.png"
    ]
  },
  {
    "id": "1194",
    "name": "Fenat Syrup",
    "description": "<p><strong>Composition : </strong>Ketotifen BP  1mg/5ml Syrup.</p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Indication :</strong> 1. Bronchial asthma as a prophylactic treatment. 2. Symptomatic treatment of allergic conditions including rhinitis and conjunctivitis.</p><p style=\"text-align: justify;\"><strong>Dosage and administration</strong> :<strong> Fenat Syrup : </strong><span class=\"redactor-invisible-space\">1-2 teaspoonfuls twice daily with food. Patients known to be easily sedated 1/2-1 teaspoonful at night for the first few days. or, as directed by the registered physician. Children under 2 years of age : 1/2 teaspoonfuls twice daily or as directed by the registered physician.</span><br></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation </strong>: Pregnancy category C by the FDA.<strong><br></strong></p><p style=\"text-align: justify;\"><strong>Packing : Fenat Syrup : </strong>100ml and 200ml syrup.<br></p>",
    "strength": "200,100",
    "uom": "ML",
    "categoryId": "41",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531715772FENAT.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1616220044Fenat 200ml Carton Pic.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744085688Fenat syrup.png"
    ]
  },
  {
    "id": "824",
    "name": "Fenaton ",
    "description": "<p><strong></strong><strong>Composition : </strong>Mefenamic Acid USP 500mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indication : </strong>Mefenamic acid is indicated\r\nfor the symptomatic relief of rheumatoid\r\narthritis, osteoarthritis and pain including\r\nmuscular, traumatic and dental pain,\r\nheadaches of most aetiology, postoperative\r\nand post-partum pain, pyrexia in\r\nchildren and for primary dysmenorrhoea.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Administration\r\nis by the oral route, preferably with food.\r\nFor relief of acute pain in adults and\r\nadolescents &gt;_12 years of age, the\r\nrecommended dose is 500mg 3 times a day. For the treatment of primary </span>dysmenorrhea, the recommended dose is 500mg 3 times a day, starting with the onset of bleeding and associated symptoms. Or, as directed by the registered physician.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy Category C. Fenaton should\r\nbe used during pregnancy only if the\r\npotential benefit justifies the potential risk\r\nto the fetus. Because of the potential for\r\nserious adverse reactions in nursing\r\ninfants from Fenaton, a decission should\r\nbe made whether to discontinue the drug,\r\ntaking into account the importance of the\r\ndrug to the mother.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>Fenaton : Each box contains 50's tablets in blister pack.</p>",
    "strength": "500",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1683366226Fenaton-500 Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745143897Fenaton-500.png"
    ]
  },
  {
    "id": "1003",
    "name": "Fenatrol",
    "description": "<p><strong></strong><strong>Composition : <em></em></strong><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">Fenofibrate USP 145 mg Tablet.</span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong>Fenofibrate is indicated as\r\nan adjunctive therapy to diet for the\r\ntreatment of adults with\r\nhypertriglyceridemia (Types IV and V\r\nhyperlipidemia). Fenofibrate is also\r\nindicated in hypercholesterolemia or,\r\nmixed Dislipidemia (type II\r\nhyperlipidemia).</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong>For the\r\ntreatment of adult patients with\r\nhypercholesterolemia or mixed\r\nhyperlipidemia, the initial dose of\r\nFenatrol is 200 mg per day. For adult\r\npatients with hypertriglyceridemia, the\r\ninitial dose is 67 to 200 mg per day.\r\nDose should be individualized according\r\nto patient response. Fenatrol should be\r\ngiven with meal there by, optimizing the\r\nbioavailability of the medication. Or, as\r\ndirected by the registered physician.</p><p style=\"text-align: justify;\"><strong>Packing :</strong><span class=\"redactor-invisible-space\"><br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Fenatrol-145 : 3 x 10's Tablet\r\nin blister pack. </span></p>",
    "strength": "145",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/16831126821531716971Fenatrol.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744085905FENATROL.png"
    ]
  },
  {
    "id": "911",
    "name": "Feripon ",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Deferiprone INN 500 mg\r\nTablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Deferiprone is indicated for\r\nthe treatment of iron overload patients\r\nwith thalassemia major when\r\ndeferoxamine therapy is contraindicated\r\nor inadequate. Deferiprone therapy\r\nshould be initiated and maintained by a\r\nphysician experienced in the treatment of\r\npatients with thalassemia.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">In adults\r\nand children over 6 years : this medicine\r\nmay be given by mouth in doses of\r\n25mg/kg three times daily. Doses above\r\n100mg/kg daily are not recommended.\r\nOr, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Deferiprone\r\nis not recommended for use in pregnant\r\n& lactating women.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\"> Feripon : 1x10's tablets in\r\nblister pack.</span></p>",
    "strength": "500",
    "uom": "mg",
    "categoryId": "101",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531718343Feripon.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1634022974Feripon.png"
    ]
  },
  {
    "id": "1088",
    "name": "Ferospan",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Ferospan timed release\r\ncapsule is a combination of blended\r\npellets of dried Ferrous Sulphate 150mg\r\nand Folic Acid 500mcg.</span></p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"margin-bottom: 10px; background-color: rgb(255, 255, 255); color: rgb(68, 68, 68); text-align: justify;\" helvetica=\"\" neue\",=\"\" helvetica,=\"\" arial,=\"\" sans-serif;\"=\"\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Ferospan is indicated for\r\nthe treatment and prophylaxis of iron and\r\nfolic acid deficiency, specially during\r\npregnancy and lactation.\r\n</span></p><p style=\"margin-bottom: 10px; background-color: rgb(255, 255, 255); color: rgb(68, 68, 68); text-align: justify;\" helvetica=\"\" neue\",=\"\" helvetica,=\"\" arial,=\"\" sans-serif;\"=\"\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">1 capsule\r\ndaily throughout pregnancy and lactation\r\nor as directed by the physician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Ferospan 6 x 10's capsules in\r\nblister pack.</span></p>",
    "strength": "150+500",
    "uom": "mg+mcg",
    "categoryId": "101",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531800741ferospan.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745143944FEROSPAN.png"
    ]
  },
  {
    "id": "1089",
    "name": "Ferozi",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Ferozi timed release\r\ncapsule is a combination of blended\r\npellets of dried Ferrous Sulphate 150mg,\r\nFolic Acid <br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">500mcg & Zinc Sulphate\r\nMonohydrate 61.8mg (Eq to 22.5mg\r\nzinc).</span></p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"margin-bottom: 10px; background-color: rgb(255, 255, 255); color: rgb(68, 68, 68); text-align: justify;\" helvetica=\"\" neue\",=\"\" helvetica,=\"\" arial,=\"\" sans-serif;\"=\"\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Ferozi is indicated for the\r\ntreatment and prophylaxis of iron, folic\r\nacid and zinc deficiency, specially during\r\npregnancy and lactation.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">1 capsule\r\ndaily throughout pregnancy and lactation\r\nor as directed by the physician.</span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Packing </strong><strong>:</strong>  Ferozi : 6 x 10's capsules in blister pack.</p>",
    "strength": "150+500+61.8",
    "uom": "mg+mcg+mg",
    "categoryId": "101",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531800869ferozi.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745143971Ferozi.png"
    ]
  },
  {
    "id": "1087",
    "name": "Ferozi - CI",
    "description": "<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\nline-height:normal\"><strong>Composition : </strong>Each timed Release Capsule Contains Elemental Iron 50mg (as\r\nCarbonyl Iron USP), Folic Acid USP 0.50mg and Zinc Sulphate Monohydrate USP\r\n61.80mg  .<o:p></o:p></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Indications\r\n:</strong> This Medicine is indicated for the\r\ntreatment and prophylaxis of iron, folic acid and zinc deficiency, specially\r\nduring pregnancy and lactation.<o:p></o:p></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Dosage\r\nand administration :<i> </i></strong>Adults:\r\nOne capsule daily before food. Or, as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Use\r\nin pregnancy and lactation :</strong>\r\nUse of any drug during the first trimester of pregnancy should be avoided if\r\npossible. Thus administration of iron during the first trimester requires\r\ndefinite evidence of iron deficiency. Prophylaxis of iron deficiency  where inadequate diet calls for supplementary\r\nzinc and folic is justified during the remainder of pregnancy.<o:p></o:p></p><p><strong>Packing:</strong>\r\n5x10’s capsules in blister pack.<br><strong></strong></p>",
    "strength": "50+0.50+61.8",
    "uom": "mg",
    "categoryId": "101",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633331066Ferozi CI = Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745143985Ferozi-CI.png"
    ]
  },
  {
    "id": "825",
    "name": "Fevedol ",
    "description": "<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\nline-height:normal\"><strong>Composition : </strong>Paracetamol USP\r\n325mg and Tramadol Hydrochloride USP 37.50mg Tablet. <o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indication :</strong>\r\nIt\r\nis indicated for the symptomatic treatment of moderate to severe pain.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage and administration :<i> </i></strong>It should be\r\nused in adults and children over 12 years of age. The recommended dose should not be\r\nexceeded. The recommended dose is 2 tablets every 6 hours as needed for pain relief up to a\r\nmaximum of 8 tablets per day. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use in pregnancy and lactation : </strong>It has been assigned to pregnancy category C by the FDA. It can be used in pregnancy if potential benefits outweigh the risk or as directed by the\r\nregistered physician. It is likely to be\r\nexcreted into the breast milk. A decision should be made whether to discontinue nursing or to\r\ndiscontinue the drug, taking into account the benefit of the drug to the mother.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><o:p></o:p></p><p class=\"MsoNormal\"><strong> </strong></p><p><strong>Packing:</strong>\r\n3x10’s tablets in blister pack.<br><strong></strong></p>",
    "strength": "362",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1635916442Fevedol Insert Book Style Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745144011FEVEDOL.png"
    ]
  },
  {
    "id": "1264",
    "name": "Fexofast Suspension",
    "description": "<p><strong>Composition :</strong><span class=\"redactor-invisible-space\"> Fexofenadine Hydrochloride USP 30mg/5ml\r\nSuspension.\r\n</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Indications :</strong><span class=\"redactor-invisible-space\"> Fexofenadine Hydrochloride is\r\nindicated for the relief from physical\r\nsymptoms associated with seasonal allergic\r\nrhinitis and treatment of chronic idiopathic\r\nurticaria. It is not cure totally but prevents the\r\naggravation of rhinitis and urticaria. It reduces\r\nthe severity of the symptoms and providing\r\nmuch relief from repeated sneezing, runny\r\nnose, itchy eyes and general body fatigue\r\ncaused by rhinitis and urticaria.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Fexofast\r\ntablets: Seasonal allergic rhinitis and chronic\r\nidiopathic urticaria: Adults and Children 12\r\nYears and Older: The recommended dose of\r\nFexofenadine Hydrochloride is 60 mg twice\r\ndaily or 180 mg once daily with water. A dose\r\nof 60 mg once daily is recommended as the\r\nstarting dose in patients with decreased renal\r\nfunction. Children 6 to 11 Years: 30 mg twice\r\ndaily with water. A dose of 30 mg once daily\r\nis recommended as the starting dose in\r\npatients with decreased renal function.</span><br></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Fexofenadine has been assigned to\r\npregnancy category C by the FDA.</span><br></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Packing :</strong><br></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">Fexofast Suspension : 50ml suspension.</span></span></span></p>",
    "strength": "30",
    "uom": "mg/5ml",
    "categoryId": "41",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531801273fexofast.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744086027Fexofast-50 ml.png"
    ]
  },
  {
    "id": "1193",
    "name": "Fexofast Tablet",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Fexofenadine Hydrochloride USP 60mg, 120mg, 180mg Tablet.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Indication : </strong>Fexofenadine Hydrochloride is indicated for the relief from physical symptoms associated with seasonal allergic rhinitis and treatment of chronic idiopathic urticaria. It is not cure totally but prevents the aggravation of rhinitis and urticaria. It reduces the severity of the symptoms and providing much relief from repeated sneezing, runny nose, itchy eyes and general body fatigue caused by rhinitis and urticaria.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Fexofast tablets: Seasonal allergic rhinitis and chronic idiopathic urticaria: Adults and Children 12 Years and Older: The recommended dose of Fexofenadine Hydrochloride is 60 mg twice daily or 180 mg once daily with water. A dose of 60 mg once daily is recommended as the starting dose in patients with decreased renal function. Children 6 to 11 Years: 30 mg twice daily with water. A dose of 30 mg once daily is recommended as the starting dose in patients with decreased renal function.</span><strong><br></strong></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Fexofenadine has been assigned to pregnancy category C by the FDA.</span><strong><br></strong></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><strong></strong>Fexofast-60 : 5x 10's tablets in blister pack.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Fexofast-120 : 3x 10's tablets in blister pack.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Fexofast-180 : 2x10's tablets in blister pack.</span></p>",
    "strength": "180,120,60",
    "uom": "mg",
    "categoryId": "41",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531801184fexofast.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744086288Fexofast-180.png",
      "https://www.admin.drug-international.com/uploads/product_images/1633344804Fexofast - 120 Carton.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744086288Fexofast-60.png"
    ]
  },
  {
    "id": "1021",
    "name": "Fintop",
    "description": "<p><strong></strong><strong>Composition : </strong>Butenafine HCl INN 1%.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Butenafine cream is\r\nindicated for the topical treatment of\r\nfollowing superficial dermatophytes: tinea\r\npedis (athletes foot), tinea corporis\r\n(ringworm), tinea cruris (jockitch) due to M.\r\nfurfur, E. floccosum, T. mentagrophytes, T.\r\nrubrum, T. tonsurans.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Patients\r\nwith tinea (pityriasis) versicolor should\r\napply butenafine once daily for two weeks.\r\nIn the treatment of interdigital tinea pedis\r\nbutenafine should be applied twice daily\r\nfor 7 days or once daily for 4 weeks.\r\nPatients with tinea corporis or tinea cruris\r\nshould apply butenafine once daily for two\r\nweeks. Or, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">No\r\nadequate and well controlled studies that\r\nhave been conducted with topically applied\r\nbutenafine in pregnant women. This drug\r\nshould be used during pregnancy only if\r\nclearly needed. It is not known if\r\nbutenafine HCl is excreted in human milk,\r\ncaution should be exercised in prescribing\r\nbutenafine Cream, to a nursing woman.\r\nPregnancy Category C.\r\n</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>Fintop Cream : 10gm in a tube. </p>",
    "strength": "1%",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531801372Fintop.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745309968Fintop.png"
    ]
  },
  {
    "id": "871",
    "name": "FLOXALONE",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\">Moxifloxacin 5mg/ml as Moxifloxacin Hydrochloride.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Floxalone eye drop is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Aerobic Gram-positive microorganisms: Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumoniae, Streptococcus viridans group.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Aerobic Gram-negative microorganisms: Acinetobacter lwoffii, Haemophilus influenzae, Haemophilus parainfluenzae. Other microorganisms: Chlamydia trachomatis.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The recommended dose is one drop in the affected eye every 8 hours (3 times) daily for 7 days. Or, as directed by the registered physician.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing : </strong>5ml in plastic dropper bottle.</p>",
    "strength": "0.50",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531801510FLOXALONE_Ed.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745122472Floxalone 5ml.png"
    ]
  },
  {
    "id": "785",
    "name": "Floxalone Tablet",
    "description": "<p><strong></strong><strong></strong><!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves></w:TrackMoves>\r\n  <w:TrackFormatting></w:TrackFormatting>\r\n  <w:PunctuationKerning></w:PunctuationKerning>\r\n  <w:ValidateAgainstSchemas></w:ValidateAgainstSchemas>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF></w:DoNotPromoteQF>\r\n  <w:LidThemeOther>EN-US</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables></w:BreakWrappedTables>\r\n   <w:SnapToGridInCell></w:SnapToGridInCell>\r\n   <w:WrapTextWithPunct></w:WrapTextWithPunct>\r\n   <w:UseAsianBreakRules></w:UseAsianBreakRules>\r\n   <w:DontGrowAutofit></w:DontGrowAutofit>\r\n   <w:SplitPgBreakAndParaMark></w:SplitPgBreakAndParaMark>\r\n   <w:DontVertAlignCellWithSp></w:DontVertAlignCellWithSp>\r\n   <w:DontBreakConstrainedForcedTables></w:DontBreakConstrainedForcedTables>\r\n   <w:DontVertAlignInTxbx></w:DontVertAlignInTxbx>\r\n   <w:Word11KerningPairs></w:Word11KerningPairs>\r\n   <w:CachedColBalance></w:CachedColBalance>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"></m:mathFont>\r\n   <m:brkBin m:val=\"before\"></m:brkBin>\r\n   <m:brkBinSub m:val=\"--\"></m:brkBinSub>\r\n   <m:smallFrac m:val=\"off\"></m:smallFrac>\r\n   <m:dispDef></m:dispDef>\r\n   <m:lMargin m:val=\"0\"></m:lMargin>\r\n   <m:rMargin m:val=\"0\"></m:rMargin>\r\n   <m:defJc m:val=\"centerGroup\"></m:defJc>\r\n   <m:wrapIndent m:val=\"1440\"></m:wrapIndent>\r\n   <m:intLim m:val=\"subSup\"></m:intLim>\r\n   <m:naryLim m:val=\"undOvr\"></m:naryLim>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"true\"\r\n  DefSemiHidden=\"true\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"267\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Normal\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"heading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" QFormat=\"true\" Name=\"caption\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" Name=\"Default Paragraph Font\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtitle\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Strong\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"59\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Table Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Placeholder Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"No Spacing\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Revision\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"List Paragraph\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"19\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"21\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"31\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"32\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"33\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Book Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"37\" Name=\"Bibliography\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" QFormat=\"true\" Name=\"TOC Heading\"></w:LsdException>\r\n </w:LatentStyles>\r\n</xml><![endif]--><!--[if gte mso 10]>\r\n<style>\r\n /* Style Definitions */\r\n table.MsoNormalTable\r\n\t{mso-style-name:\"Table Normal\";\r\n\tmso-tstyle-rowband-size:0;\r\n\tmso-tstyle-colband-size:0;\r\n\tmso-style-noshow:yes;\r\n\tmso-style-priority:99;\r\n\tmso-style-qformat:yes;\r\n\tmso-style-parent:\"\";\r\n\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\r\n\tmso-para-margin-top:0in;\r\n\tmso-para-margin-right:0in;\r\n\tmso-para-margin-bottom:8.0pt;\r\n\tmso-para-margin-left:0in;\r\n\tline-height:107%;\r\n\tmso-pagination:widow-orphan;\r\n\tfont-size:11.0pt;\r\n\tfont-family:\"Calibri\",\"sans-serif\";\r\n\tmso-ascii-font-family:Calibri;\r\n\tmso-ascii-theme-font:minor-latin;\r\n\tmso-fareast-font-family:\"Times New Roman\";\r\n\tmso-fareast-theme-font:minor-fareast;\r\n\tmso-hansi-font-family:Calibri;\r\n\tmso-hansi-theme-font:minor-latin;\r\n\tmso-bidi-font-family:\"Times New Roman\";\r\n\tmso-bidi-theme-font:minor-bidi;}\r\n</style>\r\n<![endif]--></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\nline-height:normal\"><strong>Composition : </strong>Moxifloxacin 400 mg as Moxifloxacin\r\nHydrochloride USP Tablet.<br></p><p><strong>Indication :</strong> <span class=\"redactor-invisible-space\">It is indicated for\r\ntreating the following infections : Acute Bacterial Sinusitis, Acute Bacterial\r\nExacerbation of Chronic Bronchitis, Community Acquired Pneumonia, Uncomplicated\r\nSkin and Skin Structure Infections, Complicated Skin and Skin Structure\r\nInfections, Complicated Intra-Abdominal Infections.</span></p><p><strong>Dosage and administration : Dosage\r\nfor Adult Patients: </strong>The dose of Moxifloxacin is 400mg orally once every\r\n24 hours. <span class=\"redactor-invisible-space\">Please see prescribing\r\ndescription for more information. </span></p><p><strong>Use in pregnancy and lactation:</strong> <span class=\"redactor-invisible-space\">Pregnancy\r\nCategory C. There is no adequate or well-controlled studies have been conducted\r\nin pregnant women, Moxifloxacin should be used during pregnancy only if the\r\npotential benefit justifies the potential risk to the fetus. Moxifloxacin may\r\nbe excreted in human milk. Because of the potential for serious adverse\r\nreactions in infants who are nursing from mothers taking Moxifloxacin, a\r\ndecision should be made whether to discontinue nursing or to discontinue the\r\ndrug, taking into account the importance of the drug to the mother.</span></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Packing:</strong> 1x7’s tablets\r\nin blister pack.</p><p><span class=\"redactor-invisible-space\"></span></p>",
    "strength": "400",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1621679507Floxalone Insert Book Style 2021.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745122431Floxalone- 400.png"
    ]
  },
  {
    "id": "1790",
    "name": "FLOXALONE-DX",
    "description": "<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\nline-height:normal\"><strong>Composition : </strong>Each ml Eye Drops contains Moxifloxacin 5 mg as Moxifloxacin\r\nHydrochloride USP & Dexamethasone Phosphate 1 mg as Dexamethasone Sodium\r\nPhosphate USP.<o:p></o:p></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Indication\r\n:</strong> This Eye Drops is indicated in the\r\ntreatment of eye infections caused by susceptible microorganisms and in the\r\nprevention of inflammation and bacterial infection that may occur after eye\r\nsurgery.<o:p></o:p></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Dosage\r\nand administration :<i> </i>In the\r\nprevention of infection and post-surgical ocular inflammation: </strong>Instill\r\n1 drop, 4 times a day, in the eye to be operated, from 1 day before surgery\r\nuntil 15 days after surgery. <strong>In patients undergoing cataract surgery: </strong>The\r\nday of surgery instill the medication immediately after eye surgery. <strong>In\r\npatients undergoing LASIK refractive surgery: </strong>On the day of surgery instill\r\nthe medication at least 15 minutes after ocular surgery. In eye infections\r\ncasued by susceptible microorganisms: Instill 1 drop, 4 times a day, for up to\r\n7 days. Or, as a directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Use in Pregnancy and lactation:</strong><strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Use\r\nin pregnancy : </strong>There are\r\nno adequate and well-controlled studies in pregnant women. Moxifloxacin &\r\nDexamethasone combination eye drops should be used during pregnancy only if the\r\npotential benefit justifies the potential risk to the fetus.<strong> <o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Use\r\nin lactation :</strong> Caution is advised when Moxifloxacin & Dexamethasone combination\r\neye drops is given to nursing women.<o:p></o:p></p><p><strong>Packing:\r\n</strong>5\r\nml in plastic dropper bottle.<br></p>",
    "strength": "(5mg+1mg)",
    "uom": "mg/ml",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633343965Floxalone-DX Eye Drop.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745122449Floxalone-DX.png"
    ]
  },
  {
    "id": "1276",
    "name": "Flunac  Suspension",
    "description": "<p><strong>Composition : </strong>Fluconazole USP 50mg/5ml Dry Powder for Suspension.</p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Indications : </strong>Flunac is used for the treatment of oropharyngeal, oesophageal, vaginal mucosal or systemic candidiasis, oesophagitis, candiduria, fungal urinary tract infection,  and meningitis.</p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong>Flunac is administered orally. </p><p style=\"text-align: justify;\">Adults & patients over 18 years : Mucosal candidiasis (except vaginal candidiasis)-Oropharyngeal candidiasis : the recommended dose is 50mg once daily for 7 to 14 days. For other candidal infections of the mucosa e.g. oesophagitis, non-invasive bronchopulmonary infections, candiduria, mucocutaneous candidiasis etc.: the recommended dose is 50mg daily, given for 14 to 30 days. In unusually difficult cases of mucosal candidal infections the dose can be increased to 100mg daily. Vaginal candidiasis : 150mg single oral dose. Systemic candidiasis (Cryptococcal infections e.g., meningitis) : 400mg initially, then 200mg daily. The dose can be increased upto 400mg daily if necessary. Treatment should continue according to patient's response. </p><p style=\"text-align: justify;\">Child over 1 year : Superficial candidal infections, 1-2 mg/kg daily; systemic candidiasis and Cryptococcal infections 3-6mg/kg daily. In serious life threatening infections upto 12mg/kg daily has been given to children aged 5-13 years, max 400mg daily. Or, as directed by the registered physician.<strong></strong></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>FDA approved Pregnancy Category C.</p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Package quantities : </strong>Flunac Suspension : 35ml suspension.</p>",
    "strength": "50/5",
    "uom": "mg/ml",
    "categoryId": "40",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1686547443Flunac Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745122370FLUNAC 35 ml.png"
    ]
  },
  {
    "id": "1277",
    "name": "Flunac Capsule",
    "description": "<p><strong>Composition : </strong>Fluconazole USP 50mg,150mg Capsule. </p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Indications : </strong>Flunac is used for the treatment of oropharyngeal, oesophageal, vaginal mucosal or systemic candidiasis, oesophagitis, candiduria, fungal urinary tract infection,  and meningitis.</p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong>Flunac is administered orally.</p><p style=\"text-align: justify;\">Adults & patients over 18 years : Mucosal candidiasis (except vaginal candidiasis)-Oropharyngeal candidiasis : the recommended dose is 50mg once daily for 7 to 14 days. For other candidal infections of the mucosa e.g. oesophagitis, non-invasive bronchopulmonary infections, candiduria, mucocutaneous candidiasis etc.: the recommended dose is 50mg daily, given for 14 to 30 days. In unusually difficult cases of mucosal candidal infections the dose can be increased to 100mg daily. Vaginal candidiasis : 150mg single oral dose. Systemic candidiasis (Cryptococcal infections e.g., meningitis) : 400mg initially, then 200mg daily. The dose can be increased upto 400mg daily if necessary. Treatment should continue according to patient's response.</p><p style=\"text-align: justify;\">Child over 1 year : Superficial candidal infections, 1-2 mg/kg daily; systemic candidiasis and Cryptococcal infections 3-6mg/kg daily. In serious life threatening infections upto 12mg/kg daily has been given to children aged 5-13 years, max 400mg daily. Or, as directed by the registered physician.<strong></strong></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>FDA approved Pregnancy Category C.</p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Packing : </strong>Flunac-50 Capsule : 3x10's capsules in blister pack. </p><p style=\"text-align: justify;\">Flunac-150 Capsule : 2x10's capsules in blister pack. </p>",
    "strength": "150,50",
    "uom": "mg",
    "categoryId": "40",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531801703Flunac.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745122394FLUNAC-150.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745122394FLUNAC-50.png"
    ]
  },
  {
    "id": "769",
    "name": "FLUPEN capsule",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Flucloxacillin BP 250mg,\r\n500mg Capsule. </span></p><p style=\"text-align: justify;\"><strong>Indication : </strong>Flupen is indicated for the\r\ntreatment of infections due to Grampositive\r\norganisms, including infections\r\ncaused by b-lactamase-producing\r\nstaphylococci.Typical indications\r\ninclude:Skin and soft tissue infections : boils,\r\nabscesses, carbuncles, infected skin\r\nconditions, e.g. ulcer, eczema and acne,\r\nfurunculosis, cellulitis, infected wounds,\r\ninfected burns, protection for skin grafts,\r\notitis media and externa, impetigo. Respiratory tract infections :\r\npneumonia, lung abscess, empyema,\r\nsinusitis, pharyngitis, tonsillitis, quinsy.\r\nOther infections caused by Flupensensitive\r\norganisms : osteomyelitis,\r\nenteritis, endocarditis, urinary tract\r\ninfection, meningitis, septicaemia. </p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong></p><p style=\"text-align: justify;\"> <span class=\"redactor-invisible-space\">Oral :\r\nAdults and the elderly: In mild to\r\nmoderate infections, 250mg (1 capsule)\r\n4 times daily, half to one hour before\r\nmeal.\r\nChildren : Children up to 2 years of age\r\nmay be given 125mg (1 teaspoonful)\r\nevery 6 hrs and those aged 2 to 10\r\nyears, 250mg (2 teaspoonfuls) every 6\r\nhrs, half to one hour before meal or as\r\ndirected by a registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Flucloxacillin has been assigned to\r\npregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Flupen-250 Capsule : 10x7's capsules\r\nin blister pack.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nFlupen-500 Capsule : 3x7's capsules in\r\nblister pack. </span></p>",
    "strength": "500,250",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531801828Flupen.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1684407260Flupen Carton New.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745121514FLUPEN-250.png"
    ]
  },
  {
    "id": "1284",
    "name": "FLUPEN Suspension",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Flucloxacillin BP 125mg/5ml Powder for Suspension.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication :</strong> Flupen is indicated for the treatment of infections due to Grampositive organisms, including infections caused by b-lactamase-producing staphylococci. Typical indications include:Skin and soft tissue infections : boils, abscesses, carbuncles, infected skin conditions, e.g. ulcer, eczema and acne, furunculosis, cellulitis, infected wounds, infected burns, protection for skin grafts, otitis media and externa, impetigo. Respiratory tract infections : pneumonia, lung abscess, empyema, sinusitis, pharyngitis, tonsillitis, quinsy. Other infections caused by Flupensensitive organisms : osteomyelitis, enteritis, endocarditis, urinary tract infection, meningitis, septicaemia.</p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong><em></em></p><p style=\"text-align: justify;\"><em></em><span class=\"redactor-invisible-space\"><em>Oral : </em>Adults and the elderly: In mild to moderate infections, 250mg (1 capsule) 4 times daily, half to one hour before meal. Children : Children up to 2 years of age may be given 125mg (1 teaspoonful) every 6 hrs and those aged 2 to 10 years, 250mg (2 teaspoonfuls) every 6 hrs, half to one hour before meal or as directed by a registered physician.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Flucloxacillin has been assigned to pregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\">Flupen Suspension : 100ml bottle. </p>",
    "strength": "125",
    "uom": "mg/5ml",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1669803942Flupen Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121484FLUPEN- 100 ML.png"
    ]
  },
  {
    "id": "1153",
    "name": "Fluracil",
    "description": "<p class=\"MsoNormal\"><strong>Composition:<o:p></o:p></strong></p><p class=\"MsoNormal\"><strong>Fluracil-250:</strong>\r\nEach vial (10ml) contains Fluorouracil USP 250mg (25mg/ml) Solution for IV\r\ninjection.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Fluracil-500:</strong>\r\nEach vial (10ml) contains Fluorouracil USP 500mg (50mg/ml) solution for IV\r\ninjection.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Indications\r\n:</strong><br>\r\nFluorouracil is indicated alone or in combination for-<br>\r\n<strong>1.</strong> Carcinoma of the colon or rectum<br>\r\n<strong>2.</strong> Carcinoma of the stomach and\r\nexocrine pancreas<br>\r\n<strong>3.</strong> Carcinoma of the liver<br>\r\n<strong>4.</strong> Carcinoma of the breast<br>\r\n<strong>5.</strong> Carcinoma of the bladder<br>\r\n<strong>6.</strong> Carcinoma of the lung<br>\r\n<strong>7.</strong> Epithelial ovarian carcinoma<br>\r\n<strong>8.</strong> Cervical carcinoma<o:p></o:p></p><p class=\"MsoNormal\"><strong> </strong></p><p class=\"MsoNormal\"><strong>Dosage\r\nand Administration</strong>:<br>\r\nIntravenous 5-fluorouracil can be delivered by rapid intravenous bolus\r\ninjection or slow infusion. The vial contents can rapidly be injected directly\r\ninto a peripheral vein, the commonest schedules being: 12-13.5 mg/kg (500\r\nmg/m2) daily for 5 days repeated at 4- weekly intervals. Slow intravenous\r\ninfusion requires the drug, to be diluted in 500 ml of dextrose 5% solution,\r\nthen infused over 2-3 h on 5 successive days. <strong>Usual Adult Dose:</strong> <strong>For\r\npalliative management of cancer: </strong><strong>Initial Dose:</strong> 12 mg/kgintravenously once daily for 4 successive\r\ndays. Maximum Dose: 800 mg/day. If no toxicity is observed, 6 mg/kg may be\r\nadministered on the 6th, 8th, 10th, and 12<sup>th</sup> day (No therapy is\r\ngiven on days 5, 7, 9, or 11). Discontinue at the end of day 12, even with no\r\napparent toxicity. <strong>Poor risk\r\npatients and those who are not in an adequate nutritional state:</strong> <strong>Initial Dose:</strong> 6 mg/kg/day for 3 days. <strong>Maximum Dose:</strong> 400 mg/day. If no\r\ntoxicity is observed, 3 mg/kg may be administered on days 5, 7, and 9 (No therapy\r\nis to be administered on days 4, 6, or 8). Discontinue at the end of day 9,\r\neven with no apparent toxicity. or, as direceted by the registered physicians.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Use\r\nin pregnancy and lactation:</strong> Fluorouracil is contraindicated\r\nthroughout pregnancy. The literature pertaining to pregnancy and cytotoxic\r\ndrugs is necessarily limited but it appears in general that risk of\r\nteratogenesis diminishes with the advancement of pregnancy. Therefore most\r\ncytotoxic drugs are absolutely contraindicated in the first trimester and\r\n5-fluorouracil, used in the<br>\r\nfirst trimester has been reported to cause multiple congenital abnormalities.\r\nThere are many case reports, however, of pregnancy being conducted successfully\r\nwith combination chemotherapy being given to the mother during the second and\r\nthird trimesters. Because of the age of the population and the natural history\r\nof the tumors treated, most of the data on long-term follow-up<br>\r\npertain to therapy for leukemias. More data need to be accrued on the\r\nsubsequent development of neonates before it is certain that any of these\r\ncompounds are free of late effects. <strong>Lactating\r\nmother:</strong> It is not known whether Fluorouracil is excreted in human milk.\r\nBecause Fluorouracil inhibits DNA, RNA and protein synthesis, mothers should\r\nnot nurse while receiving this drug.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Packing:\r\n<o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Fluracil-250:</strong>\r\nEach box contains one vial of 250mg Fluorouracil solution for IV injection.<br><o:p></o:p></p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\" sans-serif;=\"\" background-color:=\"\" rgb(255,=\"\"><strong>Fluracil-500:</strong> Each box contains one\r\nvial of 500mg Fluorouracil solution for IV injection.<br></p>",
    "strength": " 25,500",
    "uom": " mg (50 mg/ml)",
    "categoryId": "57",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1660642138Fluracil 250 Carton Pic(1).png",
      "https://www.admin.drug-international.com/uploads/product_images/Fluracil2.jpg"
    ]
  },
  {
    "id": "1038",
    "name": "Flutiderm",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Fluticasone propionate\r\nBP 0.005% Ointment. </span></p><p style=\"text-align: justify;\"><strong>Indication : </strong>Fluticasone propionate is a\r\nmedium potency corticosteroid indicated\r\nfor the relief of the inflammatory and\r\npruritic manifestations of corticosteroidresponsive\r\ndermatoses eczema &\r\npsoriasis.ent is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Apply a\r\nthin film of Flutiderm Ointment to the\r\naffected skin areas twice daily. Rub in\r\ngently. Or, as directed by the physician.</span></p><p style=\"text-align: justify;\"><strong>Packing :<em> </em></strong><span class=\"redactor-invisible-space\"><em> </em>Flutiderm ointment :<em> </em>10gm in\r\na tube.</span></p>",
    "strength": "0.005% w/w ",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531802045Flutiderm.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Flutiderm.jpg"
    ]
  },
  {
    "id": "1321",
    "name": "Foly",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition\r\n: Foly-5 Tablet : </strong>Each tablet contains Folinic Acid\r\n5mg as Calcium Folinate Pentahydrate BP.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Foly-15\r\nTablet : </strong>Each\r\ntablet contains Folinic  Acid 15mg as\r\nCalcium Folinate BP.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications :</strong><strong> </strong>It is indicated to diminish the toxicity\r\nand counteract the effect of folic acid antagonist. To treat the Megaloblastic\r\nanemia due to folate deficiency, as in sprue, nutritional deficiency &\r\ntreatment of the Megaloblastic anemia of pregnancy and infancy.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage and administration : Reduction of harmful\r\neffects of folic acid antagonists such as Methotrexate, Trimethoprim etc :</strong><strong> </strong>The dose is usually one 5-15mg\r\ntablet every 6 hours for 2 to 3 days.<strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Megaloblastic\r\nanemia : </strong>In the\r\ntreatment of Megaloblastic anemia, the dose is one 5-15 mg tablet daily. Or, as\r\ndirected by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use\r\nin Pregnancy and Lactation : </strong>There are no adequate and well-controlled clinical studies conducted\r\nin pregnant or breastfeeding women. It is not known whether this drug is\r\nexcreted in human milk. Because may drugs are excreted in human milk, caution\r\nshould be exercised when<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">Calcium Folinate is administered to a nursing mother.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Packing\r\n: Foly-5 Tablet : </strong>Each box contains 2 x 14's tablets in blister pack.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p><strong>Foly-15\r\nTablet : </strong>Each box\r\ncontains 2 x 14's tablets in blister pack.<br></p>",
    "strength": " 5,15",
    "uom": "mg",
    "categoryId": "104",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121450Foly-5.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745121450Foly-15.png"
    ]
  },
  {
    "id": "1324",
    "name": "Foly Injection",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Composition :</strong> <strong>Foly \r\nTablet :</strong>  Each  tablet \r\ncontains Folinic  Acid 15mg  as \r\nCalcium Folinate Pentahydrate BP. </p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Foly Injection</strong> : Each vial\r\n(5ml) contains Folinic Acid 50mg as Calcium Folinate BP. </p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Foly 100 Injection :</strong> Each\r\nvial (10ml) contains Folinic Acid 100mg as Calcium Folinate BP.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><br> </p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications :</strong> It is indicated to diminish the toxicity and\r\ncounteract the effect of impaired Methotrexate elimination, treat the\r\nMegaloblastic anemia due to folate deficiency, as in sprue, nutritional deficiency\r\n& treatment of the Megaloblastic anemia of pregnancy and infancy. Calcium\r\nFolinate injection is also used in combination with 5-fluorouracil in cytotoxic\r\ntherapy.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"> <strong>Dosage\r\nand administration :</strong> Calcium folinate should not be mixed in the same infusion\r\nas fluorouracil as a precipitate may form. OralReduction of harmful effects of\r\nfolic acid antagonists such as Methotrexate, Trimethoprimetc : The dose is\r\nusually one 15mg tablet every 6 hours for 2 to 3 days. Megaloblastic anemia :\r\nIn the treatment of Megaloblastic anemia, the dose is one 15 mg tablet daily.\r\nIntravenous Advanced Colorectal Cancer : Folinic Acid is administered at\r\n200mg/m2 by slow intravenous injection followed by 5-fluorouracil at 370 mg/m2\r\nby intravenous injection. Or 20 mg/m2 by slow intravenous injection followed by\r\n5-fluorouracil at 425 mg/m2 by intravenous injection. Treatment is repeated\r\ndaily for 5 days.This 5 day treatment course may be repeated at 4 weeks\r\ninterval, for 2 courses  and then may\r\nrepeated at 4-5 weekly intervals if the patient has recovered completely from\r\nthe toxic effects of the prior treatment course. Folinic acid rescue after high\r\ndose Methotrexate Therapy :  Calcium\r\nFolinate starts 24 hours after the beginning of the methotrexate infusion at\r\ndose of 15mg (10mg/m2) every 6 hours for 10 doses. IntramuscularFolate\r\ndeficient megaloboastic anaemia : Up to 1 mg/day. Or, as directed by the\r\nregistered physician.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Use in Pregnancy and Lactation :</strong> There are no adequate and\r\nwell-controlled clinical studies conducted in pregnant or breastfeeding women.\r\nIt is not known whether this drug is excreted in human milk. Because may drugs\r\nare excreted in human milk, caution should be exercised when Calcium Folinate\r\nis administered to a nursing mother.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Packing :</strong> </p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Foly Tablet :</strong> Each box\r\ncontains 2 x 14's tablets in blister pack. </p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Foly Injection </strong>: Each box\r\ncontains 1 glass vial of 5 ml solution. </p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Foly 100 Injection :</strong> Each box\r\ncontains 1 glass vial of 10 ml solution.</p>\r\n\r\n",
    "strength": " 100mg/10ml,50mg/5ml",
    "uom": "mg/ml",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1561609193Foly-  Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1561609193Foly 100",
      "https://www.admin.drug-international.com/ 10ml Inj Carton- Carton Pic.png",
      "https://www.admin.drug-international.com/uploads/product_images/1528785317Foly _ In.jpg.jpg"
    ]
  },
  {
    "id": "1750",
    "name": "Fosfa",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:</strong>\r\nEach vial contains Ifosfamide USP 2 gm Injection.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>Ifosfamide\r\nInjection is indicated for use in combination with certain other approved\r\nantineoplastic agents for third-line chemotherapy of germ cell testicular\r\ncancer. It should be used in combination with mesna for prophylaxis hemorrhagic\r\ncystitis.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration: </strong>Ifosfamide\r\nshould be administrated intravenously at a dose of 1.2 g/m<sup>2</sup> per day\r\nfor 5 consecutive days. Treatment is repeated every 3 weeks or<strong> </strong>after recovery from hematologic\r\ntoxicity (Platelets &gt;_ 100,000/mL, WBC &gt;_ 4,000/mL). In order to prevent\r\nbladder toxicity, ifosfamide should be given with extensive hydration consisting\r\nof at least 2 liters of oral or intravenous fluid per day. A protector, such as\r\nMesna (Mes-D), should also be used to prevent hemorrhagic cystitis. Ifosfamide\r\nshould be administrated as a slow intravenous infusion lasting a minimum of 30\r\nminutes. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and\r\nLactation: </strong>Pregnancy Category D. Ifosfamide can\r\ncause fetal harm when administered to a pregnant woman. Fetal growth\r\nretardation and neonatal anemia have been reported following exposure to\r\nifosfamide-containing chemotherapy regimens during pregnancy. Ifosfamide is\r\nexcreted in breast milk. Because of the potential for serious adverse events\r\nand the tumorigenicity shown for ifosfamide, a decision should be made whether\r\nto discontinue nursing or to discontinue the drug, taking into account the\r\nimportance of the drug to the mother.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packaging: </strong>Each\r\nbox contains one vial of Ifosfamide 2 gm Lyophilized Powder.</p>",
    "strength": "2 gm ",
    "uom": "",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1614419387Fosfa Injection Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1614419387Fosfa 2mg- Carton Pic.png"
    ]
  },
  {
    "id": "1234",
    "name": "Fuclav Suspension",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">(CefuroximeUSP 125 mg + Clavulanic Acid USP 31.25 mg)/5ml Suspension.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication :</strong>It is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below : Pharyngitis/tonsillitis, Acute bacterial otitis media, Acute bacterial maxillary sinusitis, Acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis, Uncomplicated skin and skin-structure infections, Uncomplicated urinary tract infections, Uncomplicated gonorrhea, Early lyme disease.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong>Please see prescribing description for more information.</p><p style=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\">Fuclav suspension : 70 ml suspension.</p>",
    "strength": "125+31.25",
    "uom": "mg/5ml",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531802252Fuclav.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121387Fuclav-70 ml.png"
    ]
  },
  {
    "id": "1303",
    "name": "Fuclav Tablet",
    "description": "<p><strong>Composition : </strong>Fuclav-125 : <strong> </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Cefuroxime USP 125 mg + Clavulanic Acid USP 31.25 mg Tablet. <br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong> </strong>Fuclav-250 : <strong> </strong><span class=\"redactor-invisible-space\">Cefuroxime USP 250 mg + Clavulanic Acid USP 62.5 mg Tablet. <br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong> </strong>Fuclav-500 : <strong> </strong><span class=\"redactor-invisible-space\">Cefuroxime USP 500 mg + Clavulanic Acid USP 125 mg Tablet. </span><span class=\"redactor-invisible-space\"></span><br><span class=\"redactor-invisible-space\" xss=\"removed\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication :</strong> It is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below : Pharyngitis/tonsillitis, Acute bacterial otitis media, Acute bacterial maxillary sinusitis, Acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis, Uncomplicated skin and skin-structure infections, Uncomplicated urinary tract infections, Uncomplicated gonorrhea, Early lyme disease.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong>Please see prescribing description for more information.</p><p style=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><strong></strong>Fuclav-125 : 2x7's tablets in blister pack.</p><p style=\"text-align: justify;\">Fuclav-250 : 2x7's tablets in blister pack.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Fuclav-500 : 2x7's tablets in blister pack.</span></p>",
    "strength": "500+125,250+62.5,125+31.25",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531802595Fuclav.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121419Fuclav-500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745121419Fuclav-250.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745121419Fuclav-125.png"
    ]
  },
  {
    "id": "1233",
    "name": "Furex Injection",
    "description": "<p><strong>Composition : </strong>Furex-750 mg (IM/IV): <span class=\"redactor-invisible-space\" xss=\"removed\">Cefuroxime Sodium USP 750mg/vial Injection. <br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\">Furex-1.5 gm (IV): <span class=\"redactor-invisible-space\">Cefuroxime Sodium USP 1.5 gm/vial Injection. </span><br><span class=\"redactor-invisible-space\" xss=\"removed\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Furex is indicated in the treatment of : Upper respiratory tract infections : Ear, nose, throat infections, such as otitis media, sinusitis, tonsillitis and pharyngitis. Lower respiratory tract infections : Acute and chronic bronchitis and pneumonia. Genito-urinary tract infections : Pyelonephritis, cystitis and urethritis, gonorrhoea, acute uncomplicated gonococcal urethritis and cervicitis.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Skin and soft tissue infection : Impetigo. Lyme disease : Erythema marginatum.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong>Please see prescribing description for more information.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Cefuroxime has been assigned to Pregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\">Furex-750mg (IM/IV) & 1.5gm (IV) Injection : Combipack.</p>",
    "strength": "1.5,750",
    "uom": "gm(IV)",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531802901Furex.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1684407390Furex-1.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745121317FUREX-750.png"
    ]
  },
  {
    "id": "1232",
    "name": "Furex Suspension",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Cefuroxime Sodium USP 125 mg/5ml Suspension.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Furex is indicated in the treatment of : Upper respiratory tract infections : Ear, nose, throat infections, such as otitis media, sinusitis, tonsillitis and pharyngitis. Lower respiratory tract infections : Acute and chronic bronchitis and pneumonia. Genito-urinary tract infections : Pyelonephritis, cystitis and urethritis, gonorrhoea, acute uncomplicated gonococcal urethritis and cervicitis. Skin and soft tissue infection : Impetigo. Lyme disease : Erythema marginatum.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong>Please see prescribing description for more information.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Cefuroxime has been assigned to Pregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong><span class=\"redactor-invisible-space\">.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Furex Suspension : 70ml suspension. </span></p>",
    "strength": "125",
    "uom": "mg/5ml",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531803213Furex.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121336FUREX-70ml.png"
    ]
  },
  {
    "id": "1304",
    "name": "Furex Tablet",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Cefuroxime Sodium USP 250 mg & 500 mg Tablet. </span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Furex is indicated in the treatment of : Upper respiratory tract infections : Ear, nose, throat infections, such as otitis media, sinusitis, tonsillitis and pharyngitis. Lower respiratory tract infections : Acute and chronic bronchitis and pneumonia. Genito-urinary tract infections : Pyelonephritis, cystitis and urethritis, gonorrhoea, acute uncomplicated gonococcal urethritis and cervicitis. Skin and soft tissue infection : Impetigo. Lyme disease : Erythema marginatum.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong>Please see prescribing description for more information.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Cefuroxime has been assigned to Pregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><strong></strong><span class=\"redactor-invisible-space\">Furex Tablet : 2 x 7's tablets in blister pack.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Furex-500 Tablet : 2 x 7's tablets in blister pack.</span></p>",
    "strength": "500,250",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531803089Furex.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121284FUREX-500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745121284FUREX.png"
    ]
  },
  {
    "id": "1022",
    "name": "Fusibac - H",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Fusidic Acid BP 2% and\r\nHydrocortisone Acetate USP 1% Cream.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong> Fusibac-H cream is\r\nindicated in eczema and dermatitis with\r\nsecondary bacterial infections, including\r\natopic eczema, primary irritant dermatitis\r\nand allergic and seborrhoeic dermatitis\r\nwhere the organisms responsible are\r\nknown to be or believed to be sensitive\r\nto fusidic acid.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :  </strong><span class=\"redactor-invisible-space\">The\r\nsafety in pregnancy and lactation has not\r\nbeen established for fusidic acid.\r\n</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Fusibac-H cream : 10gm in a\r\ntube.</span></p>",
    "strength": "2%+1%",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531803475Fusibac-H.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/images/Fusibac-H.jpg"
    ]
  },
  {
    "id": "1770",
    "name": "Gavinor",
    "description": "<p><strong>Composition:</strong>\r\nEach 10 ml oral suspension contains Sodium Alginate BP 500 mg and also contains\r\nSodium Bicarbonate BP 267mg and Calcium Carbonate BP 160mg.</p><p class=\"MsoNoSpacing\"><strong>Indication:</strong>Gavinor\r\nis indicated for Heart burn, Acidity, Flatulence and Heart burn during\r\npregnancy.<o:p></o:p></p><p class=\"MsoNoSpacing\"><strong>Dose\r\nand administration:<strong>Adult and children over 12 years</strong></strong>:\r\n10-20 ml after meals and at bedtime, up to four times a day. <strong>Children 6\r\nto 12 years</strong>: 5-10 mL after meals and at bedtime, up to four times a\r\nday.  <strong>Children under 6 years</strong>:\r\nNot recommended.or as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNoSpacing\"><strong> </strong></p><p class=\"MsoNoSpacing\"><strong>Precaution:</strong>\r\nCan be taken in pregnancy and breast-feeding as directed by registered\r\nphysician.<o:p></o:p></p><p class=\"MsoNoSpacing\"><strong>Storage:</strong>\r\nStore below 30<sup>0</sup> in a dry place. Keep the medicine out of reach of\r\nthe children. <o:p></o:p></p><p class=\"MsoNoSpacing\"><strong>Packing:</strong>\r\nEach box contains 200ml suspension.<o:p></o:p></p><p class=\"MsoNormal\"><a name=\"_GoBack\"></a></p>",
    "strength": " 500+267+160",
    "uom": "mg",
    "categoryId": "37",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744090753gavinor 200ml.png"
    ]
  },
  {
    "id": "1842",
    "name": "Gavinor Sachet",
    "description": "<p><strong>Composition:</strong> Each Sachet (10ml) oral\r\nsuspension contains Sodium Alginate BP 500mg, Sodium Bicarbonate BP 267mg and\r\nCalcium Carbonate BP 160mg.</p><p class=\"MsoNormal\"><strong>Indication:</strong>Gavinor sachet is indicated for\r\nheat burn and to remove acidity. It is also used to give soothing relief from\r\ngas and to suppress gastric reflux.<o></o></p><p class=\"MsoNormal\"><strong>Dose and Administration:</strong> In adults and children over 12\r\nyears: 1 to 2 sachet (10-20ml) after meals and at bedtime maximum four times a\r\nday. For children 6-12 years:5-10ml after meals and at bedtime maximum four\r\ntimes a day. Or, as directed by the registered physician.<o></o></p><p class=\"MsoNormal\"><strong>Pregnancy & Lactation:</strong> Can be taken in pregnancy and\r\nbreastfeeding as directed by registered <a name=\"_GoBack\"></a>physician.<o></o></p><p><strong>Packing:</strong> Each box contains 20 liquid\r\nsachets oral suspension.</p>",
    "strength": "500+267 +160",
    "uom": "mg",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1660731414Gavinor Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744090987gavinor.png"
    ]
  },
  {
    "id": "786",
    "name": "Gelcin Tablet",
    "description": "<p><strong></strong><strong>Composition : </strong>Gemifloxacin INN 320 mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Gemifloxacin is indicated for\r\nthe treatment of - Acute bacterial\r\nexacerbations of chronic bronchitis and\r\ncommunity-acquired pneumonia (including\r\nmulti-drug resistant strains).</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong>The dosage and administration of Gemifloxacin is given below: In Acute bacterial exacerbation of chronic bronchitis One 320mg tablet daily 5 days\r\nCommunity acquired pneumonia [mild to moderate severity]\r\nDue to known or suspected S. pneumoniae, H.  5 days\r\ninfluenzae, M. pneumoniae,or C. pneumoniae\r\ninfection One 320mg tablet daily\r\nDue to known or suspected Multi-drug resistant  7 days\r\nStreptococcus pneumonie including\r\nK. pneumoniae, or M. catarrhalis infection.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong>Gemifloxacin has been assigned to\r\npregnancy category C by the FDA.\r\nCaution should be exercised when\r\nGemifloxacin is administered to a nursing\r\nmother.Administration of drugs during pregnancy and lactation should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus or child. There is insufficient experience of the use of Salmeterol Xinafoate and Fluticasone Propionate in human pregnancy and lactation. There are no data available for human breast milk.</p><p style=\"text-align: justify;\"><strong>Packing </strong>: 1 x 7's tablets in blister pack.</p>",
    "strength": "320",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531803559Gelcin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121186Gelcin.png"
    ]
  },
  {
    "id": "1764",
    "name": "Geludrox-Hs",
    "description": "<p class=\"MsoNormal\" style=\"text-align:center\" align=\"center\"><br></p><p class=\"MsoNormal\"><strong>Composition: </strong>Composition: Each 5 ml suspension contains Aluminium Oxide\r\nBP 200 mg (As Aluminium Hydroxide gel USP), Magnesium Hydroxide BP 400 mg and\r\nSimethicone USP 30 mg.</p><p class=\"MsoNormal\"><strong>Indication: </strong> Aluminium Hydroxide and Magnesium Hydroxide is\r\nindicated for Hyperacidity, peptic ulcer, gastritis, heartburn, sour stomach\r\n& dyspepsia.</p><p class=\"MsoNormal\"><strong>Dose & Administration:</strong> 1-2 tea spoonful suspension 1-3\r\nhours after meal and before bed time or as directed by the registered physician.</p><p class=\"MsoNormal\"><strong>Storage:</strong> Store below 30<sup>0</sup> in a dry place. Keep the\r\nmedicine out of reach of the children. </p><p class=\"MsoNormal\"><strong>Packing:</strong> Each box contains 200ml suspension.<a name=\"_GoBack\"></a></p>",
    "strength": " ",
    "uom": "",
    "categoryId": "37",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744091233Geludrox-Hs.png"
    ]
  },
  {
    "id": "1351",
    "name": "Getinib",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:</strong> <strong>Getinib:</strong> Each film coated tablet contains Gefitinib INN 250\r\nmg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications</strong>: <strong>Getinib</strong> is indicated for the first-line treatment of\r\npatients with metastatic non-small cell lung cancer (NSCLC) whose tumors have\r\nepidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R)\r\nsubstitution mutations as detected by an FDA-approved test.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand Administration:</strong> The recommended dose of Getinib is\r\n250 mg orally once daily with or without food until disease progression or\r\nunacceptable toxicity. One should not take a missed dose within 12 hours of the\r\nnext dose.<strong> Administration to Patients who have Difficulty Swallowing Solids:</strong>\r\nGetinib tablets should be immersed in 4 to 8 ounces of water by dropping the\r\ntablet in water, and stirred for approximately 15 minutes. The liquid should be\r\nimmediately drunk or administered through a naso-gastric tube. The container\r\nshould be rinsed with 4 to 8 ounces of water and immediately drunk or\r\nadministered through the naso- gastric tube. Or, as directed by the registered\r\nphysician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation:</strong> There are\r\nno adequate and well controlled studies in pregnant women using Gefitinib. If\r\nit is used during pregnancy or if the patient becomes pregnant while receiving\r\nthis drug, she should be apprised of the potential hazard to the fetus or\r\npotential risk for loss of the pregnancy. <strong>Lactation:</strong> It is not known\r\nwhether Getinib is excreted in human milk. Because of the potential for serious\r\nadverse reactions in nursing infants from Getinib, women should be advised to\r\ndiscontinue breast-feeding during treatment with Getinib.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:</strong>  <strong>Getinib:</strong>Each box contains 4x7's tablets in Alu- Alu blister pack.</p>",
    "strength": "250",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/15438310091531112521Getinib250.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745303758Getinib.png"
    ]
  },
  {
    "id": "1280",
    "name": "Glucotin Max",
    "description": "<p style=\"margin-top:0in;margin-right:0in;margin-bottom:6.9pt;margin-left:0in\"><strong>Composition:</strong> Each\r\nFilm coated tablet contains Glucosamine Sulfate 750mg as Glucosamine Sulfate\r\nPotassium Chloride USP and Diacerein BP 50mg.</p><p style=\"margin-top:0in;margin-right:0in;margin-bottom:6.9pt;margin-left:0in;\r\ntext-align:justify\"><strong>Indications:</strong><span class=\"redactor-invisible-space\"> This tablet is indicated in the treatment\r\nof Osteoarthritis, Rheumatoid arthritis, Bone & Joint Injuries.</span><br>\r\n<strong>Dosage and administration:</strong><span class=\"redactor-invisible-space\"> Adult and children 12 years and older: The\r\nusual dose of Glucosamine & Diacerein combination is 1 tablet twice daily\r\n(12 hourly) taken with food. Or, as directed by the registered physician.</span></p><p style=\"margin-top:0in;margin-right:0in;margin-bottom:6.9pt;margin-left:0in;\r\ntext-align:justify\"><strong>Use in pregnancy and Lactation: </strong><span class=\"redactor-invisible-space\">Glucosamine & Diacerein should not be\r\nadministered during pregnancy. In addition, Diacerein should not be prescribed\r\nto lactating women due to reports that small amounts of Diacerein derivatives\r\npass into the maternal milk.</span></p><p><strong>Packing: </strong><span class=\"redactor-invisible-space\">Glucotin Max: Each box contains 3 X 7's tablets\r\nin blister pack.</span><br></p>",
    "strength": "750+50",
    "uom": "mg",
    "categoryId": "107",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1637663753Glucotin Max Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121146Glucotin Max.png"
    ]
  },
  {
    "id": "1271",
    "name": "Glucotin Plus",
    "description": "<p><strong>Composition :</strong><span class=\"redactor-invisible-space\"> Each Tablet Contains  (Glucosamine </span><span class=\"redactor-invisible-space\">USP 250 mg</span><span class=\"redactor-invisible-space\"> + Chondroitin\r\nSulfate Sodium USP 200 mg).</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Indications : </strong><span class=\"redactor-invisible-space\">This tablet is indicated in\r\nthe treatment of rheumatoid arthritis,\r\nOsteoarthritis of hand, spine and other\r\nlocation, large weight bearing joints,\r\nsuch as the knee and hips, inflammatory\r\nbowel disease (Crohns disease,\r\nulcerative colitis). It is also beneficial in\r\nsport injuries, vascular migraine\r\nheadache etc.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">1 to 2\r\ntablets 3 times daily or as directed by the\r\nphysician. Obese individuals may need\r\nhigher doses, based on body weight. Or\r\nas directed by the registered physician.\r\n</span><br></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Women who are pregnant or who could\r\nbecome pregnant should not supplement\r\nwith Glucosamine and Chondroitin. No\r\nstudies have evaluated the use of\r\nGlucosamine and Chondroitin during\r\npregnancy or lactation. It should be\r\ntaken with caution and medical advice\r\nduring pregnancy and lactation.</span><br></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Packing :</strong><span class=\"redactor-invisible-space\"> Glucotin-Plus : 3x7's tablets\r\nin blister pack.</span><br></span></span></span></span></p>",
    "strength": "250+200",
    "uom": "mg",
    "categoryId": "107",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1660628148Glucotin Plus Short  Insert (For Web).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121129Glucotin-Plus.png"
    ]
  },
  {
    "id": "1360",
    "name": "Grafil",
    "description": "<p><strong>COMPOSITION :</strong> Grafil pre-filled syringe injection: Each pre-filled syringe contains 0.5 ml sterile solution of Filgrastim BP 300 mcg (30 MU). </p><p><strong>INDICATIONS:Filgrastim is Indicatod forCancer patients receiving myelosuppressive chemotherapy :</strong> The decrease of the incidence of infection, as manifested by febrile neutropenia, in patients with non myeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever</p><p><strong>Cancer patients undergoing Acute Myeloid Leukemia:</strong>  The reduction of the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML).</p><p><strong></strong></p><p><strong>Cancer Patients Receiving Bone Marrow Transplantation (BMT)</strong><strong>: </strong>The reduction of the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablatlve chemotherapy followed by bone marrow transplantation.</p><p><strong>Patients with severe chronic neutropenia :</strong> The reduction of the incidence and duration of sequelae of neutropenia (e.g., fever, infection or opharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia or idiopathic neutropenia. Patients acutely exposed to myelosuppressive doses of radiation: The increase of the survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic syndrome of acute radiation syndrome).</p><p><strong>Patients with HIV infection:</strong> The prevention and treatment of persistent neutropenia (ANC &lt;_ 1.0 x 109/I) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections, when other options to manage neutropenia are inappropriate.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage & Administration:</strong> Cancer patients receiving\r\nmyelosuppressive chemotherapy or induction and/or consolidation chemotherapy\r\nfor AML: The recommended dose of Filgrastim is 0.5 MU (5 mcg)/kg/day,\r\nadministered as a single daily subcutaneous injection or by intravenous\r\ninfusion (over 30 minutes). The first dose shouldn't be administered in less\r\nthan 24 hours following cytotoxic Chemotherapy. Continue until neutrophil count\r\nin normal range, usually for 14 days (up to 38 days in AML.) Cancer patients\r\nundergoing bone marrow transplantation: The recommended dosage of Filgrastim\r\nfollowing bone marrow transplantation (BMT) is 1.0 MU (10 mcg)/kg/day given as\r\nan intravenous infusion no longer than 24 hours. Administer the first dose of\r\nFilgrastim at least 24 hours after cytotoxic chemotherapy and at least 24 hours\r\nafter bone marrow transplantation. Dose adjustment should be accordingly to\r\nabsolute neutrophil count (ANC). During the period of neutrophil recovery‚ the\r\ndaily dose of Filgrastim should be titrated against the neutrophil response as\r\nfollows:</p><table class=\"MsoTableGrid\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\" style=\"margin-left: 0.2in;\">\r\n <tbody><tr>\r\n  <td width=\"300\" valign=\"top\" style=\"width: 225pt; border-width: 1pt; border-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">Absolute Neutrophil Count</p>\r\n  </td>\r\n  <td width=\"222\" valign=\"top\" style=\"width: 166.5pt; border-top-width: 1pt; border-right-width: 1pt; border-bottom-width: 1pt; border-top-color: black; border-right-color: black; border-bottom-color: black; border-left: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">Filgrastim Dose Adjustment</p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"300\" valign=\"top\" style=\"width: 225pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">When ANC greater than 1000/mm³\r\n  for consecutive 3 days</p>\r\n  </td>\r\n  <td width=\"222\" valign=\"top\" style=\"width: 166.5pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">Reduce to 5 mcg/kg/day</p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"300\" valign=\"top\" style=\"width: 225pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">If ANC remains greater than\r\n  1000/mm³ for 3 more consecutive days</p>\r\n  </td>\r\n  <td width=\"222\" valign=\"top\" style=\"width: 166.5pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">Discontinue drug</p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"300\" valign=\"top\" style=\"width: 225pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">If ANC decreases to less than\r\n  1000/mm³</p>\r\n  </td>\r\n  <td width=\"222\" valign=\"top\" style=\"width: 166.5pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">Resume at 5 mcg/kg/day</p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\" style=\"text-align:justify\"><o:p> </o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\">Patients undergoing autologous\r\nperipheral blood progenitor cell (PBPC) collection and therapy: The recommended\r\ndosage of Filgrastim for the mobilization of autologous PBPC is 1.0 MU (10\r\nmcg)/kg/day given by subcutaneous injection for 5-7 days. Administer Filgrastim\r\nfor at least 4 days before the first leukapheresis procedure and continue until\r\nthe last leukapheresis. Discontinue Filgrastim if the white blood cell (WBC)\r\ncount rises to greater than 100,000/mm³.</p><p>Patients with severe chronic\r\nneutropenia: The recommended starting dosage in patients with congenital\r\nneutropenia is 0.6 MU (6 mcg)/kg as a twice daily subcutaneous injection and\r\nwith idiopathic or cyclic neutropenia is 0.5 MU (5 mcg)/kg as a single daily\r\nsubcutaneous injection. Dose adjustment should be accordingly to ANC and\r\ncomplete blood count (CBC). Patients acutely exposed to myelosuppressive doses\r\nof radiation hematopoietic syndrome of acute radiation syndrome : The\r\nrecommended dose of Filgrastim is 1.0 MU (10 mcg)/kg as a single daily\r\nsubcutaneous injection for patients exposed to myelosuppressive doses of\r\nradiation. Patients with HIV infection: The recommended starting dose of\r\nFilgrastim is 0.1 MU (1.0 mcg)/kg/day is given daily by subcutaneous injection\r\nwith titration up to a maximum of 0.4 MU (4 mcg) /kg/day until a normal\r\nneutrophil count is reached and can be maintained (ANC &gt; 2.0 x 109 /I), Or,\r\nas directed by the registered physicians.</p><p><strong>Use in pregnancy and lactation: </strong>Pregnancy Category C. There are no adequate\r\nand well-controlled studies in pregnant women. Nursing Mother- It is not known\r\nwhether this drug is excreted in human milk. Because many drugs are excreted in\r\nhuman milk, caution should be exercised if it is administered to women who are\r\nbreastfeeding.</p><p><strong>Packing: Grafil pre-filled syringe injection</strong>: Each per-filled syringe contains 0.5 ml sterile solution which contains Filgrastim BP 300 mcg (30 MU).<br><br></p>",
    "strength": "300",
    "uom": "Mcg",
    "categoryId": "114",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1551955056Grafil- Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1683016799Grafil Carton 05.02.23.png"
    ]
  },
  {
    "id": "793",
    "name": "Gynomix",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Neomycin Sulphate\t\t35,000 I.U.+\r\nPolymyxin B Sulphate\t\t35,000 I.U.\r\n+ Nystatin\t\t1,00,000 I.U.\r\n+ Metronidazole\t\t200 mg.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Gynomix is indicated for\r\nthe treatment of Vaginal mixed\r\ninfections, Vaginal leucorrhoeas, Vaginal\r\ntrichomoniasis if whatever their origin\r\n(Mycotic or Bacterial).</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Use in\r\nVagina 1 capsule at night for 6 days. Or,\r\nas directed by the physician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>6 capsules in a box.</p>",
    "strength": "170020",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531803763Gynomix.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121112Gynomix.png"
    ]
  },
  {
    "id": "1040",
    "name": "Happynap",
    "description": "<p><strong></strong><strong>Composition :</strong> Zinc Oxide USP 40% ointment. </p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is indicated for\r\npreventing and treating diaper rash as\r\nwell as minor skin irritations (e.g. cuts,\r\nburns, and scrapes, poison ivy). It works\r\nby providing a skin barrier to prevent and\r\nhelp to heal skin irritation.</span> </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">At first,\r\nwet and soiled diaper should be\r\nchanged. Promptly; the diaper area is\r\ncleaned & allowed drying. A thin layer of\r\nointment should be applied topically\r\nevery 8 hourly. It should be applied\r\nliberally as often as necessary, with each\r\ndiaper change, especially at bedtime or\r\nany time when exposure to wet diapers\r\nmay be prolonged. Or, as directed by the\r\nregistered physician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">15gm ointment in\r\na tube.\r\n</span></p>",
    "strength": "40% w/w ",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531803829Happynap.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/images/Happynap.jpg"
    ]
  },
  {
    "id": "1823",
    "name": "Hertinib",
    "description": "<p><strong>Composition: </strong>Each\r\ntablet contains Neratinib 40 mg as Neratinib Maleate INN.</p>\r\n\r\n<p class=\"MsoNormal\"><strong>Indications:</strong>\r\n<strong>Extended Adjuvant Treatment of Early-Stage Breast Cancer: </strong>Hertinib as a\r\nsingle agent is indicated for the extended adjuvant treatment of adult patients\r\nwith early-stage human epidermal growth factor receptor 2 (HER2)- positive\r\nbreast cancer, to follow adjuvant Trastuzumab based therapy. <strong>Advanced or\r\nMetastatic Breast Cancer: </strong>Hertinib in combination with Capecitabine is\r\nindicated for the treatment of adult patients with advanced or metastatic\r\nHER2-positive breast cancer who have received two or more prior anti-HER2 based\r\nregimens in the metastatic setting.<o></o></p>\r\n\r\n<p class=\"MsoNormal\"><strong>Dosage and Administration:</strong>\r\n<strong>Antidiarrheal Prophylaxis: </strong>Antidiarrheal prophylaxis is recommended\r\nduring the first 2 cycles (56 days) of treatment and should be initiated with\r\nthe first dose of Hertinib. Additional antidiarrheal agents may be required to\r\nmanage diarrhea in patients with loperamide-refractory diarrhea. Hertinib dose\r\ninterruptions and dose reductions may also be required to manage diarrhea. The\r\nrecommended dose of Hertinib is 240 mg (six tablets) given orally once daily\r\nwith food, continuously for one year. Patients should be instructed to take\r\nHertinib at approximately the same time every day. Hertinib tablets should be\r\nswallowed whole (tablets should not be chewed, crushed, or split prior to\r\nswallowing). If a patient misses a dose, missed dose should not be replaced,\r\nand patients should be instructed to resume Hertinib with the next scheduled\r\ndaily dose. Or, as directed by the registered physicians.<o></o></p>\r\n\r\n<p class=\"MsoNormal\"><strong>Use in Pregnancy and Lactation: </strong>Hertinib\r\ncan cause fetal harm when administered to a pregnant woman. There are no available\r\ndata in pregnant women to inform the drug-associated risk. Pregnant women\r\nshould be advised of the potential risk to a fetus.<o></o></p>\r\n\r\n<p><strong>Packing: </strong>Each\r\ncontainer contains 30 tablets in a box.</p>",
    "strength": "40",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1643535012Hertinib 30 Tab Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1643535012Hertinib 40 mg 30 Tablet- Bottle Carton Pic(2).png"
    ]
  },
  {
    "id": "1278",
    "name": "Hopso Tablet",
    "description": "<p><strong>Composition : </strong>Sofosbuvir INN 400 mg.</p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Indications : </strong><span class=\"redactor-invisible-space\">Sofosbuvir is used with other\r\nantiviral medications such as Ribavirin &\r\nPeginterferon to treat Chronic Hepatitis C\r\n(CHC) infections. Its efficacy has been\r\nestablished in subjects with HCV genotype 1,\r\n2, 3, or 4 infections, including those with\r\nhepatocellular carcinoma meeting Milan\r\ncriteria (awaiting liver transplantation) and\r\nthose with HCV/HIV-1 co-infection.</span></p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">(Dosage for\r\nAdults) : 400 mg Tablet is recommended\r\norally once daily with or without food. Please see prescribing description for more information.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Sofosbuvir should\r\nbe used only when clearly needed. Ribavirin\r\nmay cause birth defects or fetal death.\r\nCaution should be excercised highly when it\r\nis used in combination with Ribavirin or\r\nRibavirin & Peginterferon to avoid pregnancy\r\nin female patients & female partners of male\r\npatients. It is not known if Sofosbuvir passes\r\ninto breast milk. Breast-feeding while using Sofosbuvir, in combination with Ribavirin or\r\nPeginterferon, is not recommended.</span></p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Hopso : 1 x 7's tablets in blister\r\npack.</span></p>",
    "strength": "400",
    "uom": "mg",
    "categoryId": "45",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1517300144hopso.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1517300144Hopso.jpg"
    ]
  },
  {
    "id": "1792",
    "name": "HYDRASON",
    "description": "<p><strong>Composition\r\n:</strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Hydrason\r\n10 Tablet: </strong>Each\r\ntablet contains Hydrocortisone USP 10mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Hydrason\r\n20 Tablet: </strong>Each\r\ntablet contains Hydrocortisone USP 20mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Indications\r\n:</strong><strong>\r\n</strong>It\r\nis indicated for the treatment of 1. <strong>Endocrine Disorders: </strong>Primary or\r\nsecondary adrenocortical insufficiency, congenital adrenal hyperplasia,\r\nnonsuppurative thyroiditis, hypercalcemia associated with cancer <strong>2.\r\nRheumatic Disorders:</strong> Rheumatoid arthritis, including juvenile rheumatoid\r\narthritis, ankylosing spondylitis, acute and subacute bursitis, synovitis of\r\nosteoarthritis, acute non-specific tenosynovitis, post-traumatic\r\nosteoarthritis, psoriatic arthritis, epicondylitis, acute gouty arthritis <strong>3.\r\nCollagen</strong> <strong>Diseases: </strong>Systemic lupus erythematosus systemic dermatomyositis,\r\nacute rheumatic carditis <strong>4. Dermatologic Diseases: </strong>Bullous dermatitis\r\nherpetiform<strong> </strong>is, severe erythema multiforme, severe seborrheic<strong> </strong>dermatitis,\r\nexfoliative dermatitis, mycosis fungoides,<strong> </strong>pemphigus, severe psoriasis <strong>5.\r\nAllergic States: </strong>Seasonal or perennial allergic rhinitis, drug<strong> </strong>hypersensitivity\r\nreactions, serum sickness, contact<strong> </strong>dermatitis, bronchial asthma, atopic\r\ndermatitis <strong>6. Ophthalmic Diseases: </strong>Allergic corneal marginal ulcers,<strong> </strong>herpes\r\nzoster ophthalmicus, anterior segment<strong> </strong>inflammation, sympathetic\r\nophthalmia, keratitis, optic<strong> </strong>neuritis, allergic conjunctivitis\r\nchorioretinitis, iritis and iridocyclitis <strong>7. Respiratory Diseases: </strong>Symptomatic\r\nsarcoidosis, berylliosis, loeffler's syndrome not manageable by other means,\r\nfulminating or disseminated pulmonary tuberculosis when used concurrently with\r\nappropriate antituberculous chemotherapy, aspiration pneumonitis <strong>8.\r\nHematologic</strong> <strong>Disorders: </strong>Idiopathic thrombocytopenic purpura in\r\nadults, secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic\r\nanemia, erythroblastopenia (RBC anemia), congenital (erythroid) hypoplastic\r\nanemia <strong>9. Neoplastic Diseases: </strong>For palliative management of: Leukemias\r\nand lymphomas in adults, acute leukemia of childhood <strong>10. Edematous States: </strong>To\r\ninduce a diuresis or remission of proteinuria in the nephrotic syndrome,\r\nwithout uremia, of the indiopathic type or that due to lupus erythematosus <strong>11.\r\nGastrointestinal Diseases: </strong>Ulcerative colitis, regional enteritis <strong>12.</strong> <strong>Nervous System: </strong>Acute\r\nexacerbations of multiple sclerosis etc.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Dosage\r\nand administration : Asthma : Dosage and administration : </strong>The initial\r\ndosage of Hydrason tablets may vary from 20 mg to 240 mg of Hydrason per day\r\ndepending on the specific disease entity being treated. In situations of less\r\nseverity lower doses will generally suffice while in selected patients higher\r\ninitial doses may be required. The initial dosage should be maintained or\r\nadjusted until a satisfactory response is noted. If after a reasonable period\r\nof time there is a lack of satisfactory clinical response, Hydrason should be\r\ndiscontinued and the patient transferred to other appropriate therapy. <strong>IT\r\nSHOULD</strong> <strong>BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE\r\nINDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF\r\nTHE PATIENT. </strong>After a favorable response is noted, the proper maintenance\r\ndosage should be determined by decreasing the initial drug dosage in small\r\ndecrements at appropriate time intervals until the lowest dosage which will\r\nmaintain an adequate clinical response is reached. It should be kept in mind\r\nthat constant monitoring is needed in regard to drug dosage. Included in the\r\nsituations which may make dosage adjustments necessary are changes in clinical status\r\nsecondary to remissions or exacerbations in the disease process, the patient's\r\nindividual drug responsiveness, and the effect of patient exposure stressful\r\nsituations not directly related to the disease entity under treatment; in this\r\nlatter situation it may be necessary to increase the dosage of Hydrocortisone for\r\na period of time consistent with the patient's condition. If after long-term\r\ntherapy the drug is to be stopped, it is recommended that it be withdrawn\r\ngradually. Or, as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Use\r\nin Pregnancy and lactation :</strong><strong> </strong>There are no adequate and\r\nwell-controlled studies in pregnant women. Hydrocortisone should be used during\r\npregnancy only if the potential benefit justifies the potential risk to the\r\nfetus. It is not known whether this drug is excreted in human milk. Caution\r\nshould be exercised when Hydrocortisone tablet is administered to a nursing\r\nwoman.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Packing\r\n: Hydrason 10 Tablet: </strong>Each box contains 5 x10's tablets in blister pack.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><strong>                 Hydrason 20 Tablet: </strong>Each\r\nbox contains 3 x 10's tablets<strong> </strong>in blister pack.<o:p></o:p></p>",
    "strength": " 20,10mg  ",
    "uom": "mg",
    "categoryId": "63",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1633345245Hydrason 20 Carton.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744099875Hydrason.png"
    ]
  },
  {
    "id": "749",
    "name": "Hydrason Injection",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Hydrason IV/IM Injection : Each\r\nvial contains sterile powder of Hydrocortisone\r\n100 mg as Hydrocortisone Sodium Succinate\r\nUSP.</span><strong></strong></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Hydrocortisone sterile powder is\r\nindicated for IV or IM use in the following\r\nconditions : Primary or secondary adrenocortical\r\ninsufficiency, Acute adrenocortical insufficiency,\r\nShock unresponsive to conventional therapy,\r\nCongenital adrenal hyperplasia, Hypercalcemia\r\nassociated with cancer, Nonsuppurative\r\nthyroiditis, Rheumatic Disorders, Dermatologic\r\nDiseases (Allergic States, Severe seborrheic\r\ndermatitis, Severe psoriasis, Pemphigus, Severe\r\nerythema multiforme). Control of severe or\r\nincapacitating allergic conditions (Bronchial\r\nasthma, Contact dermatitis, Atopic dermatitis,\r\nSerum sickness, Seasonal or perennial allergic\r\nrhinitis, Drug hypersensitivity reactions, Urticarial\r\ntransfusion reactions, Acute non infections\r\nlaryngeal edema), Ophthalmic Diseases (Herpes\r\nzoster opthalmicus, Iritis, Iridocyclitis,\r\nChorioretinitis, Diffuse posterior uveitis and\r\nchoroiditis, Optic neuritis), Gastrointestinal\r\nDiseases, Fulminating or disseminated\r\npulmonary tuberculosis when used concurrently\r\nwith appropriate antituberculous chemotherapy,\r\nLoeffler's syndrome, Aspiration pneumonitis,\r\nHematologic Disorders (Acquired, autoimmune\r\nhemolytic anaemia, Idiopathic thrombocytopenic\r\npurpura in adults, Secondary thrombocytopenia,\r\nErythroblastopenia), Neoplastic Diseases\r\n(Leukemias and lymphomas in adults, Acute\r\nleukemia of childhood). Edematous States, Acute\r\nexacerbations of multiple sclerosis</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">By IM injection or\r\nslow IV injection or infusion. The initial dose of\r\nHydrocortisone sterile powder in 100 mg to 500\r\nmg, depending on the severity of the condition. This dose may be repeated at\r\nintervals of 2, 4 or 6 hours as indicated by the\r\npatient's response and clinical condition.\r\nChildren : By slow IV Injection, up to 1 year 25\r\nmg, 1-5 years 50 mg, 6 -12 years 100mg. Or, as\r\ndirected by the registered physician.</span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\"> There are no\r\nadequate and well-controlled studies in pregnant\r\nwomen. It should be used durign pregnancy only\r\nif the potential benefit justifies the potential risk to\r\nthe fetus. It is not known whether this drug is\r\nexcreted in human milk. Caution should be\r\nexercised when this medicine is administered to\r\na nursing woman.</span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Hydrason IV/IM Injection : Each\r\nCombipack contains 1 vial of Hydrocortisone 100\r\nmg (as Hydrocortisone Sodium Succinate USP\r\nsterile powder) with 1 ampoule of 2 ml water for\r\ninjection BP.</span><span></span><br></p>",
    "strength": "100",
    "uom": "Mg/Vial",
    "categoryId": "63",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/Hydrason Insert - 16-1-18.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Hydrason-Carton.jpg"
    ]
  },
  {
    "id": "1903",
    "name": "I-Moist Single Use Eye Drops",
    "description": "<p><strong>Composition:</strong>\r\nEach ml contains Polyethylene Glycol 400 BP 4mg and Propylene Glycol BP 3mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong>\r\nIt is indicated for the temporary relief of burning and irritation due to\r\ndryness of the eye.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration:</strong>\r\nOne drop is instilled in the affected eye(s) 4 times daily or as needed. Or as directed by the registered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and lactation:</strong>\r\nThere are no adequate and well-controlled studies in pregnant women. Caution\r\nshould be exercised when administered to a nursing woman.<o></o></p><p><strong>Packing: </strong>Each\r\nbox contains 25’s (0.4ml) single use plastic containers enclosed in a plastic\r\npouch overwrap.</p>",
    "strength": " ",
    "uom": "",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1710313154Book Style Insert I-Moist .pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1710313154Carton   I-Moist .png"
    ]
  },
  {
    "id": "1000",
    "name": "Indapa - Plus ",
    "description": "<p class=\"MsoNormal\"><strong>Composition : </strong><strong></strong>Indapa-Plus 2 :<strong> </strong>Indapamide BP 1.25 mg+Perindopril\r\nErbumine BP 2 mg Tablet.</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong></strong>Indapa-Plus 4 : <strong> </strong>Indapamide BP 1.25 mg+Perindopril\r\nErbumine BP 4 mg Tablet.</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Indications : </strong>It is\r\nindicated in the treatment of essential hypertension where blood pressure is\r\nnot adequately controlled on perindopril alone.</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Dosage and administration : </strong>1-2\r\ntablet of <strong></strong>Indapa-plus 2 or<strong> </strong>One tablet of <strong></strong>Indapaplus 4<strong> </strong>per day\r\npreferably taken in the morning before meal. In case of renal insufficiency\r\ntreatment should be start with an adequate dose.</p><strong>Use in Pregnancy and lactation : </strong>There are no adequate and well-controlled studies in pregnant woman.So in pregnancy <strong></strong>Indapa-plus<strong> </strong>is not recommended.<p style=\"text-align: justify;\">Mothers taking Indapa-plus<strong> </strong>should not breast feed. </p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Packing : </strong>Indapa-Plus 2 :<strong> </strong>2x10's tablets\r\nin blister pack.</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong></strong>Indapa-Plus 4 :<strong> </strong>1x10's tablets\r\nin blister pack.</p><br><span xss=\"removed\"><span xss=\"removed\"><span xss=\"removed\"><span xss=\"removed\"><span xss=\"removed\"><p><span class=\"redactor-invisible-space\" xss=\"removed\"></span></p></span></span></span></span></span>",
    "strength": "1.25+4.00,0.625+2.00",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531803988Indapa_plus.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/images/Indapa-SR.jpg",
      "https://www.admin.drug-international.com/uploads/images/Indapa-SR.jpg"
    ]
  },
  {
    "id": "999",
    "name": "Indapa - SR",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Indapamide  1.5mg\r\nTablet.</span></p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Indapamide is indicated for\r\nthe treatment of essential hypertension.\r\nIndapamide is also indicated for the\r\ntreatment of edema, salt and fluid\r\nretention associated with congestive\r\nheart failure.</span></p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration : </strong>One\r\ntablet daily, preferably in the morning. If\r\nresponse is inadequate, dosage may be\r\nincreased. Or, as directed by the\r\nregistered physician.</p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">There are no adequate and well controlled\r\nstudies in pregnant woman.\r\nSo indapamide is not recommended.\r\nMothers taking indapamide should not\r\nbreast feed.</span></p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">3x14's tablets in\r\nblister pack.</span></p>",
    "strength": "1.5,1.25+4.00,0.625+2.00",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633326817Indapa SR.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744099946INDAPA-SR.png",
      "https://www.admin.drug-international.com/uploads/images/Indapa-SR.jpg",
      "https://www.admin.drug-international.com/uploads/images/Indapa-SR.jpg"
    ]
  },
  {
    "id": "1314",
    "name": "Iragon",
    "description": "<p><strong>Composition :\r\nIragon : </strong>Each\r\nextended release film coated tablet contains Mirabegron INN\r\n25mg.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong><o> </o></strong></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indications : </strong>Mirabegron is a\r\nbeta-3 adrenergic agonist indicated for the treatment of\r\noveractive bladder (OAB) with symptoms of urge urinary incontinence, urgency\r\nand urinary frequency.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong><o> </o></strong></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and\r\nadministration : </strong>The\r\nrecommended starting dose is 25 mg once daily with or\r\nwithout food. It is effective within 8 weeks. Based on individual efficacy and\r\ntolerability the dose may be increased to 50 mg once daily. It should be taken with\r\nwater, swallowed whole and should not be chewed, divided, or crushed. <strong>Patients with severe renal impairment or\r\npatients with moderate </strong><strong>hepatic impairment\r\n: </strong>Maximum\r\ndose is 25 mg once daily. Patients with end stage renal disease (ESRD)\r\nor patients with severe hepatic impairment : not recommended. Or, as directed\r\nby the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Use in pregnancy\r\nand lactation : </strong>Pregnancy\r\nCategory C. There are no adequate and\r\nwell-controlled studies using in pregnant women. It should be used during pregnancy\r\nonly if the potential benefit to the patient outweighs the risk to the fetus. It is\r\nnot known whether this tablet is excreted in human milk. A decision should be\r\nmade whether to discontinue nursing or to discontinue the drug, taking into\r\naccount the importance of the drug to the mother.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong><o> </o></strong></p><p style=\"text-align: justify;\"><strong>Packing : Iragon :\r\n</strong>Each\r\nbox contains 2 x 14's tablets in a blister pack.</p>",
    "strength": "25",
    "uom": "mg",
    "categoryId": "111",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531804106Iragon.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1522142499Iragon.jpg.jpg"
    ]
  },
  {
    "id": "1751",
    "name": "Irita",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition: Irita Injection: </strong>Each\r\nvial contains Irinotecan Hydrochloride USP 40 mg/2 ml Injection.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Irita-100\r\nInjection: </strong>Each vial Contains Irinotecan\r\nHydrochloride USP 100 mg/5 ml Injection.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>Irinotecan Injection is indicated as a component of first-line\r\ntherapy in combination with 5- Fluorouracil (5-FU) and Leucovorin (LV) for\r\npatients with metastatic carcinoma of the colon or rectum. It is indicated for\r\npatients with metastatic carcinoma of the colon or rectum whose disease has\r\nrecurred or progressed following initial Fluorouracil-based therapy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration: Colorectal cancer combination regimen 1: </strong>Irinotecan\r\n125 mg/m<sup>2 </sup>IV infusion over 90 minutes on days 1, 8, 15, 22 with LV\r\n20 mg/m<sup>2 </sup>IV bolus infusion on days 1, 8, 15, 22 followed by 5-FU IV bolus\r\ninfusion on days 1, 8, 15, 22 every 6 weeks. <strong>Colorectal cancer single agent\r\nregimen 1: </strong>Irinotecan 125 mg/m<sup>2 </sup>IV infusion over 90 minutes on\r\ndays 1, 8, 15, 22 then 2-week rest. Or, as directed by the registered\r\nphysician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and Lactation: Pregnancy category D. </strong>Irinotecan\r\ncan cause fetal harm when administered to a pregnant woman. It is not known weather\r\nthis drug excreted in human milk.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packaging:</strong>\r\n<strong>Irita Injection: </strong>Each box contains 1 vial of 2 ml Irinotecan\r\nHydrochloride USP injection (40 mg).</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Irita-100\r\nInjection: </strong>Each box contains 1 vial of 5 ml\r\nIrinotecan Hydrochloride USP injection (100 mg).</p>",
    "strength": "100,40 ",
    "uom": "mg/5ml",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1614420019",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1614420019Irita 100 Injection- Carton Pic.png",
      "https://www.admin.drug-international.com/uploads/product_images/1614420019Irita 2ml Injection- Carton Pic.png"
    ]
  },
  {
    "id": "1896",
    "name": "Itazol Capsule",
    "description": "<p><strong>Composition: </strong>Each capsule contains<strong> </strong>Itraconazole pellets eqv. to\r\nItraconazole USP 100mg. </p><p><strong>Indications: </strong>Itraconazole Capsules are indicated for the treatment of\r\nVulvovaginal candiasis, Oropharyngeal candiasis, Pityriasis versicolor, tinea\r\npedis, tinea cruris, tinea corporis, tinea manuum, Onychomycosis,\r\nHistoplasmosis. It is indicated in the treatment of following systematic fungal\r\nconditions when first-line systemic <span class=\"fontstyle01\">anti-fungal therapy is\r\ninappropriate or has</span> <span class=\"fontstyle01\">proved ineffective:</span> Cryptococcosis\r\n(including cryptococcal meningitis), Aspergillosis, Candiasis. It is also used in maintenance therapy in\r\nAIDS to prevent relapse of underlying fungal infections and in the prevention\r\nof fungal infection during prolonged neutropenia.</p><p class=\"Default\"><strong>Dosage & Administration: </strong>This\r\ncapsule must be taken immediately after a meal for maximal absorption.<strong> <o></o></strong></p><p class=\"Default\" xss=\"removed\"><!--[if !supportLists]-->·        \r\n<!--[endif]--><strong>For\r\nNon-Systemic fungal infections:</strong>  Vulvovaginal candidiasis: 200mg twice\r\ndaily for 1 day. Pityriasis\r\nversicolor: 200mg once daily for 7 days. Tinea corporis and tinea cruris: 100mg once daily for 15 days\r\nor 200mg once daily for 7 days. Tinea\r\npedis and tinea manuum:  100mg\r\nonce daily for 30 days. Oropharyngeal\r\ncandidosis: 100mg once daily (200mg once daily\r\nin AIDS or neutropenia) for 15 days. Onychomycosis\r\n(toenails with or without fingernails involvement): 200mg once daily for\r\n3months. or course (pulse) of 200mg twice daily for 7 days, subsequent courses\r\nrepeated after 21days interval; fingernails two courses and toenails three\r\ncourses.</p><p class=\"Default\" xss=\"removed\"><!--[if !supportLists]-->·        \r\n<!--[endif]--><strong>For\r\nSystemic fungal infections: </strong> Aspergillosis: 200mg once daily for\r\n2-5 months, Increase\r\ndose to 200mg twice daily in case of invasive or disseminated disease. Candidiasis: 100-200 mg once daily for 3 weeks-7 months, Increase dose to\r\n200 mg twice daily in case of invasive or disseminated disease. Non-meningeal\r\ncryptococcosis: 200mg once daily for 10 weeks. Cryptococcal meningitis: 200mg\r\nonce daily for 2 months- 6 months. Histoplasmosis: 200mg once daily- twice\r\ndaily for 8months. Maintenance in AIDS: 200mg once daily until immune recovery. Prophylaxis in\r\nneutropenia: 200mg twice daily until immune recovery. </p><p class=\"Default\" xss=\"removed\">The dose and duration of treatment for systemic fungal\r\ndisease should be adjusted depending on the clinical response. Or, as\r\ndirected by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation: </strong>Not recommended during pregnancy and\r\nlactation, unless otherwise indicated by the physician.<o></o></p><p><strong>Packing:\r\n</strong>Each<strong> </strong>box contains 20 capsules in Alu-Alu blister pack.</p>",
    "strength": "100",
    "uom": "mg",
    "categoryId": "40",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1703999515Itazol Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121056Itazol.png"
    ]
  },
  {
    "id": "1310",
    "name": "Ivaten",
    "description": "<p><strong></strong><strong>Composition :</strong> <span class=\"redactor-invisible-space\" xss=\"removed\">Ivabradine INN 5mg & 7.5mg Tablet.</span></p><p><strong>Indication :</strong> <span class=\"redactor-invisible-space\">Ivabradine is indicated for symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm, who has contraindications or intolerance with beta-blockers.</span></p><p><strong>Dosage and administration :</strong> <span class=\"redactor-invisible-space\">The usual recommended starting dose of Ivabradine is 5 mg twice daily after 3-4 weeks of treatment, the dose may be increased to 7.5mg twice daily depending on therapeutic response. It may be adjusted to 2.5mg twice daily as necessary. Or, as directed by the registered physician.</span></p><p><strong>Use in pregnancy and lactation :</strong> <span class=\"redactor-invisible-space\">Ivabradine is contra-indicated during pregnancy and lactation.</span></p><p><strong>Packing :</strong> <span class=\"redactor-invisible-space\" xss=\"removed\">Ivaten-5 : 1x10's tablets in blister pack.<br></span></p><p><span class=\"redactor-invisible-space\" xss=\"removed\"> Ivaten-7.5 : 1x10's tablets in blister pack.</span></p>",
    "strength": "7.5,5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531804202Ivaten.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/15305278271518608014ivaten.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/15305278271518608014ivaten.jpg"
    ]
  },
  {
    "id": "1765",
    "name": "Ivtin",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition :  Ivtin-6 : </strong>Each Tablet Contains Ivermectin\r\nUSP 6mg.<strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Ivtin-12: </strong>Each Tablet\r\nContains Ivermectin USP 12mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>                  </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications : </strong>It is used in\r\nthe treatment of Scabies caused by sarcoptes scabiei, Filariasis caused by\r\nWuchereria bancrofti (Lymphatic filariasis). It is also used in the treatment\r\nof Peaiculosis (head lice), Onchocerciasis, Strongyloidiasis and Trichuriasis.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and\r\nadministration :  </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>For\r\nStrongyloidiasis :</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\">\r\n <tbody><tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"186\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">Body Weight\r\n  (Kg)<strong></strong></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"186\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">Dose</p>\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"186\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">15-24<strong></strong></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"186\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">3 mg</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"186\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">25-35<strong></strong></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"186\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"> 6 mg</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"186\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">36-60<strong></strong></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"186\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">9\r\n  mg</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"186\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">51-60<strong></strong></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"186\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">12\r\n  mg</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"186\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">66-79<strong></strong></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"186\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">15mg</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"186\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">&gt;80<strong></strong></p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"186\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">200\r\n  mcg/Kg<strong></strong></p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\" xss=\"removed\">                        <strong></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Ivtin </strong>Tablet should be\r\nadministered as a single dose with a full glass of water on an empty stomach.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>For\r\nOnchocerciasis :</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\"><tbody><tr xss=\"removed\"><td xss=\"removed\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">Body Weight\r\n  (Kg)<strong></strong></p></td><td xss=\"removed\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">Dose</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">15-25</p></td><td xss=\"removed\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"> 3 mg</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">26-44</p></td><td xss=\"removed\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"> 6 mg</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">45-64</p></td><td xss=\"removed\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"> 9 mg</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">65-84</p></td><td xss=\"removed\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"> 12mg_</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">&gt;80</p></td><td xss=\"removed\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"> 150 mcg/Kg</p></td></tr></tbody></table><p class=\"MsoNormal\" xss=\"removed\"><strong>Ivtin </strong>Tablet should be\r\nadministered as a single dose with a full glass of water on an empty stomach.</p><p class=\"MsoNormal\" xss=\"removed\">For\r\nthe treatment of Scabies & Head lice, lvermection should be taken as 200\r\nmcg/kg body weight & for Filariasis. Ivermection should be taken as\r\n150mcg/kg body weight (in both cases, Ivermectin should be taken with a full\r\nglass of water on an empty stomach).</p><p class=\"MsoNormal\" xss=\"removed\">Or, as directed by the registered\r\nphysician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy\r\nand lactation : </strong>Safe\r\nworsening of bronchial asthma and efficacy have not been established for\r\npregnant or lacting women.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing : Ivtin-6\r\n: </strong>Each\r\nbox contains 1 x 10's tablet in blister pack.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Ivtin-12 : </strong>Each box\r\ncontains 1 x 10's tablet in blister pack.</p>",
    "strength": "12,6",
    "uom": "mg",
    "categoryId": "121",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1621767156Ivtin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100426Ivtin-12.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744100426Ivtin-6.png"
    ]
  },
  {
    "id": "826",
    "name": "Kingdol",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Tramadol Hydrochloride\r\n50 mg Capsule.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong>It is indicated for the\r\ntreatment of moderate to severe pain. </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\"><strong>Adult &\r\nchildren over 12 years :</strong> For acute pain\r\n: an initial dose of 100 mg is usually\r\nnecessary. This can be followed by\r\ndoses of 50 mg or 100 mg not more\r\nfrequently than 4 hourly and duration of\r\ntherapy should be matched to clinical\r\nneed. The total daily dosage by mouth\r\nshould not exceed 400 mg. For chronic\r\npain : an initial dose of 50mg is\r\nrecommended and then subsequent\r\ndoses are maintained according to pain\r\nseverity. Or, as directed by the registered\r\nphysicians.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">There are no adequate and wellcontrolled\r\nstudies in pregnant women.\r\nTramadol should be used during\r\npregnancy only if the potential benefit\r\njustifies the potential risk to the fetus.\r\nTramadol has been detected in human\r\nbreast milk. A decision should be made\r\nwhether to discontinue nursing or to\r\ndiscontinue the drug, taking into account\r\nthe importance of the drug to the mother.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong> Kingdol 3 x 10's capsules in\r\nblister pack.</p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/pdf/kingdol.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745121038Kingdol.png"
    ]
  },
  {
    "id": "1879",
    "name": "Lamocard",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Composition: Lamocard\r\n2.5: </strong>Each\r\ntablet contains Levamlodipine2.5mg as Levamlodipine Maleate INN 3.21mg.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Lamocard 5: </strong>Each tablet contains\r\nLevamlodipine 5.00 mg as Levamlodipine Maleate INN 6.40mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><br></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong>Indication: </strong>S-Amlodipine\r\nis calcium channel blocker and may be used alone or in combination with other\r\nantihypertensive agents for the treatment of hypertension, to lower blood\r\npressure. Lowering blood pressure reduces the risk of fatal and nonfatal\r\ncardiovascular events, primarily strokes and myocardial infarctions.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><br></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-outline-level:4\"><strong>Dosage\r\n& Administration</strong>:<strong>Adults</strong>: The usual initial antihypertensive\r\noral dose of S-Amlodipine is 2.5 mg once daily, and the maximum dose is 5 mg\r\nonce daily. Small, fragile, or elderly patients, or patients with hepatic\r\ninsufficiency may be started on 1.25 mg once daily and this dose may be used\r\nwhen adding S-Amlodipine to other antihypertensive therapy. Adjust dosage\r\naccording to blood pressure goals. In general, wait 7 to 14 days between\r\ntitration steps. <strong>Children</strong>: The effective antihypertensive oral\r\ndose in pediatric <a name=\"_GoBack\"></a>patient’s ages 6-17 years is 1.25 mg to\r\n2.5 mg once daily. Doses in excess of 2.5 mg daily have not been studied in\r\npediatric patients. Or, as directed by the registered physician</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-outline-level:4\">. <o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-outline-level:4\"><strong>Pregnancy & Lactation: </strong>The\r\nlimited available data based on post-marketing reports with amlodipine use in\r\npregnant women are not sufficient to inform a drug-associated risk for major\r\nbirth defects and miscarriage. There\r\nare risks to the mother and fetus associated with poorly controlled\r\nhypertension in pregnancy.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-outline-level:4\"><br></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-outline-level:4\"><strong>Packing: </strong><strong>Lamocard 2.5:</strong><strong> </strong>Each\r\nbox contains 30’s tablets in blister pack.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-outline-level:4\"><strong>Lamocard 5: </strong>Lamocard 5: Each\r\nbox contains 30’s tablets in blister pack<br></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-outline-level:4\"><strong></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-outline-level:4\"><br></p>",
    "strength": "5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1687173029Lamocard-5 Insert (Not Usual Web Format).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100531LAMOCARD-5.png"
    ]
  },
  {
    "id": "1735",
    "name": "Lanib-10",
    "description": "<p><strong>Composition: Lanib-10: </strong>Each\r\ncapsule contains Lenvatinib 10mg as Lenvatinib Mesylate INN.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications</strong>:\r\n<strong>Differentiated Thyroid Cancer: </strong>Lenvatinib is indicated for the treatment\r\nof patients with locally recurrent or metastatic, progressive, radioactive\r\niodine-refractory differentiated thyroid cancer (DTC). <strong>Renal Cell Carcinoma:\r\n</strong>Lenvatinib is indicated in combination with everolimus for the treatment of\r\npatients with advanced renal cell carcinoma (RCC) following one prior\r\nanti-angiogenic therapy. <strong>Hepatocellular Carcinoma: </strong>Lenvatinib is\r\nindicated for the first-line treatment of patients with unresectable\r\nhepatocellular carcinoma (HCC). <strong>Endometrial Carcinoma: </strong>Lenvatinib, in\r\ncombination with Pembrolizumab, is indicated for the treatment of patients with\r\nadvanced endometrial carcinoma that is not microsatellite instability-high\r\n(MSI-H) or mismatch repair deficient (dMMR), who have disease progression following\r\nprior systemic therapy and are not candidates for curative surgery or\r\nradiation. This indication is approved under accelerated approval based on\r\ntumor response rate and durability of response. Continued approval for this\r\nindication may be contingent upon verification and description of clinical\r\nbenefit in the confirmatory trial.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage and\r\nadministration:</strong> <strong>Recommended Dosage for\r\nDifferentiated Thyroid Cancer (DTC): </strong>The recommended dosage of Lenvatinib\r\nis 24 mg orally once daily until disease progression or until unacceptable\r\ntoxicity. <strong>Recommended Dosage for Renal Cell Carcinoma (RCC): </strong>The\r\nrecommended dosage of Lenvatinib is 18 mg in combination with 5 mg Everolimus\r\norally once daily until disease progression or until unacceptable toxicity.\r\nRefer to Everolimus prescribing information for recommended Everolimus dosing\r\ninformation. <strong>Recommended Dosage for Hepatocellular Carcinoma (HCC): </strong>The\r\nrecommended dosage of Lenvatinib is based on actual body weight: <strong>i)</strong> 12 mg for patients greater than or\r\nequal to 60 kg or <strong>ii)</strong> 8 mg for\r\npatients less than 60 kg. Lenvatinib should be taken orally once daily until\r\ndisease progression or until unacceptable toxicity. <strong>Recommended Dosage for\r\nEndometrial Carcinoma: </strong>The recommended dosage of Lenvatinib is 20 mg orally\r\nonce daily, in combination with Pembrolizumab 200 mg administered as an\r\nintravenous infusion over 30 minutes every 3 weeks, until unacceptable toxicity\r\nor disease progression. Refer to the Pembrolizumab prescribing information for\r\nrecommended Pembrolizumab dosing information. Or, as directed by the registered\r\nphysicians.</p><p class=\"MsoNormal\" style=\"text-align:justify\">\r\n<strong>Use in Pregnancy and Lactation: </strong>Based on the mechanism of action,\r\nLenvatinib can cause embryo-fetal harm when administered to a pregnant female.\r\nPregnant women should be advised of the potential risk to a fetus. Females of\r\nreproductive potential should be advised to use effective contraception during\r\ntreatment with Lenvatinib and for at least 30 days after the last dose. It is\r\nnot known whether Lenvatinib is present in human milk. Because of the potential\r\nfor serious adverse reactions in breastfed infants, women should be advised to\r\ndiscontinue breastfeeding during treatment with Lenvatinib and for at least 1\r\nweek after the last dose.</p>\r\n\r\n<p class=\"MsoNormal\"><strong>Packing: Lanib-10: </strong>Each\r\ncontainer contains 30 capsules in a box.<br>\r\n<br>\r\n<!--[if !supportLineBreakNewLine]--><br>\r\n<!--[endif]--><o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\"><br>\r\n<!--[if !supportLineBreakNewLine]--><br>\r\n<!--[endif]--><o:p></o:p></p>",
    "strength": "10",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1577791088Lanib 4 & 10- Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1577791088Lanib-10- 30 Cap Carton Bottle Pic.png"
    ]
  },
  {
    "id": "1752",
    "name": "Lanib-4",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:</strong> Each capsule\r\ncontains Lenvatinib 4 mg as Lenvatinib Mesylate INN.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong>\r\n<strong>Differentiated Thyroid Cancer: </strong>Lenvatinib is indicated for the treatment\r\nof patients with locally recurrent or metastatic, progressive, radioactive\r\niodine-refractory differentiated thyroid cancer (DTC). <strong>Renal Cell Carcinoma:\r\n</strong>Lenvatinib is indicated in combination with Everolimus for the treatment of\r\npatients with advanced renal cell carcinoma (RCC) following one prior\r\nanti-angiogenic therapy. <strong>Hepatocellular Carcinoma: </strong>Lenvatinib is\r\nindicated for the first-line treatment of patients with unresectable\r\nhepatocellular carcinoma (HCC). <strong>Endometrial Carcinoma: </strong>Lenvatinib, in\r\ncombination with Pembrolizumab, is indicated for the treatment of patients with\r\nadvanced endometrial carcinoma.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand Administration: Recommended Dosage\r\nfor Differentiated Thyroid Cancer (DTC): </strong>The\r\nrecommended dosage of Lenvatinib is 24 mg orally once daily until disease\r\nprogression or until unacceptable toxicity. <strong>Recommended Dosage for Renal\r\nCell Carcinoma (RCC): </strong>The recommended dosage of Lenvatinib is 18 mg in\r\ncombination with 5 mg Everolimus orally once daily until disease progression or\r\nuntil unacceptable toxicity. <strong>Recommended Dosage for Hepatocellular Carcinoma\r\n(HCC): </strong>The recommended dosage of Lenvatinib is based on actual body weight.\r\nOr, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and\r\nLactation: </strong>Based on the mechanism of action,\r\nLenvatinib can cause embryo-fetal harm when administered to a pregnant female.\r\nPregnant women should be advised of the potential risk to a fetus. Females of\r\nreproductive potential should be advised to use effective contraception during\r\ntreatment with Lenvatinib and for at least 30 days after the last dose.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: </strong>Each\r\nbox contains 30 capsules in a blister pack.</p>",
    "strength": "4",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1614420433Lanib-4 Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1614420433Lanib-4 - Carton Pic.png"
    ]
  },
  {
    "id": "1734",
    "name": "Lanib-4 CH",
    "description": "",
    "strength": "4",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1577793657Lanib 4 & 10- Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1577790075Lanib-4- 30 Cap Carton Bottle Pic.png"
    ]
  },
  {
    "id": "797",
    "name": "LANSEC",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Lansoprazole USP 15 mg & 30 mg\r\nCapsule.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Healing and long term management of\r\ngastroesophageal reflux disease. Healing and\r\nmaintenance therapy for patients with duodenal\r\nulcer. Relief of reflux-like symptoms (eg. Heartburn)\r\nand/or ulcer-like symptoms (eg. upper epigastric\r\npain) associated with acid-related dyspepsia. Healing\r\nof benign gastric ulcer. Lansec is also effective in\r\npatients with benign peptic lesions, including reflux\r\noesophagitis, unresponsive to H2 receptor\r\nantagonists. Eradication of H.pylori from the upper\r\ngastro-intestinal tract in patients with duodenal ulcer\r\nor gastritis when used in combination with\r\nappropriate antibiotics. </span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong>Please see prescribing description.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Lansoprazole has\r\nbeen assigned to pregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Lansec-15 : 6 x 10's capsules in blister pack.\r\n<br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Lansec-30 : 5 x 10's capsules in blister pack.</span></p>",
    "strength": "30,15",
    "uom": "mg",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531805041Lansec.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100592LANSEC-30.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744100592LANSEC-15.png"
    ]
  },
  {
    "id": "1824",
    "name": "Latinib",
    "description": "<p><strong>COMPOSITION</strong>:\r\nEach tablet contains Lapatinib 250mg as Lapatinib Ditosylate Monohydrate INN.</p>\r\n\r\n<p class=\"MsoNormal\"><br>\r\n<strong>INDICATIONS:</strong> <strong>Lapatinib is\r\nindicated in combination with:</strong><br>\r\n• Capecitabine for the treatment of patients with advanced or metastatic breast\r\ncancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2)\r\nand who have received prior therapy including an Anthracycline, a Taxane, and\r\nTrastuzumab. <strong>Limitations of Use:</strong>\r\nPatients should have disease progression on Trastuzumab prior to initiation\r\noftreatment with Lapatinib in combination with Capecitabine.<br>\r\n• Letrozole for the treatment of postmenopausal women with hormone\r\nreceptor-positive metastatic breast cancer that overexpresses the HER2 receptor\r\nfor whom hormonal therapy is indicated. Lapatinib in combination with an\r\naromatase inhibitor has not been compared to a Trastuzumab-containing\r\nchemotherapy regimen for the treatment of metastatic breast cancer.<o></o></p>\r\n\r\n<p class=\"MsoNormal\"><strong>DOSAGE AND ADMINISTRATION</strong>:\r\n<strong>Recommended Dosing:</strong> <strong>HER2-Positive Metastatic Breast Cancer: </strong>The\r\nrecommended dose of Lapatinib is 1,250 mg given orally once daily on Days 1-21\r\ncontinuously in combination with Capecitabine 2,000 mg/m2/day (administered\r\norally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating\r\n21-day cycle. Lapatinib should be taken at least one hour before or one hour\r\nafter a meal. The dose of Lapatinib should be once daily (5 tablets\r\nadministered all at once); dividing the daily dose is not recommended.\r\nCapecitabine should be taken with food or within 30 minutes after food. If a\r\nday’s dose is missed, the patient should not double the dose the next day.\r\nTreatment should be continued until disease progression or unacceptable\r\ntoxicity occurs. <strong>Hormone Receptor-Positive, HER2-Positive Metastatic Breast\r\nCancer: </strong>The recommended dose of Lapatinib is 1,500 mg given orally once\r\ndaily continuously in combination with Letrozole. When coadministered with\r\nLapatinib, the recommended dose of Letrozole is 2.5 mg once daily. Lapatinib\r\nshould be taken at least one hour before or one hour after a meal. The dose of\r\nLapatinib should be once daily (6 tablets administered all at once); dividing\r\nthe daily dose is not recommended. Or, as directed by the registered physicians.<o></o></p>\r\n\r\n<p class=\"MsoNormal\"><strong>Use in Pregnancy& Lactation: </strong>Based\r\non findings in animal studies and its mechanism of action, Lapatinib can cause\r\nfetal harm when administered to a pregnant woman. There are no available human\r\ndata to inform of the drug associated risks. Advise pregnant women and females\r\nof reproductive potential of the potential risk to the fetus.<o></o></p>\r\n\r\n<p><strong>Packing: </strong>Each\r\ncontainer contains 30 tablets in a box.</p>",
    "strength": "250",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1643535207Latinib- 30 Tablet - Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1643535207Latinib 250mg 30 Tablet- Bottle Carton Pic(1).png"
    ]
  },
  {
    "id": "1853",
    "name": "Leroid",
    "description": "<p><strong>Composition:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><a name=\"_GoBack\"></a></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Leroid\r\n25 Tablet: </strong>Each Tablet Contains 25 mcg as Levothyroxine Sodium\r\npentahydrate BP.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Leroid\r\n50 Tablet: </strong>Each Tablet Contains 50 mcg as Levothyroxine Sodium\r\npentahydrate BP.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>It is indicated\r\nfor the treatment of- Hypothyroidism, Primary (thyroidal), secondary\r\n(pituitary), tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism.  Pituitary TSH Suppression: In the treatment\r\nor prevention of various types of euthyroidgoiters, subacute or chronic\r\nlymphocytic thyroiditis (Hashimoto's thyroiditis),multinodular goiter and as an\r\nadjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent\r\nwell-differentiated thyroid cancer.<strong><o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Dosage\r\nand administration: Adult Dosage:</strong>In order to\r\navoid irregular absorption leroid tablets should be taken preferably at a fixed\r\ntime on an empty stomach. Concomitant intake of food may decrease the\r\nabsorption of Levothyroxine. Dosing must be individualized and adjustments to\r\nbe made based on periodic assessment of the patients clinical response and laboratory\r\nparameters. Adult Dosage: Initial starting dose: 25-50 mcg/day, with gradual\r\nincrements in dose at 6-8 week intervals, as needed. The Levothyroxine Sodium\r\ndose is generally adjusted in 12.5-25 mcg increments until the patient with\r\nprimary hypothyroidism is clinically euthyroid and the serum TSH has normalized.\r\nIn patients with severe hypothyroidism: Initial dose is 12.5-25 mcg/day with\r\nincreases of 25 mcg/day every 2-4 weeks, accompanied by clinical and laboratory\r\nassessment, until the TSH level is normalized. In patients with secondary (pituitary)\r\nor tertiary (hypothalamic) hypothyroidism: Levothyroxine Sodium dose should be\r\ntitrated until the patient is clinically euthyroid and the serum free - Th\r\nlevel is restored to the upper half of the normal range. For patients older\r\nthan 50 years or for patients under 50 years of age with underlying cardiac\r\ndisease: An initial dose of 25-50 mcg/day is recommended with gradual\r\nincrements in dose at 6-8 week intervals. Please see the attached Insert for any details.</p><p class=\"MsoNormal\" xss=\"removed\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Pregnancy and lactation:</strong>Pregnancy-Category A.\r\nPregnancy may increase Levothyroxine requirements. Nursing Mother- Although\r\nthyroid hormones are excreted only minimally in human milk, caution should be exercised\r\nwhen it is administered to a nursing woman. However, adequate replacement doses\r\nof Levothyroxine are generally needed to maintain normal lactation.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:Leroid\r\n25 Tablet:</strong>Each box contains 90’s tablets in blister pack.<strong><o></o></strong></p><p><strong>Leroid 50 Tablet:</strong> Each box\r\ncontains 90’stablets in blister\r\npack.</p>",
    "strength": "50,25",
    "uom": "Mcg",
    "categoryId": "123",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1668492403",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100687Leroid 50.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744100687Leroid 25.png"
    ]
  },
  {
    "id": "1364",
    "name": "Letrozol",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>COMPOSITION</strong></p><p class=\"MsoNormal\" xss=\"removed\">Each film coated tablet contains Letrozole\r\nUSP 2.5mg Tablet.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>INDICATIONS</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Adjuvant\r\nTreatment of Early Breast Cancer:</strong>\r\nIt is indicated for the adjuvant treatment of postmenopausal women with hormone\r\nreceptor positive early breast cancer.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Extended\r\nAdjuvant Treatment of Early Breast Cancer:</strong> It is indicated for the extended adjuvant treatment\r\nof early breast cancer in postmenopausal women, who have received 5 years of\r\nadjuvant tamoxifen therapy. The effectiveness of Letrozole in extended adjuvant\r\ntreatment of early breast cancer is based on an analysis of disease-free\r\nsurvival in patients treated with Letrozole for a median of 60 months.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>First\r\nand Second-Line Treatment of Advanced Breast Cancer:</strong> It is indicated for first-line\r\ntreatment of postmenopausal women with hormone receptor positive or unknown,\r\nlocally advanced or metastatic breast cancer. Letrozole is also indicated for the\r\ntreatment of advanced breast cancer in postmenopausal women with disease\r\nprogression following antiestrogen therapy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>DOSAGE\r\nAND ADMINISTRATION</strong></p><p class=\"MsoNormal\" xss=\"removed\">The recommended dose of Letrozole is\r\none 2.5 mg tablet administered once a day, without regard to meals.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Adjuvant Treatment of Early Breast Cancer:</strong> In the adjuvant setting, the optimal duration of\r\ntreatment with Letrozole is unknown. In both the adjuvant study and the post approval\r\nadjuvant study, median treatment duration was 5 years. Treatment should be discontinued\r\nat relapse.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Extended Adjuvant Treatment of Early Breast Cancer:</strong> In the extended adjuvant setting,\r\nthe optimal treatment duration with Letrozole is not known. The planned\r\nduration of treatment in the study was 5 years. In the final updated analysis,\r\nconducted at a median follow-up of 62 months, the median treatment duration for\r\nLetrozole was 60 months. Seventy-one (71%) percent of patients were treated for\r\nat least 3 years and 58% of patients completed at least 4.5 years of extended\r\nadjuvant treatment. The treatment should be discontinued at tumor relapse.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin First and Second-Line Treatment of Advanced Breast Cancer:</strong> In patients with advanced disease,\r\ntreatment with Letrozole should continue until tumor progression is evident. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Hepatic Impairment:</strong>\r\nNo dosage adjustment is recommended for patients with mild to moderate hepatic\r\nimpairment. The dose of Letrozole in patients with cirrhosis and severe hepatic\r\ndysfunction should be reduced by 50%. The recommended dose of Letrozole for such\r\npatients is 2.5 mg administered every other day. The effect of hepatic\r\nimpairment on Letrozole exposure in noncirrhotic cancer patients with elevated\r\nbilirubin levels has not been determined.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Renal Impairment: </strong>No\r\ndosage adjustment is required for patients with renal impairment if creatinine\r\nclearance is greater than or equal to 10 ml/min.</p><p class=\"MsoNormal\" xss=\"removed\">Or, as directed by the registered\r\nphysician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy:</strong></p><p class=\"MsoNormal\" xss=\"removed\">Pregnancy Category\r\nD.</p><p class=\"MsoNormal\" xss=\"removed\">Letrozole can cause fetal harm and\r\nis contraindicated for use in women. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Lactation:</strong></p><p class=\"MsoNormal\" xss=\"removed\">It is not known if Letrozole\r\nis present in human milk. Because of the potential for serious adverse\r\nreactions in breastfed infants from Letrozole, lactating women should be\r\nadvised not to breastfeed while taking Letrozole and for at least 3 weeks after\r\nthe last dose.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:</strong> <strong>Letrozol:</strong> Each box contains 10 tablets in Alu-Alu blister pack.</p>",
    "strength": "2.5",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1683110986Letrozol Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100743Letrozol.png"
    ]
  },
  {
    "id": "872",
    "name": "LEVOFLOX",
    "description": "<p><strong>Composition : </strong>Levofloxacin INN 5mg / ml.</p><p style=\"text-align: justify;\"><strong>Indication :</strong> Levoflox eye drop is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive, gram-negative micro organisms. In some study it has been found that Levofloxacin is indicated in post-operative ocular infection.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong> Day 1 & 2\r\n: Instill 1-2 drops in the affected eye (s)\r\nevery 2 hours while awake, up to 8 times\r\nper day. Days 3 through 7 : Instill 1-2\r\ndrops in the affected eye (s) every 4\r\nhours while awake, up to 4 times per\r\nday. Or as directed by the registered\r\nphysician.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong> Pregnancy Category C by FDA.</p><p style=\"text-align: justify;\"><strong>Packing : </strong> 5ml in plastic dropper bottle.</p>",
    "strength": "0.50",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531805286LEVOFLOX.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745147167Levoflox 5ml.png"
    ]
  },
  {
    "id": "787",
    "name": "Levoflox Tablet",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Levofloxacin 500mg & 750mg\r\nTablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong>Levofloxacin is indicated for the\r\ntreatment of mild, moderate, and severe\r\ninfections caused by susceptible strains of the\r\ndesignated micro-organisms in the condition\r\nlisted below: Acute maxillary sinusitis due to\r\nStreptococcus pneumoniae, Haemophilus\r\ninfluenzae, or Moraxella catarrhalis. Acute\r\nbacterial exacerbation of chronic bronchitis due\r\nto Staphylococcus aureus, Streptococcus\r\npneumoniae, Haemophilus influenzae, or\r\nMoraxella catarrhalis. Community-acquired\r\npneumonia due to Staphylococcus aureus,\r\nStreptococcus pneumoniae, Haemophilus\r\ninfluenzae, Klebsiella pneumoniae, Moraxella\r\ncatarrhalis, Chlamydia pneumoniae, Legionella\r\npneumophila, or Mycoplasma pneumoniae. Uncomplicated & complicated urinary tract\r\ninfections due to Escherichia coli, Klebsiella\r\npneumoniae, or Staphylococcus saprophyticus. Acute pyelonephritis caused by Escherichia coli.\r\nUncomplicated & complicated skin and soft\r\ntissue infections including abscesses, cellulitis,\r\nfuruncles, impetigo, pyoderma, wound infections,\r\ndue to Staphylococcus aureus, Streptococcus\r\npyogenes, Proteus mirabilis or Enterococcus\r\nfaecalis. Enteric infections caused by\r\nEnterobacter sp., Escherichia coli,\r\nCampylobacter sp., Vibrio cholerae, Shigella sp.,\r\nSalmonella sp. </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\"> Acute sinusitis: 500mg once daily for\r\n10-14 days or 750mg once daily for 5 days. Acute Exacerbation of chronic bronchitis: 500mg once\r\ndaily for 7 days, or 750mg once daily for 3 days\r\n(Uncomplicated), 750mg once daily for 5 days\r\n(Complicated).  Community-acquired\r\npneumonia: 500mg once daily for 7-14 days, or\r\n750mg once daily for 5 days. l Uncomplicated\r\nurinary-tract infections: 250mg once daily for 3\r\ndays. l Complicated urinary-tract infections and\r\nacute pyelonephritis: 250mg once daily for 7-10\r\ndays.  Uncomplicated skin and soft-tissue\r\ninfections: 500mg once daily for 7-10 days. Complicated skin and soft-tissue infections:\r\n750mg once daily for 7-14 days.  Enteric fever:\r\n500mg once daily for 7-14 days.  Diarrhea,\r\ncholera, shigellosis & enteritis: Mild to moderate\r\ncase: 500mg (single dose), Moderate to sever\r\ncase: 500mg once daily for 3 days. Or, as\r\ndirected by the registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong> Levofloxacin\r\nhas been assigned to pregnancy category C by\r\nthe FDA. It can be presumed that Levofloxacin\r\nwill be excreted in human milk. Because of the\r\npotential for serious adverse reaction from\r\nLevofloxacin in nursing infants, a decision should\r\nbe made whether to discontinue nursing or to\r\ndiscontinue the drug, taking into account the\r\nimportance of the drug to the mother.</p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Levoflox-500 : 2 x 10's tablets in blister pack.\r\n<br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Levoflox-750 : 2 x 5's tablets in blister pack.</span></p>",
    "strength": "750,500",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/pdf/Furex.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1617786063Levoflox-750 Carton Pic.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745147136Levoflox 500.png"
    ]
  },
  {
    "id": "1901",
    "name": "Liazol",
    "description": "<p><strong>Composition:\r\nLiazol Nasal Spray: </strong>Each Metered Spray Contains Oxymetazoline\r\nHydrochloride USP 25mcg.</p><p><strong>Indications:\r\n</strong>OxymetazolineHydrochloride\r\nis applied topically to relieve nasal congestion associated with acute or chronic\r\nrhinitis, common cold, sinusitis and hay fever or other allergies. It is also\r\nused as nasal decongestant in otitis media.<br></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration: Liazol Nasal Spray:</strong>Adults and\r\nchildren (6 years of age and older): 2 or 3 sprays in each nostril twice daily\r\nfor 3-5 days. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Pregnancy and Lactation: </strong>Pregnancy:\r\nSafe use of Oxymetazoline during pregnancy has not been established. It should\r\nbe avoided by pregnant women. Nursing Mother: It is not known whether\r\nOxymetazoline is secreted in human breast milk; Caution is advised.</p><p><strong>Packing:\r\nLiazol<a name=\"_GoBack\"></a> Nasal Spray : </strong>Each\r\ncontainer contains 200 metered doses for sprays.</p>",
    "strength": "25mcg",
    "uom": "mcg/Spray",
    "categoryId": "56",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1709100830Liazol Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100788Liazol.png"
    ]
  },
  {
    "id": "1871",
    "name": "Licerin",
    "description": "",
    "strength": "30,15",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1683020721",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745147601LICERIN 30gm.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745147601LICERIN 15gm.png"
    ]
  },
  {
    "id": "1878",
    "name": "Ligotin",
    "description": "<p><strong>Composition\r\n:Ligotin 12.5 Tablet : </strong>Each film coated tablet contains Alogliptin 12.5mg\r\n(as Alogliptin Benzoate INN).</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Ligotin 25\r\nTablet :</strong>Each\r\nfilm coated tablet contains Alogliptin 25mg (as Alogliptin Benzoate INN).</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications :</strong>Alogliptin\r\nis indicated as an adjunct to diet and exercise to improve glycemic control in\r\nadults with type 2 diabetes mellitus.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage and\r\nadministration :</strong>Individualize the starting dose of\r\nAlogliptin based on the patient's current regimen with or without food. The maximum\r\nrecommended dose is 25 mg once daily. No dose adjustment of Alogliptin is\r\nnecessary for patients with mild renal impairment (creatinine clearance [CrCI]\r\n&gt;60 mL/min). The dose of Alogliptin is 12.5 mg once daily for patients with\r\nmoderate renal impairment (CrCI&gt;30 to &lt;60 mL/min). The dose of Alogliptin\r\nis 6.25 mg once daily for patients with severe renal impairment (CrCI&gt;15 to\r\n&lt;30 mL/min) or with end-stage renal disease (ESRD) (CrCl&lt;15 mL/min or\r\nrequiring hemodialysis). Or, as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Use in pregnancy and\r\nlactation :</strong>Pregnancy category B . There are no\r\nadequate and well controlled studies in pregnant woman. This tablets should be\r\nused during pregnancy only if clearly needed. Caution should be exercised when\r\nthis tablet is administered to a nursing woman.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Storage :</strong>Store\r\nbelow 30° C in a dry place.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Packing :Ligotin 12.5\r\nTablet : </strong>Each box contains 28’s tablets in blister pack.<o:p></o:p></p><p><strong>Ligotin 25 Tablet :</strong>Each\r\nbox contains 30’s tablets in blister pack.</p>",
    "strength": " 25,12.5",
    "uom": "mg",
    "categoryId": "93",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740571127Ligotin 25.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740571127Ligotin 12.5.png"
    ]
  },
  {
    "id": "927",
    "name": "Limpet",
    "description": "<p><strong>Composition : </strong><strong>Limpet-1: </strong> <span class=\"redactor-invisible-space\">Glimepiride USP 1mg Tablet.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Limpet-2: </strong>Glimepiride USP 2mg Tablet.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Limpet-3: </strong>Glimepiride USP 3mg Tablet.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"> <strong>Limpet-4: </strong>Glimepiride USP 4mg Tablet.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication :</strong>Limpet is indicated as an\r\nadjunct to diet and exercise to lower the\r\nblood glucose in patients with non-insulin\r\ndependent (Type-II) diabetes mellitus\r\n(NIDDM) whose hyperglycaemia cannot be\r\ncontrolled by diet and exercise alone. Limpet\r\nmay be used concomitantly with metformin\r\nwhen diet, exercise, and Limpet or metformin\r\nalone do not result in adequate glycemic\r\ncontrol. Limpet is also indicated for use in\r\ncombination with insulin to lower blood\r\nglucose in patients whose hyperglycaemia\r\ncan not be controlled by diet and exercise in\r\nconjunction with an oral hypoglycaemic\r\nagent.Becovent is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Becovent is also indicated for asthma patients who require systemic corticosteroid administration, where adding Becovent may reduce or eliminate the need for the systemic corticosteroids. </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The usual\r\nstarting dose of Limpet as initial therapy is 1-\r\n2mg once daily, administered with breakfast\r\nor the first main meal. The usual maintenance\r\ndose is 1-4mg once daily. The maximum\r\nrecommended dose is 8mg once daily. or, as\r\ndirected by the registered physicians.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :  </strong><span class=\"redactor-invisible-space\">Limpet\r\nhas been assigned to pregnancy category C by\r\nthe FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\">Limpet-1 : 4 x 14's tablets in blister pack</p><p style=\"text-align: justify;\">Limpet-2 : 4 x 14's tablets in blister pack. </p><p style=\"text-align: justify;\">Limpet-3 : 2 x 14's tablets in blister pack. </p><p style=\"text-align: justify;\">Limpet-4 : 2 x 14's tablets in blister pack.</p>",
    "strength": "4,3,2,1",
    "uom": "mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531805618Limpet.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740568676limpet-4.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740568676limpet 3.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740568676limpet 2.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740568676limpet 1.png"
    ]
  },
  {
    "id": "1743",
    "name": "Limpet M-1",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:\r\n</strong>Each Film Coated Tablet ContainsGlimepiride USP 1 mg and\r\nMetformin HydrochlorideUSP 500 mg as Extended Release.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication:\r\n</strong>This combination is indicated as an adjunctto diet and\r\nexercise to improve glycemic control inadults with type 2 diabetes mellitus\r\nwhen treatment withboth Glimepiride and Metformin is appropriate or incases\r\nwhere Glimepiride/Metformin mono-therapy doesnot result in adequate glycemic\r\ncontrol.</p><p class=\"MsoNormal\" xss=\"removed\"><a name=\"_GoBack\"></a> </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\n& administration: </strong>The initial recommendeddose of\r\nGlimepiride and Metformin combination tabletGlimepiride 1 mg and Metformin HCL\r\n500 mg XR tabletonce daily with breakfast or first main meal of the\r\nday.Starting dose for patients inadequately controlled on</p><p class=\"MsoNormal\" xss=\"removed\">Glimepiride or Metformin monotherapy is Limpet-M 1once daily, and\r\ngradually titrated after assessing thetherapeutic response. Titration: The\r\ndaily dose must betitrated in increments of 1 tablet. The maximumrecommended\r\ndose per day is 8 mg Glimepiride and2000 mg Metformin. When switching from\r\ncombinationtherapy of Glimepiride plus Metformin to separatetablets,\r\nGlimepiride and Metformin should beadministered separately on the basis of\r\ndosagecurrently being taken. When Glimepiride and Metformincombination tablet\r\nis used in combination or with insulin,a lower dose of the Glimepiride or\r\ninsulin may berequired to reduce the risk of hypoglycemia. Or, asdirected by\r\nthe registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation: </strong>The use of thiscombination is not\r\nrecommended in pregnancy &lactation.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:\r\n</strong>Each box contains 3 x 7's tablets in blisterpack.</p>",
    "strength": "1+500",
    "uom": "mg",
    "categoryId": "93",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1614244655Limpet-M 1 (1).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740568753limpet-m 1.png"
    ]
  },
  {
    "id": "1762",
    "name": "Limpet M-2",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:\r\n</strong>Each Film Coated Tablet Contains Glimepiride USP 2 mg and\r\nMetformin Hydrochloride USP 500 mg as Extended Release.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication:\r\n</strong>This combination is indicated as an adjunct to diet and\r\nexercise to improve glycemic control in adults with type 2 diabetes mellitus\r\nwhen treatment with both Glimepiride and Metformin is appropriate or in cases\r\nwhere Glimepiride/Metformin mono-therapy does not result in adequate glycemic\r\ncontrol.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\n& administration: </strong>The initial recommended dose of\r\nGlimepiride and Metformin combination tablet once daily with breakfast or first\r\nmain meal of the day. Starting dose for patients inadequately controlled on\r\nGlimepiride or Metformin monotherapy is Limpet-M 1 once daily, and gradually\r\ntitrated after assessing the therapeutic response. Titration: The daily dose\r\nmust be titrated in increments of 1 tablet. The maximum recommended dose per\r\nday is 8 mg Glimepiride and 2000 mg Metformin. When switching from combination\r\ntherapy of Glimepiride plus Metformin to separate tablets, Glimepiride and\r\nMetformin should be administered separately on the basis of dosage currently\r\nbeing taken. When Glimepiride and Metformin combination tablet is used in\r\ncombination or with insulin, a lower dose of the Glimepiride or insulin may be\r\nrequired to reduce the risk of hypoglycemia. Or, as directed by the registered\r\nphysician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation: </strong>The use of this combination is not\r\nrecommended in pregnancy & lactation.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:\r\n</strong>Each box contains 3 x 7's tablets in blister pack.</p>",
    "strength": "2+500",
    "uom": "mg+mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1617693439Limpet M2 Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740568797limpet-m 2.png"
    ]
  },
  {
    "id": "918",
    "name": "Linarol",
    "description": "<p><strong></strong><strong>Composition : </strong>Linagliptin 5 mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Indicated for adults with\r\ndiabetes mellitus type II along with diet\r\nand exercise to lower blood sugar, may\r\nbe used as monotherapy or in\r\ncombination with other common\r\nantidiabetic medications including\r\nmetformin, sulfonylurea, pioglitazone, or\r\ninsulin.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Linagliptin\r\n5 mg once daily. If added to metformin,\r\nthe dose of metformin should be\r\nmaintained concomitantly, when used in\r\ncombination with sulfonylurea, a lower\r\ndose of sulfonylurea may be considered\r\nto reduce the risk of hypoglycemia.\r\nPatients with renal impairment no need\r\nto dose adjustment required. Linagliptin\r\ncan be taken with or without a meal at\r\nany time of the day. Or, as directed by\r\nthe registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Linagliptin has been assigned to\r\npregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Linarol : 3 x 14's tablets in\r\nblister pack.</span></p>",
    "strength": "5,2.5+1000,2.5+850,2.5+500",
    "uom": "mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531805687Linarol.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740568882linarol 5.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740568966linarol-M 1000.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740568966linarol-M 850.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740568966linarol-M 500.png"
    ]
  },
  {
    "id": "919",
    "name": "Linarol - M ",
    "description": "<p><strong>Composition : Linarol-M 500: </strong>Linagliptin 2.5 mg + Metformin 500 mg Tablet.<span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Linarol-M 850: </strong><span class=\"redactor-invisible-space\"></span><strong> </strong>Linagliptin 2.5 mg + Metformin  850 mg Tablet.</p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Linarol-M 1000: </strong><strong> </strong>Linagliptin 2.5 mg + Metformin  1000 mg Tablet.<strong></strong></p><p style=\"text-align: justify;\"><strong>Indication : </strong>Linagliptin\r\nand Metformin<strong> </strong>tablets are indicated as an adjunct to diet and\r\nexercise to improve glycemic control in adults with type 2 diabetes mellitus\r\nwhen treatment with both Linagliptin and Metformin is appropriate.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong><strong>Adult:\r\n</strong>In\r\npatients currently not treated with Metformin, the initiate dose is one tablet\r\ntwice daily. Or, as directed by the registered physician.<strong></strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy\r\ncategory B. There are no adequate and well controlled studies in pregnant\r\nwoman. This tablets should be used during pregnancy only if clearly needed. Caution\r\nshould be exercised when this tablet is administered to a nursing woman.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p style=\"text-align: justify;\"><strong></strong><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><strong>Linarol-M 500: </strong>Each<strong> </strong>box contains 2x7’s  tablets in blister pack.</p><p style=\"text-align: justify;\"><strong>Linarol-M 850: </strong>Each<strong> </strong>box contains 2x7’s  tablets in blister pack.<strong></strong></p><p style=\"text-align: justify;\"><strong>Linarol-M 1000: </strong>Each<strong> </strong>box contains 2x7’s  tablets in blister pack.<strong></strong></p><p class=\"MsoNormal\" xss=\"removed\"><o></o></p><p><strong></strong></p>",
    "strength": "2.5+1000,2.5+850,2.5+500",
    "uom": "mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531805751linarol-M.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740568966linarol-M 1000.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740568966linarol-M 850.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740568966linarol-M 500.png"
    ]
  },
  {
    "id": "1004",
    "name": "Liploss",
    "description": "<p><strong></strong><strong>Composition : </strong>Pitavastatin 2mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indication :</strong>Pitavastatin is indicated for -\r\nas an adjunctive therapy to diet to reduce\r\nelevated total cholesterol (TC) , Lowdensity\r\nlipoprotein cholesterol (LDL-C),\r\nApolipoprotein B (Apo B), Triglycerides\r\n(TG), and to increase HDL-C in adult\r\npatients with primary hyperlipidemia or\r\nmixed dyslipidemia. </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The dose\r\nrange for Pitavastatin is 1 to 4 mg orally\r\nonce daily at any time of the day with or\r\nwithout food. The recommended starting\r\ndose is 2 mg and the maximum dose is 4\r\nmg. The administration starting dose and\r\nmaintence dose should be individualized\r\nto patient characteristics, such as goal of\r\ntherapy and response. Or, as directed by\r\nthe registered physician</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Liploss : 2x10's tablets in\r\nblister pack.</span></p>",
    "strength": "2",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531805796Liploss.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/lIPLOSS.jpg"
    ]
  },
  {
    "id": "1265",
    "name": "LORAT  Tablet",
    "description": "<p><strong>Composition : </strong>Loratadine USP 10mg Tablet.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Indications : </strong><span class=\"redactor-invisible-space\">Lorat tablet is indicated in\r\nadults for the relief of symptoms\r\nassociated with seasonal and perennial\r\nallergic rhinitis, such as sneezing, nasal\r\ndischarge and itching and ocular itching\r\nand burning. Nasal and ocular signs and\r\nsymptoms are relieved rapidly after oral\r\nadministration. Lorat tablet is also\r\nindicated for the relief of symptoms\r\nassociated with idiopathic chronic urticaria.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dosage & administration :</strong><span class=\"redactor-invisible-space\"> Adults and\r\nchildren 12 years of age and over : One\r\nLorat 10mg tablet once daily or, as\r\ndirected by the physician.</span><br></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Loratadine has been assigned to\r\nPregnancy Category B by the FDA.</span><br></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Packing :</strong><span class=\"redactor-invisible-space\"> 10 x 10's tablets in blister\r\npack.</span><br></span></span></span></span></p>",
    "strength": "10",
    "uom": "mg",
    "categoryId": "41",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531805855LORAT.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744101142Lorat.png"
    ]
  },
  {
    "id": "1825",
    "name": "Lorlanib-100",
    "description": "<p><strong>Composition: </strong>Each\r\nfilm coated tablet contains Lorlatinib INN 100mg.</p>\r\n\r\n<p class=\"MsoNormal\"><strong>Indications: </strong>It\r\nis indicated for the treatment of patients with anaplastic lymphoma kinase\r\n(ALK)-positive metastatic Non-small Cell Lung Cancer (NSCLC) whose disease has\r\nprogressed on<br>\r\n• Crizotinib and at least one other ALK inhibitor for metastatic disease; or<br>\r\n• Alectinib as the first ALK inhibitor therapy for metastatic disease; or<br>\r\n• Ceritinib as the first ALK inhibitor therapy for metastatic disease        <o></o></p>\r\n\r\n<p class=\"MsoNormal\"> </p>\r\n\r\n<p class=\"MsoNormal\"><strong>Dosage and administration: </strong>The\r\nrecommended dosage of Lorlatinib is 100 mg orally once daily, with or without\r\nfood, until disease progression or unacceptable toxicity. It should be taken at\r\nthe same time each day. If a dose is missed, then the missed dose should be\r\ntaken unless the next dose is due within 4 hours. 2 doses should not be taken\r\nat the same time to make up for a missed dose. Or, as directed by the\r\nregistered physicians.     <o></o></p>\r\n\r\n<p class=\"MsoNormal\"> </p>\r\n\r\n<p class=\"MsoNormal\"><strong>Use in pregnancy and lactation: </strong>It\r\ncan cause fetal harm when administered to a pregnant woman. Pregnant women\r\nshould be advised of the potential risk to a fetus. Women should be advised not\r\nto breastfeed during treatment with Lorlatinib and for 7 days after the final\r\ndose.<o></o></p>\r\n\r\n<p class=\"MsoNormal\"> </p>\r\n\r\n<p><strong>Packing: </strong>Each\r\ncontainer contains 30 capsules in a box.</p>",
    "strength": "100",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1643535401Lorlanib-100 - Web Insert(2).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1643535401Lorlanib-100- 30 Tablet- Bottle Carton Pic(2).png"
    ]
  },
  {
    "id": "965",
    "name": "Losardil ",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\"> Losartan Potassium+Hydrochlorothiazide, (25+12.5mg), (50+12.5mg), (100+12.5mg), (100+25mg) Tablet</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This tablet is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. This fixed dose combination is not indicated for initial therapy.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The usual starting dose of Losartan is 50mg once daily, with 25mg used in patients with possible depletion of intravascular volume and patients with a history of hepatic impairment. Losartan can be administered once or twice daily at total daily doses of 25 to 100 mg. If the antihypertensive effect measured at through using once a day dosing is inadequate, a twice a day regimen at the same total daily dose or an increase in dose may give a more satisfactory response. Hydrochlorothiazide is effective in doses of 12.5 to 50mg once daily and can be given at doses of 12.5 to 25mg as this medicine.Or, as directed by the registered physician.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">This medicine is not generally recommended during pregnancy, except under exceptional circumstances. This medicine passes into breast milk. Consequently, breast-feeding is not recommended.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Losardil 25/12.5: 4x14's tablets in blister pack.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Losardil 50/12.5: 4x14's tablets in blister pack.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Losardil 100/12.5 : 2x14's tablets in blister pack.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Losardil 100/25 : 2x10's tablets in blister pack.</span></p>",
    "strength": "100+25,100+12.5,50+12.5,25+12.5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531806004Losardil_12.5.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744101379Losardil 100-25.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744101379Losardil 100-12.5.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744101379Losardil 50-12.5.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744101379Losardil 25-12.5.png"
    ]
  },
  {
    "id": "964",
    "name": "Losardil",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Losartan Potassium 25mg,\r\n50mg & 100mg Tablet </span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This tablet is indicated for the\r\ntreatment of hypertension. It may be used\r\nalone or in combination with other\r\nantihypertensive agents. This fixed dose\r\ncombination is not indicated for initial therapy.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The usual\r\nstarting dose of Losartan is 50mg once daily,\r\nwith 25mg used in patients with possible\r\ndepletion of intravascular volume and\r\npatients with a history of hepatic impairment.\r\nLosartan can be administered once or twice\r\ndaily at total daily doses of 25 to 100 mg. If\r\nthe antihypertensive effect measured at\r\nthrough using once a day dosing is\r\ninadequate, a twice a day regimen at the\r\nsame total daily dose or an increase in dose\r\nmay give a more satisfactory response.\r\nHydrochlorothiazide is effective in doses of\r\n12.5 to 50mg once daily and can be given at\r\ndoses of 12.5 to 25mg as this medicine.Or,\r\nas directed by the registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">This\r\nmedicine is not generally recommended\r\nduring pregnancy, except under exceptional\r\ncircumstances. This medicine passes into\r\nbreast milk. Consequently, breast-feeding is\r\nnot recommended.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Losardil-25 : 4x14's tablets in\r\nblister pack.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nLosardil-50 : 2x14's tablets in blister pack.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nLosardil-100 : 2x14's tablets in blister pack. </span></p><p style=\"text-align: justify;\"><br></p><p><br></p>",
    "strength": "100,50,25",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531805918Losardil ..pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744101257Losardil - 100.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744101257Losardil 50.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744101257Losardil - 25 tablets.png"
    ]
  },
  {
    "id": "1785",
    "name": "Lotenib",
    "description": "<p class=\"MsoNormal\" xss=\"removed\">Larotrectinib INN 100 mg</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Composition: </strong>Each\r\ncapsule contains Larotrectinib INN 100 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>Lotenib\r\nis indicated for the treatment of adult and pediatric patients with solid\r\ntumors that: • have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion\r\nwithout a known acquired resistance mutation, • are metastatic or where\r\nsurgical resection is likely to result in severe morbidity, and • have no\r\nsatisfactory alternative treatments or that have progressed following\r\ntreatment.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and\r\nAdministration: Recommended Dosage in Adult and</strong>\r\n<strong>Pediatric Patients with Body Surface Area of at Least 1.0</strong> <strong>Meter-Squared:\r\n</strong>The recommended dosage of Lotenib is 100 mg orally twice daily, with or\r\nwithout food, until disease progression or until unacceptable toxicity. <strong>Recommended\r\nDosage in Pediatric Patients with</strong> <strong>Body Surface Area Less Than 1.0\r\nMeter-Squared: </strong>The recommended dosage of Lotenib is 100 mg/m2 orally twice\r\ndaily, with or without food, until disease progression or until unacceptable\r\ntoxicity. Whole capsules should be swallowed with water and the capsules should\r\nnot be chewed or crushed. A missed dose should not be made up within 6 hours of\r\nthe next scheduled dose. If vomiting occurs after taking a dose of Lotenib, the\r\nnext dose should be taken at the scheduled time. Or, as directed by the\r\nregistered physicians.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and\r\nLactation: </strong>Lotenib can cause embryo-fetal harm when\r\nadministered to a pregnant woman. There are no available data on Lotenib use in\r\npregnant women. Pregnant women should be advised of the potential risk to a\r\nfetus. <strong>Lactation: </strong>There are no data on the presence of Larotrectinib or\r\nits metabolites in human milk and no data on its effects on the breastfed child\r\nor on milk production. Because of the potential for serious adverse reactions\r\nin breastfed children, women should be advised not to breastfeed during treatment\r\nwith Larotrectinib and for 1 week after the final dose.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: </strong>Each\r\ncontainer contains 30 capsules in a box.</p>",
    "strength": "100 ",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1632209580Lotenib - Web Insert(1).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1632209580Lotenib- 30 Capsule- Bottle Carton Pic(2).png"
    ]
  },
  {
    "id": "1868",
    "name": "Lotenib-100",
    "description": "<p><strong>Composition: </strong></p><p xss=\"removed\"><strong>Lotenib-100: </strong>Each\r\ncapsule contains Larotrectinib 100mg as Larotrectinib sulfate INN<strong><o></o></strong></p><p class=\"MsoBodyText\" xss=\"removed\"><strong>Indications: </strong>Larotrectinib is indicated for the treatment of adult and pediatric patients\r\nwith solid tumors\r\nthat:<o></o></p><p class=\"MsoListParagraph\" xss=\"removed\"><!--[if !supportLists]-->• <!--[endif]-->have a neurotrophic receptor\r\ntyrosine kinase (NTRK) gene fusion\r\nwithout a known acquired resistance mutation,<o></o></p><p class=\"MsoListParagraph\" xss=\"removed\"><!--[if !supportLists]-->• <!--[endif]-->are metastatic or where surgical\r\nresection is likely to result\r\nin severe morbidity, and<o></o></p><p class=\"MsoListParagraph\" xss=\"removed\"><!--[if !supportLists]-->• <!--[endif]-->have no satisfactory alternative treatments or that have progressed following treatment.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration:</strong>  <strong>Recommended Dosage in Adult and Pediatric Patients with\r\nBody Surface Area of at Least 1.0 Meter-Squared: </strong>The recommended dosage of Larotrectinib is 100 mg orally twice daily, with or without food, until\r\ndisease progression or until unacceptable toxicity. <strong>Recommended Dosage in Pediatric Patients with Body\r\nSurface Area Less Than 1.0 Meter-Squared: </strong>The recommended dosage of Larotrectinib is 100 mg/m2\r\norally twice daily, with or without food, until disease progression or until unacceptable toxicity. Whole capsules\r\nshould be swallowed with water and the capsules should not be chewed or crushed. A missed dose should not be\r\nmade up within 6 hours of the next scheduled dose. If vomiting occurs after taking a dose of Larotrectinib, the\r\nnext dose should be taken at the scheduled time. Or, as directed by the registered physicians.<o></o></p><p class=\"MsoBodyText\" xss=\"removed\"><strong>Use in Pregnancy and\r\nLactation: </strong>Larotrectinib can cause\r\nembryo-fetal harm when administered to a pregnant\r\nwoman. There are no available data on Larotrectinib use in pregnant women.\r\nPregnant women should be advised\r\nof the potential risk to a fetus.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Lactation: </strong>There are no data on the presence\r\nof Larotrectinib or its metabolites in human milk and no data on its\r\neffects on the breastfed child or on milk production. Because of the potential\r\nfor serious adverse reactions in breastfed\r\nchildren, women should be advised not to breastfeed during treatment with\r\nLarotrectinib and for 1 week after the\r\nﬁnal dose.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: <o></o></strong></p><p><strong>Lotenib-100: </strong>Each box contains\r\n10 capsules in blister pack.</p>",
    "strength": "100",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1678341690Lotenib Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740569084lotenib-100.png"
    ]
  },
  {
    "id": "1905",
    "name": "Luzoca",
    "description": "<p xss=\"removed\"><strong>Composition:</strong>\r\nLuliconazole INN 10 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication:</strong>\r\nLuliconazole is  indicated for the\r\ntopical treatment of inter digital tinea pedis (athlete’s foot), tinea cruris,\r\nand tinea corporis.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Doasge\r\nand administration: Inter digital tinea pedis:</strong>\r\nLuzoca cream should be applied to the affected skin and immediate Surrounding\r\narea(s) once a day for two weeks.<strong>Tinea Cruris,\r\nand Tinea Corporis:</strong> Luzoca cream should be applied to the affected skin and\r\nimmediate Surrounding area(s) once a day for one week.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation:</strong> There are no adequate and well-controlled\r\nstudies of Luzoca cream in pregnant women. Luzoca cream should be used during\r\npregnancy only if the potential benefit justices the potential risk to the\r\nfetus. <strong>Lactation:</strong> It is not known whether\r\nLuliconazole is excreted in human milk. Caution should be exercised when Luzoca\r\ncream is administered to women who are breastfeeding.<o></o></p><p xss=\"removed\"><strong>Packing:</strong>\r\nEach tube contains 10 gm cream.</p>",
    "strength": "10 mg",
    "uom": "",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1715234684Luzoca Cream Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1715234684Luzoca Cream Carton.png"
    ]
  },
  {
    "id": "735",
    "name": "M - KAST",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Composition:</strong><strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>M-Kast\r\n4 ODT: </strong>Each Orodispersible Tablet Contains Montelukast USP\r\n4mg.<strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>M-Kast\r\n5 ODT:</strong>Each Orodispersible Tablet Contains Montelukast<a name=\"_GoBack\"></a> USP 5mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>M-Kast10:</strong>Each Tablet Contains Montelukast USP 10mg<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Indications:</strong>Montelukast\r\nSodium is indicated for: 1. Prophylaxis and chronic treatment of asthma. 2.\r\nAcute prevention of Exercise-Induced Bronchoconstriction (EIB). 3. Relief of\r\nsymptoms of Allergic Rhinitis (AR): Seasonal & Perennial Allergic Rhinitis.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Dosage\r\nand administration: Adult Dosage:</strong>Adults and adolescents\r\nwith asthma or seasonal allergic rhinitis: (The dosage for adults and adolescents\r\n15 years of age and older): Montelukast 10 mg tablet once daily. Pediatric\r\npatients with asthma or seasonal allergic rhinitis: (The dosage for pediatric\r\npatients 6 to 14 years of age): Montelukast 5 mg tablet once daily. (The dosage\r\nfor pediatric patients 2 years to 5 years of age): Montelukast 4 mg tablet once\r\ndaily. (The dosage for pediatric patients 6 months to 5 years of age):\r\nMontelukast 4 mg once daily. This can be administered either directly in the\r\nmouth, or mixed with a spoonful of cold water or soft food at room temperature.\r\nElderly use: The pharmacokinetic profile and the oral bioavailability of a\r\nsingle 10 mg oral dose of montelukast are similar in elderly and younger adults.\r\nThe plasma half-life of montelukast is slightly longer in the elderly. No\r\ndosage adjustment in the elderly is required. Hepatic <o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\">Insufficiency: No dosage adjustment is required in\r\npatients with mild-to-moderate hepatic insufficiency. Renal Insufficiency: No dosage\r\nadjustment is recommended in patients with renal insufficiency. Or, as directed\r\nby the registered physician. <o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Use\r\nin Pregnancy and lactation:</strong>Pregnancy category B.\r\nThere are no adequate and well controlled studies in pregnant women. It should\r\nbe used during pregnancy only if the potential benefit justifies the potential\r\nrisk to the fetus. It is not known whether this medicine is excreted in human\r\nmilk. However, other corticosteroids have been detected in human milk. Caution\r\nshould be exercised when this medicine is administered to a nursing woman.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Packing:M-Kast\r\n4 ODT:</strong>Each box contains 3x14’s tablets in blister pack.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>M-Kast\r\n5 ODT:</strong>Each box contains 3x14’s tablets in blister pack.<o:p></o:p></p><p><strong>M-Kast10:</strong>Each box contains 3x14’s tablets in blister pack.<br><strong></strong></p>",
    "strength": "10,5,4,50",
    "uom": "mg",
    "categoryId": "47",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531892116m-kast.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744103426M-kast 10.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744103426M-kast 5.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744103426M-kast 4.png",
      "https://www.admin.drug-international.com/uploads/images/M-Son.jpg"
    ]
  },
  {
    "id": "745",
    "name": "M - Son Nasal spray ",
    "description": "<p><strong></strong><strong>Composition :</strong> <span class=\"redactor-invisible-space\">Each metered spray\r\ncontains Mometasone Furoate USP 50 mcg.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong> This nasal spray is indicated\r\nfor the treatment of the nasal symptoms of\r\nseasonal & perennial allergic rhinitis in\r\nadults and pediatric patients 2 years of age\r\nand older. It is indicated for the prophylaxis\r\nof the nasal symptoms of seasonal allergic\r\nrhinitis in adult and adolescent patients 12\r\nyears of age and older. It is also indicated\r\nfor the treatment of nasal polyps in patients\r\n18 years of age and older.</p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong>  Allergic\r\nrhinitis: Adults & children 12 years of\r\nage and older: The recommended dose for\r\nprophylaxis & treatment of the nasal\r\nsymptoms of seasonal allergic rhinitis and\r\ntreatment of the nasal symptoms of\r\nperennial allergic rhinitis is 2 sprays in each\r\nnostril once daily. In patients with a known\r\nseasonal allergen that precipitates nasal\r\nsymptoms of seasonal allergic rhinitis,\r\nprophylaxis with this nasal spray, 50 mcg\r\n(200 mcg/day) is recommended 2 to 4\r\nweeks prior to the anticipated start of the\r\npollen season. Please see prescribing description for more information.<br></p><p style=\"text-align: justify;\"><strong>Packing :</strong>  <span class=\"redactor-invisible-space\">Each bottle contains 120\r\nmetered doses for sprays.</span><span></span><br></p>",
    "strength": "50",
    "uom": "mcg/Spray",
    "categoryId": "56",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531892611M-Son.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/images/M-Son.jpg"
    ]
  },
  {
    "id": "1925",
    "name": "Magolin",
    "description": "<p><strong>Composition:</strong><strong> </strong><strong>Magolin-5</strong><strong> :</strong><strong> </strong>Each film foated tablet contains\r\nMirogabalin 5 mg as Mirogabalin Besylate INN.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Magolin-10 :</strong><strong> </strong>Each\r\nfilm foated tablet contains Mirogabalin 10 mg as Mirogabalin Besylate INN.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Magolin -15 :</strong><strong> </strong>Each\r\nfilm foated tablet contains Mirogabalin 15 mg as Mirogabalin Besylate INN.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications : </strong>It is indicated to treatment of\r\nNeuropathic Pain, Diabetic peripheral neuropathic pain (DPNP), Postherpetic neuralgia\r\n(PHN), Peripheral neuropathic pain (PNP).<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage & Administration: </strong>Normally,the\r\ninitial dose for adults is 5 mg of Mirogabalin given orally twice daily, and\r\nthen the dose is gradually increased by 5 mg at an interval of at least a week\r\nto 15 mg,given orally twice daily. The dose may be adjusted appropriately\r\ndepending on patients ages and symptoms in the range of 10mg to 15mg or as\r\ndirected by a registered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation :</strong><strong> </strong><strong>Pregnancy : </strong>There is no\r\ninformation available on the safety profile on using in pregnancy\r\n&lactation .<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: Magolin -5 : </strong>Each box contains 14’s tablets in a\r\nblister pack.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Magolin -10 :</strong><strong> </strong>Each\r\nbox contains 14’s tablets in a blister pack.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p><strong>Magolin -15 :</strong><strong> </strong>Each\r\nbox contains 14’s tablets in a blister pack</p>",
    "strength": "15,10,5",
    "uom": "mg",
    "categoryId": "48",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1732782418Magolin Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1732782418Magolin-15 Carton New.png",
      "https://www.admin.drug-international.com/uploads/product_images/1732782417Magolin-10 Carton New.png",
      "https://www.admin.drug-international.com/uploads/product_images/1732782417Magolin-5 Carton New.png"
    ]
  },
  {
    "id": "1883",
    "name": "Maldrox",
    "description": "<p><strong>Composition:</strong>\r\nEach 5 ml oral suspension contains Magaldrate\r\nBP 480mg and Simethicone USP 20mg.</p><p class=\"MsoNoSpacing\" style=\"text-align:justify\"><strong>Indication:</strong>This\r\nmedication is indicated to relieve symptoms of dyspepsia, heartburn, acid indigestion,\r\nsour stomach, gastro esophageal reflux and hiatal hernia.it is also prescribed\r\nin hyperacidity associated with peptic ulcers, gastritis and esophagitis.\r\nMagaldrate may be given to children if necessary. Also indicated for the relief\r\nof flatulence, abdominal distension and windy colic.<o:p></o:p></p><p class=\"MsoNoSpacing\" style=\"text-align:justify\"><strong>Dose and administration: <strong>Adult and elderly</strong></strong>:\r\n2-4 teaspoonful’s after 20-60 minutes of meal and before sleepor on the basis\r\nof physician’s prescription. Use in children: Not recommended in children under\r\n6 years of age unless, directed by physician. Or, as directed by the registered\r\nphysician.<o:p></o:p></p><p class=\"MsoNoSpacing\"><strong> </strong></p><p class=\"MsoNoSpacing\"><strong>Precaution:</strong>\r\nCan be taken in pregnancy and breast-feeding as directed by registered\r\nphysician.<o:p></o:p></p><p class=\"MsoNoSpacing\"><strong>Storage:</strong>\r\nStore below 30<sup>0</sup> in a dry place. Keep the medicine out of reach of\r\nthe children. <o:p></o:p></p><p class=\"MsoNoSpacing\"><a name=\"_GoBack\"></a> </p><p class=\"MsoNoSpacing\"><strong>Packing:</strong>\r\nEach box contains 200ml suspension.<o:p></o:p></p>",
    "strength": "200",
    "uom": "ML",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1687173925",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744101498Maldrox.png"
    ]
  },
  {
    "id": "1808",
    "name": "Mavira",
    "description": "<p><strong>Composition : </strong>Each Capsule Contains Molnupiravir INN 200mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication :</strong> It is indicated for the treatment of mild to\r\nmoderate coronavirus disease 2019 (COVID-19) in adults with a positive\r\nSARS-COV-2 diagnostic test and who have at least one risk factor for developing\r\nsevere illness.<strong><o></o></strong></p><p xss=\"removed\"><strong>Dosage and administration:  </strong><strong>Adults:</strong>The recommended dose of Molnupiravir is 800 mg (four\r\n200 mg capsules) taken orally every 12 hours for 5 days.The safety and efficacy\r\nof Molnupiravir when administered for periods longer than 5 days have not been\r\nestablished. Molnupiravir should be\r\nadministered as soon as possible after a diagnosis of COVID-19 has been made\r\nand within 5 days of symptom onset.<o></o></p><p xss=\"removed\"><strong>Paediatric population</strong><strong>:</strong> The safety and efficacy of Molnupiravir in patients\r\nbelow 18 years of age have not been established. No data are available.<o></o></p><p xss=\"removed\">Or, as directed by the registered physician.<o></o></p><p xss=\"removed\"><strong>Use in pregnancy and lactation :</strong>\r\n<strong>Pregnancy: </strong>There\r\nare no data from the use of Molnupiravir in pregnant women. Studies in animals\r\nhave shown reproductive toxicity. Molnupiravir is not recommended during\r\npregnancy. Women of childbearing potential should use effective contraception\r\nfor the duration of treatment and for 4 days after the last dose of\r\nMolnupiravir.<o></o></p><p xss=\"removed\"><strong>Breast-feeding</strong>: It is unknown whether Molnupiravir or\r\nany of the components of molnupiravir are present in human milk, affect human\r\nmilk production, or have effect on the breastfed infant. Animal lactation\r\nstudies with molnupiravir have not been conducted.Based on the potential for\r\nadverse reactions on the infant from Molnupiravir, breast-feeding is not\r\nrecommended during treatment and for 4 days after the last dose of\r\nMolnupiravir.<o></o></p><p><strong>Packing:</strong> Each<strong> </strong>box contains 40’s capsules in\r\ncontainer.</p>",
    "strength": "200",
    "uom": "mg",
    "categoryId": "45",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1637997469Mavira200- Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1637747440Mavira Bottle Carton - 20-11-2021.jpg"
    ]
  },
  {
    "id": "943",
    "name": "Mecolin ",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong><strong> </strong><strong>Mecolin\r\n: </strong>Each film coated tablet contains Mecobalamin USP 0.5mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications :</strong><strong> </strong>Mecobalamin\r\nis indicated for following diseases.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">            - Diabetic neuropathy<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">            - Peripheral neuropathies<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">            - Diabetic retinopathy<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">             Drug induced neuropathy<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">            - Entrapment neuropathy<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">            - Intercostal neuralgia<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">            - Lumbago<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">            - Vertebral syndrome<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">            - Nerve compression syndrome<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">             -Multiple sclerosis<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\">             -Amyotrophic lateral sclerosis<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\">            -Parkinson's\r\ndisease<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\">            -Alzheimer's disease<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage & Administration :</strong><strong> </strong>Adults\r\n:\r\nOne 0.5mg tablet three times daily. Or, as directed by the registered\r\nphysician.<o:p></o:p></p><p><strong>Use in pregnancy and lactation</strong><strong> </strong><strong>:</strong><strong> </strong>Not recommended during\r\npregnancy & lactation. Not recommended for children.<br><strong></strong></p><p style=\"text-align: justify;\"><strong>Packing : </strong>Mecolin : 50's tablets in\r\nblister pack.</p>",
    "strength": "0.5",
    "uom": "mg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1634028646Mecolin (2).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744101542Mecolin.png"
    ]
  },
  {
    "id": "1854",
    "name": "Mepogest",
    "description": "<p><strong>Composition\r\n:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Mepogest 5\r\n:</strong>Each Tablet contains Medroxyprogesterone Acetate BP\r\n5 mg.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Mepogest 10\r\n:  </strong>Each\r\nTablet contains Medroxyprogesterone Acetate BP 10 mg.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong>It is indicated\r\nfor the treatment of-1. Dysfumction uterine bleeding 2. Mild to moderate endometriosis\r\n3. To oppose the endometrial effects of oestrogen in menopausal women treated\r\nwith oestrogen 4. Alleviation of menopausal vasomotor symptoms 5. Diagnostic\r\nuses: Primary amenorrhea, Secondary amenorhea.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration: Adult Dosage:Dysfunctional uterine </strong><strong>bleeing:</strong> In dysfunctional uterine bleeding this medicine may be given in doses\r\nranging from 5 to 10 mg for 5 to 10 days beginning on the assumed or calculated\r\n16th to 21st day of the cycle. When bleeding is due to a deficiency of both\r\novarian hormones, as indicated by a poorly developed proliferative endometrium,\r\nestrogens should be used in conjunction with this medicine. If bleeding is controlled\r\nsatisfactorily, two subsequent cycles of treatment should be given.  Endometriosis:  Beginning on the first day of the menstrual\r\ncycle, 10mg of this medicine may be given three times a day for 90 consecutive\r\ndays.  To oppose the Endometrial effects\r\nof estrogen in estrogen-treated post-menopausal women: 5 to 10 mg per day for\r\nat least 10 days beginning on the 16th day of a 25 day course of estrogen\r\ntherapy. Progestin withdrawal bleeding should occur, beginning on the 3rd to\r\n7th day post this medicine treatment. Menopause: 10 to 20 mg this medicine <a name=\"_GoBack\"></a>per day given continuously. \r\nPrimary and secondary amenorrhea: 5 to 10mg this medicine per day for 10\r\ndays. Progestin withdrawal bleeding should ensue within 3-7 days if the\r\nendometrium has been previously primed with adequate endogenous estrogen.\r\nPregnancy must be excluded before administration of this medicine. Or, as directed\r\nby the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Pregnancy and lactation:</strong>Medroxyprogesterone\r\nAcetate should not be used during pregnancy. There may be increased risks for hypospadias,\r\nclitoral enlargement and labial fusion in children whose mothers are exposed to\r\nMedroxyprogesterone Acetate during the first trimester of pregnancy. However, a\r\nclear association between these conditions with use of this tablet has not been\r\nestablished. This tablet should not be used during lactation. Detectable\r\namounts of progestin have been identified in the breast milk of nursing mothers\r\nreceiving progestins.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: Mepogest 5\r\n:</strong>Each\r\nbox contains 30's tablet in a blister pack.<o></o></p><p><strong>Mepogest 10 :</strong>Each box\r\ncontains 30's tablet in a blister pack.</p>",
    "strength": "10,5",
    "uom": "mg",
    "categoryId": "123",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1738142694Mepogest Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744101634Mepogest 10.png",
      "https://www.admin.drug-international.com/uploads/product_images/1668493219Mepogest 5 Carton.png"
    ]
  },
  {
    "id": "1340",
    "name": "Mes-D",
    "description": "<p><strong><span lang=\"EN-GB\">Composition:</span></strong><span lang=\"EN-GB\">Mes-D : Each Vial contains mesna BP 400 mg/4ml<strong>(IV Injection).</strong></span></p><p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-GB\">Indications:</span></strong><span lang=\"EN-GB\"> It is indicated as a prophylactic agent in preventing ifosfamide-induced hemorrhagic cystitis (syndrome of bleeding and irritation of the bladder). It is also indicated in preventing  high dose cyclophospamide-induced hemorrhagic cystitis.<o></o></span></p><p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-GB\">Dosage and Administration:</span></strong><span lang=\"EN-GB\">  For the prophylaxis of ifosfamide induced hemorrhagic cystitis, Mesna may be given on a fractionated dosing schedule of three bolus intravenous injections or a single bolus injection followed by IV administration of mesna as outlined below. Intravenous schedule: Mesna is given as intravenous bolus injection in a dosage equal to 20% of the ifosfamide dosage (w/w) at the time of ifosfamide administration and 4 and 8 hours after each dose of Ifosfamide. The total daily dose of Mesna is 60% of the ifosfamide dose. The recommended dosing schedule is outlined below:<o></o></span></p><p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-GB\">Intravenous Dosing:</span></strong><span lang=\"EN-GB\">Mesna Injection is given as intravenous bolus injections in a dosage equal to 20% of the Ifosfamide dosage (w/w) at the time of Ifosfamide administration. See leaflet inside for more information.<o></o></span></p><p class=\"MsoNormal\" xss=\"removed\"><strong><span lang=\"EN-GB\">Use in pregnancy and lactation: Pregancy Category B</span></strong><span lang=\"EN-GB\">. There are no adequate and well-controlled studies in pregnant women. Nursing Mother-It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and  because of the potential for serious adverse reactions in nursing infants from Mesna, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.<o></o></span></p><p><strong><span lang=\"EN-GB\">Packing:Mes-D:</span></strong><span lang=\"EN-GB\"> Each box contains 1 Vial of Mesna BP 400mg injection</span></p>",
    "strength": "400",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1537877176Mes-D- Insert- 23-09-2018.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1537877176Mes-D- Carton Pic.jpg"
    ]
  },
  {
    "id": "1718",
    "name": "Metanib",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Generic\r\nName:</strong> Imatinib Mesylate INN 400 mg Tablet.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:</strong>\r\nEach film coated tablet contains Imatinib 400 mg as Imatinib Mesylate INN.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Newly\r\nDiagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML):</strong>\r\nMetanib is indicated for the treatment of newly diagnosed adult and pediatric\r\npatients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+\r\nCML) in chronic phase.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Ph+\r\nCML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) after\r\nInterferon-alpha (IFN) Therapy:</strong> Metanib is indicated\r\nfor the treatment of patients with Philadelphia chromosome positive chronic\r\nmyeloid leukemia in blast crisis, accelerated phase, or in chro nic phase after\r\nfailure of interferon-alpha therapy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Adult\r\nPatients with Ph+ Acute Lymphoblastic Leukemia (ALL):</strong>\r\nMetanib is indicated for the treatment of adult patients with relapsed or\r\nrefractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+\r\nALL).</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Pediatric\r\nPatients with Ph+ Acute Lymphoblastic Leukemia (ALL):</strong>\r\nMetanib is indicated for the treatment of pediatric patients with newly\r\ndiagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+\r\nALL) in combination with chemotherapy. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Myelodysplastic/Myeloproliferative\r\nDiseases (MDS/MPD):</strong> Metanib is indicated for the treatment\r\nof adult patients with myelodysplastic/myeloproliferative diseases associated\r\nwith PDGFR (platelet-derived growth factor receptor) gene re-arrangements as\r\ndetermined with an FDA-approv ed test.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Aggressive\r\nSystemic Mastocytosis (ASM):</strong> Metanib is indicated\r\nfor the treatment of adult patients with aggressive systemic mastocytosis\r\nwithout the D816V c-Kit mutati on as determined with an FDA-approved test.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Hypereosinophilic\r\nSyndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL):</strong>\r\nMetanib is indicated for the treatment of adult patients with hypereosinophilic\r\nsyndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFR a\r\nfusion kinase (mutational analysis or FISH demonstration of CHIC2 allele\r\ndeletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR a fusion\r\nkinase negative or unknown.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dermatofibrosarcoma\r\nProtuberans (DFSP):</strong> Metanib is indicated for the treatment\r\nof adult patients with unresectable, recurrent and/or metastatic\r\ndermatofibrosarcoma pr otuberans.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Kit+\r\nGastrointestinal Stromal Tumors (GIST):</strong> Metanib is indicated\r\nfor the treatment of patients with Kit (CD117) positive unresectable and/or\r\nmetastatic malignant gastrointestinal stromal tumors.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Adjuvant\r\nTreatment of GIST:</strong> Metanib is indicated for the adjuvant\r\ntreatment of adult patients following complete gross resection of Kit (CD117)\r\npositive GIST.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand Administration:</strong> The prescribed dose should be\r\nadministered orally, with a meal and a large glass of water. Doses of 400 mg or\r\n600 mg should be administered once daily, whereas a dose of 800 mg should be\r\nadministered as 400 mg twice a day. For patients unable to swallow the\r\nfilm-coated tablets, the tablets may be dispersed in a glass of water or apple\r\njuice. The required number of tablets should be placed in the appropriate\r\nvolume of beverage (approximately 50 ml for a 100 mg tablet, and 200 ml for a\r\n400 mg tablet) and stirred with a spoon. The suspension should be administered\r\nimmediately after complete disintegration of the tablet(s). For daily dosing of\r\n800 mg and above, dosing should be accomplished using the 400 mg tablet to\r\nreduce exposure to iron. Treatment may be continued as long as there is no\r\nevidence of progressive disease or unacceptable toxicity. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Adult\r\nPatients with Ph+ CML CP, AP, or BC:</strong> The recommended dose\r\nof Metanib is 400 mg/day for adult patients in chronic phase CML and 600 mg/day\r\nfor adult patients in accelerated phase or blast crisis. In CML, a dose\r\nincrease from 400 mg to 600 mg in adult patients with chronic phase disease, or\r\nfrom 600 mg to 800 mg (given as 400 mg twice daily) in adult patients in\r\naccelerated phase or blast crisis may be considered in the absence of severe\r\nadverse drug reaction and severe non-leukemia related neutropenia or\r\nthrombocytopenia in the following circumstances: disease progression (at any\r\ntime), failure to achieve a satisfactory hematologic response after at least 3\r\nmonths of treatment, failure to achieve a cytogenetic response after 6 to 12\r\nmonths of treatment, or loss of a previously achieved hematologic or cyto\r\ngenetic response.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Pediatric\r\nPatients with Ph+ CML CP:</strong> The recommended dose of Metanib\r\nfor children with newly diagnosed Ph+ CML is 340 mg/m2/day (not to exceed 600\r\nmg). Metanib treatment can be given as a once daily dose or the daily dose may\r\nbe split into two–one portion dosed in the morning and one portion in the\r\nevening. There is no experience with Metanib treatment in children under 1 year\r\nof age.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Adult\r\nPatients with Ph+ ALL:</strong> The recommended dose of Metanib is\r\n600 mg/day for adult patients with relapsed/refractory Ph+ ALL.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Pediatric\r\nPatients with Ph+ ALL:</strong> The recommended dose of Metanib to\r\nbe given in combination with chemotherapy to children with newly diagnosed Ph+\r\nALL is 340 mg/m2/day (not to exceed 600 mg). Metanib treatment can be given as\r\na once daily dose. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Adult\r\nPatients with MDS/MPD:</strong> The recommended dose of Metanib is\r\n400 mg/day for adult patients with MDS/MPD.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Adult\r\nPatients with ASM:</strong> The recommended dose of Metanib is 400\r\nmg/day for adult patients with ASM without the D816V c-Kit mutation. For\r\npatients with ASM associated with eosinophilia, a clonal hematological disease\r\nrelated to the fusion kinase FIP1L1- PDGFR a, a starting dose of 100 mg/day is\r\nrecommended. Dose increase from 100 mg to 400 mg for these patients may be\r\nconsidered in the absence of adverse drug reactions if assessments demonstrate\r\nan insufficient response to therapy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Adult\r\nPatients with HES/CEL:</strong> The recommended dose of Metanib is\r\n400 mg/day for adult patients with HES/CEL. For HES/CEL patients with\r\ndemonstrated FIP1L1-PDGFR a fusion kinase, a starting dose of 100 mg/day is\r\nrecommended.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Adult\r\nPatients with DFSP:</strong> The recommended dose of Metanib is 800\r\nmg/day for adult patien ts with DFSP.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Adult\r\nPatients with Metastatic and/or Unresectable GIST:</strong>\r\nThe recommended dose of Metanib is 400 mg/day for adult patients with\r\nunresectable and/or metastatic, malignant GIST. A dose increase up to 800 mg\r\ndaily (given as 400 mg twice daily) may be considered, in patients showing\r\nclear signs or symptoms of disease progression at a lower dose and in the\r\nabsence of severe advers e drug reactions.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Adult\r\nPatients with Adjuvant GIST:</strong> The recommended dose\r\nof Metanib is 400 mg/day for the adjuvant treatment of adult patients following\r\ncomplete gross resection of GIST. Or, as directed by the registered physicians.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Pregnancy and Lactation:</strong> <strong>Pregnancy category D</strong>. It can cause fetal harm when administered to\r\na pregnant woman. Women should be advised to avoid pregnancy when taking\r\nMetanib. If this drug is used during pregnancy, or if the patient becomes\r\npregnant while taking this drug, the patient should be apprised of the\r\npotential hazard to the fetus.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packaging:</strong>\r\nEach box contains 28 tablets in a blister pack.</p>",
    "strength": "400",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1569217888Metanib - Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1569217888Metanib - Carton Pic.jpg"
    ]
  },
  {
    "id": "1213",
    "name": "Meth tablet",
    "description": "<p><strong>COMPOSITION:</strong></p><p style=\"text-align: justify;\"><strong>Meth-2.5 :</strong> Each film coated tablet contains Methotrexate USP 2.5 mg. </p><p style=\"text-align: justify;\"><strong>Meth-10 :</strong> Each film coated tablet contains Methotrexate USP 10 mg.</p><p style=\"text-align: justify;\"><strong>INDICATION:</strong><br></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">Meth (Methotrexate) is used as maintenance therapy for childhood acute\r\nlymphoblastic leukaemia. Other uses include choriocarcinoma, and a number of solid\r\ntumours.It is used alone or in combination with other anticancer agents in the treatment\r\nof breast cancer, epidermoid cancers of the head and neck, advanced mycosis\r\nfungoides, and lung cancer, particularly squamous cell and small cell types.It is also used\r\nin combination with other chemotherapeutic agents in the treatment of advanced\r\nstage non-Hodgkin's lymphomas.It is Indicated in moderate to severe rheumatoid\r\narthritis, malignant disease and psoriasis. It is also indicated in the management of\r\nchildren with active polyarticular-course juvenile idiopathic arthritis, who had as\r\ninsufficient therapeutic response to, or are intolerant of adequate trial of first line\r\ntherapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).</span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>DOSAGE & ADMINISTRATION:</strong><br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>In the treatment of rheumatoid arthritis: </strong>By mouth, 7.5 mg once weekly as a single\r\ndose or divided into 3 doses of 2.5 mg given at intervals of 12 hours, adjusted\r\naccording to response; maximum total weekly dose 20 mg. </span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>In juvenile idiopathic arthritis : </strong>Starting dose is 10 mg/m2/wk increasing upto 20-25\r\nmg/m2/wk in refractory disease. An alternative dosing regimen is 0.3 mg/kg/wk\r\nincreasing to 0.5 mg/kg/wk after 6 weeks and up to 1 mg/kg/wk if necessary. </span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Leukaemia in children (maintenance): </strong>By mouth, 15 mg/m2 body surface weekly\r\nin combination with other drugs. </span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Maintenance therapy of acute lymphoblastic leukaemia: </strong>A common dose of 15 -\r\n30 mg/m2 body surface, once or twice weekly by mouth with other agents.</span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">\r\n<strong>Choriocarcinoma:</strong> Treated with doses of 15 - 30 mg daily by mouth for 5 days at\r\nintervals of 1 - 2 weeks for 3 - 5 courses. Doses of 10 - 16 mg/m2 have also been\r\nemployed in the treatment of breast cancer, often in combination with\r\nCyclophosmamide & Fluorouracil.</span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">\r\n<strong>In the treatment of psoriasis:</strong> Single weekly doses of 10 - 25 mg may be given by\r\nmouth, adjusted according to response. Or, as directed by the registered physicians.</span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Use In Pregnancy And Lactation:</strong><br></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">Pregnancy Category X. Meth (Methotrexate) should be avoided during pregnancy. It\r\nis teratogenic and fertility may be reduced during therapy but this may be\r\nreversible. Following administration to a woman or a man, avoid conception for at\r\nleast 3 months after stopping. Breast-feeding should be discontinued.</span></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>PACKAGING:</strong><br></span></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Meth-2.5 :</strong> Each box contains 28 tablets in blister pack. </span></span></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Meth-10 :</strong> Each box contains 28 tablets in blister pack.</span></span></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><br></span></span></p>",
    "strength": "10,2.5",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/Meth-Insert- 1 [Converted].pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1637662009Meth - 10 Carton.png",
      "https://www.admin.drug-international.com/uploads/product_images/1637662009Meth 2.5 Carton.png"
    ]
  },
  {
    "id": "853",
    "name": "Meverine ",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Mebeverine Hydrochloride BP  135 mg\r\nTablet.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong><strong></strong><span class=\"redactor-invisible-space\"> Meverine is indicated for\r\nthe symptomatic treatment of irritable\r\nbowel syndromme and other conditions\r\nusually included in this grouping such as:\r\nchronic irritable colon, spastic\r\nconstipation, mucous colitis, spastic\r\ncolitis. Meverine is also effective in\r\ncolicky abdominal pain and cramps,\r\npersistent, non-specific diarrhoea (with\r\nor without alternating constipation) and\r\nflatulence.\r\nFor the symptomatic treatment of gastrointestinal\r\nspasm secondary to organic\r\ndiseases.<strong>\r\n</strong>Meverine-SR : Mebeverine Hydrochloride\r\nis indicated: For the symptomatic\r\ntreatment of irritable bowel syndrome\r\n(IBS), other conditions include: Chronic\r\nirritable colon, Spastic constipation,\r\nMucous Colitis, Colicky abdominal pain,\r\nPersistent non-specific diarrhoea.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> Adults & Children over 10\r\nyears, 1 tablet 3 times daily, preferably\r\n20 minutes before meals or as directed\r\nby a registered physician.\r\nMeverine-SR : Adults, elderly : 1 Capsule\r\ntwice daily, preferably 20 minutes before\r\nmeals. Or, as directed by the registered\r\nphysician.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">No\r\nteratogenicity has been shown in animal\r\nexperiments. However, the usual\r\nprecautions concerning the administration\r\nof any drug during pregnancy should be\r\nexercised. Mebeverine dose not excrete in\r\nthe breast milk after administering at\r\ntherapeutic dose.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Meverine : 5 x 10's tablets in\r\nblister pack.</span></p>",
    "strength": "135,200",
    "uom": "mg",
    "categoryId": "44",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531892879mebeverin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745147736MEVERINE.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745147755Meverine-SR.png"
    ]
  },
  {
    "id": "1209",
    "name": "Meverine - SR ",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Mebeverine Hydrochloride BP 200 mg SR Capsule.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication :</strong><span class=\"redactor-invisible-space\"> Meverine is indicated for the symptomatic treatment of irritable bowel syndromme and other conditions usually included in this grouping such as: chronic irritable colon, spastic constipation, mucous colitis, spastic colitis. Meverine is also effective in colicky abdominal pain and cramps, persistent, non-specific diarrhoea (with or without alternating constipation) and flatulence. For the symptomatic treatment of gastrointestinal spasm secondary to organic diseases.<strong> </strong>Meverine-SR : Mebeverine Hydrochloride is indicated: For the symptomatic treatment of irritable bowel syndrome (IBS), other conditions include: Chronic irritable colon, Spastic constipation, Mucous Colitis, Colicky abdominal pain, Persistent non-specific diarrhoea.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration :</strong> Adults & Children over 10 years, 1 tablet 3 times daily, preferably 20 minutes before meals or as directed by a registered physician. Meverine-SR : Adults, elderly : 1 Capsule twice daily, preferably 20 minutes before meals. Or, as directed by the registered physician.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">No teratogenicity has been shown in animal experiments. However, the usual precautions concerning the administration of any drug during pregnancy should be exercised. Mebeverine dose not excrete in the breast milk after administering at therapeutic dose.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\">Meverine SR : 3x10's Capsules in blister pack.</p>",
    "strength": "200",
    "uom": "mg",
    "categoryId": "44",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531893007mebeverin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745147755Meverine-SR.png"
    ]
  },
  {
    "id": "859",
    "name": "Mexaton",
    "description": "<p style=\"text-align: justify;\"><strong></strong><strong></strong><!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves></w:TrackMoves>\r\n  <w:TrackFormatting></w:TrackFormatting>\r\n  <w:PunctuationKerning></w:PunctuationKerning>\r\n  <w:ValidateAgainstSchemas></w:ValidateAgainstSchemas>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF></w:DoNotPromoteQF>\r\n  <w:LidThemeOther>EN-US</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables></w:BreakWrappedTables>\r\n   <w:SnapToGridInCell></w:SnapToGridInCell>\r\n   <w:WrapTextWithPunct></w:WrapTextWithPunct>\r\n   <w:UseAsianBreakRules></w:UseAsianBreakRules>\r\n   <w:DontGrowAutofit></w:DontGrowAutofit>\r\n   <w:SplitPgBreakAndParaMark></w:SplitPgBreakAndParaMark>\r\n   <w:DontVertAlignCellWithSp></w:DontVertAlignCellWithSp>\r\n   <w:DontBreakConstrainedForcedTables></w:DontBreakConstrainedForcedTables>\r\n   <w:DontVertAlignInTxbx></w:DontVertAlignInTxbx>\r\n   <w:Word11KerningPairs></w:Word11KerningPairs>\r\n   <w:CachedColBalance></w:CachedColBalance>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"></m:mathFont>\r\n   <m:brkBin m:val=\"before\"></m:brkBin>\r\n   <m:brkBinSub m:val=\"--\"></m:brkBinSub>\r\n   <m:smallFrac m:val=\"off\"></m:smallFrac>\r\n   <m:dispDef></m:dispDef>\r\n   <m:lMargin m:val=\"0\"></m:lMargin>\r\n   <m:rMargin m:val=\"0\"></m:rMargin>\r\n   <m:defJc m:val=\"centerGroup\"></m:defJc>\r\n   <m:wrapIndent m:val=\"1440\"></m:wrapIndent>\r\n   <m:intLim m:val=\"subSup\"></m:intLim>\r\n   <m:naryLim m:val=\"undOvr\"></m:naryLim>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"true\"\r\n  DefSemiHidden=\"true\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"267\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Normal\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"heading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" QFormat=\"true\" Name=\"caption\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" Name=\"Default Paragraph Font\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtitle\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Strong\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"59\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Table Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Placeholder Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"No Spacing\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Revision\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"List Paragraph\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"19\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"21\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"31\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"32\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"33\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Book Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"37\" Name=\"Bibliography\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" QFormat=\"true\" Name=\"TOC Heading\"></w:LsdException>\r\n </w:LatentStyles>\r\n</xml><![endif]--><!--[if gte mso 10]>\r\n<style>\r\n /* Style Definitions */\r\n table.MsoNormalTable\r\n\t{mso-style-name:\"Table Normal\";\r\n\tmso-tstyle-rowband-size:0;\r\n\tmso-tstyle-colband-size:0;\r\n\tmso-style-noshow:yes;\r\n\tmso-style-priority:99;\r\n\tmso-style-qformat:yes;\r\n\tmso-style-parent:\"\";\r\n\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\r\n\tmso-para-margin-top:0in;\r\n\tmso-para-margin-right:0in;\r\n\tmso-para-margin-bottom:8.0pt;\r\n\tmso-para-margin-left:0in;\r\n\tline-height:107%;\r\n\tmso-pagination:widow-orphan;\r\n\tfont-size:11.0pt;\r\n\tfont-family:\"Calibri\",\"sans-serif\";\r\n\tmso-ascii-font-family:Calibri;\r\n\tmso-ascii-theme-font:minor-latin;\r\n\tmso-fareast-font-family:\"Times New Roman\";\r\n\tmso-fareast-theme-font:minor-fareast;\r\n\tmso-hansi-font-family:Calibri;\r\n\tmso-hansi-theme-font:minor-latin;\r\n\tmso-bidi-font-family:\"Times New Roman\";\r\n\tmso-bidi-theme-font:minor-bidi;}\r\n</style>\r\n<![endif]--><!--[if gte mso 9]><xml>\r\n <o:shapedefaults v:ext=\"edit\" spidmax=\"1026\"></o:shapedefaults>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <o:shapelayout v:ext=\"edit\">\r\n  <o:idmap v:ext=\"edit\" data=\"1\"></o:idmap>\r\n </o:shapelayout></xml><![endif]--></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\nline-height:normal\"><strong>Tolperisone HCl INN</strong></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\nline-height:normal\"><strong>Composition : </strong>Tolperisone Hydrochloride INN 50mg Tablet.</p><p class=\"MsoNormal\" style=\"margin-right:-5.25pt;text-align:justify\"><strong>Indication :</strong> It is indicated for-</p><p class=\"MsoNormal\" style=\"margin-right:-5.25pt;text-align:justify\">1.\r\nT<span class=\"redactor-invisible-space\">reatment of increased tone of skeletal\r\nmuscles due to organic neurological disorders (injury of the pyramidal tract,\r\nmultiple sclerosis, myelopathy, encephalomyelitis).</span></p><p class=\"MsoNormal\" style=\"margin-right:-5.25pt;text-align:justify\"><span class=\"redactor-invisible-space\">2. Treatment of muscular spasm, muscular\r\ncontracture, rigidity, spinal automatism.</span></p><p class=\"MsoNormal\" style=\"margin-right:-5.25pt;text-align:justify\"><span class=\"redactor-invisible-space\">3. In the treatment of vascular diseases\r\n(Obliterative arteriosclerosis, diabetic angiopathy, obliterative\r\nthromboangitis, Raynaud's disease, diffuse scleroderma).</span></p><p class=\"MsoNormal\" style=\"margin-right:-5.25pt;text-align:justify\"><span class=\"redactor-invisible-space\">4. In individual cases, post-thrombotic\r\nvenous and lymphatic circulation disorders and crural ulcer.</span></p><p class=\"MsoNormal\" style=\"margin-right:-5.25pt;text-align:justify\"><strong>Dosage and administration :<i> </i></strong><span class=\"redactor-invisible-space\">The recommended dose is as following:\r\nAdult: 50-150mg three times daily according to the individual requirement and\r\ntolerance of the patient. Children (from 3 months to 6 years): 5mg/kg/day in\r\nthree divided doses. Children (from 6 to 14 years): 2- 4mg/kg/day in three\r\ndivided doses. Or, as directed by the registered physician.</span></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Use\r\nin pregnancy and lactation :</strong> Mexaton\r\nshould be used in pregnancy according to physician's advice. It should not be\r\nused during breast feeding.</p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Packing:</strong> 4x14’s tablets\r\nin blister pack.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"></span></p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "55",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1729934469Untitled-1.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1729763468Mexaton Carton.png"
    ]
  },
  {
    "id": "1025",
    "name": "Micoderm",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:</strong> Miconazole Nitrate USP  2% Cream.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indications :</strong> It is indicated for the treatment of\r\nmycotic infections of the skin & nails , super infection due to grampus itive\r\nbacteria and also topically used in the treatment of tinea pedis (athlete's foot),\r\ntinea cruris, tinea corporis, cutaneous candidias is (moniliasis ), tinea vers\r\nicolor, stomatitis, angularis , otitis externa.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration :</strong> (For all the\r\nages ) : It should be usually applied 1 to 2 times daily for 2 to 4 weeks . <strong>For skin infections:</strong> The cream should\r\nbe applied twice daily (morning & evening) to the lesions. Treatment\r\nshould be prolonged for 10 days after all lesions have disappeared to prevent\r\nrelapse. <strong>For nail infections:</strong> The\r\ncream should be applied once or twice daily to the lesions. Treatment should\r\nbe prolonged for 10 days after all les ions have disappeared to prevent relapse.\r\nOr, as directed by the registered physicians.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Packing : Micoderm Cream :</strong> Each tube\r\ncontains 10gm cream.</p>",
    "strength": "2% w/w",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531893084Micoderm Cream.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Micoderm.jpg"
    ]
  },
  {
    "id": "1052",
    "name": "Micoderm",
    "description": "<p><strong>Composition : </strong>Miconazole BP  2% Oral Gel. </p><p><strong>Indication : </strong><span class=\"redactor-invisible-space\">This gel is indicated for oral treatment and prevention of fungal infections of the oropharynx and of super infections due to Grampositive bacteria.</span></p><p><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">For localized lesions of the mouth, a small amount of gel may be applied directly to the affected area with a clean finger. For topical treatment of the oropharynx, the gel should be kept in the mouth for as long as possible. Treatment should be continued for up to 2 days after the symptoms have cleared. For oral candidosis, dental prostheses should be removed at night and brushed with the gel. Or, as directed by the registered physician.</span></p><p><strong>Packing : </strong><span class=\"redactor-invisible-space\" style=\"background-color: initial;\">Micoderm Oral Gel : 15gm in a tube</span></p>",
    "strength": "2% w/w",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531893363Micoderm.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/images/Micodgel.jpg"
    ]
  },
  {
    "id": "1026",
    "name": "Micoderm HC",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition: Micoderm-HC\r\nCream:</strong> Miconazole Nitrate BP 2% & Hydrocortisone BP 1% Cream.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indications:</strong> For the topical treatment of topical inflamed dermatoses where infection\r\nby susceptible organisms and inflammation coexist e.g. intertrigo and infected\r\neczema. For moist or dry eczema or dermatitis including atopic eczema, primary\r\nirritant or contact allergic eczema or seborrhoeic eczema including that associated\r\nwith acne. Also for intertriginious eczema including inflammatory intertrigo,\r\nperinial and genital dermatitis. Organisms which are susceptible to miconazole\r\nare dermatophytes and pathogenic yeasts (e.g. Candida spp.). Also many gram positive\r\nbacteria including many strains of streptococcus and </p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\">staphylococcus .</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration:</strong> It should be applied topically to the affected area two or three\r\ntime’s daily .The same dosage applies to both adults & children. In infants,\r\nlong term continuous topical corticosteroid therapy should be avoided. Occlusive dressing is usually only necessary in the case of nail lesions . Or, as\r\ndirected by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Packing : Micoderm-HC\r\nCream:</strong> 10 gm in a tube.</p>",
    "strength": "(2% + 1%) w/w",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531893447Micoderm  Hc.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745310122Micoderm-HC.png"
    ]
  },
  {
    "id": "852",
    "name": "Migon",
    "description": "<p><strong>Composition: </strong>Migon Tablet: Each Film Coated tablet contains Flunarizine 1O mg as Flunarizine Dihydrochloride BP.<span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indications: </strong>Flunarizine tablets are indicated for the  treatment of prophylaxis of classic (with aura) or common (without aura) migraine, Symptomatic treatment of vestibular vertigo (due to a diagnosed functional disorder of the vestibular system), Peripheral vascular disease (PVD), Motion sickness, Refractory epilepsy resistant to conventoinal antiepilepitc therapy.</p><p style=\"text-align: justify;\"><strong>Dosage & Administration: </strong>Adults and elderly-Migraine prophylaxis: Starting Dose- 10 mg daily (at night) for adult patients aged 18 to 64 years and 5 mg daily (at night) for elderly patients aged 65 years and older. If during this treatment depressive, extra pyramidal & other unacceptable adverse experiences occur, administration should be discontinued. If after 2 months of this initial treatment  no significant improvement is observed, the patient should be considered a non-responder and administration should be discontinued.</p><p style=\"text-align: justify;\"><strong>Use In pregnancy & Lactation: </strong>Pregnancy: There are no adequate data and well controlled studies in pregnant women. lactation : It is unknown whether flunarizine is excreted in human milk. This tablet should be used during pregnancy only if clearly needed. Caution should be exercised when this tablet is administered to a nursing woman.</p><p style=\"text-align: justify;\"><strong>Packing: </strong>Migon Tablet: Each box contains 4x14's tablets in blister pack.</p><p style=\"text-align: justify;\"><strong></strong><br></p>",
    "strength": "10,5",
    "uom": "mg",
    "categoryId": "42",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745147890Migon-10.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745147890Migon-5.png"
    ]
  },
  {
    "id": "851",
    "name": "Miotrol",
    "description": "<p><strong>Composition : </strong>Each film coated tablet contains Zolmitriptan USP 2.5mg .<br><strong></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:6.25pt;line-height:normal\"><strong>Indication :</strong> Zolmitriptan\r\nis indicated for the acute treatment of migraine with or without aura in adult<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:6.25pt;line-height:normal\"><strong>Dosage and administration :</strong> The recommended dose of Zolmitriptan to treat a\r\nmigraine attack is 2.5mg. If symptoms persist or return within 24 hours, a\r\nsecond dose has been shown to be effective. If a second dose is required, it\r\nshould not be taken within 2 hours of the initial dose. If a patient does not achieve\r\nsatisfactory relief with 2.5mg doses, subsequent attacks can be treated with\r\n5mg doses of Zolmitriptan. In the event of recurrent attacks, it is recommended\r\nthat the total intake of Zolmitriptan in a 24 hour period should not exceed\r\n15mg. Or, as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:6.25pt;line-height:normal\"><strong>Pregnancy and lactation :</strong> Pregnancy\r\nCategory C by FDA.<o:p></o:p></p><p><strong>Packing :</strong> Miotrol\r\n: 5 x 10's tablets in blister pack.<br></p>",
    "strength": "2.5",
    "uom": "mg",
    "categoryId": "42",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1683361320Miotrol book style insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744102004MIOTROL.png"
    ]
  },
  {
    "id": "1778",
    "name": "Momodol Extra",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition : </strong>Paracetamol\r\nBP 500.00mg and Caffeine BP 65.00mg Tablet.<br></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication :</strong>\r\nIt is indicated for the treatment of most painful and febrile conditions, for example,\r\nheadache, including migraine, backache, toothache, rheumatic pain and dysmenorrhea,\r\nand relief of the symptoms of colds, influenza and sore throat. </p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and administration :<i> </i></strong>Adults and children16 years and over. Two tablets every 4-6\r\nhours up to four times daily. Do not exceed 8 tablets in 24 hours. Children and\r\nchildren aged 12-15 years: One tablet every 4-6 hours up to four times daily.\r\nDo not exceed 4 tablets in 24 hours. Not recommended for children under 12\r\nyears. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation :</strong> Paracetamol-caffeine\r\nis not recommended for use during pregnancy due to the possible increase risk\r\nof lower birth weight and spontaneous abortion associated with caffeine\r\nconsumption, Caffeine in breast milk may potentially have a stimulating effect\r\non breast fed infants. Due to the caffeine content of this product it should\r\nnot be used in pregnant or breast feeding women.</p><p class=\"MsoNormal\"><strong> </strong></p><p class=\"MsoNormal\"><strong>Packing:</strong>\r\n60’s tablets in blister pack.</p>",
    "strength": "500 +65",
    "uom": "mg",
    "categoryId": "97",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1628332698Momodol Extra Insert 2021.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745147957Momodol Extra.png"
    ]
  },
  {
    "id": "1884",
    "name": "Momodol Suppository",
    "description": "<p><strong>Composition :</strong> Paracetamol BP 125mg, 250mg & 500mg Suppository.</p><p class=\"MsoNormal\"><strong>Indication :</strong> It\r\nis indicated for fever, common cold and influenza, headache, toothache,\r\nearache, bodyache, back pain, inflammatory pain, post-vaccination pain, fever\r\nof children & osteoarthritic pain.</p><p class=\"MsoNormal\"><strong>Dosage &\r\nAdministration :</strong> Suppository should be administered rectally.</p><p class=\"MsoNormal\">&gt; Children 3 months - 1 year: 1-2 suppository (60-120mg).\r\nThe dosage should be based on age & weight i.e. 3 months (5kg)-60mg (1\r\nsuppository), 1 year (10kg)-120mg (2 suppositories of 60mg)</p><p class=\"MsoNormal\">&gt; Children below 5 years: 125-250mg, 2-3 times daily.</p><p class=\"MsoNormal\">&gt; Children 6-12 years: 250-500mg, 2-3 times daily.</p><p class=\"MsoNormal\">&gt; Adults & children over 12 years: 500-1000mg, 2-3\r\ntimes daily.</p><p class=\"MsoNormal\">Or, as directed by the registered physician.</p><p class=\"MsoNormal\"><strong>Use in Pregnancy and\r\nlactation :</strong>  Paracetamol is safe in\r\nall stages of pregnancy and lactation.</p><p class=\"MsoNormal\"><strong>Packing : <o></o></strong></p><p class=\"MsoNormal\">Momodol 125 Suppository : Each box contains 30 Suppositories\r\nin blister pack.</p><p class=\"MsoNormal\">Momodol 250 Suppository : Each box contains 30 Suppositories\r\nin blister pack.</p><p>Momodol 500 Suppository : Each box contains 25 Suppositories\r\nin blister pack.</p>",
    "strength": "250,125",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1688364105",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745147933Momodol 250.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745147933Momodol 125.png"
    ]
  },
  {
    "id": "1009",
    "name": "Monocard",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Isosorbide-5-Mononitrate\r\n 20mg Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">For the treatment &\r\nprophylaxis of angina pectoris.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The usual\r\noral dose is 1 tablet (20mg) 2 times daily,\r\nfirst dose in the morning and another 7\r\nhours apart. Although maintenance\r\ndoses ranging from 20mg to 120mg (1-6\r\ntablets), a dose of 10mg (1/2 tablet) is\r\nsuitable when lower dosage is used at\r\nthe starting of treatment or as directed by\r\na registered physician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Monocard : 10 x 10's tablets\r\nin blister pack.</span></p>",
    "strength": "20",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633327480Monocard.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744103521MONOCARD-20.png"
    ]
  },
  {
    "id": "1244",
    "name": "Monocard SR",
    "description": "<p><strong>Composition :</strong> Each Sustained Release Capsule Contains Isosorbide-5-<br>Mononitrate 50mg.<strong><br></strong></p><p style=\"text-align: justify;\"><strong>Indications : </strong>Monocard-SR is indicated for use in the treatment &prophylaxis of angina pectoris . Dos age & Administration : The usual oral dose is 1 capsule (50mg) daily or as directed by the registered physician.</p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> The usual oral dose is 1 tablet (20 mg) 2 times daily, first dose in the morning and another 7 hours apart. Although maintenance doses ranging from 20 mg to 120 mg (1-6 tablets), a dose of 10 mg (1/2 tablet) is suitable when lower dosage is used at the starting of treatment or as directed by a registered physician. <br></p><p style=\"text-align: justify;\"><strong>Pregnancy & Lactation: </strong>Pregnancy Category C by FDA<strong></strong><br></p><p style=\"text-align: justify;\"><strong>Packing : Monocard-SR : </strong>Each box contains 6 x 7's capsules in blister pack.</p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531894610Monocard SR.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/MonocardSR.jpg"
    ]
  },
  {
    "id": "1807",
    "name": "Mukof",
    "description": "<p><strong>Composition : Mukof\r\nTablet : </strong>Each\r\nDispersible Tablet Contains Acetylcysteine USP 600mg.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications : </strong>It is indicated\r\nas an adjunctive treatment for patients with abnormal, viscid or inspissated\r\nmucus secretions associated with conditions such as<o:p></o:p></p><p class=\"MsoListParagraphCxSpFirst\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\nmso-add-space:auto;text-indent:-.25in;line-height:normal;mso-list:l0 level1 lfo1;\r\nmso-layout-grid-align:none;text-autospace:none\"><!--[if !supportLists]-->·          <!--[endif]-->Acute and\r\nchronic bronchopulmonary disorders (e.g. pneumonia, bronchitis, emphysema,\r\ntracheobronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis,\r\nprimary amyloidosis of the lung) <o:p></o:p></p><p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;margin-bottom:\r\n.0001pt;mso-add-space:auto;text-indent:-.25in;line-height:normal;mso-list:l0 level1 lfo1;\r\nmso-layout-grid-align:none;text-autospace:none\"><!--[if !supportLists]-->·          <!--[endif]-->Atelectasis\r\ncaused by mucus obstruction <o:p></o:p></p><p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;margin-bottom:\r\n.0001pt;mso-add-space:auto;text-indent:-.25in;line-height:normal;mso-list:l0 level1 lfo1;\r\nmso-layout-grid-align:none;text-autospace:none\"><!--[if !supportLists]-->·           <!--[endif]-->Pulmonary\r\ncomplications of cystic fibrosis<o:p></o:p></p><p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;margin-bottom:\r\n.0001pt;mso-add-space:auto;text-indent:-.25in;line-height:normal;mso-list:l0 level1 lfo1;\r\nmso-layout-grid-align:none;text-autospace:none\"><!--[if !supportLists]-->·          <!--[endif]-->Pulmonary\r\ncomplications of thoracic and cardiovascular surgery &<o:p></o:p></p><p class=\"MsoListParagraphCxSpLast\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\nmso-add-space:auto;text-indent:-.25in;line-height:normal;mso-list:l0 level1 lfo1;\r\nmso-layout-grid-align:none;text-autospace:none\"><!--[if !supportLists]-->·          <!--[endif]-->Post-traumatic\r\nchest conditions. It is effective in all respiratory airways disease causing\r\nformation of a dense secretion that cannot be or can only partially be expectorated\r\nsuch as acute and chronic bronchitis, laryngitis, sinusitis, tracheitis,\r\ninfluenza & bronchial asthma. Acetylcysteine is also indicated in the\r\ntreatment of Paracetamol overdose. Treatment option is optimal if given within\r\n8 hours of Paracetamol ingestion.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Dosage\r\nand administration : Adults & children above 6 years of age: </strong>1 tablet daily<strong>\r\n</strong>(Preferably in the evening). The duration of<strong> </strong>treatment should be\r\n5-10 days in acute<strong> </strong>treatment. <strong>In Paracetamol overdose: </strong>Initially<strong>\r\n</strong>140 mg/kg, followed by 70 mg/kg every 4 hours<strong> </strong>for an additional 17\r\ndoses. Dissolve 1 tablet in a<strong> </strong>glass of water (200 ml) to drink. Or, as\r\ndirected<strong> </strong>by the registered physician.<strong><o:p></o:p></strong></p><p><strong>Use\r\nin Pregnancy and lactation: </strong>Pregnancy category B. Caution should be\r\ntaken in case of pregnancy & lactation while using Acetylcysteine.</p>",
    "strength": " 600",
    "uom": "mg",
    "categoryId": "47",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1637665149Mukof.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744103696Mukof.png"
    ]
  },
  {
    "id": "1041",
    "name": "Muron",
    "description": "<p><strong></strong><strong>Composition : </strong>: Mupirocin USP 2%.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Muron ointment 2% is\r\nindicated for the topical treatment of\r\nimpetigo due to : Staphylococcus aureus\r\nand Streptococcus pyogenes.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">A small\r\namount of Muron ointment should be\r\napplied to the affected area three times\r\ndaily. The area may be covered with a\r\ngauze dressing if desired. Or as directed\r\nby the registered physician.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong> Muron Ointment :10gm in a\r\ntube.</p>",
    "strength": "2% w/w",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531901409Muron.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745310323Muron.png"
    ]
  },
  {
    "id": "1027",
    "name": "Mycofree",
    "description": "<p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong></strong><strong><em></em></strong><!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves></w:TrackMoves>\r\n  <w:TrackFormatting></w:TrackFormatting>\r\n  <w:PunctuationKerning></w:PunctuationKerning>\r\n  <w:ValidateAgainstSchemas></w:ValidateAgainstSchemas>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF></w:DoNotPromoteQF>\r\n  <w:LidThemeOther>EN-US</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables></w:BreakWrappedTables>\r\n   <w:SnapToGridInCell></w:SnapToGridInCell>\r\n   <w:WrapTextWithPunct></w:WrapTextWithPunct>\r\n   <w:UseAsianBreakRules></w:UseAsianBreakRules>\r\n   <w:DontGrowAutofit></w:DontGrowAutofit>\r\n   <w:SplitPgBreakAndParaMark></w:SplitPgBreakAndParaMark>\r\n   <w:DontVertAlignCellWithSp></w:DontVertAlignCellWithSp>\r\n   <w:DontBreakConstrainedForcedTables></w:DontBreakConstrainedForcedTables>\r\n   <w:DontVertAlignInTxbx></w:DontVertAlignInTxbx>\r\n   <w:Word11KerningPairs></w:Word11KerningPairs>\r\n   <w:CachedColBalance></w:CachedColBalance>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"></m:mathFont>\r\n   <m:brkBin m:val=\"before\"></m:brkBin>\r\n   <m:brkBinSub m:val=\"--\"></m:brkBinSub>\r\n   <m:smallFrac m:val=\"off\"></m:smallFrac>\r\n   <m:dispDef></m:dispDef>\r\n   <m:lMargin m:val=\"0\"></m:lMargin>\r\n   <m:rMargin m:val=\"0\"></m:rMargin>\r\n   <m:defJc m:val=\"centerGroup\"></m:defJc>\r\n   <m:wrapIndent m:val=\"1440\"></m:wrapIndent>\r\n   <m:intLim m:val=\"subSup\"></m:intLim>\r\n   <m:naryLim m:val=\"undOvr\"></m:naryLim>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"true\"\r\n  DefSemiHidden=\"true\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"267\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Normal\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"heading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" QFormat=\"true\" Name=\"caption\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" Name=\"Default Paragraph Font\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtitle\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Strong\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"59\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Table Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Placeholder Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"No Spacing\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Revision\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"List Paragraph\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"19\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"21\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"31\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"32\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"33\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Book Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"37\" Name=\"Bibliography\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" QFormat=\"true\" Name=\"TOC Heading\"></w:LsdException>\r\n </w:LatentStyles>\r\n</xml><![endif]--><!--[if gte mso 10]>\r\n<style>\r\n /* Style Definitions */\r\n table.MsoNormalTable\r\n\t{mso-style-name:\"Table Normal\";\r\n\tmso-tstyle-rowband-size:0;\r\n\tmso-tstyle-colband-size:0;\r\n\tmso-style-noshow:yes;\r\n\tmso-style-priority:99;\r\n\tmso-style-qformat:yes;\r\n\tmso-style-parent:\"\";\r\n\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\r\n\tmso-para-margin-top:0in;\r\n\tmso-para-margin-right:0in;\r\n\tmso-para-margin-bottom:8.0pt;\r\n\tmso-para-margin-left:0in;\r\n\tline-height:107%;\r\n\tmso-pagination:widow-orphan;\r\n\tfont-size:11.0pt;\r\n\tfont-family:\"Calibri\",\"sans-serif\";\r\n\tmso-ascii-font-family:Calibri;\r\n\tmso-ascii-theme-font:minor-latin;\r\n\tmso-fareast-font-family:\"Times New Roman\";\r\n\tmso-fareast-theme-font:minor-fareast;\r\n\tmso-hansi-font-family:Calibri;\r\n\tmso-hansi-theme-font:minor-latin;\r\n\tmso-bidi-font-family:\"Times New Roman\";\r\n\tmso-bidi-theme-font:minor-bidi;}\r\n</style>\r\n<![endif]-->\r\n\r\n</p><!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves></w:TrackMoves>\r\n  <w:TrackFormatting></w:TrackFormatting>\r\n  <w:PunctuationKerning></w:PunctuationKerning>\r\n  <w:ValidateAgainstSchemas></w:ValidateAgainstSchemas>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF></w:DoNotPromoteQF>\r\n  <w:LidThemeOther>EN-US</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables></w:BreakWrappedTables>\r\n   <w:SnapToGridInCell></w:SnapToGridInCell>\r\n   <w:WrapTextWithPunct></w:WrapTextWithPunct>\r\n   <w:UseAsianBreakRules></w:UseAsianBreakRules>\r\n   <w:DontGrowAutofit></w:DontGrowAutofit>\r\n   <w:SplitPgBreakAndParaMark></w:SplitPgBreakAndParaMark>\r\n   <w:DontVertAlignCellWithSp></w:DontVertAlignCellWithSp>\r\n   <w:DontBreakConstrainedForcedTables></w:DontBreakConstrainedForcedTables>\r\n   <w:DontVertAlignInTxbx></w:DontVertAlignInTxbx>\r\n   <w:Word11KerningPairs></w:Word11KerningPairs>\r\n   <w:CachedColBalance></w:CachedColBalance>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"></m:mathFont>\r\n   <m:brkBin m:val=\"before\"></m:brkBin>\r\n   <m:brkBinSub m:val=\"--\"></m:brkBinSub>\r\n   <m:smallFrac m:val=\"off\"></m:smallFrac>\r\n   <m:dispDef></m:dispDef>\r\n   <m:lMargin m:val=\"0\"></m:lMargin>\r\n   <m:rMargin m:val=\"0\"></m:rMargin>\r\n   <m:defJc m:val=\"centerGroup\"></m:defJc>\r\n   <m:wrapIndent m:val=\"1440\"></m:wrapIndent>\r\n   <m:intLim m:val=\"subSup\"></m:intLim>\r\n   <m:naryLim m:val=\"undOvr\"></m:naryLim>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"true\"\r\n  DefSemiHidden=\"true\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"267\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Normal\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"heading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" QFormat=\"true\" Name=\"caption\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" Name=\"Default Paragraph Font\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtitle\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Strong\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"59\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Table Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Placeholder Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"No Spacing\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Revision\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"List Paragraph\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"19\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"21\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"31\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"32\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"33\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Book Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"37\" Name=\"Bibliography\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" QFormat=\"true\" Name=\"TOC Heading\"></w:LsdException>\r\n </w:LatentStyles>\r\n</xml><![endif]--><!--[if gte mso 10]>\r\n<style>\r\n /* Style Definitions */\r\n table.MsoNormalTable\r\n\t{mso-style-name:\"Table Normal\";\r\n\tmso-tstyle-rowband-size:0;\r\n\tmso-tstyle-colband-size:0;\r\n\tmso-style-noshow:yes;\r\n\tmso-style-priority:99;\r\n\tmso-style-qformat:yes;\r\n\tmso-style-parent:\"\";\r\n\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\r\n\tmso-para-margin-top:0in;\r\n\tmso-para-margin-right:0in;\r\n\tmso-para-margin-bottom:8.0pt;\r\n\tmso-para-margin-left:0in;\r\n\tline-height:107%;\r\n\tmso-pagination:widow-orphan;\r\n\tfont-size:11.0pt;\r\n\tfont-family:\"Calibri\",\"sans-serif\";\r\n\tmso-ascii-font-family:Calibri;\r\n\tmso-ascii-theme-font:minor-latin;\r\n\tmso-fareast-font-family:\"Times New Roman\";\r\n\tmso-fareast-theme-font:minor-fareast;\r\n\tmso-hansi-font-family:Calibri;\r\n\tmso-hansi-theme-font:minor-latin;\r\n\tmso-bidi-font-family:\"Times New Roman\";\r\n\tmso-bidi-theme-font:minor-bidi;}\r\n</style>\r\n<![endif]--><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\nline-height:normal\"><strong><br></strong></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\nline-height:normal\"><strong>Composition : </strong>Terbinafine USP 250 mg as Terbinafine Hydrochloride Tablet.</p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Indication\r\n:</strong> Mycofree tablet is indicated for\r\nthe treatment of : Onychomycosis of fingernails and toenails due to\r\ndermatophytes. Fungal infections of the skin (Tinea corporis, Tinea cruris,\r\nTinea pedis). Hair and scalp infections (Tinea capitis). Yeast infections of\r\nthe skin caused by the genus Candida (e.g. Candida albicans), where oral\r\ntherapy is generally considered appropriate owing to the site, severity or\r\nextent of the infection.</p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Dosage\r\nand administration :<i> </i></strong>For\r\nTinea cruris: 250mg tablet once daily for 2 to 4 weeks. For Tinea pedis: 250mg\r\ntablet once daily for 2 to 6 weeks. For Tinea corporis: 250mg tablet once daily\r\nfor 4 weeks. For dermatophyte infections of the finger & toenails : 250mg\r\ntablet once daily for 6 to 12 weeks. Longer treatment is necessary for toenail\r\ninfections. For skin and hair infections : 250mg tablet once daily for 2 to 6\r\nweeks. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Use\r\nin pregnancy and lactation :</strong>\r\nPregnancy : Pregnancy category B. It should not be used during pregnancy unless\r\nthe potential benefits clearly outweigh the risk. Lactation : It should not be\r\ngiven to nursing mothers because the drug is excreted in breast milk.</p><p class=\"MsoNormal\"><strong>Packing:</strong>\r\n1x10’s tablets in blister pack.</p><p><br></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"></span><span class=\"redactor-invisible-space\"></span></p>",
    "strength": "250",
    "uom": "mg",
    "categoryId": "40",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1612944733Mycofree Insert (Book Style).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745148087Mycofree-250.png"
    ]
  },
  {
    "id": "1301",
    "name": "Mycofree Cream",
    "description": "<p><strong>Composition : </strong>Terbinafine Hydrochloride BP 1% Cream. </p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Indications : </strong>It is used to treat fungal infections of the skin caused by Trichophyton(e.g.T.Rubrum,T.Mentagrop hytes, T.Verrucosum, T.Violaceum), Microsporum canis and Epidermophyton floccosum. It ia also used to treat yeast infections of the skin,principally those caused by the genus Candida (e.g.C.albicans).</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Dosage and administration : Adult: </strong>It can be applied once or twice daily after drying the affected areas thoroughly. Apply the cream to the affected skin and surrounding area in a thin layer and rub in lightly. In the case of intertriginous infections (submammary, interdigital, intergluteal, inguinal) the application may be covered with a gauze strip, especially at night. The likely durations of treatment are as follows. Tinea corporis,cruris: 1 to 2 weeks, Tinea pedis: 1 week, Cutaneous candidiasis: 2 weeks,Pityriasis versicolor: 2 weeks. <strong>Children: </strong>The experience with topical cream in children is still limited and its use cannot therefore be recommended. Or, as directed by the registered physician.</p><p style=\"text-align: justify;\"><strong>Packing : Mycofree Cream </strong>: 15gm Cream in a tube.</p>",
    "strength": "1%",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531901647Mycofree_c.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745310360Mycofree.png"
    ]
  },
  {
    "id": "1320",
    "name": "Mydipin",
    "description": "<p><strong>Composition:</strong></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>MYDIPIN 5:</strong> Each film-coated tablet\r\ncontains Cilnidipine  5 mg.<o></o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>MYDIPIN 10:</strong> Each\r\nfilm-coated tablet contains Cilnidipine  10 mg.<o></o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Indications:</strong>\r\nHypertension.<o></o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Dosage &\r\nadministration:</strong> The recommended adult oral dosage of Cilnidipine is 5-10 mg\r\nonce daily.  The dosage can be increased\r\nup to 20 in a day, if needed. Or, as directed by the registered physician.<o></o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Use in pregnancy\r\n& lactation:</strong> No specific information about USFDA pregnancy category.\r\nCaution should be exercised during Cilnidipine use in pregnancy. Nursing\r\nmothers should consult a physician before taking Cilnidipine.<o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Packaging:</strong> <o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>MYDIPIN 5:</strong> Each box contains 3 x 14's\r\ntablets in blister pack.<o></o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><o></o></p><p style=\"text-align: justify;\"><strong>MYDIPIN 10:</strong> Each\r\nbox contains 2 x 14's tablets in blister pack. </p>",
    "strength": "10,5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531901765Mydipin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744103753MYDIPIN-10.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744103753MYDIPIN-5.png"
    ]
  },
  {
    "id": "1855",
    "name": "Mygest",
    "description": "<p><strong>Composition:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Mygest<a name=\"_GoBack\"></a> 100: </strong>Each Soft Gelatin Capsule\r\nContains Progesterone (Micronized) 100mg USP 100mg.<strong><o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Mygest\r\n200 : </strong>Each Soft Gelatin Capsule Contains Progesterone\r\n(Micronized) USP 200mg.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:\r\n</strong>Progesterone\r\nsoftgel capsule is indicated in- 1) Maintenance of Pregnancy in cases of\r\nThreatened / Recurrent abortion. 2) Luteal support during IUI and ART\r\nprocedures IVF-ET. 3) Luteal support in cases of proven luteal phase insufficiency.\r\n4) Along with estrogen in post-menopausal hormone replacement therapy (HRT)\r\neither in sequential or in continuous regimen. 5) To prevent endometrial\r\nhyperplasia where endogenous estrogen is present. 6) As progesterone challenge\r\ntest in secondary amenorrhoea. 7) For cycle control along with estrogen\r\ntherapy. 8) Dysfunctional uterine bleeding (DUB). 9) Premenstrual tension. 10)\r\nEndometriosis. 11) Oocyte donation programme. 12) Benign mastopathy.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\n&Administration: </strong>The usual recommended dose: Progesterone 100mg/200mg\r\n2 to 3 soft gel capsules daily by the oral or vaginal routes in divided doses.\r\nFlexible dosage regimen can be followed depending on the indication and\r\nrequirements of patients. Maintenance of Pregnancy in cases of Threatened /\r\nRecurrent abortion: Progesterone 200 to 400mg per day in divided doses.\r\nIn-vitro fertilization and embryo transfer: Progesterone 200mg thrice a day\r\nfrom the day of embryo transfer till pregnancy is confirmed. If pregnant, it is\r\ncontinued till 12’h week of pregnancy. HRT: In sequential regimen: Progesterone\r\n200mg daily for 12 days in last 2 weeks of each therapeutic cycle. In continuous\r\nregimen: Progesterone 100mg daily throughout the month along with estrogen.\r\nOocyte Donationprogramme: Progesterone 100mg twice daily from the day of\r\ntransfer till pregnancy is confirmed.This may be increased to a maximum of\r\n600mg per day and continued till 12th week of pregnancy. Luteal support:\r\nProgesterone 100mg thrice a day from the 17’thday of the cycle for 10 days in\r\ninduced cycle. If pregnant, it is continued till 12th week of pregnancy. Luteal\r\nphase insufficiency: Progesterone 100mg thrice daily to be continued up to 12\r\nweeks of pregnancy, increasing the dose by 100mg/day/week to a maximum of\r\n600mg/day in divided doses if required. In secondary amenorrhoea: Progesterone\r\n300mg for 10 days results in withdrawal bleeding in 80% of cases. Premenstrual syndrome:\r\nProgesterone 100-200mg daily for 10 days from 17th to 26th day of each\r\nmenstrualcycle. Benign mastopathy: Progesterone 200-300mg for 10 days per month,\r\nusually from 17th to 26th day of the monthly cycle. Or, as directed by the\r\nregistered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Pregnancy and lactation: </strong>Pregnancy\r\ncategory B. Caution should be exercised when Progesterone Capsules are\r\nadministered to a nursing woman.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:\r\nMygest 100: </strong>Each\r\nbox contains 30's tablet in a blister pack.<o></o></p><p><strong>Mygest 200: </strong>Each box\r\ncontains 30's tablet in a blister pack.</p>",
    "strength": "200,100",
    "uom": "mg",
    "categoryId": "123",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1738142535Mygest Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744104008Mygest 200.png",
      "https://www.admin.drug-international.com/uploads/product_images/1674550619Mygest-100.png"
    ]
  },
  {
    "id": "1761",
    "name": "Mylastin",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition : Mylastin\r\nTablet : </strong>Each\r\nFilm Coated Tablet Contains Bilastine INN 20mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications\r\n: Allergic Rhinitis :<i> </i></strong>Bilastine is\r\nindicated for the symptomatic relief of nasal and non-nasal symptoms of\r\nallergic rhinitis. <strong>Allergic\r\nRhinoconjunctivitis : </strong>Bilastine is indicated for the relief of the\r\nsymptoms associated with allergic rhinoconjunctiviotis. <strong>Urticaria : </strong>Bilastine is\r\nindicated for the relief of symptoms with urticaria (e.g. pruritus and hives).</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration : <i>Adults & adolescents (12 years of age and over): </i></strong>20mg bilastine\r\n(1 tablet) once daily for the<strong><i> </i></strong>relief of symptoms of allergic\r\nrhinnoconjunctiviotis<strong><i> </i></strong>and urticaria. The maximum<strong><i> </i></strong>recommended\r\ndaily dose is 20mg (1 tablet)<strong><i> </i></strong>and should not be exceeded. If a\r\ndose is<strong><i> </i></strong>missed, the next scheduled dose should be<strong><i> </i></strong>taken.\r\nAn extra dose should not be taken.</p><p class=\"MsoNormal\" xss=\"removed\">20mg\r\ntablet once daily should be swallowed with water on an empty stomach to achieve\r\noptimal exposure to Bilastine. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Pregnancy and lactation: </strong>Pregnancy category C. There are no\r\nadequate & well controlled studies in pregnant women. It should be avoided\r\nby pregnant women. It is not known whether this medicine is excreated in human\r\nbreast milk.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing : Mylastin\r\nTablet : </strong>Each\r\nbox contains 2 x 14's tablet in blister pack.</p>",
    "strength": "20",
    "uom": "mg",
    "categoryId": "41",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1617692050Mylastin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744104114Mylastin-20.png"
    ]
  },
  {
    "id": "1753",
    "name": "Mylomid",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:</strong>\r\n<strong>Mylomid-10: </strong>Each capsule contains Lenalidomide INN 10 mg. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>                       Mylomid-25: </strong>Each\r\ncapsule contains Lenalidomide INN 25 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong>\r\n<strong>Multiple Myeloma: </strong>Lenalidomide in combination with Dexamethasone is\r\nindicated for the treatment of adult patients with multiple myeloma (MM). <strong>Myelodysplastic\r\nSyndromes: </strong>Lenalidomide is indicated for the treatment of adult patients\r\nwith transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic\r\nsyndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or\r\nwithout additional cytogenetic abnormalities. <strong>Mantle Cell Lymphoma: </strong>Lenalidomide\r\nis indicated for the treatment of adult patients with mantle cell lymphoma\r\n(MCL) whose disease has relapsed or progressed after two prior therapies, one\r\nof which included Bortezomib. <strong>Follicular Lymphoma: </strong>Lenalidomide in\r\ncombination with a Rituximab product, is indicated for the treatment of adult\r\npatients with previously treated follicular lymphoma (FL).</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand Administration: Recommended Dosage\r\nfor Multiple Myeloma: Lenalidomide Combination Therapy: </strong>The\r\nrecommended starting dose of Lenalidomide is 25 mg orally once daily on Days\r\n1-21 of repeated 28-day cycles in combination with Dexamethasone. For patients\r\ngreater than 75 years old, the starting dose of Dexamethasone may be reduced.\r\nTreatment should be continued until disease progression or unacceptable\r\ntoxicity. <strong>Recommended Dosage for Myelodysplastic Syndromes: </strong>The\r\nrecommended starting dose of Lenalidomide is 10 mg daily. Treatment is\r\ncontinued or modified based upon clinical and laboratory findings. Continue\r\ntreatment until disease progression or unacceptable toxicity. <strong>Recommended\r\nDosage for Mantle Cell Lymphoma: </strong>The recommended starting dose of\r\nLenalidomide is 25 mg/day orally on Days 1-21 of repeated 28-day cycles for\r\nrelapsed or refractory mantle cell lymphoma. Treatment should be continued\r\nuntil disease progression or unacceptable toxicity. <strong>Recommended Dosage for\r\nFollicular Lymphoma or Marginal Zone Lymphoma: </strong>The recommended starting\r\ndose of Lenalidomide is 20 mg orally once daily on Days 1-21 of repeated 28-day\r\ncycles for up to 12 cycles of treatment in combination with a\r\nRituximab-product. Or, as directed by the registered physicians.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and\r\nLactation: </strong>Based on the mechanism of action,\r\nLenalidomide can cause embryo-fetal harm when administered to a pregnant female\r\nand is contraindicated during pregnancy. There is no information regarding the\r\npresence of Lenalidomide in human milk, the effects of Lenalidomide on the\r\nbreastfed infant, or the effects of Lenalidomide on milk production.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: Mylomid-10: </strong>Each\r\nbox contains 28 capsules in alu-alu blister pack.</p><p class=\"MsoNormal\" xss=\"removed\">                <strong>Mylomid-25: </strong>Each box\r\ncontains 21 capsules in alu-alu blister pack.</p>",
    "strength": "25,10",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1614421018",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1614421018Mylomid-25- Carton Pic.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744104208Mylomid-10.png"
    ]
  },
  {
    "id": "1834",
    "name": "Mylomid-25",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:</strong> <strong>Mylomid-10: </strong>Each capsule contains Lenalidomide INN 10 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Mylomid-25: </strong>Each capsule contains Lenalidomide INN 25 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong> <strong>Multiple Myeloma: </strong>Lenalidomide in combination with Dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM). <strong>Myelodysplastic Syndromes: </strong>Lenalidomide is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. <strong>Mantle Cell Lymphoma: </strong>Lenalidomide is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included Bortezomib. <strong>Follicular Lymphoma: </strong>Lenalidomide in combination with a Rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration: Recommended Dosage for Multiple Myeloma: Lenalidomide Combination Therapy: </strong>The recommended starting dose of Lenalidomide is 25 mg orally once daily on Days 1-21 of repeated 28-day cycles in combination with Dexamethasone. For patients greater than 75 years old, the starting dose of Dexamethasone may be reduced. Treatment should be continued until disease progression or unacceptable toxicity. <strong>Recommended Dosage for Myelodysplastic Syndromes: </strong>The recommended starting dose of Lenalidomide is 10 mg daily. Treatment is continued or modified based upon clinical and laboratory findings. Continue treatment until disease progression or unacceptable toxicity. <strong>Recommended Dosage for Mantle Cell Lymphoma: </strong>The recommended starting dose of Lenalidomide is 25 mg/day orally on Days 1-21 of repeated 28-day cycles for relapsed or refractory mantle cell lymphoma. Treatment should be continued until disease progression or unacceptable toxicity. <strong>Recommended Dosage for Follicular Lymphoma or Marginal Zone Lymphoma: </strong>The recommended starting dose of Lenalidomide is 20 mg orally once daily on Days 1-21 of repeated 28-day cycles for up to 12 cycles of treatment in combination with a Rituximab-product. Or, as directed by the registered physicians.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and Lactation: </strong>Based on the mechanism of action, Lenalidomide can cause embryo-fetal harm when administered to a pregnant female and is contraindicated during pregnancy. There is no information regarding the presence of Lenalidomide in human milk, the effects of Lenalidomide on the breastfed infant, or the effects of Lenalidomide on milk production.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: Mylomid-10: </strong>Each box contains 28 capsules in alu-alu blister pack.</p><p><strong>Mylomid-25: </strong>Each box contains 21 capsules in alu-alu blister pack.</p>",
    "strength": "25",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/16537938931614421018Mylomid - 10 & 25 Cap Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/16537938931614421018Mylomid-25- Carton Pic.png"
    ]
  },
  {
    "id": "1215",
    "name": "Mylostat Capsule",
    "description": "<p><strong>Composition :</strong>Each Capsule Contains Hydroxyurea USP 500mg.</p><p><span class=\"redactor-invisible-space\"><strong>Indications :</strong><span class=\"redactor-invisible-space\">Significant tumour response to Hydroxyurea has been demonstrated in melanoma,\r\nresistant chronic myeloid leukaemia and recurrent metastatic or inoperable carcinoma of the ovary.\r\nHydroxyurea used concomitantly with irradiation therapy is intended for use in the local control of\r\nprimary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip and\r\ncarcinoma of the cervix. Hydroxyurea used in the management of β thalassemia, essential\r\nthrombocythemia and polycythemia vera. Hydroxyurea is indicated to reduce the frequency of\r\npainful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia\r\nwith recurrent moderate to severe painful crises.</span><br></span></p><p><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dosage and administration :</strong><span class=\"redactor-invisible-space\">To minimize the risk of dermal exposure, always wear impervious\r\ngloves when handling Hydroxyurea capsules. Hydroxyurea capsules should not be opened.\r\nPersonnel should avoid exposure to crushed or opened capsules. If contact with crushed or opened\r\ncapsules occurs, wash immediately and thoroughly. More information is available in the references\r\nlisted below. Because of the rarity of melanoma,resistant chronic myelocytic leukemia, carcinoma of\r\nthe ovary and carcinomas of the head and neck in pediatric patients, dosage regimens have not\r\nbeen established. All dosage should be based on the patient's actual or ideal weight, whichever is\r\nless.Concurrent use of Hydroxyurea with other myelosuppressive agents may require adjustment of\r\ndosages. Since Hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric\r\nmedication may be necessary. Please see prescribing description for more information.</span><br></span></span></p><p><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Use in pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> Pregnancy category D. There are no adequate and wellcontrolled\r\nstudies in pregnant women. There are potential risk to fetus and women should avoid\r\nbecoming pregnant while being treated with hydroxyurea. It is excreted in human milk. Because\r\nof the potential for serious adverse reactions in a breastfed infant from hydroxyurea, including\r\ncarcinogenicity, patients should be discontinue breastfeeding during treatment with\r\nhydroxyurea.</span><br></span></span></span></p><p><strong>Packing :</strong>Each box contains 4x7's capsules in blister pack.<br></p><p><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><br></span></span></p>",
    "strength": "500",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/Mylostat 50mg- Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745304188Mylostat.png"
    ]
  },
  {
    "id": "1369",
    "name": "MYPART",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:</strong> Mypart: Each ml\r\nsolution contains Insulin Aspart (rDNA) USP 100IU (Eqv. to\r\n3.5mg).\r\n\r\n</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong> Insulin Aspart is\r\nindicated to improve glycemic control in adults and children\r\nwith diabetes mellitus.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Subcutaneous\r\nInjection:</strong>Insulin Aspart should be administered by\r\nsubcutaneous</p><p class=\"MsoNormal\" xss=\"removed\">injection in the abdominal region,\r\nbuttocks, thigh, or upper arm. Because Insulin Aspart has a\r\nmore rapid onset and a shorter duration of activity\r\nthan human</p><p class=\"MsoNormal\" xss=\"removed\">regular insulin, it should be injected\r\nimmediately (within 5-10 minutes) before a meal. Blood glucose\r\nmonitoring is essential in all patients with\r\ndiabetes. Patients who change their level of physical activity or\r\nmeal plan may require adjustment of insulin dosage.Injection sites should be rotated within\r\nthe same region from one injection to the next to reduce\r\nthe risk of lipodys trophy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Intravenous\r\nUse:</strong>Insulin Aspart can be administered\r\nintravenously under</p><p class=\"MsoNormal\" xss=\"removed\">medical supervision for glycemic control\r\nwith close monitoring of blood glucose and potassium\r\nlevels to avoid hypoglycemia and hypokalemia. For\r\nintravenous</p><p class=\"MsoNormal\" xss=\"removed\">use, Insulin Aspart should be used at\r\nconcentrations from 0.05 U/ml to 1.0 U/ml Insulin Aspart\r\nin infusion systems using polypropylene infusion bags.\r\nInsulin Aspart has been shown to be stable in\r\ninfusion fluids such as 0.9% sodium chloride. Inspect\r\nInsulin Aspart for particulate matter and discoloration prior\r\nto parenteral</p><p class=\"MsoNormal\" xss=\"removed\">administration. Or, as directed by the\r\nregistered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Pregnancy and Lactation:</strong> Pregnancy: Pregnancy category B. Careful monitoring\r\nof glucose control is essential in pregnant patients\r\nbecause insulin</p><p class=\"MsoNormal\" xss=\"removed\">requirements change during different\r\nstages of pregnany. Therefore, female patients\r\nshould be advised to tell their physician if they intend to\r\nbecome or if they</p><p class=\"MsoNormal\" xss=\"removed\">become pregnant while taking Insulin\r\nAspart.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Lactation:</strong> It is unknown\r\nwhether Insulin Aspart is excreted in human milk. Use of Insulin\r\nAspart is compatible with breastfeeding, but women\r\nwith diabetes who are lactating may require adjustments\r\nof their insulin doses.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:</strong> Mypart: Each box\r\ncontains 1x3ml vial.</p>",
    "strength": "100,100 IU",
    "uom": "w/v, IU/ml, IU/ml",
    "categoryId": "114",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1565083729Mypart 100 Vial- Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1565083729Mypart 100 Vial- Carton Pic.png",
      "https://www.admin.drug-international.com/uploads/product_images/1614681441Mypart Mix 100 IU Penset - Carton Pic.png"
    ]
  },
  {
    "id": "1372",
    "name": "MYPART",
    "description": "<p class=\"MsoNormal\" xss=removed align=\"left\"><strong>Composition:</strong> Mypart: Each ml\r\nsolution contains Insulin Aspart (rDNA) USP 100IU (Eqv. to 3.5mg).</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\"> </p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\"><strong>Indications:</strong> Insulin Aspart is\r\nindicated to improve glycemic control in adults and children with diabetes mellitus.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\"> </p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\"><strong>Dosage:</strong></p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\"><strong>Subcutaneous\r\nInjection</strong></p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\">Insulin Aspart should be\r\nadministered by subcutaneous injection in the abdominal region, buttocks,\r\nthigh, or upper arm. Because Insulin Aspart has a more rapid onset and a\r\nshorter duration of activity than human regular insulin, it should be injected\r\nimmediately (within</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\">5-10 minutes) before a meal. Blood\r\nglucose monitoring is essential in all patients with diabetes. Patients who change\r\ntheir level of physical activity or meal plan may require adjustment of insulin\r\ndosage. Injection sites should be rotated within the same region from one\r\ninjection to the next to reduce the risk of lipodystrophy.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\"><strong>Intravenous\r\nUse</strong></p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\">Insulin Aspart can be administered\r\nintravenously under medical supervision for glycemic control with close monitoring\r\nof blood glucose and potassium levels to avoid hypoglycemia and hypokalemia.\r\nFor intravenous use, Insulin Aspart should be used at concentrations from 0.05\r\nU/ml to 1.0 U/ml Insulin Aspart in infusion systems using polypropylene\r\ninfusion bags. Insulin</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\">Aspart has been shown to be stable\r\nin infusion fluids such as 0.9% sodium chloride. Inspect Insulin Aspart for particulate\r\nmatter and discoloration prior to parenteral administration. Or, as directed by\r\nthe registered physician.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\"> </p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\"><strong>Use\r\nin Pregnancy and Lactation:</strong> Pregnancy: Pregnancy category B. Careful monitoring\r\nof glucose control is essential in pregnant patients because insulin requirements\r\nchange during different stages of pregnany. Therefore, female patients should\r\nbe advised to tell their physician if they intend to become or if they become\r\npregnant while taking Insulin Aspart.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\"><strong> </strong></p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\"><strong>Lactation:</strong> It is unknown\r\nwhether Insulin Aspart is excreted in human milk. Use of Insulin Aspart is compatible\r\nwith breastfeeding, but women with diabetes who are lactating may require\r\nadjustments of their insulin doses.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\"> </p>\r\n\r\n<p class=\"MsoNormal\" xss=removed align=\"left\"><strong>Packing:</strong> Mypart: Each box\r\ncontains 1x3ml vial.</p>\r\n\r\n",
    "strength": "100,100 IU",
    "uom": "w/v, IU/ml, IU/ml",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1565085461Mypart 100 Vial- Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1565085461Mypart 100 Vial- Carton Pic.png",
      "https://www.admin.drug-international.com/uploads/product_images/1614681441Mypart Mix 100 IU Penset - Carton Pic.png"
    ]
  },
  {
    "id": "1756",
    "name": "Mypart Mix ",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition: Mypart Mix Penset: </strong>Each ml suspension contains Insulin Aspart (rDNA) BP 100 IU\r\n(equivalent to 3.5 mg) as 30% SolubleInsulin Aspart& 70% Insulin Aspart\r\nProtamine.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>Mypart Mix\r\nis a mixture of Insulin Aspart and Insulin Aspart Protamine indicated to\r\nimprove glycemic control in patients with diabetes mellitus.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage: </strong>Mypart Mix is\r\ntypically dosed twice-daily (with each dose intendedto cover 2 meals or a meal\r\nand a snack). Individualize and adjust the dosage of Mypart Mix based on\r\ntheindividual's metabolic needs, blood glucose monitoring results and glycemic\r\ncontrol goal.Dosage adjustments may be needed with changes in physical\r\nactivity, changes in meal patterns, changes in renal or hepatic function or\r\nduring acute illness.Dosage adjustment may be needed when switching from\r\nanother insulin to Mypart Mix. Or, as directed by the registered physician.<strong></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and Lactation: </strong>Pregnancy: Pregnancy category B. There are no available data in\r\npregnant women to inform a <a name=\"_GoBack\"></a>drug-associated risk. There\r\nare risks to the mother and fetus associated with poorly controlled diabetes in\r\npregnancy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: Mypart Mix Penset: </strong>Each\r\nbox contains 3x3ml glass cartridges.</p>",
    "strength": "100 IU",
    "uom": "",
    "categoryId": "93",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1614681441Mypart Mix Penset- Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1614681441Mypart Mix 100 IU Penset - Carton Pic.png"
    ]
  },
  {
    "id": "1756",
    "name": "Mypart Mix ",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition: Mypart Mix Penset: </strong>Each ml suspension contains Insulin Aspart (rDNA) BP 100 IU\r\n(equivalent to 3.5 mg) as 30% SolubleInsulin Aspart& 70% Insulin Aspart\r\nProtamine.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>Mypart Mix\r\nis a mixture of Insulin Aspart and Insulin Aspart Protamine indicated to\r\nimprove glycemic control in patients with diabetes mellitus.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage: </strong>Mypart Mix is\r\ntypically dosed twice-daily (with each dose intendedto cover 2 meals or a meal\r\nand a snack). Individualize and adjust the dosage of Mypart Mix based on\r\ntheindividual's metabolic needs, blood glucose monitoring results and glycemic\r\ncontrol goal.Dosage adjustments may be needed with changes in physical\r\nactivity, changes in meal patterns, changes in renal or hepatic function or\r\nduring acute illness.Dosage adjustment may be needed when switching from\r\nanother insulin to Mypart Mix. Or, as directed by the registered physician.<strong></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and Lactation: </strong>Pregnancy: Pregnancy category B. There are no available data in\r\npregnant women to inform a <a name=\"_GoBack\"></a>drug-associated risk. There\r\nare risks to the mother and fetus associated with poorly controlled diabetes in\r\npregnancy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: Mypart Mix Penset: </strong>Each\r\nbox contains 3x3ml glass cartridges.</p>",
    "strength": "100 IU,100 IU",
    "uom": "",
    "categoryId": "93",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1614681441Mypart Mix Penset- Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1614681441Mypart Mix 100 IU Penset - Carton Pic.png",
      "https://www.admin.drug-international.com/uploads/product_images/1626063323Mypart Mix 100 IU Vial- Carton Pic.png"
    ]
  },
  {
    "id": "1371",
    "name": "MYPART Penset",
    "description": "<p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Composition:</strong> Mypart Penset: Each ml solution\r\ncontains Insulin Aspart (rDNA) USP 100IU (equivalent to 3.5mg).</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Indications:</strong> Insulin Aspart is an insulin\r\nanalogue indicated to improve glycemic control in patients with diabetes\r\nmellitus.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Dosage and\r\nadministration:</strong>\r\nInsulin Aspart has a faster onset and a shorter duration of action than soluble\r\nhuman insulin. Due to the faster onset of action, Insulin Aspart should\r\ngenerally be given immediately before a meal. When necessary Insulin Aspart may\r\nbe given soon after a meal.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\">Dosage of Insulin Aspart is individual and determined\r\non the basis of the physician's advice in accordance with the needs of the\r\npatient. It should normally be used in combination with long-acting insulin\r\ngiven at least once a day. The individual insulin requirement is usually\r\nbetween 0.5 and 1.0 IU/kg/day in adults and children over 2 years of age. In a meal-related\r\ntreatment 50-70% of this requirement may be</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\">provided by Insulin Aspart and the remainder by\r\nlong-acting insulin. Adjustment of dosage may also be necessary if patients undertake\r\nincreased physical activity or change their usual diet. Exercise taken\r\nimmediately after a meal may increase the risk of hypoglycaemia.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Subcutaneous\r\nInjection</strong></p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\">Insulin Aspart should be administered by subcutaneous\r\ninjection in the abdominal region, buttocks, thigh, or upper arm. Injection sites\r\nshould be rotated within the same region from one injection to the next to\r\nreduce the risk of lipodystrophy. Because Insulin Aspart has a more rapid onset\r\nand a shorter duration of activity than human regular insulin, it should be\r\ninjected immediately(within 5-10 minutes) before a meal.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Continuous\r\nSubcutaneous Insulin Infusion (CSII) by External</strong></p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Pump</strong></p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\">Insulin Aspart can also be infused subcutaneously by\r\nan external insulin pump. The initial programming of the external insulin infusion\r\npump should be based on the total daily insulin dose of the previous regimen.\r\nApproximately 50% of the total dose is usually given as meal-related boluses of\r\nInsulin Aspart and the remainder is given as a basal infusion. When used with\r\nan infusion pump Insulin Aspart should not be mixed with any other insulin.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Intravenous Use</strong></p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\">Insulin Aspart can be administered intravenously under\r\nmedical supervision for glycemic control with close monitoring of blood glucose\r\nand potassium levels to avoid hypoglycaemia and hypokalaemia. For intravenous\r\nuse, Insulin Aspart should be used at concentrations from 0.05 IU/ml to 1.0\r\nIU/ml Insulin Aspart in infusion systems using polypropylene infusion bags.\r\nInsulin Aspart has been shown to be stable in infusion fluids such as 0.9%\r\nsodium chloride. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Use in pregnancy and\r\nlactation:</strong>\r\nPregnancy: Pregnancy category B.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Lactation:</strong> There are no restrictions on\r\ntreatment with Insulin Aspart during lactation. Insulin treatment of the\r\nnursing mother should not affect the baby. However, dosage may need to be adjusted.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Packing:</strong> Mypart Penset: Each box contains\r\n3x3ml glass cartridges.</p>",
    "strength": "100,100 IU",
    "uom": "w/v, IU/ml, IU/ml",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1565084856Mypart 100 IU Penset- Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1565084856Mypart 100 IU Penset Carton pic.png",
      "https://www.admin.drug-international.com/uploads/product_images/1614681441Mypart Mix 100 IU Penset - Carton Pic.png"
    ]
  },
  {
    "id": "1370",
    "name": "MYPART Penset",
    "description": "<p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong><br></strong></p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Composition:</strong> Mypart Penset: Each ml solution\r\ncontains Insulin Aspart (rDNA) USP 100IU (equivalent to 3.5mg).</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Indications:</strong> Insulin Aspart is an insulin\r\nanalogue indicated to improve glycemic control in patients with diabetes\r\nmellitus.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Dosage and\r\nadministration:</strong>\r\nInsulin Aspart has a faster onset and a shorter  uration of action than soluble human\r\ninsulin. Due to the faster onset of action, Insulin Aspart should\r\ngenerally be given immediately before a meal. When necessary\r\nInsulin Aspart may be given soon after a meal. Dosage of Insulin Aspart is individual and determined\r\non the basis of the physician's advice in accordance with the\r\nneeds of the patient. It should normally be used in combination\r\nwith</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\">long-acting insulin given at least once a day.The individual insulin requirement is usually between\r\n0.5 and 1.0IU/kg/day in adults and children over 2 years of age.\r\nIn a meal-related treatment 50-70% of this requirement may\r\nbe provided by Insulin Aspart and the remainder by\r\nlong-acting insulin. Adjustment of dosage may also be necessary if\r\npatients undertake increased physical activity or change their\r\nusual diet. Exercise taken immediately after a meal may increase\r\nthe risk of hypoglycaemia.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Subcutaneous\r\nInjection</strong></p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\">Insulin Aspart should be administered by subcutaneous\r\ninjectionin the abdominal region, buttocks, thigh, or upper arm.\r\nInjection sites should be rotated within the same region from\r\none injection to the next to reduce the risk of lipodystrophy.\r\nBecause Insulin Aspart has a more rapid onset and a shorter duration\r\nof activity</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\">than human regular insulin, it should be injected\r\nimmediately (within 5-10 minutes) before a meal.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Continuous\r\nSubcutaneous Insulin Infusion (CSII) by External Pump</strong></p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\">Insulin Aspart can also be infused subcutaneously by\r\nan external insulin pump. The initial programming of the external\r\ninsulin infusion pump should be based on the total daily\r\ninsulin dose of the previous regimen. Approximately 50% of the total\r\ndose is usually given as meal-related boluses of Insulin\r\nAspart and the remainder is given as a basal infusion. When used with\r\nan infusion pump Insulin Aspart should not be mixed with any\r\nother insulin.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Intravenous Use</strong></p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\">Insulin Aspart can be administered intravenously under\r\nmedical supervision for glycemic control with close monitoring\r\nof blood glucose and potassium levels to avoid hypoglycaemia\r\nand hypokalaemia. For intravenous use, Insulin Aspart\r\nshould be used at concentrations from 0.05 IU/ml to 1.0 IU/ml\r\nInsulin Aspart in infusion systems using polypropylene infusion bags.\r\nInsulin Aspart has been shown to be stable in infusion fluids\r\nsuch as 0.9% sodium chloride. Or, as directed by the\r\nregistered physician.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Use in pregnancy and\r\nlactation:</strong>\r\nPregnancy: Pregnancy category B.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Lactation:</strong> There are no restrictions on\r\ntreatment with Insulin Aspart during lactation. Insulin treatment of the\r\nnursing mother should not affect the baby. However, dosage may need\r\nto be adjusted.</p><p class=\"MsoNormal\" xss=\"removed\" align=\"left\"><strong>Packing:</strong> Mypart Penset: Each box contains\r\n3x3ml glass cartridges.</p>",
    "strength": "100,100 IU",
    "uom": "w/v, IU/ml, IU/ml",
    "categoryId": "114",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1565084321Mypart 100 IU Penset- Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1565084321Mypart 100 IU Penset Carton pic.png",
      "https://www.admin.drug-international.com/uploads/product_images/1614681441Mypart Mix 100 IU Penset - Carton Pic.png"
    ]
  },
  {
    "id": "1876",
    "name": "Mysema-7",
    "description": "<p><strong>Composition :</strong> Mysema-7 : Each Tablet contains\r\nSemaglutide INN 7mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications :</strong>Semaglutide is indicated as an\r\nadjunct to diet and exercise to improve glycemic control in adults with type 2\r\ndiabetes mellitus.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage &Administration :</strong>Semaglutide should be started with 3 mg once daily for 30 days.\r\nThe 3mg dose is intended for treatment initiation and is not effective for\r\nglycemic control. After 30 days on the 3 mg dose, increase the dose to 7 mg\r\nonce daily. Dose may be increased to 14 mg once daily if additional glycemic\r\ncontrol is needed after at least 30 days on the7 mg dose. Taking two 7 mg\r\ntables to achieve a 14 mg dose is not recommended. If a dose is missed, the\r\nmissed dose should be skipped, and the next dose should be taken the following day.\r\nOr, as directed by the registered physician.<br></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and\r\nLactation :</strong>There are limited data with semaglutide use in pregnant women.\r\nSemaglutide should be used during pregnancy only if the potential benefit\r\njustifies the potential risk to the fetus. There are no data on the presence of\r\nSemaglutide in human milk, the effects on the breastfed infant, or theeffects\r\non milk production. Discontinue Semaglutide in<a name=\"_GoBack\"></a>women at\r\nleast 2 months before a planned pregnancydue to the long washout period for\r\nSemaglutide.</p><p class=\"MsoNormal\" xss=\"removed\"> <strong>Packing :</strong> Mysema-7 : Each box contains 60’s tablets in a blister pack.<span></span></p>",
    "strength": "7",
    "uom": "mg",
    "categoryId": "93",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1684651644Mysema Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1684651644Mysema-7 Carton.png"
    ]
  },
  {
    "id": "1329",
    "name": "Mysulin 30/70 injection 100 ",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition\r\n:   Mysulin 30/70 injection 100 IU:</strong>\r\nEach ml suspension contains Insulin Human (rDNA) USP 100 IU (equivalent to 3.47\r\nmg) as 30% soluble Insulin (Regular) and 70% Isophane Insulin. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications\r\n:</strong>\r\nIt is indicated as an adjunct to diet and exercise to improve glycaemic control\r\nin adult  patients with type 1 and type 2\r\ndiabetes mellitus.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\n:</strong>\r\nThe dosage and administration time of the insulin are different due to the  individual differences of each patient. It\r\nshould be given subcutaneously approximately 15-30 minutes before a meal. The\r\naverage range of total daily insulin requirement for maintenance therapy in\r\ntype 1 diabetic patients lies between 0.5 and 1.0 IU/kg/day. However, in pre-pubertal\r\nchildren it usually varies  from 0.7 to 1\r\nIU/kg/day. In situations of insulin resistance, e.g. during puberty or due to\r\nobesity, the daily  insulin requirement\r\nmay be substantially higher. Initial dosages for patients with diabetes are\r\noften  lower, e.g., 0.3 to 0.6 IU/kg/day.\r\nOr, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation : </strong>There are no restrictions\r\non the treatment of diabetes with insulin during pregnancy, as insulin does not\r\npass the placental barrier. Insulin treatment of the nursing mother presents no\r\nrisk to the baby.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing\r\n:</strong>\r\n<strong>Mysulin 30/70 injection 100IU:</strong>  Each box contains 10ml glass vial.</p>",
    "strength": "100,10",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "114",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1534238177Mysulin-Insert.pdf.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1534237424Mysulin 30-70- 100C.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1537950322Mysulin 30-70- 40 IU Carton Picture- 01.jpg"
    ]
  },
  {
    "id": "1329",
    "name": "Mysulin 30/70 injection 100 ",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition\r\n:   Mysulin 30/70 injection 100 IU:</strong>\r\nEach ml suspension contains Insulin Human (rDNA) USP 100 IU (equivalent to 3.47\r\nmg) as 30% soluble Insulin (Regular) and 70% Isophane Insulin. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications\r\n:</strong>\r\nIt is indicated as an adjunct to diet and exercise to improve glycaemic control\r\nin adult  patients with type 1 and type 2\r\ndiabetes mellitus.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\n:</strong>\r\nThe dosage and administration time of the insulin are different due to the  individual differences of each patient. It\r\nshould be given subcutaneously approximately 15-30 minutes before a meal. The\r\naverage range of total daily insulin requirement for maintenance therapy in\r\ntype 1 diabetic patients lies between 0.5 and 1.0 IU/kg/day. However, in pre-pubertal\r\nchildren it usually varies  from 0.7 to 1\r\nIU/kg/day. In situations of insulin resistance, e.g. during puberty or due to\r\nobesity, the daily  insulin requirement\r\nmay be substantially higher. Initial dosages for patients with diabetes are\r\noften  lower, e.g., 0.3 to 0.6 IU/kg/day.\r\nOr, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation : </strong>There are no restrictions\r\non the treatment of diabetes with insulin during pregnancy, as insulin does not\r\npass the placental barrier. Insulin treatment of the nursing mother presents no\r\nrisk to the baby.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing\r\n:</strong>\r\n<strong>Mysulin 30/70 injection 100IU:</strong>  Each box contains 10ml glass vial.</p>",
    "strength": "100",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "114",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1534238177Mysulin-Insert.pdf.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1534237424Mysulin 30-70- 100C.jpg"
    ]
  },
  {
    "id": "1329",
    "name": "Mysulin 30/70 injection 100 ",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition\r\n:   Mysulin 30/70 injection 100 IU:</strong>\r\nEach ml suspension contains Insulin Human (rDNA) USP 100 IU (equivalent to 3.47\r\nmg) as 30% soluble Insulin (Regular) and 70% Isophane Insulin. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications\r\n:</strong>\r\nIt is indicated as an adjunct to diet and exercise to improve glycaemic control\r\nin adult  patients with type 1 and type 2\r\ndiabetes mellitus.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\n:</strong>\r\nThe dosage and administration time of the insulin are different due to the  individual differences of each patient. It\r\nshould be given subcutaneously approximately 15-30 minutes before a meal. The\r\naverage range of total daily insulin requirement for maintenance therapy in\r\ntype 1 diabetic patients lies between 0.5 and 1.0 IU/kg/day. However, in pre-pubertal\r\nchildren it usually varies  from 0.7 to 1\r\nIU/kg/day. In situations of insulin resistance, e.g. during puberty or due to\r\nobesity, the daily  insulin requirement\r\nmay be substantially higher. Initial dosages for patients with diabetes are\r\noften  lower, e.g., 0.3 to 0.6 IU/kg/day.\r\nOr, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation : </strong>There are no restrictions\r\non the treatment of diabetes with insulin during pregnancy, as insulin does not\r\npass the placental barrier. Insulin treatment of the nursing mother presents no\r\nrisk to the baby.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing\r\n:</strong>\r\n<strong>Mysulin 30/70 injection 100IU:</strong>  Each box contains 10ml glass vial.</p>",
    "strength": "100,100",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "114",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1534238177Mysulin-Insert.pdf.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1534237424Mysulin 30-70- 100C.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1534238986Mysulin 30-70P.jpg"
    ]
  },
  {
    "id": "1329",
    "name": "Mysulin 30/70 injection 100 ",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition\r\n:   Mysulin 30/70 injection 100 IU:</strong>\r\nEach ml suspension contains Insulin Human (rDNA) USP 100 IU (equivalent to 3.47\r\nmg) as 30% soluble Insulin (Regular) and 70% Isophane Insulin. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications\r\n:</strong>\r\nIt is indicated as an adjunct to diet and exercise to improve glycaemic control\r\nin adult  patients with type 1 and type 2\r\ndiabetes mellitus.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\n:</strong>\r\nThe dosage and administration time of the insulin are different due to the  individual differences of each patient. It\r\nshould be given subcutaneously approximately 15-30 minutes before a meal. The\r\naverage range of total daily insulin requirement for maintenance therapy in\r\ntype 1 diabetic patients lies between 0.5 and 1.0 IU/kg/day. However, in pre-pubertal\r\nchildren it usually varies  from 0.7 to 1\r\nIU/kg/day. In situations of insulin resistance, e.g. during puberty or due to\r\nobesity, the daily  insulin requirement\r\nmay be substantially higher. Initial dosages for patients with diabetes are\r\noften  lower, e.g., 0.3 to 0.6 IU/kg/day.\r\nOr, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation : </strong>There are no restrictions\r\non the treatment of diabetes with insulin during pregnancy, as insulin does not\r\npass the placental barrier. Insulin treatment of the nursing mother presents no\r\nrisk to the baby.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing\r\n:</strong>\r\n<strong>Mysulin 30/70 injection 100IU:</strong>  Each box contains 10ml glass vial.</p>",
    "strength": "100,100",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "114",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1534238177Mysulin-Insert.pdf.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1534237424Mysulin 30-70- 100C.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1551955501Mysulin 50  50 Vial 100 IU ml- Carton Pic.png"
    ]
  },
  {
    "id": "1329",
    "name": "Mysulin 30/70 injection 100 ",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition\r\n:   Mysulin 30/70 injection 100 IU:</strong>\r\nEach ml suspension contains Insulin Human (rDNA) USP 100 IU (equivalent to 3.47\r\nmg) as 30% soluble Insulin (Regular) and 70% Isophane Insulin. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications\r\n:</strong>\r\nIt is indicated as an adjunct to diet and exercise to improve glycaemic control\r\nin adult  patients with type 1 and type 2\r\ndiabetes mellitus.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\n:</strong>\r\nThe dosage and administration time of the insulin are different due to the  individual differences of each patient. It\r\nshould be given subcutaneously approximately 15-30 minutes before a meal. The\r\naverage range of total daily insulin requirement for maintenance therapy in\r\ntype 1 diabetic patients lies between 0.5 and 1.0 IU/kg/day. However, in pre-pubertal\r\nchildren it usually varies  from 0.7 to 1\r\nIU/kg/day. In situations of insulin resistance, e.g. during puberty or due to\r\nobesity, the daily  insulin requirement\r\nmay be substantially higher. Initial dosages for patients with diabetes are\r\noften  lower, e.g., 0.3 to 0.6 IU/kg/day.\r\nOr, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation : </strong>There are no restrictions\r\non the treatment of diabetes with insulin during pregnancy, as insulin does not\r\npass the placental barrier. Insulin treatment of the nursing mother presents no\r\nrisk to the baby.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing\r\n:</strong>\r\n<strong>Mysulin 30/70 injection 100IU:</strong>  Each box contains 10ml glass vial.</p>",
    "strength": "100,100",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "114",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1534238177Mysulin-Insert.pdf.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1534237424Mysulin 30-70- 100C.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1551955721Mysulin 50-50 Penset.png"
    ]
  },
  {
    "id": "1329",
    "name": "Mysulin 30/70 injection 100 ",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition\r\n:   Mysulin 30/70 injection 100 IU:</strong>\r\nEach ml suspension contains Insulin Human (rDNA) USP 100 IU (equivalent to 3.47\r\nmg) as 30% soluble Insulin (Regular) and 70% Isophane Insulin. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications\r\n:</strong>\r\nIt is indicated as an adjunct to diet and exercise to improve glycaemic control\r\nin adult  patients with type 1 and type 2\r\ndiabetes mellitus.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\n:</strong>\r\nThe dosage and administration time of the insulin are different due to the  individual differences of each patient. It\r\nshould be given subcutaneously approximately 15-30 minutes before a meal. The\r\naverage range of total daily insulin requirement for maintenance therapy in\r\ntype 1 diabetic patients lies between 0.5 and 1.0 IU/kg/day. However, in pre-pubertal\r\nchildren it usually varies  from 0.7 to 1\r\nIU/kg/day. In situations of insulin resistance, e.g. during puberty or due to\r\nobesity, the daily  insulin requirement\r\nmay be substantially higher. Initial dosages for patients with diabetes are\r\noften  lower, e.g., 0.3 to 0.6 IU/kg/day.\r\nOr, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation : </strong>There are no restrictions\r\non the treatment of diabetes with insulin during pregnancy, as insulin does not\r\npass the placental barrier. Insulin treatment of the nursing mother presents no\r\nrisk to the baby.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing\r\n:</strong>\r\n<strong>Mysulin 30/70 injection 100IU:</strong>  Each box contains 10ml glass vial.</p>",
    "strength": "100,100,40",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "114",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1534238177Mysulin-Insert.pdf.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1534237424Mysulin 30-70- 100C.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1614245714Mysulin R 100 IU Inj - Carton Pic.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1614245714Mysulin R 40 IU Inj - Carton Pic (1).jpg"
    ]
  },
  {
    "id": "1841",
    "name": "Mytus",
    "description": "<p><strong>Composition\r\n: Mytus 100 IU vial : </strong>Each\r\nml solution contains Insulin Glargine (rDNA) USP 100 IU.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"> </p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Mytus\r\n100 IU PenSet : </strong>Each\r\nml solution contains Insulin Glargine (rDNA) USP 100 IU.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"> </p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Indications\r\n: Mytus </strong>is\r\nindicated to improve glycemic control in adults and children with type 1\r\ndiabetes mellitus and in adults with type 2 diabetes mellitus.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"> </p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Dosage\r\nand administration : </strong>Mytus exhibits a\r\nrelatively constant glucose-lowering profile over 24 hours that permits once-daily\r\ndosing. Potency of insulin glargine is approximately the same as human insulin.\r\nMytus is recommended for once daily subcutaneous administration & may be\r\nadministered at any time during the day. However, once started should be\r\nadministered at the same time every day. The dose of Mytus must be\r\nindividualized based on clinical response. Blood glucose monitoring is\r\nessential in all patients with diabetes. In patients with type 1 diabetes,\r\nMytus must be used in regimens with<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">short-acting insulin. Mytus is not\r\nrecommended for intravenous administration. Intravenous administration of the\r\nusual subcutaneous dose could result in severe hypoglycemia. Injection sites\r\nshould be rotated within the same region (abdomen, thigh, or deltoid) from one\r\ninjection to the next. or, as directed by the registered physician.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"> </p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Use\r\nin pregnancy and lactation : Pregnancy : </strong>Pregnancy category C. Insulin glargine should be\r\nused during pregnancy only if the potential benefit justifies the potential\r\nrisk to the fetus.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Lactation\r\n: </strong>lt is unknown\r\nwhether insulin glargine is excreted in human milk. Because many drugs,\r\nincluding human insulin, are excreted in human milk, caution should be\r\nexercised when Insulin glargine is administered to a nursing woman. Lactating women\r\nmay require adjustments in insulin dose & diet.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Storage : </strong>Store at 2ºC to 8ºC in a\r\nrefrigerator. Do not freeze. Protect from light.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"> </p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Packing : Mytus 100 IU vial : </strong>Each box contains 3 ml glass\r\nvial.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"> </p>\r\n\r\n<p><strong>Mytus\r\n100 IU PenSet : </strong>Each\r\nBox contains 3 ml glass cartridge.</p>",
    "strength": "100",
    "uom": "w/v, IU/ml, IU/ml",
    "categoryId": "93",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1660638977Mytus Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1659947416Mitas Carton Pic.png"
    ]
  },
  {
    "id": "1242",
    "name": "Nalipsy ",
    "description": "<p><strong>Composition :</strong> Sodium Valproate BP\r\n200 mg.</p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Indications :</strong><span class=\"redactor-invisible-space\"> It is indicated for the\r\ntreatment of all types of epilepsy, e.g.\r\npartial seizures, absence seizures, generalized tonic-clonic seizures, myoclonic seizures, atonic\r\nseizures, mixed seizures that include\r\nabsence attack.</span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Dosage and Administration :</strong> Epilepsy:\r\nAdults: Initially 600mg daily in 2 divided\r\ndoses, preferably after food, increased\r\nby 200mg at 3 days intervals to\r\nmaximum 2.5gm per day in divided\r\ndoses until control of seizure is\r\nachieved. Usual maintenance dose: 1-\r\n2gm daily (20-30mg/kg daily). Children\r\nbodyweight up to 20kg: Initially\r\n20mg/kg daily in divided doses, may be\r\nincreased provided plasma concentration\r\nmonitored (dose above 40mg/kg daily\r\nalso monitor clinical chemistry and\r\nhaematological parameters). Children\r\nunder 12 years bodyweight over 20kg:\r\nInitially 400mg daily in divided doses\r\nincreased according to response (usual\r\nrange 20-30mg/kg daily), maximum\r\n35mg/kg daily. Or, as directed by the\r\nregistered physician.<br></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> Sodium valproate crosses the placenta\r\nin humans; exposure to valproate in the\r\nfirst trimester causes neural tube defects\r\nsuch as anencephaly and spina bifida in\r\nnewborn. Sodium valproate is excreted\r\nin human breast milk. It is not known\r\nwhat effect this would have on a breastfed\r\ninfant. This drug should be used\r\nduring pregnancy & lactation only if\r\nclearly needed.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Nalipsy Tablet: Each box\r\ncontains 10x10's tablets in blister pack.</span></p>",
    "strength": "200",
    "uom": "mg",
    "categoryId": "48",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532147575nalipsy.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Nalipsy.jpg"
    ]
  },
  {
    "id": "828",
    "name": "Napsec",
    "description": "<p><strong>Composition : Napsec-375:  </strong><span class=\"redactor-invisible-space\">Naproxen BP 325 mg + Esomeprazole USP 20 mg Enteric Coated Tablet.<br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Napsec-500:  </strong><span class=\"redactor-invisible-space\">Naproxen BP 500 mg + Esomeprazole USP 20 mg Enteric Coated Tablet.</span><span class=\"redactor-invisible-space\"><br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This is indicated for the relief of\r\nsigns and symptoms of osteoarthritis,\r\nrheumatoid arthritis and ankylosing spondylitis,\r\ndysmenorrhoea and to decrease the risk of\r\ndeveloping gastric ulcers in patients at risk of\r\ndeveloping NSAID-associated gastric ulcers.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\"><strong>Rheumatoid\r\nArthritis, Osteoarthritis and Ankylosing\r\nSpondylitis :</strong> The dosage is one tablet twice\r\ndaily of 375mg naproxen and 20mg of\r\nesomeprazole or 500mg naproxen and 20mg\r\nof esomeprazole The tablets are to be\r\nswallowed whole with liquid. This drug is to be\r\ntaken at least 30 minutes before meals.\r\n<strong>Geriatric Patients : </strong>Studies indicate that\r\nalthough total plasma concentration of\r\nnaproxen is unchanged, the unbound plasma\r\nfraction of naproxen is increased in the elderly.\r\nUse caution when high doses are required and\r\nsome adjustment of dosage may be required\r\nelderly patients. <strong>Patients with Moderate to\r\nSevere Renal Impairment :</strong></span>Naproxen-containing products are not\r\nrecommended for use in patients with moderate to severe or severe renal impairment <strong>.Hepatic Insufficiency:</strong> Monitor\r\n patients   with   mild   to   moderate   hepaticimpairment  closely  \r\nand  consider  a  possible dose   reduction   based   on   the   \r\nnaproxen component of this drug.It   should be avoided in patients   \r\nwith   severe   hepatic   impairment.<strong>Paediatric Patients : </strong>The\r\nsafety and efficacy of this drug in children younger than 18 years has not been\r\nestablished. Or, as directed by the registered physician<span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Pregnancy and lactation :</strong><span class=\"redactor-invisible-space\">Pregnancy\r\nCategory C. In late pregnancy, it should be\r\navoided because it may cause premature\r\nclosure of ductus arteriosus. Lactation :\r\nNaproxen is distributed in breast milk; avoid\r\nuse because of prostaglandin inhibition\r\neffects in newborn.</span><br></p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\">Napsec-375 : 3x10's tablets in blister pack.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nNapsec-500 : 3x10's tablets blister pack.</span></p>",
    "strength": "500,375",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532148000napsec.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745148181NAPSEC-500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1684407478Napsec-375 Carton.png"
    ]
  },
  {
    "id": "1886",
    "name": "Natrol Nasal Spray",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Composition:\r\nNatrol 0.05% Nasal Spray: </strong>Each ml Contains\r\nXylometazoline Hydrochloride BP 0.5mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Natrol\r\n0.1% Nasal Spray:</strong> Each ml Contains Xylometazoline Hydrochloride BP\r\n1mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><br></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Indications:</strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong></strong>This Nasal Spray\r\nis indicated for the treatment of the symptomatic relief of nasal congestion,\r\nperennial and allergic rhinitis (including hay fever)and sinusitis.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><br></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Dosage\r\nand administration : Natrol0.05% Nasal Spray \r\n:  Children from 2  -12 years \r\nold : </strong>1  spray, per nostril not more\r\noften than three times per day. <strong>Natrol 0.1% Nasal Spray: Adults and\r\nadolescents (over 12 years of age</strong>): 1 spray into each nostril, 1 to 3 times\r\ndaily as needed.  Do not exceed 3\r\napplications daily into each nostril. Or, as directed by the registered\r\nphysician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><br></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Use\r\nin Pregnancy and Lactation: </strong>There are no\r\nadequate and well controlled studies in pregnant women. Xylometazo<a name=\"_GoBack\"></a>line nasal spray should be used during pregnancy only if the\r\npotential benefit justifies   the\r\npotential risk of the   fetus.  Caution should be exercised when\r\nXylometazoline is administered to a nursing woman.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><br></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Packing\r\n: Natrol 0.05% Nasal Spray : </strong>Each container\r\ncontains 120 metered doses for sprays.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><o:p></o:p></p><p><strong>Natrol\r\n0.1% Nasal Spray: </strong>Each container contains 120 metered doses for\r\nsprays.</p>",
    "strength": " 0.05,1",
    "uom": "mg/ml",
    "categoryId": "56",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1738142389Natrol Nasal Spray Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745304387Natrol 0.05%.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745304387Natrol 0.1%.png"
    ]
  },
  {
    "id": "987",
    "name": "Nebifast",
    "description": "<p class=\"MsoNormal\"><strong>Composition :</strong> <strong>Nebifast-2.5:</strong> Nebivolol INN  2.5 mg Tablet.</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Nebifast-5:</strong> Nebivolol INN 5 mg Tablet.<br></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Indications :</strong> Nebivolol tablets are indicated for the\r\nmanagement of hypertension one of several preferred initial therapies in\r\nhypertensive patients with heart failure, post myocardial infarction, high CHD\r\nrisk and diabetes mellitus.</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Dosage and administration :</strong> Hypertension: 5 mg daily,elderly\r\ninitially dose 2.5 mg daily, increased if necessary to 5 mg daily. Adjunct in\r\nheart failure: Initially 1.25 mg once daily, then if tolerated increased at\r\nintervals of 1-2 weeks to 2.5 mg once daily, then to 5 mg once daily, then to\r\nmax. 10 mg once daily. Or, as directed by the registered physicians.</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Packing :</strong> <strong>Nebifast-2.5 :</strong> 2X14's tablets in blister\r\npack.</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Nebifast-5 : </strong>2X14's tablets in blister pack.</p><p class=\"MsoNormal\"><br></p>",
    "strength": "5,2.5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/nebifast.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744104687Nebifast-5.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744104687nebifast-2.5.png"
    ]
  },
  {
    "id": "875",
    "name": "NEO - DP ",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\"><strong>Neo-DP:</strong> Each ml contains  (Dexamethasone USP 1mg+\r\nNeomycin Sulfate USP 3,500 IU+ Polymyxin\r\nB Sulfate USP 6,000 IU).</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Neo-DP is indicated for\r\nthe short term treatment of steroid\r\nresponsive conditions of the eye when\r\nprophylactic antibiotic treatment is also\r\nrequired, after excluding the presence of\r\nfungal and viral disease.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Apply one or\r\ntwo drops to each affected eye up to six\r\ntimes daily or more frequently if required.\r\nSevere infections may require one or two\r\ndrops every 15-20 minutes initially,\r\nreducing the frequency of instillation\r\ngradually as the infection is controlled.\r\nOr as directed by registered physician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>5ml in plastic dropper bottle.</p>",
    "strength": "0.1,3500,6000,0.5% + 1%",
    "uom": "w/v, IU/ml, IU/ml",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532148841NEO-DP.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/images/NEO-DP.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1745148211NEO-B.png"
    ]
  },
  {
    "id": "875",
    "name": "NEO - DP ",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\"><strong>Neo-DP:</strong> Each ml contains  (Dexamethasone USP 1mg+\r\nNeomycin Sulfate USP 3,500 IU+ Polymyxin\r\nB Sulfate USP 6,000 IU).</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Neo-DP is indicated for\r\nthe short term treatment of steroid\r\nresponsive conditions of the eye when\r\nprophylactic antibiotic treatment is also\r\nrequired, after excluding the presence of\r\nfungal and viral disease.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Apply one or\r\ntwo drops to each affected eye up to six\r\ntimes daily or more frequently if required.\r\nSevere infections may require one or two\r\ndrops every 15-20 minutes initially,\r\nreducing the frequency of instillation\r\ngradually as the infection is controlled.\r\nOr as directed by registered physician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>5ml in plastic dropper bottle.</p>",
    "strength": "0.1,3500,6000",
    "uom": "w/v, IU/ml, IU/ml",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532148841NEO-DP.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/images/NEO-DP.jpg"
    ]
  },
  {
    "id": "1090",
    "name": "Neoplat Injection",
    "description": "<p class=\"MsoNormal\"><strong>Composition:</strong><br>\r\nNeoplat-10: Each vial contains Cisplatin BP 10 mg (1 mg/ml). <br>\r\nNeoplat-50: Each vial contains Cisplatin BP 50 mg (1 mg/ml).<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\"> </p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications:</strong><br>\r\nNeoplat injection is indicated as therapy to be employed as follows: <strong>Metastatic\r\nTesticular</strong> <strong>Tumors</strong> - In established combination therapy with other\r\napproved chemotherapeutic agents in patients with metastatic testicular tumors\r\nwho have already received appropriate surgical and/or radio therapeutic\r\nprocedures. <strong>Metastatic Ovarian Tumors</strong>- In established combination\r\ntherapy with other approved chemotherapeutic agents in patients with metastatic\r\novarian tumors who have already received appropriate surgical and/or radio\r\ntherapeutic procedures. An established combination consists of Neoplat (Cisplatin)\r\nand cyclophosphamide. Neoplat, as a single agent, is indicated as secondary\r\ntherapy in patients with metastatic ovarian tumors refractory to standard\r\nchemotherapy who have not previously received Cisplatin Injection therapy. <strong>Advanced\r\nBladder Cancer</strong> - Neoplat (Cisplatin) is indicated as a single agent for\r\npatients with transitional cell bladder cancer which is no longer amenable to\r\nlocal treatments such as surgery and/or radiotherapy. <strong>Non</strong> <strong>Small Cell\r\nLung Carcinoma-</strong> Neoplat (Cisplatin) in combination with other <br>\r\nchemotherapeutic agent is indicated for the treatment of non small cell lung\r\ncancer in patients who are not candidates for potential curative surgery and/\r\nor radiation therapy.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"> </p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage and\r\nAdministration:<o:p></o:p></strong></p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\">Cisplatin injection is\r\nadministered by slow intravenous infusion. It should not be given by <br>\r\nrapid intravenous injection. <strong>Note:</strong> Needles or intravenous sets\r\ncontaining aluminum parts that may come in contact with Cisplatin Injection\r\nshould not be used for preparation or administration. Aluminum reacts with\r\nCisplatin Injection, causing precipitate formation and a loss of potency. <strong>Metastatic</strong>\r\n<strong>Testicular Tumors-</strong> The usual Cisplatin Injection dose for the treatment\r\nof testicular cancer in combination with other approved chemotherapeutic agents\r\nis 20 mg/m<sup>2</sup> IV daily for 5 days per cycle. <strong>Metastatic Ovarian\r\nTumors-</strong> The usual Cisplatin Injection dose for the treatment of metastatic\r\novarian tumors in combination with cyclophosphamide is 75 to 100 mg/m<sup>2</sup>\r\nIV per cycle once every 4 weeks (DAY 1). The dose of cycloposphamide when used\r\nin combination with Cisplatin is 600 mg/m<sup>2</sup> IV once every four weeks\r\n(DAY 1). In combination therapy, Cisplatin Injection and Cyclophosphamide are\r\nadministered sequentially. As a single agent, Cisplatin Injection should be\r\nadministered at a dose of 100 mg/m<sup>2</sup> IV per cycle once every four\r\nweeks. <strong>Advanced Bladder Cancer- </strong>Cisplatin Injection should be\r\nadministered as a single agent at a dose of 50 to 70 mg/m<sup>2</sup> IV per\r\ncycle once every 3 to 4 weeks depending on the extent of prior exposure to\r\nradiation therapy and/or prior chemotherapy. For heavily pretreated patients an\r\ninitial dose of 50 mg/m<sup>2</sup> per cycle repeated every 4 weeks is recommended.\r\n<strong>Non Small Cell Lung Carcinoma-</strong> Cisplatin Injection (75 mg/m<sup>2</sup>)\r\nshould be administered in combination with Paclitaxel (135 mg/m<sup>2</sup>) in\r\nevery three weeks. Or, as directed by the registered physicians.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"> </p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Use in Pregnancy and\r\nLactation:</strong> Pregnancy Category D. There are no adequate and\r\nwell controlled studies in pregnant women. Cisplatin has been reported to be\r\nfound in human milk. It is not known whether Cisplatin is excreted in human.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"> </p>\r\n\r\n<p class=\"MsoNormal\"><strong>Packing:</strong><br>\r\nNeoplat-10: Each box contains one vial of 10 ml solution. <br><o:p></o:p></p><p>Neoplat-50: Each box contains one vial of 50 ml solution.<br><strong></strong></p>",
    "strength": " 1,1",
    "uom": "mg/ml",
    "categoryId": "57",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1660639687Neoplat 50 Carton Pic.png",
      "https://www.admin.drug-international.com/uploads/product_images/Neoplat10.jpg"
    ]
  },
  {
    "id": "1274",
    "name": "Neuropen",
    "description": "<p><strong>Composition : </strong>Gabapentin USP 300mg Tablet.</p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Indications : </strong>Neuropen (gabapentin) is indicated for the management of postherpetic neuralgia in adults. Neuropen (gabapentin) is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. Neuropen is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3-12 years.</p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> Postherpetic Neuralgia : In adults with postherpetic neuralgia, Neuropen therapy may be initiated as a single 300mg dose on day 1, 600 mg /day on day 2 (divided BID), and 900 mg/day on day 3 (divided TID). The dose can subsequently be titrated up to as needed for pain relief to a daily dose of 1800 mg. Epilepsy : Patients &gt;12 years of age : The effective dose of Neuropen is 900 to 1800 mg /day and given in divided doses (three times a day). The starting dose is 300 mg three times a day. In case of Children 3-12 years : The starting dose should range from 10-15 mg /kg/day in 3 divided doses. The effective dose of Neuropen in patients 5 years of age and older is 25-35 mg/kg/day and given in divided doses. Or, as directed by the registered physicians.</p><p style=\"text-align: justify;\"><strong>Pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> Pregnancy Category C by FDA.</span><br></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong> Neuropen : 3x10's tablets in blister pack.</p>",
    "strength": "300",
    "uom": "mg",
    "categoryId": "48",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532149046Neuropen.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745148233Neuropen.png"
    ]
  },
  {
    "id": "1006",
    "name": "Niapid XR",
    "description": "<p><strong></strong><strong>Composition :</strong> Niacin USP 500mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indication : </strong>Niapid is indicated as an\r\nadjunct to diet for reduction of elevated\r\nTC, CDL-C, Apo B and TG levels and to\r\nincrease HDL-C in patients with primary\r\nhypercholesterolemia and mixed\r\ndyslipidemia (Fredrickson Types IIa and\r\nIIb) when the response to an appropriate\r\ndiet has been inadequate. It is also\r\nindicated as an adjunctive therapy for\r\ntreatment of adult patients with very high\r\ntriglyceride levels (Type IV\r\nhyperlipidemia) </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\"> Initially 500mg\r\ntablet at bedtime from 1 to 4 weeks.\r\nMaintenance Dose : the daily dosage\r\nshould not be increased by more than\r\n500mg in any 4 week period. The\r\nrecommended maintenance dose is\r\n1000mg (two tablet) to 2000 mg (4\r\ntablets) once daily at bedtime. Dose\r\ngreater than 2000 mg daily are not\r\nrecommended. Or, as directed by the\r\nregistered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy Category C by FDA.</p><p style=\"text-align: justify;\"><strong>Packing : </strong>Niapid : 3 x 10's tablets in\r\nblister pack.</p>",
    "strength": "500",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532247550Niapid.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/niapid Wr.jpg"
    ]
  },
  {
    "id": "1011",
    "name": "Nidocard - Spray",
    "description": "<p><strong></strong><strong>Composition : </strong>Glyceryl\r\nTrinitrate BP 0.4mg/ Spray.</p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Indication :</strong> Acute angina pectoris.\r\nPrevention of the anginal attack by\r\nadministering the drug before physical\r\nexercise. Adjuvant therapy in emergency\r\ncases of acute left ventricular failure. </p><p xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">By each\r\npressing 0.4mg of Glyceryl Trinitrate, in\r\nthe form of spray, is released from the\r\ncontainer.\r\nAt the onset of the attack: one or two\r\nsprays should be applied sublingually,\r\nthen the mouth should be closed. If\r\nnecessary, three sprays may be used but\r\nnot more than 3 sprays at any one time. </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>For prophylaxis:</strong> one to two sprays\r\n(0.4mg-0.8mg) immediately prior to an\r\nangina inducing event. Or, as directed by\r\nthe registered physician.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong> <strong></strong><span class=\"redactor-invisible-space\"><strong>Nidocard Spray :</strong> Each\r\ncontainer contains 200 metered doses\r\n(12.2ml) solution.</span></p>",
    "strength": "0.4",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532247641Nidocard-Spray.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745304431Nidocard spray.png"
    ]
  },
  {
    "id": "1257",
    "name": "NIDOCARD Injection",
    "description": "<p><strong>Composition : Nidocard Injection: </strong>Each ampoule (10 ml) contains Nitroglycerin USP 50mg.</p><p style=\"text-align: justify;\"><strong>Indication  : </strong>Nitroglycerin Injection is indicated for the treatment of peri-operative hypertension; for controlling of congestive heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and beta blockers and for induction of Intra-operative hypotension.</p><p style=\"text-align: justify;\"><strong>Nidocard Injection : </strong>Each pack contains one ampoules in blister pack.</p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532247809Nidocard InJection.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745304573NIDOCARD.png"
    ]
  },
  {
    "id": "1010",
    "name": "Nidocard Retard",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Nitroglycerin USP 2.6mg &\r\n6.4mg Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Nidocard is indicated for\r\nthe prophylaxis of angina pectoris due to\r\ncoronary artery diseases. It is indicated\r\nfor the supplementary treatment of heart\r\nfailure refractory to digitalis and diuretic\r\ntreatment. It is not suitable for treating an\r\nattack that has already started as the\r\ntablets will take too long to start working.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">It should be\r\nindividualized depending on the\r\nnitroglycerin sensitivity of the patient, the\r\nseverity of illness and the occurrence of\r\nside effects.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy Category C by FDA.</p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"> Nidocard-Retard-2.6 : 4 x\r\n14's tablets in blister pack.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nNidocard-Retard-6.4 : 4 x 14's tablets in\r\nblister pack.</span></p>",
    "strength": "6.4,2.6",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532247899Nidocard-Retard.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744104756NIDOCARD RETARD-6.4.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744104756NIDOCARD RETARD.png"
    ]
  },
  {
    "id": "997",
    "name": "Nifecap",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\"><strong>Nifecap:</strong> </span><strong></strong><span class=\"redactor-invisible-space\">Nifedipine USP 10 mg\r\nSoft Capsule.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Coronary heart disease\r\nand Hypertension.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong><span class=\"redactor-invisible-space\"> Coronary heart disease:\r\nInitially 1 capsule 3 times daily with or\r\nafter food. Increased to 2 capsules 3\r\ntimes daily if necessary.\r\nHypertension : 1-2 capsule twice daily\r\nafter food, initial one capsule twice daily,\r\nmay be increased to 4 capsules twice\r\ndaily if necessary or, as directed by the\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy Category C by FDA.</p><p style=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\n<strong>Nifecap:</strong> 3 </span>x 10 soft <span class=\"redactor-invisible-space\">Capsules in blister pack.</span></p>",
    "strength": "10",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531718656Nifecap.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/images/Nifecap.jpg"
    ]
  },
  {
    "id": "1803",
    "name": "Nilonib",
    "description": "<p><strong>Composition: </strong>Each\r\ncapsule contains Nilotinib 200 mg as Nilotinib Monohydrochloride Monohydrade\r\nINN.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><o:p> </o:p></p><h4 style=\"margin:0in;margin-bottom:.0001pt;text-align:justify\"><strong>Indications:</strong> Adult And\r\nPediatric Patients with Newly Diagnosed Ph+ CML-CP: Nilonib\r\n(nilotinib) is indicated for the treatment of adult and pediatric patients\r\ngreater than or equal to 1 year of age with newly diagnosed Philadelphia\r\nchromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Adult Patients with Resistant or Intolerant Ph+ CML-CP\r\nand CML-AP: Nilonib is indicated for the treatment of adult patients with chronic\r\nphase and accelerated phase Philadelphia chromosome positive chronic\r\nmyelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that\r\nincluded imatinib. Pediatric Patients with\r\nResistant or Intolerant Ph+ CML-CP: Nilonib is indicated for the\r\ntreatment of pediatric patients greater than or equal to 1 year of age with\r\nchronic phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+\r\nCML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI)\r\ntherapy.<o:p></o:p></h4><h4 style=\"margin:0in;margin-bottom:.0001pt;text-align:justify\"> </h4><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage\r\nand Administration: </strong><strong>Dosage in Adult Patients with Newly Diagnosed Ph+ CML-CP:</strong> The recommended dose of Nilonib is 300 mg orally twice\r\ndaily. Or, as directed by the registered physician.<o:p></o:p></p><h5 style=\"margin-top:0in;text-align:justify\"><strong>Dosage\r\nin Adult Patients with Resistant or Intolerant Ph+ CML-CP and CML-AP:</strong> The recommended\r\ndose of Nilonib is 400 mg orally twice daily.<strong><o:p></o:p></strong></h5><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage in Pediatric Patients with Newly\r\nDiagnosed Ph+ CML-CP Or Resistant or Intolerant Ph+ CML-CP:</strong> The recommended dose of Nilonib for pediatric patients\r\nis 230 mg/m² orally twice daily, rounded to the nearest 50 mg dose (to a\r\nmaximum single dose of 400 mg). Or, as directed by the registered\r\nphysician.</p><p style=\"text-align:justify\"><strong>Use in\r\nPregnancy and Lactation: </strong>Nilonib\r\ncan cause fetal harm when administered to a pregnant woman. So, Females should\r\nbe advised to inform their healthcare provider if they are pregnant or become\r\npregnant.</p><p><strong>Packing: </strong>Each\r\nbox contains 30’s capsules in a Container.</p>",
    "strength": " 200",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1637661159Nilonib-200 - Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1637661159Nilonib 200 Carton.png"
    ]
  },
  {
    "id": "1187",
    "name": "Nitanid Suspension",
    "description": "<p class=\"MsoNormal\"><strong>Composition:<o:p></o:p></strong></p><p class=\"MsoNormal\"><strong>Nitanid-500:</strong> Each film coated tablet contains\r\nNitazoxanide INN 500mg.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Nitanid Suspension:</strong> Each 5ml reconstituted suspension\r\ncontains Nitazoxanide INN 100mg.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Indications: </strong><strong>1.</strong>\r\nDiarrhoea caused by <i>Cryptosporidium\r\nparvum</i> and <i>Giardia lamblia</i>; <strong>2.</strong> Amebiasis and helminth infections.<o:p></o:p></p><p class=\"MsoNormal\"><br>\r\n<strong>Dosage & administration: </strong><strong>Age\r\n1-3 years:</strong> 5ml (100 mg) twice daily for 3 days. <strong>Age 4-11 years:</strong> 10ml (200 mg) twice daily for 3 days. <strong>Age 12 years:</strong> 500mg or one tablet twice\r\ndaily for 3 days. Nitanid should be taken with food. Or, as directed by the\r\nregistered physician.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Use\r\nin pregnancy and lactation</strong>: Pregnancy category B. This drug\r\nshould be used during pregnancy only if clearly needed. Because many drugs are\r\nexcreted in human milk, caution should be exercised when Nitazoxanide is\r\nadministered to a nursing woman.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Packing:<o:p></o:p></strong></p><p class=\"MsoNormal\"><strong>Nitanid-500:</strong>\r\nEach box contains 20 tablets in a blister pack.<o:p></o:p></p><p><strong>Nitanid\r\nSuspension:</strong> Each bottle contains dry powder for\r\npreparation of 60ml suspension.<br></p>",
    "strength": "100/5",
    "uom": "mg/ml",
    "categoryId": "43",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1660728229Nitanid Local Insert English Part Com.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740569229nitanidbox.png"
    ]
  },
  {
    "id": "1164",
    "name": "Nitanid-500  Tablet",
    "description": "<p class=\"MsoNormal\"><strong>Composition:<o:p></o:p></strong></p><p class=\"MsoNormal\"><strong>Nitanid-500:</strong> Each film coated tablet contains\r\nNitazoxanide INN 500mg.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Nitanid Suspension:</strong> Each 5ml reconstituted suspension\r\ncontains Nitazoxanide INN 100mg.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Indications: </strong><strong>1.</strong>\r\nDiarrhoea caused by <i>Cryptosporidium\r\nparvum</i> and <i>Giardia lamblia</i>; <strong>2.</strong> Amebiasis and helminth infections.<o:p></o:p></p><p class=\"MsoNormal\"><br>\r\n<strong>Dosage & administration: </strong><strong>Age\r\n1-3 years:</strong> 5ml (100 mg) twice daily for 3 days. <strong>Age 4-11 years:</strong> 10ml (200 mg) twice daily for 3 days. <strong>Age 12 years:</strong> 500mg or one tablet twice\r\ndaily for 3 days. Nitanid should be taken with food. Or, as directed by the\r\nregistered physician.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Use\r\nin pregnancy and lactation</strong>: Pregnancy category B. This drug\r\nshould be used during pregnancy only if clearly needed. Because many drugs are\r\nexcreted in human milk, caution should be exercised when Nitazoxanide is\r\nadministered to a nursing woman.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Packing:<o:p></o:p></strong></p><p class=\"MsoNormal\"><strong>Nitanid-500:</strong>\r\nEach box contains 20 tablets in a blister pack.<o:p></o:p></p><p><strong>Nitanid\r\nSuspension:</strong> Each bottle contains dry powder for\r\npreparation of 60ml suspension.<br><strong></strong></p><p style=\"text-align: justify;\"><br></p>",
    "strength": "500",
    "uom": "mg",
    "categoryId": "43",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1660727293Nitanid Local Insert English Part Com.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740569195Nitanid500.png"
    ]
  },
  {
    "id": "829",
    "name": "Nofenac ",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Aceclofenac BP 100mg\r\nTablet.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong><strong></strong><span xss=\"removed\"> Nofenac is used for the\r\nrelief of pain and inflammation in the\r\nfollowing conditions:</span></p><p style=\"text-align: justify;\"><span xss=\"removed\">\r\n* Acute and chronic rheumatoid arthritis</span></p><p style=\"text-align: justify;\"><span xss=\"removed\">\r\n* Osteoarthritis <br></span></p><p style=\"text-align: justify;\"><span xss=\"removed\">* Ankylosing spondylitis </span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span xss=\"removed\">* Pain and inflammation in orthopaedic,\r\ngynecologic, dental and other minor surgery</span></p><p style=\"text-align: justify;\"><span xss=\"removed\">\r\n* Post operative pain </span></p><p style=\"text-align: justify;\"><span xss=\"removed\">* Low back pain and other acute\r\nmusculoskeletal disorder </span></p><p style=\"text-align: justify;\"><span xss=\"removed\">* Primary dysmenorrhea</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span xss=\"removed\">\r\n* Severe traumatic injuries</span></p><p style=\"text-align: justify;\"><span xss=\"removed\">\r\n* Severe migraine attacks </span></p><p style=\"text-align: justify;\"><span xss=\"removed\">* Renal and biliary colic</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adults : The\r\nrecommended dose is 100mg, twice\r\ndaily. Children : There are no clinical\r\ndata on the use of Aceclofenac in\r\nchildren. Elderly : Generally no dose\r\nadjustment is necessary.Or as directed by registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">There are no well controlled studies the\r\nsafe use of drug in pregnant woman.\r\nThis drug should not be used during\r\npregnancy unless the benefits to the\r\nmother justify the potential risk to the\r\nfetus.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>Nofenac : 5 x 10's tablets .</p>",
    "strength": "100",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532248218nofenac.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745148267Nofenac.png"
    ]
  },
  {
    "id": "1195",
    "name": "Nomosic  ",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Meclizine hydrochloride USP  50mg Tablet.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This tablet is indicated for the management of nausea and vomiting, and dizziness associated with motion sickness, vertigo associated with diseases affecting the vestibular system.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">For the prevention and treatment of nausea, vomiting and vertigo associated with motion sickness, the usual oral dosage of meclizine hydrochloride in adults and children 12 years of age or older is 25- 50mg once daily. Vertigo : for the control of vertigo associated with diseases affecting the vestibular system, the recommended dose is 25 to 100mg daily, in divided doses, depending upon clinical response. Motion Sickness : The initial dose of 25 to 50mg should be taken one hour prior to embarkation for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy Category B by FDA.</p><p style=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\">Nomosic Tablet : 5x10’s tablets in blister pack</p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "39",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532248331Nomosic.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745148303Nomosic.png"
    ]
  },
  {
    "id": "874",
    "name": "NOPAIN ",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\">Diclofenac sodium\r\nBP 1.00mg/ml.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Postoperative inflammation\r\nafter cataract surgery and other surgical\r\nprocedures. Preoperative and\r\npostoperative prevention of cystoid\r\nmacular oedema associated with lens\r\nextraction and intraocular lens\r\nimplantation. Non-infectious\r\ninflammatory conditions affecting the\r\nanterior region of the eye (e.g. chronic\r\nnon-infectious conjunctivitis). Posttraumatic\r\ninflammation in penetrating\r\nwounds (as an adjuvant to local antiinfective\r\ntherapy).</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :<em> </em></strong>Preoperative : up to 5x1 drop over the 3\r\nhours preceding surgery. Postoperative :\r\n3x1 drop immediately after surgery,\r\nthereafter 3-5x1 drop daily for as long as\r\nrequired.</p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\">5ml in plastic dropper bottle.<br></p>",
    "strength": "0.10",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532248796NOPAINED.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/images/NOPAIN.jpg"
    ]
  },
  {
    "id": "831",
    "name": "Nopain Extra",
    "description": "<p><strong></strong><strong>Composition : </strong>Nopain Extra 50 : <span class=\"redactor-invisible-space\">Diclofenac Sodium USP 50 mg + Misoprostol BP 0.2 mg Enteric Coated Tablet.<br></span></p><p style=\"text-align: justify;\">Nopain Extra 75 : <span class=\"redactor-invisible-space\">Diclofenac Sodium USP 75 mg + Misoprostol BP 0.2 mg Enteric Coated Tablet.\r\n</span><br><span class=\"redactor-invisible-space\">\r\n</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is indicated for treatment of the\r\nsigns and symptoms of osteoarthritis or rheumatoid\r\narthritis in patients at high risk of developing\r\nNSAID-induced gastric and duodenal ulcers and\r\ntheir complications.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Osteoarthritis: The\r\nrecommended dosage for maximal GI mucosal\r\nprotection is Nopain Extra 50 tid. For patients who\r\nexperience intolerance, Nopain Extra 75 bid or\r\nNopain Extra 50 bid can be used. Rheumatoid\r\nArthritis: The recommended dosage is Nopain Extra\r\n50 tid or qid. For patients who experience\r\nintolerance, Nopain Extra 75 bid or Nopain Extra 50\r\nbid can be used. Special Dosing Considerations:\r\nNopain Extra contains misoprostol, which provides\r\nprotection against gastric and duodenal ulcers. For\r\ngastric ulcer prevention, the 0.2mg qid and tid\r\nregimens are therapeutically equivalent, but more\r\nprotective than the bid regimen. Or, as directed by\r\nthe registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : <em></em></strong><span class=\"redactor-invisible-space\">In late\r\npregnancy, as with other NSAIDs, this drug should\r\nbe avoided because it may cause premature\r\nclosure of the ductus arteriosus.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\">Nopain Extra 50 : 2x10's tablets. </p><p style=\"text-align: justify;\">Nopain Extra 75 : 3x10's tablets.</p>",
    "strength": "75,50",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532248969nopain-extra.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/nopainextra75.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/nopainextra50.jpg"
    ]
  },
  {
    "id": "1898",
    "name": "Nopain Suppository",
    "description": "<p><strong>Composition\r\n:</strong> Each Suppository Contains Diclofenac Sodium BP 50.00mg.</p><p class=\"MsoNormal\"><strong>Indications\r\n:</strong> It is indicated for the treatment of pain and inflammation in the\r\nfollowing diseases- Rheumatoid arthritis, Osteoarthritis, Ankylosing\r\nspondylitis,  Acute gout,  Migraine attacks,  Acute musculoskeletal disorders and trauma\r\nsuch as periarthritis (specially frozen shoulder), tendinitis, tenosynovitis,\r\nbursitis, sprains, strains, fracture, low back pain, Orthopedic, dental and\r\nother minor surgery.</p><p class=\"MsoNormal\"><strong>Dosage and\r\nadministration :</strong> Suppository should be inserted well in to the\r\nrectum. Adult : 75-150mg daily in divided dose. The total daily dose should\r\ngenerally be divided into 2 to 3 separate doses. The recommended maximum daily\r\ndose is 150 mg. Or, as directed by the registered physician.</p><p class=\"MsoNormal\"><strong>Use in\r\npregnancy and lactation :</strong> Pregnancy Category C. There are no well\r\ncontrolled studies in pregnant woman. This drug should not be used during\r\npregnancy unless the benefits to the mother justify the potential risk to the fetus.</p><p><strong>Packing :</strong> Each\r\nbox contains 10’s  Suppositories  in blister pack.</p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1704015158Nopain-50 Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1704015158Nopain-50 Carton.png"
    ]
  },
  {
    "id": "830",
    "name": "Nopain Tablet",
    "description": "<p class=\"MsoNormal\"><strong>Composition :</strong> Diclofenac Potassium 25 mg & 50 mg Tablet.</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Indications :</strong> It is indicated for the treatment of pain and\r\ninflammation in the following diseases- # Rheumatoid arthritis, #\r\nOsteoarthritis, # Ankylosing spondylitis, # Acute gout, # Migraine attacks,\r\n# Acute musculoskeletal disorders and trauma such as periarthritis (especially\r\nfrozen shoulder), tendinitis, tenosynovitis,bursitis, sprains, strains,\r\nfracture, low back pain, # Orthopaedic, dental and other minor surgery.</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Dosage and administration : Adults :</strong> Generally for adults 100- 150mg daily in 2-3 divided doses.In milder cases, as well as for children over 14 years 75-100mg. daily\r\nin 2-3 divided doses.In migraine an initial dose of 50mg should be taken at the first signs\r\nof \r\n\r\nan impending attack. In cases where relief 2 hours after the first dose\r\nis not sufficient, a further dose of 50mg may be taken. If needed, further\r\ndoses of 50mg may be taken at intervals 4-6 hours, not exceeding a total dose\r\nof  200mg per day .or as directed by the\r\nregistered physician</p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy Category C. There are no well controlled studies in  pregnant woman.This drug should not be used\r\nduring pregnancy unless the benefits to the mother justify the potential risk\r\nto the fetus.</p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\">Nopain-25 : 10 x 10's tablets. </p><p style=\"text-align: justify;\">Nopain-50 : 5 x 10's tablets</p>",
    "strength": "50,25",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532249079nopain-new.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745148382Nopain-50 tablets.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745148382Nopain-25.png"
    ]
  },
  {
    "id": "1028",
    "name": "Novirax",
    "description": "<p><strong></strong><strong> Composition : </strong>Acyclovir BP 5%.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Novirax cream is indicated\r\nfor the treatment of Herpes simplex virus\r\ninfections of the skin and mucous\r\nmembranes including initial and\r\nrecurrent genital herpes. Novirax cream\r\nis also indicated for the prophylaxis of\r\nherpes simplex infections in\r\nimmunocompro-mised patients.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Novirax\r\ncream should be used every 4 hours for\r\n5 days in the affected area. If after 5\r\ndays, healing is not complete then\r\ntreatment may be continued for a further\r\n5 days. Or as directed by the physician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Novirax cream : 5gm in a\r\ntubes</span></p>",
    "strength": "5% w/w",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1683111314Novirax Cream.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745148444NOVIRAX.png"
    ]
  },
  {
    "id": "1300",
    "name": "Novirax - HC",
    "description": "<p><strong>Composition :</strong> Aciclovir BP  5% and Hydrocortisone BP 1%.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indications :</strong> It is indicated for the early treatment of recurrent herpes labialis (Cold sores) to shorten the lesion healing time in adults and children.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\">Dosage and administration : A thin film is applied to lesions 5 times per day for 5- 10 days, starting at first sign of attack.Or, as directed by the registered physician.</p><p style=\"text-align: justify;\"><strong>Packing: Novirax-HC Cream:</strong>10gm in a tube.</p>",
    "strength": "5%",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532249256novirax-hc.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1517309659NoviraxHC.jpg"
    ]
  },
  {
    "id": "1160",
    "name": "Novirax Tablet",
    "description": "<p><strong></strong><strong>Composition :</strong> Aciclovir BP 200mg & 400mg Tablet<strong>.</strong></p><p style=\"text-align: justify;\"><strong>Indications : </strong>Novirax tablet is indicated for the treatment of viral infections due to herpes simplex virus (type I & II) and vericella zoster virus (herpes zoster & chicken pox). It is indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes. Novirax tablet is also indicated for the prophylaxis of herpes simplex infections in immunocompromised patients<strong>.</strong></p><p style=\"text-align: justify;\"><strong>Dosage & administration :</strong>Oral : Herpes simplex initial therapy :200mg 5 times daily for 10 days. Herpes simplex chronic suppressive therapy : 200-400mg 2 to 4 times daily for 12 months. Herpes Zoster : 800mg 5 times at 4 hrs intervals for 7-10 days. Varicela Zoster : 20mg/kg (not more than 800mg) 4 times daily for 5 days.</p><p style=\"text-align: justify;\">Children : Under 2 years should be given half of these doses. Elderly : Dosage may also be reduced as required. Or,  as directed by the physician.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>There are no adequate and well controlled studies in pregnant women. Novirax should be administered to a nursing mother with caution and only when indicated. Novirax should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<strong></strong></p><p style=\"text-align: justify;\"><strong>Packing :</strong> </p><p style=\"text-align: justify;\">Novirax-200 : 3 x 10's tablets in blister pack.</p><p style=\"text-align: justify;\">Novirax-400 : 2 x 10's tablets in blister pack.</p>",
    "strength": "400,200",
    "uom": "mg",
    "categoryId": "45",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532249508Novirax_Tab.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745148470NOVIRAX-400.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745148470NOVIRAX-200.png"
    ]
  },
  {
    "id": "1809",
    "name": "Obetic",
    "description": "<p><strong>Composition:</strong><strong>Obetic-5 Tablet: </strong>Each\r\nfilm coated tablet contains Obeticholic Acid INN 5 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Obetic-10\r\nTablet: </strong>Each film coated tablet contains Obeticholic Acid INN 10 mg.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><span class=\"markedcontent\"><strong>Indications:</strong></span><span class=\"markedcontent\">Obeticholic acid is indicated for the treatment of\r\nadultpatients with primary biliary cholangitis (PBC) without cirrhosis or with\r\ncompensated cirrhosis who do not have evidence of portal hypertension, Either\r\nin combination with Ursodeoxycholic Acid (UDCA) with an inadequate response to\r\nUDCA or as monotherapy in patients unable to tolerate UDCA.</span><o></o></p><p class=\"MsoNormal\" xss=\"removed\"><span class=\"markedcontent\"><strong>Dosage\r\nand administration:</strong></span><span class=\"markedcontent\">\r\nThe usual starting dosage for PBC patients without cirrhosis or with\r\ncompensated cirrhosis who do not have evidence of portal hypertension who have\r\nnot achieved an adequate biochemical response to an appropriate dosage of<a name=\"_GoBack\"></a> Ursodeoxycholic Acid (UDCA) for at least 1 year or are\r\nintolerant to UDCA follows bellow:</span><br>\r\n<span class=\"markedcontent\">Start with dosage of 5mg once daily for first 3\r\nmonths. After 3 months, for patients who have not achieved adequate reduction\r\nin Alkaline phosphate (ALP) and/or total bilirubin and who are tolerating\r\nObeticholic Acid increase to the maximum dosage 10 mg once daily. <o></o></span></p><p class=\"MsoNormal\" xss=\"removed\"><span class=\"markedcontent\">Management\r\nof patient with intolerable pruritus: Add an antihistamine or bile acid binding\r\nresin. Reduce the dosage to 5 mg every other day, for patients intolerable to 5\r\nmg once daily, 5 mg once daily, for patients intolerant to 10 mg once daily.\r\nTemporarily interrupt dosing for up to 2 weeks followed by restart at a reduced\r\ndosage and titrate the dosage to 10 mg once daily based on biochemical\r\nresponse. Or, as directed by the registered physician.<o></o></span></p><p class=\"MsoNoSpacing\" xss=\"removed\"><span class=\"markedcontent\"><strong>Use\r\nin pregnancy and lactation:</strong></span><span class=\"markedcontent\">\r\nThe limited available human data on the use of obeticholicacid during pregnancy\r\nare not sufficient to inform a drug-associated risk. There is no information on\r\nthe presence of obeticholic acid in human milk, the effects on the breast-fed\r\ninfant or the effects on milk production.<o></o></span></p><p class=\"MsoNoSpacing\" xss=\"removed\"><span class=\"markedcontent\"> </span></p><p><span class=\"markedcontent\"><strong>Packing:</strong></span><span class=\"markedcontent\"> Obetic-5 Tablet: Each box contains 2 x 10's tablets\r\nin blister pack.Obetic-10 Tablet: Each box contains 1 x 10's tablets in blister\r\npack.</span></p>",
    "strength": " 10, 5",
    "uom": "mg",
    "categoryId": "110",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1637997017Obetic insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745148501Obetic-10.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745148501Obetic-5.png"
    ]
  },
  {
    "id": "788",
    "name": "Oflacin ",
    "description": "<p><strong></strong><strong>Composition : </strong></p><p style=\"margin-top:0in;margin-right:0in;margin-bottom:3.55pt;margin-left:\r\n0in;line-height:12.0pt\"><span class=\"redactor-invisible-space\"><strong>Oflacin\r\n200:</strong></span><span class=\"redactor-invisible-space\"> Each film coated tablet\r\ncontains Ofloxacin BP 200 mg.</span><o:p></o:p></p><p><strong><strong>Oflacin 400:</strong> </strong>Each film coated tablet contains Ofloxacin BP 400 mg.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">The following infections caused\r\nby Ofloxacin susceptible Staphylococcus,\r\nStreptococcus pyogenes, Hemolytic\r\nstreptococci, Streptococcus pneumoniae,\r\nPeptostreptococcus sp., Neisseria\r\ngonorrhoeae, Escherichia coli, Citrobacter sp.,\r\nShigella sp., Klebsiella pneumoniae,\r\nEnterobacter sp., Serratia sp., Proteus sp.,\r\nPseudomonas aeruginosa, Haemophilus\r\ninfluenzae, Acinetobacter sp., and\r\nCampylobacter sp.,\r\na)  Pneumonia, Chronic Bronchitis, Diffuse\r\npanbronchiolitis, Bronchiectasis with\r\ninfection, Secondary infections of chronic\r\nrespiratory diseases.\r\nb) Pharyngolaryngitis, Tonsillitis and Acute\r\nbronchitis.\r\nc) Pyelonephritis, Cystitis, Prostatitis,\r\nEpididymitis, Gonococcal urethritis, Nongonococcal\r\nurethritis.\r\nd) Intrauterine infection, Adnexitis,\r\n Bartholinitis.\r\ne) Folliculitis, Furuncle, Furunculosis,\r\nCarbuncle, Erysipelas phlegmon,\r\nLymphangitis, Felon, Subcutaneous\r\nabscess, Spiradenitis, Acne conglobata,\r\nInfectious atheroma, Perianal abscess.\r\nf) Mastadenitis, Superficial secondary\r\ninfections after traumas, Burns, Surgery,\r\nTraumas.\r\ng) Cholecystitis, Cholangitis.\r\nh) Otitis media, Sinusitis.\r\ni)  Blepharitis, Hordeolum, Dacryocystitis,\r\nTarsadenitis, Keratohelcosis.\r\nj) Bacillary dysentery, Enteritis.\r\nk) Periodontitis, Pericoronitis, Gnathitis.\r\nl) Skin & soft tissue infections.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">General dosage\r\nrecommedation : The dose of OFLACIN is\r\ndetermined by the type and severity of the\r\ninfection. The dosage range of adults is 200mg\r\nto 800mg daily. Up to 400mg may be given as a\r\nsingle dose, preferably in the morning, larger\r\ndoses should be given as two divided doses.\r\nOFLACIN should not be taken within two hours of\r\nmagnesium/aluminium containing antacids or iron\r\npreparations since reduction of absorption of\r\nofloxacin can occur.\r\nLower Urinary Tract Infections : 200-400mg\r\ndaily preferably in the morning.\r\nUpper Urinary Tract Infections : 200-400mg\r\ndaily preferably in the morning, increasing, if\r\nnecessary, to 400mg twice daily.\r\nLower Respiratory Tract Infections : 400mg\r\ndaily preferably in the morning increasing, if\r\nnecessary, to 400mg twice daily.\r\nUncomplicated Urethral and Cervical\r\nGonorrhoea : A single dose of 400mg.\r\nNon Gonococcal Urethritis and Cervicitis :\r\n400mg daily in single or divided doses.\r\nImpaired renal function : 100mg should be\r\ngiven every 48 hours, when creatinine clearance\r\nis less than 20ml/minute (serum creatinine\r\ngreater than 5mg/dl).\r\nElderly : No adjustment of dosage is required in\r\nthe elderly.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Duration of treatment:</strong> The usual treatment period is\r\n5-10 days except in uncomplicated gonorrhoea where a single dose is\r\nrecommended. Or, as directed by the registered physician.<br></span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>There\r\nare however, no adequate and well-controlled studies in pregnant women.\r\nOfloxacin should be used during pregnancy only if the potential benefit justifies\r\nthe potential risk to the fetus. It can be presumed that Ofloxacin will be\r\nexcreted in human milk. Because of  the potential\r\nfor serious adverse reaction from Ofloxacin in nursing infants, a decision should\r\nbe made whether to discontinue nursing or to  discontinue the drug, taking into account the\r\nimportance of the drug to the mother.</p><p style=\"text-align: justify;\"><strong>Packing :</strong> </p><p style=\"margin-top:0in;margin-right:0in;margin-bottom:3.55pt;margin-left:\r\n0in;line-height:12.0pt\"><span class=\"redactor-invisible-space\"><strong>Oflacin\r\n200:</strong></span> 2x10's tablets in blister pack.<o:p></o:p></p><p style=\"text-align: justify;\"><strong>Oflacin 400 :</strong><span class=\"redactor-invisible-space\">\r\n2x10's tablets in blister pack.</span><br></p>",
    "strength": "400,200",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532326172oflacin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745310495OFLAZCIN-400.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745310495OFLAZCIN-200.png"
    ]
  },
  {
    "id": "1889",
    "name": "Olapag ",
    "description": "<p><strong>Composition: Olapag 25 : </strong>Each film coated\r\ntablet contains Eltrombopag Olamine  INN  25 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Olapag 50 : </strong>Each film coated tablet contains\r\nEltrombopag Olamine INN  50 mg.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications : </strong>Eltrombopag is indicated for the treatment\r\nof thrombocytopenia in adult and pediatric patients 1 year and older with\r\nchronic immune Idiopathic Thrombocytopenia (ITP) who have had an insufficient\r\nresponse to corticosteroids, immunoglobulin, or splenectomy. Eltrombopag is\r\nindicated for the treatment of thrombocytopenia in patients with chronic\r\nhepatitis C to allow the initiation and maintenance of interferon- based\r\ntherapy. Eltrombopag is indicated for the treatment of patients with severe\r\naplastic anemia who have had an insufficient response to immunosuppressive\r\ntherapy.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage & Administration :</strong><strong> </strong>Take orally on\r\nan empty stomach ( 1 hours before or 2 hours after a meal).<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Chronic ITP : </strong>Adult and\r\nPediatric Patients 6 Years and Older with ITP: Initiate Eltrombopag at a dose\r\nof 50 mg once daily. For Pediatric Patients with ITP Aged 1 to 5 Years:\r\nInitiate Eltrombopag at a dose of  25 mg\r\nonce daily. Adjust to maintain platelet count greater than or equal to\r\n50x109/L. Do not exceed 75mg per day.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Chronic\r\nHepatitis C-Associated Thrombocytopenia : </strong>Initiate Eltrombopag at a dose of\r\n25 mg<strong> </strong>once daily for all patients. Adjust to achieve target<strong> </strong>platelet\r\ncount required to initiate antiviral therapy.<strong> </strong>Do not exceed a daily dose\r\nof 100 mg.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Severe Aplastic\r\nAnemia : </strong>Initiate\r\nEltrombopag at 50 mg once daily. Adjust to maintain platelet count greater than\r\n50 x 109/L. Do not exceed 150mg per day. Or, as directed by the registered\r\nphysician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation :</strong><strong> </strong><strong>Pregnancy : </strong>Pregnancy\r\ncategory C. <strong>Nursing mother : </strong>It is<strong> </strong>not known whether Eltrombopag\r\nis excreted in<strong> </strong>human milk.A decision should be made whether<strong> </strong>to\r\ndiscontinue nursing or to discontinue Eltrombopag<strong> </strong>taking into account\r\nthe importance of<strong> </strong>Eltrombopag to the mother.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:\r\nOlapag-25 : </strong>Each\r\nbox contains 10’s tablets in blister pack.<o></o></p><p><strong> Olapag-50 : </strong>Each box contains 10’s tablets in\r\nblister pack.</p>",
    "strength": "50,25",
    "uom": "mg",
    "categoryId": "101",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1692263612",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1692263612Olapag-50 Carton.png",
      "https://www.admin.drug-international.com/uploads/product_images/1692263612Olapag-25 Carton.png"
    ]
  },
  {
    "id": "1857",
    "name": "Olapag-25",
    "description": "",
    "strength": "25",
    "uom": "mg",
    "categoryId": "101",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1669195316Olapag-25 Insert pdf.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745148571Olapag-25.png"
    ]
  },
  {
    "id": "1839",
    "name": "Olapag-50",
    "description": "",
    "strength": " 50",
    "uom": "mg",
    "categoryId": "101",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1659610584Olapag-50 Insert (Compressed).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745148590Olapag-50.png"
    ]
  },
  {
    "id": "966",
    "name": "Olmetic",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Olmesartan Medoxomil 20 mg Tablet.\r\n</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Olmesartan Medoxomil is\r\nindicated for the treatment of hypertension. It\r\nmay be used alone or in combination with\r\nother antihypertensive agents.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Olmetic :\r\nAdults: Dosage must be individualized. The\r\nusual recommended starting dose of\r\nOlmesartan Medoxomil is 10 to 20 mg once\r\ndaily when used as monotherapy. For\r\npatients requiring further reduction in blood\r\npressure after 2 weeks of therapy, the dose of\r\nOlmesartan Medoxomil may be increased to\r\n20 to 40 mg. Maximum recommended daily\r\ndose is 40mg. Elderly and renal\r\nimpairment: The maximum dose in elderly\r\nand patients with mild to moderate renal\r\nimpairment is 20mg daily. Children and\r\nadolescents: The safety and efficacy have\r\nnot been established in children and\r\nadolescents up to 18 years of age. Patients\r\nwith Hepatic Impairment : No dosage\r\nadjustment is necessary with hepatic\r\nimpairment. Or, as directed by the registered\r\nphysicians.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy Categories C (first trimester) and\r\nD (second and third trimesters). It is not\r\nknown whether Olmesartan Medoxomil is\r\nexcreted in human milk. Mothers must not\r\nbreast-feed if they are taking Olmesartan\r\nMedoxomil. Drugs that act directly on the\r\nrenin-angiotensin system can cause fetal and\r\nneonatal morbidity and death when\r\nadministered to pregnant women. When\r\npregnancy is detected, this drug should be\r\ndiscontinued as soon as possible.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Olmetic : 3 x 14's tablets in blister\r\npack.</span></p>",
    "strength": "20",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633325225Olmetic.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744105194Olmetic.png"
    ]
  },
  {
    "id": "967",
    "name": "Olmetic Plus",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Olmetic Plus :</span><span class=\"redactor-invisible-space\"> Olmesartan Medoxomil 20 mg +\r\nHydrochlorothiazide  12.5 mgTablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Olmesartan Medoxomil is indicated\r\nfor the treatment of hypertension. It may be used\r\nalone or in combination with other\r\nantihypertensive agents.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration</strong> <strong>: </strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Olmetic Plus : </strong>A\r\npatient whose blood pressure is inadequately\r\ncontrolled by olmesartan or hydrochlorothiazide\r\nalone may be switched to one tablet (olmesaran\r\nmedoxomil 20mg-hydrochlorothiazide 12.5mg)\r\nonce daily.<strong> </strong></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Patients with Renal Impairment : </strong>The\r\nusual regimens of therapy with olmesartanhydrochlorothiazide\r\nmay be followed provided the\r\npatient's creatinine clearance is &gt;30 mL/min. In\r\npatients with more severe renal impairment, loop\r\ndiuretics are preferred to thiazides, so\r\nolmesartan-hydrochlorothiazide is not\r\nrecommended. Patients with Hepatic\r\nImpairment : No dosage adjustment is necessary\r\nwith hepatic impairment. Or, as directed by the\r\nregistered physicians.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy\r\nCategories C (first trimester) and D (second and\r\nthird trimesters). It is not known whether\r\nOlmesartan Medoxomil is excreted in human milk.\r\nMothers must not breast-feed if they are taking\r\nOlmesartan Medoxomil. Drugs that act directly on\r\nthe renin-angiotensin system can cause fetal and\r\nneonatal morbidity and death when administered\r\nto pregnant women. When pregnancy is detected,\r\nthis drug should be discontinued as soon as\r\npossible. Thiazides appear in human milk.\r\nBecause of the potential for adverse effects on\r\nthe nursing infant, a decision should be made\r\nwhether to discontinue nursing or discontinue the\r\ndrug, taking into account the importance of the\r\ndrug to the mother.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Olmetic Plus : 3 x 14's tablets in\r\nblister pack.</span></p>",
    "strength": "20+12.5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633325453Olmetic Plus.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744105000Olmetic plus.png"
    ]
  },
  {
    "id": "908",
    "name": "OMG - 3",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Omega-3-Acid Ethyl\r\nEsters BP 1 gm (A combination of\r\nEicosapentaenoic Acid &\r\nDocosahexaenoic Acid ) Soft Capsule.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">OMG-3 is indicated as an\r\nadjunct to diet to reduce very high\r\n(500mg/dL) triglyceride (TG) level in\r\nadult patients.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">In\r\nHypertriglyceridaemia, it can be taken as\r\nsingle dose 4 capsules (4 gm) or 2\r\ncapsules (2 gm) twice daily with food.\r\nPatients should be placed on an\r\nappropriate lipid lowering diet before\r\nreceiving OMG-3 and should continue\r\nthis diet during treatment. Or, as directed\r\nby the registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">There are no adequate and well controlled\r\nstudies in pregnant women.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong> OMG-3 : 6 x 5's soft capsules\r\nin blister pack.</p>",
    "strength": "1",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532326447omg.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744105301OMG-3.png"
    ]
  },
  {
    "id": "1197",
    "name": "ONDASON  Tablet",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Ondansetron 8mg Tablet. </span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is used in the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. It is also used for the prevention and treatment of postoperative nausea and vomiting.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration :</strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">1) Prevention of Nausea and Vomiting Associated Chemotherapy :</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Adults : The recommended adult oral dosage for highly emetogenic cancer chemotherapy is 24 mg given as three 8 mg tablets administered 30 minutes before the start of emetogenic chemotherapy. For moderate emetogenic cancer chemotherapy the recommended adult oral dosage is 8 mg (one tablet) or 10 ml Syrup (8 mg) should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. one 8mg tablet or 10ml syrup (8mg) should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy. Pediatric : For pediatric patients 4 to 11 years of age, the dosage is 4mg tablet or 5ml Syrup (4mg). The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 4 and 8 hours after the first dose. one 4mg tablet or 5ml syrup (4mg) should be administered 3 times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">2) Prevention of Nausea and Vomiting Associated With Radiotherapy:</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Adults : For total body irradiation : One tablet (8mg) or 10ml (8mg) syrup should be administered 1 to 2 hours before each fraction of radiotherapy administered each day. For single high-dose fraction radiotherapy to the abdomen: One tablet (8mg) or 10ml (8mg) syrup should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy. For daily fractionated radiotherapy to the abdomen : One tablet (8mg) or 10ml (8mg) syrup should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">3) Postoperative nausea and vomiting :</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Adults : The recommended dosage is 16mg given as two tablets (8mg) or 20ml syrup (16mg) 1 hour before induction of anesthesia. Or, as directed by the registered physician.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong> Ondason-8 : 3 x 10's tablets in blister pack. </p>",
    "strength": "8",
    "uom": "mg",
    "categoryId": "39",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532326654ONDASON.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745208757Ondason-8.png"
    ]
  },
  {
    "id": "1198",
    "name": "ONDASON Injection",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\">Ondansetron USP 2mg/ml\r\nInjection.</span><span class=\"redactor-invisible-space\" xss=\"removed\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is used for the prevention of\r\nnausea and vomiting associated with initial\r\nand repeat courses of emetogenic cancer\r\nchemotherapy. It is also used for the\r\nprevention of postoperative nausea and/or\r\nvomiting.</span><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration :</strong></p><p style=\"text-align: justify;\">1) Prevention\r\nof Nausea and Vomiting Associated with\r\nInitial and Repeat Courses of Emetogenic\r\nChemotherapy : Adults : 32mg single dose\r\ninfused over 15 minutes by diluting with\r\n50ml saline (5% dextrose or 0.9% Nacl) 30\r\nminutes before starting chemotherapy.\r\nAlternatively, three dose of 0.15mg/kg body\r\nweight. The first dose is infused over 15\r\nminutes beginning 30 minutes before the\r\nstarting chemotherapy. Subsequent doses\r\n(0.15mg/kg) are administered 4 and 8 hours\r\nafter the first dose of administration.\r\nPediatric : 6months onwards: three dose of\r\n0.15mg/kg body weight. The first dose is\r\ninfused over 15 minutes beginning 30\r\nminutes before starting moderately to highly\r\nemetogenic chemotherapy. Subsequent\r\ndoses (0.15mg/kg) are administered 4 and 8\r\nhours after the first dose of administration. 2)\r\nPrevention of Postoperative Nausea and\r\nVomiting: Adults: Undiluted 4mg\r\nintravenously or intramuscularly immediately\r\nbefore induction of anesthesia. The rate of\r\nadministration should not be less than 30\r\nseconds, preferably over 2 to 5 minutes.\r\nAlternatively, the dose can be administered\r\npost-operatively if the patient experiences\r\nnausea and/or vomiting shortly after surgery.\r\nPediatrics (1 months to 12 years) : Weighing\r\nless than 40kg: 0.1mg/kg body weight in a\r\nsingle dose. Weighing more than 40kg: 4mg\r\nsingle dose. The dose should be\r\nimmediately before induction of anesthesia.\r\nThe rate of administration should not be less\r\nthan 30 seconds, preferably over 2 to 5\r\nminutes. Alternatively, the dose can be\r\nadministered post-operatively if the patient\r\nexperiences nausea and/or vomiting shortly\r\nafter surgery. Or, as directed by the\r\nregistered physician.<br></p><p style=\"text-align: justify;\"><strong>Pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy\r\nCategory B by FDA.</span><br></p><p style=\"text-align: justify;\"><strong>Packing : Ondason Injection (IV/IM) : </strong>1 x 3's ampoules in blister pack.</p>",
    "strength": "2",
    "uom": "mg/ml (IV/IM)",
    "categoryId": "39",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532326747ONDA_inj.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745310543Ondason Injection.png"
    ]
  },
  {
    "id": "1196",
    "name": "ONDASON Syrup",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Ondansetron USP 4mg/5ml Syrup.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is used in the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. It is also used for the prevention and treatment of postoperative nausea and vomiting.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration :</strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">1) Prevention of Nausea and Vomiting Associated Chemotherapy :</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Adults : The recommended adult oral dosage for highly emetogenic cancer chemotherapy is 24mg given as three 8mg tablets administered 30 minutes before the start of emetogenic chemotherapy. For moderate emetogenic cancer chemotherapy the recommended adult oral dosage is 8mg (one tablet) or 10ml Syrup (8mg) should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. one 8mg tablet or 10ml syrup (8mg) should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy. Pediatric : For pediatric patients 4 to 11 years of age, the dosage is 4mg tablet or 5ml Syrup (4mg). The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 4 and 8 hours after the first dose. one 4mg tablet or 5ml syrup (4mg) should be administered 3 times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">2) Prevention of Nausea and Vomiting Associated With Radiotherapy:</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Adults : For total body irradiation : One tablet (8mg) or 10ml (8mg) syrup should be administered 1 to 2 hours before each fraction of radiotherapy administered each day. For single high-dose fraction radiotherapy to the abdomen: One tablet (8mg) or 10ml (8mg) syrup should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy. For daily fractionated radiotherapy to the abdomen : One tablet (8mg) or 10ml (8mg) syrup should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">3) Postoperative nausea and vomiting :</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Adults : The recommended dosage is 16mg given as two tablets (8mg) or 20ml syrup (16mg) 1 hour before induction of anesthesia. Or, as directed by the registered physician.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong> Ondason syrup : 50ml Ondason syrup.</p>",
    "strength": "4",
    "uom": "mg/5ml",
    "categoryId": "39",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532326607ONDASON.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745208729Ondason 50 ml.png"
    ]
  },
  {
    "id": "1296",
    "name": "Ontaxel",
    "description": "<p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Composition: <o:p></o:p></strong></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\">Ontaxel-30 IV Injection: Each vial\r\ncontains 16.7ml solution containing Paclitaxel USP 30 mg (6 mg/ml).<strong><o:p></o:p></strong></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"> Ontaxel-100 IV Injection: Each vial contains 16.7ml\r\nsolution containing Paclitaxel USP 100 mg (6 mg/ml).<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\">Ontaxel-300 IV Injection: Each vial contains 50ml\r\nsolution containing Paclitaxel USP 300 mg (6 mg/ml).<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Indications: </strong><strong>Ovarian Carcinoma:</strong>\r\nOntaxel is indicated as first line and subsequent therapy for the treatment of\r\nadvanced carcinoma of the ovary.As first line therapy,Ontaxel is indicated in\r\ncombination with cisplatin.<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Breast carcinoma:</strong>\r\nOntaxel is indicated for the adjuvant treatment of node positive breast cancer\r\nadministered sequentially to standard doxorubicincontaining combination\r\nchemotherapy. Ontaxel is indicated for the treatment of breast cancer after\r\nfailure of combination chemotherapy for metastatic disease or relapse within 6\r\nmonths of adjuvant chemotherapy. Prior therapy should have included an\r\nanthracline unless clinically contraindicated. Ontaxel is indicated for the\r\nfirst line therapy of advanced or metastatic breast cancer either in\r\ncombination with an anthracycline in patients for whom anthracline therapy is\r\nsuitable or in combination with trastuzumab in patients who over express HER-2\r\nat a 2+ or 3+ level as determined by immunohistochemistry. Gemoxen, in\r\ncombination of Ontaxel .is indicated in the treatment of patients with\r\nunresectable,locally recurrent or metastatic breast cancer who have relapsed\r\nfollowing adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have\r\nincluded an anthracycline unless clinically contraindicated. Ontaxel is\r\nindicated for the treatment of metastatic cancer of the breast,in combination\r\nwith trastuzumab (Herceptin), in patients who have tumors that over-express\r\nHER-2 and who have not received previous chemotherapy for their metastatic\r\ndisease.<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Non Small Cell Lung Carcinoma:</strong> Ontaxel, in combination with cisplatin, is indicated for\r\nthe first line treatment of non small cell lung cancer in patients who are not\r\ncandidates for potential curative surgery and/or radiation therapy.<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Kaposi's Saocoma:</strong>\r\nOntaxel is indicated for the second line treatment of AIDS related Kaposi's\r\nSarcoma.<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Gastric Carcinoma:</strong>\r\nOntaxel is indicated for the treatment of Gastric Carcinoma.<br>\r\n<!--[if !supportLineBreakNewLine]--><br>\r\n<!--[endif]--><o:p></o:p></p><p style=\"margin: 0in 0in 6.05pt; background-image: initial; background-color: white;\"><strong>Dosage &\r\nAdministration: </strong>All patients should be premedicated\r\nprior to paclitaxel injection administration in order to prevent severe\r\nhypersensitivity reactions. Such premedication may consist of dexamethasone 20 mg PO administered\r\napproximately 12 and 6 hours before paclitaxel injection, diphenhydramine (or\r\nits equivalent) 50 mg IV 30 to 60 minutes prior to paclitaxel injection, and\r\ncimetidine (300 mg) or ranitidine (50 mg) IV 30 to 60 minutes before paclitaxel\r\ninjection.</p><p style=\"margin:0in;margin-bottom:.0001pt;text-align:justify\"><strong>Ovarian Carcinoma:</strong><strong> </strong>For patients with carcinoma of the ovary, the\r\nfollowing regimens are recommended:<o:p></o:p></p><p style=\"margin:0in;margin-bottom:.0001pt;text-align:justify\">1. For previously untreated patients\r\nwith carcinoma of the ovary, one of the following recommended regimens may be\r\ngiven every 3 weeks. In selecting the appropriate regimen, differences in\r\ntoxicities should be considered.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left:0in;text-align:justify;text-indent:-.25in;\r\nmso-list:l0 level1 lfo1;tab-stops:list .25in\"><!--[if !supportLists]-->·        \r\n<!--[endif]-->Paclitaxel\r\nInjection administered intravenously over 3 hours at a dose of 175 mg/m²\r\nfollowed by cisplatin at a dose of 75 mg/m²; or<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left:0in;text-align:justify;text-indent:-.25in;\r\nmso-list:l0 level1 lfo1;tab-stops:list .25in\"><!--[if !supportLists]-->·        \r\n<!--[endif]-->Paclitaxel\r\nInjection administered intravenously over 24 hours at a dose of 135 mg/m²\r\nfollowed by cisplatin at a dose of 75 mg/m².<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left:.25in;text-align:justify;text-indent:\r\n-.25in;mso-list:l1 level1 lfo2;tab-stops:list .25in\"><!--[if !supportLists]-->1.      <!--[endif]-->In patients previously treated with\r\nchemotherapy for carcinoma of the ovary, paclitaxel injection has been used at\r\nseveral doses and schedules; however, the optimal regimen is not yet clear. The\r\nrecommended regimen is paclitaxel injection 135 mg/m² or 175 mg/m² administered\r\nintravenously over 3 hours every 3 weeks.<o:p></o:p></p><p style=\"margin:0in;margin-bottom:.0001pt;text-align:justify\"><strong>Breast Carcinoma:</strong><strong> </strong>For patients with carcinoma of the breast, the following\r\nregimens are recommended:<o:p></o:p></p><p class=\"MsoNormal\" style=\"mso-margin-bottom-alt:auto;margin-left:.25in;\r\ntext-align:justify;text-indent:-.25in;mso-list:l3 level1 lfo3;tab-stops:list .25in\"><!--[if !supportLists]-->1.      <!--[endif]-->For the adjuvant treatment of\r\nnode-positive breast cancer, the recommended regimen is paclitaxel injection,\r\nat a dose of 175 mg/m² intravenously over 3 hours every 3 weeks for 4 courses administered\r\nsequentially to doxorubicin-containing combination chemotherapy. The clinical\r\ntrial used 4 courses of doxorubicin and cyclophosphamide.<o:p></o:p></p><p class=\"MsoNormal\" style=\"mso-margin-bottom-alt:auto;margin-left:.25in;\r\ntext-align:justify;text-indent:-.25in;mso-list:l3 level1 lfo3;tab-stops:list .25in\"><!--[if !supportLists]-->2.      <!--[endif]-->After failure of initial chemotherapy\r\nfor metastatic disease or relapse within 6 months of adjuvant chemotherapy,\r\npaclitaxel injection at a dose of 175 mg/m² administered intravenously over 3\r\nhours every 3 weeks has been shown to be effective.<o:p></o:p></p><p style=\"margin-top:0in;margin-right:0in;margin-bottom:15.15pt;margin-left:\r\n0in;text-align:justify\"><strong>Non-small\r\ncell lung carcinoma</strong><strong>:</strong> For patients with non-small cell lung carcinoma, the recommended regimen, given\r\nevery 3 weeks, is paclitaxel injection administered intravenously over 24 hours\r\nat a dose of 135 mg/m² followed by cisplatin, 75 mg/m².<o:p></o:p></p><p style=\"margin-top:15.15pt;margin-right:0in;margin-bottom:15.15pt;margin-left:\r\n0in;text-align:justify\"><strong>AIDS-related Kaposi's\r\nSarcoma:</strong> For patients\r\nwith AIDS-related Kaposi's\r\nsarcoma,<strong> </strong>paclitaxel injection administered at a dose of 135\r\nmg/m² given intravenously over 3 hours every 3 weeks or at a dose of 100 mg/m²\r\ngiven intravenously over 3 hours every 2 weeks is recommended (dose intensity\r\n45-50 mg/m²/week). In the 2 clinical trials evaluating these schedules, the\r\nformer schedule (135 mg/m² every 3 weeks) was more toxic than the latter. In\r\naddition, all patients with low performance status were treated with the latter\r\nschedule (100 mg/m² every 2 weeks).<o:p></o:p></p><p style=\"margin:0in;margin-bottom:.0001pt;text-align:justify\">Based upon the  immunosupreesion in\r\npatients with advanced HIV disease, the following modifications are\r\nrecommended in these patients:<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left:.25in;text-align:justify;text-indent:\r\n-.25in;mso-list:l2 level1 lfo4;tab-stops:list .25in\"><!--[if !supportLists]-->1.      <!--[endif]-->Reduce the dose of dexamethasone as 1\r\nof the 3 premedication drugs to 10 mg PO (instead of 20 mg PO);<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left:.25in;text-align:justify;text-indent:\r\n-.25in;mso-list:l2 level1 lfo4;tab-stops:list .25in\"><!--[if !supportLists]-->2.      <!--[endif]-->Initiate or repeat treatment with\r\npaclitaxel injection only if the neutrophil count is atleast\r\n1000 cells/mm³;<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left:.25in;text-align:justify;text-indent:\r\n-.25in;mso-list:l2 level1 lfo4;tab-stops:list .25in\"><!--[if !supportLists]-->3.      <!--[endif]-->Reduce the dose of subsequent courses\r\nof paclitaxel injection by 20% for patients who experience severe neutropenia  (neutrophil\r\n&lt; 500 cells/mm³ for a week or longer); and<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left:.25in;text-align:justify;text-indent:\r\n-.25in;mso-list:l2 level1 lfo4;tab-stops:list .25in\"><!--[if !supportLists]-->4.      <!--[endif]-->Initiate concomitant hematopoietic\r\ngrowth factor (G-CSF) as clinically indicated.<o:p></o:p></p><p style=\"margin:0in;margin-bottom:.0001pt;text-align:justify\">For the therapy of patients with solid\r\ntumors (ovary, breast, and NSCLC), courses of paclitaxel injection should not\r\nbe repeated until the neutrophil count is at least 1500 cells/mm³ and the <a href=\"https://www.rxlist.com/script/main/art.asp?articlekey=9939\">p</a>latlet count is at least 100,000 cells/mm³.\r\nPaclitaxel Injection should not be given to patients with AIDS-related Kaposi's\r\nsarcoma if the baseline or subsequent neutrophil count is less than 1000\r\ncells/mm³. Patients who experience severe neutropenia (neutrophil &lt; 500\r\ncells/mm³ for a week or longer) or severe peripheral neutropathy during paclitaxel injection\r\ntherapy should have dosage reduced by 20% for subsequent courses of paclitaxel\r\ninjection. The incidence of neurotoxicity and the severity of  neutropenia\r\nincrease with dose.<o:p></o:p></p><p style=\"margin: 0in 0in 6.05pt; background-image: initial; background-color: white;\"> \r\n<!--[if !supportLineBreakNewLine]--><br>\r\n<!--[endif]--><o:p></o:p></p><p style=\"margin: 0in 0in 6.05pt; background-image: initial; background-color: white;\"><strong>Use in Pregnancy and\r\nLactation: </strong><span class=\"redactor-invisible-space\">Pregnancy Category D. There is no adequate and well-\r\ncontrolled clinical studies in pregnant or breastfeeding women. It should only\r\nbe used in pregnant women if the potential benefit justifies the potential risk\r\nto the foetus. Since it is not known if Paclitaxel is distributed into milk,the\r\ndrug should be used with caution in nursing women.</span><br>\r\n<!--[endif]--><o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Packaging: <o:p></o:p></strong></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><span class=\"redactor-invisible-space\">Ontaxel 30\r\ninjection: </span>Each box contains 1 vial (5 ml) Paclitaxel.</p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><span class=\"redactor-invisible-space\">Ontaxel 100\r\ninjection: Each box contains 1 vial (16.7ml) Paclitaxel. <o:p></o:p></span></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><span class=\"redactor-invisible-space\">Ontaxel 300\r\ninjection: Each box contains 1 vial (50ml) Paclitaxel.<o:p></o:p></span></p><p>.<br></p>",
    "strength": "300,100",
    "uom": "mg/ml",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1517307447",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1517307447Ontaxel-300IV.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1517307447Ontaxel-100IV.jpg"
    ]
  },
  {
    "id": "1319",
    "name": "Ontaxel-30",
    "description": "<p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Composition: <o:p></o:p></strong></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\">Ontaxel-30 IV Injection: Each vial\r\ncontains 16.7ml solution containing Paclitaxel USP 30 mg (6 mg/ml).<strong><o:p></o:p></strong></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"> Ontaxel-100 IV Injection: Each vial contains 16.7ml\r\nsolution containing Paclitaxel USP 100 mg (6 mg/ml).<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\">Ontaxel-300 IV Injection: Each vial contains 50ml\r\nsolution containing Paclitaxel USP 300 mg (6 mg/ml).<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Indications: </strong><strong>Ovarian Carcinoma:</strong>\r\nOntaxel is indicated as first line and subsequent therapy for the treatment of\r\nadvanced carcinoma of the ovary.As first line therapy,Ontaxel is indicated in\r\ncombination with cisplatin.<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Breast carcinoma:</strong>\r\nOntaxel is indicated for the adjuvant treatment of node positive breast cancer\r\nadministered sequentially to standard doxorubicincontaining combination\r\nchemotherapy. Ontaxel is indicated for the treatment of breast cancer after\r\nfailure of combination chemotherapy for metastatic disease or relapse within 6\r\nmonths of adjuvant chemotherapy. Prior therapy should have included an\r\nanthracline unless clinically contraindicated. Ontaxel is indicated for the\r\nfirst line therapy of advanced or metastatic breast cancer either in\r\ncombination with an anthracycline in patients for whom anthracline therapy is\r\nsuitable or in combination with trastuzumab in patients who over express HER-2\r\nat a 2+ or 3+ level as determined by immunohistochemistry. Gemoxen, in\r\ncombination of Ontaxel .is indicated in the treatment of patients with\r\nunresectable,locally recurrent or metastatic breast cancer who have relapsed\r\nfollowing adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have\r\nincluded an anthracycline unless clinically contraindicated. Ontaxel is\r\nindicated for the treatment of metastatic cancer of the breast,in combination\r\nwith trastuzumab (Herceptin), in patients who have tumors that over-express\r\nHER-2 and who have not received previous chemotherapy for their metastatic\r\ndisease.<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Non Small Cell Lung Carcinoma:</strong> Ontaxel, in combination with cisplatin, is indicated for\r\nthe first line treatment of non small cell lung cancer in patients who are not\r\ncandidates for potential curative surgery and/or radiation therapy.<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Kaposi's Saocoma:</strong>\r\nOntaxel is indicated for the second line treatment of AIDS related Kaposi's\r\nSarcoma.<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Gastric Carcinoma:</strong>\r\nOntaxel is indicated for the treatment of Gastric Carcinoma.<br>\r\n<!--[if !supportLineBreakNewLine]--><br>\r\n<!--[endif]--><o:p></o:p></p><p style=\"margin: 0in 0in 6.05pt; background-image: initial; background-color: white;\"><strong>Dosage &\r\nAdministration: </strong>All patients should be premedicated prior to paclitaxel injection administration in order to prevent severe hypersensitivity reactions. Such premedication may consist of dexamethasone 20 mg PO administered approximately 12 and 6 hours before paclitaxel injection, diphenhydramine (or its equivalent) 50 mg IV 30 to 60 minutes prior to paclitaxel injection, and cimetidine (300 mg) or ranitidine (50 mg) IV 30 to 60 minutes before paclitaxel injection.</p><p style=\"margin: 0in 0in 0.0001pt; text-align: justify;\"><strong>Ovarian Carcinoma:</strong><strong> </strong>For patients with carcinoma of the ovary, the following regimens are recommended:<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; text-align: justify;\">1. For previously untreated patients with carcinoma of the ovary, one of the following recommended regimens may be given every 3 weeks. In selecting the appropriate regimen, differences in toxicities should be considered.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left: 0in; text-align: justify; text-indent: -0.25in;\">· Paclitaxel Injection administered intravenously over 3 hours at a dose of 175 mg/m² followed by cisplatin at a dose of 75 mg/m²; or<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left: 0in; text-align: justify; text-indent: -0.25in;\">· Paclitaxel Injection administered intravenously over 24 hours at a dose of 135 mg/m² followed by cisplatin at a dose of 75 mg/m².<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left: 0.25in; text-align: justify; text-indent: -0.25in;\">1. In patients previously treated with chemotherapy for carcinoma of the ovary, paclitaxel injection has been used at several doses and schedules; however, the optimal regimen is not yet clear. The recommended regimen is paclitaxel injection 135 mg/m² or 175 mg/m² administered intravenously over 3 hours every 3 weeks.<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; text-align: justify;\"><strong>Breast Carcinoma:</strong><strong> </strong>For patients with carcinoma of the breast, the following regimens are recommended:<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left: 0.25in; text-align: justify; text-indent: -0.25in;\">1. For the adjuvant treatment of node-positive breast cancer, the recommended regimen is paclitaxel injection, at a dose of 175 mg/m² intravenously over 3 hours every 3 weeks for 4 courses administered sequentially to doxorubicin-containing combination chemotherapy. The clinical trial used 4 courses of doxorubicin and cyclophosphamide.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left: 0.25in; text-align: justify; text-indent: -0.25in;\">2. After failure of initial chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy, paclitaxel injection at a dose of 175 mg/m² administered intravenously over 3 hours every 3 weeks has been shown to be effective.<o:p></o:p></p><p style=\"margin: 0in 0in 15.15pt; text-align: justify;\"><strong>Non-small cell lung carcinoma</strong><strong>:</strong> For patients with non-small cell lung carcinoma, the recommended regimen, given every 3 weeks, is paclitaxel injection administered intravenously over 24 hours at a dose of 135 mg/m² followed by cisplatin, 75 mg/m².<o:p></o:p></p><p style=\"margin: 15.15pt 0in; text-align: justify;\"><strong>AIDS-related Kaposi's Sarcoma:</strong> For patients with AIDS-related Kaposi's sarcoma,<strong> </strong>paclitaxel injection administered at a dose of 135 mg/m² given intravenously over 3 hours every 3 weeks or at a dose of 100 mg/m² given intravenously over 3 hours every 2 weeks is recommended (dose intensity 45-50 mg/m²/week). In the 2 clinical trials evaluating these schedules, the former schedule (135 mg/m² every 3 weeks) was more toxic than the latter. In addition, all patients with low performance status were treated with the latter schedule (100 mg/m² every 2 weeks).<o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; text-align: justify;\">Based upon the  immunosupreesion in patients with advanced HIV disease, the following modifications are recommended in these patients:<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left: 0.25in; text-align: justify; text-indent: -0.25in;\">1. Reduce the dose of dexamethasone as 1 of the 3 premedication drugs to 10 mg PO (instead of 20 mg PO);<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left: 0.25in; text-align: justify; text-indent: -0.25in;\">2. Initiate or repeat treatment with paclitaxel injection only if the neutrophil count is atleast 1000 cells/mm³;<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left: 0.25in; text-align: justify; text-indent: -0.25in;\">3. Reduce the dose of subsequent courses of paclitaxel injection by 20% for patients who experience severe neutropenia  (neutrophil &lt; 500 cells/mm³ for a week or longer); and<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-left: 0.25in; text-align: justify; text-indent: -0.25in;\">4. Initiate concomitant hematopoietic growth factor (G-CSF) as clinically indicated.<o:p></o:p></p><p style=\"margin: 0in 0in 6.05pt; background-image: initial; background-color: white;\"><span class=\"redactor-invisible-space\">For the therapy of patients with solid tumors (ovary, breast, and NSCLC), courses of paclitaxel injection should not be repeated until the neutrophil count is at least 1500 cells/mm³ and the <a href=\"https://www.rxlist.com/script/main/art.asp?articlekey=9939\">p</a>latlet count is at least 100,000 cells/mm³. Paclitaxel Injection should not be given to patients with AIDS-related Kaposi's sarcoma if the baseline or subsequent neutrophil count is less than 1000 cells/mm³. Patients who experience severe neutropenia (neutrophil &lt; 500 cells/mm³ for a week or longer) or severe peripheral neutropathy during paclitaxel injection therapy should have dosage reduced by 20% for subsequent courses of paclitaxel injection. The incidence of neurotoxicity and the severity of neutropenia increase with dose.Ovarian Cancer First line treatment in combination with\r\ncisplatin : Ontaxel administered intravenously over 3 hours at a dose of 175\r\nmg/m2 followed by cisplatin at a dose of 75 mg/m2 every 3 weeks Ontaxel\r\nadministered intravenously over 24 hours at a dose of 135 mg/m2 followed by\r\ncisplatin at a dose of 75 mg/m2 every 3 weeks In patients previously treated\r\nwith chemotherapy for carcinoma of the ovary, Ontaxel has been use at several\r\ndoses and schedules; however,the optimal regimem is not yet clear.The\r\nrecommended regimen is Ontaxel (paclitaxel) 135 mg/m2 or 175 mg/m2 administered\r\nintravenously over 3 hours every 3 weeks. Breast Cancer : - 175 mg/m2\r\nadministered IV over 3 hours every 3 weeks has been shown to be effective after\r\nfailure of chemotherapy for metastatic disease or relapse within 6 months of\r\nadjuvant chemotherapy. AIDS-related Kaposi's sarcoma : - 135 mg/m2 given IV\r\nover 3 hours every 3 weeks or at a dose of 100 mg/m2 given IV. over 3 hours\r\nevery 2 weeks is recommended (dose intensity 45-50 mg/ m2 /week) Lung cancer :\r\n- For the first-line treatment of NSCLC, in combination with cisplatin, in\r\npatients who are not candidates for potentially curative surgery and/or\r\nradiation therapy. -135 mg/m2 IV administered over 24 hours followed by\r\ncisplatin. The regimen to be repeated every 3 weeks based on the clinical\r\nstatus of the patient. Gastric Cancer : - Once daily 210 mg/m2 (Body surface\r\narea) by 3 hours intravenous infusion for adults. At least 3 week of dosing\r\ninterval is of absolute necessity. Dosage modification for toxicity (solid\r\ntumors, including ovary, breast, and lung carcinoma) : Courses of Paclitaxel\r\nshould not be repeated until the neutrophil count is&gt; 1500 cells/mm3 and the\r\nplatelet count is&gt; 100,000 cells/mm3; reduce dosage by 20% for patients\r\nexperiencing severe peripheral neuropathy or severe neutropenia (neutrophil\r\n&lt;500&gt;</span><br>\r\n<!--[if !supportLineBreakNewLine]--><br>\r\n<!--[endif]--><o:p></o:p></p><p style=\"margin: 0in 0in 6.05pt; background-image: initial; background-color: white;\"><strong>Use in Pregnancy and\r\nLactation: </strong><span class=\"redactor-invisible-space\">Pregnancy Category D. There is no adequate and well-\r\ncontrolled clinical studies in pregnant or breastfeeding women. It should only\r\nbe used in pregnant women if the potential benefit justifies the potential risk\r\nto the foetus. Since it is not known if Paclitaxel is distributed into milk,the\r\ndrug should be used with caution in nursing women.</span><br>\r\n<!--[if !supportLineBreakNewLine]--><br>\r\n<!--[endif]--><o:p></o:p></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><strong>Packaging: <o:p></o:p></strong></p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><span class=\"redactor-invisible-space\">Ontaxel 30\r\ninjection: </span>Each box contains 1 vial (5 ml) Paclitaxel.</p><p style=\"margin: 0in 0in 0.0001pt; background-image: initial; background-color: white;\"><span class=\"redactor-invisible-space\">Ontaxel 100\r\ninjection: Each box contains 1 vial (16.7ml) Paclitaxel. <o:p></o:p></span></p><p>Ontaxel 300\r\ninjection: Each box contains 1 vial (50ml) Paclitaxel.<br></p>",
    "strength": "30/5",
    "uom": "mg/ml",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1525760942Ontaxel_in.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1525760942Ontaxel_30.jpg"
    ]
  },
  {
    "id": "1159",
    "name": "Opegus",
    "description": "<p><strong>Composition :</strong> Ribavirin USP 200 mg.<strong></strong></p><p style=\"text-align: justify;\"><strong>Indications :</strong><span class=\"redactor-invisible-space\"> Ribavirin is used in\r\ncombination with Interferon /PegInterferon\r\nand other oral anti-viral drugs\r\nsuch as Sofosbuvir to treat patients with\r\nChronic Hepatitis C (CHC).</span><strong><br></strong></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><strong>Dosage and Administration :</strong> Ribavirin\r\ncapsule is taken orally two times daily\r\nwith food at a consistent manner. These\r\nindications are based on achieving\r\nunnoticeable HCV-RNA after treatment\r\nfor 24 or 48 weeks and maintaining a\r\nSustained Virologic Response (SVR) 24\r\nweeks after the last dose. The\r\nRecommended dosage of Ribavirin in\r\nthe combination therapy is given below :\r\n1) The daily dose of Ribavirin +\r\nInterferon alpha-2a/Interferon alpha-2b\r\n(3 MIU 3 times weekly\r\nsubcutaneously):\r\ni) \r\n<!--[if gte mso 9]><xml>\r\n <o:OfficeDocumentSettings>\r\n  <o:AllowPNG></o:AllowPNG>\r\n </o:OfficeDocumentSettings>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves></w:TrackMoves>\r\n  <w:TrackFormatting></w:TrackFormatting>\r\n  <w:PunctuationKerning></w:PunctuationKerning>\r\n  <w:ValidateAgainstSchemas></w:ValidateAgainstSchemas>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF></w:DoNotPromoteQF>\r\n  <w:LidThemeOther>EN-GB</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables></w:BreakWrappedTables>\r\n   <w:SnapToGridInCell></w:SnapToGridInCell>\r\n   <w:WrapTextWithPunct></w:WrapTextWithPunct>\r\n   <w:UseAsianBreakRules></w:UseAsianBreakRules>\r\n   <w:DontGrowAutofit></w:DontGrowAutofit>\r\n   <w:SplitPgBreakAndParaMark></w:SplitPgBreakAndParaMark>\r\n   <w:EnableOpenTypeKerning></w:EnableOpenTypeKerning>\r\n   <w:DontFlipMirrorIndents></w:DontFlipMirrorIndents>\r\n   <w:OverrideTableStyleHps></w:OverrideTableStyleHps>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"></m:mathFont>\r\n   <m:brkBin m:val=\"before\"></m:brkBin>\r\n   <m:brkBinSub m:val=\"&#45;-\"></m:brkBinSub>\r\n   <m:smallFrac m:val=\"off\"></m:smallFrac>\r\n   <m:dispDef></m:dispDef>\r\n   <m:lMargin m:val=\"0\"></m:lMargin>\r\n   <m:rMargin m:val=\"0\"></m:rMargin>\r\n   <m:defJc m:val=\"centerGroup\"></m:defJc>\r\n   <m:wrapIndent m:val=\"1440\"></m:wrapIndent>\r\n   <m:intLim m:val=\"subSup\"></m:intLim>\r\n   <m:naryLim m:val=\"undOvr\"></m:naryLim>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"false\"\r\n  DefSemiHidden=\"false\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"371\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" QFormat=\"true\" Name=\"Normal\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal Indent\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footnote text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"header\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footer\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index heading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"caption\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"table of figures\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"envelope address\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"envelope return\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footnote reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"line number\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"page number\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"endnote reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"endnote text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"table of authorities\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"macro\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"toa heading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" QFormat=\"true\" Name=\"Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Closing\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Signature\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"Default Paragraph Font\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Message Header\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" QFormat=\"true\" Name=\"Subtitle\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Salutation\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Date\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text First Indent\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text First Indent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Note Heading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Block Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Hyperlink\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"FollowedHyperlink\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" QFormat=\"true\" Name=\"Strong\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" QFormat=\"true\" Name=\"Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Document Map\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Plain Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"E-mail Signature\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Top of Form\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Bottom of Form\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal (Web)\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Acronym\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Address\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Cite\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Code\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Definition\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Keyboard\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Preformatted\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Sample\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Typewriter\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Variable\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal Table\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation subject\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"No List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Contemporary\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Elegant\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Professional\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Subtle 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Subtle 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Balloon Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"Table Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Theme\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Placeholder Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" QFormat=\"true\" Name=\"No Spacing\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Revision\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" QFormat=\"true\"\r\n   Name=\"List Paragraph\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" QFormat=\"true\" Name=\"Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" QFormat=\"true\"\r\n   Name=\"Intense Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"19\" QFormat=\"true\"\r\n   Name=\"Subtle Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"21\" QFormat=\"true\"\r\n   Name=\"Intense Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"31\" QFormat=\"true\"\r\n   Name=\"Subtle Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"32\" QFormat=\"true\"\r\n   Name=\"Intense Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"33\" QFormat=\"true\" Name=\"Book Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"37\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"Bibliography\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"TOC Heading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"41\" Name=\"Plain Table 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"42\" Name=\"Plain Table 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"43\" Name=\"Plain Table 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"44\" Name=\"Plain Table 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"45\" Name=\"Plain Table 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"40\" Name=\"Grid Table Light\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"Grid Table 1 Light\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"Grid Table 6 Colorful\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"Grid Table 7 Colorful\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"List Table 1 Light\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"List Table 6 Colorful\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"List Table 7 Colorful\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 6\"></w:LsdException>\r\n </w:LatentStyles>\r\n</xml><![endif]--><!--[if gte mso 10]>\r\n<style>\r\n /* Style Definitions */\r\n table.MsoNormalTable\r\n\t{mso-style-name:\"Table Normal\";\r\n\tmso-tstyle-rowband-size:0;\r\n\tmso-tstyle-colband-size:0;\r\n\tmso-style-noshow:yes;\r\n\tmso-style-priority:99;\r\n\tmso-style-parent:\"\";\r\n\tmso-padding-alt:0cm 5.4pt 0cm 5.4pt;\r\n\tmso-para-margin-top:0cm;\r\n\tmso-para-margin-right:0cm;\r\n\tmso-para-margin-bottom:8.0pt;\r\n\tmso-para-margin-left:0cm;\r\n\tline-height:107%;\r\n\tmso-pagination:widow-orphan;\r\n\tfont-size:11.0pt;\r\n\tfont-family:\"Calibri\",sans-serif;\r\n\tmso-ascii-font-family:Calibri;\r\n\tmso-ascii-theme-font:minor-latin;\r\n\tmso-hansi-font-family:Calibri;\r\n\tmso-hansi-theme-font:minor-latin;\r\n\tmso-bidi-font-family:\"Times New Roman\";\r\n\tmso-bidi-theme-font:minor-bidi;\r\n\tmso-fareast-language:EN-US;}\r\n</style>\r\n<![endif]-->≤75 kg = (400+600) mg for 48\r\nweeks (Genotype 1 & 4).\r\nii) &gt;75 kg = (600+600) mg for 24\r\nweeks (Genotype 2 & 3).\r\n2) Ribavirin daily dose with PegInterferon\r\nalpha-2a/ Peg-interferon\r\nalpha -2b (180 µgm once weekly\r\nsubcutaneously).\r\ni) &lt;75 kg=\r\n(600+600) mg for 48 weeks (Genotype\r\n1 & 4). ii) (400+400) mg for 24 weeks\r\n(Genotype 2 & 3). Or, as directed by the\r\nregistered physicians.<br></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Ribavirin\r\nmust not be used during pregnancy. It is\r\nnot known whether this drug passes into\r\nbreast milk. Caution should be advised\r\nhighly for the administration of Ribavirin\r\nto nursing women to avoid any serious\r\nadverse reactions in infants.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Opegus : 3 x 7's capsules in\r\nblister pack.\r\n</span></p>",
    "strength": "200",
    "uom": "mg",
    "categoryId": "45",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532327085opegus.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Opegus.jpg"
    ]
  },
  {
    "id": "1791",
    "name": "Opthacol",
    "description": "<p><strong>Composition : </strong>Each ml contains: Chloramphenicol BP 5.00mg.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Indications\r\n:</strong> <strong>Eye:</strong> Chloramphenicol is broad spectrum bacteriostatic antibiotic.\r\nIt is a active against a wide variety of gram-negative & gram-positive\r\norganisms as well as rickettsiae and spirochaetes. It is indicated for use as\r\ntopical antibacterial in the treatment of superficial ocular infections caused\r\nby sensitive organisms.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Ear:</strong> External\r\near canal infections. <o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Dosage\r\nand administration :<i> </i>Eye: For </strong><strong>adults (including\r\nthe elderly):</strong> One to two drops applied to each\r\naffected eye upto six times daily or more frequently if required. (Severe\r\ninfections may require one to two drops every fifteen to twenty minutes\r\ninitially, reducing the frequency of instillation gradually as the infection is\r\ncontrolled).<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Ear: </strong>2-3 drops\r\ninto the ear canal three to four times a day. Or, as directed by the registered\r\nphysicisan.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal\"><strong>Use\r\nin pregnancy and lactation :</strong>\r\nSafety for use in pregnancy and lactation has not been established. Therefore,\r\nuse only considered essential by the physician. <o:p></o:p></p>\r\n\r\n<p><strong>Packing:</strong>\r\n10 ml in plastic dropper bottle.</p>",
    "strength": "5.00",
    "uom": "mg/ml",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633344331Opthacol Eye & Drop Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1633344248OpthacolEye & Ear Drop Carton Pic.png"
    ]
  },
  {
    "id": "877",
    "name": "OPTHAFLOX",
    "description": "<p><strong></strong><strong>Composition :</strong> Lomefloxacin INN 3mg/ml Sterile Eye Drops.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Bacterial infections including\r\nconjunctivitis, blepharitis, blepharoconjunctivitis,\r\nlomefloxacin susceptible\r\norganisms and staphylococcus aureus induced\r\ncorneal ulcers.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adults\r\nand children (above 1 year of age) :\r\nInsert 1 drop into the lower conjunctival\r\nsac 2-3 times daily. At the beginning of\r\nthe treatment, applications should be\r\nmore frequent, apply 1 drop every hour\r\nduring 6-10 hour. Duration of the\r\ntreatment: 7 to 9 days. Or as directed by\r\nthe physician</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy Category C by FDA.</p><p style=\"text-align: justify;\"><strong>Packing : </strong>5ml in plastic dropper bottle.</p>",
    "strength": "0.50",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532327140OPTHAFLOX_sey.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745208786Opthaflox 5ml.png"
    ]
  },
  {
    "id": "914",
    "name": "Oramet  ",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Metformin Hydrochloride BP\r\n500mg & 850mg Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Oramet is an oral\r\nantihyperglycemic drug used in the\r\nmanagement of non-insulin dependent\r\ndiabetes mellitus (NIDDM) & Polycystic\r\novarian syndrome.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The usual\r\nstarting dose is one tablet 2 or 3 times\r\ndaily given during or after meals. The\r\nmaximum recommended dose of\r\nmetformin is 3gm daily.\r\nOr, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Metformin has been assigned to\r\npregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Oramet-500 : 5 x 10's tablets\r\nin blister pack. </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Oramet-850 : 5 x 10's tablets in blister\r\npack.</span></p>",
    "strength": "850,500,1,500",
    "uom": "mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532327228oramet.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740569360oramet.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569304oramet 500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569391oramet-SR 1gm.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569391oramet-SR 500.png"
    ]
  },
  {
    "id": "914",
    "name": "Oramet  ",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Metformin Hydrochloride BP\r\n500mg & 850mg Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Oramet is an oral\r\nantihyperglycemic drug used in the\r\nmanagement of non-insulin dependent\r\ndiabetes mellitus (NIDDM) & Polycystic\r\novarian syndrome.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The usual\r\nstarting dose is one tablet 2 or 3 times\r\ndaily given during or after meals. The\r\nmaximum recommended dose of\r\nmetformin is 3gm daily.\r\nOr, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Metformin has been assigned to\r\npregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Oramet-500 : 5 x 10's tablets\r\nin blister pack. </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Oramet-850 : 5 x 10's tablets in blister\r\npack.</span></p>",
    "strength": "850,500,1,500",
    "uom": "mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532327228oramet.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740569360oramet.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569304oramet 500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569391oramet-SR 1gm.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569391oramet-SR 500.png"
    ]
  },
  {
    "id": "1165",
    "name": "Ornid",
    "description": "<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Composition:</strong> Each film coated tablet contains\r\nOrnidazole INN 500mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications: Ornid </strong>is\r\nindicated in the treatment of susceptible protozoal infections and prophylaxis\r\nof anaerobic bacterial infections.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage &\r\nadministration: </strong>The usual\r\nadults dosage<o:p></o:p></p><table class=\"MsoTableGrid\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"676\" style=\"width: 507.3pt;\">\r\n <tbody><tr style=\"mso-yfti-irow:0;mso-yfti-firstrow:yes;height:13.7pt\">\r\n  <td width=\"211\" valign=\"top\" style=\"width: 2.2in; border-width: 1pt; border-color: windowtext; padding: 0in 5.4pt; height: 13.7pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\"><strong>Diseases</strong></p>\r\n  </td>\r\n  <td width=\"240\" valign=\"top\" style=\"width: 179.8pt; border-top-width: 1pt; border-right-width: 1pt; border-bottom-width: 1pt; border-top-color: windowtext; border-right-color: windowtext; border-bottom-color: windowtext; border-left: none; padding: 0in 5.4pt; height: 13.7pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\"><strong>Dosage</strong></p>\r\n  </td>\r\n  <td width=\"225\" valign=\"top\" style=\"width: 169.1pt; border-top-width: 1pt; border-right-width: 1pt; border-bottom-width: 1pt; border-top-color: windowtext; border-right-color: windowtext; border-bottom-color: windowtext; border-left: none; padding: 0in 5.4pt; height: 13.7pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\"><strong>Duration of treatment</strong></p>\r\n  </td>\r\n </tr>\r\n <tr style=\"mso-yfti-irow:1;height:14.2pt\">\r\n  <td width=\"211\" valign=\"top\" style=\"width: 2.2in; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; border-top: none; padding: 0in 5.4pt; height: 14.2pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Amoebiasis<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"240\" valign=\"top\" style=\"width: 179.8pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 14.2pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Ornid tablet twice daily<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"225\" valign=\"top\" style=\"width: 169.1pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 14.2pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">5-10 days<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr style=\"mso-yfti-irow:2;height:13.7pt\">\r\n  <td width=\"211\" valign=\"top\" style=\"width: 2.2in; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; border-top: none; padding: 0in 5.4pt; height: 13.7pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Amoebic dysentery<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"240\" valign=\"top\" style=\"width: 179.8pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 13.7pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">3 Ornid tablets as single dose<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"225\" valign=\"top\" style=\"width: 169.1pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 13.7pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">3 days<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr style=\"mso-yfti-irow:3;height:14.2pt\">\r\n  <td width=\"211\" valign=\"top\" style=\"width: 2.2in; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; border-top: none; padding: 0in 5.4pt; height: 14.2pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Giardiasis<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"240\" valign=\"top\" style=\"width: 179.8pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 14.2pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">3 Ornid tablets as single dose<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"225\" valign=\"top\" style=\"width: 169.1pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 14.2pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">1-2 days<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr style=\"mso-yfti-irow:4;mso-yfti-lastrow:yes;height:14.2pt\">\r\n  <td width=\"211\" valign=\"top\" style=\"width: 2.2in; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; border-top: none; padding: 0in 5.4pt; height: 14.2pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Trichomoniasis<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"240\" valign=\"top\" style=\"width: 179.8pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 14.2pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">3 Ornid tablets as single dose<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"225\" valign=\"top\" style=\"width: 169.1pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 14.2pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">5 days<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>* Anaerobic\r\nbacterial infections Ornid tablet twice daily 5 - 10 days. Children dose<o:p></o:p></strong></p><table class=\"MsoTableGrid\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"682\" style=\"width: 511.8pt;\"><tbody><tr style=\"mso-yfti-irow:0;mso-yfti-firstrow:yes;height:17.15pt\"><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-width: 1pt; border-color: windowtext; padding: 0in 5.4pt; height: 17.15pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\"><strong>Disease</strong><o:p></o:p></p></td><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-top-width: 1pt; border-right-width: 1pt; border-bottom-width: 1pt; border-top-color: windowtext; border-right-color: windowtext; border-bottom-color: windowtext; border-left: none; padding: 0in 5.4pt; height: 17.15pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\"><strong>mg/kg/body/weight</strong><o:p></o:p></p></td><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-top-width: 1pt; border-right-width: 1pt; border-bottom-width: 1pt; border-top-color: windowtext; border-right-color: windowtext; border-bottom-color: windowtext; border-left: none; padding: 0in 5.4pt; height: 17.15pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\"><strong>Dosage</strong><o:p></o:p></p></td><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-top-width: 1pt; border-right-width: 1pt; border-bottom-width: 1pt; border-top-color: windowtext; border-right-color: windowtext; border-bottom-color: windowtext; border-left: none; padding: 0in 5.4pt; height: 17.15pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\"><strong>Duration of treatment</strong><o:p></o:p></p></td></tr><tr style=\"mso-yfti-irow:1;height:16.55pt\"><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; border-top: none; padding: 0in 5.4pt; height: 16.55pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Amoebiasis<o:p></o:p></p></td><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 16.55pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">25mg per Kg body weight<o:p></o:p></p></td><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 16.55pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Single dose<o:p></o:p></p></td><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 16.55pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">5 - 10 days<o:p></o:p></p></td></tr><tr style=\"mso-yfti-irow:2;height:16.55pt\"><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; border-top: none; padding: 0in 5.4pt; height: 16.55pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Amoebic dysentery<o:p></o:p></p></td><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 16.55pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">40mg per Kg body weight<o:p></o:p></p></td><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 16.55pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Single dose<o:p></o:p></p></td><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 16.55pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">3 days<o:p></o:p></p></td></tr><tr style=\"mso-yfti-irow:3;mso-yfti-lastrow:yes;height:17.15pt\"><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; border-top: none; padding: 0in 5.4pt; height: 17.15pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Giardiasis<o:p></o:p></p></td><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 17.15pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">40mg per Kg body weight<o:p></o:p></p></td><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 17.15pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">Single dose<o:p></o:p></p></td><td width=\"171\" valign=\"top\" style=\"width: 127.95pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: windowtext; padding: 0in 5.4pt; height: 17.15pt;\"><p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\">2 days<o:p></o:p></p></td></tr></tbody></table><p class=\"MsoNormal\" style=\"text-align:justify\">** Anaerobic\r\nbacterial infections 10mg/kg/twice daily 5-10 days. Or, as directed by the\r\nregistered physicians.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong> </strong></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Use in pregnancy and lactation:</strong> Pregnancy category C. The use of <strong>Ornid</strong> should be avoided during pregnancy, especially the first\r\ntrimester and high dose regimen. Women taking the drug should not breast-feed\r\ntheir babies.<o:p></o:p></p><p><strong>Packing:</strong> Each box contains\r\n50’s tablets in a blister pack.<br><strong></strong></p>",
    "strength": "500",
    "uom": "mg",
    "categoryId": "43",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1660728449Ornid Insert Local English Part Com.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740569420ornid500.png"
    ]
  },
  {
    "id": "1352",
    "name": "Osinib",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:</strong> <strong>Osinib</strong>: Each\r\nfilm coated tablet contains Osimertinib 80 mg as Osimertinib Mesylate INN.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong> Osinib is indicated for the treatment of patients with\r\nmetastatic epidermal growth factor receptor (EGFR) T790M mutation-positive\r\nnon-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose\r\ndisease has progressed on or after EGFR tyrosine kinase inhibitor (TKI)\r\ntherapy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand Administration:</strong> The recommended dose of Osinib is\r\n80 mg tablet once a day until disease progression or unacceptable toxicity. It\r\ncan be taken with or without food. If a dose is missed, one should not make up\r\nthe missed dose and take the next dose as scheduled. Or, as directed by the\r\nregistered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation: </strong>There\r\nare no adequate and well-controlled studies in pregnant women using\r\nOsimertinib. If it is used during pregnancy or if the patient becomes pregnant\r\nwhile receiving this drug, she should be apprised of the potential hazard to\r\nthe fetus or potential risk for loss of the pregnancy. <strong>Lactation:</strong> There\r\nare no data on the presence of Osimertinib in human milk, the effects of\r\nOsimertinib on the breastfed infant or on milk production. Because of the\r\npotential for serious adverse reactions in breastfed infants from Osimertinib,\r\na lactating woman should be advised not to breastfeed during treatment with\r\nOsinib and for 2 weeks after the final dose.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packaging:</strong> Each box contains 3x10's tablets in Alu- Alu blister pack.</p>",
    "strength": "80",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/15438313781531116108Osinib.pdf.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745304606Osinib.png"
    ]
  },
  {
    "id": "1716",
    "name": "Osinib CH",
    "description": "<p><strong><span lang=\"ZH-CN\">奥希替尼</span></strong></p><p class=\"MsoNormal\" align=\"left\"><strong><span lang=\"ZH-CN\">成分</span></strong><strong>:</strong><span lang=\"ZH-CN\">奥希替尼</span>:<span lang=\"ZH-CN\">每片薄膜包衣片剂含有</span>80<span lang=\"ZH-CN\">毫克的奥希替尼，作为甲磺酸奥希替尼。</span><o></o></p><p class=\"MsoNormal\" align=\"left\"><o> </o></p><p class=\"MsoNormal\" align=\"left\"><strong><span lang=\"ZH-CN\">适应症</span></strong><strong>:</strong><span lang=\"ZH-CN\">奥昔布适用于治疗转移性表皮生长因子受体</span>(EGFR) T790M<span lang=\"ZH-CN\">突变阳性的非小细胞肺癌</span>(<span lang=\"ZH-CN\">非小细胞肺癌</span>)<span lang=\"ZH-CN\">，其疾病在</span>EGFR<span lang=\"ZH-CN\">酪氨酸激酶抑制剂</span>(TKI)<span lang=\"ZH-CN\">治疗期间或之后发展。</span><span lang=\"ZH-CN\"> </span><o></o></p><p class=\"MsoNormal\" align=\"left\"><o> </o></p><p class=\"MsoNormal\" align=\"left\"><strong><span lang=\"ZH-CN\">剂量和给药</span></strong><strong>:</strong><span lang=\"ZH-CN\">建议剂量为</span>80<span lang=\"ZH-CN\">毫克，每天一次，直至病情恶化或出现不可接受的毒性。它可以与食物共同服用，也可以不共同。如果错过了一个剂量，应该弥补错过的剂量，并按计划服用下一个剂量。或者按照注册医生的指示。</span><o></o></p><p class=\"MsoNormal\" align=\"left\"><o> </o></p><p class=\"MsoNormal\" align=\"left\"><strong><span lang=\"ZH-CN\">用于怀孕和哺乳</span></strong><strong>:</strong><span lang=\"ZH-CN\">没有对孕妇使用奥希替尼进行充分和良好控制的研究。如果在怀孕期间使用，或者如果患者在接受这种药物时怀孕，应告知她对胎儿的潜在危险或失去妊娠的潜在危险。</span><o></o></p><p class=\"MsoNormal\" align=\"left\"><strong><span lang=\"ZH-CN\">哺乳</span></strong><strong>:</strong><span lang=\"ZH-CN\">没有关于母乳中存在奥希替尼、奥希替尼对母乳喂养婴儿或产奶量的影响的数据。由于奥希替尼母乳喂养的婴儿可能出现严重的不良反应，应建议哺乳期妇女在奥希替尼治疗期间和最终剂量后</span>2<span lang=\"ZH-CN\">周内不要母乳喂养。</span><span lang=\"ZH-CN\"> </span><o></o></p><p><strong><span lang=\"ZH-CN\">包装</span></strong><strong>:</strong><span lang=\"ZH-CN\">每箱装</span>3x10<span lang=\"ZH-CN\">的药片，采用</span>Alu- Alu<span lang=\"ZH-CN\">泡罩包装。</span></p>",
    "strength": "80",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1568795773OSINIB.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1568795773Osinib 30 Tablet- Carton Pic.png"
    ]
  },
  {
    "id": "1926",
    "name": "Ovajet",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Composition:</strong><strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Ovajet\r\n50 Tablet: </strong>Each Tablet contains \r\nClomifene Citrate BP 50 mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Ovajet\r\n100 Tablet:</strong> Each Tablet contains  ClomifeneCitrate BP 100 mg<strong>.<o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Indications:</strong>It is  indicatedfor the treatment of ovulatory failure\r\nin female patients who wish to become pregnant. This therapy will not be\r\nsuccessful unless the patient though unovulatory, is capable of ovulation &\r\nher partner is fertile. It is also indicated for the Polycystic ovary syndrome,\r\nMenorrhagia caused by hyperplastic endometrium, Amenorrhea with galactorrhea\r\nsyndrome, Psychogenic amenorrhea syndrome, Secondary amenorrhea of unknown\r\ncause, Amenorrhea during post oral contraceptive period.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Dosage\r\n& Administration: </strong>The usual dose for the\r\nfirst course of Clomiphene is 50 mg (1 tablet) a day for 5 days in the early\r\nfollicular phase of the cycle, following normal menstruation or a progestagen-induced\r\nwithdrawal bleeding. Many regimes have been used, but most common begin either\r\non day 2 or day 5. If this dose induces ovulation, there is no need to increase\r\nthe dose in the following courses. If this dose induces ovulation, but pregnancy\r\ndoes not occur, stimulation with Clomiphene Citrate is to be continued, but up\r\nto 6 stimulative courses. If <o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\">the first course does not induce ovulation, the\r\nsecond course should be started with 100 mg a day (2 tablets of 50 mg taken in\r\na single dose) for 5 days. If ovulation is not induced, 2 more stimulative\r\ncourses of the same dose should be given. If the next three stimulative courses\r\ndo not produce a successful result, the therapeutic trial is considered to be\r\nfinished. If ovulation is induced, but pregnancy does not occur, maximum 6\r\ncourses with Clomiphene are recommended. However, if menstrual bleeding does\r\nnot occur, the patient should be examined carefully for the possible pregnancy,\r\nand the next course of therapy should be delayed until the correct diagnosis\r\nhas been determined. Or, as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><a name=\"_GoBack\"></a> </p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Use\r\nin Pregnancy and lactation:</strong>This is not recommended in\r\npregnancy. In some cases Clomiphene citrate may reduce lactation, if it is\r\nadministered to a woman during lactating period. So it should be avoided during\r\nlactational period.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Packing:Ovajet\r\n50 Tablet :</strong>Each box contains 30's tablets in a blister pack.<strong><o:p></o:p></strong></p><p><strong>Ovajet\r\n100 Tablet :</strong>Each box contains 30's tablets in a blister pack.</p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "123",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1738208998Ovajet Web Insert New pattern.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1738143736Ovajet 50 Carton 2.png"
    ]
  },
  {
    "id": "1356",
    "name": "Oxiplat",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>COMPOSITION:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Oxiplat 50 Injection: </strong>Each vial contains 10ml solution\r\ncontaining Oxaliplatin USP 50mg(5mg/ml).</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Oxiplat 100 Injection: </strong>Each vial contains 20ml solution\r\ncontaining Oxaliplatin USP 100mg (5mg/ml).</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Oxiplat 200 Injection: </strong>Each vial contains 40ml solution\r\ncontaining Oxaliplatin USP 200mg (5mg/ml).</p><p class=\"MsoNormal\" xss=\"removed\"><strong>DESCRIPTION: </strong>Oxaliplatin is slightly soluble\r\nin water, very slightly soluble in methanol and practically insoluble in\r\nethanol.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Mechanism Of Action: </strong>Oxaliplatin undergoes\r\nnonenzymatic conversion in physiologic solutions to active derivatives\r\nvia displacement of the labile oxalate ligand. Several transient reactive\r\nspecies are formed, including monoaquo and diaquo DACH platinum, which\r\ncovalently bind with macromolecules. Both inter-and intrastrand Pt-DNA\r\ncrosslinks are formed. Crosslinks are formed between the N7 positions of two\r\nadjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated\r\nby an intervening nucleotide (GNG). These crosslinks inhibit DNA replication\r\nand ranscription. Cytotoxicity is cell-cycle nonspecific. In vivo studies have\r\nshown antitumor activity of oxaliplatin against colon carcinoma. In combination\r\nwith 5-fluorouracil, oxaliplatin exhibits in vitro and in vivo\r\nantiproliferative activity greater than either compound alone in several tumor\r\nmodels [HT29 (colon), GR (mammary), and L1210 (leukemia)].</p><p class=\"MsoNormal\" xss=\"removed\"><strong>INDICATIONS: </strong>Oxaliplatin, used in combination\r\nwith infusional 5-fluorouracil/folinic acid, is indicated for: • Adjuvant\r\ntreatment of stage III colon cancer in patients who have undergone complete resection\r\nof the primary tumor. • Treatment of advanced colorectal cancer.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>DOSAGE AND ADMINISTRATION:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage: </strong>Administer oxaliplatin in\r\ncombination with 5-fluorouracil/folinic acid every 2 weeks. For advanced\r\ndisease, treatment is recommended until disease progression or unacceptable toxicity.\r\nFor adjuvant use, treatment is recommended for a total of 6 months (12 cycles).\r\nDay 1: Oxaliplatin 85 mg/m² intravenous infusion in 250-500 mL 5% Dextrose\r\ninjection, USP and folinic acid 200 mg/m² intravenous infusion in 5% Dextrose\r\nInjection, USP both given over 120 minutes at the same time in separate bags\r\nusing a Y-line, followed by 5-fluorouracil 400 mg/m² intravenous bolus given\r\nover 2-4 minutes, followed by 5-fluorouracil 600 mg/m² intravenous infusion in\r\n500 mL 5% Dextrose Injection, USP (recommended) as a 22-hour continuous\r\ninfusion. Day 2: Folinic acid 200 mg/m² intravenous infusion over 120 minutes,\r\nfollowed by 5-fluorouracil 400 mg/m² intravenous bolus given over 2-4 minutes,\r\nfollowed by 5-fluorouracil 600 mg/m² intravenous infusion in 500 mL 5% Dextrose\r\nInjection, USP (recommended) as a 22-hour continuous infusion.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy: </strong>Pregnancy Category D.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing : Oxiplat 50 Injection: </strong>Each box contains 1 vial of 10ml\r\nsolution.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Oxiplat 100 Injection: </strong>Each box contains 1 vial of 20ml\r\nsolution.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Oxiplat 200 Injection: </strong>Each box contains 1 vial of 40ml\r\nsolution.</p>",
    "strength": "200,100,50",
    "uom": "Mg/Vial",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1546850038Oxiplat Injection- Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1546850038Oxiplat 200mg Injection- Carton Pic.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1546850038Oxiplat 100mg Injection- Carton Pic.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1546850038Oxiplat 50- Carton Pic.jpg"
    ]
  },
  {
    "id": "1856",
    "name": "Padi D ",
    "description": "<p><strong>Composition :</strong><strong> </strong>Each\r\nml Oral Drop Solution Contains Cholecalciferol (Vitamin D3) USP 10000 IU (200 IU/Drop).</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications :</strong><strong> </strong>It\r\nis indicated for the treatment & prevention of (Vitamin D3) deficiency. It\r\nis also<o></o></p><p class=\"MsoNormal\" xss=\"removed\">indicated\r\nas an adjunct to specific therapy for osteoporosis in patients with vitamin D3 deficiency.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage & administration :<o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Treatment of deficiency : Children and adolescents:</strong><strong> </strong>The\r\ndose should be adjusted<strong> </strong>dependent\r\nupon desirable serum levels of<strong> </strong>25-hydroxy-cholecalciferol\r\n25(OH) D, the severity of<strong> </strong>the\r\ndisease and the patients response to treatment.<strong> </strong>The daily dose should not exceed 1000 IU\r\n(5 drops)<strong> </strong>per day for infants &lt;1&gt; children\r\n1-10 years and 4000 IU per day for<strong> </strong>adolescents&gt;11years.<strong> <o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>For Adults :</strong><strong> </strong>Higher\r\ndoses should be adjusted<strong> </strong>dependent\r\nupon desirable serum levels of<strong><o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\">25-hydroxycholecalciferol\r\n25(OH)D, the severity of the disease and the patients response to treatment. The\r\ndaily dose 4000 IU (20 drops per day).<strong> <o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>For Prevention :</strong><strong> </strong>Children\r\n0-11 years old : with an identified risk, the recommended dose is 2 drops (400\r\nIU) per day Adolescents 12-18 years old : with an identified risk, the\r\nrecommended dose is 3-4 drops (600-800 IU) per day.<strong> <o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>For adults :</strong><strong> </strong>For\r\nprevention of vitamin D deficiency and as in adjunct to specific therapy for osteoporosis:\r\nrecommended dose is 3-4 drops(600-8001U) per day.<strong> </strong><o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>For pregnant women :</strong><strong> </strong>The\r\nrecommended daily intake for pregnant women is 400 IU (2 drops) however, in\r\nwomen who are considered to be vitamin D3 deficient a higher dose may be required\r\n(up to 2000 IU/day-10 drops). Or, as directed by the registered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation :</strong><strong> </strong>shown safe use\r\nof doses up to 4000 IU during  pregnancy.\r\nThe recommended daily intake for pregnant women is 400 IU, however in women who\r\nare considered to be vitamin D3 deficient a higher dose may be required. During\r\npregnancy women should follow the advice of their medical practitioner as their\r\nrequirements may vary depending on the severity of their disease and their\r\nresponse to treatment. Vitamin D3 and its metabolites are excreted in breast\r\nmilk. The dose should be monitored for pregnant and lactating women.<o></o></p><p><strong>Packing :</strong><strong> </strong>30ml\r\nbottle with a plastic dropper. For measurement use 0.5ml supplied dropper\r\n(200IU = 1drop)</p>",
    "strength": "10000 ",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1669194614Padi-D pdf insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1669195543Padi-D Carton.png"
    ]
  },
  {
    "id": "1900",
    "name": "Padi-D 400",
    "description": "<p style=\"text-align: justify;\">Padi -D 400</p><p style=\"text-align: justify;\">Vitamin D3 Oral Solution</p><p style=\"text-align: justify;\">Composition : Each ml Oral Solution Contains Cholecalciferol (Vitamin D3) USP 400 IU/ml.</p><p style=\"text-align: justify;\">Indications : It is indicated for the treatment & prevention of (Vitamin D3) deficiency. It is also indicated as an adjunct to specific therapy for osteoporosis in patients with vitamin D3 deficiency.</p><p style=\"text-align: justify;\">Dosage & administration : 400 IU Per day beginning soon after birth. 0 to 6 months: 0.50 ml twice a day. 6 months & above: 1.00 ml twice a day. The American Academy of Pediatrics (AAP) recommended that infant has to get 400 IU OF Vitamin D3 per day beginning soon after birth, an amount that is not possible to get from breast milk) alone. Treatment of deficiency : Children and adolescents: The dose should be adjusted dependent upon desirable serum levels of 25-hydroxy-cholecalciferol 25(OH) D, the severity of the disease and the patients response to treatment. The daily dose should not exceed 1000 IU (5 drops) per day for infants &lt;1&gt;11- years.</p><p style=\"text-align: justify;\">For pregnant women : The recommended daily intake for pregnant women is 400 IU (2 drops) however, in women who are considered to be vitamin D3 deficient a higher dose may be required (up to 2000 IU/day-10 drops). Or, as directed by the registered physician.</p><p style=\"text-align: justify;\">Use in pregnancy and lactation : See dosage & Administration.</p><p style=\"text-align: justify;\">Packing : 20ml bottle with a plastic dropper. For measurement use supplied dropper.</p>",
    "strength": " 400IU/ml",
    "uom": "",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1707631890Padi-D 400 Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744105567Padi-D.png"
    ]
  },
  {
    "id": "1185",
    "name": "Pair",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\">Ketorolac tromethamine USP 5\r\nmg/ml.</span></p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Ketorolac tromethamine\r\nophthalmic solution is indicated for the\r\ntemporary relief of ocular itching due to\r\nseasonal allergic conjunctivitis. Ketorolac\r\ntromethamine ophthalmic solution is also\r\nindicated for the treatment of\r\npostoperative inflammation in patients\r\nwho have undegone cataract extraction.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The\r\nrecommended dose of ketorolac\r\ntromethamine ophthalmic solution is one\r\ndrop (0.25 mg) four times a day for relief\r\nof ocular itching due to seasonal allergic\r\nconjunctivitis. For the treatment of\r\npostoperative inflammation in patients\r\nwho have undergone cataract extraction,\r\none drop of ketorolac tromethamine\r\nophthalmic solution should be applied to\r\nthe affected eye(s) four times daily\r\nbeginning 24 hours after cataract surgery\r\nand continuing through the first 2 weeks\r\nof the postoperative period. Or, as\r\ndirected by the registered physician.</span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy Category C by FDA.<span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong> 5ml in plastic dropper bottle.<br> </p>",
    "strength": "0.5%",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532327405PAIR-drops.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745208809Pair.png"
    ]
  },
  {
    "id": "1219",
    "name": "Pair Injection",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Ketorolac tromethamine USP 30mg/ml (IV/IM) injection.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Pair  Injection are indicated for the short-term management of moderate to severe acute post-operative pain.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration :</strong> Pair injection : Ketorolac is for administration by intramuscular or bolus intravenous injection. The recommended initial dose of Ketorolac Tromethamine is 10mg, followed by 10mg to 30mg every four to six hours as required. A total daily dose of 90mg for adults and 60mg for the elderly, renal-impaired patients and patients less than 50kg should not be exceeded. The maximum duration of treatment should not exceed two days. Or, as directed by the registered physician.<br></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy Category C.There are no well controlled studies in\r\npregnant woman.This drug should not be used during\r\npregnancy unless the benefits to the mother justify the\r\npotential risk to the fetus.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong><span class=\"redactor-invisible-space\" xss=\"removed\"> Pair-30 (IV/IM) Injection : 1x1's ampoule.</span></p>",
    "strength": "30",
    "uom": "mg/ml",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532327488pair-tabinj.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/pair-30.jpg"
    ]
  },
  {
    "id": "832",
    "name": "Pair Tablet",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Ketorolac tromethamine USP\r\n10mg Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Pair Tablet are\r\nindicated for the short-term management of\r\nmoderate to severe acute post-operative\r\npain.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Pair Tablet :\r\nAdults : 10mg every 4 to 6 hours as required.\r\nDoses exceeding 40mg per day are not\r\nrecommended. Tablet are recommended for\r\nshort term use only (up to 7 days) and are not\r\nrecommended for chronic use</span>.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy\r\nCategory C.There are no well controlled studies in\r\npregnant woman.This drug should not be used during\r\npregnancy unless the benefits to the mother justify the\r\npotential risk to the fetus.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\"><strong>Pair Tablet : </strong>3x10's tablets. </span></p>",
    "strength": "10",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532327532pair-tabinj.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1684407530Pair Carton.png"
    ]
  },
  {
    "id": "1779",
    "name": "Palbo-125",
    "description": "<p class=\"MsoNormal\">Palbociclib INN 125 mg</p><p class=\"MsoNormal\"><strong>Composition: </strong>Each\r\ncapsule contains Palbociclib INN 125 mg capsule.</p><p class=\"MsoNormal\"><strong>Indications:</strong>\r\nPalbociclib is indicated for the treatment of adult patients with hormone\r\nreceptor (HR)-positive, human epidermal growth factor receptor 2\r\n(HER2)-negative advanced or metastatic breast cancer in combination with:<br>\r\n• An aromatase inhibitor as initial endocrine-based therapy in postmenopausal\r\nwomen or in men; or • Fulvestrant in patients with disease progression\r\nfollowing endocrine therapy.</p><p class=\"MsoNormal\"><strong>Dosage & Administration:</strong>\r\n<strong>Recommended Dose and Schedule</strong>: The recommended dose of Palbociclib is a\r\n125 mg capsule taken orally once daily for 21 consecutive days followed by 7\r\ndays off treatment to comprise a complete cycle of 28 days. Palbociclib should\r\nbe taken with food. Patients should be encouraged to take their dose of\r\nPalbociclib at approximately the same time each day. For men treated with\r\ncombination Palbociclib plus aromatase inhibitor therapy, consider treatment\r\nwith an LHRH agonist according to current clinical practice standards. Or, as\r\ndirected by the registered physician.</p><p class=\"MsoNormal\"><strong>Use in Pregnancy & Lactation: </strong>Palbociclib\r\ncan cause fetal harm when administered to a pregnant woman. Advise pregnant\r\nwomen of the potential risk to a fetus. Risk of major birth defects and\r\nmiscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.</p><p><strong>Packaging: </strong>Each box contains</p><p>21capsules in a blister pack.<br xss=\"removed\"></p><p><br xss=\"removed\"></p>",
    "strength": "125",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1631692417Palbo-125- Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744105602Palbo-125.png"
    ]
  },
  {
    "id": "1207",
    "name": "Palnox Injection",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Palonosetron INN 0.25mg IV Injection.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Moderately emetogenic cancer chemotherapy : prevention of acute and delayed nausea and vomiting associated with initial and repeat courses.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"> A single 0.25mg I.V dose administered over 30 seconds. Dosing should occur 30 minutes before the start of chemotherapy.</span></span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong>Pregnancy : Pregnancy category B. There are no adequate and wellcontrolled studies in pregnant women. Therefore, Palonosetron should be used during pregnancy only if clearly needed.</p><p style=\"text-align: justify;\"><strong>Packing :</strong><span class=\"redactor-invisible-space\" xss=\"removed\"> Palnox 0.25 Injection (IV) : 1 x 3's Ampoules (5ml) in a blister pack.</span></p>",
    "strength": "0.25",
    "uom": "mg/5ml",
    "categoryId": "39",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532327635Palnox.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Palnoxi.jpg"
    ]
  },
  {
    "id": "1206",
    "name": "Palnox Tablet",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Palonosetron BP 0.5mg Tablet. </span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Moderately emetogenic cancer chemotherapy : prevention of acute and delayed nausea and vomiting associated with initial and repeat courses.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">Chemotherapy-Induced Nausea and Vomiting (Dosage for Adults) Tablet : 0.5 mg tablet approximately 1 hour before the start of chemotherapy.</span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong>Pregnancy : Pregnancy category B. There are no adequate and wellcontrolled studies in pregnant women. Therefore, Palonosetron should be used during pregnancy only if clearly needed.</p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Palnox 0.5 tablet : 2 x 14's tablets in blister pack. </span></p>",
    "strength": "0.5",
    "uom": "mg",
    "categoryId": "39",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1635133912Palnox(2).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745208848Palnox 0.5.png"
    ]
  },
  {
    "id": "909",
    "name": "Pancil",
    "description": "<p class=\"MsoNormal\" style=\"text-align:justify\"><strong> </strong></p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Composition\r\n:</strong>\r\nPancil Tablet: Each Tablet Contains Cilostazol USP 100mg. </p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications\r\n: </strong>Cilostazol\r\nis indicated for the reduction of symptoms of intermittent claudication, as\r\nindicated by an increased walking distance.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage\r\nand administration :</strong> The recommended dosage of Cilostazol is\r\n100 mg twice daily taken at least half an hour before or two hours after\r\nbreakfast and dinner. A dose of 50 mg twice daily should be considered during\r\nco-administration of ketoconazole, Itraconazole, Fluconazole, Omeprazole,\r\nErythromycin, Diltiazem. Or,  as directed\r\nby the registered physicians.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Use\r\nin pregnancy and lactation :</strong> Pregnancy Category-C.\r\nThere are no adequate and well-controlled studies in pregnant women. It is\r\nexcreted in human milk. Because of the potential risk to nursing infants, a\r\ndecision should be made to discontinue nursing or to discontinue Cilostazol.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Packing\r\n:</strong>\r\nPancil Tablet : Each box contains 2 x 14's tablets in blister pack.</p>\r\n\r\n",
    "strength": "100",
    "uom": "mg",
    "categoryId": "106",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531283864Pancil.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/images/pancil.jpg"
    ]
  },
  {
    "id": "1203",
    "name": "Pansec Injection",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Pantoprazole 40mg Injection.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication :</strong></p><p style=\"text-align: justify;\"><strong></strong><span class=\"redactor-invisible-space\">Pansec is registered for the following indications :</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\">1) Duodenal ulcer</p><p style=\"text-align: justify;\">2) Gastric ulcer</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">3) Moderate to severe reflux esophagitis</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">4) Eradication of Helicobacter pylori</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">5) Treatment of ulcers resistant to H2 antagonists</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">6) Maintenance of ulcer remission</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\">7) Zollinger Ellison syndrome</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">8) Treatment of ulcers induced by non-steroidal anti-inflammatory drugs (NSAIDs).</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\"> Zollinger- Ellison syndrome : the recommended adult dose is 40mg twice daily. To treat gastroesophageal reflux disease : 40mg once a day, preferably in the morning for 4 to 8 weeks. To treat gastric ulcers : 40mg once a day, preferably in the morning for 4 to 8 weeks. To treat duodenal ulcers : 40mg once a day, preferably in the morning for 2 weeks. Eradication of Helicobacter pylori : Triple therapy of Pansec 40mg twice daily plus clarithromycin 500mg and metronidazole 500mg both three times daily.For more details please see in prescribing description.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pantoprazole has been assigned to pregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Pansec-40 Injection : 1 combipack.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><br></span></p>",
    "strength": "40",
    "uom": "mg(IV)",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532327910Pansec.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744108275Pansec-40 injection.png"
    ]
  },
  {
    "id": "1190",
    "name": "Pansec Tablet",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Pantoprazole 20mg, 40mg Tablet.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication :</strong></p><p style=\"text-align: justify;\"><strong></strong><span class=\"redactor-invisible-space\">Pansec is registered for the following indications :</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\">1) Duodenal ulcer</p><p style=\"text-align: justify;\">2) Gastric ulcer</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">3) Moderate to severe reflux esophagitis</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">4) Eradication of Helicobacter pylori</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">5) Treatment of ulcers resistant to H2 antagonists</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">6) Maintenance of ulcer remission</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\">7) Zollinger Ellison syndrome</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">8) Treatment of ulcers induced by non-steroidal anti-inflammatory drugs (NSAIDs).</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The dose of pantoprazole will be different for different patients. Treatment of erosive esophagitis adult oral dose is 40mg given once daily for upto 8 weeks. Maintenance of healing of erosive esophagitis the recommended adult oral dose is one tablet daily (40mg). Zollinger- Ellison syndrome : the recommended adult dose is 40mg twice daily. To treat gastroesophageal reflux disease : 40mg once a day, preferably in the morning for 4 to 8 weeks. To treat gastric ulcers : 40mg once a day, preferably in the morning for 4 to 8 weeks. To treat duodenal ulcers : 40mg once a day, preferably in the morning for 2 weeks. Eradication of Helicobacter pylori : Triple therapy of Pansec 40mg twice daily plus clarithromycin 500mg and metronidazole 500mg both three times daily.For more details please see in prescribing description.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pantoprazole has been assigned to pregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\">Pansec-20 : 4 x 14's Tablet in blister pack.</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Pansec-40 : 4 x 14's Tablet in blister pack.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><br></p>",
    "strength": "40,20",
    "uom": "mg",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532327804Pansec.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744108204Pansec-40.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744108204Pansec-20.png"
    ]
  },
  {
    "id": "1737",
    "name": "Parib-150",
    "description": "<p class=\"MsoNormal\" align=\"center\">Olaparib INN</p><p class=\"MsoNormal\">Composition: Parib-150: Each tablet contains Olaparib INN\r\n150mg.</p><p class=\"MsoNormal\">Indications: First-Line Maintenance Treatment of\r\nBRCA-mutated Advanced Ovarian Cancer: Olaparib is indicated for the maintenance\r\ntreatment of adult patients with deleterious or suspected deleterious germline\r\nor somatic BRCA-mutated (gBRCAmor sBRCAm) advanced epithelial ovarian,\r\nfallopian tube or primary peritoneal cancer who are in complete or partial\r\nresponse to first-line platinum-based chemotherapy. Select patients for therapy\r\nbased on an FDA-approved companion diagnostic for Olaparib. Maintenance\r\nTreatment of Recurrent Ovarian Cancer: Olaparib is indicated for the\r\nmaintenance treatment of adult patients with recurrent epithelial ovarian,\r\nfallopian tube or primary peritoneal cancer, who are in complete or partial\r\nresponse to platinum-based chemotherapy. Advanced gBRCA-mutated Ovarian Cancer\r\nAfter 3 or More Lines of Chemotherapy: Olaparib is indicated for the treatment\r\nof adult patients with deleterious or suspected deleterious gBRCAm advanced\r\novarian cancer who have been treated with three or more prior lines of\r\nchemotherapy. Select patients for therapy based on an FDA-approved companion\r\ndiagnostic for Olaparib. Germline BRCA-mutated HER2-negative Metastatic Breast\r\nCancer: Olaparib is indicated in patients with deleterious or suspected\r\ndeleterious gBRCAm, HER2-negative metastatic breast cancer, who have been\r\ntreated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.\r\nPatients with hormone receptor (HR)-positive breast cancer should have been\r\ntreated with a prior endocrine therapy or be considered inappropriate for\r\nendocrine therapy. Select patients for therapy based on an FDA-approved\r\ncompanion diagnostic for Olaparib.</p><p class=\"MsoNormal\">Dosage and Administration:</p><p class=\"MsoNormal\">Recommended Dosing: The recommended dose of Olaparib is 300\r\nmg (two 150 mg tablets) taken orally twice daily, with or without food, for a\r\ntotal daily dose of 600 mg. The 100 mg tablet is available for dose reduction.\r\nIf a patient misses a dose of Olaparib, instruct patient to take their next\r\ndose at its scheduled time. Instruct patients to swallow tablets whole. Do not\r\nchew, crush, dissolve, or divide tablet. First-Line Maintenance Treatment of\r\nBRCA-mutated Advanced Ovarian Cancer: Continue treatment until disease\r\nprogression, unacceptable toxicity, or completion of 2 years of treatment.\r\nPatients with a complete response (no radiological evidence of disease) at 2\r\nyears should stop treatment. Patients with evidence of disease at 2 years, who\r\nin the opinion of the treating healthcare provider can derive further benefit\r\nfrom continuous treatment, can be treated beyond 2 years. Maintenance Treatment\r\nof Recurrent Ovarian Cancer: Continue treatment until disease progression or\r\nunacceptable toxicity. Advanced gBRCA-mutated Ovarian Cancer: Continue\r\ntreatment until disease progression or unacceptable toxicity.</p><p class=\"MsoNormal\">Germline BRCA-mutated HER2-negative Metastatic Breast\r\nCancer: Continue treatment until disease progression or unacceptable toxicity. </p><p class=\"MsoNormal\">Use in Pregnancy and Lactation: Based on mechanism of action\r\nOlaparib can cause fetal harm when administered to a pregnant woman. There are\r\nno available data on Olaparib use in pregnant women to inform the drug associated\r\nrisk. Pregnant women should be apprised of the potential hazard to the fetus\r\nand the potential risk for loss of the pregnancy.</p><p>Packing: Parib-150: Each container contains 120 tablets in a\r\nbox.</p>",
    "strength": "150",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1577790933Parib 150mg - Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1577790933Parib-150  120 Tablet- Bottle Carton Pic.png"
    ]
  },
  {
    "id": "1736",
    "name": "Parib-50",
    "description": "<p class=\"MsoNormal\" align=\"center\">Olaparib INN</p><p class=\"MsoNormal\">Composition: Parib-: Each Capsule contains Olaparib INN 50mg.</p><p class=\"MsoNormal\">Indications: Advanced gBRCA-mutated Ovarian Cancer after 3\r\nor More Lines of Chemotherapy: Olaparib is indicated for the treatment of adult\r\npatients with deleterious or suspected deleterious germline BRCA-mutated\r\n(gBRCAm) advanced ovarian cancer who have been treated with three or more prior\r\nlines of chemotherapy. Select patients for therapy based on an FDA-approved\r\ncompanion diagnostic for Olaparib.</p><p class=\"MsoNormal\">Dosage and Administration:</p><p class=\"MsoNormal\">Recommended Dosing: The recommended dose of Olaparib is 400\r\nmg (eight 50 mg capsules) taken orally twice daily with or without food, for a\r\ntotal daily dose of 800 mg. Continue treatment until disease progression or\r\nunacceptable toxicity. If a patient misses a dose of Olaparib, instruct\r\npatients to take their next dose at its scheduled time. Swallow capsule whole.\r\nDo not chew, dissolve, or open capsule. Do not take capsules which appear\r\ndeformed or show evidence of leakage.</p><p class=\"MsoNormal\">Use in Pregnancy and Lactation: Based on mechanism of action\r\nOlaparib can cause fetal harm when administered to a pregnant woman. There are\r\nno available data on Olaparib use in pregnant women to inform the drug\r\nassociated risk. Pregnant women should be apprised of the potential hazard to\r\nthe fetus and the potential risk for loss of the pregnancy. Because of the\r\npotential for serious adverse reactions in</p><p class=\"MsoNormal\">the breastfed infants from Olaparib, lactating woman should\r\nbe advised not to breastfeed during treatment with Olaparib and for one month\r\nafter receiving the last dose.</p><p>Packing: Parib: Each container contains 112 capsule in a\r\nbox.</p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1577791687Parib 50mg - Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1577791687Parib 50mg- 112 Capsule- Bottle Carton Pic.png"
    ]
  },
  {
    "id": "944",
    "name": "Paricap",
    "description": "<p><strong>Composition: </strong>Each Soft Gelatin Capsule Contains Paricalcitol\r\nUSP 1mcg.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p style=\"text-align: justify;\"><strong>Indication: </strong>It is indicated for the treatment\r\nand prevention of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4, Stage 5 in\r\npatients on hemodialysis (HD) or peritonial dialysis (PD).<br></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage & Administration: Chronic Kidney Disease Stages 3 and 4: </strong>Paricalcitol capsules may be\r\nadministered daily or three times a week. When dosing three times weekly, the\r\ndose should be administered not more frequently than every other day.<o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Initial Dose:</strong>The Initial dose of this capsules for CKD Stage 3 and\r\n4 patients is based on baseline intact parathyroid hormone (iPTH) levels.<o></o></p><table class=\"MsoNormalTable\" xss=\"removed\" width=\"384\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\">\r\n <tbody><tr>\r\n  <td xss=\"removed\" style=\"text-align: justify;\" width=\"132\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Baseline iPTH Level<o></o></strong></p>\r\n  </td>\r\n  <td xss=\"removed\" style=\"text-align: justify;\" width=\"78\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Daily Dose<o></o></strong></p>\r\n  </td>\r\n  <td xss=\"removed\" style=\"text-align: justify;\" width=\"174\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Three Times a Week Dose<o></o></strong></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td xss=\"removed\" style=\"text-align: justify;\" width=\"132\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\" align=\"center\">≤500pg/ml<o></o></p>\r\n  </td>\r\n  <td xss=\"removed\" style=\"text-align: justify;\" width=\"78\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\" align=\"center\">1 mcg<o></o></p>\r\n  </td>\r\n  <td xss=\"removed\" style=\"text-align: justify;\" width=\"174\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\" align=\"center\">2mcg<o></o></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td xss=\"removed\" style=\"text-align: justify;\" width=\"132\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\" align=\"center\">&gt;500pg/ml<o></o></p>\r\n  </td>\r\n  <td xss=\"removed\" style=\"text-align: justify;\" width=\"78\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\" align=\"center\">2mcg<o></o></p>\r\n  </td>\r\n  <td xss=\"removed\" style=\"text-align: justify;\" width=\"174\" valign=\"top\">\r\n  <p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\" align=\"center\">4mcg<o></o></p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Chronic Kidney Disease Stages 5:<o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\">This\r\nCapsules are to be administered three times a week. Or, as directed by the\r\nregistered physicians.<o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p style=\"text-align: justify;\"><strong>Use in Pregnancy & Lactation:  </strong>There are no adequate and\r\nwell-controlled clinical studies in pregnant women. This Capsules should be\r\nused during pregnancy only if the potential benefit to the mother justifies the\r\npotential risk to the fetus. It is not known whether paricalcitol is excreted\r\nin human milk. It should be made whether to discontinue nursing or to\r\ndiscontinue the drug, taking into account the importance of the drug to the\r\nmother.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Packing: </strong>Each  box contains  1x10’s soft capsules in blister pack.<o></o></p><p style=\"text-align: justify;\"> <br></p><p class=\"MsoNormal\" xss=\"removed\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\"><o></o></p>",
    "strength": "1",
    "uom": "Mcg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532327959paricap.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Pari.jpg"
    ]
  },
  {
    "id": "1208",
    "name": "Paridon Suspension",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Domperidone BP  5mg/5ml Suspension.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : <em></em></strong><span class=\"redactor-invisible-space\">Paridon is indicated for the treatment of 1. Functional dyspepsia 2. Stimulation of gut mobility (a) non-ulcer dyspepsia (b) esophageal reflux, reflux esophagitis and gastritis 3. Acute treatment of nausea and vomiting, in adults. 4. For up to 12 weeks treatment of nausea and vomiting caused by L-dopa and bromocriptine.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong>The recommended oral dose of Paridon Suspension for : Adults : 10 - 20ml every 4-8 hours daily. Children : 0.2 - 0.4mg/kg every 4 - 8 hours daily. For the treatment of nausea and vomiting - Adults (including the elderly) : 10-20 mg orally at 4-8 hourly intervals. Or, as directed by the physician. </p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy Category C by FDA.</p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\" xss=\"removed\"> Paridon suspension : 100ml bottle.</span></p>",
    "strength": "5",
    "uom": "mg/5ml",
    "categoryId": "39",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532328076Paridon.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745310576PARIDON.png"
    ]
  },
  {
    "id": "847",
    "name": "Paridon Tablet",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Domperidone BP 10mg\r\nTablet. </span></p><p style=\"text-align: justify;\"><strong>Indication : <em></em></strong><span class=\"redactor-invisible-space\">Paridon is indicated for the\r\ntreatment of\r\n1. Functional dyspepsia 2. Stimulation of\r\ngut mobility (a) non-ulcer dyspepsia (b)\r\nesophageal reflux, reflux esophagitis and\r\ngastritis 3. Acute treatment of nausea\r\nand vomiting, in adults. 4. For up to 12\r\nweeks treatment of nausea and vomiting\r\ncaused by L-dopa and bromocriptine.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> \r\nFor the treatment of symptoms of\r\nfunctional dyspepsia & others : Adults\r\n(including the elderly): Tablets up to 10-\r\n20mg orally 3 times daily before meals\r\nand 10-20mg at night depending on\r\nclinical response. A course of treatment\r\nshould not exceed 12 weeks. Or, as\r\ndirected by the physician.Becovent inhaler is for oral inhalation use only. Patients should be given a starting dose of inhaled Becovent appropriate to the severity of their disease. The dose may then be adjusted until control is achieved or reduced to the minimum effective dose according to individual response. Management of chronic asthma (Adults & Children over 12 years): 100-400 mcg twice daily. Maximum 1000 mcg twice daily. Children (5-12 years): 100-200 mcg twice daily. the dose may be adjusted as necessary.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy Category C by FDA.</p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Paridon : 7x14's tablets in\r\nblister pack. </span></p>",
    "strength": "10",
    "uom": "mg",
    "categoryId": "39",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532328149Paridon.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745208891PARIDON 10MG.png"
    ]
  },
  {
    "id": "1786",
    "name": "Pazonib-200",
    "description": "<p class=\"MsoNormal\" xss=\"removed\">Pazopanib INN 200 mg\r\nTablet</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Composition: </strong>Each\r\nfilm coated tablet contains Pazopanib 200 mg as Pazopanib HCl INN.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong>\r\nPazonib-200 is indicated for the treatment of patients with advanced renal cell\r\ncarcinoma (RCC). Pazonib-200 is indicated for the treatment of patients with\r\nadvanced soft tissue sarcoma (STS) who have received prior chemotherapy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and\r\nAdministration: </strong>The recommended starting dose of\r\nPazonib-200 is 800 mg orally once daily without food (at least 1 hour before or\r\n2 hours after a meal). The dose of Pazonib-200 should not exceed 800 mg.\r\nTablets should not be crushed due to the potential for increased rate of\r\nabsorption which may affect systemic exposure. If a dose is missed, it should\r\nnot be taken if it is less than 12 hours until the next dose. Or, as directed\r\nby the registered physicians.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and\r\nLactation: </strong>Pazonib-200 can cause fetal harm when\r\nadministered to a pregnant woman. There are no available data in pregnant women\r\nto inform a drug-associated risk. Pregnant women or women should be advised of\r\nchildbearing potential of the potential risk to a fetus. <strong>Lactation: </strong>There\r\nis no information regarding the presence of Pazopanib or its metabolites in\r\nhuman milk, or their effects on the breastfed infant, or on milk production.\r\nBecause of the potential for serious adverse reactions in breastfed infants\r\nfrom Pazonib-200, a lactating woman should be advised not to breastfeed during\r\ntreatment with Pazonib-200 and for 2 weeks after the final dose.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: </strong>Each\r\nbox contains 28 tablets in a blister pack.</p>",
    "strength": "200",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1683111086Pazonib-200 Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744108320Pazonib-200.png"
    ]
  },
  {
    "id": "748",
    "name": "Pednisol",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Prednisolone Acetate\r\nUSP 10mg/ml.</span><strong></strong></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">For steroid responsive\r\ninflammation of the palpebral and bulbar\r\nconjunctiva, cornea and anterior\r\nsegment of the globe.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">1 to 2\r\ndrops instilled into the conjunctival sac\r\ntwo to four times daily. During the initial\r\n24 to 48 hours the doses may be safely\r\nincreased to 2 drops every hour. Care\r\nshould be taken not to discontinue\r\ntherapy prematurely or as directed by the\r\nregistered physician.</span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy\r\nCategory C by FDA.</span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Packing : </strong>5ml in plastic dropper bottle.<br></p>",
    "strength": "5",
    "uom": "mg",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532328371PEDNISODL.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209037Pednisol 5ml.png"
    ]
  },
  {
    "id": "1212",
    "name": "Pednisol Tablet",
    "description": "<p><strong>Composition : Pednisol 5 Tablet :</strong><span class=\"redactor-invisible-space\">Each Film\r\nCoated Tablet Contains Prednisolone USP 5mg.</span></p><p><span class=\"redactor-invisible-space\"><strong>Pednisol 10 Tablet :</strong><span class=\"redactor-invisible-space\">Each Film Coated Tablet\r\nContains Prednisolone USP 10mg.</span><br></span></p><p><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Pednisol 20 Tablet :</strong><span class=\"redactor-invisible-space\">Each Film Coated Tablet\r\nContains Prednisolone USP 20mg.</span><br></span></span></p><p><strong></strong></p><p><strong>Indications :</strong><span class=\"redactor-invisible-space\"> It is indicated in the treatment of\r\nAllergy and anaphylaxis : Bronchial asthma,\r\ndrug hypersensitivity reactions, angioneurotic\r\noedema, anaphylaxis. Respiratory disease :\r\nAllergic pneumonitis, asthma. Rheumatic\r\ndisorders : Rheumatoid arthritis, juvenile chronic\r\narthritis, systemic lupus erythematosus, mixed\r\nconnective tissue disease. Please see prescribing description for more information.</span><strong><br></strong></p><p><strong>Dosage and Administration :</strong> The initial dosage\r\nmay vary from 5mg to 60mg daily in divided\r\ndoses, as a single daily dose after breakfast, or\r\nas a double dose on alternative days depending\r\non the specific disease entity being treated.\r\nThe appropriate individual dose must be\r\ndetermined by trial and error and must be reevaluated\r\nregularly according to activity of the\r\ndisease. Please see prescribing description for more information.</p><p><strong>Use in pregnancy and lactation :</strong><span class=\"redactor-invisible-space\">There are\r\nno adequate and well-controlled studies in\r\npregnant women. It should be used during\r\npregnancy only if the potential benefit justifies\r\nthe potential risk to the fetus. Corticosteroids\r\nare excreted in small amounts in breast milk\r\nand infants of mothers taking pharmacological\r\ndoses of steroids should be monitored carefully\r\nfor signs of adrenal suppression.</span></p><p><strong>Packing : </strong><span class=\"redactor-invisible-space\">Pednisol 5 Tablet : Each box\r\ncontains 10 x 10's tablets in blister pack.\r\nPednisol 10 Tablet : Each box contains 10 x\r\n10's tablets in blister pack. </span></p><p><span class=\"redactor-invisible-space\">Pednisol 20 Tablet : Each box contains 5 x\r\n10's tablets in blister pack.</span></p>",
    "strength": "20,10,5",
    "uom": "mg",
    "categoryId": "63",
    "insertFile": "https://www.admin.drug-international.com/uploads/pdf/PEDNISODL.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745304708Pednisol 20.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745304708Pednisol 10.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745304708Pednisol 5ml.png"
    ]
  },
  {
    "id": "789",
    "name": "Peflox",
    "description": "                <p><strong></strong><strong>Composition : </strong>: Pefloxacin BP 400 mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Pefloxacin is a synthetic,\r\n4-quinolone derivative with bactericidal\r\nactivity against a wide range of gramnegative\r\nand gram-positive organisms.\r\nPefloxacin is indicated for the treatment\r\nof the following infections caused by\r\nsensitive bacteria : Severe systemic infections, Respiratory tract infections, Ear, nose and throat infections,\tUrinary tract infections, Skin & soft tissue infections, Gastro-intestinal infections, Eye infections, Biliary tract infections, Intra abdominal infections, Bone and joint infections, Pelvic infections and gonorrhoea, Prostate infections</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :  </strong><span class=\"redactor-invisible-space\">General dosage recommendation :\r\nThe dosage for adults is 400 mg twice\r\ndaily.\r\nGonorrhoea : 800 mg (2 tablets) once.\r\nInfections of the lower and upper\r\nurinary tract : 400 mg twice daily.\r\nIn respiratory tract infections : 400 mg\r\ntwice daily.\r\nImpaired renal function : Dosage\r\nadjustments are not usually required.\r\nDuration of treatment : 5-10 days or as\r\ndirected by a registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pefloxacin has been assigned to\r\npregnancy category C by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong> 2 x 10's tablets in blister pack.</p>              ",
    "strength": "400",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1686546776Peflox Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209081PEFLOX.png"
    ]
  },
  {
    "id": "1349",
    "name": "Pemeta",
    "description": "<p class=\"MsoNormal\"><strong>Composition:\r\nPemeta:</strong> Each vial contains Pemetrexed 100mg as Pemetrexed\r\nDisodium Heptahydrate USP lyophilized powder for IV infusion.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\"><strong>Pemeta-500:</strong>\r\nEach vial contains Pemetrexed 500mg as Pemetrexed Disodium Heptahydrate USP\r\nlyophilized powder for IV infusion.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\"><strong>Indications:</strong><br>\r\n<strong>Non-Squamous Non-Small Cell Lung Cancer (NSCLC)</strong>: Pemetrexed is\r\nindicated:<br>\r\n• in combination with Pembrolizumab and platinum chemotherapy, for the initial\r\ntreatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK\r\ngenomic tumor aberrations.<br>\r\n• in combination with Cisplatin for the initial treatment of patients with\r\nlocally advanced or metastatic, nonsquamous, non-small cell lung cancer\r\n(NSCLC).<br>\r\n• as a single agent for the maintenance treatment of patients with locally\r\nadvanced or metastatic, nonsquamous NSCLC whose disease has not progressed\r\nafter four cycles of platinum-based first-line chemotherapy.<br>\r\n• as a single agent for the treatment of patients with recurrent, metastatic non-squamous,\r\nNSCLC after prior chemotherapy.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\"><strong>Dosage and Administration: </strong><br>\r\n<strong>Recommended Dosage for Non-Squamous NSCLC:</strong><br>\r\n• The recommended dose of Pemetrexed when administered with Pembrolizumab and\r\nplatinum chemotherapy for the initial treatment of metastatic non-squamous\r\nNSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault\r\nequation) of 45 mL/min or greater is 500 mg/m<sup>2</sup> as an intravenous\r\ninfusion over 10 minutes administered after Pembrolizumab and prior to\r\nCarboplatin or Cisplatin on Day 1 of each 21-day cycle for 4 cycles. Following\r\ncompletion of platinum-based therapy, treatment with Pemetrexed with or without\r\nPembrolizumab is administered until disease progression or unacceptable\r\ntoxicity. <o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\">• The recommended dose of Pemetrexed\r\nwhen administered with Cisplatin for initial treatment of locally advanced or metastatic\r\nnon-squamous NSCLC in patients with a creatinine clearance (calculated by\r\nCockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m<sup>2</sup> as an\r\nintravenous infusion over 10 minutes administered prior to Cisplatin on Day 1\r\nof each 21-day cycle for up to six cycles in the absence of disease progression\r\nor unacceptable toxicity.<br>\r\n• The recommended dose of Pemeta for maintenance treatment of non-squamous\r\nNSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault\r\nequation) of 45 mL/min or greater is 500 mg/m<sup>2</sup> as an intravenous\r\ninfusion over 10 minutes on Day 1 of each 21-day cycle until disease\r\nprogression or unacceptable toxicity after four cycles of platinum-based\r\nfirst-line chemotherapy.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\">• The recommended dose of Pemetrexed for\r\ntreatment of recurrent non-squamous NSCLC in patients with a creatinine clearance\r\n(calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m<sup>2</sup>\r\nas an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until\r\ndisease progression or unacceptable toxicity. Or, as directed\r\nby the registered physician.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\"><strong>Use\r\nin Pregnancy and Lactation: </strong>can cause\r\nfetal harm when administered to a pregnant woman. There are no available data\r\non Pemetrexed use in pregnant women. Pregnant women should be advised of the\r\npotential risk to a fetus. <strong>Lactation</strong>: There is no information regarding\r\nthe presence of Pemetrexed or its metabolites in human milk, the effects on the\r\nbreastfed infant, or the effects on milk production.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\"><strong>Packing: Pemeta: </strong>Each\r\nbox contains one vial of 100mg Pemetrexed USP lyophilized powder for IV\r\ninfusion.<strong><o:p></o:p></strong></p>\r\n\r\n<p class=\"MsoNormal\" xss=\"removed\"><strong>Pemeta-500:</strong>\r\nEach box contains one vial of 500mg Pemetrexed USP lyophilized powder for IV\r\ninfusion.<br></p>",
    "strength": " 500,100",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1683016611Pemeta-500 Carton.png",
      "https://www.admin.drug-international.com/uploads/product_images/1543645798Pemeta- Carton Pic.jpg"
    ]
  },
  {
    "id": "1865",
    "name": "Percanib",
    "description": "<p><strong>Composition:\r\n</strong>Each capsule contains Selpercatinib\r\nINN 80mg.</p><p><br></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications</strong><br></p><p xss=\"removed\"><strong>• RET\r\nFusion-Positive Non-Small Cell Lung Cancer:</strong> Selpercatinib is indicated for the treatment of adult patients with\r\nlocally advanced or metastatic non-small cell lung cancer (NSCLC) with a\r\nrearranged during transfection (RET) gene fusion, as detected by an\r\nFDA-approved test. <o></o></p><p xss=\"removed\"><strong>• RET-Mutant\r\nMedullary Thyroid Cancer:</strong>\r\nSelpercatinib is indicated for the treatment of adult and pediatric patients 12\r\nyears of age and older with advanced or metastatic medullary thyroid cancer\r\n(MTC) with a RET mutation, as detected by an FDA-approved test, who require\r\nsystemic therapy. This indication is approved under accelerated approval based\r\non overall response rate and duration of response. Continued approval for this\r\nindication may be contingent upon verification and description of clinical\r\nbenefit in confirmatory trial(s). <o></o></p><p xss=\"removed\"><strong>• RET\r\nFusion-Positive Thyroid Cancer:</strong>\r\nSelpercatinib is indicated for the treatment of adult and pediatric patients 12\r\nyears of age and older with advanced or metastatic thyroid cancer with a RET\r\ngene fusion, as detected by an FDA-approved test, who require systemic therapy\r\nand who are radioactive iodine-refractory (if radioactive iodine is\r\nappropriate). This indication is approved under accelerated approval based on\r\noverall response rate and duration of response. Continued approval for this\r\nindication may be contingent upon verification and description of clinical\r\nbenefit in confirmatory trial(s). <o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>• Other RET\r\nFusion-Positive Solid Tumors:</strong>\r\nSelpercatinib is indicated for the treatment of adult patients with locally\r\nadvanced or metastatic solid tumors with a RET gene fusion that have progressed\r\non or following prior systemic treatment or who have no satisfactory\r\nalternative treatment options.<o></o></p><p class=\"MsoNormal\"><strong>Dosage and Administration: </strong>The recommended dosage of Selpercatinib based on body\r\nweight is: <strong>i)</strong> Less than 50 kg:\r\n120mg, <strong>ii)</strong> 50 kg or greater: 160mg.\r\nIt may be taken with or without food unless coadministered with a proton pump\r\ninhibitor. It should be taken orally twice daily (approximately every 12 hours)\r\nuntil disease progression or unacceptable toxicity, should swallow the capsules\r\nwhole, should not crush or chew the capsules. If vomiting occurs after its\r\nadministration, should not take an additional dose and continue to the next\r\nscheduled time for the next dose. <strong><o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation: </strong>It can cause fetal\r\nharm when administered to a pregnant woman. There are no available data on\r\nSelpercatinib use in pregnant women to inform drug- associated risk. Pregnant\r\nwomen should be advised of the potential risk to a fetus.  <strong>Lactation:</strong>\r\nThere are no data on the presence of Selpercatinib or its metabolites in human\r\nmilk or on their effects on the breastfed child or on milk production. Because\r\nof the potential for serious adverse reactions in breastfed children, women\r\nshould be advised not to breastfeed during treatment with Selpercatinib and for\r\n1 week after the final dose.<strong><o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing</strong>: Each box contains 120 capsules in a container.<o></o></p>",
    "strength": "80",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1678013895Percanib Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1678013895Percanib-80 Carton.png"
    ]
  },
  {
    "id": "765",
    "name": "Perinem Injection",
    "description": "<p><strong></strong><strong>Composition :</strong> Doripenem INN 500 mg as Doripenem\r\nMonohydrate sterile powder for IV injection.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Doripenem is indicated in the treatment\r\nof the following infections. Complicated IntraAbdominal\r\nInfections : Complicated intra-abdominal\r\ninfections caused by Escherichia coli, Klebsiella\r\npneumoniae, Pseudomonas aeruginosa, Bacteroides\r\ncaccae, Bacteroides fragilis, Bacteroides\r\nthetaiotaomicron, Bacteroides uniformis, Bacteroides\r\nvulgatus, Streptococcus intermedius, Streptococcus\r\nconstellatus and Peptostreptococcus micros.\r\nComplicated Urinary Tract Infections, Including\r\nPyelonephritis : Complicated urinary tract infections,\r\nincluding pyelonephritis caused by Escherichia coli\r\nincluding cases with concurrent bacteremia,\r\nKlebsiella pneumoniae, Proteus mirabilis,\r\nPseudomonas aeruginosa, and Acinetobacter\r\nbaumannii.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The recommended\r\ndosage is 500mg administered every 8 hours by\r\nintravenous infusion over one hour in patient's &gt;18\r\nyears of age. Please see prescribing description for more information.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy\r\ncategory B. There are no adequate and wellcontrolled\r\nstudies in pregnant women. This drug\r\nshould be used during pregnancy only if clearly\r\nneeded. It is not known whether this drug is excreted\r\nin human breast milk. Because many drugs are\r\nexcreted in human milk, caution should be exercised\r\nwhen Doripenem is administered to a nursing woman.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>Perinem (IV) Injection : 1 Combipack</p>",
    "strength": "500",
    "uom": "mg(IV)",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532328527perinem.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Perinem-500.jpg"
    ]
  },
  {
    "id": "1860",
    "name": "Piozena-15",
    "description": "<p><strong>Composition :</strong>Piozena - 15 Tablet : Each Film\r\nCoated Tablet Contains Pioglitazone Hydrochloride USP 15 mg.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications :</strong>It is indicated as an adjunct to\r\ndiet and exercise to improve glycemic control in patients with type Il diabetes\r\n(NIDDM). It also indicated for monotherapy and also indicated for use in\r\ncombination with a sulfonylurea, metformin or insulin when diet and exercise\r\nplus the single agent does not result in adequate glycemic control.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage and administration :</strong>Pioglitazonen can be taken once\r\ndaily without regard to meals. The management of antidiabetic therapy should be\r\nindividualized. Pioglitazone monotherapy in patients not adequatelycontrolled\r\nwith diet and exercise may beinitiated at 15 mg or 30 mg once daily.\r\nForpatients who respond inadequately to theinitial dose of pioglitazone,the\r\ndose can beincreased up to 45 mg once daily. Or, asdirected by the registered\r\nphysicians.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use in pregnancy &lactation :</strong>Pregnancy-There are no adequate\r\nand well controlledstudies in pregnant women. Pioglitazoneshould be used during\r\npregnancy only if thepotential benefit justifies the potential risk to the\r\nfetus. Nursing mothers- It is not knownwhether pioglitazone is secreted in\r\nhumanmilk. Because many drugs are excreted inhuman milk, it should not be\r\nadministered to abreast feeding women.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><a name=\"_GoBack\"></a> </p><p><strong>Packing :</strong>Piozena -15 Tablet : Each box contains\r\n28's, tablets in blister pack.</p>",
    "strength": "15",
    "uom": "mg",
    "categoryId": "93",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1674553393Piozena-15 Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209133PIOZENA-15.png"
    ]
  },
  {
    "id": "1044",
    "name": "Povicid",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition : </strong>Povidone-Iodine\r\nUSP 50mg.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indications : </strong>This ointment\r\nis indicatedfor the primary or secondary topical infections, infected surgical\r\nincisions, infected decubitus or stasis ulcers, pyodermas, secondarily infected\r\ndermatoses and infected traumatic lesions. It is used to prevent microbial contamination\r\nin burns, incisions and other topical lesions, for degerming skin in\r\nhyperalimentation and catheter care. This ointment is used for abrasions, minor\r\ncuts and wounds may prevent the development of infections and permit wound\r\nhealing.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration : For the treatment of infection : </strong>Apply two or three times daily at dressing changes for a maximum of 14\r\ndays. <strong>For the prevention of infection : </strong>Apply once or twice a week for as long as necessary. Or, as directed\r\nby the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Packing : Povicid Ointment : </strong>15gm in\r\na tube.</p>",
    "strength": " 15",
    "uom": "gm(IM)",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1683111283Povicid Ointment.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209147Povicid.png"
    ]
  },
  {
    "id": "1169",
    "name": "Prelin ",
    "description": "<p style=\"text-align: justify;\"><strong></strong><strong></strong><!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves></w:TrackMoves>\r\n  <w:TrackFormatting></w:TrackFormatting>\r\n  <w:PunctuationKerning></w:PunctuationKerning>\r\n  <w:ValidateAgainstSchemas></w:ValidateAgainstSchemas>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF></w:DoNotPromoteQF>\r\n  <w:LidThemeOther>EN-US</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables></w:BreakWrappedTables>\r\n   <w:SnapToGridInCell></w:SnapToGridInCell>\r\n   <w:WrapTextWithPunct></w:WrapTextWithPunct>\r\n   <w:UseAsianBreakRules></w:UseAsianBreakRules>\r\n   <w:DontGrowAutofit></w:DontGrowAutofit>\r\n   <w:SplitPgBreakAndParaMark></w:SplitPgBreakAndParaMark>\r\n   <w:DontVertAlignCellWithSp></w:DontVertAlignCellWithSp>\r\n   <w:DontBreakConstrainedForcedTables></w:DontBreakConstrainedForcedTables>\r\n   <w:DontVertAlignInTxbx></w:DontVertAlignInTxbx>\r\n   <w:Word11KerningPairs></w:Word11KerningPairs>\r\n   <w:CachedColBalance></w:CachedColBalance>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"></m:mathFont>\r\n   <m:brkBin m:val=\"before\"></m:brkBin>\r\n   <m:brkBinSub m:val=\"--\"></m:brkBinSub>\r\n   <m:smallFrac m:val=\"off\"></m:smallFrac>\r\n   <m:dispDef></m:dispDef>\r\n   <m:lMargin m:val=\"0\"></m:lMargin>\r\n   <m:rMargin m:val=\"0\"></m:rMargin>\r\n   <m:defJc m:val=\"centerGroup\"></m:defJc>\r\n   <m:wrapIndent m:val=\"1440\"></m:wrapIndent>\r\n   <m:intLim m:val=\"subSup\"></m:intLim>\r\n   <m:naryLim m:val=\"undOvr\"></m:naryLim>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"true\"\r\n  DefSemiHidden=\"true\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"267\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Normal\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"heading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 7\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 8\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"toc 9\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" QFormat=\"true\" Name=\"caption\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" Name=\"Default Paragraph Font\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtitle\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Strong\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"59\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Table Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Placeholder Text\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"No Spacing\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" UnhideWhenUsed=\"false\" Name=\"Revision\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"List Paragraph\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Quote\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 1\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 2\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 3\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 4\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 5\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Light Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Shading 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium List 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 1 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 2 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Medium Grid 3 Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Dark List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Shading Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful List Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" Name=\"Colorful Grid Accent 6\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"19\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"21\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Emphasis\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"31\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Subtle Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"32\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Intense Reference\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"33\" SemiHidden=\"false\"\r\n   UnhideWhenUsed=\"false\" QFormat=\"true\" Name=\"Book Title\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"37\" Name=\"Bibliography\"></w:LsdException>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" QFormat=\"true\" Name=\"TOC Heading\"></w:LsdException>\r\n </w:LatentStyles>\r\n</xml><![endif]--><!--[if gte mso 10]>\r\n<style>\r\n /* Style Definitions */\r\n table.MsoNormalTable\r\n\t{mso-style-name:\"Table Normal\";\r\n\tmso-tstyle-rowband-size:0;\r\n\tmso-tstyle-colband-size:0;\r\n\tmso-style-noshow:yes;\r\n\tmso-style-priority:99;\r\n\tmso-style-qformat:yes;\r\n\tmso-style-parent:\"\";\r\n\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\r\n\tmso-para-margin-top:0in;\r\n\tmso-para-margin-right:0in;\r\n\tmso-para-margin-bottom:10.0pt;\r\n\tmso-para-margin-left:0in;\r\n\tline-height:115%;\r\n\tmso-pagination:widow-orphan;\r\n\tfont-size:11.0pt;\r\n\tfont-family:\"Calibri\",\"sans-serif\";\r\n\tmso-ascii-font-family:Calibri;\r\n\tmso-ascii-theme-font:minor-latin;\r\n\tmso-fareast-font-family:\"Times New Roman\";\r\n\tmso-fareast-theme-font:minor-fareast;\r\n\tmso-hansi-font-family:Calibri;\r\n\tmso-hansi-theme-font:minor-latin;\r\n\tmso-bidi-font-family:\"Times New Roman\";\r\n\tmso-bidi-theme-font:minor-bidi;}\r\n</style>\r\n<![endif]-->\r\n\r\n</p><p class=\"MsoNormal\" style=\"margin-bottom:5.35pt;line-height:normal\"><strong>Pregabalin</strong></p><p class=\"MsoNormal\" style=\"margin-bottom:5.35pt;line-height:normal\"><strong>Composition : </strong>Prelin-25:\r\nPregabalin BP 25 mg Capsule.</p><p class=\"MsoNormal\" style=\"margin-bottom:5.35pt;text-align:justify;line-height:\r\nnormal\">Prelin- 50: Pregabalin BP 50 mg\r\nCapsule.</p><p class=\"MsoNormal\" style=\"margin-bottom:5.35pt;text-align:justify;line-height:\r\nnormal\">Prelin- 75: Pregabalin BP 75mg\r\nCapsule.</p><p class=\"MsoNormal\" style=\"margin-bottom:5.35pt;text-align:justify;line-height:\r\nnormal\"><strong>Indications : </strong>Pregabalin is indicated for the treatment of Neuropathic\r\npain associated with diabetic peripheral neuropathy, Fibromyalgia, Post\r\nherpetic neuralgia, Generalized anxiety disorder in adults. It can be also used\r\nas adjunctive therapy in adults with partial onset seizures with or without\r\nsecondary generalization.</p><p class=\"MsoNormal\" style=\"margin-bottom:5.35pt;text-align:justify;line-height:\r\nnormal\"><strong>Dosage and administration : </strong>Diabetic neuropathic pain : Adult over 18 years: initially\r\n150 mg daily, increased if necessary after 3-7 days to 300 mg daily,increased\r\nfurther if necessary after 7days to max. 600 mg daily in divided doses. Post\r\nherpetic neuralgia: Adult over 18 years: The recommended dose of pregabalin is\r\n75 to 150 mg two times a day and may be increased to 300 mg/day within 1 week\r\nbased on efficacy and tolerability. Fibromyalgia: Adult over 18 years: The\r\nrecommended dose for fibromyalgia is 300 to 450 mg/day. Dosing should begin at\r\n75 mg two times a day (150 mg/day) and may be increased up to 150mg two times a\r\nday (300 mg/day) within 1 week based on efficacy and tolerability. Generalized\r\nanxiety disorder: Adult over 18 years: Initially 150 mg daily, increased if\r\nnecessary at 7 day intervals in steps of 150 mg daily; maximum 600 mg daily in\r\ndivided doses. Epilepsy: Adult over 18 years: The recommended dose of\r\nPregabalin is 150 to 600 mg/ day as adjunctive therapy in the treatment of\r\npartial onset seizures in adults. Or, as prescribed by the registered\r\nphysician.</p><p class=\"MsoNormal\" style=\"margin-bottom:5.35pt;text-align:justify;line-height:\r\nnormal\"><strong>Use in pregnancy and lactation\r\n: </strong>Pregnancy Category C by FDA.</p><p class=\"MsoNormal\" style=\"margin-bottom:5.35pt;text-align:justify;line-height:\r\nnormal\"><strong>Packing :</strong></p><p class=\"MsoNormal\" style=\"margin-bottom:5.35pt;text-align:justify;line-height:\r\nnormal\">Prelin-25 : 3x10's capsules in\r\nblister pack.</p><p class=\"MsoNormal\" style=\"margin-bottom:5.35pt;text-align:justify;line-height:\r\nnormal\">Prelin-50 : 2x10's capsules in\r\nblister pack.</p><p class=\"MsoNormal\" style=\"margin-bottom:5.35pt;text-align:justify;line-height:\r\nnormal\">Prelin-75 : 2x10's capsules in\r\nblister pack.</p><p class=\"MsoNormal\" style=\"margin-bottom:5.35pt;text-align:justify;line-height:\r\nnormal\">Prelin-150 : 1x10's capsules in\r\nblister pack.</p><p style=\"text-align: justify;\"><br></p>",
    "strength": "150,75,50,25",
    "uom": "mg",
    "categoryId": "48",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532328653Prelin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Prelin-150.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1745209209Prelin-75.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745209209Prelin-50.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745209209Prelin-25.png"
    ]
  },
  {
    "id": "1204",
    "name": "Pronex Capsule",
    "description": "<p><strong>Composition :</strong> Esomeprazole USP 20mg & 40mg Capsule.</p><p style=\"text-align: justify;\"><strong>Indication :</strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">1) Treatment of Gastroesophageal Reflux Disease (GERD)</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">2) H. Pylori eradication to reduce the risk of duodenal ulcer recurrence.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration :</strong></p><p style=\"text-align: justify;\"><strong></strong>Please see prescribing description.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\">Pronex-20 : 5 x 10's capsules in blister pack.</p><p style=\"text-align: justify;\">Pronex-40 : 4 x 7's  capsules in blister pack.</p>",
    "strength": "40,20",
    "uom": "mg",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532328759Pronex.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744110574pronex-40.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744110574pronex-20 capsules.png"
    ]
  },
  {
    "id": "1205",
    "name": "Pronex Injection",
    "description": "<p><strong>Composition :</strong>Esomeprazole 40mg Injection.</p><p style=\"text-align: justify;\"><strong>Indication :</strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">1) Treatment of Gastroesophageal Reflux Disease (GERD)</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">2) H. Pylori eradication to reduce the risk of duodenal ulcer recurrence.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration :</strong></p><p style=\"text-align: justify;\"><strong></strong>Please see prescribing description.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\">Pronex-40 : 1 combipack.</p>",
    "strength": "40",
    "uom": "mg(IV)",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532328793Pronex.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744110656pronex-40 injection.png"
    ]
  },
  {
    "id": "1191",
    "name": "Pronex Tablet",
    "description": "<p><strong>Composition : </strong>Esomeprazole USP 20mg & 40mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indication :</strong></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">1) Treatment of Gastroesophageal Reflux Disease (GERD)</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">2) H. Pylori eradication to reduce the risk of duodenal ulcer recurrence.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration :</strong></p><p style=\"text-align: justify;\"><strong></strong>Please see prescribing description.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong></p><p style=\"text-align: justify;\">Pronex-20 : 4 x 14's tablets in blister pack.</p><p style=\"text-align: justify;\">Pronex-40 : 4 x 14's tablets in blister pack.</p><p><br></p>",
    "strength": "40,20",
    "uom": "mg",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532328713Pronex.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744110414Pronex- 40.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744110414pronex-20.png"
    ]
  },
  {
    "id": "1747",
    "name": "Pronex-MUPS",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition: Pronex-MUPS: </strong>Each MUPS (Multiple-Unit Pellet System) tablet contains Esomeprazole\r\nUSP 20mg as Esomeprazole Magnesium Trihydrate USP.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>This\r\ntablet is used in the treatment of Gastroesophageal Reflux Disease (GERD). Also\r\nused to reduce the risk of NSAID associated gastric ulcer, H.pylorieradication\r\n(triple therapy), duodenal and qastric ulcer and Zollinger-Ellison Syndrome.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and administration: </strong>Adult from ageof 18 Erosive Reflux Oesophagitis :\r\nTherecommended dosage is one 20mg once daily before meal, given for 4 weeks.\r\nFor those patients not fully healed after the initial course, healing usually\r\noccurs during a furher 4 weeks treatment. Patients with Reflux OesophagitisRefractory\r\nto Other Therapy: The recommended dosage is 40mg once daily before meal.\r\nHealing usually occurs within 8 weeks. Duodenal Ulcer: The usual dose is one\r\n20mg once daily, before meal for 4 weeks. In severe cases the dose may be\r\nincreased to 40mg once daily before meal. Gastric Ulcer: The usual dose is one\r\n20mg tablet once daily before meal for 8 weeks. In severe cases, the dose may\r\nbe increased to 40mg tablet once daily. Long-term maintenance treatment with is\r\nnot recommended. Zollinger-Ellison Syndrome: The recommended initial dosage is\r\n60mg (40mg + 20mg) once daily before meal. The dosage should be adjusted\r\nindividually and treatment continued as long as clinically indicated. More than\r\n90% of patients with severe disease and inadequate response to other therapies\r\nhave been effectively controlled on doses of 20mg 120mg daily, With doses above\r\n80mg daily, the dose should be divided and given twice daily. Elderly: Dose\r\nadjustment is not required in the elderly.Or,as directed by the registered\r\nphysicians.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:Pron<a name=\"_GoBack\"></a>ex-MUPS 20 Tablet: </strong>Each box contains 30's tablets in\r\nbister pack.</p>",
    "strength": " 40,20",
    "uom": "mg",
    "categoryId": "37",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744110710Pronex-MUPS 40.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744110710pronex-mups 20.png"
    ]
  },
  {
    "id": "890",
    "name": "Prostam",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Tamsulosin hydrochloride USP\r\n0.4mg Capsule.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong> It is indicated for the\r\ntreatment of symptomatic benign\r\nprostatic hyperplasia (BPH). </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\"> 1 (one)\r\nProstam capsules once daily is\r\nrecommended as the dose for the\r\ntreatment of the signs and symptoms of\r\nBPH. It should be administered\r\napproximately one-half hour following the\r\nsame meal each day. For those patients\r\nwho fail to respond to the 0.4mg dose\r\nafter two to four weeks of dosing, the\r\ndose of the capsule can be increased to\r\n0.8mg once daily if the capsules\r\nadministration is discontinued or\r\ninterrupted for several days at either the\r\n0.4mg or 0.8mg dose, therapy should be\r\nstarted again with the 0.4mg once daily\r\ndose. Or, as directed by the physician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Prostam : 3 x 10's capsules\r\nin blister</span></p>",
    "strength": "0.4",
    "uom": "mg",
    "categoryId": "46",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532328852Prostam.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209238PROSTAM.png"
    ]
  },
  {
    "id": "794",
    "name": "Psudonil",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Amikacin USP 100mg, 250mg &\r\n500mg injection.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Amikacin Sulfate\r\ninjection is indicated in the short-term\r\ntreatment of serious infections due to\r\nsusceptible strains of gram negative\r\nbacteria, including Pseudomonas species,\r\nEscherichia coli, species of indole-positive\r\nand indole-negative Proteus, providencia\r\nspecies, Klebsiella-Enterobacter-Serratia\r\nspecies and Acinetobacter species.\r\nClinical Studies have shown Amikacin,\r\nsulfate Injection to be effective in bacterial\r\nsepticemia; in serious infections of the\r\nrespiratory tract, bones and joints, central\r\nnervous system and skin and soft tissue,\r\nintra-abdominal infections; and in burns\r\nand post operative infection. Clinical\r\nstudies have shown Amikacin also to be\r\neffective in serious complicated and\r\nrecurrent urinary tract infections due to\r\nthese organisms.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Serious\r\ninfection caused by susceptible organisms:\r\nAdults & Children's: 15mg/kg/day in two\r\nequally divided doses every 8 to 12 hours\r\nIM or IV (if IV, diluted in 100 or 200 ml\r\ninfusion solution or normal saline given\r\nover 30 to 60 minutes) the dose may be\r\nincreased maximum 500 mg every 8\r\nhours. Neonates with normal renal\r\nfunction: Initially\r\nloading 10 mg/kg daily divided dosage by\r\nIM or IV (if given by IV an infusion period\r\nof 1 to 2 hours recommended) than 7.5\r\nmg/kg every 18 to 24 hours.\r\nUncomplicated UTI: Adults 250mg I.M or\r\nIV b.i.d. Clinical Tuburculosis: Adults,\r\nchildren's and infants 15mg/kg I.M daily\r\nfive times weekly as an adjunct to other\r\nantitubercular durgs. Or as directed by the\r\nregistered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Amikacin has been assigned to pregnancy\r\ncategory D by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\"><strong></strong><span class=\"redactor-invisible-space\">Psudonil-100mg Injection : 1 x 5\r\nampoules in a blister pack. </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Psudonil-250mg Injection : 1 x 5\r\nampoules in a blister pack.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nPsudonil-500mg Injection : 1 x 5\r\nampoules in a blister pack.</span></p>",
    "strength": "500,250,100",
    "uom": "mg/2ml(IV/IM)",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532328906psudonil.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209285PSUDONIL-500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745209285PSUDONIL-250.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745209285PSUDONIL-100.png"
    ]
  },
  {
    "id": "912",
    "name": "Purinol ",
    "description": "<p><strong></strong><strong>Composition : </strong></p><p><strong></strong>Purinol-100: Allopurinol BP 100mg Tablet.</p><p>Purinol-300: Allopurinol BP 300mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Allopurinol is indicated in 1.\r\nThe management of patients with signs\r\nand symptoms of primary or secondary\r\ngout (acute attacks, tophi, joint\r\ndestruction, uric acid). 2. The\r\nmanagement of patients with leukemia,\r\nlymphoma and malignancies who\r\nreceive cancer therapy</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The\r\naverage is 200 to 300 mg per day for\r\npatients with mild gout and 400 to 600\r\nmg per day for those with moderately\r\nsevere tophaceous gout. The\r\nappropriate dosage may be administered\r\nin divided doses or as a single equivalent\r\ndose with the 300 mg tablet. The minimal\r\neffective dosage is 100 to 200 mg daily\r\nand the maximal recommended dosage\r\nis 800 mg daily. Or, as directed by the\r\nRegistered Physician.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong> </p><p style=\"text-align: justify;\">Purinol-100 : 5x10's tablets in\r\nblister pack.</p><p style=\"text-align: justify;\">Purinol-300 : 3x10's tablets in blister pack.<br></p>",
    "strength": " 300,100",
    "uom": "mg",
    "categoryId": "108",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209319Purinol 300.png",
      "https://www.admin.drug-international.com/uploads/images/pu_100.jpg"
    ]
  },
  {
    "id": "800",
    "name": "RABESEC ",
    "description": "<p><strong></strong><strong>Composition :</strong><span class=\"redactor-invisible-space\"> Rabeprazole Sodium 20mg\r\nTablet.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong>  </p><p style=\"text-align: justify;\">It is indicated for the\r\ntreatment of </p><p style=\"text-align: justify;\">i) Gastric ulcer </p><p style=\"text-align: justify;\">ii) Peptic ulcer disease (PUD) </p><p style=\"text-align: justify;\">iii) Maintenance of healing of erosive or\r\nulcerative GERD </p><p style=\"text-align: justify;\">iv) Healing of Duodenal ulcer </p><p style=\"text-align: justify;\">v) Treatment of Symptomatic GERD </p><p style=\"text-align: justify;\">vi) Zollinger-Ellison Symdrome </p><p style=\"text-align: justify;\">vii) Helicobacter pylori eradication to reduce\r\nrisk of Duodenal ulcer recurrence.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Usual Adult\r\nDose for Duodenal Ulcer : 20 mg orally\r\nonce a day, after the morning meal. The\r\nusual duration of therapy is four weeks in\r\nmost patients. Usual Adult Dose for Erosive\r\nEsophagitis : 20 mg orally once a day, after\r\nthe morning meal. Therapy should be\r\ncontinued for 4 to 8 weeks. Usual Adult\r\nDose for Gastric Ulcer : 20 mg orally once a\r\nday, after the morning meal. Therapy should\r\nbe continued for 4 to 8 weeks. Usual Adult\r\nDose for Duodenal Ulcer Prophylaxis : 20\r\nmg orally once a day, after the morning meal.\r\nStudies evaluating maintenance therapy for\r\nduodenal ulcers have not extended beyond\r\n12 months. Usual Adult Dose for\r\nGastroesophageal Reflux Disease : 20 mg\r\norally once a day, after the morning meal.\r\nTherapy should be continued for 4 to 8\r\nweeks. Usual Adult Dose for Helicobacter\r\npylori Infection : Three drug regimen:\r\nrabeprazole 20 mg, amoxicillin 1000 mg, and\r\nclarithromycin 500 mg orally two times daily\r\nwith morning and evening meals for 7 days. Usual Adult Dose for Zollinger-Ellison\r\nSyndrome : Initial: 60 mg orally once a day,\r\nafter the morning meal. Maintenance: Doses up to 100 mg orally once a day or 60 mg\r\norally twice a day have been administered.\r\nPatients have been treated continuously for\r\nup to one year. Or, as directed by the\r\nregistered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Rabeprazole is\r\nFDA Pregnancy Category B.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong><span class=\"redactor-invisible-space\"> Rabesec : 4x14's tablets in blister\r\npack.</span> </p>",
    "strength": "20",
    "uom": "mg",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633325913Rabesec.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744110787Rabesec.png"
    ]
  },
  {
    "id": "960",
    "name": "Ramicard",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\">Ramipril  1.25mg, 2.5mg & 5mg Tablet.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Ramicard is indicated in the treatment of : (1) Mild to severe hypertension, where it may be used alone or in combination with thiazide diuretics. (2) Congestive heart failure. (3) To reduce the risk of stroke, myocardial infarction and death from cardiovascular events in patients with a history of cardiovascular disease. (4) Proteinuric non-diabetic nephropathy.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration :</strong></p><p style=\"text-align: justify;\"><strong></strong><span class=\"redactor-invisible-space\">Dosage of Ramicard must be adjusted according to the patient tolerance and response. Hypertension: For the management of hypertension in adults not receiving a diuretic, the usual initial dose of Ramicard is 1.25 - 2.5 mg once daily. Dosage generally is adjusted no more rapidly than at 2-week intervals. The usual maintenance dosage in adults is 2.5 - 20 mg daily given as a single dose or in 2 divided doses daily. If BP is not controlled with Ramicard alone, a diretic may be added. Congestive heart failure after myocardial infarction: In this case, Ramicard therapy may be initiated as early as 2 days after myocardial infarction. An initial dose of 2.5 mg twice daily is recommended, but if hypotension occurs, dose should be reduced to 1.25 mg twice daily. Therapy is then titrated to a target daily dose of 5 mg twice daily. Prevention of major cardiovascular events: In this case, the recommended dose is 2.5 mg once daily for the first week of therapy and 5 mg once daily for the following 3 weeks; dosage then may be increased, as tolerated, to a maintenance dosage of 10 mg once daily. Dosage in renal impariment: For the patients with hypertension and renal impairment, the recommended initial dose is 1.25 mg Ramicard once daily. Subsequent dosage should be titrated according to individual tolerance and BP response, up to a maximum of 5 mg daily. For the patients with heart failure and renal impairment, the recommended dose is 1.25 mg once daily. The dose may be increased to 1.25 mg twice daily and up to a maximum dose of 2.5 mg twice daily depending upon clinical response and tolerability. Or as directed by registered physician.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Ramicard-1.25mg tablet : 4 x 14's tablets in blister pack. <br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\" xss=\"removed\">Ramicard-2.5mg tablet : 4 x 14's tablets in blister pack. <br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\" xss=\"removed\">Ramicard-5mg tablet : 4 x 14's tablets in blister pack.</span></p>",
    "strength": "5,2.5,1.25",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532329128Ramicard.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744111069Ramicard-5.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744111069Ramicard 2.5.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744111069Ramicard 1.25.png"
    ]
  },
  {
    "id": "961",
    "name": "Ramicard Plus",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal\"><strong>Composition :</strong>  Ramicard\r\n2.5 Plus: Ramipril  2.5 mg + Hydrochlorothiazide 12.5 mg Tablet. <strong><br></strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal\"><strong></strong>Ramicard 5 Plus: Ramipril  5 mg + Hydrochlorothiazide 25 mg Tablet. </p><p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal\"><strong>Indications : </strong>Ramicard 2.5 Plus & Ramicard\r\n5 Plus is indicated for the treatment of hypertension.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage\r\nand administration :</strong> Hypertension: The usual starting dose of\r\nRamicard 2.5 Plus or Ramicard 5 Plus is one tablet once daily. If necessary,\r\nthe dose may be increased to two tablets of Ramicard 2.5 Plus or Ramicard 5\r\nPlus once daily. Dosage in renal impairment: For patients with a creatinine\r\nclearance between 60 and 30 ml/min, the recommended initial dose is Ramipril\r\n1.25 mg monotherapy. If blood pressure is not adequately controlled, the dose\r\nof Ramipril may be increased to 2.5mg. If blood pressure is still not\r\ncontrolled, patient may be switched to one tablet of Ramicard 2.5 Plus once\r\ndaily. Dosage may be titrated upward to Ramicard 5 Plus untill blood pressure\r\nis controlled. Or, as directed by the registered physician. </p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Pregnancy\r\nand lactation :</strong> Ramicard 2.5 Plus or Ramicard 5 Plus\r\nshould not be used during pregnancy and lactation. Hydrochlorothiazide\r\nPregnancy Category B, Ramipril C by FDA. </p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Packing\r\n:</strong>\r\n <strong>Ramicard\r\n2.5 Plus</strong>: 4x14's tablets in blister pack. </p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Ramicard   5 \r\nPlus: </strong>2x14's tablets in blister pack. </p>",
    "strength": "5+25,2.5+12.5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532329194Ramicard_plus.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Ramicpl5.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1744111158Ramicard 2.5 plus.png"
    ]
  },
  {
    "id": "795",
    "name": "Rantoin ",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Nitrofurantoin 100mg\r\nTablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is indicated only for the\r\ntreatment of acute uncomplicated urinary\r\ntract infections caused by susceptible\r\nstrains of Escherichia coli or\r\nStaphylococcus saprophyticus. It is also\r\nactive against certain susceptible strains\r\nof Klebsiella, Enterococci,\r\nStaphylococcus aureus and\r\nEnterobacter species.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adults:\r\n50-100mg four times a day-the lower\r\ndosage level is recommended for\r\nuncomplicated urinary tract infections.\r\nTherapy should be continued for one\r\nweek or for at least 3 days after sterility\r\nof the urine is obtained. For long-term\r\nsuppressive therapy in adults, a\r\nreduction of dosage to 50-100mg at\r\nbedtime may be adequate. Nitrofurantoin\r\nshould be given with food to improve\r\ndrug absorption.\r\nOr, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy category \"B\". There are no\r\nadequate and well-controlled studies in\r\npregnant women. This drug should be\r\nused during pregnancy only if clearly\r\nneeded. Nitrofurantoin has been\r\ndetected in human breast milk in trace\r\namounts. Because of the potential for\r\nserious adverse reactions from\r\nnitrofurantoin in nursing infants under\r\none month of age, a decision should be\r\nmade whether to discontinue nursing or\r\nto discontinue the drug, taking into\r\naccount the importance of the drug to the\r\nmother.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Rantoin Tablet : 3x10's\r\ntablets in blister pack.\r\n</span></p>",
    "strength": "100",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532331368rantoin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Rantoin.jpg"
    ]
  },
  {
    "id": "945",
    "name": "Ratinol  Forte ",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Vitamin A USP  50,000 I.U. Soft Capsule.\r\n</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Illness due to vitamin A\r\ndeficiency in ophthalmology such as\r\nnight blindness, xerophthalmia and\r\ndermatological such as changes in skin,\r\nhair and nails. Concomitant therapy of\r\nmucosa illnesses such as sinusitis,\r\nbronchitis, in acne vulgaris, ichthyosis,\r\nDarier's disease, psoriasis etc.\r\nTo meet vitmin A demand in growth,\r\nresistance to infections and night\r\nblindness. Ratinol Forte is also indicated\r\nto meet vitamin A deficiency after\r\ndiarrhoea and prophylaxis of measles</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">For Adults : 50,000 I.U -\r\n1,00,000 I.U daily up to 2,00,000 I.U if\r\nnecessary</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Ratinol Forte-50,000 : 6 x 10's soft\r\ncapsules blister pack. </span></p>",
    "strength": "50000",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531975567ratinol_forte.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209340Ratinol Forte.png"
    ]
  },
  {
    "id": "1846",
    "name": "Reknib-100",
    "description": "<p><strong>Composition: Reknib-100:</strong> Each\r\ncapsule contains Entrectinib INN 100 mg.</p><p xss=\"removed\"><strong>Indications:\r\n<o></o></strong></p><p xss=\"removed\">•<strong>ROS1-Positive Non-Small Cell Lung Cancer: </strong>Entrectinib is indicated\r\nfor the treatment of adult patients with metastatic non- small cell lung cancer\r\n(NSCLC) whose tumors are ROS1- positive. </p><p xss=\"removed\">•<strong>NTRK Gene Fusion- Positive Solid Tumors: </strong>Entrectinib is indicated\r\nfor the treatment of adult and pediatric patients 12 years of age and older\r\nwith solid tumors that: </p><p xss=\"removed\">• have a neurotrophic tyrosine\r\nreceptor kinase (NTRK) gene fusion without a </p><p xss=\"removed\"> \r\nknown acquired resistance mutation, </p><p xss=\"removed\">•\r\nare metastatic or where surgical resection is likely to result in severe\r\nmorbidity, and </p><p xss=\"removed\">• have either progressed following\r\ntreatment or have no satisfactory </p><p xss=\"removed\"> \r\nalternative therapy.</p><p xss=\"removed\"><strong> </strong></p><p xss=\"removed\"><strong>Dosage and\r\nAdministration:</strong> <o></o></p><p xss=\"removed\">•<strong>Recommended Dosage for ROS1-Positive Non- Small Cell Lung Cancer: </strong>The\r\nrecommended dosage of Entrectinib is 600 mg orally once daily with or without\r\nfood until disease progression or unacceptable toxicity. </p><p xss=\"removed\">•<strong>Recommended Dosage for NTRK Gene Fusion- Positive Solid Tumors: Adults:</strong>\r\nThe recommended dosage of Entrectinib in adults is 600 mg orally once daily\r\nwith or without food until disease progression or unacceptable toxicity. Or, as\r\ndirected by the registered physician.</p><p xss=\"removed\"><strong>Dosing in</strong> <strong>Pediatric Patients 12 Years and Older (Adolescents): <o></o></strong></p><p xss=\"removed\"><strong> </strong></p><table class=\"MsoNormalTable\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\r\n <tbody><tr xss=\"removed\">\r\n  <td width=\"169\" valign=\"top\" xss=\"removed\">\r\n  <p class=\"MsoNormal\" align=\"center\" xss=\"removed\"><strong>Body Surface Area (BSA)<o></o></strong></p>\r\n  </td>\r\n  <td width=\"222\" valign=\"top\" xss=\"removed\">\r\n  <p class=\"MsoNormal\" align=\"center\" xss=\"removed\"><strong>Recommended Dosage (Orally Once Daily)<o></o></strong></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"169\" valign=\"top\" xss=\"removed\">\r\n  <p class=\"MsoNormal\" align=\"center\" xss=\"removed\">Greater than 1.50 m<sup>2</sup></p>\r\n  </td>\r\n  <td width=\"222\" valign=\"top\" xss=\"removed\">\r\n  <p class=\"MsoNormal\" align=\"center\" xss=\"removed\">600 mg</p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"169\" valign=\"top\" xss=\"removed\">\r\n  <p class=\"MsoNormal\" align=\"center\" xss=\"removed\">1.11 to 1.50 m<sup>2</sup></p>\r\n  </td>\r\n  <td width=\"222\" valign=\"top\" xss=\"removed\">\r\n  <p class=\"MsoNormal\" align=\"center\" xss=\"removed\">500 mg</p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"169\" valign=\"top\" xss=\"removed\">\r\n  <p class=\"MsoNormal\" align=\"center\" xss=\"removed\">0.91 to 1.10 m<sup>2</sup></p>\r\n  </td>\r\n  <td width=\"222\" valign=\"top\" xss=\"removed\">\r\n  <p class=\"MsoNormal\" align=\"center\" xss=\"removed\">400 mg</p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Recommended\r\nDose Reductions for </strong><strong>Entrectinib Adverse Reactions:<o></o></strong></p><table class=\"MsoNormalTable\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"608\" xss=\"removed\">\r\n <tbody><tr xss=\"removed\">\r\n  <td width=\"84\" xss=\"removed\">\r\n  <p class=\"Default\" xss=\"removed\"><strong>Action </strong></p>\r\n  </td>\r\n  <td width=\"174\" valign=\"top\" xss=\"removed\">\r\n  <p class=\"Default\" xss=\"removed\"><strong>Adults and Pediatric Patients\r\n  12 Years and Older with BSA Greater than 1.50 m2 (Orally once daily) </strong></p>\r\n  </td>\r\n  <td width=\"186\" xss=\"removed\">\r\n  <p class=\"Default\" xss=\"removed\"><strong>Pediatric Patients 12 Years\r\n  and Older with BSA of 1.11 to 1.50 m2 (Orally once daily) </strong></p>\r\n  </td>\r\n  <td width=\"164\" xss=\"removed\">\r\n  <p class=\"Default\" xss=\"removed\"><strong>Pediatric Patients 12 Years\r\n  and Older with BSA of 0.91 to 1.10 m2 (Orally once daily) </strong></p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td width=\"84\" xss=\"removed\">\r\n  <p class=\"Default\" align=\"center\" xss=\"removed\">First dose reduction</p>\r\n  </td>\r\n  <td width=\"174\" xss=\"removed\">\r\n  <p class=\"Default\" align=\"center\" xss=\"removed\">400 mg</p>\r\n  </td>\r\n  <td width=\"186\" xss=\"removed\">\r\n  <p class=\"Default\" align=\"center\" xss=\"removed\">400 mg</p>\r\n  </td>\r\n  <td width=\"164\" xss=\"removed\">\r\n  <p class=\"Default\" align=\"center\" xss=\"removed\">300 mg</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td width=\"84\" xss=\"removed\">\r\n  <p class=\"Default\" align=\"center\" xss=\"removed\">Second dose reduction</p>\r\n  </td>\r\n  <td width=\"174\" xss=\"removed\">\r\n  <p class=\"Default\" align=\"center\" xss=\"removed\">200 mg</p>\r\n  </td>\r\n  <td width=\"186\" xss=\"removed\">\r\n  <p class=\"Default\" align=\"center\" xss=\"removed\">200 mg</p>\r\n  </td>\r\n  <td width=\"164\" xss=\"removed\">\r\n  <p class=\"Default\" align=\"center\" xss=\"removed\">200 mg</p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\" xss=\"removed\"><o> </o></p><p class=\"CM38\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and Lactation: </strong>Entrectinib can cause fetal harm when administered to a pregnant\r\nwoman. There are no available data on Entrectinib use in pregnant women. Advise pregnant women of the potential risk to a\r\nfetus. <o></o></p><p class=\"MsoNormal\" xss=\"removed\">The\r\npregnancy status should be verified of females of reproductive potential prior\r\nto initiating Entrectinib. Female patients of\r\nreproductive potential are advised to use effective contraception during\r\ntreatment with Entrectinib and for at least 5\r\nweeks following the final dose. Male patients with female partners of\r\nreproductive potential are advised to use effective contraception during\r\ntreatment with Entrectinib and for 3 months\r\nfollowing the final dose.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Lactation:</strong> There are no data on the presence of Entrectinib or its\r\nmetabolites in human milk or their effects on either the breastfed child or on\r\nmilk production. Because of the potential adverse reactions in breastfed\r\nchildren from Entrectinib, lactating woman should be advised to discontinue\r\nbreastfeeding during treatment with Entrectinib and for 7 days after the final\r\ndose. <o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p><strong>Packaging: Reknib-100: </strong>Each<strong> </strong>box contains 30 capsules in a\r\ncontainer.</p>",
    "strength": "100",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1661420980Reknib-100 Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1661420980Reknib Carton.png"
    ]
  },
  {
    "id": "1047",
    "name": "Relitch",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Betamethasone BP 0.05%, Phenylephrine\r\nhydrochloride BP 0.1% & Lignocaine\r\nhydrochloride BP 2.5%.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong><strong>Relitch is indicated for:</strong>\r\nrelief of the symptoms of itching,\r\nirritation, discomfort or pain associated\r\nwith local non-infective anal or peri-anal\r\nconditions such as external hemorrhoids.</p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> a course\r\nof treatment should be limited to 7 days.\r\nApply a small amount of ointment two or\r\nthree times a day initially, using the\r\napplicator if internal administration is\r\nrequired. When inflammation is\r\nsubsiding, once-daily application is\r\nsufficient in most cases. Or as directed\r\nby the physicians</p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\"><strong>Relitch rectal ointment :</strong> 15\r\ngram in a tube.</span></p>",
    "strength": "(0.05% + 0.1% +2.5%) w/w",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532331478Relitch.PDF.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745310617Relitch.png"
    ]
  },
  {
    "id": "1838",
    "name": "REMATIB",
    "description": "<p><strong>Composition:\r\n</strong>Each\r\nExtended-Release Tablet Contains Upadacitinib 15mg as Upadacitinib Hemihydrate.</p><p class=\"MsoNormal\"><strong>Indication:\r\n</strong>Rematib\r\nis a Janus Kinase (JAK) inhibitor indicated for the treatment of adults with\r\nmoderately to severely active rheumatoid arthritis who have had an inadequate\r\nresponse or intolerance to one or more TNF blockers. Adults and pediatric\r\npatients 12 years of age and older with refractory, moderate to severe atopic\r\ndermatitis whose disease is not adequately controlled with other systemic drug\r\nproducts, including biologics, or when use of those therapies are inadvisable.\r\nAdults with moderately to severely active ulcerative colitis who have had an\r\ninadequate response or intolerance to one or more TNF blockers.<o></o></p><p class=\"MsoNormal\"><strong>Dosage\r\nand administration: </strong>Do not initiate Rematib if absolute\r\nlymphocyte count &lt;500&gt;3, an absolute Neutrophil count\r\n(ANC) &lt;1000&gt;3, or haemoglobin level &lt;8&gt; <o></o></p><p class=\"MsoNormal\"><strong><u>Rheumatoid\r\nArthritis and Psoriatic Arthritis:</u></strong> The recommended dosage\r\nis 15 mg once daily. <o></o></p><p class=\"MsoNormal\"><strong><u>Atopic\r\nDermatitis</u></strong><strong>:</strong>\r\n<i>Pediatric Patients 12 years of age and\r\nolder weighing at least 40 kg and adults less than 65 years of age:</i>\r\nInitiate treatment with 15 mg orally once daily. If an adequate response is not\r\nachieved, consider increasing the dosage to 30 mg orally once daily. <i>Adults 65 Years of Age and Older:</i>\r\nRecommended dosage is 15 mg once daily.<o></o></p><p class=\"MsoNormal\"><strong><u>Ulcerative\r\nColitis:</u></strong> <i>Adults:\r\n</i>The recommended induction dosage is 45 mg once daily for 8 weeks. The\r\nrecommended maintenance dosage is 15 mg once daily. Or, as directed by the\r\nregistered physician.<o></o></p><p class=\"MsoNormal\"><strong>Use\r\nin Pregnancy and lactation: </strong>Pregnancy-There are no\r\nadequate and well-controlled studies in pregnant women. It should be avoided\r\nduring pregnancy. Lactation-It is advised to avoid Upadacitinib during\r\nlactation.<o></o></p><p><strong>Packing:\r\n</strong>Each\r\nbox contains 1x10’s tablets in blister pack.</p>",
    "strength": "15",
    "uom": "mg",
    "categoryId": "107",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1658225084Rematib Web Book Style Insert Final (27-06-22).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209448REMATIB.png"
    ]
  },
  {
    "id": "1768",
    "name": "Rematib",
    "description": "<p class=\"MsoBodyText\" xss=\"removed\">组成：每片缓释片含乌帕替尼布15mg</p><p class=\"MsoBodyText\" xss=\"removed\">每片缓释片含有15毫克乌帕西尼布半水合物旅馆。</p><p class=\"MsoNormal\">药理学：Upadacitinib是一种通过抑制Janus激酶（JAKs）发挥作用的DMARD，JAKs激酶</p><p class=\"MsoNormal\">是促炎细胞因子的重要下游细胞信号介质。人们相信</p><p class=\"MsoNormal\">这些促炎细胞因子在许多自身免疫性炎症疾病中发挥作用，例如</p><p class=\"MsoNormal\">类风湿性关节炎。在临床试验中，upadacitinib降低了促炎活性</p><p class=\"MsoNormal\">白细胞介素，一过性升高淋巴细胞水平，而无显著性降低</p><p class=\"MsoNormal\">从基线检查免疫球蛋白。</p><p class=\"MsoNormal\">适应症：它是一种Janus激酶（JAK）抑制剂，用于治疗成人中度抑郁症</p><p class=\"MsoNormal\">严重活动性类风湿性关节炎患者对药物反应不足或不耐受</p><p class=\"MsoNormal\">甲氨蝶呤。</p><p class=\"MsoNormal\">剂量和给药：» Upadacitinib INN的推荐剂量为15mg，每天一次。« 它</p><p class=\"MsoNormal\">可作为单一疗法或与甲氨蝶呤或其他非生物药物联合使用。</p><p class=\"MsoNormal\">如果淋巴细胞绝对计数小于500个细胞/毫米*绝对值，避免启动或中断Rematib</p><p class=\"MsoNormal\">中性粒细胞计数低于1000细胞/毫米*或血红蛋白水平低于8克/分升。或者，按照</p><p class=\"MsoNormal\">注册医生。</p><p class=\"MsoNormal\">禁忌症：对于已知对Upadacitinib或INN过敏的患者禁忌症</p><p class=\"MsoNormal\">本产品的任何成分。</p><p class=\"MsoNormal\">注意事项：« 严重感染：避免对活动性严重感染患者使用Upadacitinib，</p><p class=\"MsoNormal\">包括局部感染。*恶性肿瘤：考虑Upadacitinib治疗的风险和益处</p><p class=\"MsoNormal\">在已知恶性肿瘤患者开始治疗前。» 血栓形成：考虑风险和</p><p class=\"MsoNormal\">在治疗可能增加血栓风险的患者之前的益处。及时评估</p><p class=\"MsoNormal\">对有血栓形成症状的患者进行适当治疗。« 胃肠穿孔：使用</p><p class=\"MsoNormal\">对于风险可能增加的患者要小心。» 实验室监测：由于</p><p class=\"MsoNormal\">淋巴细胞、中性粒细胞、血红蛋白、肝酶和脂质的潜在变化。» 胚胎致死</p><p class=\"MsoNormal\">毒性：根据动物研究，Upadacitinib可能造成致命伤害。建议女性生育</p><p class=\"MsoNormal\">对胎儿的潜在风险和使用有效的避孕措施。« 接种疫苗：避免使用</p><p class=\"MsoNormal\">含活疫苗的Upadacitinib。*Upadacitinib INN与其他JAK抑制剂联合使用，</p><p class=\"MsoNormal\">生物性DMARDs，或与有效的免疫抑制剂，如硫唑嘌呤和环孢霉素是不允许的</p><p class=\"MsoNormal\">推荐。</p><p class=\"MsoNormal\">副作用：不良反应（大于或等于1%）为：上呼吸道感染，</p><p class=\"MsoNormal\">恶心、咳嗽和发热。</p><p class=\"MsoNormal\">妊娠期和哺乳期使用：妊娠期没有足够的和良好的对照研究</p><p class=\"MsoNormal\">孕妇。怀孕期间应该避免。哺乳期应避免服用乌帕西尼布</p><p class=\"MsoNormal\">哺乳期。</p><p class=\"MsoNormal\">在儿童中的应用：Upadacitinib在18岁以下儿童中的安全性和有效性</p><p class=\"MsoNormal\">年龄尚未确定。</p><p class=\"MsoNormal\">药物相互作用：» 在接受慢性前列腺炎治疗的患者中，应谨慎使用Upadacitinib</p><p class=\"MsoNormal\">强CYP3A处理¢4种抑制剂（如酮康唑）.*与乌帕西尼布合用</p><p class=\"MsoNormal\">不建议使用强CYP3A4诱导剂（如利福平）。</p><p class=\"MsoNormal\">用药过量：如果用药过量，患者应立即就医。病人应该</p><p class=\"MsoNormal\">根据症状进行治疗，并给予支持性护理。</p><p class=\"MsoNormal\">储藏：30分钟储藏°在干燥的地方。</p><p class=\"MsoNormal\">包装：每盒含10片泡罩包装。</p>",
    "strength": "15 ",
    "uom": "mg",
    "categoryId": "107",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1748509381Rematib Export Carton.png"
    ]
  },
  {
    "id": "1787",
    "name": "Renib",
    "description": "<p class=\"MsoNormal\" xss=\"removed\">Regorafenib INN 40 mg</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Composition: </strong>Each\r\nfilm coated tablet contains Regorafenib 40mg as Regorafenib Monohydrate INN.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong>\r\n<strong>Colorectal Cancer: </strong>Renib is indicated for the treatment of patients with\r\nmetastatic colorectal cancer (CRC) who have been previously treated with\r\nfluoropyrimidine-, oxaliplatin-and irinotecan-based chemotherapy, an anti-VEGF\r\ntherapy, and, if RAS wild-type, an anti-EGFR therapy. <strong>Gastrointestinal\r\nStromal Tumors: </strong>Renib is indicated for the treatment of patients with\r\nlocally advanced, unresectable or metastatic gastrointestinal stromal tumor\r\n(GIST) who have been previously treated with Imatinib Mesylate and Sunitinib\r\nMalate. <strong>Hepatocellular Carcinoma: </strong>Renib is indicated for the treatment\r\nof patients with hepatocellular carcinoma (HCC) who have been previously\r\ntreated with Sorafenib.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and\r\nAdministration: </strong>The recommended dose is 160 mg Renib\r\n(four 40 mg tablets) taken orally once daily for the first 21 days of each\r\n28-day cycle. Treatment should be continued until disease progression or\r\nunacceptable toxicity. Renib should be taken at the same time each day and\r\nswallowed tablet whole with water after a low-fat meal that contains less than\r\n600 calories and less than 30% fat. Two doses of Renib should not be taken on\r\nthe same day to make up for a missed dose from the previous day. Or, as\r\ndirected by the registered physicians.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and\r\nLactation: </strong>There are no available data on Renib use\r\nin pregnant women. Pregnant women should be advised of the potential hazard to\r\na fetus. <strong>Lactation: </strong>There are no data on the presence of Regorafenib or\r\nits metabolites in human milk, the effects of Regorafenib on the breastfed\r\ninfant, or on milk production. Because of the potential for serious adverse\r\nreactions in breastfed infants from Renib, breastfeed should not be done during\r\ntreatment with Renib and for 2 weeks after the final dose.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: </strong>Each\r\nbox contains 30 tablets in a blister pack.</p>",
    "strength": "40 ",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1632212768Renib Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744101297Renib.png"
    ]
  },
  {
    "id": "1245",
    "name": "Resant",
    "description": "<p><strong>Composition :</strong> Mirtazapine USP 15 mg.</p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Indications : </strong><span class=\"redactor-invisible-space\">Mirtazapine is indicated for\r\nthe treatment of major depressive\r\ndisorder.</span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Dosage and Administration :</strong> Adults:\r\nInitially 15 mg daily at bedtime. The\r\neffective daily dose range is generally 15\r\nto 45 mg. The daily dosage is increased\r\nwithin 2-4 weeks as a single dose or in 2\r\ndivided doses according to response.\r\nOr, as directed by the registered\r\nphysicians.<br></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> Pregnancy Category C. There are no\r\nadequate and well-controlled studies in\r\npregnant women. So, It should be used\r\nduring pregnancy only if clearly needed.\r\nIt may be excreted into breast milk.\r\nCaution should be exercised during\r\nadministration to a nursing woman.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>2 x 14's tablets in blister pack</p>",
    "strength": "15",
    "uom": "mg",
    "categoryId": "48",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532331548resant.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Resant.jpg"
    ]
  },
  {
    "id": "1171",
    "name": "Resco",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition : </strong><strong>Resco-1 : </strong>Each\r\ntablet contains Risperidone USP 1.0mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Resco-2\r\n:  </strong>Each tablet contains\r\nRisperidone USP 2.0mg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications :</strong><strong> </strong>Resco\r\n(Risperidone) is indicated for the treatment of Acute and chronic schizophrenic\r\npsychosis, and other psychotic conditions, in which positive symptoms (such as\r\nhallucinations, delusions, thought disturbances, hostility, suspiciousness)\r\nand/or negative symptoms (such as blunted affect, emotional and social withdrawal,\r\npoverty of speech) are prominent. Risperidone also alleviates affective symptoms\r\n(such as depression, guilt feelings, anxiety) associated with schizophrenia.\r\nAlso<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\">indicated\r\nat behavioral disturbances in patients with dementia where aggressive symptoms\r\n(verbal outbursts, physical violence), activity disturbances (agitation, wandering) or\r\npsychotic symptoms are prominent<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage and administration :</strong><strong> </strong>Adults\r\n: Resco can be given in 1 or 2 divided doses daily. The usual initial dose of\r\nResco is 2mg on the first day, 4mg on the second day and 6mg on the third day.\r\nFurther dosage adjustment may be needed and should generally be made at intervals\r\nof not less than one week; usual maintenance dose is 4 to 6mg daily. Extrapyramidal\r\nsymptoms may be more likely with doses above 10mg daily. Behavioral disturbances\r\nin patients with dementia : Start 0.25mg b.i.d; adjust by 0.25mg b.i.d, every\r\nother day. Optimum 0.5mg b.i.d, some may benefit from 1mg b.i.d. Once target\r\nreached, consider once daily dosing. Elderly & renal or liver disease : A\r\nstarting dose of 0.5mg b.i.d is recommended. This doses can be increased 1 to\r\n2mg b.i.d. Or, as directed\r\nby the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use in pregnancy and lactation : </strong>Pregnancy\r\ncategory C. It should be used with<strong> </strong>caution\r\nduring pregnancy and breast feeding<strong> </strong>and\r\nonly if clearly needed.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Packing :</strong><strong> </strong><strong>Resco-1\r\n: </strong>Each box contains 5 x 10's tablets in blister pack.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p><strong>Resco-2\r\n: </strong>Each box contains 5 x 10's tablets in blister pack.<br><strong></strong></p>",
    "strength": "2,1",
    "uom": "mg",
    "categoryId": "48",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532331724Resco.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1634029200Resco-2.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744101281Resco-1.png"
    ]
  },
  {
    "id": "1046",
    "name": "Retocain",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Cinchocaine Hydrochloride BP\r\n5mg, Hydrocortisone BP 5mg, Framycetin\r\nSulphate BP 10mg & Esculin BP 10mg.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong> </p><p style=\"text-align: justify;\">For the treatment of :</p><p style=\"text-align: justify;\">* Internal and externa haemorrhoids.</p><p style=\"text-align: justify;\">* Haemorrhoids post-partum.</p><p style=\"text-align: justify;\">* Anal pruritus, peri-anal eczema, anal fissures and proctitis</p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">*Post-haemorrhoidectomy application to\r\nrelieve pain and discomfort.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Ointment : Apply\r\nthe ointment in a small quantity with the finger,\r\non the painful or pruritic area, morning and\r\nevening and after each stool. For deep\r\napplication attach cannula/ applicator\r\n(supplied) to tube, insert to full extent and\r\nsqueeze tube gently from lower end whilst\r\nwithdawing. Or, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong>Should not\r\nbe used during pregnancy.</p><p style=\"text-align: justify;\"><strong>Packing :</strong> Retocain Ointment : 15gm of\r\nointment with an Applicator in a tube.</p>",
    "strength": "(0.5%+0.5%+1%+1%) w/w",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532331854retocain.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/retocainWr.jpg"
    ]
  },
  {
    "id": "1269",
    "name": "Rhinocort ",
    "description": "<p><strong>Composition :</strong><span class=\"redactor-invisible-space\"> Rhinocort Nasal Spray :\r\nEach metered spray contains\r\nBudesonide BP 100 mcg.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Indications : </strong><span class=\"redactor-invisible-space\">This nasal spray indicated\r\nfor prophylaxis and the treatment of\r\nseasonal and perennial allergic rhinitis\r\nand prophylaxis and the treatment of\r\nvasomotor rhinitis. lt is also indicated for\r\nthe treatment of symptomatic relief of\r\nnasal polyposis and prevention against\r\nnasal polyps after polypectomy.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adults\r\nand Children 6 years of age and older :\r\n100 mcg per day administered as one\r\nspray per nostril once daily.\r\nThe maximum recommended dose for\r\nadults (12 years of age and older) is 400\r\nmcg per day administered as four sprays\r\nper nostril once daily.\r\nOr, as directed by the registered\r\nphysicians.</span><br></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Use in Pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy category B. There are no\r\nadequate and well controlled studies in\r\npregnant women. Budesonide nasal\r\nspray, like other corticosteroids, should\r\nbe used during pregnancy only if the\r\npotential benefit justifies the potential risk\r\nto the fetus. lt is not known whether\r\nBudesonide is excreted in human milk.\r\nBecause other corticosteroids are\r\nexcreted in human milk, caution should\r\nbe exercised when Budesonide nasal\r\nspray is administered to nursing woman.</span><br></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Packing :</strong><span class=\"redactor-invisible-space\"> Rhinocort Nasal Spray : Each\r\nbottle contains 120 metered doses for\r\nsprays.</span><br></span></span></span></span></p>",
    "strength": "100",
    "uom": "mcg/Spray",
    "categoryId": "56",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532331905Rhinocort Nasal Spray.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1517291937Rhinocort.jpg"
    ]
  },
  {
    "id": "1890",
    "name": "Ritumab-500",
    "description": "<p><strong>COMPOSITION:\r\n</strong>Each\r\nvial (50ml) contains Rituximab INN 500mg (10mg/ml) solution for IV infusion.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>INDICATION:\r\n• Non–Hodgkin’s Lymphoma (NHL):</strong> Rituximab is indicated\r\nfor the treatment of adult patients with: • Relapsed or refractory, low-grade\r\nor follicular, CD20-positive, B-cell NHL as a single agent. • Previously\r\nuntreated follicular, CD20-positive, B-cell NHL in combination with first line\r\nchemotherapy and, in patients achieving a complete or partial response to a\r\nrituximab product in combination with chemotherapy, as single-agent maintenance\r\ntherapy. • Non-progressing (including stable disease), low-grade,\r\nCD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide,\r\nvincristine, and prednisone (CVP) chemotherapy. • Previously untreated diffuse\r\nlarge B-cell, CD20-positive NHL in combination with cyclophosphamide,\r\ndoxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy\r\nregimens. Rituximab is indicated for the treatment of pediatric patients aged 6\r\nmonths and older with: • Previously untreated, advanced stage, CD20-positive\r\ndiffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like\r\nlymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with\r\nchemotherapy. <strong>• Chronic Lymphocytic\r\nLeukemia (CLL):</strong> Rituximab, in combination with fludarabine and\r\ncyclophosphamide (FC), is indicated for the treatment of adult patients with\r\npreviously untreated and previously treated CD20-positive CLL. <strong>• Rheumatoid Arthritis (RA):</strong> Rituximab,\r\nin combination with methotrexate, is indicated for the treatment of adult\r\npatients with moderately- to severely-active rheumatoid arthritis who have had\r\nan inadequate response to one or more TNF antagonist therapies. <strong>• Granulomatosis with Polyangiitis (GPA)\r\n(Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA):</strong> Rituximab,\r\nin combination with glucocorticoids, is indicated for the treatment of adult\r\nand pediatric patients 2 years of age and older with Granulomatosis with\r\nPolyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis\r\n(MPA). <strong>• Pemphigus Vulgaris (PV):</strong>\r\nRituximab is indicated for the treatment of adult patients with moderate to\r\nsevere pemphigus vulgaris.<strong><o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>DOSAGE\r\nAND ADMINISTRATION: Administration only as an Intravenous Infusion:</strong>\r\nIt should not be administered as an intravenous push or bolus. Rituximab should\r\nonly be administered by a healthcare professional with appropriate medical\r\nsupport to manage severe infusion-related reactions that can be fatal if they\r\noccur. It should be premedicated before each infusion. Or, as directed by the\r\nregistered physicians. Please see the full insert inside.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>USE\r\nIN PREGNANCY: </strong>Rituximab can\r\ncause fetal harm when administered to a pregnant woman. Rituximab can cause adverse developmental outcomes including B-cell\r\nlymphocytopenia in infants exposed to Rituximab\r\nin-utero. Adverse outcomes in pregnancy occur regardless of the health of the\r\nmother or the use of medications. The background risk of major birth defects\r\nand miscarriage for the indicated populations is unknown. <strong>Lactation: </strong>There\r\nare limited data on the presence of Rituximab in human milk and the effect on\r\nthe breastfed child, and there are no data on the effect on milk production.\r\nRituximab has also been reported to be excreted at low concentrations in human\r\nbreast milk. Given that the clinical significance of this finding for children\r\nis not known, Women should not be advised to breastfeed during treatment with Rituximab and for 6 months after the last dose due to the potential\r\nof serious adverse reactions in breastfed children.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>PACKAGING:\r\n</strong>Each box contains one vial of 50ml sterile\r\nsolution of Rituximab 500mg for IV infusion.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p>",
    "strength": "500",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1694415614Ritumab-500 Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1694415614Ritumab-500 Carton.png"
    ]
  },
  {
    "id": "1754",
    "name": "Rizonib",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:</strong> Each capsule contains Crizotinib\r\nINN 250 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>ALK-Positive\r\nMetastatic NSCLC:</strong>\r\nRizonib is indicated for the treatment of patients with metastatic Non-small\r\ncell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase\r\n(ALK)-positive as detected by an FDA-approved test.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>ROS1-Positive\r\nMetastatic NSCLC:</strong>\r\nRizonib is indicated for the treatment of patients with metastatic NSCLC whose\r\ntumors are ROS1-positive.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and\r\nAdministration:</strong>\r\nThe recommended dose of Rizonib is 250 mg orally, twice daily until disease\r\nprogression or no longer tolerated by the patient. The recommended dose of\r\nRizonib in patients with severe renal impairment [creatinine clearance (CLcr)\r\n&lt; 30&gt;\r\n\r\n</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy\r\nand Lactation:</strong>\r\nThere are no adequate and well-controlled studies in pregnant women using\r\nCrizotinib. Females of reproductive potential should be advised of the\r\npotential risk to a fetus and to inform their healthcare provider of a known or\r\nsuspected pregnancy. Females of reproductive potential should be advised to use\r\neffective contraception during treatment with Rizonib and for at least 45 days\r\nafter the final dose.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:</strong> Each box contains 30 capsules in\r\nblister pack.</p>",
    "strength": "250",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1683361140Rizonib 250mg Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740569457rizonib.png"
    ]
  },
  {
    "id": "1717",
    "name": "Rizonib (CH)",
    "description": "<p class=\"MsoNormal\"><strong><span lang=\"ZH-CN\">成分</span></strong><strong>:</strong><span lang=\"ZH-CN\">每粒胶囊含克唑替尼</span>250<span lang=\"ZH-CN\">毫克。</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">作用机制</span>:<span lang=\"ZH-CN\">克唑替尼是受体酪氨酸激酶的抑制剂，包括</span>ALK<span lang=\"ZH-CN\">，肝细胞生长</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">因子受体</span>(HGFR<span lang=\"ZH-CN\">，</span>c-Met)<span lang=\"ZH-CN\">，</span>ROS1 (c-ros)<span lang=\"ZH-CN\">，和受体</span>d'Origine Nantais (RON)<span lang=\"ZH-CN\">。转移可以</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">影响导致致癌融合蛋白表达的</span>ALK<span lang=\"ZH-CN\">基因。</span>ALK<span lang=\"ZH-CN\">聚变的形成</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">蛋白质导致基因表达和信号的激活和失调，表达这些蛋白的肿瘤细胞增殖和存活增加。克唑替尼证明，肿瘤细胞检测中</span>ALK<span lang=\"ZH-CN\">、</span>ROS1<span lang=\"ZH-CN\">和</span>c-Met<span lang=\"ZH-CN\">磷酸化的浓度依赖性抑制，表达棘皮动物肿瘤异种移植物的小鼠中的细胞系和显示的抗肿瘤活性，微管相关蛋白样</span>4 (EML4)-<span lang=\"ZH-CN\">或核蛋白</span>(NPM)-ALK<span lang=\"ZH-CN\">融合蛋白或</span>c-Met<span lang=\"ZH-CN\">。</span></p><p class=\"MsoNormal\"><strong><span lang=\"ZH-CN\">药效学</span></strong><strong>:</strong><span lang=\"ZH-CN\">在一项对</span>52<span lang=\"ZH-CN\">例</span>ALK<span lang=\"ZH-CN\">阳性非小细胞肺癌患者进行的心电图亚研究中</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">克唑替尼</span>250<span lang=\"ZH-CN\">毫克，每天两次，最大平均</span>QTcF(<span lang=\"ZH-CN\">用弗里德里克氏法校正的</span>QT)<span lang=\"ZH-CN\">从</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">基线为</span>12.3<span lang=\"ZH-CN\">毫秒</span>(<span lang=\"ZH-CN\">双侧</span>90%<span lang=\"ZH-CN\">上置信区间</span>:19.5<span lang=\"ZH-CN\">毫秒</span>)<span lang=\"ZH-CN\">。暴露量定量分析显示克唑替尼血浆</span> QTcF<span lang=\"ZH-CN\">的浓度依赖性增加。</span><span lang=\"ZH-CN\"> </span></p><p class=\"MsoNormal\"><strong><span lang=\"ZH-CN\">药代动力学</span></strong><strong>:</strong> <span lang=\"ZH-CN\">吸收</span>:<span lang=\"ZH-CN\">单剂量口服后，克唑替尼以中位时间吸收达到峰值</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">浓度为</span>4<span lang=\"ZH-CN\">至</span>6<span lang=\"ZH-CN\">小时。克唑替尼的平均绝对生物利用度为</span>43%(<span lang=\"ZH-CN\">范围</span>:32%-66%) <span lang=\"ZH-CN\">单次口服</span>250<span lang=\"ZH-CN\">毫克后。高脂肪餐将克唑替尼的</span>AUC<span lang=\"ZH-CN\">从时间零点降低到无穷大</span>(AUCinf) <span lang=\"ZH-CN\">最大观察血浆浓度</span>(Cmax)<span lang=\"ZH-CN\">约为</span>14%<span lang=\"ZH-CN\">。</span></p><p class=\"MsoNormal\"><strong><span lang=\"ZH-CN\">分布</span></strong><strong>:</strong><span lang=\"ZH-CN\">克唑替尼静脉注射后的几何平均分布体积为</span>1772<span lang=\"ZH-CN\">升</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">给予</span>50<span lang=\"ZH-CN\">毫克剂量，表明血浆广泛分布于组织中。</span></p><p class=\"MsoNormal\"><strong><span lang=\"ZH-CN\">消除</span></strong><strong>:</strong><span lang=\"ZH-CN\">单剂量克唑替尼后，克唑替尼的平均表观血浆终末半衰期为，病人</span>42<span lang=\"ZH-CN\">小时。在给健康人施用单一</span>250<span lang=\"ZH-CN\">毫克放射性标记的克唑替尼剂量后，受试者在粪便和尿液中分别回收了</span>63%<span lang=\"ZH-CN\">和</span>22%<span lang=\"ZH-CN\">的给药剂量。</span><span lang=\"ZH-CN\"> </span></p><p class=\"MsoNormal\"><strong><span lang=\"ZH-CN\">代谢</span></strong><strong>:</strong><span lang=\"ZH-CN\">克唑替尼主要由</span>CYP3A4/5<span lang=\"ZH-CN\">代谢。中的主要代谢途径，人类将哌啶环氧化成克唑替尼内酰胺和脱烷基，随后是第</span>2<span lang=\"ZH-CN\">阶段</span> O-<span lang=\"ZH-CN\">脱烷基代谢物的缀合。</span></p><p class=\"MsoNormal\"><strong><span lang=\"ZH-CN\">适应症</span></strong><strong>:</strong> ALK<span lang=\"ZH-CN\">阳性转移性非小细胞肺癌</span>:<span lang=\"ZH-CN\">里索尼用于治疗转移性非小细胞肺癌患者，肿瘤为间变性淋巴瘤激酶</span>(ALK)<span lang=\"ZH-CN\">阳性的细胞肺癌</span> FDA<span lang=\"ZH-CN\">批准的测试。</span> ROS1-<span lang=\"ZH-CN\">阳性转移性非小细胞肺癌</span>:<span lang=\"ZH-CN\">瑞索尼布适用于转移性非小细胞肺癌患者的治疗肿瘤</span>ROS1<span lang=\"ZH-CN\">阳性。</span><span lang=\"ZH-CN\"> </span><strong><span lang=\"ZH-CN\">剂量和给药</span></strong><strong>:</strong><span lang=\"ZH-CN\">利松尼的推荐剂量为</span>250<span lang=\"ZH-CN\">毫克口服，每日两次，直至患病进展或不再被患者耐受。重症患者使用利松尼的推荐剂量</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">不需要透析的肾损害</span>[<span lang=\"ZH-CN\">肌酐清除率</span>&lt; 30<span lang=\"ZH-CN\">毫升</span>/<span lang=\"ZH-CN\">分钟</span>]<span lang=\"ZH-CN\">为</span>250<span lang=\"ZH-CN\">毫克口服，每天一次。</span> Rizonib<span lang=\"ZH-CN\">可以带食物或不带食物服用。整个吞下胶囊。如果错过了一剂，就应补上，除非下一剂在</span>6<span lang=\"ZH-CN\">小时内到期。如果服用一剂利松尼后呕吐，服用</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">定期服用下一剂。</span></p><p class=\"MsoNormal\"><strong><span lang=\"ZH-CN\">剂量修改</span></strong><strong>:</strong><span lang=\"ZH-CN\">如果由于以下原因需要减少一次或多次剂量，剂量应减少如下：国家癌症研究所通用术语定义的</span>3<span lang=\"ZH-CN\">级或</span>4<span lang=\"ZH-CN\">级严重不良反应</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">不良事件标准</span>(NCI CTCAE)4.0<span lang=\"ZH-CN\">版</span>: <span lang=\"ZH-CN\">首次剂量减少</span>:<span lang=\"ZH-CN\">每日口服两次，每次</span>200<span lang=\"ZH-CN\">毫克。</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">第二次剂量减少</span>:<span lang=\"ZH-CN\">每日口服一次利松尼</span>250<span lang=\"ZH-CN\">毫克。</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">如果不能耐受每日口服一次的利松尼</span>250<span lang=\"ZH-CN\">毫克，则永久停用。</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">或者按照注册医生的指示。</span></p><p class=\"MsoNormal\"><strong><span lang=\"ZH-CN\">副作用</span></strong><strong>: </strong><span lang=\"ZH-CN\">肝毒性、间质性肺病、</span>QT<span lang=\"ZH-CN\">间期延长、心动过缓、严重视力丧失。</span></p><p class=\"MsoNormal\"><strong><span lang=\"ZH-CN\">禁忌症</span></strong><strong>:</strong><span lang=\"ZH-CN\">已知对克唑替尼或任何其他药物过敏的患者禁用本产品的组件。</span><span lang=\"ZH-CN\"> </span></p><p class=\"MsoNormal\"><strong><span lang=\"ZH-CN\">用于怀孕和哺乳</span></strong><strong>:</strong><span lang=\"ZH-CN\">没有对孕妇使用克唑替尼。应告知具有生殖潜力的女性胎儿的潜在风险，并告知她们</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">已知或疑似妊娠的医疗保健提供者。应该建议具有生殖潜力的女性</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">在使用利松尼治疗期间和最终剂量后至少</span>45<span lang=\"ZH-CN\">天内使用有效避孕方法。</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">具有生殖潜力的女性和男性</span>:<span lang=\"ZH-CN\">具有生殖潜力的女性和男性应该</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">告知</span>Rizonib<span lang=\"ZH-CN\">有可能降低生育率。男性患者与女性生殖伙伴</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">应建议潜在患者在使用利松尼治疗期间以及最终治疗后至少</span>90<span lang=\"ZH-CN\">天内使用避孕套</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">剂量。</span><span lang=\"ZH-CN\"> </span></p><p class=\"MsoNormal\"><strong><span lang=\"ZH-CN\">哺乳</span></strong><strong>:</strong><span lang=\"ZH-CN\">应建议女性在使用利松尼治疗期间和治疗后</span>45<span lang=\"ZH-CN\">天内不要母乳喂养</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">最终剂量。</span> Rizonib <span lang=\"ZH-CN\">克唑替尼</span>INN 250<span lang=\"ZH-CN\">毫克胶囊</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">不孕不育</span>:<span lang=\"ZH-CN\">应该告知有生育能力的女性和男性生育能力下降的可能性</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">来自里佐尼布。</span></p><p class=\"MsoNormal\"><strong><span lang=\"ZH-CN\">药物相互作用</span></strong><strong>:</strong> <span lang=\"ZH-CN\">可能增加克唑替尼血浆浓度的药物</span>:<span lang=\"ZH-CN\">克唑替尼与强</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">细胞色素</span>P450 (CYP) 3A<span lang=\"ZH-CN\">抑制剂增加克唑替尼血浆浓度。强力的伴随使用</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">应避免使用</span>CYP3A<span lang=\"ZH-CN\">抑制剂，包括但不限于阿扎那韦、克拉霉素、茚地那韦，</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">伊曲康唑、酮康唑、奈法唑酮、奈非那韦、利托那韦、沙奎那韦、特利霉素、曲莱多霉素和</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">伏立康唑。葡萄柚或葡萄柚汁应该避免，这也可能增加血浆浓度</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">克唑替尼。应谨慎使用中度</span>CYP3A<span lang=\"ZH-CN\">抑制剂。可能</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">降低克唑替尼血浆浓度</span>:<span lang=\"ZH-CN\">克唑替尼与强</span>CYP3A<span lang=\"ZH-CN\">诱导剂合用</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">降低克唑替尼的血浆浓度。应避免同时使用强</span>CYP3A<span lang=\"ZH-CN\">诱导剂，</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">包括但不限于卡马西平、苯巴比妥、苯妥英、利福布丁、利福平和圣约翰草。</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">克唑替尼可能改变血浆浓度的药物</span>:<span lang=\"ZH-CN\">克唑替尼抑制</span>CYP3A <span lang=\"ZH-CN\">体外和体内。应避免同时使用治疗范围窄的</span>CYP3A<span lang=\"ZH-CN\">底物，</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">包括但不限于阿芬太尼、环孢菌素、二氢麦角胺、麦角胺、芬太尼、匹莫齐特，</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">服用克唑替尼患者的奎尼丁、西罗莫司和他克莫司。如果伴随使用这些</span>CYP3A<span lang=\"ZH-CN\">底物</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">服用克唑替尼的患者需要窄的治疗范围，降低</span>CYP3A<span lang=\"ZH-CN\">底物的剂量</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">可能因不良反应而需要。</span></p><p class=\"MsoNormal\" style=\"text-align:left;line-height:22.5pt;\r\nmso-pagination:widow-orphan;background:#FCFCFC\" align=\"left\"><strong><span lang=\"ZH-CN\">注意事项</span></strong><strong>: </strong></p><p class=\"MsoNormal\" style=\"text-align:left;line-height:22.5pt;\r\nmso-pagination:widow-orphan;background:#FCFCFC\" align=\"left\"><strong><span lang=\"ZH-CN\">肝毒性</span></strong><strong>:</strong><span lang=\"ZH-CN\">在</span>1719<span lang=\"ZH-CN\">名患者中，有</span>2<span lang=\"ZH-CN\">名</span>(0.1%)<span lang=\"ZH-CN\">出现了药物性肝毒性，并导致死亡</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">在临床试验中使用利松尼进行治疗。肝功能检查，包括谷丙转氨酶、谷草转氨酶和总胆红素应</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">在治疗的前两个月每两周监测一次，然后每月监测一次，根据临床指示，</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">随着更频繁地重复检测肝转氨酶、碱性磷酸酶或总胆红素</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">转氨酶升高的患者。</span>Rizonib<span lang=\"ZH-CN\">应暂停使用，减少剂量，或在这种情况下永久停产。</span><span lang=\"ZH-CN\"> </span></p><p class=\"MsoNormal\" style=\"text-align:left;line-height:22.5pt;\r\nmso-pagination:widow-orphan;background:#FCFCFC\" align=\"left\"><strong><span lang=\"ZH-CN\">间质性肺病</span></strong><strong>(</strong><strong><span lang=\"ZH-CN\">肺炎</span></strong><strong>):</strong><span lang=\"ZH-CN\">严重、危及生命或致命的间质性肺病</span> (ILD)/<span lang=\"ZH-CN\">肺炎可发生在用利松尼治疗的患者中。间质性肺病一般发生在</span>3 Rizonib<span lang=\"ZH-CN\">成立几个月后。表示</span>ILD/<span lang=\"ZH-CN\">肺炎的肺部症状患者应为</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">监控。</span>ILD/<span lang=\"ZH-CN\">肺炎的其他潜在原因应排除在外，利佐尼应永久排除</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">被诊断为与药物相关的</span>ILD/<span lang=\"ZH-CN\">肺炎患者停用。</span></p><p class=\"MsoNormal\">QT<span lang=\"ZH-CN\">间期延长</span>:<span lang=\"ZH-CN\">接受利松尼治疗的患者可能出现</span>QTc<span lang=\"ZH-CN\">延长。</span>Rizonib<span lang=\"ZH-CN\">在中的使用</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">应避免患有先天性长</span>QT<span lang=\"ZH-CN\">综合征的患者。心电图和电解质应在</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">充血性心力衰竭、缓慢性心律失常、电解质异常或正在服用</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">已知能延长</span>QT<span lang=\"ZH-CN\">间期的药物。</span>Rizonib<span lang=\"ZH-CN\">应在患者中永久停用</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">与</span>Torsade de<span lang=\"ZH-CN\">的基线相比，谁出现大于</span>500 ms<span lang=\"ZH-CN\">或大于或等于</span>60 ms<span lang=\"ZH-CN\">的</span>QTc<span lang=\"ZH-CN\">变化</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">尖端或多形性室性心动过速或严重心律失常的迹象</span>/<span lang=\"ZH-CN\">症状。</span>Rizonib<span lang=\"ZH-CN\">应该是</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">在恢复到一个</span>QTc<span lang=\"ZH-CN\">之前，在至少两个单独的</span>ECg<span lang=\"ZH-CN\">上出现超过</span>500 ms<span lang=\"ZH-CN\">的</span>QTc<span lang=\"ZH-CN\">的</span>n<span lang=\"ZH-CN\">名患者被扣留</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">小于或等于</span>480<span lang=\"ZH-CN\">毫秒，则在这种情况下，应恢复低剂量的利松尼。</span></p><p class=\"MsoNormal\"><strong><span lang=\"ZH-CN\">心动过缓</span></strong><strong>:</strong><span lang=\"ZH-CN\">症状性心动过缓可能发生在接受利松尼的患者身上。结合使用</span>Rizonib <span lang=\"ZH-CN\">与已知引起心动过缓的其他药物</span>(<span lang=\"ZH-CN\">例如</span>β-<span lang=\"ZH-CN\">阻断剂、非二氢吡啶钙通道</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">阻断剂、可乐定和地高辛</span>)<span lang=\"ZH-CN\">应尽可能避免。心率和血压应该</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">受到定期监控。如果出现不危及生命的症状性心动过缓，应服用利松尼</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">在恢复到无症状心动过缓或心率达到</span>60 bpm<span lang=\"ZH-CN\">或以上之前，重新评估</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">合并用药，并调整利松尼的剂量。它应该永久停止，因为</span> Rizonib<span lang=\"ZH-CN\">引起的危及生命的心动过缓。</span></p><p class=\"MsoNormal\" style=\"text-align:left;line-height:22.5pt;\r\nmso-pagination:widow-orphan;background:#FCFCFC\" align=\"left\"><strong><span lang=\"ZH-CN\">严重视力丧失</span></strong><strong>:</strong><span lang=\"ZH-CN\">在所有临床试验中，</span>4<span lang=\"ZH-CN\">级视野缺损伴视力丧失的发生率为</span> 0.2% (4/1719)<span lang=\"ZH-CN\">。据报道，视神经萎缩和视神经紊乱是视力丧失的潜在原因。</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">新出现严重视力丧失</span>(<span lang=\"ZH-CN\">最佳矫正视力低于</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">一只或两只眼睛</span>20/200)<span lang=\"ZH-CN\">。眼科评估应包括最佳矫正</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">视敏度、视网膜照片、视野、光学相干断层扫描和其他评估</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">适用于新出现的严重视力丧失。</span></p><p class=\"MsoNormal\" style=\"text-align:left;line-height:22.5pt;\r\nmso-pagination:widow-orphan;background:#FCFCFC\" align=\"left\"><strong><span lang=\"ZH-CN\">胚胎</span></strong><strong>-</strong><strong><span lang=\"ZH-CN\">胎儿毒性</span></strong><strong>:</strong><span lang=\"ZH-CN\">根据其作用机制，利松尼注射给药时会对胎儿造成伤害</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">孕妇。孕妇应该被告知对胎儿的潜在风险。育龄女性</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">应建议潜在患者在使用利松尼治疗期间至少</span>45<span lang=\"ZH-CN\">天使用有效避孕方法</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">在最后一剂之后。应该建议有生殖潜力的女性伴侣的男性患者使用</span><span lang=\"ZH-CN\"> </span><span lang=\"ZH-CN\">在使用利松尼治疗期间以及最终剂量后至少</span>90<span lang=\"ZH-CN\">天使用避孕套。</span><span lang=\"ZH-CN\"> </span></p><p class=\"MsoNormal\" style=\"text-align:left;line-height:22.5pt;\r\nmso-pagination:widow-orphan;background:#FCFCFC\" align=\"left\"><strong><span lang=\"ZH-CN\">用药过量</span></strong><strong>:</strong><span lang=\"ZH-CN\">目前还没有已知的里佐尼过量病例。里佐尼没有解药。</span><span lang=\"ZH-CN\"> </span><strong><span lang=\"ZH-CN\">储存</span></strong><strong>:</strong><span lang=\"ZH-CN\">储存在</span>30℃<span lang=\"ZH-CN\">以下阴凉干燥的地方，远离阳光。放在孩子们够不着的地方。</span><span lang=\"ZH-CN\"> </span></p><p class=\"MsoNormal\" style=\"text-align:left;line-height:22.5pt;\r\nmso-pagination:widow-orphan;background:#FCFCFC\" align=\"left\"><strong><span lang=\"ZH-CN\">包装</span></strong><strong>:</strong><span lang=\"ZH-CN\">每箱装</span>60<span lang=\"ZH-CN\">粒胶囊，泡罩包装。</span></p><p class=\"MsoNormal\"><strong> </strong></p>",
    "strength": "250",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1569218797Rizonib.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1569216969Rizonib 250 mg 60 Capsule- Carton Pic.png"
    ]
  },
  {
    "id": "1201",
    "name": "Rofumil ",
    "description": "<p><strong>Composition :</strong> Roflumilast INN 500mcg Tablet.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Roflumilast is indicated for\r\nthe maintenance treatment of severe\r\nCOPD associated with chronic bronchitis\r\nwith a history of frequent exacerbation.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The\r\nrecommended dose of Roflumilast is one\r\n500 microgram(mcg) tablet once daily.\r\nThe tablet should be swallowed with\r\nwater and can be taken with or without\r\nfood. Or, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Roflumilast is pregnancy category C by\r\nthe FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>Rofumil : 2x10's tablets in\r\nblister pack.</p>",
    "strength": "500",
    "uom": "Mcg",
    "categoryId": "47",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532331966ROFUMIL.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/ROFUMIL.jpg"
    ]
  },
  {
    "id": "1283",
    "name": "Ropenem  ",
    "description": "<p><strong>Composition :</strong><span class=\"redactor-invisible-space\"> Meropenem USP  500mg & 1gm\r\ninjection.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Indications : </strong><span class=\"redactor-invisible-space\">Meropenem IV is indicated for the\r\ntreatment, in adults and children, of the following\r\ninfections caused by single or multiple bacteria\r\nsensitive to Meropenem. These are as follows:\r\nPneumonias and nosocomial pneumonias,\r\nUrinary tract infections, Intra-abdominal\r\ninfections, Gynaecological Infections, such as\r\nendometritis Skin and Skin structure infections,\r\nMeningitis, septicaemia, Empiric treatment,\r\nincluding monotherapy, for presumed infections\r\nin adult patient with febrile neutropenia.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Please see prescribing description for more information.<br></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Use in pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> Meropenem\r\nhas been assigned to pregnancy category B by\r\nthe FDA.</span><br></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Packing :</strong><span class=\"redactor-invisible-space\"> 1 Combipack.<br></span></span></span></span></p>",
    "strength": "1,500",
    "uom": "gm(IV)",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532332078Ropenem.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209797ROPENEM-1gm.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745209797ROPENEM-500.png"
    ]
  },
  {
    "id": "1007",
    "name": "Rostatin",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">: Rosuvastatin 5 mg, 10 mg &\r\n20 mg Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong> Rostatin is indicated for -\r\nHeterozygous Hypercholesterolemia\r\n(Familial and Nonfamilial), Homozygous\r\nHypercholesterolemia (Familial), Mixed\r\nDyslipidemia (Fredrickson Type IIa and IIb). </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Heterozygous Hypercholesterolemia\r\n(Familial and Nonfamilial) and Mixed\r\nDyslipidemia (Fredrickson Type IIa and IIb):\r\nThe usual recommended starting dose of\r\nRostatin is 10mg once daily. Initiation of\r\ntherapy with 5mg once daily may be\r\nconsidered for patients requiring less\r\naggressive LDL-C reductions or who have\r\npredisposing factors for myopathy. For\r\npatients with marked hypercholesterolemia\r\n(LDL-C&gt;190 mg/dL) and aggressive lipid\r\ntargets, a 20mg starting dose may be\r\nconsidered.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"> Homozygous Hypercholesterolemia\r\n(Familial): The recommended\r\nstarting dose of Rostatin is 20mg once daily\r\nin patients with Homozygous FH. The\r\nmaximum recommended daily dose is\r\n40mg. </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Dosage in Patients with Renal\r\nInsufficiency : For patients with severe\r\nrenal impairment (CLcr &lt;30 ml/min/1.73m2)\r\nnot on hemodialysis, dosing of Rostatin\r\nshould be started at 5mg once daily and not\r\nto exceed 10mg once daily.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"> Pediatric\r\npatients : The safety and effectiveness in\r\npediatric patients have not been\r\nestablished. Or, as directed by the\r\nregistered physician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\"><strong></strong><span class=\"redactor-invisible-space\">Rostatin-5 : 3 X 14's tablets in\r\nblister pack.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">\r\nRostatin-10 : 2 X 14's tablets in blister pack. </span></p><p style=\"text-align: justify;\">Rostatin-20 : 1 X 14's tablets in blister pack.</p>",
    "strength": "20,10,5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531975886Rostatin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744101240Rostatin-20.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744101240Rostatin-10.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744101240Rostatin-5.png"
    ]
  },
  {
    "id": "1811",
    "name": "Rupsol",
    "description": "<p><strong>Composition:</strong> Each gram oral paste contains Amlexanox\r\nINN 50 mg.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><span></span><strong>Indications:</strong> For the treatment of Aphthous ulcers.</p><p class=\"MsoNormal\" style=\"text-align:justify\" rel=\"text-align:justify\"><strong>Dosage &\r\nAdministration:</strong> <strong>1.</strong>\r\nApply the paste as soon as possible after noticing the symptoms of an aphthous\r\nulcer. Continue to use the paste four times daily, preferably following oral\r\nhygiene after breakfast, lunch, dinner, and at bedtime. Dry the ulcer (s) by\r\ngently patting it with a soft, clean cloth. Wash hands before applying, Moister\r\nthe tip of the index finger. <strong>2.</strong>\r\nSqueeze a dab of paste approximately 1 /4 inch (0.5 cm) on to a finger tip. <strong>3.</strong> Gently dab the paste on to the\r\nulcer. Repeat the process if more than one ulcer. <strong>4.</strong> Wash hands when done applying. Wash eyes promptly if they should come in contact with the paste. <strong>5.</strong> Use the paste until the ulcer heals. If significant healing or pain relief has not occurred in 10 days. Consultation\r\nwith the physician is required. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><span></span><strong>Use in pregnancy and\r\nlactation: </strong>Pregnancy Category B. There are no\r\nadequate and well controlled studies in pregnant women. This drug should be\r\nused during pregnancy only if clearly needed. Amlexanox was found in the milk of lactating rats; therefore caution\r\nexercised when administering Amlexanox oral paste to a nursing woman.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><span></span><strong>Packing: </strong>Tube\r\ncontaining 5 gm oral paste.<span></span></p>",
    "strength": " 50",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1638609678Rupsol Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209833Rupsol.png"
    ]
  },
  {
    "id": "1840",
    "name": "Rutinib",
    "description": "<p><strong>Composition: </strong>Ruxolitinib\r\nPhosphate INN 1.5% cream.</p><p class=\"CM38\" xss=\"removed\"><strong>Indication: </strong><span class=\"redactor-invisible-space\">Ruxolitinib\r\n</span>is a Janus kinase (JAK) inhibitor indicated for the topical\r\nshort-term and non-continuous chronic treatment of mild to moderate atopic\r\ndermatitis (AD) in non-immunocompromised patients 12 years of age and older\r\nwhose disease is not adequately controlled with topical prescription therapies\r\nor when those therapies are not advisable.</p><p xss=\"removed\"><strong>Dosage and administration: </strong>A thin layer of cream should be applied to the affected\r\nareas BID of up to 20% body surface area; not to exceed &gt;60 g/week.\r\nIt should stop using when signs and symptoms (eg,\r\nitch, rash, redness) of atopic dermatitis resolve. If signs and symptoms do not\r\nimprove within 8 weeks, re-examine patient. Or,\r\nas directed by the registered physician.<o></o></p><p xss=\"removed\"><strong>Use in pregnancy and lactation: </strong>There\r\nis no data available.</p><p xss=\"removed\"><o> </o></p><p><strong>Packing: </strong>Each tube contains 30 gm cream.</p>",
    "strength": "30",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1659780765Rutinib Insert Date - 06-08-2022 Compressed.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1659781469Rutinib Cream Web Carton Pic.png"
    ]
  },
  {
    "id": "1867",
    "name": "Rutinib",
    "description": "<p><strong>Composition: </strong>Each gram cream contains Ruxolitinib 15mg Ruxolitinib\r\nPhosphate INN.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication:</strong> Ruxolitinib is a Janus kinase (JAK) inhibitor, which\r\nis indicated for atopic dermatitis and vitiligo.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>•Atopic Dermatitis:</strong> Ruxolitinib is used in the topical short-term and\r\nnon-continuous chronic treatment of mild to moderate atopic dermatitis in\r\nnon-immunocompromised adult and pediatric patients 12 years of age and older\r\nwhose disease is not adequately controlled with topical prescription therapies\r\nor when those therapies are not advisable. <o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>•Vitiligo:</strong> Ruxolitinib is used in the topical treatment of\r\nnonsegmental vitiligo in adult and pediatric patients 12 years of age and\r\nolder.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration:</strong> <o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Administration Instruction:</strong> Ruxolitinib cream should not use more than 60 gram\r\nper week or 100 gram per 2 weeks. It is for topical use only. It is not for\r\nintraocular, oral, or intravaginal use.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Recommended Dosage for Atopic\r\nDermatitis:</strong> Patients should apply a\r\nthin layer of Ruxolitinib twice daily to affected areas of up to 20% body\r\nsurface area. When signs and symptoms (e.g., itch, rash, and redness) of atopic\r\ndermatitis resolve it should be stopped. If signs and symptoms do not improve\r\nwithin 8 weeks, patients should be re-examined by registered doctor. <strong>Recommended Dosage for Nonsegmental\r\nVitiligo:</strong> Patients should apply a thin layer of Ruxolitinib twice daily to\r\naffected areas of up to 10% body surface area. Satisfactory patient response\r\nmay require treatment with<strong> </strong>Ruxolitinib\r\nfor more than 24 weeks. If the patient does not find the repigmentation\r\nmeaningful by 24 weeks, the patient should be re-evaluated by registered\r\ndoctor.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and Lactation:</strong> Because of the serious adverse findings in adults,\r\nincluding risks of serious infections, thrombocytopenia, anemia, and\r\nneutropenia, women should not breastfeed during treatment with Ruxolitinib and\r\nfor approximately four weeks after the last dose.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: </strong>Each tube contains 15 gm cream.<o></o></p>",
    "strength": "15",
    "uom": "gm(IV)",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1678338616Rutinib Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1678338616Rutinib Carton.png"
    ]
  },
  {
    "id": "1802",
    "name": "Rutinib-10",
    "description": "<p><strong>Composition: </strong>Each\r\ntablet contains Ruxolitinib 10mg as Ruxolitinib Phosphate INN.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications:</strong> <strong>Myelofibrosis:</strong>\r\nIt is indicated for treatment of patients with intermediate or high-risk\r\nmyelofibrosis (MF), including primary MF, post-polycythemia vera MF and\r\npost-essential thrombocythemia MF.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Polycythemia Vera:</strong> Ruxolitinib is indicated for treatment of\r\npatients with polycythemia vera (PV) who have had an inadequate response to or\r\nare intolerant of hydroxyurea.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage\r\nand Administration: </strong><strong>Myelofibrosis:\r\n</strong>The recommended starting dose of Ruxolitinib is based on platelet count. </p>\r\n\r\n<div align=\"center\">\r\n\r\n<table class=\"MsoTableGrid\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\" style=\"margin-left: 5.4pt;\">\r\n <tbody><tr>\r\n  <td width=\"390\" colspan=\"2\" valign=\"top\" style=\"width: 292.5pt; border-width: 1pt; border-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Ruxolitinib Starting Doses for Myelofibrosis<o:p></o:p></strong></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"210\" valign=\"top\" style=\"width: 157.5pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Platelet Count<o:p></o:p></strong></p>\r\n  </td>\r\n  <td width=\"180\" valign=\"top\" style=\"width: 135pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Starting Dose<o:p></o:p></strong></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"210\" valign=\"top\" style=\"width: 157.5pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">Greater than 200 X 10<sup>9</sup>/L</p>\r\n  </td>\r\n  <td width=\"180\" valign=\"top\" style=\"width: 135pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">20 mg orally twice daily</p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"210\" valign=\"top\" style=\"width: 157.5pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">100 X 10<sup>9</sup>/L to 200 X\r\n  10<sup>9</sup>/L</p>\r\n  </td>\r\n  <td width=\"180\" valign=\"top\" style=\"width: 135pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">15 mg orally twice daily</p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"210\" valign=\"top\" style=\"width: 157.5pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">50 X 10<sup>9</sup>/L to less\r\n  than 100 X 10<sup>9</sup>/L</p>\r\n  </td>\r\n  <td width=\"180\" valign=\"top\" style=\"width: 135pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">5 mg orally twice daily</p>\r\n  </td>\r\n </tr>\r\n</tbody></table>\r\n\r\n</div>\r\n\r\n<p style=\"margin:0in;margin-bottom:.0001pt;text-align:justify\"><strong>Polycythemia Vera:</strong> The recommended\r\nstarting dose of Ruxolitinib is 10 mg twice daily. Doses may be titrated based\r\non safety and efficacy. Or as directed by the registered physician.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"> </p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Use\r\nin Pregnancy and Lactation: </strong>There are no adequate and\r\nwell-controlled studies in pregnant women. Nursing mother: It is not known\r\nwhether Ruxolitinib is excreted in human milk. Because many drugs are excreted\r\nin human milk, breastfeeding should be discontinued during treatment with\r\nRuxolitinib and for two weeks after the final dose.</p>\r\n\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><o:p> </o:p></p>\r\n\r\n<p><strong>Packing: </strong>Each\r\nbox contains 30’s tablets in a Container.</p>",
    "strength": " 10",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1637660650Rutinib-10 - Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1637660650Rutinib-10 Carton.png"
    ]
  },
  {
    "id": "1769",
    "name": "Rutinib-5",
    "description": "<p class=\"MsoNormal\">组成：每片含磷酸鲁索利替尼5mg。</p><p class=\"MsoNormal\">作用机制：激酶抑制剂Ruxolitinib抑制Janus<a name=\"_GoBack\"></a>相关激酶JAK1和JAK2，JAK1和JAK2介导对造血和免疫功能重要的多种细胞因子和生长因子的信号传导。JAK信号涉及到STATs（信号转导子和转录激活子）向细胞因子受体的募集、激活和随后定位到细胞核导致基因表达的调节。骨髓纤维化（MF）是一种骨髓增生性肿瘤（MPN），已知与JAK1和JAK2信号失调有关。口服ruxolitinib可预防脾肿大，优先减少脾脏中的JAK2V617F突变细胞，并减少循环炎性细胞因子（如TNF-α、IL-6）。</p><p class=\"MsoNormal\">药代动力学：</p><p class=\"MsoNormal\">吸收：口服Ruxolitinib后，Ruxolitinib迅速被吸收，给药后1至2小时内达到最大血浆浓度（Cmax）。鲁索替尼的口服吸收率估计至少为95%。分布：在骨髓纤维化患者的MF和PV患者中，稳态下鲁索替尼的平均分布体积为72\r\nL。半衰期：鲁索替尼及其代谢物的平均半衰期约为5.8小时。消除半衰期：ruxolitinib的平均消除半衰期约为3小时AUC：ruxolitinib的平均Cmax和总暴露量（AUC）在5-200mg的单剂量范围内成比例增加。血浆蛋白结合率97%，主要与白蛋白结合。代谢：鲁索替尼由CYP3A4代谢，在较小程度上由CYP2C9代谢。排泄：健康成人受试者单剂量口服放射性标记的ruxolitinib后，排泄主要通过代谢进行，74%的放射性通过尿液排出，22%通过粪便排出。未改变的药物占排泄总放射性活度的不到1%</p><p class=\"MsoNormal\">适应症：</p><p class=\"MsoNormal\">骨髓纤维化：Ruxolitinib适用于治疗中度或高危骨髓纤维化（MF），包括成人原发性MF、真性红细胞增多症后MF和原发性血小板增多症后MF。</p><p class=\"MsoNormal\">真性红细胞增多症：对于对羟基脲反应不足或不能耐受的成人，Ruxolitinib适用于治疗真性红细胞增多症（PV）。</p><p class=\"MsoNormal\">急性移植物抗宿主病：Ruxolitinib用于治疗12岁及以上的成人和儿童类固醇难治性急性移植物抗宿主病（GVHD）。</p><p class=\"MsoNormal\">剂量和给药：</p><p class=\"MsoNormal\">骨髓纤维化：建议的Ruxolitinib起始剂量基于血小板计数。开始治疗前，必须每2至4周进行一次全血计数（CBC）和血小板计数，直到剂量稳定，然后根据临床指示进行。剂量可根据安全性和有效性进行滴定。</p><table class=\"MsoNormalTable\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\">\r\n <tbody><tr xss=\"removed\">\r\n  <td colspan=\"2\" xss=\"removed\" width=\"314\" valign=\"top\">\r\n  <p class=\"TableParagraph\" xss=\"removed\">Ruxolitinib治疗骨髓纤维化的剂量</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"157\" valign=\"top\">\r\n  <p class=\"TableParagraph\">血小板计数</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"157\" valign=\"top\">\r\n  <p class=\"TableParagraph\" xss=\"removed\">立桩剂量</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"157\" valign=\"top\">\r\n  <p class=\"TableParagraph\" xss=\"removed\">大于200X10°/L</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"157\" valign=\"top\">\r\n  <p class=\"TableParagraph\" xss=\"removed\">20毫克口服，每日两次</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"157\" valign=\"top\">\r\n  <p class=\"TableParagraph\" xss=\"removed\">100X10°/L到200X10\"/L</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"157\" valign=\"top\">\r\n  <p class=\"TableParagraph\" xss=\"removed\">15mg口服，每日两次</p>\r\n  </td>\r\n </tr>\r\n <tr xss=\"removed\">\r\n  <td xss=\"removed\" width=\"157\" valign=\"top\">\r\n  <p class=\"TableParagraph\" xss=\"removed\">50X10\"/L到小于100X10\"/L</p>\r\n  </td>\r\n  <td xss=\"removed\" width=\"157\" valign=\"top\">\r\n  <p class=\"TableParagraph\" xss=\"removed\">5毫克口服，每日两次</p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\">真性红细胞增多症：建议的开始剂量为10毫克，每天两次。剂量可根据安全性和有效性进行滴定。如果血红蛋白计数8小于12克/分升，血小板计数50小于75\r\nX 10“L，考虑将剂量减少到5毫克，每天两次。</p><p class=\"MsoNormal\">急性移植物抗宿主病：建议剂量为5毫克，每日两次。如果ANC和血小板计数相对于ruxolitinib给药的第一天没有减少50%或更多，考虑在至少治疗3天后增加剂量至10mg，每天两次。或按照注册医生的指示。</p><p class=\"MsoNormal\">副作用：最常见的副作用是:</p><p class=\"MsoNormal\">•血小板减少、贫血和中性粒细胞减少</p><p class=\"MsoNormal\">•感染、瘀伤、头晕、头痛的风险</p><p class=\"MsoNormal\">•Ruxolitinib治疗中断或中断后症状恶化</p><p class=\"MsoNormal\">非黑色素瘤皮肤癌</p><p class=\"MsoNormal\">禁忌症：对鲁索替尼或本品任何其他成分有过敏史的患者禁用。</p><p class=\"MsoNormal\">妊娠期和哺乳期使用：目前还没有针对孕妇的充分和良好的对照研究。奶妈：不知道鲁索利替尼是否在母乳中排出。由于许多药物是从母乳中排出的，因此在使用鲁索替尼治疗期间和最后一次给药后的两周内，应停止母乳喂养。</p><p class=\"MsoNormal\">在儿童中的应用：Ruxolitinib在儿童患者中的安全性和有效性尚未确定。</p><p class=\"MsoNormal\">药物相互作用：</p><p class=\"MsoNormal\">氟康唑：由于抑制CYP3A4和CYP2C9代谢途径，每天服用超过200mg的鲁索替尼可能会增加鲁索替尼的暴露。增加接触可能增加接触相关不良反应的风险。除急性移植物抗宿主病患者外，避免同时使用鲁索利替尼和氟康唑（每日剂量大于200毫克）。</p><p class=\"MsoNormal\">强效CYP3A4抑制剂：与强效CYP3A4抑制剂同时服用鲁索替尼会增加鲁索替尼的暴露。增加接触可能增加接触相关不良反应的风险。当使用强效CYP3A4抑制剂给药时，考虑减少剂量。在急性移植物抗宿主病患者中，只有与酮康唑合用时，才按建议减少鲁索替尼的剂量，与伊曲康唑合用时，更频繁地监测血细胞计数是否有毒性，必要时调整剂量。</p><p class=\"MsoNormal\">强CYP3A4诱导剂：与强CYP3A4诱导剂同时施用鲁索替尼可减少鲁索替尼暴露。不建议调整剂量；但是，应经常监测患者，并根据安全性和有效性调整Ruxolitinib的剂量。</p><p class=\"MsoNormal\">注意事项：</p><p class=\"MsoNormal\">血小板减少、贫血和中性粒细胞减少症：用鲁索替尼治疗可引起血小板减少、贫血和中性粒细胞减少症。通过减少剂量或暂时中断Ruxolitinib治疗血小板减少症。血小板输注</p><p class=\"MsoNormal\">可能是必要的。出现贫血的患者可能需要输血和/或调整鲁索利替尼的剂量。严重的中性粒细胞减少症（ANC小于0.5 X\r\n109/L）通常可以通过停止使用鲁索利替尼直到痊愈而逆转。每2到4周进行一次治疗前全血计数（CBC）并监测CBC，直到剂量稳定，然后根据临床指示。</p><p class=\"MsoNormal\">感染风险：已发生严重的细菌、分枝杆菌、真菌和病毒感染。延迟使用鲁索替尼开始治疗，直到活动性严重感染得到解决。观察接受鲁索利替尼治疗的患者的感染症状和体征，并及时处理。</p><p class=\"MsoNormal\">肺结核：据报道，接受鲁索替尼治疗的患者有肺结核感染。观察接受鲁索替尼治疗的患者是否有活动性肺结核的症状和体征，并及时处理。在开始使用鲁索替尼治疗前，应评估患者是否有肺结核的危险因素，对高危患者应进行潜伏感染检测。危险因素包括但不限于以前在结核病高发国家居住或旅行、与活动性肺结核患者密切接触、有活动性或潜伏性肺结核病史且不能确定适当的疗程。对于有活动性或潜伏性肺结核证据的患者，在开始使用Ruxolitinib之前，咨询一位有结核病治疗经验的医生。在活动性肺结核的治疗过程中继续使用鲁索利替尼的决定应基于总体风险效益的确定。</p><p class=\"MsoNormal\">进行性多灶性白质脑病：进行性多灶性白质脑病（PML）发生在Ruxolitinib治疗。如果怀疑PML，停止鲁索替尼并进行评估。</p><p class=\"MsoNormal\">带状疱疹建议患者有关带状疱疹的早期症状和体征，如果怀疑，应尽早寻求治疗。</p><p class=\"MsoNormal\">乙型肝炎病毒载量（HBV-DNA滴度）增加，伴随或不伴随丙氨酸转氨酶和天冬氨酸转氨酶升高，在慢性HBV感染患者服用鲁索替尼的报道。Ruxolitinib对慢性HBV感染患者病毒复制的影响尚不清楚。慢性HBV感染者应根据临床指南进行治疗和监测。</p><p class=\"MsoNormal\">中断或中止鲁索替尼治疗后症状恶化在中断鲁索替尼治疗后，骨髓增生性肿瘤的症状可能在大约一周内恢复到预处理水平。一些MF患者在停用Ruxolitinib后出现以下一种或多种不良事件：发热、呼吸窘迫、低血压、DIC或多器官衰竭。如果其中一个或多个发生在停止使用或逐渐减少剂量的鲁索替尼后，评估和治疗任何并发疾病，并考虑重新开始或增加剂量的鲁索替尼。指导患者在未咨询医生的情况下不要中断或中止鲁索利替尼治疗。当因血小板减少或中性粒细胞减少以外的原因停止或中断鲁索替尼治疗时，考虑逐渐减少鲁索替尼的剂量，而不是突然停止。</p><p class=\"MsoNormal\">非黑色素瘤皮肤癌-非黑色素瘤皮肤癌包括基底细胞癌、鳞状细胞癌和Merkel细胞癌都发生在使用Ruxolitinib治疗的患者中。定期进行皮肤检查。</p><p class=\"MsoNormal\">Ruxolitinib治疗的血脂升高与包括总胆固醇、低密度脂蛋白（LDL）胆固醇和甘油三酯在内的血脂参数升高有关。这些脂质参数升高对心血管疾病发病率和死亡率的影响尚未确定。在开始Ruxolitinib治疗后大约8-12周评估脂质参数。根据高脂血症管理的临床指南进行监测和治疗。</p><p class=\"MsoNormal\">过量服用：目前还没有已知的解毒剂过量使用鲁索替尼。单次给药200mg，急性耐受性可接受。高于推荐的重复剂量与骨髓抑制增加有关，包括白细胞减少、贫血和血小板减少。应给予适当的支持治疗。血液透析并不能促进鲁索替尼的清除。</p><p class=\"MsoNormal\">贮存：30℃以下贮存° 在干燥的地方，远离阳光。放置在儿童接触不到的地方。包装：每盒含50片泡罩包装。</p>",
    "strength": "5",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1625134867Rutinib 5mg 50 Tablet- Carton Pic.png"
    ]
  },
  {
    "id": "1801",
    "name": "Rutinib-5",
    "description": "<p><strong>Composition: </strong>Each\r\ntablet contains Ruxolitinib 5mg as Ruxolitinib Phosphate INN.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications:</strong> <strong>Myelofibrosis:</strong>\r\nIt is indicated for treatment of patients with intermediate or high-risk\r\nmyelofibrosis (MF), including primary MF, post-polycythemia vera MF and\r\npost-essential thrombocythemia MF.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Polycythemia Vera:</strong> Ruxolitinib is indicated for treatment of\r\npatients with polycythemia vera (PV) who have had an inadequate response to or\r\nare intolerant of hydroxyurea.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage\r\nand Administration: </strong><strong>Myelofibrosis:\r\n</strong>The recommended starting dose of Ruxolitinib is based on platelet count. </p><table class=\"MsoTableGrid\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\" style=\"margin-left: 5.4pt;\">\r\n <tbody><tr>\r\n  <td width=\"390\" colspan=\"2\" valign=\"top\" style=\"width: 292.5pt; border-width: 1pt; border-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Ruxolitinib Starting Doses for Myelofibrosis<o:p></o:p></strong></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"210\" valign=\"top\" style=\"width: 157.5pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Platelet Count<o:p></o:p></strong></p>\r\n  </td>\r\n  <td width=\"180\" valign=\"top\" style=\"width: 135pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Starting Dose<o:p></o:p></strong></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"210\" valign=\"top\" style=\"width: 157.5pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">Greater than 200 X 10<sup>9</sup>/L</p>\r\n  </td>\r\n  <td width=\"180\" valign=\"top\" style=\"width: 135pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">20 mg orally twice daily</p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"210\" valign=\"top\" style=\"width: 157.5pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">100 X 10<sup>9</sup>/L to 200 X\r\n  10<sup>9</sup>/L</p>\r\n  </td>\r\n  <td width=\"180\" valign=\"top\" style=\"width: 135pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">15 mg orally twice daily</p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"210\" valign=\"top\" style=\"width: 157.5pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">50 X 10<sup>9</sup>/L to less\r\n  than 100 X 10<sup>9</sup>/L</p>\r\n  </td>\r\n  <td width=\"180\" valign=\"top\" style=\"width: 135pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"MsoNormal\" style=\"text-align:justify\">5 mg orally twice daily</p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p style=\"margin:0in;margin-bottom:.0001pt;text-align:justify\"><strong>Polycythemia Vera:</strong> The recommended\r\nstarting dose of Ruxolitinib is 10 mg twice daily. Doses may be titrated based\r\non safety and efficacy. Or as directed by the registered physician.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Use\r\nin Pregnancy and Lactation: </strong>There are no adequate and\r\nwell-controlled studies in pregnant women. Nursing mother: It is not known\r\nwhether Ruxolitinib is excreted in human milk. Because many drugs are excreted\r\nin human milk, breastfeeding should be discontinued during treatment with\r\nRuxolitinib and for two weeks after the final dose.</p><p><strong>Packing: </strong>Each\r\nbox contains 50’s tablets in blister pack.</p>",
    "strength": " 5",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1637660249Rutinib-5 - Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1637660249Rutinib-5 Carton.png"
    ]
  },
  {
    "id": "1806",
    "name": "Savatril",
    "description": "<p><span class=\"markedcontent\"><strong>Composition:</strong></span><span class=\"markedcontent\">\r\nSavatril-50: Each film coated tablet contains Sacubitril INN 24 mg &\r\nValsartan USP 26 mg.</span></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal;tab-stops:423.0pt\"><span class=\"markedcontent\"><strong>Indications:</strong></span><span class=\"markedcontent\">Sacubitril\r\n/ Valsartan combination is indicated to reduce the risk of cardiovascular death\r\nand hospitalization for heart failure in adult patients with chronicheart\r\nfailure and reduced left ventricular ejection fraction. For the treatment of\r\nsymptomatic heart failure with systemic </span><span class=\"markedcontent\">left ventricular systolic dysfunction in pediatric\r\npatients aged one year and older. It reduces NT-proBNP and is expected to\r\nimprove cardiovascular outcome.<o:p></o:p></span></p><p class=\"Default\"><strong>Dosage and administration:\r\n<o:p></o:p></strong></p><table class=\"MsoTableGrid\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"613\" style=\"width: 459.9pt;\">\r\n <tbody><tr style=\"mso-yfti-irow:0;mso-yfti-firstrow:yes;height:15.9pt\">\r\n  <td width=\"175\" rowspan=\"2\" valign=\"top\" style=\"width: 131.4pt; border-width: 1pt; border-color: black; padding: 0in 5.4pt; height: 15.9pt;\">\r\n  <p class=\"Default\" align=\"center\" style=\"text-align:center\"><strong>Indication<o:p></o:p></strong></p>\r\n  </td>\r\n  <td width=\"438\" colspan=\"3\" valign=\"top\" style=\"width: 328.5pt; border-top-width: 1pt; border-top-color: black; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt; height: 15.9pt;\">\r\n  <p class=\"Default\" align=\"center\" style=\"text-align:center\"><strong>Titration Step Dose (Twice Daily)<o:p></o:p></strong></p>\r\n  </td>\r\n </tr>\r\n <tr style=\"mso-yfti-irow:1;height:12.5pt\">\r\n  <td width=\"96\" valign=\"top\" style=\"width: 1in; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt; height: 12.5pt;\">\r\n  <p class=\"Default\" align=\"center\" style=\"text-align:center\"><strong>Starting<o:p></o:p></strong></p>\r\n  </td>\r\n  <td width=\"192\" valign=\"top\" style=\"width: 2in; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt; height: 12.5pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\"><strong>second<o:p></o:p></strong></p>\r\n  </td>\r\n  <td width=\"150\" valign=\"top\" style=\"width: 112.5pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt; height: 12.5pt;\">\r\n  <p class=\"MsoNormal\" align=\"center\" style=\"margin-bottom:0in;margin-bottom:.0001pt;\r\n  text-align:center;line-height:normal\"><strong>Final<o:p></o:p></strong></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"175\" valign=\"top\" style=\"width: 131.4pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"Default\"><strong>Adult Heart Failure<o:p></o:p></strong></p>\r\n  </td>\r\n  <td width=\"96\" valign=\"top\" style=\"width: 1in; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"Default\" align=\"center\" style=\"text-align:center\">49/51 mg<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"342\" colspan=\"2\" valign=\"top\" style=\"width: 256.5pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"Default\" align=\"center\" style=\"text-align:center\">97/103 mg<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"175\" valign=\"top\" style=\"width: 131.4pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"Default\"><strong>Pediatric </strong><strong>Heart Failure</strong><strong> at least 40 kg, less than 50kg</strong></p>\r\n  </td>\r\n  <td width=\"96\" valign=\"top\" style=\"width: 1in; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"Default\" align=\"center\" style=\"text-align:center\">24/26 mg<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"192\" valign=\"top\" style=\"width: 2in; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"Default\" align=\"center\" style=\"text-align:center\">49/51 mg<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"150\" valign=\"top\" style=\"width: 112.5pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"Default\" align=\"center\" style=\"text-align:center\">72/78 mg <o:p></o:p></p>\r\n  <p class=\"Default\" align=\"center\" style=\"text-align:center\">(Three 24/26 mg Tablet)<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width=\"175\" valign=\"top\" style=\"width: 131.4pt; border-right-width: 1pt; border-bottom-width: 1pt; border-left-width: 1pt; border-right-color: black; border-bottom-color: black; border-left-color: black; border-top: none; padding: 0in 5.4pt;\">\r\n  <p class=\"Default\"><strong>Pediatric </strong><strong>Heart Failure</strong><strong> at least 50kg</strong></p>\r\n  </td>\r\n  <td width=\"96\" valign=\"top\" style=\"width: 1in; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"Default\" align=\"center\" style=\"text-align:center\">49/51  mg<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"192\" valign=\"top\" style=\"width: 2in; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: windowtext; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"Default\" align=\"center\" style=\"text-align:center\">72/78 mg <o:p></o:p></p>\r\n  <p class=\"Default\" align=\"center\" style=\"text-align:center\">(Three 24/26 mg Tablet)<o:p></o:p></p>\r\n  </td>\r\n  <td width=\"150\" valign=\"top\" style=\"width: 112.5pt; border-top: none; border-left: none; border-bottom-width: 1pt; border-bottom-color: black; border-right-width: 1pt; border-right-color: black; padding: 0in 5.4pt;\">\r\n  <p class=\"Default\" align=\"center\" style=\"text-align:center\">97/103 mg<o:p></o:p></p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"Default\"><strong> </strong><br></p><p class=\"Default\"><strong> </strong></p><p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;\r\ntext-align:justify;line-height:normal;tab-stops:423.0pt\">Adjust adult dose every 2 to 4 weeks and pediatric doses every\r\n2weeks to the target maintainance dose, as tolerated by the patient. <strong>Reduce\r\nthe starting dose to 50 mg twice-daily for:</strong>\r\npatients not currently taking an angiotensin-converting enzyme inhibitor (ACE)\r\nor an angiotensin II receptor blocker (ARB) or previously taking a low dose of\r\nthese agents, patients with severe renal impairment and with moderate hepatic\r\nimpairment. Or, as directed by the registered physician.<br></p><p class=\"MsoNormal\"><span class=\"markedcontent\"><strong>Precautions:</strong></span><span class=\"markedcontent\"> </span>Most common adverse reactions include angioedema, hypotension,\r\nhyperkalemia, cough, dizziness, and renal failure.</p><p class=\"MsoNormal\"><o:p></o:p></p><p class=\"MsoNormal\"><span class=\"markedcontent\"><strong>Pregnancy and Lactation:</strong> Sacubitril/valsartan can cause fetal harm when\r\nadministered to a pregnant woman. Because of the potential for serious adverse\r\nreactions in breastfed infants breastfeeding is not recommended during\r\ntreatment with sacubitril/valsartan. <br></span></p><p><span class=\"markedcontent\"><strong>Packing:</strong></span><span class=\"markedcontent\"> Savatril-50 : Each box contains 1 x 10's tablets in\r\na blister pack.</span></p>",
    "strength": " 50",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1637664182Savatril.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744101212Savatril-50.png"
    ]
  },
  {
    "id": "946",
    "name": "Seacal - D",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong><strong> </strong><strong>Seacal-D\r\nTablet : </strong>Each film coated tablet contains Calcium Carbonate (from Coral\r\nsource) BP 1250 mg eq. to 500 mg of elemental Calcium and Vitamin D3 BP 200 IU.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indication :</strong>This combination medication is used to\r\nprevent or treat conditions caused by low calcium levels such as bone loss\r\n(osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the\r\nparathyroid gland (hypoparathyroidism), and a certain muscle disease (latent\r\ntetany). It may also be used in certain patients to make sure they are getting\r\nenough calcium (e.g., women who are pregnant, nursing, or postmenopausal, people\r\ntaking certain medications such as phenytoin, phenobarbital, or prednisone).Vitamin\r\nD helps the patient's body to absorb calcium and phosphorus.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage and administration :</strong><strong> </strong>One\r\ntablet once or twice daily with plenty of water.Taking in full stomach ensures\r\nbetter absorption. Or, as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use in pregnancy and lactation :</strong><strong> </strong>Can\r\nbe given to pregnant and lactating mothers as per recommendation of physician.<o:p></o:p></p><p><strong>Packing :</strong><strong> </strong><strong>Seacal-D\r\nTablet : </strong>Each box contains 4 x 7's tablets in blister pack.<br></p>",
    "strength": "500+200",
    "uom": "gm(IV)",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1634029793Seacal D Book Style  Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209880Seacal-D.png"
    ]
  },
  {
    "id": "1302",
    "name": "Seacal - DX",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition : </strong><strong>Seacal-DX : </strong>Each film coated\r\ntablet contains Calcium Carbonate (from coral source) BP 1500 mg eq. to\r\nelemental Calcium 600 mg and Vitamin D3 BP 400 IU as Colecalciferol.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications : </strong>This tablet is indicated in the\r\ntreatment and prevention of osteoporosis,rickets, osteomalacia, tetany and\r\nparathyroid disease. It is also used as phosphate binder in chronic renal\r\nfailure, during therapy with antiseizure medications, in the prevention and treatment\r\nof calcium and vitamin D3 deficiency specially in the elderly patients.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage and administration :</strong><strong> </strong>2\r\ntablets per day,\r\npreferably one tablet in the morning and the other in the evening with plenty\r\nof water Or, as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use in Pregnancy and Lactation : </strong>This tablet can\r\nbe given to pregnant and lactating mothers as per recommendation of registered\r\n.<o:p></o:p></p><p><strong>Packing :</strong><strong> </strong><strong>Seacal-DX : </strong>Each box contains 4 x7's\r\ntablets in blister pack.<br></p><p><br></p><p><br></p><p><br></p>",
    "strength": "1250+600",
    "uom": "mg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1634030008Seacal DX book style  Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209864Seacal-DX.png"
    ]
  },
  {
    "id": "780",
    "name": "SEFANID  Suspension",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Cefadroxil USP 125mg/5ml Suspension</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Cefadroxil is indicated for\r\nthe treatment of patients with urinary\r\ntract infection caused by Escherichia\r\ncoli, Proteus mirabilis and Klebsiella\r\nspecies. Skin and skin structure\r\ninfections caused by staphylococci,\r\nPharyngitis and Tonsillitis caused by\r\nstreptococcus pyogenes (Group A betahemolytic\r\nstreptococci).</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Administered orally and with food.\r\nAdults : Urinary Tract Infections : The\r\nusual dosage is 1gm  or\r\n2gm  per day in single or\r\ndivided doses.\r\nSkin and Skin Structure Infections :\r\nThe usual dosage is 1gm\r\nper day in single or divided doses.\r\nPharyngitis and Tonsillitis : The usual\r\ndosage is 1gm per day in\r\nsingle or divided doses.\r\nFor urinary tract infections, the\r\nrecommended daily dosage for children\r\nis 30mg/kg/day in divided doses every\r\n12 hours.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Cefadroxil has been assigned to\r\npregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong> <span class=\"redactor-invisible-space\">\r\nSefanid Suspension : 100ml\r\nSuspension.</span></p>",
    "strength": "125",
    "uom": "mg/5ml",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1669801898Sefanid Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/sefanid_sus.jpg"
    ]
  },
  {
    "id": "1255",
    "name": "Sefanid Capsule",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Cefadroxil USP 500mg Capsule.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Cefadroxil is indicated for the treatment of patients with urinary tract infection caused by Escherichia coli, Proteus mirabilis and Klebsiella species. Skin and skin structure infections caused by staphylococci, Pharyngitis and Tonsillitis caused by streptococcus pyogenes (Group A betahemolytic streptococci).</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Administered orally and with food. Adults : Urinary Tract Infections : The usual dosage is 1gm (2 capsules) or 2gm (4-capsules) per day in single or divided doses. Skin and Skin Structure Infections : The usual dosage is 1gm (2 capsules) per day in single or divided doses. Pharyngitis and Tonsillitis : The usual dosage is 1gm (2 capsules) per day in single or divided doses. For urinary tract infections, the recommended daily dosage for children is 30mg/kg/day in divided doses every 12 hours.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Cefadroxil has been assigned to pregnancy category B by the FDA.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong> <span class=\"redactor-invisible-space\" xss=\"removed\">Sefanid Capsule : 3 x10</span>'s capsules in blister pack.</p>",
    "strength": "500",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1669801770Sefanid Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Sefanid-Carton.jpg"
    ]
  },
  {
    "id": "803",
    "name": "Semecon",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Simethicone USP 67mg/ml\r\nPaediatric Drop.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong><span class=\"redactor-invisible-space\"> Flatulence,\r\nabdominal distention, fullness, gas and\r\nwindy colic: Semecon is an excellent and\r\neffective antiflatulent. It is used for relief\r\nof the painful symptoms of excess gas in\r\nthe digestive tract. Semecon drop is\r\nespecially used in infants. Large bowel preparation : Addition of\r\nSemecon to a polyethylene glycol bowel\r\npreparation produces symptomatic\r\nimprovement prior to investigation in\r\npatients undergoing colonoscopy. Treatment of poisoning : Semecon has\r\nan anecdotal use as an antifoaming\r\nagent in the management of accidental\r\ningestion of foaming detergents.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Take after\r\nmeals and at bedtime. Can be given with\r\ninfant's feeds. Shake the bottle well\r\nbefore each use.\r\nChildren less than 2 years of age : 20mg\r\n(0.3ml Semecon drops) 4 times daily up\r\nto 240mg (3.6ml Semecon drops)/day.\r\nChildren 2 - 12 years of age : 40mg\r\n(0.6ml Semecon drops) 4 times daily.\r\nAdults : 40 - 80mg (0.6 - 1.2ml Semecon\r\ndrops) 4 times daily, up to 500mg (7.5ml\r\nSemecon drops)/day.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Administration of drugs during pregnancy and lactation should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus or child. There is insufficient experience of the use of Salmeterol Xinafoate and Fluticasone Propionate in human pregnancy and lactation. There are no data available for human breast milk.</p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Semecon Paediatric Drops :\r\n15ml drops with a plastic dropper.</span></p>",
    "strength": "67",
    "uom": "mg/ml",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1531977428Semecon.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744101192Semecon.png"
    ]
  },
  {
    "id": "1347",
    "name": "Seraflo 50/100 Mycap ",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Composition\r\n: Seraflo 50/100 Mycap : </strong>Each Capsule Contains Salmeterol 50mcg as Salmeterol</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\">Xinafoate\r\nBP and Fluticasone Propionate BP 100mcg inhalation powder.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Seraflo\r\n50/250 Mycap :</strong>\r\nEach Capsule Contains Salmeterol 50mcg as Salmeterol\r\nXinafoate BP and Fluticasone Propionate BP\r\n250mcg inhalation powder.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Indications\r\n: Treatment of asthma : </strong>Fluticasone Propionate & Salmeterol Xinafoate\r\ncombination is indicated for the treatment of asthma in patients aged 4 years\r\nand older. It is indicated for patients not adequately controlled on a\r\nlong-term asthma control medication, such as an inhaled corticosteroid or whose\r\ndisease severity clearly warrants initiation of treatment with both an inhaled corticosteroid\r\nand LABA. Once asthma control is achieved and maintained, assess the patient at\r\nregular intervals and step down therapy if possible without loss of asthma\r\ncontrol and maintain the patient on a long-term asthma control medication, such\r\nas an inhaled corticosteroid. It is not indicated for the relief of acute bronchospasm.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Maintenance\r\ntreatment of COPD: </strong>Fluticasone\r\nPropionate & Salmeterol Xinafoate combination is indicated for the\r\nmaintenance treatment of airflow obstruction and to reduce exacerbations in patients\r\nwith chronic obstructive pulmonary disease, including chronic bronchitis or\r\nemphysema.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Dosage\r\nand administration : Asthma</strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Adult\r\nand Adolescent (12 Years and Older) :</strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Seraflo\r\n50/100 Mycap : </strong>1\r\nMycap capsule, twice daily (morning and evening, approximately 12</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">hours apart). The recommended\r\nstarting dosages for Seraflo 50/100 Mycap & Seraflo 50/250 Mycap for\r\npatients aged 12 years and older are based upon patients' asthma severity.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Pediatric\r\nPatients (4 to 11 Years):</strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\">For\r\npatients with asthma who are not controlled on an inhaled corticosteroid, the\r\ndosage is <strong>Seraflo50/100 Mycap : </strong>1 Mycap capsule, twice daily (morning\r\nand evening, approximately 12 hours apart). </p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Chronic\r\nobstructive pulmonary disease :</strong> <strong>Seraflo\r\n50/250 Mycap:</strong> 1 Mycap capsule, twice daily (Morning and evening,\r\napproximately 12 hours apart). Or,  as\r\ndirected by the registered physician. Rinsing  the mouth after each  inhalation is advised.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Use\r\nin Pregnancy and lactation : </strong>Pregnancy category C. There are no adequate\r\nand well</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\">controlled\r\nstudies of this drug in pregnant woman. It should be used during pregnancy only\r\nif the</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\">potential\r\nbenefit justifies the potential risk to the fetus. Caution should be exercised\r\nwhen the drug is administered to a nursing  mothers.</p><p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><strong>Packing\r\n: Seraflo 50/100 Mycap : </strong>Each box contains 3x10's capsules in\r\nAlu-Alu blister pack.</p><p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><strong>Seraflo\r\n50/250 Mycap : </strong>Each box contains 3x10's capsules in\r\nAlu-Alu blister pack.</p>",
    "strength": "50/100",
    "uom": "Mcg",
    "categoryId": "116",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1555574800Seraflo- 50-100, 50-250 Insert Correction.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1636430829Seraflo 50-100.png"
    ]
  },
  {
    "id": "1347",
    "name": "Seraflo 50/100 Mycap ",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Composition\r\n: Seraflo 50/100 Mycap : </strong>Each Capsule Contains Salmeterol 50mcg as Salmeterol</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\">Xinafoate\r\nBP and Fluticasone Propionate BP 100mcg inhalation powder.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Seraflo\r\n50/250 Mycap :</strong>\r\nEach Capsule Contains Salmeterol 50mcg as Salmeterol\r\nXinafoate BP and Fluticasone Propionate BP\r\n250mcg inhalation powder.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Indications\r\n: Treatment of asthma : </strong>Fluticasone Propionate & Salmeterol Xinafoate\r\ncombination is indicated for the treatment of asthma in patients aged 4 years\r\nand older. It is indicated for patients not adequately controlled on a\r\nlong-term asthma control medication, such as an inhaled corticosteroid or whose\r\ndisease severity clearly warrants initiation of treatment with both an inhaled corticosteroid\r\nand LABA. Once asthma control is achieved and maintained, assess the patient at\r\nregular intervals and step down therapy if possible without loss of asthma\r\ncontrol and maintain the patient on a long-term asthma control medication, such\r\nas an inhaled corticosteroid. It is not indicated for the relief of acute bronchospasm.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Maintenance\r\ntreatment of COPD: </strong>Fluticasone\r\nPropionate & Salmeterol Xinafoate combination is indicated for the\r\nmaintenance treatment of airflow obstruction and to reduce exacerbations in patients\r\nwith chronic obstructive pulmonary disease, including chronic bronchitis or\r\nemphysema.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Dosage\r\nand administration : Asthma</strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Adult\r\nand Adolescent (12 Years and Older) :</strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Seraflo\r\n50/100 Mycap : </strong>1\r\nMycap capsule, twice daily (morning and evening, approximately 12</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">hours apart). The recommended\r\nstarting dosages for Seraflo 50/100 Mycap & Seraflo 50/250 Mycap for\r\npatients aged 12 years and older are based upon patients' asthma severity.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Pediatric\r\nPatients (4 to 11 Years):</strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\">For\r\npatients with asthma who are not controlled on an inhaled corticosteroid, the\r\ndosage is <strong>Seraflo50/100 Mycap : </strong>1 Mycap capsule, twice daily (morning\r\nand evening, approximately 12 hours apart). </p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Chronic\r\nobstructive pulmonary disease :</strong> <strong>Seraflo\r\n50/250 Mycap:</strong> 1 Mycap capsule, twice daily (Morning and evening,\r\napproximately 12 hours apart). Or,  as\r\ndirected by the registered physician. Rinsing  the mouth after each  inhalation is advised.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Use\r\nin Pregnancy and lactation : </strong>Pregnancy category C. There are no adequate\r\nand well</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\">controlled\r\nstudies of this drug in pregnant woman. It should be used during pregnancy only\r\nif the</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\">potential\r\nbenefit justifies the potential risk to the fetus. Caution should be exercised\r\nwhen the drug is administered to a nursing  mothers.</p><p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><strong>Packing\r\n: Seraflo 50/100 Mycap : </strong>Each box contains 3x10's capsules in\r\nAlu-Alu blister pack.</p><p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><strong>Seraflo\r\n50/250 Mycap : </strong>Each box contains 3x10's capsules in\r\nAlu-Alu blister pack.</p>",
    "strength": "50/100,50/250",
    "uom": "Mcg",
    "categoryId": "116",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1555574800Seraflo- 50-100, 50-250 Insert Correction.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1636430829Seraflo 50-100.png",
      "https://www.admin.drug-international.com/uploads/product_images/1636430871Seraflo 50-250.png"
    ]
  },
  {
    "id": "1267",
    "name": "SERAFLO HFA Inhaler",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Each metered dose (Puff) contains Salmeterol BP 25 mcg as Salmeterol Xinafoate and Fluticasone Propionate BP 250 mcg.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Indication : </strong>This Inhaler is indicated in the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: Patients not adequately controlled with inhaled corticosteroids and \"as needed\" inhaled short acting beta-2- agonist or, Patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adults and adolescents 12 years and older : Two inhalations of 25 micrograms salmeterol and 250 micrograms fluticasone propionate twice daily. Or as directed by the registered physician.</span><strong><br></strong></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Administration of drugs during pregnancy and lactation should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus or child. There is insufficient experience of the use of Salmeterol Xinafoate and Fluticasone Propionate in human pregnancy and lactation. There are no data available for human breast milk.</span><strong><br></strong></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong> Each box contains one inhaler of 60 & 120 Puffs.</p>",
    "strength": " 50+125,25+250, 25+125,50/100",
    "uom": "mcg/puf",
    "categoryId": "53",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1677995427Seraflo Carton.png",
      "https://www.admin.drug-international.com/uploads/product_images/1517290127seraflo.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1744101170Seraflo.png",
      "https://www.admin.drug-international.com/uploads/product_images/1636430829Seraflo 50-100.png"
    ]
  },
  {
    "id": "743",
    "name": "SERAVENT HFA Inhaler",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Each metered dose\r\n(puff) contains Salmeterol BP 25 mcg as\r\nSalmeterol Xinafoate.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong>  Seravent is indicated for\r\nreversible airways obstruction (including\r\nnocturnal asthma and prevention of\r\nexercise-included bronchospasm) in\r\npatients requiring long term regular\r\nbronchodilator therapy.<br></p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong>  Adults: 50\r\nmicrograms (two puffs) twice daily. More\r\nsevere cases: 100 micrograms (four\r\npuffs) twice daily. Children 5-12 years: 50\r\nmicrograms (two puffs) twice daily. Or, as\r\ndirected by the registered physician.<strong><br></strong></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Each\r\nbox contains one inhaler of 200 Puffs.</span><span></span><br></p>",
    "strength": "25",
    "uom": "mcg/puf",
    "categoryId": "53",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532332472SERAVENT.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/SERAVENT.jpg"
    ]
  },
  {
    "id": "1275",
    "name": "Sertal",
    "description": "<p><strong>Composition : </strong>Sertraline Hydrochloride BP 25 mg, 50 mg & 100 mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indications : </strong>Sertal is indicated for the treatment of symptoms of depressive illness, including accompanying symptoms of anxiety. Following satisfactory response continuation with Sertal therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes, including accompanying symptoms of anxiety.</p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong>Dosage for Adult : Major Depressive Disorder and Obsessive- Compulsive Disorder-Sertal treatment should be administered at a dose of 50mg once daily. Panic Disorder, Posttraumatic Stress Disorder and Social Anxiety Disorder- Sertal treatment should be initiated with a dose of 25mg once daily. After one week, the dose should be increased to 50mg once daily. Prementstrual Dysphoric Disorder- Sertal treatment should be initiated with a dose of 50mg/day, either daily throughout the menstrual cycle or limited to the luteal phase of the menstrual cycle, depending on physician assessment.</p><p style=\"text-align: justify;\"><strong>Dosage for Pediatric Population : </strong>Sertal treatment should be initiated with a dose of 25mg once daily in children (ages 6-12) and at a dose of 50mg once daily in adolescents (ages 13-17). Sertal should be administered once daily, either in the morning or evening. Or as directed by the registered physician.</p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>There are no adequate and well controlled studies in pregnant women, since animal reproduction studies are not always predictive of human response. Sertal should be used during pregnancy only if the perceived benefits outweigh the risks. Limited data concerning sertraline levels in breast milk are available, hence it is not recommended in nursing mother. Pregnancy Category C by FDA.</p><p style=\"text-align: justify;\"><strong>Packing : </strong></p><p style=\"text-align: justify;\">Sertal-25 : 5 x 10's tablets in blister pack.</p><p style=\"text-align: justify;\">Sertal-50 : 5 x 10's tablets in blister pack.</p><p style=\"text-align: justify;\">Sertal-100 : 3 x 10's tablets in blister pack.</p>",
    "strength": "100,50,25",
    "uom": "mg",
    "categoryId": "48",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/15319777085sertal.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209940Sertal-100.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745209940Sertal-50.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745209940Sertal-25.png"
    ]
  },
  {
    "id": "1343",
    "name": "Silofast",
    "description": "<p><strong>Composition\r\n: Silofast-4 : </strong>Each capsule contains Silodosin INN 4 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Silofast-8\r\n: </strong>Each capsule contains Silodosin INN 8 mg.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications\r\n: </strong>Silodosin is a selective alpha-1 adrenergic receptor antagonist,\r\nis indicated for the treatment of the signs and symptoms of benign prostatic\r\nhyperplasia (BPH).<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration : </strong>8 mg capsules taken orally\r\nonce daily with a meal. 4 mg capsules taken orally once daily with a meal for\r\nthose with moderate renal impairment [Creatinine Clearance (CCr) 30-50 mL/min].\r\nOr, as directed by the registerd physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation : </strong>Silodosin is not indicated for\r\nuse in women.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing\r\n: Silofast-4 : </strong>Each box contains 2 x 10's capsules in\r\nblister pack.<o></o></p><p><strong>Silofast-8\r\n: </strong>Each box contains 2 x 10's capsules in blister pack.</p>",
    "strength": "8,4",
    "uom": "mg",
    "categoryId": "46",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1537957076Silofast-Insert1.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745209971Silofast-8.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745209971Silofast-4.png"
    ]
  },
  {
    "id": "1030",
    "name": "Silvec",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition : </strong>Silver\r\nSulfadiazine USP 10mg.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indications : </strong>Silver\r\nSulfadiazine cream is indicated as an adjunct for the prevention and treatment\r\nof wound sepsis in patients with second and thirddegree burns.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and Administration : </strong>After cleaning\r\nand debridement, Silver Sulfadiazine should be applied once to twice daily to a\r\nthickness of approximately 1/16 inches. The cream may be reapplied whenever\r\nnecessary to affected area if it is removed by activity or washing. Dressings\r\nare not required, However, if individual patient requirements make dressings\r\nnecessary, they may be used. Or, as directed by the registered physician.</p><p style=\"text-align: justify;\"><strong>Packing : Silvec Cream : </strong>30 gm in a tube</p>",
    "strength": "1% w/w",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532332556silvec.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745310664Silvec.png"
    ]
  },
  {
    "id": "920",
    "name": "Sixtin",
    "description": "<p><strong></strong><strong>Composition : </strong>Saxagliptin INN 2.5 mg & 5mg Tablet.</p><p style=\"text-align: justify;\"><strong>Indications: </strong> Saxagliptin is a dipeptidyl peptidase-4 (DPP4) inhibitor. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</p><p style=\"text-align: justify;\"><strong>Dosage & Administration: </strong><span class=\"redactor-invisible-space\"></span>The recommended dosage is 2.5 mg or 5mg once daily taken regardless of meals. Patients with renal impairment : No dosage adjustment is required for mild renal impaired Patient. 2.5 mg is taken once daily for patient with moderate or severe renal impairment, or with end-stage renal disease (ESRD) requiring hemodialysis (creatinine clearance [CrC1] &lt;_ 50 mL/min). Saxagliptin should be administered following hemodialysis. Or, as directed by the registered physician.</p><p style=\"text-align: justify;\"><strong>Pregnency & Lactation: </strong>Pregnancy Category-B. There are no adequate and well-controlled studies in pregnant women. It is unknown whether Saxagliptin is secreted in human milk. It should be used with caution during pregnancy & Iactation only if elearly needed.</p><p style=\"text-align: justify;\"><strong>Packing: </strong> Sixtin 2.5 Tablet : 1 x 14's tablets in blister pack.</p><p style=\"text-align: justify;\">Sixtin 5 Tablet : 1 x 14's tablets in blister pack.</p>",
    "strength": "5,2.5",
    "uom": "mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532332607sixtin.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Sixtin-5.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/Sixtin-2.5.jpg"
    ]
  },
  {
    "id": "924",
    "name": "Sliptin - M ",
    "description": "<p><strong>Composition : Sliptin-M 500: </strong>Sitagliptin INN 50 mg +Metformin Hydrochloride USP 500 mg.  <strong></strong></p><p style=\"text-align: justify;\"><strong>Sliptin-M 1000: </strong>Sitagliptin INN 50 mg +Metformin Hydrochloride USP 1000 mg. <strong></strong></p><p style=\"text-align: justify;\"><strong>Indications: </strong>It is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of sitagliptin and metformin as separate tablets.</p><p style=\"text-align: justify;\"><strong>Dosage & Administration: </strong>The dosage should be individualized on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin. This medicine should generally be given twice daily with meals, With gradual dose escalation, to reduce the gastrointestinal (GI) side effects due to metformin. The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin/500 mg metformin hydrochloride twice daily. The starting dose in patients already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken. Or, as directed by total daily dose and the dose of metformin already being taken. Or, asdirected by the registered physician.</p><p style=\"text-align: justify;\"><strong>Use in Pregnency & Lactation: </strong>Sliptin-M has been assigned to pregnancy category B by the FDA.</p><p style=\"text-align: justify;\"><strong>Packing: </strong>Sliptin-M 500 : 2x7's tablets in blister pack.</p><p style=\"text-align: justify;\">Sliptin-M 1000 : 2x7's tablets in blister pack.<span></span></p><p><span class=\"redactor-invisible-space\" xss=\"removed\"></span></p>",
    "strength": "1000,500, 25, 50,100,1000,500",
    "uom": "mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532332743Sliptin-M.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740569561sliptin-M 1000.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569561sliptin-M 500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569502sliptin-25.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569502sliptin-50.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569502sliptin-100.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569592sliptin-M 1000 ER.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569592sliptin-M 500 ER.png"
    ]
  },
  {
    "id": "924",
    "name": "Sliptin - M ",
    "description": "<p><strong>Composition : Sliptin-M 500: </strong>Sitagliptin INN 50 mg +Metformin Hydrochloride USP 500 mg.  <strong></strong></p><p style=\"text-align: justify;\"><strong>Sliptin-M 1000: </strong>Sitagliptin INN 50 mg +Metformin Hydrochloride USP 1000 mg. <strong></strong></p><p style=\"text-align: justify;\"><strong>Indications: </strong>It is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of sitagliptin and metformin as separate tablets.</p><p style=\"text-align: justify;\"><strong>Dosage & Administration: </strong>The dosage should be individualized on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin. This medicine should generally be given twice daily with meals, With gradual dose escalation, to reduce the gastrointestinal (GI) side effects due to metformin. The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin/500 mg metformin hydrochloride twice daily. The starting dose in patients already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken. Or, as directed by total daily dose and the dose of metformin already being taken. Or, asdirected by the registered physician.</p><p style=\"text-align: justify;\"><strong>Use in Pregnency & Lactation: </strong>Sliptin-M has been assigned to pregnancy category B by the FDA.</p><p style=\"text-align: justify;\"><strong>Packing: </strong>Sliptin-M 500 : 2x7's tablets in blister pack.</p><p style=\"text-align: justify;\">Sliptin-M 1000 : 2x7's tablets in blister pack.<span></span></p><p><span class=\"redactor-invisible-space\" xss=\"removed\"></span></p>",
    "strength": "1000,500,1000,500",
    "uom": "mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532332743Sliptin-M.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740569561sliptin-M 1000.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569561sliptin-M 500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569592sliptin-M 1000 ER.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569592sliptin-M 500 ER.png"
    ]
  },
  {
    "id": "924",
    "name": "Sliptin - M ",
    "description": "<p><strong>Composition : Sliptin-M 500: </strong>Sitagliptin INN 50 mg +Metformin Hydrochloride USP 500 mg.  <strong></strong></p><p style=\"text-align: justify;\"><strong>Sliptin-M 1000: </strong>Sitagliptin INN 50 mg +Metformin Hydrochloride USP 1000 mg. <strong></strong></p><p style=\"text-align: justify;\"><strong>Indications: </strong>It is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of sitagliptin and metformin as separate tablets.</p><p style=\"text-align: justify;\"><strong>Dosage & Administration: </strong>The dosage should be individualized on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin. This medicine should generally be given twice daily with meals, With gradual dose escalation, to reduce the gastrointestinal (GI) side effects due to metformin. The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin/500 mg metformin hydrochloride twice daily. The starting dose in patients already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken. Or, as directed by total daily dose and the dose of metformin already being taken. Or, asdirected by the registered physician.</p><p style=\"text-align: justify;\"><strong>Use in Pregnency & Lactation: </strong>Sliptin-M has been assigned to pregnancy category B by the FDA.</p><p style=\"text-align: justify;\"><strong>Packing: </strong>Sliptin-M 500 : 2x7's tablets in blister pack.</p><p style=\"text-align: justify;\">Sliptin-M 1000 : 2x7's tablets in blister pack.<span></span></p><p><span class=\"redactor-invisible-space\" xss=\"removed\"></span></p>",
    "strength": "1000,500,1000,500",
    "uom": "mg",
    "categoryId": "64",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532332743Sliptin-M.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740569561sliptin-M 1000.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569561sliptin-M 500.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569592sliptin-M 1000 ER.png",
      "https://www.admin.drug-international.com/uploads/product_images/1740569592sliptin-M 500 ER.png"
    ]
  },
  {
    "id": "1763",
    "name": "Solina",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><a name=\"_GoBack\"><strong>Composition :</strong></a>Each Film Coated Tablet Contains\r\nSolifenacin Succinate BP 5mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication:</strong>Solifenacin is indicated for the\r\nSymptomatic treatment of urge incontinence and/or increased urinary frequency\r\nand urgency as may occur in patients with overactive bladder syndrome.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and administration</strong> :The recommended dose\r\nfor adults and elderly is Solifenacin Succinate 5 mg once daily. If needed, the\r\ndose may be increased to Solifenacin Succinate 10 mg once daily.Or, as directed\r\nby the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation\r\n: </strong>Pregnancy Category-C. There are no\r\nadequate and well-controlled studies in pregnant women. Baclofen should be used\r\nduring pregnancy only if the potential benefit justifies the potential risk to\r\nthe fetus. It is not known whether this drug is excreted in human milk. Because\r\nmany drugs are excreted in human milk, caution should be exercised when\r\nbaclofen is administered to a nursing woman.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing :</strong><span></span></p><p class=\"MsoNormal\" xss=\"removed\">Solina-5 : Each Box Contains 1x14's\r\ntablets in blister pack.</p>",
    "strength": " 10,5",
    "uom": "mg",
    "categoryId": "111",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1634623910Solina 10 Carton.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745210095Solina-5.png"
    ]
  },
  {
    "id": "1866",
    "name": "Solung",
    "description": "<p><strong>Composition: </strong>Each film coated tablet contains Sotorasib INN 120mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>It is an inhibitor of the RAS GTPase family indicated\r\nfor the treatment of adult patients with KRAS G12C-mutated locally advanced or\r\nmetastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved\r\ntest, who have received at least one prior systemic therapy. (1) This\r\nindication is approved under accelerated approval based on overall response\r\nrate (ORR) and duration of response (DOR). Continued approval for this\r\nindication may be contingent upon verification and description of clinical\r\nbenefit in a confirmatory trial(s).<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and\r\nadministration: </strong>The recommended\r\ndosage of Sotorasib is 960 mg (eight 120 mg tablets) orally once daily until\r\ndisease progression or unacceptable toxicity. Sotorasib should be taken at the\r\nsame time each day with or without food. Whole tablet should be swallowed. It\r\nshould not be chewed, or crushed. If a dose of Sotorasib is missed by more than\r\n6 hours, The next dose should take as prescribed the next day. Do not take 2\r\ndoses at the same time to make up for the missed dose. If vomiting occurs after\r\ntaking Sotorasib, do not take an additional dose. Take the next dose as\r\nprescribed the next day.<o></o></p><p class=\"MsoNormal\" align=\"center\" xss=\"removed\"><strong>Recommended </strong><strong>Sotorasib Dose Reduction Levels for\r\nAdverse Reactions</strong><o></o></p><table class=\"MsoNormalTable\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"527\" xss=\"removed\">\r\n <tbody><tr>\r\n  <td width=\"50%\" xss=\"removed\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong>Dose Reduction Level<o></o></strong></p>\r\n  </td>\r\n  <td width=\"50%\" xss=\"removed\">\r\n  <p class=\"MsoNormal\" xss=\"removed\"><strong>Dose<o></o></strong></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td xss=\"removed\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">First dose reduction<o></o></p>\r\n  </td>\r\n  <td xss=\"removed\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">480 mg (4 tablets) once daily<o></o></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td xss=\"removed\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">Second dose reduction<o></o></p>\r\n  </td>\r\n  <td xss=\"removed\">\r\n  <p class=\"MsoNormal\" xss=\"removed\">240 mg (2 tablets) once daily<o></o></p>\r\n  </td>\r\n </tr>\r\n</tbody></table><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in\r\npregnancy and lactation: </strong>There\r\nare no available data on Sotorasib use in pregnant women. <strong>Lactation:</strong> There are no data on the presence of Sotorasib or its\r\nmetabolites in human milk, the effects on the breastfed child or on milk\r\nproduction. Because of the potential for serious adverse reactions in breastfed\r\nchildren, advise women not to breastfeed during treatment with Sotorasib and\r\nfor1 week after the final dose.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in\r\nchild: </strong>The safety and\r\neffectiveness of Sotorasib have not been established in pediatric patients.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: </strong>Each\r\nbox contains 240 tablets in a container.<o></o></p>",
    "strength": "120",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1678338059Solung Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1678014061Solung Carton.png"
    ]
  },
  {
    "id": "1313",
    "name": "Sonib",
    "description": "<p><strong>Composition : Sonib\r\n: </strong>Each\r\nfilm coated tablet contains Sorafenib 200mg as Sorafenib<strong> </strong>Tosylate INN.</p><p class=\"MsoNormal\" xss=\"removed\"><strong><o> </o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications :<o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong><o> </o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Hepatocellular\r\nCarcinoma : </strong>Sonib\r\nis indicated for the treatment of patients with unresectable hepatocellular\r\ncarcinoma (HCC).<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Renal Cell\r\nCarcinoma : </strong>Sonib\r\nis indicated for the treatment of patients with advanced renal cell carcinoma\r\n(RCC).<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong><o> </o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Special\r\nPopulation : Renal Function Impairment: </strong>No dose adjustments are necessary for\r\nmild, moderate or severe renal function impairment in patients not undergoing\r\ndialysis.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong><o> </o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Hepatic Function\r\nImpairment : </strong>Mild\r\n(Child-Pugh class A) and moderate (Child-Pugh class B) hepatic function\r\nimpairment decreased AUC by 23% and 65% respectively. Not studied in severe\r\n(Child-Pugh class C) hepatic function impairment.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong><o> </o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and\r\nadministration : </strong>The\r\nrecommended daily dose of Sonib is 400 mg (2 x 200 mg tablets) taken twice daily without\r\nfood (at least 1 hour before or 2 hours after a meal). Treatment should\r\ncontinue until the patient is no longer clinically benefiting from therapy or\r\nuntil unacceptable toxicity occurs. It is recommended that Sorafenib should be\r\nadministered without food or with a low or moderate fat meal. If the patient\r\nintends to have a high-fat meal, Sorafenib tablets should be taken at least 1\r\nhour before or 2 hours after the meal. The tablets should be swallowed with a\r\nglass of water. Management of suspected adverse drug reactions may require\r\ntemporary interruption and/or dose reduction of Sonib. When dose reduction is\r\nnecessary, the Sonib dose may be reduced to 400 mg once daily. If additional\r\ndose reduction is required, Sonib may be reduced to a single 400 mg dose every\r\nother day. Or, as directed by the registered physicians.</p><p class=\"MsoNormal\" xss=\"removed\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong><o> </o></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy\r\nand lactation : </strong>Pregnancy\r\nCategory D.  Sorafenib<o></o></p><p class=\"MsoNormal\" xss=\"removed\">should not be used during pregnancy.\r\nIt is not known whether Sorafenib is excreted in human milk.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packaging : Sonib\r\nTablet: </strong>Each\r\nbox contains 4x7's tablets in Alu-Alu<o></o></p><p class=\"MsoNormal\"><o></o></p><p>blister pack.</p>",
    "strength": "200",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1522142385Sonib  Insert.pdf.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1531116782Sonib -c.jpg"
    ]
  },
  {
    "id": "790",
    "name": "Sparonex",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Sparfloxacin INN  200mg\r\nTablet.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong> Sparfloxacin is indicated\r\nfor the treatment of adults with following\r\ninfections caused by susceptible strains\r\nof the designated microorganisms:\r\nCommunity Acquired Pneumonia, Acute\r\nbacterial exacerbations of chronic\r\nbronchitis, Sinusitis, Bronchitis, Chronic\r\nObstructive Pulmonary Disease (COPD),\r\nLung abscess, all other RTIs. Sparonex\r\ncan also be indicated in Skin and Soft\r\nTissue Infections, Urinary Tract\r\nInfections. </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The\r\nrecommended daily adult dose is two\r\ntablets (400mg) on first day as a loading\r\ndose, followed by one tablet (200mg)\r\ndaily as a maintenance dose. Duration of\r\nmaintenance treatment is 5 to 10 days. It\r\ncan be taken with or without food. or as\r\ndirected by a registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong>Sparfloxacin has been\r\nassigned to pregnancy category C by the\r\nFDA.</p><p style=\"text-align: justify;\"><strong>Packing :</strong> 2 x 10's tablets in blister\r\npack.</p>",
    "strength": "200",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532332855Sparonex.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210117Sparonex.png"
    ]
  },
  {
    "id": "1001",
    "name": "Spiretic",
    "description": "<p><strong></strong><strong>Composition :</strong> Spironolactone  25mg Tablet</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Spironolactone is indicated in the\r\nmanagement of oedema and ascites in hepatic\r\ncirrhosis, malignant ascites, nephrotic syndrome,\r\ncongestive cardiac failure and primary\r\naldosteronism.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Administration of\r\nSpironolactone once daily with a meal is\r\nrecommended.<em>\r\nAdults:</em> Congestive cardiac faliure: Usual dose\r\n100mg/day. In difficult or severe cases the dosage\r\nmay gradually increased up to 400mg/day. When\r\noedema is controlled, the usual maintenance level\r\nis 75mg-200mg/day.\r\nHepatic cirrhosis with ascites and oedema: If\r\nurinary Na+/K+ ratio is greater than 1.0,\r\n100mg/day. If the ratio is less than 1.0, 200-\r\n400mg/day. Maintenance dosage should be\r\nindividually determined.\r\n<em>Malignant ascites:</em> Initial dose usually 100-\r\n200mg/day. In severe cases the dosage may be\r\ngradually increased up to 400mg/day. When\r\noedema is controlled, maintenance dosage should\r\nbe individually determined.\r\nNephrotic syndrome: Usual dose 100-\r\n200mg/day. Spironolactone has not been shown\r\nto be anti-inflammatory, nor to affect the basic\r\npathological process. Its use only advised if\r\nglucocorticords by themselves are insufficiently\r\neffective<em>.<strong>\r\n</strong>Diagnosis and treatment of primary\r\naldosteronism:</em> Spironolactone may employed as\r\nan initial diagnostic measure to provide\r\npresumptive evidence of primary\r\nhyperaldosteronism while patients are on normal\r\ndiets.\r\nLong test : Spironolactone is administered at a\r\ndaily dosage of 400mg for three to four weeks.\r\nCorrection of hypokalamia and of hypertension\r\nprovides presumptive evidence for the diagnosis\r\nof primary hyperaldosteronism.<em>\r\nShort test :</em> Spironolactone is administered at a\r\ndaily dosage of 400mg for four days. If serum\r\npotassium increses during Spironolactone\r\nadministration but drops when Spironolactone is\r\ndiscontinued, a presumptive diagnosis of primary\r\nhyperaldosteronism should be considered.\r\nChildren : Initial daily dosage should provide 3mg\r\nof spironolactone per kilogram body weight given\r\nin divided doses. Dosage should be adjusted on\r\nthe basis of response and tolerance. If necessary\r\na suspension may be prepared by crushing\r\nSpironolactone tablets.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Spiretic : 3 x 10'stablets in blister\r\npack.</span></p>",
    "strength": "25",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532332917Spiretic.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744101077Spiretic.png"
    ]
  },
  {
    "id": "1874",
    "name": "splac Oral solution",
    "description": "<p><strong>Composition:</strong> Each 5ml Oral Solution contains Sodium Picosulfate USP\r\n5mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong> Sodium Picosulfate is indicated in the following\r\nconditions-constipation of any etiology, relief from prolonged & recurrent\r\nconstipation, bowel clearance before surgery, childbirth or radiological\r\ninvestigations.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and administration:</strong> For oral administration: The following\r\ndosages are recommended to be taken at night to produce evacuation the\r\nfollowing morning. It is recommended to start with the lowest dose. The dose\r\nmay be adjusted up to the maximum recommended dose to produce regular stools.\r\nThe maximum recommended daily dose should not be exceeded: Adults and children\r\nover 10 years of age-Tablet: 5-10 mg per day. Or, as directed by the registered\r\nphysicians.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and Lactation:</strong> There are no reports of undesirable\r\nor damaging effects during pregnancy or to the foetus attributable to the use\r\nof this product. Use of the drug should be avoided during the first trimester.\r\nClinical data show that neither the active moiety of sodium Picosulfate (BHPM\r\nor bis-(p hydroxyphenyl)-pyridyl-2-methane) nor its glucuronides are excreted\r\ninto the milk of healthy lactating females.</p><p><strong>Packing:</strong> Each box contains a bottle of 100ml containing Sodium\r\nPicosulfate 5mg/5ml.</p>",
    "strength": "5mg/5ml",
    "uom": "mg/ml",
    "categoryId": "54",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1684407945SPLAC Sus Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744101027SPLAC ORAL.png"
    ]
  },
  {
    "id": "1875",
    "name": "splac Tablet",
    "description": "<p><strong>Composition:</strong> Each Tablet contains Sodium Picosulfate USP 10mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong> Sodium Picosulfate is indicated in the following\r\nconditions-constipation of any etiology, relief from prolonged & recurrent\r\nconstipation, bowel clearance before surgery, childbirth or radiological\r\ninvestigations.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and administration:</strong> For oral administration: The following\r\ndosages are recommended to be taken at night to produce evacuation the\r\nfollowing morning. It is recommended to start with the lowest dose. The dose\r\nmay be adjusted up to the maximum recommended dose to produce regular stools.\r\nThe maximum recommended daily dose should not be exceeded: Adults and children\r\nover 10 years of age-Tablet: 5-10 mg per day. Or, as directed by the registered\r\nphysicians.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and Lactation:</strong> There are no reports of undesirable\r\nor damaging effects during pregnancy or to the foetus attributable to the use\r\nof this product. Use of the drug should be avoided during the first trimester.\r\nClinical data show that neither the active moiety of sodium Picosulfate (BHPM\r\nor bis-(p hydroxyphenyl)-pyridyl-2-methane) nor its glucuronides are excreted\r\ninto the milk of healthy lactating females.</p><p><strong>Packing:</strong> Each box contains 30’s tablets in a blister pack.</p>",
    "strength": "10",
    "uom": "mg",
    "categoryId": "54",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1684408184SPLAC Tab Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100997SPLAC.png"
    ]
  },
  {
    "id": "879",
    "name": "STENICOL",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">(Chloramphenicol BP 5 mg +\r\nDexamethasone phosphate USP 1 mg) /ml.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">For steroid-responsive\r\ninflammatory ocular condition for which a\r\ncorticosteroid is indicated and where\r\nbacterial infection or a risk of bacterial\r\nocular infection exists. For inflammatory\r\nconditions of the palpebral and bulbar\r\nconjunctiva, cornea and anterior segment\r\nof the globe. For chronic anterior uveitis\r\nand corneal injury from chemical,\r\nradiation or thermal burns, or penetration\r\nof foreign bodies</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">1 or 2\r\ndrops is instilled into the affected eyes\r\nevery 3 or 4 hours, or more frequently if\r\nadvised by the prescribing physician.\r\nAdministration should be continued day\r\nand night for the first 48 hours, after\r\nwhich the interval between applications\r\nshould be increased. Treatment should be\r\ncontinued for at last 48 hours, after the\r\neye appears normal. Or as directed by\r\nthe physician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>5ml in plastic dropper bottle.</p>",
    "strength": "0.5&0.1",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532333031STENICOL.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/images/STENICOL.jpg"
    ]
  },
  {
    "id": "1291",
    "name": "Sudac ",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\">Sulindac USP  100 mg & 200\r\nmg Tablet.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Indications : </strong><span class=\"redactor-invisible-space\">Sulindac is indicated for the\r\nsymptomatic treatment of rheumatoid\r\narthritis, osteoarthritis, ankylosing\r\nspondylitis, periarticular inflammatory\r\ndisorders, acute painful shoulder, acute\r\ngouty arthritis, diabetic neuropathy &\r\ndiabetic retinopathy.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dosage and administration :</strong><span class=\"redactor-invisible-space\"> Sulindac\r\nshould be administered orally twice a day\r\nwith food. The maximum dosage is 400\r\nmg per day. Dosages above 400 mg per\r\nday are not recommended. In\r\nosteoarthritis, rheumatoid arthritis &\r\nankylosing spondylitis, the recommended\r\nstarting dosage is 150 mg. In acute\r\npainful shoulder & acute gouty arthritis\r\nthe recommended dosage is 200 mg\r\ntwice a day. The dosage may be lowered\r\nor raised depending on the response.\r\nAfter a satisfactory response has been\r\nachieved, the dosage may be reduced\r\naccording to the response. Or, as\r\ndirected by the registered physicians.</span></span><br></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Use in pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> There\r\nare no adequate and well-controlled\r\nstudies in pregnant women. Sulindac\r\nshould be used during pregnancy only if\r\nthe potential benefit justifies the potential\r\nrisk to the fetus. It is not known whether\r\nthis drug is excreted in human milk.</span><br></span></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Packing : </strong><span class=\"redactor-invisible-space\"></span></span></span></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">Sudac-100: 5X10's tablets in\r\nblister pack. </span></span></span></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">Sudac-200: 2X10's tablets in blister\r\npack.</span><br></span></span></span></span></span></p>",
    "strength": "200,100",
    "uom": "mg",
    "categoryId": "35",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532143378sudac.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210146Sudac-200.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745210146Sudac-100.png"
    ]
  },
  {
    "id": "834",
    "name": "Sulfacol ",
    "description": "<p><strong></strong><strong>Composition : </strong>Sulfasalazine USP  500mg Enteric Coated Tablet.</p><p style=\"text-align: justify;\"><strong>Indication :</strong><strong> </strong><span class=\"redactor-invisible-space\"><strong>Rheumatoid arthritis &\r\nJuvenile arthritis : </strong>Sulfasalazine is\r\nindicated for Rheumatic arthritis and Juvenile\r\narthritis which has failed to responded to nonsteroidal\r\nanti-inflammatory drugs (NSAIDs).</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Ulcerative colitis and Crohn's disease :\r\nSulfasalazine is also indicated for the\r\ntreatment and management of severe and\r\nacute attacks of Ulcerative colitis, and in the\r\ntreatment of Crohn's disease, especially in\r\npatients with colonic involvement.<br></span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">The dosage of\r\nSulfasalazine (Sulfacol) tablets should be\r\nindividually adjusted according to the\r\npatient's tolerance and response to the\r\ntreatment and taken in evenly divided doses\r\npreferably after meals. Please see prescribing description for more information.</span></p><p style=\"text-align: justify;\"><strong>Pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> Pregnancy catergory B. Sulfasalazine\r\nshould be administered during pregnancy\r\nonly if the potential benefits outweigh the\r\npotential risk to the fetus. Caution should be\r\nexercised when sulfasalazine is administered\r\nto a nursing mother.</span><br></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">3x10's tablets in blister\r\npack.</span></p>",
    "strength": "500",
    "uom": "mg",
    "categoryId": "107",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532333118sulfacol.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210166Sulfacol.png"
    ]
  },
  {
    "id": "950",
    "name": "Supra-B",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition : </strong>Each film coated tablet contains\r\nThiamine Hydrochloride (Vitamin B1) BP 100mg, Pyridoxine Hydrochloride (Vitamin\r\nB6) BP 200mg andCyanocobalamin (Vitamin B12) BP 200mcg.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indication :</strong><strong> </strong>Chronic\r\npains like sciatica, lumbago, trigeminal neuralgia, diabetic neuropathy, facial\r\nparalysis, optic neuritis as well as neuropathy & besides these,deficiency\r\nexits of these relevant Vitamins.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage and administration :</strong><strong> </strong>Supra-B\r\ntablet : 1-2 tablets per day. Or, as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Use in Pregnancy and lactation :</strong><strong> </strong>Supra-B\r\nis safe for pregnant woman. It is not known whether Thiamine (Vitamin B1) is excreted\r\nin breast milk or not, but may be taken cautiously during lactation. Vitamin B6\r\nhas no adverse effect during lactation.There is no known adverse effect\r\noVitamin B12 therapy also.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p><strong>Packing :</strong><strong> </strong>Each\r\nbox contains 50's tablet's in blister pack.<br><strong></strong></p>",
    "strength": " 100+200+200",
    "uom": "mg+mcg+mg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1634030600Supra-B (1).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210225Supra-B.png"
    ]
  },
  {
    "id": "1249",
    "name": "Supra-Z",
    "description": "<p><strong>Composition: </strong>Supra-Z Syrup :Each 5ml syrup contains Iron (III) Hydroxide olymaltose Complex INN 200mg equivalent to elemental Iron 50mg, Thiamine Hydrochloride BP 5mg, Riboflavin 5-phosphate S odium BP 2.74mg equivalent to Riboflavin 2mg, Pyridoxine Hydrochloride BP 2mg, Nicotinamide BP 20mg and Zinc Sulphate BP 27.45mg equivalent to elemental Zinc 10mg.</p><p style=\"text-align: justify;\"><strong>Indications:</strong> Supra-Z Syrup is indicated for the treatment and prevention of Iron, B-vitamins and Zinc deficiencies .</p><p style=\"text-align: justify;\"><strong>Dosage & Administration: </strong>Adults : 5ml - 10ml (1 to 2 spoonful) 3 times daily. Children : 5ml (1 spoonful) 3 times daily. Infant : 5ml (1 spoonful) daily. Or, as directed by the registered physician.</p><p style=\"text-align: justify;\"><strong>Use in Pregnency & Lactation: </strong>Recommended.</p><p style=\"text-align: justify;\"><strong>Use in Children: </strong>Recommended.<br></p><p style=\"text-align: justify;\"><strong>Packing: </strong><span class=\"redactor-invisible-space\"></span>Supra-Z Syrup : Each bottle contains 100ml syrup with a plastic cup.</p><p style=\"text-align: justify;\" rel=\"text-align: justify;\">Supra-Z Syrup : Each bottle contains 200ml syrup with a plastic cup.<span></span></p>",
    "strength": "100",
    "uom": "mg/5ml",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532333296supra-Z.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210509Supra-Z.png"
    ]
  },
  {
    "id": "949",
    "name": "Supracod",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Each 5ml Syrup contains\r\nVitamin A 2000 IU, Vitamin D 200 IU,\r\nVitamin B1 (as Thiamine Hydrochloride)\r\n0.7mg, Vitamin B2 (as Riboflavin 5'\r\nPhosphate Sodium) 0.85mg, Vitamin B6\r\n(as Pyridoxin Hydrochloride) 0.35mg,\r\nVitamin E 1.5mg, Nicotinamide 9.00mg,\r\nVitamin C (as Ascorbic Acid) 17.5mg and\r\nCod Liver Oil 100mg.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This multivitamin is\r\nindicated for the treatment and\r\nprevention of multivitamin deficiencies\r\nassociated with restricted diets and\r\nimproper food intake. It is also mediated\r\nin children with increased requirements\r\nfor vitamins due to acute and chronic\r\ndisease, vitamin lacking symptom for\r\ngrowing child, lack of appetite child,\r\nincluding patient under rehabilitating\r\nperiod.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong><span class=\"redactor-invisible-space\"> Infant (1-12 months)\t: 1\r\n/2\tteaspoonful (2.5ml) / day.\r\nChild (1-4 years)\t: 1\tteaspoonful (5ml) / day.\r\nChild (Above 4 years)\t: 11\r\n/2\tteaspoonful (7.5ml) / day<br></span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Supracod : 100ml\r\nmultivitamin syrup with Cod Liver Oil and\r\na measuring Cup.</span></p>",
    "strength": "100",
    "uom": "ML",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532333358Supracod.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1635401499Supracod (1).png"
    ]
  },
  {
    "id": "947",
    "name": "Supravit",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong> Each Supravit\r\nsoft capsule contains :<br></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">Vitamin A 5000 IU<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">Vitamin D3 400 IU<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">Vitamin C 75 mg<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">Vitamin B1 1.50 mg<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">Vitamin B2 10 mg<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">Vitamin B6 1 mg<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">Vitamin B3 13 mg<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">Vitamin B5 5 mg<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\">Vitamin E 5 IU<o:p></o:p></p><p class=\"MsoNormal\">Vitamin B12 2 mcg<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indication : Supravit </strong>is\r\nindicated for the treatment and prevention of vitamin deficiencies.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage and\r\nadministration : </strong>Orally\r\none capsule daily for adults and children over 5 years of age or as directed by\r\nthe physician.<o:p></o:p></p><p><strong>Packing : Supravit : </strong>60's\r\ncapsules in blister pack.<br></p>",
    "strength": "54654,100ml,50",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1659949992Supravit Insert (For Web).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210384Supravit.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745210292Supravit-M.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745210307Supravit-PN.png"
    ]
  },
  {
    "id": "1225",
    "name": "Supravit - M ",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong> <strong> </strong>Each Supravit-M soft capsule Contains Multivitamins &\r\nMinerals. .<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications :</strong> <strong>Supravit-M </strong>is indicated for the\r\ntreatment and prevention of vitamin and mineral deficiencies.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage & Administration :</strong> Orally one\r\ncapsule daily for adults and children over 5 years of age or as directed by the\r\nregistered physician.<o:p></o:p></p><p><strong>Packing :</strong> Each box\r\ncontains 60's soft capsules in blister pack.<br></p>",
    "strength": "100ml,50,100",
    "uom": "gm(IV/IM)",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1643011688Supravit-M BOOK STYLE INSERT.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210292Supravit-M.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745210307Supravit-PN.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745210345Supravit-G.png"
    ]
  },
  {
    "id": "1225",
    "name": "Supravit - M ",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong> <strong> </strong>Each Supravit-M soft capsule Contains Multivitamins &\r\nMinerals. .<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications :</strong> <strong>Supravit-M </strong>is indicated for the\r\ntreatment and prevention of vitamin and mineral deficiencies.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage & Administration :</strong> Orally one\r\ncapsule daily for adults and children over 5 years of age or as directed by the\r\nregistered physician.<o:p></o:p></p><p><strong>Packing :</strong> Each box\r\ncontains 60's soft capsules in blister pack.<br></p>",
    "strength": "100ml,50",
    "uom": "gm(IV/IM)",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1643011688Supravit-M BOOK STYLE INSERT.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210292Supravit-M.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745210307Supravit-PN.png"
    ]
  },
  {
    "id": "1225",
    "name": "Supravit - M ",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong> <strong> </strong>Each Supravit-M soft capsule Contains Multivitamins &\r\nMinerals. .<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications :</strong> <strong>Supravit-M </strong>is indicated for the\r\ntreatment and prevention of vitamin and mineral deficiencies.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage & Administration :</strong> Orally one\r\ncapsule daily for adults and children over 5 years of age or as directed by the\r\nregistered physician.<o:p></o:p></p><p><strong>Packing :</strong> Each box\r\ncontains 60's soft capsules in blister pack.<br></p>",
    "strength": "100ml,50",
    "uom": "gm(IV/IM)",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1643011688Supravit-M BOOK STYLE INSERT.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210292Supravit-M.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745210307Supravit-PN.png"
    ]
  },
  {
    "id": "1225",
    "name": "Supravit - M ",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong>Composition :</strong> <strong> </strong>Each Supravit-M soft capsule Contains Multivitamins &\r\nMinerals. .<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Indications :</strong> <strong>Supravit-M </strong>is indicated for the\r\ntreatment and prevention of vitamin and mineral deficiencies.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;line-height:normal;mso-layout-grid-align:none;text-autospace:none\"><strong> </strong></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;line-height:\r\nnormal;mso-layout-grid-align:none;text-autospace:none\"><strong>Dosage & Administration :</strong> Orally one\r\ncapsule daily for adults and children over 5 years of age or as directed by the\r\nregistered physician.<o:p></o:p></p><p><strong>Packing :</strong> Each box\r\ncontains 60's soft capsules in blister pack.<br></p>",
    "strength": "100ml,50,100",
    "uom": "gm(IV/IM)",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1643011688Supravit-M BOOK STYLE INSERT.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210292Supravit-M.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745210307Supravit-PN.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745210326Supravit-S.png"
    ]
  },
  {
    "id": "1346",
    "name": "Sutinib",
    "description": "<p class=\"MsoNormal\"><strong><br></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:\r\n</strong>Each\r\ncapsule contains Sunitinib 50 mg as Sunitinib Malate INN.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:\r\nGastrointestinal Stromal Tumors (GIST): </strong>It is indicated for the\r\ntreatment of gastrointestinal stromal tumors after disease progression on or\r\nintolerance to Imatinib Mesylate. <strong>Advanced\r\nRenal Cell Carcinoma (RCC): </strong>It is indicated for the treatment of advanced\r\nrenal cell carcinoma. <strong>Adjuvant</strong> <strong>Renal Cell Carcinoma (RCC): </strong>It is\r\nindicated for the adjuvant treatment of adult patients at high risk of\r\nrecurrent RCC following nephrectomy. <strong>Advanced\r\nPancreatic Neuroendocrine Tumors (pNET): </strong>It is indicated for the treatment\r\nof progressive, well- differentiated pancreatic neuroendocrine tumors in\r\npatients with unresectable locally advanced or metastatic disease.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration: Recommended Dose for GIST and Advanced RCC:</strong>\r\nThe recommended dose of Sutinib for gastrointestinal stromal tumor (GIST) and\r\nadvanced renal cell carcinoma (RCC) is one 50 mg oral dose taken once daily, on\r\na schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2). It\r\nmay be taken with or without food. <strong>Recommended\r\nDose for Adjuvant Treatment of RCC:</strong> The recommended dose of Sutinib for the\r\nadjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4\r\nweeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week\r\ncycles. It may be taken with or without food. <strong>Recommended Dose for pNET:</strong> The recommended dose of Sutinib for\r\npancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily\r\ncontinuously without a scheduled off-treatment period. It may be taken with or\r\nwithout food. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin pregnancy and lactation:</strong> It can cause fetal harm when\r\nadministered to a pregnant woman. There are no available data in pregnant women\r\nto inform a drug-associated risk. If it is used during pregnancy, or if the\r\npatient becomes pregnant while taking this drug, the patient should be apprised\r\nof the potential hazard to the fetus. <strong>Lactation:</strong>\r\nThere is no information regarding the presence of Sunitinib and its metabolites\r\nin human milk. Because of the potential for serious adverse reactions in\r\nbreastfed infants from Sutinib, a lactating woman should be advised not to\r\nbreastfeed during treatment with Sutinib and for at least 4 weeks after the\r\nlast dose. </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packaing:</strong>\r\nEach box contains 1x7’s capsules in blister pack.</p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1543048207Sutinib  Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1543048207Sutinib Carton Pic- Final.jpg"
    ]
  },
  {
    "id": "881",
    "name": "SYNTAR",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">(Dextran 70 USP 1 mg +\r\nHypromellose USP 3mg) /ml.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This eye lubricant is\r\nformulated for relief of various ocular\r\nirritation syndromes (dry and irritated\r\neyes) and for use as a protectant against\r\nfurther irritation. It may also be used to\r\ntreat drying, inflammation of cornea and\r\nconjunctiva of eyes.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Instill 1-2\r\ndrops in the affected eye (s) as needed.\r\nor, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>10ml in plastic dropper bottle</p>",
    "strength": "0.1,0.3",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532333993SYNTAR.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210598SYNTAR.png"
    ]
  },
  {
    "id": "1894",
    "name": "Syntar Single Use Eye Drops",
    "description": "<p><strong>Composition: </strong>Each\r\nml sterile eye drops contains Dextran 70 USP 1mg  and Hypromellose USP 3mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: </strong>As a lubricant\r\nand artificial tear in dry eye and other ocular irritation syndromes associated\r\nwith deficient tear or mucous secretion. This combination also prevents cornea\r\nto damage in patients with keratoconjunctivitis and ocular lubrication. It is\r\nalso used for the temporary relief of burning and irritation due to dryness of\r\nthe eye and for use as the protectant against further irritation.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand Administration: </strong>Adults and children: One or two drops three\r\ntimes daily, or as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and lactation: </strong>There\r\nis insufficient evidence as to the safety in pregnancy and lactation.\r\nTherefore, this product should only be used in pregnancy and lactation if it is\r\nconsidered essential by the physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: </strong>Each\r\nbox contains 25’s (0.4ml) single use plastic containers enclosed in a plastic\r\npouch overwrap.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p>",
    "strength": "1+3",
    "uom": "mg",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1701162022Syntar Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210578SYNTAR 10 ML.png"
    ]
  },
  {
    "id": "781",
    "name": "T - CEF Capsule",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Cefixime USP 200mg & 400mg\r\nCapsule.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Cefixime is generally classified as a\r\nthird-generation cephalosporin antibiotic and is\r\ngiven by mouth in the treatment of susceptible\r\ninfections, including gonorrhoea, otitis media,\r\npharyngitis, lower respiratory-tract infections such\r\nas bronchitis and urinary tract infections and\r\nShigellosis, caused by Shigella flexneri (54%), S.\r\nboydii (30%), S. dysenteriae non-type 1 (6%) and\r\nS. Sonnei (10%).</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> Adults : The recommended dose of T-cef is 400mg\r\ndaily. This may be given as 200mg capsule every 12 hours. For the treatment of\r\nuncomplicated cervical/urethral gonococcal infections, a single oral dose of\r\n400mg is recommended.Typhoid fever : Oral T-cef 5mg/kg 12 hourly for 14 days.\r\nShigellosis : 8mg/kg/day as a single dose or in 2 divided doses for 5 days. </p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt\"><o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt\">Paediatric (6 Months or older) : The\r\nrecommended dose is 8mg/kg/day of the suspension. This may be administered as a\r\nsingle daily dose or may be given in two divided doses, as 4mg/kg every 12\r\nhours. <o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt\">Typhoid fever : Oral T-cef 5mg/kg 12 hourly for\r\n14 days. <o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt\">Shigellosis : 8mg/kg/day as a single dose or in\r\n2 divided doses for 5 days. Or, as directed by the registered physician.<o:p></o:p></p><p class=\"MsoNormal\">Please see\r\nprescribing description for more information.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">: Cefixime has\r\nbeen assigned to pregnancy category B. by the\r\nFDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">T-cef Capsule : 2 x 7's capsules in blister pack.\r\n<br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">T-cef 400 Capsule : 1 x 7's capsules in blister\r\npack. </span></p>",
    "strength": "400,200",
    "uom": "mg",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532339472T-cef.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210698T-CEF 400.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745210698T-CEF.png"
    ]
  },
  {
    "id": "1237",
    "name": "T - CEF Suspension",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Cefixime USP 25mg/ml Paediatric Drops, 100mg/5ml & 200mg/5ml Suspension.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Cefixime is generally classified as a third-generation cephalosporin antibiotic and is given by mouth in the treatment of susceptible infections, including gonorrhoea, otitis media, pharyngitis, lower respiratory-tract infections such as bronchitis and urinary tract infections and Shigellosis, caused by Shigella flexneri (54%), S. boydii (30%), S. dysenteriae non-type 1 (6%) and S. Sonnei (10%).</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration :</strong> Adults : The recommended dose of T-cef is 400mg\r\ndaily. This may be given as 200mg capsule every 12 hours. For the treatment of\r\nuncomplicated cervical/urethral gonococcal infections, a single oral dose of\r\n400mg is recommended.Typhoid fever : Oral T-cef 5mg/kg 12 hourly for 14 days.\r\nShigellosis : 8mg/kg/day as a single dose or in 2 divided doses for 5 days. </p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt\"><o:p></o:p></p>\r\n\r\n\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt\">Paediatric (6 Months or older) : The\r\nrecommended dose is 8mg/kg/day of the suspension. This may be administered as a\r\nsingle daily dose or may be given in two divided doses, as 4mg/kg every 12\r\nhours. <o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt\">Typhoid fever : Oral T-cef 5mg/kg 12 hourly for\r\n14 days. <o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt\">Shigellosis : 8mg/kg/day as a single dose or in\r\n2 divided doses for 5 days. Or, as directed by the registered physician.<o:p></o:p></p>\r\n\r\n<p class=\"MsoNormal\"><o:p></o:p></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\">Please see\r\nprescribing description for more information.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">: Cefixime has been assigned to pregnancy category B. by the FDA.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">T-cef Paediatric Drops : 21ml suspension. <br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\" xss=\"removed\">T-cef Suspension : 30ml, 50ml suspension. <br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\" xss=\"removed\">T-cef DS : 50ml suspension.</span></p>",
    "strength": "25,200,100,100",
    "uom": "mg/ml",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532339890T-cef.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/T-cef_pd.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/T-cef_ds.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/T-CEF--Carto.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/T-cef_sus.jpg"
    ]
  },
  {
    "id": "1162",
    "name": "T - fovir",
    "description": "<p><strong></strong><strong>Composition : </strong>Tenofovir Disoproxil Fumarate INN 300 mg Tablet.</p><p style=\"text-align: justify;\"><strong></strong><strong>Indications : </strong>This tablet is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection and also indicated for the treatment of chronic hepatitis B. <strong></strong></p><p style=\"text-align: justify;\"><strong></strong><strong>Dosage and administration : </strong>For the treatment of HIV-1 or chronic hepatitis B:</p><p style=\"text-align: justify;\">The recommended dose of Tenofovir is 300mg once daily taken orally with or without food. Please see prescribing description for more information.<strong></strong></p><p style=\"text-align: justify;\"><strong>Use in Pregnancy and lactation : </strong>Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. Tenofovir should be used during pregnancy only if clearly needed and after careful consideration of the risks and benefits. Because of both the potential for HIV transmission and the potential serious serious adverse reaction in nursing infants, mother should not be instructed to breast feed if they are receiving Tenofovir.</p><p style=\"text-align: justify;\"><strong>Packing : </strong>T-fovir :1 x 7's tablets in alu-alu blister pack.</p>",
    "strength": "300",
    "uom": "mg",
    "categoryId": "45",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1683369281T-Fovir Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210801T-fovir.png"
    ]
  },
  {
    "id": "1864",
    "name": "T-Fovir A",
    "description": "<p><strong>Composition:</strong></p><p class=\"MsoNormal\" xss=\"removed\">Each\r\nfilm coated tablet contains Tenofovir Alafenamide 25mg as Tenofovir Alafenamide\r\nFumarate INN.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications: <o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\">It is indicated for the treatment of chronic hepatitis B virus\r\ninfection in adults with compensated liver disease.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration: <o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\">The recommended dosage is 25 mg (one tablet) taken orally once daily\r\nwith food. Or, as directed by the registered physician. <o></o></p><p class=\"MsoNormal\" xss=\"removed\">No\r\ndosage adjustment of T-Fovir A is required in patients with mild, moderate, or\r\nsevere renal impairment. It is not recommended in patients with end stage renal\r\ndisease (estimated creatinine clearance below 15 ml/ min). No dosage adjustment\r\nis required in patients with mild hepatic impairment (Child-Pugh A). It is not\r\nrecommended in patients with decompensated (Child-Pugh B or C) hepatic\r\nimpairment.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and Lactation: <o></o></strong></p><p class=\"MsoNormal\" xss=\"removed\">There\r\nare no human data on the use of Tenofovir Alafenamide in pregnant women to\r\ninform a drug-associated risk of adverse fetal developmental outcome. It is not\r\nknown whether Tenofovir Alafenamide and its metabolites are present in human\r\nbreast milk, affect human milk production, or have effects on the breastfed\r\ninfant.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: <o></o></strong></p><p>Each box contains\r\n10’s tablets in blister pack.</p>",
    "strength": "25",
    "uom": "mg",
    "categoryId": "45",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1677995756T-Fovir A Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210762T-fovir A.png"
    ]
  },
  {
    "id": "1826",
    "name": "Tamodex",
    "description": "<p class=\"MsoNormal\"><strong>Composition:\r\nTamodex-10: </strong>Each film coated tablet contains Tamoxifen 10mg as Tamoxifen Citrate\r\nUSP.<br>\r\n<strong>Tamodex-20: </strong>Each film coated tablet contains Tamoxifen 20mg as Tamoxifen\r\nCitrate USP.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Indications: </strong><strong>Metastatic Breast Cancer:</strong>\r\nTamodex is effective in the treatment of metastatic breast cancer in women and\r\nmen. In premenopausal women with metastatic breast cancer, Tamodex is an\r\nalternative to oophorectomy or ovarian irradiation. Available evidence\r\nindicates that patients whose tumors are estrogen receptor positive are more\r\nlikely to benefit from Tamodex therapy. <strong>Adjuvant\r\nTreatment of Breast Cancer:</strong> Tamodex is indicated for the treatment of\r\nnode-positive breast cancer in women following total mastectomy or segmental\r\nmastectomy, axillary dissection, and breast irradiation. In some Tamodex\r\nadjuvant studies, most of the benefit to date has been in the subgroup with\r\nfour or more positive axillary nodes. <strong>Ductal\r\nCarcinoma in Situ (DCIS):</strong> In women with DCIS, following breast surgery and\r\nradiation, Tamodex is indicated to reduce the risk of invasive breast cancer.\r\nCurrent data from clinical trials support five years of adjuvant Tamodex\r\ntherapy for patients with breast cancer. <strong>Reduction\r\nin Breast Cancer Incidence in High Risk Women:</strong> Tamodex is indicated to\r\nreduce the incidence of breast cancer in women at high risk for breast cancer.\r\nTamodex is indicated only for high-risk women. \"High risk\" is defined\r\nas women at least 35 years of age with a 5-year predicted risk of breast cancer\r\n1.67%, as calculated by the Gail Model.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Dosage and administration: </strong>For\r\npatients with breast cancer, the recommended daily dose is 20-40mg. Dosages\r\ngreater than 20mg per day should be given in divided doses (morning and\r\nevening). In three single agent adjuvant studies in women, one 10mg Tamoxifen\r\nCitrate tablet was administered two or three times a day for two years. <strong>Ductal Carcinoma in Situ (DCIS):</strong> The\r\nrecommended dose is Tamodex 20mg daily for 5 years. <strong>Reduction in Breast Cancer Incidence in High Risk Women: </strong>The\r\nrecommended dose is Tamodex 20mg daily for 5 years. There are no data to\r\nsupport the use of Tamodex other than for 5 years. Or, as directed by the\r\nregistered physicians.<o:p></o:p></p><p class=\"MsoNormal\"><strong>Use in Pregnancy and Lactation: </strong>Pregnancy\r\nCategory D. It can cause fetal harm when administered to a pregnant woman.\r\nTamoxifen has been reported to inhibit lactation. It is not known if Tamodex is\r\nexcreted in human milk. Because of the potential for serious adverse reactions\r\nin nursing infants from Tamodex, women taking Tamodex should not breast feed.<o:p></o:p></p><p class=\"MsoNormal\"><strong> </strong></p><p class=\"MsoNormal\"><strong>Packaging: Tamodex-10: </strong>Each\r\nbox contains 30 tablets in a blister pack.<br><o:p></o:p></p><p><strong>Tamodex-20: </strong>Each box contains 30 tablets in a blister pack.<br></p>",
    "strength": " 20,10",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100940Tamodex-20.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744100940Tamodex-10.png"
    ]
  },
  {
    "id": "955",
    "name": "Tannox - Plus",
    "description": "<p style=\"text-align: justify;\"><strong></strong><strong>Composition :  </strong><span class=\"redactor-invisible-space\">Each soft capsule\r\ncontains:\r\nBeta Carotene\r\n(Eq. to Vitamin A 2000 IU)\tBP\t\r\n6mg\r\nAscorbic Acid (Vitamin C)\tBP\t200mg\r\nVitamin E\tBP\t50mg\r\nVitamin K\tBP\t75mcg\r\nZinc\tBP\t15mg\r\nSelenium\tUSP\t70mcg\r\nCopper\tBP\t1mg\r\nManganese\tBP\t3mg</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is used as the treatment\r\nof develop immune system, prevents\r\nosteoporosis, arteriosclerosis, protects\r\nhuman skin from UV-induced damage,\r\nprevents the well known deficiency\r\ndiseases such as scurvy, beriberi,\r\npellagra and others, prevents certain\r\ntypes of cancer by blocking the formation\r\nof cancer causing substances in the\r\nbody. It has a role in retinal metabolism\r\nand may be beneficial in macular\r\ndegeneration. It is also capable of\r\ncombating cardiovascular and\r\nimmunological disorders.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">once capsule daily. Or, as directed\r\nby the registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Recommended by the consultation with\r\nthe registered physician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">5 x 10's soft\r\ncapsules in blister pack.</span></p>",
    "strength": "456",
    "uom": "mg/5ml",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532340104tannoxp.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/images/tannoxp.jpg"
    ]
  },
  {
    "id": "1357",
    "name": "Tanzil",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition: </strong>Azilsartan equivalent to Azilsartan\r\nMedoxomil 40mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication: </strong>Azilsartan Medoxomil is indicated\r\nfor the treatment of hypertension to lower blood pressure. Lowering blood pressure\r\nreduces the risk of fatal and nonfatal cardiovascular events, primarily stroke\r\nand myocardial infarction. Azilsartan medoxomil may be used either alone or in combination\r\nwith other antihypertensive agents.</p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration: </strong>The recommended\r\nstarting dose in adults is 40mg (1 tablet) taken orally once daily. The dose\r\nmay be increased to a maximum of 80 mg once daily, if required. Consider a starting\r\ndose of 40mg for patients who are treated with high doses of diuretics. Azilsartan\r\nmay be taken with or without food.</p><p class=\"MsoNormal\" xss=\"removed\">Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy and Lactation: </strong>Pregnancy Category D. The risk to the fetus reduces renal function\r\n& death increases if Azilsartan Medoxomil is administered during the second\r\nor third trimesters of pregnancy. It is not known whether Azilsartan Medoxomil\r\nis excreted in human milk.<br></p><p class=\"MsoNormal\" xss=\"removed\"><br><span></span></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: Tanzil Tablet: </strong>1 x 14's\r\ntablets in Alu-Alu blister pack.</p>",
    "strength": " 40",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1547537806Tanzil-Tablet.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1547537806Tanzil.jpg"
    ]
  },
  {
    "id": "1745",
    "name": "Tazumab",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition</strong>:\r\n<strong>Tazumab Injection: </strong>Each vial contains Trastuzumab INN 440 mg lyophilized\r\npowder for IV infusion.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Diluent for Tazumab\r\nInjection: </strong>Each vial contains Bacteriostatic Water\r\nfor Injection 20ml (Benzyl Alcohol USP 1.1%).</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Adjuvant Breast Cancer:\r\n</strong>Trastuzumab\r\nis indicated for adjuvant treatment of HER2 overexpressing node positive or\r\nnode negative ER/PR negative or with one high risk feature breast cancer</p><p class=\"MsoNormal\" xss=\"removed\">• as part of a\r\ntreatment regimen consisting of doxorubicin, cyclophosphamide, and either\r\npaclitaxel or docetaxel</p><p class=\"MsoNormal\" xss=\"removed\">• as part of a\r\ntreatment regimen with docetaxel and carboplatin</p><p class=\"MsoNormal\" xss=\"removed\">• as a single agent\r\nfollowing multi-modality anthracycline based therapy</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Metastatic Breast\r\nCancer: </strong>Trastuzumab is indicated:</p><p class=\"MsoNormal\" xss=\"removed\">• In combination with\r\npaclitaxel for first-line treatment of HER2-overexpressing metastatic breast\r\ncancer</p><p class=\"MsoNormal\" xss=\"removed\">• As a single agent for\r\ntreatment of HER2-overexpressing breast cancer in patient who have received one\r\nor more chemotherapy regimens for metastatic disease. overexpressing breast\r\ncancer in patient</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Metastatic Gastric\r\nCancer: </strong>Trastuzumab is indicated, in combination with\r\ncisplatin and capecitabine or 5-fluorouracil, for the treatment of patients\r\nwith HER2-overexpressing metastatic gastric or gastroesophageal junction\r\nadenocarcinoma who have not received prior treatment for metastatic disease.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand Administration:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Recommended Doses and\r\nSchedules: </strong>Do not administer as an intravenous push\r\nor bolus. Do not mix Trastuzumab with other drugs.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Adjuvant Treatment,\r\nBreast Cancer: </strong>Administer according to one of the\r\nfollowing doses and schedules for a total of 52 weeks of Trastuzumab therapy:</p><p class=\"MsoNormal\"><strong>Use in pregnancy\r\n& lactation:</strong> </p>\r\n\r\n<p class=\"MsoNormal\"><strong>Use in Pregnancy:</strong>\r\nIt can cause fetal harm when administered to a pregnant woman. Verify the\r\npregnancy status of females of reproductive potential prior to the initiation\r\nof Trastuzumab. Advise pregnant women and females of reproductive potential\r\nthat exposure to Trastuzumab during pregnancy or within 7 months prior to\r\nconception can result in fetal harm. Advise females of reproductive potential\r\nto use effective contraception during treatment and for 7 months following the\r\nlast dose of Trastuzumab. </p>\r\n\r\n<p class=\"MsoNormal\"><strong>Use in Lactation: </strong>There\r\nis no information regarding the presence of Trastuzumab in human milk, the\r\neffects on the breastfed infant, or the effects on milk production.</p>\r\n\r\n<p class=\"MsoNormal\"><o:p> </o:p></p>\r\n\r\n<p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:</strong> Each\r\ncombipack contains 1 vial of Tazumab Injection and 1 vial of Diluent for\r\nTazumab Injection.<br></p>",
    "strength": "440",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1614397041Tazumab Inj - 440mg Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1614397041Tazumab Injection Carton Pic.png"
    ]
  },
  {
    "id": "1374",
    "name": "Telmicard",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition: Telmicard-40: </strong>Each\r\nfilm coated tablet contains Telmisartan 40mg .</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication: </strong>It is indicated\r\nfor the treatment of hypertension.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration: </strong>Dosage\r\nmust be individualized. The usual starting dose of telmisartan tablet is 40mg\r\nonce a day. It may be used alone or in combination with other anti-hypertensive\r\nagent. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and laction: </strong>When\r\npregnancy is diagnosed telmisartan should be discontinued as soon as possible because it directly acts on the\r\nrennin-angiotensin system during second and third trimester associated with\r\nfetal and neonatal injury. It is contraindicated during lactation since it is not known whether it\r\nis excreted in human milk.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing: Telmicard: </strong>Each\r\nbox contains 2X14's tablets in blister pack.</p>",
    "strength": "40",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1634022215Telmicard.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100868TELMICARD-40.png"
    ]
  },
  {
    "id": "1843",
    "name": "Telmicard 5/40",
    "description": "<p><strong>Composition:</strong> Each tablet contains Telmisartan\r\nUSP 40mg & Amlodipine USP 5mg Tablet.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication:</strong>Telmisartan or Amlodipine tablet\r\nare indicated for the treatment of hypertension, alone or with other\r\nantihypertensive agents to lower blood pressure. Lowering blood pressure\r\nreduces the risk of fatal and non-fatal cardiovascular events, primarily\r\nstrokes and myocardial infractions.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dose and\r\nAdministration:</strong>Dosage\r\nmust be individualized the usual starting dose of this tablet 40mg. It may be\r\nused alone or in combination with other hypertensive agents. Or, as directed by\r\nthe registered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy\r\n& Lactation:</strong>\r\nWhen pregnancy is diagnosed Telmisartan should be discontinued as soon as\r\npossible. Because it directly acts on the Rennin- Angiotensin System during\r\nsecond and third trimester associated with fatal and nonfatal injury. It is\r\ncontraindicated during lactation. Since it is not known whether it is excreted\r\nin human milk.<o></o></p><p><strong>Packing:</strong> Each box contains 28’s tablets\r\nin a blister pack.</p>",
    "strength": "40+5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1660731862Telmicard 5-40 Insert- 15-02-2020-1.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100889TELMICARD 5-40.png"
    ]
  },
  {
    "id": "1367",
    "name": "Temozar",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>COMPOSITION:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Temozar:</strong> Each capsule contains Temozolomide USP 100 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Temozar-250:</strong> Each capsule\r\ncontains Temozolomide USP 250 mg.<br></p><p class=\"MsoNormal\" xss=\"removed\"><strong>INDICATIONS: </strong></p><p class=\"MsoNormal\" xss=\"removed\">Newly Diagnosed Glioblastoma\r\nMultiforme Temozolomide is indicated for the treatment of adult patients with\r\nnewly diagnosed glioblastoma multiforme concomitantly with radiotherapy and\r\nthen as maintenance treatment. Refractory Anaplastic Astrocytoma Temozolomide\r\nis indicated for the treatment of adult patients with refractory anaplastic\r\nastrocytoma, i.e., patients who have experienced disease progression on a drug\r\nregimen containing  nitrosourea and\r\nprocarbazine. DOSAGE AND ADMINISTRATION Newly Diagnosed GBM: 75 mg/m2 for 42\r\ndays concomitant with focal radiotherapy followed by initial maintenance dose\r\nof 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of Temozolomide for 6\r\ncycles. Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m2 once daily\r\nfor 5 consecutive days per 28-day treatment cycle. USE IN SPECIFIC POPULATIONS\r\nPregnancy: Pregnancy Category D. There are no adequate and well-controlled\r\nstudies in pregnant women. If this drug is used during pregnancy, or if the\r\npatient becomes pregnant while taking this drug, the patient should be apprised\r\nof the potential hazard to a fetus. Women of childbearing potential should be\r\nadvised to avoid becoming pregnant during therapy with Temozolomide.</p><p class=\"MsoNormal\"><strong>Dosage &\r\nAdministration:<o:p></o:p></strong></p><p class=\"MsoNormal\" xss=\"removed\">Newly Diagnosed GBM: 75 mg/m2 for 42 days concomitant with\r\nfocal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily\r\nfor Days 1-5 of a 28-day cycle of Temozolomide for 6 cycles. Refractory\r\nAnaplastic Astrocytoma: Initial dose 150 mg/m2 once daily for 5 consecutive\r\ndays per 28-day treatment cycle.<br></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Side Effects</strong>:</p><p class=\"MsoNormal\" xss=\"removed\"> The most common adverse reactions (&gt; _10%\r\nincidence) are: alopecia, fatigue, nausea, vomiting, headache, constipation,\r\nanorexia, convulsions, rash, hemiparesis, diarrhea, asthenia, fever, dizziness,\r\ncoordination abnormal, viral infection, amnesia, and insomnia.  The most common Grade 3 to 4 hematologic\r\nlabcratory abnormalities (&gt; _ 10% incidence) that have developed during\r\ntreatment with Temozolomide are: lymphopenia, thrombocytopenia, neutropenia,\r\nand leukopenia. Allergic reactions have also been reported. DRUG INTERACTIONS\r\nValproic Acid: Administration of valproic acid decreases oral clearance of\r\ntemozolomide by about 5%. The clinical implication of this effect is not known.\r\n</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy & Lactation: </strong>Pregnancy Category D. There are\r\nno adequate and well-controlled studies in pregnant women. If this drug is used\r\nduring pregnancy, or if the patient becomes pregnant while taking this drug,\r\nthe patient should be apprised of the potential hazard to a fetus. Women of\r\nchildbearing potential should be advised to avoid becoming pregnant during\r\ntherapy with Temozolomide. <strong>Nursing\r\nMothers:</strong> It is not known whether this drug is excreted in human milk.\r\nBecause many drugs are excreted in human milk and because of the potential for\r\nserious adverse reactions in nursing infants and tumorigenicity shown for\r\nTemozolomide in animal studies, a decision should be made whether to\r\ndiscontinue nursing or to discontinue the drug, taking into account the\r\nimportance of the drug to the mother from Temozolomide.<br></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Storage:</strong> Store below 30o C in a dry place.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packaging</strong>:  Temozar: Each box\r\ncontains 7 Capsules in Alu-Alu blister pack.</p><p class=\"MsoNormal\" xss=\"removed\">Temozar-250: Each box contains 7 Capsules in\r\nAlu-Alu blister pack.<br></p>",
    "strength": "100",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1683111188Temozar Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1683111188Temozar-250 Carton.png"
    ]
  },
  {
    "id": "985",
    "name": "Tenobis",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Bisoprolol Fumarate\r\nUSP 2.5mg & 5mg Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This tablet is indicated for\r\nthe management of hypertension and in\r\nthe treatment of coronary heart disease\r\n(angina pectoris). It may be used alone or\r\nin combination with other antihypertensive\r\nagents.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> <span class=\"redactor-invisible-space\">In\r\nhypertension or Angina Pectoris : The\r\nusual dose of Bisoprolol Fumarate is 5 to\r\n10mg as single daily dose. The maximum\r\nrecommended dose is 20mg daily. In\r\nheart failure : The inItial dose of\r\nbisoprolol Fumarate is 1.25mg once daily.\r\nIf tolerated, the dose should be doubled\r\nafter 1 week and then increased gradually\r\nat 1 to 4 week intervals to the maximum\r\ndose tolerated, this should not exceed\r\n10mg once daily. Patients with Renal or\r\nHepatic Impairment: In patients with\r\nhepatic impairment (hepatitis or cirrhosis)\r\nor renal dysfunction (creatinine clearance\r\n&lt;40 ml/min), the initial daily dose should\r\nbe 2.5 mg and caution should be used in\r\ndose-titration. Since limited data suggest\r\nthat Bisoprolol fumarate is not dialyzable,\r\ndrug replacement is not necessary in\r\npatients undergoing dialysis. Or as\r\ndirected by the registered physician.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong><span class=\"redactor-invisible-space\"> Tenobis-2.5 : 4x14's tablets in\r\nblister pack.\r\n<br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Tenobis-5 : 3x14's tablets in blister pack</span></p>",
    "strength": "5,2.5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532340162Tenobis.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100774Tenobis-5.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744100774Tenobis-2.5.png"
    ]
  },
  {
    "id": "1844",
    "name": "Tenobis A 2.5/5",
    "description": "<p><strong>Composition:</strong> Each tablet contains BisoprololFumarate\r\nUSP 2.5mg & Amlodipine USP 5mg Tablet</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indication:</strong>Bisoprolol Plus Amlodipine is\r\nindicated for the treatment of hypertension and angina. It is also indicated\r\nfor the treatment of hypertension and substitution therapy in patient\r\nadequately controlled or not controlled with the individual product given\r\nconcurrently at the same dosage level as in the combination, but as separate\r\ntablet. It is also indicated for those patient with angina pectoris and\r\nhypertension as co-existing disease. <o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dose and\r\nAdministration:</strong>The\r\nusual starting dose is one tablet daily with or without food. If the desired\r\ntherapeutic effect cannot be achieved the dose may be increased. The dose\r\nhowever should be individualized. Or, as directed by the registered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in Pregnancy\r\n& Lactation:</strong>T<a name=\"_GoBack\"></a>here are no adequate and well controlled studies in pregnant\r\nwomen. This combination should be used during pregnancy only if the potential\r\nbenefit justifies the potential risk to fetus. This combination should be\r\nstopped during breast feeding.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing:</strong> Each box contains 28’s tablets\r\nin a blister pack.<o></o></p><p class=\"MsoNormal\"><o> </o></p>",
    "strength": "2.5+5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1660732260Tenobis A Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100841Tenobis- A 2.5-5.png"
    ]
  },
  {
    "id": "986",
    "name": "Tenobis Plus",
    "description": "<p><strong>Composition :</strong> <span class=\"redactor-invisible-space\">Tenobis Plus 2.5 : </span>Bisoprolol Fumarate USP 2.5 mg + Hydrochlorothiazide USP 6.25 mg Tablet<span class=\"redactor-invisible-space\"><br></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Tenobis Plus 5 : </span>Bisoprolol Fumarate USP 5 mg + Hydrochlorothiazide USP 6.25 mg Tablet & </p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Tenobis Plus 10 : </span>Bisoprolol Fumarate USP 10 mg + Hydrochlorothiazide USP 6.25 mg Tablet.</p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is indicated in the management of\r\nhypertension.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Bisoprolol is an effective\r\ntreatment of hypertension in once-daily doses of 2.5 to\r\n40 mg, while hydrochlorothiazide is effective in doses of\r\n12.5 to 50 mg . In clinical trials of\r\nbisoprolol/hydrochlorothiazide combination therapy\r\nusing bisoprolol doses of Tenobis Plus 2.5 to 20 mg\r\nand hydrochlorothiazide doses of 6.25 to 25 mg, the\r\nantihypertensive effects increased with increasing\r\ndoses of either component. Initial Therapy :\r\nAntihypertensive therapy may be initiated with the\r\nlowest dose of one 2.5/6.25 mg tablet once daily.\r\nSubsequent titration (14 day intervals) may be carried\r\nout with Tenobis Plus up to the maximum\r\nrecommended dose 20/12.5 mg once daily, as\r\nappropriate. Replacement Therapy : The combination\r\nmay be substituted for the titrated individual\r\ncomponents. Therapy Guided by Clinical Effect : A\r\npatient whose blood pressure is not adequately\r\ncontrolled with 2.5-20 mg bisoprolol daily may instead\r\nbe given Tenobis Plus. Patients whose blood\r\npressures are adequately controlled with 50mg of\r\nhydrochlorothiazide daily, but who experience significant\r\npotassium loss with this regimen, may achieve similar\r\nblood pressure control without electrolyte disturbance if\r\nthey are switched to Tenobis Plus. Or, as directed by\r\nthe registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy\r\nCategory C : There are no adequated and wellcontrolled\r\nstudies in pregnant women. Bisoprolol\r\nfumarate and hydrochlorothiazide combination should\r\nbe used during pregnancy only if the potential benefit\r\njustifies the risk to the fetus. Nursing mothers :\r\nBisoprolol fumarate alone or in combination with HCTZ\r\nhas not been studied in nursing mothers. Thiazides are\r\nexcreted in human breast milk. Small amounts of\r\nbisoprolol fumarate have been detected in the milk of\r\nlactating rats. Because of the potential for serious\r\nadverse reactions in nursing infants, a decision should\r\nbe made whether to discontinue nursing or to\r\ndiscontinue the drug, taking in to account the\r\nimportance of the drug to the mother.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Tenobis Plus 2.5 : 2x14's, tablets in blister pack.\r\n<br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Tenobis Plus 5 : 2x14's, tablets in blister pack.\r\n<br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Tenobis Plus 10 : 1x10's, tablets in blister pack.</span></p>",
    "strength": "10+6.25,2.5+6.25",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532145485Tenobis_plus.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100809Tenobis plus 5.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744100809Tenobis plus 2.5.png"
    ]
  },
  {
    "id": "880",
    "name": "TEXA ",
    "description": "<p><strong></strong><strong>Composition : (</strong><span class=\"redactor-invisible-space\">Tobramycin BP 3mg +\r\nDexamethasone BP 1 mg)/ml</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong>Texa is indicated for\r\nsteroid-responsive inflammatory ocular\r\nconditions for which a corticosteroid is\r\nindicated and where superficial bacterial\r\nocular infection or a risk of bacterial\r\ninfection exists. </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">One or\r\ntwo drops instilled into the conjunctival\r\nsac(s) every four to six hours. During the\r\ninitial 24 to 48 hours, the dosage may be\r\nincreased to one or two drops every two\r\n(2) hours. Frequency should be\r\ndecreased gradually as warranted by\r\nimprovement in clinical signs. Or, as\r\ndirected by the registered physician.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong> 5ml in plastic dropper bottle</p>",
    "strength": "0.3 & 0.1",
    "uom": "w/v",
    "categoryId": "34",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532340391TEXA.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210741Texa 5ml.png"
    ]
  },
  {
    "id": "1266",
    "name": "THEOVENT - SR ",
    "description": "<p><strong>Composition :</strong><span class=\"redactor-invisible-space\"> Theophylline USP 200mg, 300mg\r\n& 400mg Tablet.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Indications : </strong><span class=\"redactor-invisible-space\">Theovent-SR tablet is\r\nindicated for the treatment of the symptoms\r\nand reversible airflow obstruction\r\nassociated with chronic asthma and other\r\nchronic lung diseases, e.g., emphysema\r\nand chronic bronchitis. Also indicated for\r\nthe treatment of left ventricular and\r\ncongestive cardiac failure.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">TheoventSR\r\ntablets can be taken once a day in the\r\nmorning or evening. It is recommended that\r\nTheovent-SR should be taken with meals.\r\nTheovent-SR 200 : Dose 200mg every 12\r\nhours. Increased according to response to\r\n400mg every 12 hours. Theovent-SR 300 :\r\nOne tablet every 12 hours. Or as directed\r\nby the registered physician.</span><br></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Theophylline has been assigned to\r\npregnancy category C by the FDA.</span><br></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Packing : </strong></span></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong></strong><span class=\"redactor-invisible-space\">Theovent-SR tablet : 5 x 10's tablets in\r\nblister pack. </span></span></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">Theovent-SR 200 : 10 x 10's tablets in\r\nblister pack. </span></span></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">Theovent-SR 300 : 10 x 10's tablets in\r\nblister pack.</span><br></span></span></span></span></p>",
    "strength": "400,300,200",
    "uom": "mg",
    "categoryId": "47",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532340558THEOVENT-SR.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100717THEOVENT-SR 400.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744100717THEOVENT-SR 300.png",
      "https://www.admin.drug-international.com/uploads/product_images/1744100717THEOVENT-SR 200.png"
    ]
  },
  {
    "id": "1892",
    "name": "Tibomax ",
    "description": "<p><strong>Composition:</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Tibomax\r\n2.5 Tablet: </strong>Each Tablet Contains Tibolone BP 2.5 mg. <o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:\r\n</strong>Treatment\r\nof symptoms resulting from the natural or surgical menopause in post-menopausal\r\nwomen. Prevention of osteoporosis in women who have gone through the menopause\r\nand are at high risk of fractures, but cannot Take\r\nother medicines used to prevent osteoporosis.</p><p class=\"MsoNormal\" xss=\"removed\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration: Adult Dosage: </strong>Treatment of\r\nsymptoms resulting from the natural or surgical menopause: The recommended dose\r\nis 2.5 mg once daily.  Prevention of post-menopausal\r\nbone mineral density loss:  The recommended\r\ndose is 2.5 mg once daily. Improvement of symptoms generally occurs within a\r\nfew weeks, but optimal results are obtained when therapy is continued for at\r\nleast 3 months. Review should be needed for continuation of Treatment after 6 months, taking into account the\r\nrisk-benefit ratio for the individual user at that moment. Starting Tibolone Women\r\nexperiencing a natural menopause should commence treatment with Tibolone at\r\nleast 12 months after Their last natural bleed. In case of a surgical\r\nmenopause, treatment with Tibolone may commence immediately. Switching from\r\ncombined / oestrogen only hormone Replacement therapy (HRT): In women with a uterus\r\nwho change from an oestrogen-only preparation, a withdrawal bleed should be\r\ninduced before starting Tibolone. If changing from a sequential HRT\r\npreparation, treatment with Tibolone Should be started after the progestagen phase has been\r\ncompleted. If changing from a continuous-combined HRT preparation, treatment\r\ncan be started at any time. If abnormal vaginal bleeding is the reason for\r\nswitching from combined HRT, it is advised to investigate the cause of\r\nbleeding before starting Tibolone.</p><p class=\"MsoNormal\" xss=\"removed\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\">Missed tablets a missed dose should be taken as soon\r\nas remembered, unless it is more than 12 hours overdue. In the latter case, the\r\nmissed dose should be skipped and the next dose should be taken at the normal\r\ntime. Missing a dose may increase the likelihood of breakthrough bleeding and\r\nspotting. Or, as directed by the registered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><a name=\"_GoBack\"></a> </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Pregnancy and lactation: </strong>Tibolone is contraindicated\r\nin lactating women.<o></o></p><p><strong>Packing:\r\nTibomax 2.5 Tablet:</strong>Each box contains 30's tablets in blister pack.</p>",
    "strength": "2.5",
    "uom": "mg",
    "categoryId": "123",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1697608849Tibomax 2.5 Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100687Tibomax 2.5.png"
    ]
  },
  {
    "id": "982",
    "name": "Tiga",
    "description": "<p><strong></strong><strong>Composition : </strong>Ticagrelor 90mg Tablet</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Ticagrelor is indicated to\r\nreduce the rate of thrombotic\r\ncardiovascular events in patients with\r\nacute coronary syndrome (ACS)\r\n(unstable angina, non-ST elevation\r\nmyocardial infarction, or ST elevation\r\nmyocardial infarction). It has been shown\r\nto reduce the rate of cardiovascular\r\ndeath, myocardial infarction or stroke\r\ncompared to clopidogrel. In patients\r\ntreated with PCI, it also reduces the rate\r\nof stent thrombosis.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Initiate\r\nTicagrelor treatment with a 180mg (two\r\n90mg tablets) loading dose and continue\r\ntreatment with 90mg twice daily. After the\r\ninitial loading dose of aspirin (usually\r\n325mg) use Ticagrelor with a daily\r\nmaintenance dose of aspirin of 75-\r\n100mg. It can be administered with or\r\nwithout food. A patient who misses a\r\ndose of Ticagrelor should take one 90mg\r\ntablet (their next dose) at its scheduled\r\ntime. Or, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Ticagrelor Hydrochloride should be used\r\nduring pregnancy & lactation only if the\r\npotential benefit to the mother justifies\r\nthe potential risk to the fetus.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Tiga-90: 1x14's tablets in blister\r\npack.</span></p>",
    "strength": "90",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1633328429Tiga.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100657tiga-90.png"
    ]
  },
  {
    "id": "1933",
    "name": "Tixepa-‎5",
    "description": "",
    "strength": "5",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1747718263",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1747718263tixepa.jpeg"
    ]
  },
  {
    "id": "1261",
    "name": "Tocit ",
    "description": "<p><strong>Composition :</strong><span class=\"redactor-invisible-space\" xss=\"removed\">Tocit Tablet: Each Film Coated Tablet Contains Tofacitinib 5 mg as Tofacitinib Citrate INN.</span></p><p><span class=\"redactor-invisible-space\"><strong>Indication :</strong><span class=\"redactor-invisible-space\">Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It can be used as monotherapy or in combination with methotrexate or other nonbiologic Disease Modifying Antirheumatic Drugs (DMARDs).</span><br></span></p><p><span class=\"redactor-invisible-space\"><strong>Dosage and administration :</strong><span class=\"redactor-invisible-space\">The recommended dose of Tofacitinib is 5 mg twice daily. Or, as directed by the registered physician.</span><br></span></p><p><span class=\"redactor-invisible-space\"><strong>Pregnancy and lactation :</strong><span class=\"redactor-invisible-space\">Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Tofacitinib should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this medicine is excreted in human milk. Caution should be exercised when this product is administered to a nursing woman.</span><br></span></p><p><strong>Packing : Tocit Tablet:</strong><span class=\"redactor-invisible-space\" xss=\"removed\"> Each box contains 1x14's tablets in blister pack.</span></p>",
    "strength": "5,11",
    "uom": "mg",
    "categoryId": "107",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1637663630Tocit & Tocit XR.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1637662172Tocit carton.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745210824Tocit XR.png"
    ]
  },
  {
    "id": "1312",
    "name": "Tocit XR ",
    "description": "<p><strong>Composition\r\n: Tocit XR Tablet: </strong>Each  Extended Release Tablet Contains Tofacitinib\r\n11 mg as Tofacitinib Citrate INN.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indication : </strong>Tofacitinib is\r\nindicated for the treatment of adult patients with moderately to severely active rheumatoid\r\narthritis who have had an inadequate response or intolerance to methotrexate.\r\nIt can be used as monotherapy or in combination with methotrexate or other\r\nnonbiologic Disease Modifying Antirheumatic Drugs (DMARDs).</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and\r\nadministration : </strong>The\r\nrecommended dose is 11 mg once daily. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Pregnancy and\r\nlactation : </strong>Pregnancy\r\nCategory C. There are no adequate and well-controlled studies in pregnant women.Tofacitinib should be used during pregnancy only if the potential benefit\r\njustifies the potential risk to the fetus. It is not known whether this medicine\r\nis excreted in human milk. Caution should be exercised when this product is\r\nadministered to a nursing woman.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><o> </o></p><p style=\"text-align: justify;\"><strong>Packing : Tocit XR\r\nTablet: </strong>Each\r\nbox contains 1x14's tablets in blister pack.</p>",
    "strength": "11, 5,11",
    "uom": "mg",
    "categoryId": "107",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1637663600Tocit & Tocit XR.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210824Tocit XR.png",
      "https://www.admin.drug-international.com/uploads/product_images/1748511306Tocit Carton 29-05-2025.png",
      "https://www.admin.drug-international.com/uploads/product_images/1569834655Tocit XR- 30 Tab Carton Pic.png"
    ]
  },
  {
    "id": "1312",
    "name": "Tocit XR ",
    "description": "<p><strong>Composition\r\n: Tocit XR Tablet: </strong>Each  Extended Release Tablet Contains Tofacitinib\r\n11 mg as Tofacitinib Citrate INN.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indication : </strong>Tofacitinib is\r\nindicated for the treatment of adult patients with moderately to severely active rheumatoid\r\narthritis who have had an inadequate response or intolerance to methotrexate.\r\nIt can be used as monotherapy or in combination with methotrexate or other\r\nnonbiologic Disease Modifying Antirheumatic Drugs (DMARDs).</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and\r\nadministration : </strong>The\r\nrecommended dose is 11 mg once daily. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Pregnancy and\r\nlactation : </strong>Pregnancy\r\nCategory C. There are no adequate and well-controlled studies in pregnant women.Tofacitinib should be used during pregnancy only if the potential benefit\r\njustifies the potential risk to the fetus. It is not known whether this medicine\r\nis excreted in human milk. Caution should be exercised when this product is\r\nadministered to a nursing woman.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" style=\"text-align: justify;\"><o> </o></p><p style=\"text-align: justify;\"><strong>Packing : Tocit XR\r\nTablet: </strong>Each\r\nbox contains 1x14's tablets in blister pack.</p>",
    "strength": "11",
    "uom": "mg",
    "categoryId": "107",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1637663600Tocit & Tocit XR.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745210824Tocit XR.png"
    ]
  },
  {
    "id": "1094",
    "name": "Toposar",
    "description": "<p><strong></strong><strong>Composition : </strong>Toposar : Each capsule contains Etoposide USP 50mg</p><p><strong></strong></p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Etoposide is indicated in the management of Small Cell Lung Cancer: Etoposide is indicated in combination with\r\nother approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer.</span></p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\"><strong>Dosage and administration :</strong> Small cell lung cancer: The dose in combination with other approved chemotherapeutic drugs ranges from 35\r\nmg/m2/day for 4 days to 50 mg/m2/day for 5 days.Or, as directed by the registered physicians.</p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\"><strong>Use in pregnancy and lactation :</strong> Pregnancy category D. There are no adequate and well controlled studies in pregnant\r\nwoman Etoposide has been reported to be found in human milk. Patient recieves Etoposide should not be breast\r\nfeed.<strong></strong></p><p><strong>Packing : </strong>Toposar: Each box contains 4 x 7's capsules in blister pack.</p>",
    "strength": "100/20",
    "uom": "mg/ml",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/Toposar.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744100630Toposar.png"
    ]
  },
  {
    "id": "1236",
    "name": "Toposar Injection",
    "description": "<p><strong>Composition : </strong>Toposar : Each 5 ml lnjectable solution contains Etoposide USP 100mg.</p><p><strong></strong></p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Etoposide is indicated in the management of the following neoplasms: Small Cell Lung\r\nCancer: Etoposide is indicated in combination with other approved chemotherapeutic agents as first line\r\ntreatment in patients with small cell lung cancer. Refractory Testicular Tumors: Etoposide is also indicated in\r\ncombination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors\r\nwho have already received appropriate surgical, chemotherapeutic, and radio therapeutic therapy</span><span class=\"redactor-invisible-space\"></span></p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\"><strong>Dosage and administration :</strong> Small cell lung cancer: The dose in combination with other approved chemotherapeutic drugs ranges from 35\r\nmg/m2/day for 4 days to 50 mg/m2/day for 5 days. Refractory Testicular Tumors: The usual dose of Etoposide in\r\ntesticular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100\r\nmg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5. For recommended dosing adjustments in\r\npatients with renal impairment chemotherapy courses are repeated at 3- to 4-week intervals after adequate\r\nrecovery from any toxicity.Or, as directed by the registered physicians</p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\"><strong>Use in pregnancy and lactation :</strong> Pregnancy category D.There are no adequate and well controlled studies in pregnant woman Etoposide has been\r\nreported to be found in human milk. Patient recieves Etoposide should not be breast feed.<strong></strong></p><p><strong>Packing : </strong>Toposar: Each box contains one vial of 5ml solution</p>",
    "strength": "5",
    "uom": "ML",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/Toposar IV Injection- Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/toposar10.jpg"
    ]
  },
  {
    "id": "1031",
    "name": "Trialon",
    "description": "<p class=\"MsoNormal\" xss=\"removed\"><strong>Composition:</strong> Trialon Cream : Triamcinolone Acetonide BP 0.1% .</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indications :</strong> This is indicated for the relief of the inflammatory and\r\npruritic manifestations of corticosteroid responsive dermatoses. </p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and administration :</strong> It should be applied to affected area two or</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\">three\r\ntimes daily. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Packing : Trialon Cream :</strong> Each tube contains 10gm Cream.</p>",
    "strength": "0.1% w/w",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532145822Trialon Cream.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745310711Trialon Cream.png"
    ]
  },
  {
    "id": "1221",
    "name": "Trialon Injection",
    "description": "<p><strong>Composition :</strong><span class=\"redactor-invisible-space\"> Triamcinolone Acetonide\r\nUSP 40mg/1ml (IM) Injection.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Indications:</strong><span class=\"redactor-invisible-space\"> Trialon is\r\nindicated for alleviating the joint pain,\r\nswelling and stiffness associated with\r\nrheumatoid arthritis and osteoarthrosis\r\nwith an inflammatory component, also for\r\nbursitis, epicondylitis and tenosynovitis.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dosage & administration :</strong><span class=\"redactor-invisible-space\">The dose of\r\nTrialon is dependent on the size of the\r\njoint to be treated and on the severity of\r\nthe condition. Doses of 2.5-5mg (0.0625-\r\n0.1250ml) for smaller joint and 5-15mg\r\n(0.125-0.375ml) for larger joints usually\r\nalleviate the symptoms. Trialon 40mg/ml\r\nis available to facilitate administration of\r\nlarger doses. Or, as directed by the\r\nregistered physician.</span><br></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> Pregnancy\r\nCategory-C. As with all drugs,\r\nTriamcinolone should only be prescribed\r\nwhen the benefits to the mother and\r\nchild outweigh the risks. Corticosteroids\r\nmay pass into breast milk, although no\r\ndata are available for Triamcinolone.</span><br></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Packing :</strong><span class=\"redactor-invisible-space\"> Trialon Injection (IM) : 1 x 3's vials.<br></span></span></span></span></p>",
    "strength": "40",
    "uom": "mg/ml",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532341619trialon-inj.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/trialon-inj.jpg"
    ]
  },
  {
    "id": "1270",
    "name": "Trialon Nasal Spray",
    "description": "<p><strong>Composition :</strong><span class=\"redactor-invisible-space\" xss=\"removed\"> Trialon Nasal Spray : Each metered spray contains Triamcinolone Acetonide BP 55 mcg.</span></p><p style=\"text-align: justify;\"><strong></strong></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This nasal spray indicated for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis in adults and children 6 years of age and older.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adults and children 12 years of age and older: The recommended starting and maximum dose is 220 mcg per day as two sprays in each nostril once daily. Children 6 to 12 years of age: The recommended starting dose is 110 mcg per day given as one spray in each nostril once daily. The maximum recommended dose is 220 mcg per day as two sprays per nostril once daily. Children 2 to 5 years of age : Starting and maximum dose 110 mcg per day as one spray in each nostril once daily. Not recommended for children under 2 years of age. Or, as directed by the registered physician.</span><span class=\"redactor-invisible-space\"></span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy category C. There are no adequate and well controlled studies in pregnant women. Triamcinolone Acetonide nasal spray, like other corticosteroids, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Triamcinolone Acetonide is excreted in human milk. Because other corticosferoids are excreted in human milk, caution should be exercised when Triamcinolone Acetonide nasal spray is administered to a nursing woman.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Trialon Nasal Spray : Each bottle contains 120 metered doses for sprays.</span></p>",
    "strength": "55",
    "uom": "mcg/Spray",
    "categoryId": "56",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532341773Trialon Nasal Spray.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1517292286Trialon--Carton-Pic.jpg"
    ]
  },
  {
    "id": "1053",
    "name": "Trialon Oral Paste",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Triamcinolone Acetonide USP \r\n0.1%.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is indicated for aphthous\r\nulcers, ulcerative stomatitis, denture\r\nstomatitis, desquamative gingivitis,\r\nerosive lichen planus and lesions of the\r\noral mucosa of traumatic origin.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adults and\r\nChildren : To be applied to the lesion at\r\nbedtime and two to four times daily,\r\npreferably after meals. Apply to the\r\naffected area; do not rub in.\r\nElderly : Corticosteroids should be used\r\nsparingly and for short periods of time. or\r\nas directed by the registered physician</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Triamcinolone should only be prescribed\r\nwhen the benefits to the mother & child\r\noutweigh the risks. Some of\r\ncorticosteroids may pass into breast\r\nmilk, but no data are available for\r\nTriamcinolone Acetonide. Pregnancy\r\nCategory C.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Trialon Oral Paste : 10 gram\r\nin a tube.</span></p>",
    "strength": " 0.1% w/w",
    "uom": "mg",
    "categoryId": "66",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532341903TrialonPaste.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/Trialon Oral Paste.jpg"
    ]
  },
  {
    "id": "969",
    "name": "Trimet",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Trimetazidine\r\nDihydrochloride BP 20mg & Modified release\r\n35mg Tablet.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">This tablet is indicated for\r\nthe treatment of Ischaemic heart disease\r\n(angina pectoris, sequelae of infarction),\r\nadjuvant symptomatic treatment of vertigo\r\nand tinnitus, adjuvant treatment of the\r\ndecline visual acuity and visual field\r\ndisturbances, presumably of vascular\r\norigin.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Trimet\r\nOne tablet (20mg) thrice daily after meals.\r\nTrimet-MR one tablet twice daily at\r\nmealtimes in the morning and evening. Or\r\nas directed by the registered physician.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :</strong>: No drug interactions\r\nhave so far been reported. In particular,\r\nno interactions of Trimetazidine with betablockers,\r\ncalcium antagonists, nitrates,\r\nheparin, hypolipidemic agents or digitalis\r\nhave been reported.</p><p style=\"text-align: justify;\"><strong>Packing :</strong> Trimet : 5x10’s tablets in\r\nblister pack.</p>",
    "strength": "20",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532342032Trimet.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/images/Trimet.jpg"
    ]
  },
  {
    "id": "970",
    "name": "Trimet - MR",
    "description": "<p style=\"margin-bottom: 10px; color: rgb(68, 68, 68); font-family: Roboto, \" helvetica=\"\" neue\",=\"\" helvetica,=\"\" arial,=\"\" sans-serif;=\"\" background-color:=\"\" rgb(255,=\"\" 255,=\"\" 255);\"=\"\"><strong>Composition :</strong> Trimetazidine Dihydrochloride 20mg & Modified release 35mg Tablet.<strong></strong></p><p style=\"margin-bottom: 10px; color: rgb(68, 68, 68); text-align: justify;\" helvetica=\"\" neue\",=\"\" helvetica,=\"\" arial,=\"\" sans-serif;=\"\" background-color:=\"\" rgb(255,=\"\" 255,=\"\" 255);\"=\"\"><strong>Indication : </strong>This tablet is indicated for the treatment of Ischaemic heart disease (angina pectoris, sequelae of infarction), adjuvant symptomatic treatment of vertigo and tinnitus, adjuvant treatment of the decline visual acuity and visual field disturbances, presumably of vascular origin.</p><p style=\"margin-bottom: 10px; color: rgb(68, 68, 68); text-align: justify;\" helvetica=\"\" neue\",=\"\" helvetica,=\"\" arial,=\"\" sans-serif;=\"\" background-color:=\"\" rgb(255,=\"\" 255,=\"\" 255);\"=\"\"><strong>Dosage and administration :</strong> Trimet One tablet (20mg) thrice daily after meals. Trimet-MR one tablet twice daily at mealtimes in the morning and evening. Or as directed by the registered physician.</p><p style=\"margin-bottom: 10px; color: rgb(68, 68, 68); text-align: justify;\" helvetica=\"\" neue\",=\"\" helvetica,=\"\" arial,=\"\" sans-serif;=\"\" background-color:=\"\" rgb(255,=\"\" 255,=\"\" 255);\"=\"\"><strong>Use in pregnancy and lactation : </strong>No drug interactions have so far been reported. In particular, no interactions of Trimetazidine with betablockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis have been reported.</p><p style=\"text-align: justify;\"><strong>Packing :</strong><strong> </strong>Trimet-MR : 2x14’s tablets in blister pack.</p>",
    "strength": "35",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532342111Trimet.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744025270Trimet-MR.png"
    ]
  },
  {
    "id": "860",
    "name": "Trolen - 25",
    "description": "<p><strong></strong><strong>Composition : </strong>Dantrolene Sodium USP 25 mg.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">In Chronic Spasticity :\r\nDantrolene Sodium is indicated in controlling the\r\nmanifestations of clinical spasticity resulting\r\nfrom upper motor neuron disorders such as\r\nspinal cord injury, stroke, cerebral palsy or\r\nmultiple sclerosis. It is of particular benefit to the\r\npatient whose functional rehabilitation has been\r\nretarded by the sequelae of spasticity</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">For use in\r\nChronic Spasticity : Adults Patients : The\r\nfollowing gradual titration schedule is\r\nsuggested. Some patients will not respond until\r\nhigher daily dosage is achieved. Each dosage\r\nlevel should be maintained for seven days to\r\ndetermine the patient's response. If no further\r\nbenefit is observed at the next higher dose,\r\ndosage should be decreased to the previous\r\nlower dose. 25 mg once daily for seven days,\r\nthen 25 mg 3 times for seven days, 50 mg 3\r\ntimes for seven days, 100 mg 3 times. For</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Pregnancy\r\nCategory C. Dantrolene should be used during\r\npregnancy only if the potential benefit justifies\r\nthe potential risk to the fetus. Dantrolene should\r\nnot be used in nursing mothers.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Trolen-25 : 2 x 10's capsules in\r\nblister pack.</span></p>",
    "strength": "25",
    "uom": "mg",
    "categoryId": "55",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532342249trolen-25.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1684407755Trolen-25 Carton.png"
    ]
  },
  {
    "id": "782",
    "name": "Trum 3",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Ceftazidime USP 250mg, 500mg &\r\n1gm Injection.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is indicated for the treatment of\r\nsingle infections and for mixed infections caused\r\nby susceptible organisms. S evere infections in\r\ngeneral : for example septicaemia, bacteraemia,\r\nperitonitis, meningitis, infections in\r\nimmunosuppressed patients and in patients in\r\nintensive care units with specific problems.\r\nR espiratory tract infections : for example,\r\npneumonia, bronchopneumonia, infected\r\npleuris y, empyema, lung abs cess, infected\r\nbronchiectasis, bronchitis and lung infections in\r\npatients with cystic fibrosis. E ar, nose and throat\r\ninfections : otitis media, otitis externa,\r\nmastoiditis, sinusitis and other severe ear and\r\nthroat infections. Urinary tract infections: acute\r\nand chronic pyelonephritis, pyelitis, prostatitis,\r\ncystitis, urethritis, renal abscess. S kin and soft\r\ntissue infections: abscess, cellulitis, infected burn\r\nand wounds, skin ulcers etc. Gastrointestinal\r\nbiliary and abdominal infections : cholangitis,\r\ncholecystitis, intraabdominal abscess, peritonitis\r\netc. Bone and joint infections : Osteomyelitis,\r\nseptic arthritis etc.\r\n</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration </strong>:Adults : The adult dosage range for\r\nCeftazidime is 1gm to 6gm per day 8 or 12 hourly\r\n(IM or IV). In the majority of infections, 1gm 8\r\nhourly or 2gm 12 hourly should be given. In\r\nurinary tract infections and many less serious\r\ninfections, 250mg or 500mg or 1gm 12 hourly is\r\nusually adequate. In very severe infections,\r\nespecially immunocompromis ed patients,\r\nincluding those with neutropenia, 2gm 8 or 12\r\nhourly or 3gm 12 hourly should be administered\r\nor as directed by the registered physician.\r\nInfants and children : The usual dosage range for\r\nchildren aged over 2 months is 30 to\r\n100mg/kg/day, given as two or three divided\r\ndoses.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">Ceftazidime has been assigned to pregnancy\r\ncategory B by the FDA.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong>1 Combipack.</p>",
    "strength": "1,500,250",
    "uom": "gm(IV/IM)",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532342398Trum_3.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745211154TRUM 3 1gm.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745211154TRUM 3 500mg.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745211154TRUM 3.png"
    ]
  },
  {
    "id": "1934",
    "name": "Tyzepa",
    "description": "<p>Composition: Each pre-filled syringe contains Tirzepatide 5 mg/0.5 ml. </p><p>Indication: Tyzepa is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • Chronic obesity (with a BMI of 30 kg/m2 or greater). • Overweight (with a BMI of 27 kg/m2 or greater), in the presence of at least one weight-related comorbid condition such as hypertension, cardiovascular disease, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea.</p><p>Dosage and administration: Please see prescribing description.</p><p>Use in pregnancy and lactation: Tirzepatide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p><p>Packing:</p><p>Tyzepa 5 mg SC Injection: Each box contains 1 pre-filled syringe of Tyzepa 5 injection and 1 alcohol pad.</p>",
    "strength": "5",
    "uom": "mg/ml",
    "categoryId": "131",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1750733799Tyzepa 5 Insert (For Website).pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1750733704Tyzepa Branding.png"
    ]
  },
  {
    "id": "1281",
    "name": "Ulcar ",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\">Ranitidine USP 150mg &\r\n300mg Tablet.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Indications : </strong><span class=\"redactor-invisible-space\">Ulcar is indicated for the\r\ntreatment of duodenal ulcer and benign\r\ngastric ulcer, including that associated\r\nwith non-steroidal anti-inflammatory\r\nagents.\r\nUlcar tablet is also indicated for the\r\ntreatment of post-operative ulcer,\r\noesophageal reflux disease and\r\nZollinger-Ellison Syndrome. Other\r\npatients with chronic episodic dyspepsia,\r\ncharacterised by pain (epigastric or\r\nretrosternal) which is related to meals or\r\ndisturbs sleep but is not associated with\r\nthe preceding conditions may benefit\r\nfrom Ranitidine treatment. Ulcar is\r\nindicated for conditions where reduction\r\nof gastric secretion and acid output is\r\ndesirable such as: the prophylaxis of\r\ngastro-intestinal haemorrhage from\r\nstress ulceration in seriously ill patients,\r\nthe prophylaxis of recurrent haemorrhage\r\nin patients with bleeding peptic ulcers\r\nand before general anaesthesia in\r\npatients considered to be at risk of acid\r\naspiration (Mendelson's Syndrome),\r\nparticularly obstetric patients during\r\nlabour.</span><br></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Ulcar\r\nTablet : The recommended oral dosage\r\nof Ulcar for adults is 150mg tablet twice\r\ndaily. An alternate dosage of 300mg daily\r\nat bed time can be used for patients in\r\nwhom dosing convenience is important.\r\nOr as directed by a registered physician.\r\n</span><br></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Use in pregnancy and lactation :</strong><span class=\"redactor-invisible-space\"> Ranitidine has been assigned to\r\npregnancy category B by the FDA.</span><br></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><strong>Packing :</strong><br></span></span></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">Ulcar 150mg Tablet : 10x10's tablets in\r\nformed pack. </span></span></span></span></span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\"><span class=\"redactor-invisible-space\">Ulcar 300mg Tablet : 5x10's tablets in\r\nformed pack.</span></span></span></span></span></p>",
    "strength": "300,150",
    "uom": "mg",
    "categoryId": "37",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532338654Ulcar.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1517301853Ulcar.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1562217154Ulcar.jpg"
    ]
  },
  {
    "id": "783",
    "name": "Unipim",
    "description": "<p><strong></strong><strong>Composition : </strong>: Cefepime USP 500 mg & 1gm injection.</p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is indicated for moderate to severe\r\nPneumonia caused by Pseudomonas aeruginosa,\r\nKlebsiella pneumoniae, Streptococcus pneumoniae,\r\nand other Gram negative organisms; Empiric\r\ntherapy for Febrile Neutropenia; Treatment of\r\nUncomplicated and Complicated Urinary Tract\r\nInfections, including pyelonephritis caused by\r\ntypical urinary tract pathogens; Uncomplicated Skin\r\nand Skin structure infections caused by\r\nStaphylococcus aureus or Streptococcus pyogenes;\r\nIt is also used for Complicated Intra-abdominal\r\ninfections used in combination with metronidazole.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong><strong> </strong><span class=\"redactor-invisible-space\"><strong>Adult :\r\n</strong>Recommended Dosage Schedule Moderate to severe Pneumonia : 1-2gm IV every\r\n12hr for 10 days. Empiric therapy for febrile Neutropenia : 2gm IV\r\nevery 8hr for 7 days.\r\nMild to moderate Complicated or Uncomplicated\r\nUrinary Tract Infection, including pyelonephritis :\r\n500mg-1gm IV every 12hr for 7-10 days. Severe Complicated or Uncomplicated Urinary\r\nTract Infection, including pyelonephritis : 2gm IV\r\nevery 12hr for 10 days. Moderate to severe Uncomplicated skin and skin\r\nstructure infections : 2gm IV every 12hr for 10 days. Complicated Intra-abdominal Infections used in\r\ncombination with Metronidazole : 2gm IV every 12hr\r\nfor 7-10 days. </span>Please see\r\nprescribing description for more information.</p><p class=\"MsoNormal\"><o:p></o:p></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>P<strong></strong><span class=\"redactor-invisible-space\" style=\"background-color: initial;\">regnancy category B by the\r\nFDA.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong> <span class=\"redactor-invisible-space\">Unipim-500 (IV/IM) injection : 1 Combipack.<strong> </strong></span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><strong>Unipim-1gm (IV/IM) injection :</strong> 1 Combipack</span></p>",
    "strength": "1,500",
    "uom": "gm(IV/IM)",
    "categoryId": "38",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532338797Unipim.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745211198UNIPIM- 1GM.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745211198UNIPIM-500.png"
    ]
  },
  {
    "id": "1216",
    "name": "Ursolic Suspension",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Ursodeoxycholic Acid BP  250mg/5ml Suspension.</span></p><p style=\"text-align: justify;\"><strong>Indication :</strong>: This drug is indicated for the dissolution of small to medium sized radiolucent, cholesterol rich gall-stones in functioning gall bladders. This drug is also indicated for the treatment of primary biliary cirrhosis.</p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adults and Elderly : Dissolution of gallstones : 8- 12mg/kg body weight daily as a single dose at bedtime or in two divided doses, for up to 2 years; treatment is continued for 3-4 months after stones dissolve.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Children : Not recommended. Or, as directed by the registered physician. Please see prescribing description for more information.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong>Pregnancy Category B by FDA</p><p style=\"text-align: justify;\"><strong>Packing :</strong><span class=\"redactor-invisible-space\"></span></p><p style=\"text-align: justify;\">Ursolic Suspension : 50ml oral suspension.</p>",
    "strength": "250",
    "uom": "mg/5ml",
    "categoryId": "110",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532339140ursolic.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/urso.jpg"
    ]
  },
  {
    "id": "910",
    "name": "Ursolic Tablet",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Ursodeoxycholic Acid BP\r\n150mg, 300mg Tablet. </span></p><p style=\"text-align: justify;\"><strong>Indication :</strong>: This drug is indicated for\r\nthe dissolution of small to medium sized\r\nradiolucent, cholesterol rich gall-stones\r\nin functioning gall bladders. This drug is\r\nalso indicated for the treatment of\r\nprimary biliary cirrhosis. </p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Adults and\r\nElderly : Dissolution of gallstones : 8-\r\n12mg/kg body weight daily as a single\r\ndose at bedtime or in two divided doses,\r\nfor up to 2 years; treatment is continued\r\nfor 3-4 months after stones dissolve.</span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Children : Not recommended. Or, as directed\r\nby the registered physician. Please see prescribing description for more information.</span></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :  </strong>Pregnancy Category B by FDA</p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Ursolic 150 : 2x10's tablets in blister\r\npack. </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\">Ursolic 300 : 1x10's tablets in blister\r\npack. </span></p><p style=\"text-align: justify;\"><span class=\"redactor-invisible-space\"><br></span></p>",
    "strength": "300,150",
    "uom": "mg",
    "categoryId": "110",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532338977ursolic.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745211228Ursolic-300.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745211228Ursolic-150.png"
    ]
  },
  {
    "id": "1885",
    "name": "Urtin 10 ",
    "description": "<p><strong>Composition:Urtin\r\n10 Tablet :</strong>Each Film Coated Tablet Contains Ebastine BP 10mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong>It is indicated\r\nfor the symptomatic treatment of: <o></o></p><p class=\"MsoNormal\" xss=\"removed\">1)\r\nSeasonal and Perennial Allergic Rhinitis.<o></o></p><p class=\"MsoNormal\" xss=\"removed\">2)\r\nChronic Idiopathic Urticaria.<o></o></p><p class=\"MsoNormal\" xss=\"removed\">3)\r\nAllergic skin Disorders.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage\r\nand administration : Adults (more than 12 years of age): </strong>10 mg (one tablet) once daily.<strong> Children (6-12 years of age): </strong>5 mg\r\n(half tablet) once daily.Ebastine may be taken with or without food. Or, as\r\ndirected by the registered physician.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong> </strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use\r\nin Pregnancy and Lactation: </strong>The safety of\r\nEbastine during pregnancy and lactation has not been established.<o></o></p><p><strong>Packing\r\n:<a name=\"_GoBack\"></a>Urtin 10 Tablet : </strong>Each\r\nbox contains 3 x 10's tablets in blister pack.</p>",
    "strength": "10",
    "uom": "mg",
    "categoryId": "41",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1690455853Urtin 10 Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744025198Urtin 10.png"
    ]
  },
  {
    "id": "1829",
    "name": "Vancin",
    "description": "<p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Composition: Vancin-500 IV Infusion : </strong>Each\r\nVial Contains Vancomycin 500mg sterile powder (As Vancomycin Hydrochloride\r\nUSP).<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Vancin-1gm IV Infusion : </strong>Each Vial Contains Vancomycin 1 gm sterile powder (As Vancomycin Hydrochloride USP).<br></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Indications\r\n: </strong>Vancomycin is indicated for\r\nthe treatment of serious or severe infections caused by susceptible strains of methicillin-resistant\r\n(beta-lactamresistant) staphylococci. It is indicated for penicillin-allergic\r\npatients, for patients who cannot receive or who have failed to respond to\r\nother drugs, including the penicillins or cephalosporins, and for infections\r\ncaused by vancomycin-susceptible organisms that are resistant to other antimicrobial\r\ndrugs. Vancomycin is indicated for initial therapy when methicillin-resistant\r\nstaphylococci are suspected, but after susceptibility data are available,\r\ntherapy should be adjusted accordingly.Vancomycin is effective in the treatment\r\nof staphylococcal endocarditis. Its effectiveness has been documented in other\r\ninfections due to staphylococci, including septicemia, bone infections, lower\r\nrespiratory tract infections, skin and skin structure infections. When\r\nstaphylococcal infections are localized and purulent, antibiotics are used as\r\nadjuncts to appropriate surgical measures.<o:p></o:p></p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><strong>Dosage\r\nand Administration: </strong>Vancomycin should be administered intravenously. For\r\ndetail please see detailed Insert.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;margin-bottom:.0001pt;text-align:\r\njustify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align:\r\nnone;text-autospace:none\"><o:p></o:p></p><p><strong>Packing: Vancin-500 IV Infusion : </strong>Each\r\nbox contains 1 vial of Vancomycin 500mg sterile powder (As Vancomycin\r\nHydrochloride USP).<br></p><p><strong>Vancin-1gm IV Infusion : </strong>Each box contains 1 vial of Vancomycin 1gm sterile powder (As Vancomycin Hydrochloride USP).<br></p><p><br></p>",
    "strength": " 1,500",
    "uom": "gm(IV)",
    "categoryId": "38",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745211265Vancin-1gm.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745211265Vancin-500.png"
    ]
  },
  {
    "id": "1311",
    "name": "Varox",
    "description": "<p><strong>Composition :<br></strong></p><p><strong>Varox :</strong>Each film coated\r\ntablet contains Rivaroxaban INN 2.5 mg.</p><p><strong>Varox-10 :</strong> Each film coated tablet contains Rivaroxaban INN 10 mg<br></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Indications : Varox :</strong> The medicine is indicated for the prevention of atherothrombotic events in adult patients after an Acute Coronary Syndrome (ACS) with elevated cardic biomarkers\r\n(Troponin or CK-MB). It is co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Varox-10 :</strong>Prevention of venous thromboembolism (VTE) in adult patientsundergoing elective hip or knee replacement  surgery. Treatment of DVT, PE & extendedtreatment of prevention of recurrent DVT & PE in adult.Reduction in Risk of Stroke & Systemic Embolism in Non valvular Atrial Fibrillation.<br></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong><o> </o></strong></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Dosage and\r\nadministration : </strong><strong>Varox :</strong>The\r\nrecommended dose is 2.5 mg twice daily, Patients should\r\nalso take a daily dose 75- 100 mg Aspirin or a daily of 75-100mg aspirin in addition\r\nto either a daily dose of 75 mg clopidogrel or a standard daily dose of ticlopidine.\r\nTreatment with Varox should be started as soon as possible after stabilization\r\nof the ACS event; at the earliest 24 hours after admission to hospital & at\r\nthe time when parenteral anticoagulation therapy would normally be dicontinued.<strong><br></strong></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Varox-10 :</strong> See the full Medicine Description.Or,\r\nas directed by the registered physicians.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o> </o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><strong>Use in Pregnancy\r\nand lactation : </strong>Pregnancy\r\ncategory C. There is no adequate or\r\nwell-controlled studies of Rivaroxaban in pregnant women, It should be used with\r\ncaution in pregnant women only if the potential benefit justifies the potential risk to\r\nthe mother & fetus. It is not known if Rivaroxaban is excreted in human milk. A\r\ndecision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.</p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o></o></p><p class=\"MsoNormal\" xss=\"removed\" style=\"text-align: justify;\"><o> </o></p><p style=\"text-align: justify;\"><strong>Packing : </strong><strong>Varox : </strong><strong></strong>Each box contains\r\n2 x 14's tablets in blister pack.</p><p style=\"text-align: justify;\"><strong>Varox-10 : </strong><strong></strong><strong></strong>Each box contains 1 x 14's tablets in blister pack.<strong></strong><br></p>",
    "strength": " 10,2.5",
    "uom": "mg",
    "categoryId": "65",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1569999885Varox Insert [Converted].pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1569999885V-10.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/15699998851522141958Varox.jpg (2).jpg"
    ]
  },
  {
    "id": "1831",
    "name": "VENETA-10",
    "description": "<p><strong>Composition: Veneta-10:\r\n</strong>Each\r\nfilm coated tablet contains Venetoclax INN 10mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong>\r\n<strong>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: </strong>Venetoclax is\r\nindicated for the treatment of adult patients with chronic lymphocytic leukemia\r\n(CLL) or small lymphocytic lymphoma (SLL). <strong>Acute Myeloid Leukemia: </strong>Venetoclax\r\nis indicated in combination with Azacitidine, or Decitabine, or low-dose\r\nCytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in\r\nadults 75 years or older, or who have comorbidities that preclude use of\r\nintensive induction chemotherapy.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage &\r\nadministration: In Combination with Obinutuzumab: </strong>Start\r\nObinutuzumab administration at 100 mg on Cycle 1 Day 1, followed by 900 mg on\r\nCycle 1 Day 2. Administer 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of\r\neach subsequent 28-day cycle for a total of 6 cycles. Refer to the Obinutuzumab\r\nprescribing information for additional dosing information. On Cycle 1 Day 22,\r\nstart Venetoclax according to the 5-week ramp-up dosing schedule (see Table 1).\r\nAfter completing the ramp-up phase on Cycle 2 Day 28, continue Venetoclax at a\r\ndose of 400 mg orally once daily from Cycle 3 Day 1 until the last day of Cycle\r\n12. <strong>In Combination with Rituximab: </strong>Start Rituximab administration after\r\nthe patient has completed the 5-week ramp-up dosing schedule for Venetoclax\r\n(see Table 1) and has received Venetoclax at the recommended dosage of 400 mg\r\norally once daily for 7 days. Administer rituximab on Day 1 of each 28-day\r\ncycle for 6 cycles, at a dose of 375 mg/m² intravenously for Cycle 1 and 500\r\nmg/m² intravenously for Cycles 2-6. Continue Venetoclax 400 mg orally once\r\ndaily for 24 months from Cycle 1 Day 1 of Rituximab. <strong>Monotherapy: </strong>The\r\nrecommended dosage of Venetoclax is 400 mg once daily after completion of the\r\n5-week ramp-up dosing schedule. Continue Venetoclax until disease progression\r\nor unacceptable toxicity. Or, as directed by the\r\nregistered physicians.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Pregnancy &\r\nlactation: </strong>Venetoclax may cause embryo-fetal harm\r\nwhen administered to a pregnant woman. There are no available data on\r\nVenetoclax use in pregnant women to inform a drug-associated risk. There are no\r\ndata on the presence of Venetoclax in human milk or the effects on the\r\nbreastfed child or milk production.<o></o></p><p><strong>Packaging: Veneta-10: </strong>Each\r\nbox contains 30 tablets in a blister pack.</p>",
    "strength": "10",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1651128753Veneta-10, 50 & 100 Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744025144Veneta-10.png"
    ]
  },
  {
    "id": "1817",
    "name": "VENETA-100",
    "description": "<p><strong>Composition:\r\nVeneta-100: </strong>Each film coated tablet contains\r\nVenetoclax INN 100mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications:</strong>\r\n<strong>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: </strong>Venetoclax is\r\nindicated for the treatment of adult patients with chronic lymphocytic leukemia\r\n(CLL) or small lymphocytic lymphoma (SLL). <strong>Acute Myeloid Leukemia: </strong>Venetoclax\r\nis indicated in combination with Azacitidine, or Decitabine, or low-dose\r\nCytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in\r\nadults 75 years or older, or who have comorbidities that preclude use of\r\nintensive induction chemotherapy.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage &\r\nadministration: In Combination with Obinutuzumab: </strong>Start\r\nObinutuzumab administration at 100 mg on Cycle 1 Day 1, followed by 900 mg on\r\nCycle 1 Day 2. Administer 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of\r\neach subsequent 28-day cycle for a total of 6 cycles. Refer to the Obinutuzumab\r\nprescribing information for additional dosing information. On Cycle 1 Day 22,\r\nstart Venetoclax according to the 5-week ramp-up dosing schedule (see Table 1).\r\nAfter completing the ramp-up phase on Cycle 2 Day 28, continue Venetoclax at a\r\ndose of 400 mg orally once daily from Cycle 3 Day 1 until the last day of Cycle\r\n12. <strong>In Combination with Rituximab: </strong>Start Rituximab administration after\r\nthe patient has completed the 5-week ramp-up dosing schedule for Venetoclax\r\n(see Table 1) and has received Venetoclax at the recommended dosage of 400 mg\r\norally once daily for 7 days. Administer rituximab on Day 1 of each 28-day\r\ncycle for 6 cycles, at a dose of 375 mg/m² intravenously for Cycle 1 and 500\r\nmg/m² intravenously for Cycles 2-6. Continue Venetoclax 400 mg orally once\r\ndaily for 24 months from Cycle 1 Day 1 of Rituximab. <strong>Monotherapy: </strong>The\r\nrecommended dosage of Venetoclax is 400 mg once daily after completion of the\r\n5-week ramp-up dosing schedule. Continue Venetoclax until disease progression\r\nor unacceptable toxicity. Or, as directed by the\r\nregistered physicians.<o></o></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Pregnancy &\r\nlactation: </strong>Venetoclax may cause embryo-fetal harm\r\nwhen administered to a pregnant woman. There are no available data on\r\nVenetoclax use in pregnant women to inform a drug-associated risk. There are no\r\ndata on the presence of Venetoclax in human milk or the effects on the\r\nbreastfed child or milk production.<o></o></p><p><strong>Packaging: Veneta-100: </strong>Each\r\nbox contains 30 tablets in a blister pack.</p>",
    "strength": "100",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1643013399Veneta 100- Tablet Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1744025171Veneta-100.png"
    ]
  },
  {
    "id": "1832",
    "name": "VENETA-50",
    "description": "<p><strong>Composition: Veneta-50:\r\n</strong>Each\r\nfilm coated tablet contains Venetoclax INN 50mg.</p>\r\n\r\n<p class=\"MsoNormal\" xss=removed><strong>Indications:</strong>\r\n<strong>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: </strong>Venetoclax is\r\nindicated for the treatment of adult patients with chronic lymphocytic leukemia\r\n(CLL) or small lymphocytic lymphoma (SLL). <strong>Acute Myeloid Leukemia: </strong>Venetoclax\r\nis indicated in combination with Azacitidine, or Decitabine, or low-dose\r\nCytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in\r\nadults 75 years or older, or who have comorbidities that preclude use of\r\nintensive induction chemotherapy.<o></o></p>\r\n\r\n<p class=\"MsoNormal\" xss=removed><strong>Dosage &\r\nadministration: In Combination with Obinutuzumab: </strong>Start\r\nObinutuzumab administration at 100 mg on Cycle 1 Day 1, followed by 900 mg on\r\nCycle 1 Day 2. Administer 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of\r\neach subsequent 28-day cycle for a total of 6 cycles. Refer to the Obinutuzumab\r\nprescribing information for additional dosing information. On Cycle 1 Day 22,\r\nstart Venetoclax according to the 5-week ramp-up dosing schedule (see Table 1).\r\nAfter completing the ramp-up phase on Cycle 2 Day 28, continue Venetoclax at a\r\ndose of 400 mg orally once daily from Cycle 3 Day 1 until the last day of Cycle\r\n12. <strong>In Combination with Rituximab: </strong>Start Rituximab administration after\r\nthe patient has completed the 5-week ramp-up dosing schedule for Venetoclax\r\n(see Table 1) and has received Venetoclax at the recommended dosage of 400 mg orally\r\nonce daily for 7 days. Administer rituximab on Day 1 of each 28-day cycle for 6\r\ncycles, at a dose of 375 mg/m² intravenously for Cycle 1 and 500 mg/m²\r\nintravenously for Cycles 2-6. Continue Venetoclax 400 mg orally once daily for\r\n24 months from Cycle 1 Day 1 of Rituximab. <strong>Monotherapy: </strong>The recommended\r\ndosage of Venetoclax is 400 mg once daily after completion of the 5-week ramp-up\r\ndosing schedule. Continue Venetoclax until disease progression or unacceptable\r\ntoxicity. Or,\r\nas directed by the registered physicians.<o></o></p>\r\n\r\n<p class=\"MsoNormal\" xss=removed><strong>Pregnancy &\r\nlactation: </strong>Venetoclax may cause embryo-fetal harm\r\nwhen administered to a pregnant woman. There are no available data on\r\nVenetoclax use in pregnant women to inform a drug-associated risk. There are no\r\ndata on the presence of Venetoclax in human milk or the effects on the\r\nbreastfed child or milk production.<o></o></p>\r\n\r\n<p><strong>Packaging: Veneta-50: </strong>Each\r\nbox contains 30 tablets in a blister pack.</p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1651128987Veneta-50 Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1651128987Veneta-50 Carton Pic.png"
    ]
  },
  {
    "id": "1816",
    "name": "VENEX",
    "description": "<p class=\"MsoNormal\"><strong>Composition: VENEX-10: </strong>Each\r\ntablet contains Venetoclax INN 10mg.<br>\r\n<strong>VENEX-50: </strong>Each tablet contains Venetoclax INN 50mg.<br>\r\n<strong>VENEX-100: </strong>Each tablet contains Venetoclax INN 100mg.<strong><o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong> </strong></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications:</strong>\r\n<strong>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: </strong>Venetoclax is\r\nindicated for the treatment of adult patients with chronic lymphocytic leukemia\r\n(CLL) or small lymphocytic lymphoma (SLL). <strong>Acute Myeloid Leukemia: </strong>Venetoclax\r\nis indicated in combination with Azacitidine, or Decitabine, or low-dose\r\nCytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in\r\nadults 75 years or older, or who have comorbidities that preclude use of\r\nintensive induction chemotherapy</p><h4 style=\"text-align:justify\">Dosage and administration:</h4><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>In Combination with\r\nObinutuzumab: </strong>Start Obinutuzumab administration at 100\r\nmg on Cycle 1 Day 1, followed by 900 mg on Cycle 1 Day 2. Administer 1000 mg on Days 8 and\r\n15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for a total of 6 cycles. Refer\r\nto the Obinutuzumab prescribing information for additional dosing information. On\r\nCycle 1 Day 22, start Venetoclax according to the 5-week ramp-up dosing schedule (see Table 1).\r\nAfter completing the ramp-up phase on Cycle 2 Day 28, continue Venetoclax at a dose\r\nof 400 mg orally once daily from Cycle 3 Day 1 until the last day of Cycle 12.<br>\r\n<strong>In Combination with Rituximab: </strong>Start Rituximab administration after the\r\npatient has completed the 5-week ramp-up dosing schedule for Venetoclax (see Table 1) and\r\nhas received Venetoclax at the recommended dosage of 400 mg orally once daily for 7 days.\r\nAdminister rituximab on Day 1 of each 28-day cycle for 6 cycles, at a dose of 375 mg/m²\r\nintravenously for Cycle 1 and 500 mg/m² intravenously for Cycles 2-6. Continue Venetoclax 400 mg\r\norally once daily for 24 months from Cycle 1 Day 1 of Rituximab.<br>\r\n<strong>Monotherapy: </strong>The recommended dosage of Venetoclax is 400 mg once daily\r\nafter completion<br>\r\nof the 5-week ramp-up dosing schedule (see Table 1). Continue Venetoclax until\r\ndisease<br>\r\nprogression or unacceptable toxicity. Or, as directed by the registered\r\nphysician.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Pregnancy &\r\nlactation: </strong>Venetoclax may cause embryo-fetal harm\r\nwhen administered to a pregnant woman. There are no available data on Venetoclax use in pregnant women\r\nto inform a drug-associated risk. Administration of Venetoclax to pregnant mice during\r\nthe period of organogenesis was fetotoxic at exposures 1.2 times the human exposure at the\r\nrecommended dose of 400 mg daily based on AUC. Advise pregnant women of the potential risk\r\nto a fetus. The estimated background risk of major birth defects and miscarriage for the\r\nindicated population is unknown. All pregnancies have a background risk of birth defect,\r\nloss, or other adverse outcomes.<strong> <o:p></o:p></strong></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong> </strong></p><p class=\"MsoNormal\"><strong>Packaging: VENEX-10: </strong>Each\r\ncontainer contains 30 tablets in a box.<br>\r\n<strong>VENEX-50: </strong>Each container contains 30 tablets in a box.<br>\r\n<strong>VENEX-100: </strong>Each container contains 30 tablets in a box.<br><o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>VENEX-100: </strong>Each container contains 120 tablets in a box.<br></p>",
    "strength": " 100,100",
    "uom": "mg",
    "categoryId": "57",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1643172905Venex-100-120 Tablet-Carton Pic.png",
      "https://www.admin.drug-international.com/uploads/product_images/1643172723Venex-100-30 Tablet-Carton Pic.png"
    ]
  },
  {
    "id": "739",
    "name": "VENTIL PLUS ",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Each metered dose\r\n(puff) contains Salbutamol BP 100 mcg and Ipratropium\r\nBromide BP 20 mcg. </span><strong></strong></p><p style=\"text-align: justify;\"><strong>Indication : </strong>This Inhaler is indicated for\r\npatients with chronic obstructive\r\npulmonary disease (COPD) on a regular\r\naerosol bronchodilator who continue to\r\nhave evidence of bronchospasm and\r\nwho require a second bronchodilator.</p><p style=\"text-align: justify;\"><strong>Dosage and administration :  </strong><span class=\"redactor-invisible-space\">The\r\nrecommended dose of this inhaler is two\r\ninhalations four times a day. Patients\r\nmay take additional inhalations as\r\nrequired; however, the total number of\r\ninhalations should not exceed 12 in 24\r\nhours. Or, as directed by the registered\r\nphysician</span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :  </strong><span class=\"redactor-invisible-space\">There are no adequate and well-controlled\r\nstudies of Ventil Plus in\r\npregnant women. This Inhaler should be\r\nused during pregnancy only if the\r\npotential benefit justifies the potential risk\r\nto the fetus. It is not known whether the\r\ncomponents of Ventil Plus are excreted\r\nin human milk, caution should be\r\nexercised when this Inhaler is\r\nadministered to a nursing mother.</span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Each box contains one inhaler of 200\r\nPuffs.</span><span></span><br></p>",
    "strength": "120,100",
    "uom": "mcg/puf",
    "categoryId": "53",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532338439VENTIL _PLUS.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/VENTIL_ PLUS.jpg",
      "https://www.admin.drug-international.com/uploads/product_images/1517291443ventil.jpg"
    ]
  },
  {
    "id": "739",
    "name": "VENTIL PLUS ",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Each metered dose\r\n(puff) contains Salbutamol BP 100 mcg and Ipratropium\r\nBromide BP 20 mcg. </span><strong></strong></p><p style=\"text-align: justify;\"><strong>Indication : </strong>This Inhaler is indicated for\r\npatients with chronic obstructive\r\npulmonary disease (COPD) on a regular\r\naerosol bronchodilator who continue to\r\nhave evidence of bronchospasm and\r\nwho require a second bronchodilator.</p><p style=\"text-align: justify;\"><strong>Dosage and administration :  </strong><span class=\"redactor-invisible-space\">The\r\nrecommended dose of this inhaler is two\r\ninhalations four times a day. Patients\r\nmay take additional inhalations as\r\nrequired; however, the total number of\r\ninhalations should not exceed 12 in 24\r\nhours. Or, as directed by the registered\r\nphysician</span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation :  </strong><span class=\"redactor-invisible-space\">There are no adequate and well-controlled\r\nstudies of Ventil Plus in\r\npregnant women. This Inhaler should be\r\nused during pregnancy only if the\r\npotential benefit justifies the potential risk\r\nto the fetus. It is not known whether the\r\ncomponents of Ventil Plus are excreted\r\nin human milk, caution should be\r\nexercised when this Inhaler is\r\nadministered to a nursing mother.</span><strong><br></strong></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Each box contains one inhaler of 200\r\nPuffs.</span><span></span><br></p>",
    "strength": "120",
    "uom": "mcg/puf",
    "categoryId": "53",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532338439VENTIL _PLUS.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/VENTIL_ PLUS.jpg"
    ]
  },
  {
    "id": "1932",
    "name": "Vilsin-1.34",
    "description": "<p>Avatrombopag(<span lang=\"ZH-CN\" xss=\"removed\">阿伐曲波帕</span> ) INN 1.34mg<span lang=\"ZH-CN\" xss=\"removed\">片剂 </span>Vilsin-1.34</p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">组成</span>:<span lang=\"ZH-CN\">每片薄膜包衣片含马来酸阿维菌素1.34</span>mg</p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">药理学</span>:Avatrombopag <span lang=\"ZH-CN\">是一种口服生物利用的小分子</span>TPO<span lang=\"ZH-CN\">受体激动剂</span>,<span lang=\"ZH-CN\">可刺激骨髓祖细胞巨核细胞的增殖和分化</span>,<span lang=\"ZH-CN\">从而增加血小板的生成。中位最高浓度时间</span>(Tmax)<span lang=\"ZH-CN\">出现在给药后</span>5~6<span lang=\"ZH-CN\">小时。</span>Avatrombopagl <span lang=\"ZH-CN\">的平均分布容积</span>(C<span lang=\"ZH-CN\">估计为</span>180<span lang=\"ZH-CN\">升</span>(25%)Avatrombopag-<span lang=\"ZH-CN\">与人血浆蛋白的结合率大于</span>96%avatrombopag <span lang=\"ZH-CN\">的平均血浆消除半衰期</span>(%CV<span lang=\"ZH-CN\">约为</span>19<span lang=\"ZH-CN\">小时</span>(19%)<span lang=\"ZH-CN\">。</span>avatrombopag <span lang=\"ZH-CN\">清除率的平均值</span>(%C)<span lang=\"ZH-CN\">估计为</span>6.9/hr(29%)Avatromopag <span lang=\"ZH-CN\">主要由细胞色素</span>P450<span lang=\"ZH-CN\">、</span>yP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">代谢粪便排泄量占给药剂量的</span>88%,<span lang=\"ZH-CN\">其中</span>34%<span lang=\"ZH-CN\">以无变化的</span>Avatronopag <span lang=\"ZH-CN\">形式排出。只有</span>6%<span lang=\"ZH-CN\">的给药剂量是在尿液中发现的</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">适应症</span>:<span lang=\"ZH-CN\">慢性肝病患者血小板减少症</span>(CLD)<span lang=\"ZH-CN\">的治疗</span>:<span lang=\"ZH-CN\">适用于计划接受手术的成人慢性肝病患者血小板减少症的治疗。慢性免疫性血小板减少症</span>(ITP)<span lang=\"ZH-CN\">患者血小板减少症的治疗</span>:<span lang=\"ZH-CN\">适用于对既往治疗反应不足的成人慢性免疫性血小板减少症患者血小板减少症的治疗。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">剂量与给药</span>:<span lang=\"ZH-CN\">慢性肝病患者推荐剂量</span>:</p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>1:<span lang=\"ZH-CN\">计划接受手术的慢性肝病患者的推荐剂量和持续时间</span></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" rel=\"font-size: 14px; width: 807px;\"><tbody><tr xss=\"removed\"><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">血小板计数</span></p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每日一次</span></p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">时长</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">小于</span> 40×10₉/L</p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">60mg (3<span lang=\"ZH-CN\">片剂</span>)</p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">5<span lang=\"ZH-CN\">天</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">40 <span lang=\"ZH-CN\">小于</span>50 10₉/L</p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">40mg (2<span lang=\"ZH-CN\">片剂</span>)</p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">5<span lang=\"ZH-CN\">天</span></p></td></tr></tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">慢性免疫性血小板减少症患者的推荐剂量：初始剂量方案：开始剂量为</span>20mg<span lang=\"ZH-CN\">（</span>1<span lang=\"ZH-CN\">片）的</span>Avatromopag<span lang=\"ZH-CN\">，每天随食物服用一次。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>2<span lang=\"ZH-CN\">：慢性免疫性血小板减少症患者的</span>Avatrombopag<span lang=\"ZH-CN\">剂量调整</span></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" rel=\"font-size: 14px; width: 807px;\"><tbody><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">血小板计数</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">剂量调整或作用</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">使用</span>Avatrombopag x10 9/L<span lang=\"ZH-CN\">至少</span>2<span lang=\"ZH-CN\">周后少于</span>50</p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">根据表</span>3<span lang=\"ZH-CN\">增加一个剂量水平。</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">等待</span>2<span lang=\"ZH-CN\">周以评估此方案的效果和随后的剂量调整。</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">200<span lang=\"ZH-CN\">到</span>400×10 9/L<span lang=\"ZH-CN\">之间</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">根据表</span>3<span lang=\"ZH-CN\">减少一个剂量水平。</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">我等了</span>2<span lang=\"ZH-CN\">周来评估这个方案的效果和随后的剂量调整。</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">大于</span>400 10 9/L</p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">停止阿伐曲波帕</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">增加血小板监测到每周两次。</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">当血小板计数低于</span>150x10 9/L<span lang=\"ZH-CN\">时，根据表</span>3<span lang=\"ZH-CN\">减少一个剂量水平并重新开始治疗。</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">4<span lang=\"ZH-CN\">周后少于</span>50<span lang=\"ZH-CN\">每天服用一次</span>40<span lang=\"ZH-CN\">毫克</span>X 10 9/L <span lang=\"ZH-CN\">阿伐曲波帕</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">停止阿伐曲波帕</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">2<span lang=\"ZH-CN\">周后大于</span>400<span lang=\"ZH-CN\">每周服用</span>20<span lang=\"ZH-CN\">毫克阿伐曲波帕</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">停止阿伐曲波帕</span></p></td></tr></tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>3<span lang=\"ZH-CN\">：用于慢性免疫性血小板减少症患者滴定的</span>Avatrombopag<span lang=\"ZH-CN\">剂量水平</span></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" rel=\"font-size: 14px; width: 807px;\"><tbody><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">剂量</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">剂量水平</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每日</span>40<span lang=\"ZH-CN\">毫克</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">6</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每周</span>3<span lang=\"ZH-CN\">次，每次</span>40<span lang=\"ZH-CN\">毫克，每周剩余</span>4<span lang=\"ZH-CN\">天服用</span>20<span lang=\"ZH-CN\">毫克</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">5</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每日</span>20<span lang=\"ZH-CN\">毫克</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">4</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">20<span lang=\"ZH-CN\">毫克每周三次</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">3</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每周两次服用</span>20<span lang=\"ZH-CN\">毫克或每周服用</span>40<span lang=\"ZH-CN\">毫克</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">2</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">20<span lang=\"ZH-CN\">毫克每周</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">1</p></td></tr><tr xss=\"removed\"><td colspan=\"2\" xss=\"removed\" width=\"568\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">*<span lang=\"ZH-CN\">除</span>CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">中、强双重抑制剂或中、强双重抑制剂外，所有患者的初始剂量方案</span></p></td></tr></tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>4<span lang=\"ZH-CN\">：基于联合用药的慢性免疫性血小板减少症患者的</span>Avatrombopag<span lang=\"ZH-CN\">推荐起始剂量</span><a name=\"_GoBack\"></a></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" rel=\"font-size: 14px; width: 807px;\"><tbody><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">联合用药</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">推荐起始剂量</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">的中度或强双重抑制物</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">20mg<span lang=\"ZH-CN\">（</span>1<span lang=\"ZH-CN\">片），每周</span>3<span lang=\"ZH-CN\">次</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">的模式比率或强双产业</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">40mg<span lang=\"ZH-CN\">（</span>2<span lang=\"ZH-CN\">片），每日</span></p></td></tr></tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">或按照注册医生的指示。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">禁忌：对</span>Avatronopag<span lang=\"ZH-CN\">或本品任何成分过敏的患者禁用。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">预防措施：血栓性</span>/<span lang=\"ZH-CN\">血栓栓塞性并发症：</span>Avatrombopag<span lang=\"ZH-CN\">是血小板生成素（</span>TPO<span lang=\"ZH-CN\">）受体激动剂，</span>TPO<span lang=\"ZH-CN\">受体激动剂与慢性肝病或慢性免疫性血小板减少症患者的血栓性和血栓塞性并发症有关。监测血小板计数和血栓栓塞事件，并及时进行治疗。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">副作用：在慢性肝病患者中，最常见的不良反应是发热、腹痛、恶心、头痛、疲劳和周围水肿。在慢性免疫性血小板减少症患者中，最常见的不良反应是头痛、疲劳、神志不清、鼻出血、上呼吸道感染、关节痛、牙龈出血、瘀斑和鼻咽炎。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">在怀孕和哺乳期使用：孕妇应被告知对胎儿的潜在风险。具有生殖潜力的女性应告知其处方医生已知或疑似怀孕。哺乳期母亲：建议妇女在使用</span>Avatrombopag<span lang=\"ZH-CN\">治疗期间和最后一次给药后至少</span>2<span lang=\"ZH-CN\">周内不要母乳喂养。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">在</span>Child<span lang=\"ZH-CN\">中使用：没有可用的数据。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">药物相互作用：在接受</span>Avatrombopag<span lang=\"ZH-CN\">的同时开始中度或重度</span>CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">双重抑制剂治疗的患者，监测血小板计数并根据需要调整</span>Avatrombopag<span lang=\"ZH-CN\">的剂量。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">过量：没有可用的数据。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">贮存：在</span>30℃<span lang=\"ZH-CN\">以下干燥处贮存。</span></p><p><span lang=\"ZH-CN\" xss=\"removed\">包装：每盒含</span>28<span lang=\"ZH-CN\" xss=\"removed\">片泡罩包装。</span></p>",
    "strength": "1.34",
    "uom": "mg",
    "categoryId": "101",
    "insertFile": null,
    "images": [
      "https://www.admin.drug-international.com/"
    ]
  },
  {
    "id": "1927",
    "name": "Vilsin-20",
    "description": "<p>Avatrombopag(<span lang=\"ZH-CN\" style=\"background-color: initial;\">阿伐曲波帕</span> ) INN 20mg<span lang=\"ZH-CN\" style=\"background-color: initial;\">片剂 </span>Vilsin-20</p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">组成</span>:<span lang=\"ZH-CN\">每片薄膜包衣片含马来酸阿维菌素</span>20mg</p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">药理学</span>:Avatrombopag <span lang=\"ZH-CN\">是一种口服生物利用的小分子</span>TPO<span lang=\"ZH-CN\">受体激动剂</span>,<span lang=\"ZH-CN\">可刺激骨髓祖细胞巨核细胞的增殖和分化</span>,<span lang=\"ZH-CN\">从而增加血小板的生成。中位最高浓度时间</span>(Tmax)<span lang=\"ZH-CN\">出现在给药后</span>5~6<span lang=\"ZH-CN\">小时。</span>Avatrombopagl <span lang=\"ZH-CN\">的平均分布容积</span>(C<span lang=\"ZH-CN\">估计为</span>180<span lang=\"ZH-CN\">升</span>(25%)Avatrombopag-<span lang=\"ZH-CN\">与人血浆蛋白的结合率大于</span>96%avatrombopag <span lang=\"ZH-CN\">的平均血浆消除半衰期</span>(%CV<span lang=\"ZH-CN\">约为</span>19<span lang=\"ZH-CN\">小时</span>(19%)<span lang=\"ZH-CN\">。</span>avatrombopag <span lang=\"ZH-CN\">清除率的平均值</span>(%C)<span lang=\"ZH-CN\">估计为</span>6.9/hr(29%)Avatromopag <span lang=\"ZH-CN\">主要由细胞色素</span>P450<span lang=\"ZH-CN\">、</span>yP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">代谢粪便排泄量占给药剂量的</span>88%,<span lang=\"ZH-CN\">其中</span>34%<span lang=\"ZH-CN\">以无变化的</span>Avatronopag <span lang=\"ZH-CN\">形式排出。只有</span>6%<span lang=\"ZH-CN\">的给药剂量是在尿液中发现的</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">适应症</span>:<span lang=\"ZH-CN\">慢性肝病患者血小板减少症</span>(CLD)<span lang=\"ZH-CN\">的治疗</span>:<span lang=\"ZH-CN\">适用于计划接受手术的成人慢性肝病患者血小板减少症的治疗。慢性免疫性血小板减少症</span>(ITP)<span lang=\"ZH-CN\">患者血小板减少症的治疗</span>:<span lang=\"ZH-CN\">适用于对既往治疗反应不足的成人慢性免疫性血小板减少症患者血小板减少症的治疗。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">剂量与给药</span>:<span lang=\"ZH-CN\">慢性肝病患者推荐剂量</span>:</p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>1:<span lang=\"ZH-CN\">计划接受手术的慢性肝病患者的推荐剂量和持续时间</span></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" style=\"font-size: 14px; width: 807px;\" rel=\"font-size: 14px; width: 807px;\"><tbody><tr xss=\"removed\"><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">血小板计数</span></p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每日一次</span></p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">时长</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">小于</span> 40×10₉/L</p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">60mg (3<span lang=\"ZH-CN\">片剂</span>)</p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">5<span lang=\"ZH-CN\">天</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">40 <span lang=\"ZH-CN\">小于</span>50 10₉/L</p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">40mg (2<span lang=\"ZH-CN\">片剂</span>)</p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">5<span lang=\"ZH-CN\">天</span></p></td></tr></tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">慢性免疫性血小板减少症患者的推荐剂量：初始剂量方案：开始剂量为</span>20mg<span lang=\"ZH-CN\">（</span>1<span lang=\"ZH-CN\">片）的</span>Avatromopag<span lang=\"ZH-CN\">，每天随食物服用一次。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>2<span lang=\"ZH-CN\">：慢性免疫性血小板减少症患者的</span>Avatrombopag<span lang=\"ZH-CN\">剂量调整</span></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" style=\"font-size: 14px; width: 807px;\" rel=\"font-size: 14px; width: 807px;\"><tbody><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">血小板计数</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">剂量调整或作用</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">使用</span>Avatrombopag x10 9/L<span lang=\"ZH-CN\">至少</span>2<span lang=\"ZH-CN\">周后少于</span>50</p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">根据表</span>3<span lang=\"ZH-CN\">增加一个剂量水平。</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">等待</span>2<span lang=\"ZH-CN\">周以评估此方案的效果和随后的剂量调整。</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">200<span lang=\"ZH-CN\">到</span>400×10 9/L<span lang=\"ZH-CN\">之间</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">根据表</span>3<span lang=\"ZH-CN\">减少一个剂量水平。</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">我等了</span>2<span lang=\"ZH-CN\">周来评估这个方案的效果和随后的剂量调整。</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">大于</span>400 10 9/L</p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">停止阿伐曲波帕</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">增加血小板监测到每周两次。</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">当血小板计数低于</span>150x10 9/L<span lang=\"ZH-CN\">时，根据表</span>3<span lang=\"ZH-CN\">减少一个剂量水平并重新开始治疗。</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">4<span lang=\"ZH-CN\">周后少于</span>50<span lang=\"ZH-CN\">每天服用一次</span>40<span lang=\"ZH-CN\">毫克</span>X 10 9/L <span lang=\"ZH-CN\">阿伐曲波帕</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">停止阿伐曲波帕</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">2<span lang=\"ZH-CN\">周后大于</span>400<span lang=\"ZH-CN\">每周服用</span>20<span lang=\"ZH-CN\">毫克阿伐曲波帕</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">停止阿伐曲波帕</span></p></td></tr></tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>3<span lang=\"ZH-CN\">：用于慢性免疫性血小板减少症患者滴定的</span>Avatrombopag<span lang=\"ZH-CN\">剂量水平</span></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" style=\"font-size: 14px; width: 807px;\" rel=\"font-size: 14px; width: 807px;\"><tbody><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">剂量</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">剂量水平</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每日</span>40<span lang=\"ZH-CN\">毫克</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">6</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每周</span>3<span lang=\"ZH-CN\">次，每次</span>40<span lang=\"ZH-CN\">毫克，每周剩余</span>4<span lang=\"ZH-CN\">天服用</span>20<span lang=\"ZH-CN\">毫克</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">5</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每日</span>20<span lang=\"ZH-CN\">毫克</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">4</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">20<span lang=\"ZH-CN\">毫克每周三次</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">3</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每周两次服用</span>20<span lang=\"ZH-CN\">毫克或每周服用</span>40<span lang=\"ZH-CN\">毫克</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">2</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">20<span lang=\"ZH-CN\">毫克每周</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">1</p></td></tr><tr xss=\"removed\"><td colspan=\"2\" xss=\"removed\" width=\"568\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">*<span lang=\"ZH-CN\">除</span>CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">中、强双重抑制剂或中、强双重抑制剂外，所有患者的初始剂量方案</span></p></td></tr></tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>4<span lang=\"ZH-CN\">：基于联合用药的慢性免疫性血小板减少症患者的</span>Avatrombopag<span lang=\"ZH-CN\">推荐起始剂量</span><a name=\"_GoBack\"></a></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" style=\"font-size: 14px; width: 807px;\" rel=\"font-size: 14px; width: 807px;\"><tbody><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">联合用药</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">推荐起始剂量</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">的中度或强双重抑制物</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">20mg<span lang=\"ZH-CN\">（</span>1<span lang=\"ZH-CN\">片），每周</span>3<span lang=\"ZH-CN\">次</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">的模式比率或强双产业</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">40mg<span lang=\"ZH-CN\">（</span>2<span lang=\"ZH-CN\">片），每日</span></p></td></tr></tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">或按照注册医生的指示。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">禁忌：对</span>Avatronopag<span lang=\"ZH-CN\">或本品任何成分过敏的患者禁用。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">预防措施：血栓性</span>/<span lang=\"ZH-CN\">血栓栓塞性并发症：</span>Avatrombopag<span lang=\"ZH-CN\">是血小板生成素（</span>TPO<span lang=\"ZH-CN\">）受体激动剂，</span>TPO<span lang=\"ZH-CN\">受体激动剂与慢性肝病或慢性免疫性血小板减少症患者的血栓性和血栓塞性并发症有关。监测血小板计数和血栓栓塞事件，并及时进行治疗。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">副作用：在慢性肝病患者中，最常见的不良反应是发热、腹痛、恶心、头痛、疲劳和周围水肿。在慢性免疫性血小板减少症患者中，最常见的不良反应是头痛、疲劳、神志不清、鼻出血、上呼吸道感染、关节痛、牙龈出血、瘀斑和鼻咽炎。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">在怀孕和哺乳期使用：孕妇应被告知对胎儿的潜在风险。具有生殖潜力的女性应告知其处方医生已知或疑似怀孕。哺乳期母亲：建议妇女在使用</span>Avatrombopag<span lang=\"ZH-CN\">治疗期间和最后一次给药后至少</span>2<span lang=\"ZH-CN\">周内不要母乳喂养。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">在</span>Child<span lang=\"ZH-CN\">中使用：没有可用的数据。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">药物相互作用：在接受</span>Avatrombopag<span lang=\"ZH-CN\">的同时开始中度或重度</span>CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">双重抑制剂治疗的患者，监测血小板计数并根据需要调整</span>Avatrombopag<span lang=\"ZH-CN\">的剂量。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">过量：没有可用的数据。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">贮存：在</span>30℃<span lang=\"ZH-CN\">以下干燥处贮存。</span></p><p><span lang=\"ZH-CN\" style=\"background-color: initial;\">包装：每盒含</span>28<span lang=\"ZH-CN\" style=\"background-color: initial;\">片泡罩包装。</span></p>",
    "strength": "20 ",
    "uom": "mg/5ml",
    "categoryId": "101",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1739866209vilsin.jpeg",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1740548420vilsin-details-20.jpeg"
    ]
  },
  {
    "id": "1931",
    "name": "Vilsin-5",
    "description": "<p>Avatrombopag(<span lang=\"ZH-CN\" xss=\"removed\">阿伐曲波帕</span> ) INN 5mg<span lang=\"ZH-CN\" xss=\"removed\">片剂 </span>Vilsin-5</p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">组成</span>:<span lang=\"ZH-CN\">每片薄膜包衣片含马来酸阿维菌素5</span>mg</p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">药理学</span>:Avatrombopag <span lang=\"ZH-CN\">是一种口服生物利用的小分子</span>TPO<span lang=\"ZH-CN\">受体激动剂</span>,<span lang=\"ZH-CN\">可刺激骨髓祖细胞巨核细胞的增殖和分化</span>,<span lang=\"ZH-CN\">从而增加血小板的生成。中位最高浓度时间</span>(Tmax)<span lang=\"ZH-CN\">出现在给药后</span>5~6<span lang=\"ZH-CN\">小时。</span>Avatrombopagl <span lang=\"ZH-CN\">的平均分布容积</span>(C<span lang=\"ZH-CN\">估计为</span>180<span lang=\"ZH-CN\">升</span>(25%)Avatrombopag-<span lang=\"ZH-CN\">与人血浆蛋白的结合率大于</span>96%avatrombopag <span lang=\"ZH-CN\">的平均血浆消除半衰期</span>(%CV<span lang=\"ZH-CN\">约为</span>19<span lang=\"ZH-CN\">小时</span>(19%)<span lang=\"ZH-CN\">。</span>avatrombopag <span lang=\"ZH-CN\">清除率的平均值</span>(%C)<span lang=\"ZH-CN\">估计为</span>6.9/hr(29%)Avatromopag <span lang=\"ZH-CN\">主要由细胞色素</span>P450<span lang=\"ZH-CN\">、</span>yP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">代谢粪便排泄量占给药剂量的</span>88%,<span lang=\"ZH-CN\">其中</span>34%<span lang=\"ZH-CN\">以无变化的</span>Avatronopag <span lang=\"ZH-CN\">形式排出。只有</span>6%<span lang=\"ZH-CN\">的给药剂量是在尿液中发现的</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">适应症</span>:<span lang=\"ZH-CN\">慢性肝病患者血小板减少症</span>(CLD)<span lang=\"ZH-CN\">的治疗</span>:<span lang=\"ZH-CN\">适用于计划接受手术的成人慢性肝病患者血小板减少症的治疗。慢性免疫性血小板减少症</span>(ITP)<span lang=\"ZH-CN\">患者血小板减少症的治疗</span>:<span lang=\"ZH-CN\">适用于对既往治疗反应不足的成人慢性免疫性血小板减少症患者血小板减少症的治疗。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">剂量与给药</span>:<span lang=\"ZH-CN\">慢性肝病患者推荐剂量</span>:</p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>1:<span lang=\"ZH-CN\">计划接受手术的慢性肝病患者的推荐剂量和持续时间</span></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" rel=\"font-size: 14px; width: 807px;\"><tbody><tr xss=\"removed\"><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">血小板计数</span></p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每日一次</span></p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">时长</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">小于</span> 40×10₉/L</p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">60mg (3<span lang=\"ZH-CN\">片剂</span>)</p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">5<span lang=\"ZH-CN\">天</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">40 <span lang=\"ZH-CN\">小于</span>50 10₉/L</p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">40mg (2<span lang=\"ZH-CN\">片剂</span>)</p></td><td xss=\"removed\" width=\"189\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">5<span lang=\"ZH-CN\">天</span></p></td></tr></tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">慢性免疫性血小板减少症患者的推荐剂量：初始剂量方案：开始剂量为</span>20mg<span lang=\"ZH-CN\">（</span>1<span lang=\"ZH-CN\">片）的</span>Avatromopag<span lang=\"ZH-CN\">，每天随食物服用一次。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>2<span lang=\"ZH-CN\">：慢性免疫性血小板减少症患者的</span>Avatrombopag<span lang=\"ZH-CN\">剂量调整</span></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" rel=\"font-size: 14px; width: 807px;\"><tbody><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">血小板计数</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">剂量调整或作用</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">使用</span>Avatrombopag x10 9/L<span lang=\"ZH-CN\">至少</span>2<span lang=\"ZH-CN\">周后少于</span>50</p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">根据表</span>3<span lang=\"ZH-CN\">增加一个剂量水平。</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">等待</span>2<span lang=\"ZH-CN\">周以评估此方案的效果和随后的剂量调整。</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">200<span lang=\"ZH-CN\">到</span>400×10 9/L<span lang=\"ZH-CN\">之间</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">根据表</span>3<span lang=\"ZH-CN\">减少一个剂量水平。</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">我等了</span>2<span lang=\"ZH-CN\">周来评估这个方案的效果和随后的剂量调整。</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">大于</span>400 10 9/L</p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">停止阿伐曲波帕</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">增加血小板监测到每周两次。</span></p><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">当血小板计数低于</span>150x10 9/L<span lang=\"ZH-CN\">时，根据表</span>3<span lang=\"ZH-CN\">减少一个剂量水平并重新开始治疗。</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">4<span lang=\"ZH-CN\">周后少于</span>50<span lang=\"ZH-CN\">每天服用一次</span>40<span lang=\"ZH-CN\">毫克</span>X 10 9/L <span lang=\"ZH-CN\">阿伐曲波帕</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">停止阿伐曲波帕</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">2<span lang=\"ZH-CN\">周后大于</span>400<span lang=\"ZH-CN\">每周服用</span>20<span lang=\"ZH-CN\">毫克阿伐曲波帕</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">|<span lang=\"ZH-CN\">停止阿伐曲波帕</span></p></td></tr></tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>3<span lang=\"ZH-CN\">：用于慢性免疫性血小板减少症患者滴定的</span>Avatrombopag<span lang=\"ZH-CN\">剂量水平</span></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" rel=\"font-size: 14px; width: 807px;\"><tbody><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">剂量</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">剂量水平</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每日</span>40<span lang=\"ZH-CN\">毫克</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">6</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每周</span>3<span lang=\"ZH-CN\">次，每次</span>40<span lang=\"ZH-CN\">毫克，每周剩余</span>4<span lang=\"ZH-CN\">天服用</span>20<span lang=\"ZH-CN\">毫克</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">5</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每日</span>20<span lang=\"ZH-CN\">毫克</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">4</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">20<span lang=\"ZH-CN\">毫克每周三次</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">3</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">每周两次服用</span>20<span lang=\"ZH-CN\">毫克或每周服用</span>40<span lang=\"ZH-CN\">毫克</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">2</p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">20<span lang=\"ZH-CN\">毫克每周</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">1</p></td></tr><tr xss=\"removed\"><td colspan=\"2\" xss=\"removed\" width=\"568\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">*<span lang=\"ZH-CN\">除</span>CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">中、强双重抑制剂或中、强双重抑制剂外，所有患者的初始剂量方案</span></p></td></tr></tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">表</span>4<span lang=\"ZH-CN\">：基于联合用药的慢性免疫性血小板减少症患者的</span>Avatrombopag<span lang=\"ZH-CN\">推荐起始剂量</span><a name=\"_GoBack\"></a></p><table class=\"MsoTableGrid\" xss=\"removed\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" rel=\"font-size: 14px; width: 807px;\"><tbody><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">联合用药</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\"><span lang=\"ZH-CN\">推荐起始剂量</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">的中度或强双重抑制物</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">20mg<span lang=\"ZH-CN\">（</span>1<span lang=\"ZH-CN\">片），每周</span>3<span lang=\"ZH-CN\">次</span></p></td></tr><tr xss=\"removed\"><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">的模式比率或强双产业</span></p></td><td xss=\"removed\" width=\"284\" valign=\"top\"><p class=\"MsoNormal\" xss=\"removed\">40mg<span lang=\"ZH-CN\">（</span>2<span lang=\"ZH-CN\">片），每日</span></p></td></tr></tbody></table><p class=\"MsoNormal\"><span lang=\"ZH-CN\">或按照注册医生的指示。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">禁忌：对</span>Avatronopag<span lang=\"ZH-CN\">或本品任何成分过敏的患者禁用。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">预防措施：血栓性</span>/<span lang=\"ZH-CN\">血栓栓塞性并发症：</span>Avatrombopag<span lang=\"ZH-CN\">是血小板生成素（</span>TPO<span lang=\"ZH-CN\">）受体激动剂，</span>TPO<span lang=\"ZH-CN\">受体激动剂与慢性肝病或慢性免疫性血小板减少症患者的血栓性和血栓塞性并发症有关。监测血小板计数和血栓栓塞事件，并及时进行治疗。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">副作用：在慢性肝病患者中，最常见的不良反应是发热、腹痛、恶心、头痛、疲劳和周围水肿。在慢性免疫性血小板减少症患者中，最常见的不良反应是头痛、疲劳、神志不清、鼻出血、上呼吸道感染、关节痛、牙龈出血、瘀斑和鼻咽炎。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">在怀孕和哺乳期使用：孕妇应被告知对胎儿的潜在风险。具有生殖潜力的女性应告知其处方医生已知或疑似怀孕。哺乳期母亲：建议妇女在使用</span>Avatrombopag<span lang=\"ZH-CN\">治疗期间和最后一次给药后至少</span>2<span lang=\"ZH-CN\">周内不要母乳喂养。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">在</span>Child<span lang=\"ZH-CN\">中使用：没有可用的数据。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">药物相互作用：在接受</span>Avatrombopag<span lang=\"ZH-CN\">的同时开始中度或重度</span>CYP2C9<span lang=\"ZH-CN\">和</span>CYP3A4<span lang=\"ZH-CN\">双重抑制剂治疗的患者，监测血小板计数并根据需要调整</span>Avatrombopag<span lang=\"ZH-CN\">的剂量。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">过量：没有可用的数据。</span></p><p class=\"MsoNormal\"><span lang=\"ZH-CN\">贮存：在</span>30℃<span lang=\"ZH-CN\">以下干燥处贮存。</span></p><p><span lang=\"ZH-CN\" xss=\"removed\">包装：每盒含</span>28<span lang=\"ZH-CN\" xss=\"removed\">片泡罩包装。</span></p>",
    "strength": "5",
    "uom": "mg",
    "categoryId": "101",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1747041589",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1747041589vilsin-5.jpeg"
    ]
  },
  {
    "id": "1093",
    "name": "Vinstin Injection",
    "description": "<p><strong></strong><strong>Composition : </strong>Vinstin : Each vial contains 2 ml solution containing Vincristine Sulfate USP 2 mg</p><p><strong></strong></p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">Vincristine sulfate is indicated in acute leukemia. Vincristine sulfate has also been shown to be useful in\r\ncombination with other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphomas\r\n(lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types), rhabdomyosarcoma,\r\nneuroblastoma, and Wilms'tumor.</span></p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\"><strong>Dosage and administration :</strong> Extreme care must be used in calculating and administering the dose of vincristine,since overdosage may have a\r\nvery serious or fatal outcome.The drug is given i.v. at weekly intervals. Fatal if given intrathecally.Adults: The usual\r\ndose of vincristine is 1.4 mg/m2. Children: The usual dose of vincristine is 1.5- 2 mg/m2. For children weighing 10\r\nkg or less, the initial dose of vincristine should be 0.05 mg/kg once a week, with careful increasing of dosing\r\nthereafter based on effects. Vincristine should not be administered to patients receiving radiation therapy\r\nthrough ports that include the liver. When vincristine is used in combination with L-asparaginase, it should be\r\ngiven 12 to 24 hours prior to administration of the enzyme in order to minimize toxicity because L-asparaginase\r\nmay reduce hepatic clearance of vincristine.Or, as directed by the registered physician. Please see prescribing description for more information.</p><p xss=\"removed\" helvetica=\"\" helvetica,=\"\" arial,=\"\"><strong>Use in pregnancy and lactation :</strong> Category D. There are no adequate and well controlled studies in pregnant woman\r\nVincristine has been reported to be found in human milk. Patient recieves Vincristine should not be breast feed.<strong></strong></p><p><strong>Packing : </strong>Vinstin : Each box contains 1 vial of 2 ml.</p>",
    "strength": "2,2",
    "uom": "mg/ml",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/Vinestin IV Injection - Insert-.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/vinstin10.jpg"
    ]
  },
  {
    "id": "1210",
    "name": "Visonium Injection",
    "description": "<p><strong>Composition : </strong><span class=\"redactor-invisible-space\" xss=\"removed\">Tiemonium Methylsulfate INN  5mg/2ml Injection.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is indicated for treatment of gastroenteritis, diarrhoea, dysentery, biliary, colic, enterocolitis, cholecystitis, colonopathies, mild cystitis. Visonium is the drug of choice for the treatment of spasmodic dysmenorrhoea.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Dosage and administration :</strong> Visonium Injection (IM/IV) : The usual dosage is 5mg (1 ampoule) three times daily by intramuscular or slow intravenous injection. Or, as directed by the registered physician.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">The drug should be used with caution during pregnancy and lactation.</span></p><p style=\"text-align: justify;\" rel=\"text-align: justify;\"><strong>Packing :</strong><strong> Visonium Injection (IM/IV) : </strong>1x5's ampoules (2ml) in a blister pack.</p>",
    "strength": "5",
    "uom": "Mg/2ml",
    "categoryId": "44",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532146648visonium.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745310869Visonium.png"
    ]
  },
  {
    "id": "854",
    "name": "Visonium Tablet",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Tiemonium Methylsulfate INN\r\n50mg Tablet. </span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is indicated for treatment\r\nof gastroenteritis, diarrhoea, dysentery,\r\nbiliary, colic, enterocolitis, cholecystitis,\r\ncolonopathies, mild cystitis. Visonium is\r\nthe drug of choice for the treatment of\r\nspasmodic dysmenorrhoea.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration :</strong> Visonium\r\nTablet : In adults, the usual dosage is 2\r\nto 6 tablets is given in a dose of 100 to\r\n300mg daily in divided doses by mouth. Or, as directed by\r\nthe registered physician.</p><p style=\"text-align: justify;\"><strong>Use in pregnancy and lactation : </strong><span class=\"redactor-invisible-space\">The\r\ndrug should be used with caution during\r\npregnancy and lactation.</span></p><p style=\"text-align: justify;\"><strong>Packing :</strong><strong></strong></p><p style=\"text-align: justify;\"><strong></strong><strong>Visonium Tablet  : </strong> Each Box Contains 5x10's tablets  in a blister pack.</p>",
    "strength": "50",
    "uom": "mg",
    "categoryId": "44",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532146841visonium.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745211373Visonium 50mg.png"
    ]
  },
  {
    "id": "1888",
    "name": "Vorizol 200 Injection",
    "description": "<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Composition: </strong>Each\r\nvial contains Voriconazole USP 200mg sterile lyophilized powder.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications: </strong>It\r\nis indicated for the treatment of adults and pediatric patients 2 years of age\r\nand older with: Invasive aspergillosis, Candidemia in non-neutropenics and\r\nother deep tissue Candida infections, Esophageal candidiasis, Serious fungal\r\ninfections caused by Scedosporium apiospermum and Fusarium species including\r\nFusarium solani, in patients intolerant of, or refractory to, other therapy.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage and\r\nAdministration: </strong>For pediatric patients\r\naged 12 to 14 years weighing greater than or equal to 50kg and those aged 15\r\nyears and older regardless of body weight use adult dosage. Or, as directed by the registered physician. <strong>Reconstitution:</strong> Voriconazole injection\r\nrequires reconstitution and dilution prior to administration as intravenous\r\ninfusion. The powder is reconstituted with 19 ml of water for injection to\r\nobtain an extractable volume of 20ml of clear concentrate containing 10mg/ml of\r\nvoriconazole. Shake the vial until all the powder is dissolved. This medicinal product is for single use only and any unused\r\nsolution should be discarded.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Use in Pregnancy and\r\nLactation: </strong>There are no adequate data on the use of\r\nVoriconazole in pregnant women available. Voriconazole must not be used during\r\npregnancy unless the benefit to the mother clearly outweighs the potential risk\r\nto the foetus. The excretion of Voriconazole into breast milk has not been\r\ninvestigated.<o:p></o:p></p><p><strong>Packing: </strong><strong>Vorizol-200 Injection (IV):</strong>\r\nEach combipack contains 1 vial of Voriconazole USP 200mg sterile lyophilized\r\npowder, with two ampoules of 10ml Water for Injection BP.</p>",
    "strength": "200",
    "uom": "mg(IV)",
    "categoryId": "40",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1692259048Vorizol Injection Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745120847Virizol-200.png"
    ]
  },
  {
    "id": "1845",
    "name": "Vorizol Suspension",
    "description": "<p><strong>Composition :</strong> </p><p><strong>Vorizol-50:</strong> Each film coated tablet contains Voriconazole USP 50 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Vorizol-200: </strong>Each film coated tablet contains Voriconazole USP 200 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Vorizol Suspension:</strong> Each 5ml powder for suspension contains Voriconazole USP 200 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications :</strong> Vorizol is an azole antifungal medicine. It is indicated for use in patients 12 years of age and older in the treatment of following fungal infections.</p><p class=\"MsoNormal\" xss=\"removed\">* Invasive aspergillosis</p><p class=\"MsoNormal\" xss=\"removed\">* Candidemia (nonneutropenics) and disseminated candidiasis in skin, abdomen kidney, bladder wall and wounds.</p><p class=\"MsoNormal\" xss=\"removed\">* Esophageal candidiasis</p><p class=\"MsoNormal\" xss=\"removed\">* Serious infections caused by Scedosporium apiospermum and Fusarium Species including Fusarium solani, in patients intolerant of, or refractory to, other therapy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration :</strong> Vorizol tablet and powder for suspension are to be taken at Ieast one hour before or one hour following a meal.</p><p class=\"MsoNormal\" xss=\"removed\">* At or over 40 kg body weight is loading dose regimen is 400 mg or 10 ml every 12 hours (for the first 24 hours) and maintenance dose (after first 24 hours) is 200 mg or 5 ml twice daily.</p><p class=\"MsoNormal\" xss=\"removed\">* Below 40 Kg body weight is loading dose regimen is 200 mg or 5 ml every 12 hours (for the first 24 hours) and maintenance dose (after first 24 hours) is 100 mg or 2.5 ml twice daily. Or, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Reconstitution Instructions :</strong> Shake the bottle well before adding water to loosen the powder. Add 25 ml of boiled and cooled water to the bottle (5 spoon of provided spoon). Shake the closed bottle vigorously until powder mixed completely with the water. Store reconstituted suspension between 15- 30 degree celsius.</p><p class=\"MsoNormal\" xss=\"removed\">Discard suspension 14 days after reconstitution.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation :</strong> There are no adequate and well-controlled studies in pregnant woman. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether it is excreted in human milk. So a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing :</strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Vorizol-50:</strong> Each box contains 1 x 10's tablets in blister pack.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Vorizol-200:</strong> Each box contains 1 x 7's tablets in blister pack.</p><p><strong>Vorizol Suspension:</strong> Each bottle contains 40ml powder for suspension.</p>",
    "strength": "40",
    "uom": "ML",
    "categoryId": "40",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1669804641Vorizol Insert for Web.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1661420120Vorizol Carton.png"
    ]
  },
  {
    "id": "1373",
    "name": "Vorizol Tablet",
    "description": "<p class=\"MsoNormal\" xss=\"removed\" align=\"center\"><strong><br></strong></p><p class=\"MsoNormal\" xss=\"removed\"><strong>Composition :</strong> </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Vorizol-50:</strong> Each film coated tablet contains\r\nVoriconazole USP 50 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Vorizol-200: </strong>Each film coated\r\ntablet contains Voriconazole USP 200 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Vorizol Suspension:</strong> Each 5ml\r\npowder for suspension contains Voriconazole USP 200 mg.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Indications :</strong> Vorizol is an azole antifungal medicine. It is\r\nindicated for use in patients 12 years of age and older in the treatment of\r\nfollowing fungal infections.</p><p class=\"MsoNormal\" xss=\"removed\"> * Invasive aspergillosis</p><p class=\"MsoNormal\" xss=\"removed\">* Candidemia (nonneutropenics)\r\nand disseminated candidiasis in skin, abdomen kidney, bladder wall and wounds.</p><p class=\"MsoNormal\" xss=\"removed\">* Esophageal candidiasis</p><p class=\"MsoNormal\" xss=\"removed\">* Serious infections caused by\r\nScedosporium apiospermum and Fusarium Species including Fusarium solani, in\r\npatients intolerant of, or refractory to, other therapy.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Dosage and Administration :</strong> Vorizol tablet and powder for\r\nsuspension are to be taken at Ieast one hour before or one hour following a\r\nmeal.</p><p class=\"MsoNormal\" xss=\"removed\">* At or over 40 kg body weight is\r\nloading dose regimen is 400 mg or 10 ml every 12 hours (for the first 24 hours)\r\nand maintenance dose (after first 24 hours) is 200 mg or 5 ml twice daily.</p><p class=\"MsoNormal\" xss=\"removed\">* Below 40 Kg body weight is\r\nloading dose regimen is 200 mg or 5 ml every 12 hours (for the first 24 hours)\r\nand maintenance dose (after first 24 hours) is 100 mg or 2.5 ml twice daily.\r\nOr, as directed by the registered physician.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Reconstitution Instructions :</strong>\r\nShake the bottle well before adding water to loosen the powder. Add 25 ml of\r\nboiled and cooled water to the bottle (5 spoon of provided spoon). Shake the\r\nclosed bottle vigorously until powder mixed completely with the water. Store\r\nreconstituted suspension between 15- 30 degree celsius.</p><p class=\"MsoNormal\" xss=\"removed\">Discard suspension 14 days after\r\nreconstitution.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Use in pregnancy and lactation :</strong> There are no adequate and\r\nwell-controlled studies in pregnant woman. It should be used during pregnancy\r\nonly if the potential benefit justifies the potential risk to the fetus. It is\r\nnot known whether it is excreted in human milk. So a decision should be made\r\nwhether to discontinue nursing or to discontinue the drug, taking into account\r\nthe importance of the drug to the mother.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Packing :</strong> </p><p class=\"MsoNormal\" xss=\"removed\"><strong>Vorizol-50:</strong>  Each\r\nbox contains 1 x 10's tablets in blister pack.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Vorizol-200:</strong> Each box contains 1\r\nx 7's tablets in blister pack.</p><p class=\"MsoNormal\" xss=\"removed\"><strong>Vorizol Suspension:</strong> Each bottle\r\ncontains 40ml powder for suspension.</p>",
    "strength": "200,50",
    "uom": "mg",
    "categoryId": "40",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1565244151Vorizol Insert [Converted].pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1633925938Vorizol - 200 Carton.png",
      "https://www.admin.drug-international.com/uploads/product_images/1745120878Virizol-50.png"
    ]
  },
  {
    "id": "956",
    "name": "Ziton",
    "description": "<p><strong></strong><strong>Composition : </strong><span class=\"redactor-invisible-space\">Zinc Sulphate\r\nMonohydrate USP  Eq. to 10mg of elemental\r\nZinc/5ml Syrup.</span></p><p style=\"text-align: justify;\"><strong>Indication : </strong><span class=\"redactor-invisible-space\">It is indicated for the\r\nfollowing conditions-growth retardation,\r\nRTI, alopecia, dermatitis, diarrhoea,\r\nimmunological dysfunction,\r\npsychological disturbances, gonadal\r\natrophy, impaired spermatogenesis,\r\ncongenital malformation.</span></p><p style=\"text-align: justify;\"><strong>Dosage and administration : </strong><span class=\"redactor-invisible-space\">Children\r\nunder 10kg : 22.5mg (2\r\n1\r\n-\r\n4 spoonful) Ziton\r\nsyrup daily in divided doses. Children\r\nover 10kg to 30kg : 22.5mg (2\r\n1\r\n-\r\n4 spoonful)\r\n1 to 3 times daily. Adult & children over\r\n30kg : 45mg (4\r\n1\r\n-\r\n2 spoonful) 1 to 3 times\r\ndaily after food.\r\nOr, as directed by the registered\r\nphysician.</span></p><p style=\"text-align: justify;\"><strong>Packing : </strong><span class=\"redactor-invisible-space\">Ziton :100ml in amber glass\r\nbottle.</span></p>",
    "strength": "4124",
    "uom": "I.U+I.U+I.U+mg",
    "categoryId": "67",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1532334178ziton.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1745211392Ziton.png"
    ]
  },
  {
    "id": "1887",
    "name": "Zoletrust",
    "description": "<p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Composition:</strong>\r\nEach vial contains Zoledronic Acid 4mg/5ml as Zoledronic Acid Monohydrate INN concentrate solution for IV infusion.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Indications:\r\nHypercalcemia of Malignancy:</strong> Zoledronic Acid is\r\nindicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected\r\ncalcium (cCa) of greater than or equal to 12mg/dL [3.0mmol/L] using the\r\nformula: cCa inmg/dL=Ca in mg/dL + 0.8 (4.0 g/dL -patient albumin [g/dL]). <strong>Multiple Myeloma and Bone Metastases of\r\nSolid Tumors:</strong> Zoledronic Acid is indicated for the treatment of patients\r\nwith multiple myeloma and patients with documented bone metastases from solid\r\ntumors, in conjunction with standard antineoplastic therapy. Prostate cancer\r\nshould have progressed after treatment with at least one hormonal therapy. <strong>Important Limitation of Use:</strong> The safety\r\nand efficacy of Zoledronic Acid in the treatment of hypercalcemia associated\r\nwith hyperparathyroidism or with other non tumor-related conditions have not\r\nbeen established.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Dosage\r\nand Administration: Hypercalcemia of Malignancy:</strong>\r\nThe maximum recommended dose of Zoledronic Acid in hypercalcemia of malignancy (albumin-corrected serum calcium greater than or equal to 12mg/dL [3.0mmol/L])\r\nis 4mg. The 4mg dose must be given as a single-dose intravenous infusion over\r\nno less than 15 minutes. Patients who receive Zoledronic Acid should have serum creatinine assessed prior to each treatment. Dose adjustments of Zoledronic\r\nAcid are not necessary in treating patients for hypercalcemia of malignancy\r\npresenting with mild-to-moderate renal impairment prior to initiation of therapy (serum creatinine less than 400pmol/L or less than 4.5mg/dL). Retreatment with\r\nZoledronic Acid 4mg may be considered if serum calcium does not return to\r\nnormal or remain normal after initial treatment. It is recommended that a\r\nminimum of 7 days elapse before retreatment, to allow for full response to the\r\ninitial dose. Renal function must be carefully monitored in all patients\r\nreceiving Zoledronic Acid and serum creatinine must be assessed prior to\r\nretreatment with Zoledronic Acid. <strong>Multiple\r\nMyeloma and Metastatic Bone Lesions of Solid Tumors:</strong> The recommended dose\r\nof Zoledronic Acid in patients with multiple myeloma and metastatic bone lesions\r\nfrom solid tumors for patients with creatinine clearance (CrCl) greater than 60mL/min\r\nis 4mg infused over no less than 15 minutes every 3 to 4 weeks. The optimal\r\nduration of therapy is not known. Patients should also be administered an oral\r\ncalcium supplement of 500mg and a multiple vitamin containing 400 international\r\nunits of vitamin D daily. <strong>Patients with\r\nRenal Impairment:</strong> The use of Zoledronic Acid is not recommended in patients\r\nwith severe renal impairment (Creatinine clearance &lt; 30ml/min). No dose\r\nadjustment is necessary in patients with Creatinine clearance 60ml/min. Or, as\r\ndirected by the registered physicians.</p><p class=\"MsoNormal\" style=\"text-align:justify\"><o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Use\r\nin Pregnancy and Lactation:</strong> Pregnancy Category D. There are no\r\nadequate and well-controlled studies of Zoledronic Acid in pregnant women. Zoledronic\r\nAcid may cause fetal harm when administered to a pregnant woman. <strong>Nursing Mothers:</strong> It is not known\r\nwhether Zoledronic Acid is excreted in human milk. Because many drugs are\r\nexcreted in human milk, and because of the potential for serious adverse reactions\r\nin nursing infants from Zoledronic Acid, a decision should be made to discontinue\r\nnursing or to discontinue the drug, taking into account the importance of the\r\ndrug to the mother.<o:p></o:p></p><p class=\"MsoNormal\" style=\"text-align:justify\"><strong>Packaging:</strong>\r\nEach box contains one vial of Zoledronic Acid INN 4mg/5ml concentrate solution for IV infusion.</p>",
    "strength": "4mg",
    "uom": "mg/5ml",
    "categoryId": "57",
    "insertFile": "https://www.admin.drug-international.com/uploads/product_pdf/1690969274Web Insert.pdf",
    "images": [
      "https://www.admin.drug-international.com/uploads/product_images/1690969274Carton.png"
    ]
  }
];

//export default products;